Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"MS evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific NX"	"RNA single cell type specificity"	"RNA single cell type distribution"	"RNA single cell type specificity score"	"RNA single cell type specific NX"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific NX"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific NX"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific NX"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific NX"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific pTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific pTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"CCD Protein"	"CCD Transcript"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [NX]"	"Tissue RNA - adrenal gland [NX]"	"Tissue RNA - amygdala [NX]"	"Tissue RNA - appendix [NX]"	"Tissue RNA - basal ganglia [NX]"	"Tissue RNA - bone marrow [NX]"	"Tissue RNA - breast [NX]"	"Tissue RNA - cerebellum [NX]"	"Tissue RNA - cerebral cortex [NX]"	"Tissue RNA - cervix, uterine [NX]"	"Tissue RNA - colon [NX]"	"Tissue RNA - corpus callosum [NX]"	"Tissue RNA - ductus deferens [NX]"	"Tissue RNA - duodenum [NX]"	"Tissue RNA - endometrium 1 [NX]"	"Tissue RNA - epididymis [NX]"	"Tissue RNA - esophagus [NX]"	"Tissue RNA - fallopian tube [NX]"	"Tissue RNA - gallbladder [NX]"	"Tissue RNA - heart muscle [NX]"	"Tissue RNA - hippocampal formation [NX]"	"Tissue RNA - hypothalamus [NX]"	"Tissue RNA - kidney [NX]"	"Tissue RNA - liver [NX]"	"Tissue RNA - lung [NX]"	"Tissue RNA - lymph node [NX]"	"Tissue RNA - midbrain [NX]"	"Tissue RNA - olfactory region [NX]"	"Tissue RNA - ovary [NX]"	"Tissue RNA - pancreas [NX]"	"Tissue RNA - parathyroid gland [NX]"	"Tissue RNA - pituitary gland [NX]"	"Tissue RNA - placenta [NX]"	"Tissue RNA - pons and medulla [NX]"	"Tissue RNA - prostate [NX]"	"Tissue RNA - rectum [NX]"	"Tissue RNA - retina [NX]"	"Tissue RNA - salivary gland [NX]"	"Tissue RNA - seminal vesicle [NX]"	"Tissue RNA - skeletal muscle [NX]"	"Tissue RNA - skin 1 [NX]"	"Tissue RNA - small intestine [NX]"	"Tissue RNA - smooth muscle [NX]"	"Tissue RNA - spinal cord [NX]"	"Tissue RNA - spleen [NX]"	"Tissue RNA - stomach 1 [NX]"	"Tissue RNA - testis [NX]"	"Tissue RNA - thalamus [NX]"	"Tissue RNA - thymus [NX]"	"Tissue RNA - thyroid gland [NX]"	"Tissue RNA - tongue [NX]"	"Tissue RNA - tonsil [NX]"	"Tissue RNA - urinary bladder [NX]"	"Tissue RNA - vagina [NX]"	"Tissue RNA - B-cells [NX]"	"Tissue RNA - dendritic cells [NX]"	"Tissue RNA - granulocytes [NX]"	"Tissue RNA - monocytes [NX]"	"Tissue RNA - NK-cells [NX]"	"Tissue RNA - T-cells [NX]"	"Tissue RNA - total PBMC [NX]"	"Cell RNA - A-431 [NX]"	"Cell RNA - A549 [NX]"	"Cell RNA - AF22 [NX]"	"Cell RNA - AN3-CA [NX]"	"Cell RNA - ASC diff [NX]"	"Cell RNA - ASC TERT1 [NX]"	"Cell RNA - BEWO [NX]"	"Cell RNA - BJ [NX]"	"Cell RNA - BJ hTERT+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]"	"Cell RNA - CACO-2 [NX]"	"Cell RNA - CAPAN-2 [NX]"	"Cell RNA - Daudi [NX]"	"Cell RNA - EFO-21 [NX]"	"Cell RNA - fHDF/TERT166 [NX]"	"Cell RNA - GAMG [NX]"	"Cell RNA - HaCaT [NX]"	"Cell RNA - HAP1 [NX]"	"Cell RNA - HBEC3-KT [NX]"	"Cell RNA - HBF TERT88 [NX]"	"Cell RNA - HDLM-2 [NX]"	"Cell RNA - HEK 293 [NX]"	"Cell RNA - HEL [NX]"	"Cell RNA - HeLa [NX]"	"Cell RNA - Hep G2 [NX]"	"Cell RNA - HHSteC [NX]"	"Cell RNA - HL-60 [NX]"	"Cell RNA - HMC-1 [NX]"	"Cell RNA - HSkMC [NX]"	"Cell RNA - hTCEpi [NX]"	"Cell RNA - hTEC/SVTERT24-B [NX]"	"Cell RNA - hTERT-HME1 [NX]"	"Cell RNA - hTERT-RPE1 [NX]"	"Cell RNA - HUVEC TERT2 [NX]"	"Cell RNA - JURKAT [NX]"	"Cell RNA - K-562 [NX]"	"Cell RNA - Karpas-707 [NX]"	"Cell RNA - LHCN-M2 [NX]"	"Cell RNA - MCF7 [NX]"	"Cell RNA - MOLT-4 [NX]"	"Cell RNA - NB-4 [NX]"	"Cell RNA - NTERA-2 [NX]"	"Cell RNA - OE19 [NX]"	"Cell RNA - PC-3 [NX]"	"Cell RNA - REH [NX]"	"Cell RNA - RH-30 [NX]"	"Cell RNA - RPMI-8226 [NX]"	"Cell RNA - RPTEC TERT1 [NX]"	"Cell RNA - RT4 [NX]"	"Cell RNA - SCLC-21H [NX]"	"Cell RNA - SH-SY5Y [NX]"	"Cell RNA - SiHa [NX]"	"Cell RNA - SK-BR-3 [NX]"	"Cell RNA - SK-MEL-30 [NX]"	"Cell RNA - SuSa [NX]"	"Cell RNA - T-47d [NX]"	"Cell RNA - THP-1 [NX]"	"Cell RNA - TIME [NX]"	"Cell RNA - U-138 MG [NX]"	"Cell RNA - U-2 OS [NX]"	"Cell RNA - U-2197 [NX]"	"Cell RNA - U-251 MG [NX]"	"Cell RNA - U-266/70 [NX]"	"Cell RNA - U-266/84 [NX]"	"Cell RNA - U-698 [NX]"	"Cell RNA - U-87 MG [NX]"	"Cell RNA - U-937 [NX]"	"Cell RNA - WM-115 [NX]"	"Blood RNA - basophil [NX]"	"Blood RNA - classical monocyte [NX]"	"Blood RNA - eosinophil [NX]"	"Blood RNA - gdT-cell [NX]"	"Blood RNA - intermediate monocyte [NX]"	"Blood RNA - MAIT T-cell [NX]"	"Blood RNA - memory B-cell [NX]"	"Blood RNA - memory CD4 T-cell [NX]"	"Blood RNA - memory CD8 T-cell [NX]"	"Blood RNA - myeloid DC [NX]"	"Blood RNA - naive B-cell [NX]"	"Blood RNA - naive CD4 T-cell [NX]"	"Blood RNA - naive CD8 T-cell [NX]"	"Blood RNA - neutrophil [NX]"	"Blood RNA - NK-cell [NX]"	"Blood RNA - non-classical monocyte [NX]"	"Blood RNA - plasmacytoid DC [NX]"	"Blood RNA - T-reg [NX]"	"Blood RNA - total PBMC [NX]"	"Brain RNA - amygdala [NX]"	"Brain RNA - basal ganglia [NX]"	"Brain RNA - cerebellum [NX]"	"Brain RNA - cerebral cortex [NX]"	"Brain RNA - hippocampal formation [NX]"	"Brain RNA - hypothalamus [NX]"	"Brain RNA - midbrain [NX]"	"Brain RNA - olfactory region [NX]"	"Brain RNA - pons and medulla [NX]"	"Brain RNA - thalamus [NX]"	"Single Cell Type RNA - Alveolar cells type 1 [NX]"	"Single Cell Type RNA - Alveolar cells type 2 [NX]"	"Single Cell Type RNA - B-cells [NX]"	"Single Cell Type RNA - Basal glandular cells [NX]"	"Single Cell Type RNA - Basal keratinocytes [NX]"	"Single Cell Type RNA - Bipolar cells [NX]"	"Single Cell Type RNA - Cardiomyocytes [NX]"	"Single Cell Type RNA - Cholangiocytes [NX]"	"Single Cell Type RNA - Ciliated cells [NX]"	"Single Cell Type RNA - Club cells [NX]"	"Single Cell Type RNA - Collecting duct cells [NX]"	"Single Cell Type RNA - Cone photoreceptor cells [NX]"	"Single Cell Type RNA - Cytotrophoblasts [NX]"	"Single Cell Type RNA - Distal tubular cells [NX]"	"Single Cell Type RNA - Ductal cells [NX]"	"Single Cell Type RNA - Early spermatids [NX]"	"Single Cell Type RNA - Endothelial cells [NX]"	"Single Cell Type RNA - Enterocytes [NX]"	"Single Cell Type RNA - Erythroid cells [NX]"	"Single Cell Type RNA - Exocrine glandular cells [NX]"	"Single Cell Type RNA - Extravillous trophoblasts [NX]"	"Single Cell Type RNA - Fibroblasts [NX]"	"Single Cell Type RNA - Glandular cells [NX]"	"Single Cell Type RNA - granulocytes [NX]"	"Single Cell Type RNA - Hepatocytes [NX]"	"Single Cell Type RNA - Hofbauer cells [NX]"	"Single Cell Type RNA - Horizontal cells [NX]"	"Single Cell Type RNA - Intestinal endocrine cells [NX]"	"Single Cell Type RNA - Ito cells [NX]"	"Single Cell Type RNA - Kupffer cells [NX]"	"Single Cell Type RNA - Late spermatids [NX]"	"Single Cell Type RNA - Leydig cells [NX]"	"Single Cell Type RNA - Macrophages [NX]"	"Single Cell Type RNA - Melanocytes [NX]"	"Single Cell Type RNA - monocytes [NX]"	"Single Cell Type RNA - Mucus-secreting cells [NX]"	"Single Cell Type RNA - Muller glia cells [NX]"	"Single Cell Type RNA - Pancreatic endocrine cells [NX]"	"Single Cell Type RNA - Paneth cells [NX]"	"Single Cell Type RNA - Peritubular cells [NX]"	"Single Cell Type RNA - Proximal tubular cells [NX]"	"Single Cell Type RNA - Rod photoreceptor cells [NX]"	"Single Cell Type RNA - Sertoli cells [NX]"	"Single Cell Type RNA - Smooth muscle cells [NX]"	"Single Cell Type RNA - Spermatocytes [NX]"	"Single Cell Type RNA - Spermatogonia [NX]"	"Single Cell Type RNA - Suprabasal keratinocytes [NX]"	"Single Cell Type RNA - Syncytiotrophoblasts [NX]"	"Single Cell Type RNA - T-cells [NX]"	"Single Cell Type RNA - Undifferentiated cells [NX]"	"Single Cell Type RNA - Urothelial cells [NX]"
ABCB1	"ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1"	ENSG00000085563	"ATP binding cassette subfamily B member 1"	P08183	7	87503633-87713323	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport	Translocase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 57.8;intestine: 49.6"	"Cell type enhanced"	"Detected in many"	13	"Cholangiocytes: 104.4;Enterocytes: 174.5;Paneth cells: 77.2"	"Cancer enhanced"	"Detected in many"		"renal cancer: 14.2"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 19.2"	"Group enriched"	"Detected in many"	8	"NK-cells: 11.4;T-cells: 19.2"	"Cell line enhanced"	"Detected in some"		"CACO-2: 30.1;HEK 293: 9.3;HEL: 16.7;Hep G2: 8.2;RPTEC TERT1: 11.5;SH-SY5Y: 36.8"									"CAB001716, HPA002199, HPA074614"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		NA	NA			"Nucleoplasm, Plasma membrane"	"Focal adhesion sites"	"CAB001716: , HPA002199: AB_1844428, HPA074614: "	"unprognostic (5.38e-3)"	"unprognostic (2.45e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.25e-2)"	"unprognostic (9.99e-5)"	"unprognostic (2.23e-3)"	"unprognostic (5.65e-3)"	"unprognostic (1.14e-1)"	"unprognostic (5.17e-2)"	"prognostic favorable (3.33e-4)"	"unprognostic (5.19e-1)"	"prognostic favorable (2.95e-4)"	"unprognostic (2.06e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.83e-1)"	"unprognostic (6.12e-2)"	2.6	57.8	9.4	3.2	11.5	1.2	3.4	5.1	10.5	5.5	22.7	3.8	2.0	14.4	9.4	3.5	2.0	3.2	9.0	1.8	9.2	6.6	19.1	15.6	3.8	2.2	9.4	5.7	2.2	1.5	1.7	1.3	3.1	11.1	2.7	10.7	7.6	1.5	2.1	1.1	1.3	49.6	5.7	9.0	2.4	1.7	1.3	8.6	0.1	2.4	1.4	2.2	2.6	5.9	1.9	0.0	0.1	0.0	11.4	19.2	1.5	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	30.1	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	9.3	16.7	1.9	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	11.5	0.1	0.4	36.8	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.9	0.0	0.4	3.2	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	7.8	0.0	19.2	0.4	2.0	4.7	0.0	1.9	1.2	4.8	0.1	11.4	0.0	0.0	0.0	1.5	9.4	11.5	5.1	10.5	9.2	6.6	9.4	5.7	11.1	8.6	0.0	4.8	5.9	0.1	0.7	0.6	2.8	104.4	1.4	1.2	47.1	0.0	5.0	5.0	10.2	21.6	23.1	174.5	23.3	1.6	0.1	0.5	0.1	3.5	32.6	0.4	0.0	0.0	3.7	1.2	2.5	0.9	0.8	0.0	0.0	8.9	0.0	11.4	77.2	0.0	44.0	0.9	0.0	0.8	0.5	0.4	0.5	8.2	27.3	1.7	0.1
ABCG2	"ABCP, BCRP, CD338, EST157481, MXR"	ENSG00000118777	"ATP binding cassette subfamily G member 2 (Junior blood group)"	Q9UNQ0	4	88090264-88231322	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Transport	Translocase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ductus deferens: 49.6;intestine: 56.6;seminal vesicle: 61.0"	"Cell type enhanced"	"Detected in many"	15	"Enterocytes: 135.7;Extravillous trophoblasts: 47.1;Hofbauer cells: 105.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 5.7"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A549: 18.8;BEWO: 32.9;OE19: 25.5;RPMI-8226: 16.5;SuSa: 12.7"									"CAB037299, HPA054719"	Enhanced		Supported	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"CAB037299: AB_476804, HPA054719: "	"unprognostic (5.04e-1)"	"unprognostic (3.05e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.01e-3)"	"unprognostic (9.19e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.30e-1)"	"unprognostic (9.14e-2)"	"unprognostic (1.37e-1)"	"unprognostic (3.01e-3)"	"unprognostic (4.52e-2)"	"unprognostic (1.67e-3)"	"unprognostic (8.82e-3)"	"unprognostic (7.04e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.92e-1)"	2.8	2.5	11.6	0.8	14.8	1.2	2.4	4.3	9.7	13.6	12.5	8.4	49.6	24.9	14.4	4.2	1.5	6.1	3.3	2.0	16.0	12.2	2.3	19.7	3.0	0.8	17.6	5.6	5.6	0.6	3.2	7.0	12.3	17.0	5.5	8.1	6.9	2.9	61.0	0.4	0.6	56.6	11.8	15.7	0.9	1.2	1.9	5.5	0.0	3.8	0.8	1.3	2.0	3.1	1.2	0.5	0.0	0.2	2.4	5.7	0.7	0.6	18.8	5.6	0.0	0.2	0.0	32.9	0.7	0.6	1.0	1.6	4.1	0.2	0.0	0.2	0.1	2.4	5.5	0.1	0.5	1.4	5.3	0.8	0.2	0.1	5.6	0.0	0.2	0.0	0.1	2.3	2.2	0.1	0.5	1.7	0.4	0.4	0.0	0.6	10.9	2.6	0.0	1.9	25.5	0.0	1.2	0.0	16.5	0.0	4.0	0.0	0.2	3.9	0.4	0.5	12.7	0.1	0.0	0.0	0.7	0.7	0.2	0.0	5.2	1.9	0.0	1.4	0.0	0.8	0.0	0.0	0.0	1.9	0.0	5.7	0.1	0.7	0.6	0.0	1.2	0.7	0.3	0.0	2.4	0.2	0.5	1.7	0.7	11.6	14.8	4.3	9.7	16.0	12.2	17.6	5.6	17.0	5.5	3.0	1.4	0.5	0.2	3.4	0.0	1.1	0.0	1.4	0.0	0.0	0.0	14.3	1.7	0.0	2.6	9.0	135.7	0.0	0.2	47.1	2.1	0.2	5.7	25.0	105.8	0.0	2.9	13.5	1.0	0.4	1.1	1.1	5.0	0.0	2.9	0.9	0.1	35.1	0.4	4.5	0.2	0.0	1.4	0.9	3.4	0.4	31.5	0.8	0.8	0.1
ACE	"ACE1, CD143, DCP1"	ENSG00000159640	"Angiotensin I converting enzyme"	P12821	17	63477061-63498380	"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"Carboxypeptidase, Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"intestine: 205.6"	"Group enriched"	"Detected in many"	25	"Early spermatids: 470.5;Late spermatids: 1015.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 3.7"	"Group enriched"	"Detected in many"	23	"B-cells: 3.7;monocytes: 2.0;T-cells: 1.9"	"Group enriched"	"Detected in some"	4	"ASC TERT1: 36.7;HUVEC TERT2: 18.7"									"CAB002426, CAB002921, HPA029298, HPA069790"	Enhanced		Approved	Vesicles	"Secreted to blood"	NA	NA	104000000	92000000	Vesicles		"CAB002426: AB_442052, CAB002921: , HPA029298: AB_10960255, HPA069790: AB_2686197"	"unprognostic (4.72e-2)"	"unprognostic (4.16e-1)"	"unprognostic (1.93e-3)"	"unprognostic (6.06e-2)"	"unprognostic (2.78e-1)"	"unprognostic (1.35e-2)"	"unprognostic (4.37e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.25e-2)"	"unprognostic (3.13e-2)"	"unprognostic (2.38e-1)"	"unprognostic (7.66e-2)"	"unprognostic (9.07e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.76e-2)"	6.8	2.0	0.5	2.4	4.2	0.0	2.9	0.5	1.1	5.3	83.2	0.7	37.7	46.4	4.5	5.1	1.7	1.5	4.4	4.7	0.6	0.7	2.6	1.4	16.3	2.2	0.4	0.7	1.4	3.0	3.6	3.6	3.6	0.8	3.4	1.4	1.7	2.5	20.1	3.6	1.3	205.6	2.4	0.6	1.4	1.9	32.6	1.3	0.5	6.9	3.1	2.2	1.7	1.6	3.7	0.1	0.0	2.0	0.0	1.9	0.4	0.0	0.0	0.0	0.0	1.5	36.7	0.4	1.3	2.7	0.0	0.0	0.5	3.2	0.7	1.1	6.2	0.0	0.0	1.7	0.0	0.0	0.0	0.7	3.5	0.0	0.0	0.8	0.0	0.0	2.4	0.0	0.0	0.0	0.6	18.7	0.0	3.1	0.0	0.0	0.6	0.0	0.8	0.3	6.3	0.4	0.1	0.2	0.5	0.0	0.0	4.6	3.2	0.0	0.0	0.0	0.7	1.6	0.2	0.0	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.4	0.6	0.9	3.7	1.9	1.4	0.1	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.4	0.5	4.2	0.5	1.1	0.6	0.7	0.4	0.7	0.8	1.3	0.0	3.5	0.0	1.5	1.3	3.1	1.4	0.0	0.0	1.2	0.0	0.0	0.1	0.0	3.4	470.5	13.5	29.6	0.0	0.4	0.1	1.0	6.0	6.9	0.0	4.4	0.0	17.3	2.5	18.5	1015.1	4.0	5.1	3.3	0.0	8.7	1.9	0.7	10.2	2.5	10.7	1.0	0.0	0.9	8.1	3.4	0.1	0.1	0.9	8.6	2.1
ACKR1	"CCBP1, CD234, DARC, Dfy, FY, GPD"	ENSG00000213088	"Atypical chemokine receptor 1 (Duffy blood group)"	Q16570	1	159203307-159206500	"Blood group antigen proteins, CD markers, G-protein coupled receptors, Predicted membrane proteins"		"Blood group antigen, G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"adipose tissue: 109.8"	"Cell type enhanced"	"Detected in many"	26	"Bipolar cells: 50.1;Endothelial cells: 278.7;Erythroid cells: 116.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"HEL: 22.5;HSkMC: 24.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA016421, HPA017672"	Enhanced					NA	NA					"HPA016421: AB_1849219, HPA017672: AB_1849221"	"unprognostic (8.74e-3)"	"prognostic favorable (2.52e-5)"	"unprognostic (9.73e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.34e-3)"	"unprognostic (3.84e-3)"	"prognostic favorable (1.48e-4)"	"unprognostic (7.80e-2)"	"unprognostic (2.22e-1)"	"unprognostic (3.46e-2)"	"unprognostic (1.65e-3)"	"unprognostic (1.81e-1)"	"unprognostic (3.82e-3)"	"unprognostic (5.17e-3)"	"unprognostic (2.40e-1)"	"prognostic unfavorable (9.76e-4)"	"unprognostic (2.30e-2)"	109.8	4.0	6.7	16.2	4.2	5.7	54.5	23.3	5.4	40.1	13.1	2.4	10.2	6.5	28.8	23.0	32.6	27.1	26.9	47.1	9.1	3.4	5.7	1.3	27.8	36.8	19.2	0.6	22.3	8.1	3.9	2.0	5.8	14.0	29.1	7.1	5.3	12.8	9.8	38.3	19.8	11.5	36.6	9.4	25.0	13.0	21.6	6.4	3.0	16.5	29.9	15.5	42.3	24.2	0.0	0.0	0.0	0.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	22.5	0.0	0.0	4.2	0.0	0.0	24.5	0.0	0.0	3.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.1	0.0	0.0	0.1	0.0	0.0	1.1	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	6.7	4.2	23.3	5.3	9.1	3.4	19.2	0.6	14.0	6.4	6.0	19.1	0.0	1.6	0.0	50.1	8.1	0.0	1.4	3.4	0.0	2.0	0.2	0.0	0.0	1.6	278.7	0.0	116.8	9.1	0.2	6.3	1.9	4.7	0.0	0.8	6.4	0.0	6.7	0.8	2.0	1.1	0.2	0.0	0.0	0.0	6.4	0.0	0.0	0.4	0.0	3.6	0.0	0.0	0.2	0.4	0.0	0.1	0.0	0.0	0.9
ADAM10	"CD156c, HsT18717, kuz, MADM"	ENSG00000137845	"ADAM metallopeptidase domain 10"	O14672	15	58588807-58749978	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Notch signaling pathway"	"Hydrolase, Metalloprotease, Protease"	"Alzheimer disease, Amyloidosis, Cancer-related genes, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-2197: 77.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001709, HPA050670"	Approved		Supported	"Nucleoplasm,Vesicles,Plasma membrane"	"Intracellular and membrane"	NA	NA		8200000	"Plasma membrane"	"Nucleoplasm, Vesicles"	"CAB001709: , HPA050670: "	"unprognostic (1.43e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.77e-1)"	"unprognostic (5.04e-2)"	"unprognostic (3.09e-1)"	"unprognostic (2.70e-3)"	"unprognostic (7.48e-2)"	"prognostic unfavorable (8.46e-5)"	"unprognostic (3.99e-2)"	"unprognostic (1.19e-1)"	"prognostic unfavorable (1.90e-4)"	"unprognostic (6.69e-2)"	"unprognostic (2.57e-2)"	"unprognostic (2.57e-3)"	"unprognostic (9.14e-2)"	"unprognostic (2.09e-2)"	"unprognostic (1.60e-2)"	25.9	11.1	15.5	17.1	17.7	15.6	20.0	25.2	17.6	18.6	20.1	15.7	12.7	13.9	19.9	11.8	17.1	13.8	18.0	18.8	17.6	13.7	20.8	14.8	25.0	26.1	23.1	12.4	13.9	13.1	10.9	11.6	36.1	14.5	23.6	16.7	14.6	12.4	19.1	8.9	15.4	15.6	12.8	30.4	40.4	18.4	8.5	18.9	38.5	27.3	9.2	14.9	30.0	19.1	6.2	12.7	26.9	23.7	9.8	12.2	12.8	12.1	27.4	7.5	8.1	9.6	13.9	18.9	10.4	31.0	7.7	10.7	12.6	16.1	5.6	32.2	9.3	13.5	24.8	4.5	11.0	10.2	8.4	5.8	9.6	10.0	11.7	10.7	6.8	27.7	12.1	8.1	5.4	7.9	11.2	14.9	12.2	6.0	15.3	13.5	4.5	22.4	7.7	10.2	4.0	3.9	9.3	24.5	14.4	17.9	32.7	8.1	5.3	11.3	13.2	18.0	17.1	7.8	13.6	10.5	10.1	11.3	77.5	10.0	8.6	18.5	6.1	14.1	13.1	17.6	12.9	18.8	10.4	8.1	21.5	12.2	5.3	8.0	7.1	12.7	6.2	8.4	7.0	26.9	9.8	23.7	5.8	10.3	12.8	15.5	17.7	25.2	16.9	17.6	13.7	23.1	12.4	14.5	18.9	77.4	49.8	30.6	25.8	23.7	20.2	29.7	30.6	30.8	35.2	76.8	25.5	27.4	1.7	45.7	21.6	61.6	39.3	0.0	27.7	46.7	28.8	75.5	27.9	30.4	56.9	42.9	34.7	76.1	87.0	16.2	16.7	64.0	43.9	13.6	45.8	27.0	37.3	43.2	15.9	20.3	32.7	12.9	28.3	13.6	16.2	19.4	22.2	43.6	33.7	59.6
ADAM17	"CD156B, cSVP, TACE"	ENSG00000151694	"ADAM metallopeptidase domain 17"	P78536	2	9488486-9555792	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Notch signaling pathway"	"Hydrolase, Metalloprotease, Protease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010738, HPA051575"	Approved		Supported	Cytosol	"Intracellular and membrane"	NA	NA		27000	Cytosol		"HPA010738: AB_1078100, HPA051575: AB_2681539"	"unprognostic (2.28e-1)"	"unprognostic (1.29e-3)"	"unprognostic (1.28e-1)"	"unprognostic (3.51e-3)"	"unprognostic (1.57e-1)"	"unprognostic (5.15e-2)"	"unprognostic (2.12e-3)"	"unprognostic (1.55e-1)"	"unprognostic (4.09e-2)"	"unprognostic (3.69e-1)"	"unprognostic (3.53e-3)"	"unprognostic (3.13e-1)"	"unprognostic (3.82e-3)"	"unprognostic (8.63e-2)"	"unprognostic (2.61e-1)"	"unprognostic (4.48e-2)"	"prognostic unfavorable (4.23e-5)"	18.6	11.0	13.6	15.4	13.8	21.9	14.7	20.4	15.5	14.0	11.7	13.8	8.3	8.7	14.2	15.8	18.7	10.7	17.4	13.4	11.2	12.4	12.4	7.8	24.7	15.0	11.6	11.7	18.1	9.6	10.9	11.9	29.0	11.2	8.2	9.4	10.6	12.5	9.8	12.3	16.7	11.1	13.9	14.3	21.4	8.9	17.4	12.3	14.7	12.5	13.9	20.3	12.3	14.4	7.0	7.7	16.0	10.2	6.0	7.9	6.0	7.7	12.7	13.4	13.9	26.4	19.7	24.1	8.1	13.8	9.3	13.9	11.2	18.6	22.0	11.7	10.1	27.3	14.1	9.8	17.2	12.8	8.8	9.8	11.2	9.6	9.9	37.3	11.0	12.6	22.0	17.3	14.9	29.0	20.8	23.4	8.4	15.3	8.5	10.0	7.3	8.2	11.0	11.0	10.8	5.1	9.6	13.1	10.4	12.4	12.8	7.9	19.7	9.0	11.0	19.2	15.1	5.7	14.2	18.7	16.6	8.7	11.6	15.4	11.1	9.9	19.2	13.8	7.1	19.7	16.0	9.8	7.6	6.1	10.2	7.9	7.0	5.0	5.1	7.7	5.1	4.5	4.6	11.8	6.0	9.5	4.3	5.7	6.0	13.6	13.8	20.4	13.1	11.2	12.4	11.6	11.7	11.2	12.3	44.7	76.6	33.0	41.9	115.4	24.9	2.8	12.7	25.4	40.9	29.6	51.1	25.3	5.0	20.9	64.8	44.9	15.5	23.3	16.8	39.0	58.0	41.4	29.0	11.0	32.9	9.5	18.9	42.4	70.5	10.4	17.5	74.4	38.8	26.2	13.4	12.3	18.2	17.3	15.2	7.5	38.2	38.8	26.7	25.4	37.8	135.3	46.8	26.2	12.5	92.9
ADAM8	"CD156, CD156a, MS2"	ENSG00000151651	"ADAM metallopeptidase domain 8"	P78325	10	133262403-133276868	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 56.8;bone marrow: 37.1;lymphoid tissue: 28.3"	"Cell type enhanced"	"Detected in many"	11	"Extravillous trophoblasts: 82.5;Macrophages: 42.6;monocytes: 115.4;T-cells: 46.3;Urothelial cells: 41.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"basophil: 20.7;eosinophil: 56.8;neutrophil: 32.9"	"Lineage enriched"	"Detected in all"	7	"granulocytes: 56.8"	"Cell line enhanced"	"Detected in some"		"A-431: 22.9;BEWO: 32.9;CAPAN-2: 27.9;HaCaT: 27.4;HDLM-2: 17.6;U-87 MG: 14.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA064637	Approved				"Intracellular and membrane"	NA	NA					"HPA064637: AB_2685306"	"unprognostic (8.24e-2)"	"unprognostic (6.07e-3)"	"unprognostic (1.27e-3)"	"unprognostic (5.18e-2)"	"unprognostic (8.26e-2)"	"unprognostic (6.47e-2)"	"unprognostic (5.59e-2)"	"unprognostic (2.22e-1)"	"unprognostic (2.57e-1)"	"unprognostic (1.94e-3)"	"unprognostic (3.37e-2)"	"unprognostic (5.47e-2)"	"prognostic unfavorable (3.99e-10)"	"unprognostic (1.92e-1)"	"unprognostic (3.02e-2)"	"unprognostic (1.28e-1)"	"unprognostic (9.32e-2)"	4.8	1.0	0.7	18.0	1.6	37.1	3.1	1.7	1.2	3.8	4.8	0.9	0.2	3.5	1.8	1.6	2.8	3.6	10.1	4.1	0.8	1.1	2.8	4.3	13.0	25.0	1.0	0.2	1.7	2.4	0.1	2.0	7.5	1.6	2.9	0.9	2.9	5.5	0.7	1.5	1.9	6.0	1.6	1.5	28.3	6.9	2.3	0.5	6.6	2.0	1.8	19.7	12.0	2.8	2.5	8.6	56.8	5.4	5.5	5.5	4.6	22.9	0.7	0.2	0.3	0.2	0.0	32.9	0.2	0.5	0.1	0.1	1.8	27.9	0.4	0.6	0.0	0.2	27.4	0.0	4.7	0.0	17.6	0.3	0.3	0.1	0.0	0.2	1.3	6.4	0.1	0.4	0.2	0.4	1.5	0.0	0.2	1.2	1.0	0.0	1.8	0.0	7.7	0.1	2.7	0.6	0.1	0.2	2.5	0.3	0.5	0.0	0.3	0.1	0.1	0.4	0.4	0.4	0.7	0.6	0.0	0.6	0.2	0.4	1.4	0.8	0.2	14.0	0.7	0.1	20.7	5.4	56.8	5.5	2.1	4.0	2.5	3.7	5.2	8.6	1.5	1.4	2.0	32.9	5.5	2.0	0.1	3.8	4.6	0.7	1.6	1.7	1.2	0.8	1.1	1.0	0.2	1.6	0.5	3.0	14.6	0.9	1.4	6.9	4.1	2.0	2.5	5.3	5.7	0.0	7.9	4.1	1.7	3.0	0.9	2.2	0.0	0.0	2.3	82.5	2.9	5.5	11.6	2.1	24.1	0.0	0.0	3.1	11.1	0.2	0.9	42.6	6.8	115.4	0.2	0.2	22.9	0.0	0.0	0.3	5.3	0.0	0.8	1.4	0.7	5.6	16.7	46.3	0.4	41.4
ADGRE2	"CD312, EMR2"	ENSG00000127507	"Adhesion G protein-coupled receptor E2"	Q9UHX3	19	14732393-14778541	"CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins"	"Cell adhesion, Inflammatory response"	"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 28.7;lymphoid tissue: 38.9"	"Cell type enhanced"	"Detected in many"	15	"granulocytes: 44.2;Kupffer cells: 60.1;Macrophages: 39.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"basophil: 19.6;eosinophil: 24.2;intermediate monocyte: 15.7;neutrophil: 19.1;non-classical monocyte: 28.7"	"Group enriched"	"Detected in many"	8	"granulocytes: 24.2;monocytes: 28.7"	"Cell line enhanced"	"Detected in some"		"HEL: 10.3;HMC-1: 16.6;NB-4: 10.1;RPMI-8226: 7.3;U-937: 13.2"									HPA055200			Uncertain	Vesicles,Cytosol		NA	NA			Vesicles	Cytosol	"HPA055200: "	"unprognostic (2.46e-2)"	"unprognostic (3.58e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.66e-1)"	"unprognostic (9.10e-2)"	"unprognostic (3.58e-2)"	"unprognostic (2.77e-2)"	"unprognostic (3.88e-2)"	"unprognostic (4.28e-1)"	"unprognostic (1.22e-1)"	"unprognostic (2.32e-1)"	"unprognostic (2.70e-2)"	"prognostic unfavorable (4.35e-6)"	"unprognostic (1.46e-1)"	"unprognostic (2.45e-3)"	"unprognostic (2.50e-1)"	"unprognostic (1.01e-1)"	6.3	3.1	1.7	22.9	1.9	7.2	4.4	1.0	1.3	14.9	8.1	2.5	0.9	2.4	12.0	1.0	1.9	2.3	3.3	7.3	2.0	1.8	3.4	4.3	15.6	37.4	2.2	0.0	5.3	3.5	0.7	1.6	10.9	2.4	3.8	2.5	3.2	2.4	3.9	3.5	3.0	3.0	2.0	3.1	38.9	2.0	2.2	1.4	2.8	3.4	5.2	2.8	7.5	2.1	0.1	3.1	24.2	28.7	1.2	0.0	1.8	0.2	1.0	0.1	0.2	0.1	0.3	1.1	0.8	1.1	0.0	0.0	0.2	0.2	0.2	0.1	0.7	2.1	1.7	0.3	0.1	0.0	0.2	0.2	10.3	3.3	0.2	0.5	3.8	16.6	0.8	1.5	3.7	0.6	0.1	0.1	0.9	2.4	0.4	1.2	0.5	1.3	10.1	0.4	0.7	0.2	0.1	1.4	7.3	0.0	0.3	0.1	0.2	2.1	1.8	0.4	0.2	0.3	4.8	0.3	0.3	0.3	0.2	0.1	0.2	0.1	0.2	1.0	13.2	0.6	19.6	4.4	24.2	0.0	15.7	0.0	0.0	0.0	0.0	3.1	0.1	0.0	0.0	19.1	1.2	28.7	0.6	0.0	1.8	1.7	1.9	1.0	1.3	2.0	1.8	2.2	0.0	2.4	1.4	3.0	10.6	5.4	4.4	0.0	0.7	0.6	0.0	4.0	4.5	0.0	0.0	0.1	0.0	0.0	2.0	0.4	0.0	0.0	0.0	0.3	0.3	1.7	44.2	0.4	13.5	0.0	1.2	1.3	60.1	2.0	0.0	39.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.2	0.2	0.3	0.0	0.3	0.7	0.0	3.0
ADGRE5	"CD97, TM7LN1"	ENSG00000123146	"Adhesion G protein-coupled receptor E5"	P48960	19	14380501-14408725	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"	"Cell adhesion"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 95.3"	"Cell type enhanced"	"Detected in many"	8	"Alveolar cells type 2: 102.4;Kupffer cells: 83.8;T-cells: 152.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA013707	Enhanced		Approved	Cytosol	"Secreted to blood"	NA	Yes	10000000	930000	Cytosol		"HPA013707: AB_1846345"	"unprognostic (3.16e-1)"	"unprognostic (1.80e-1)"	"unprognostic (5.10e-2)"	"unprognostic (2.30e-1)"	"unprognostic (2.85e-2)"	"unprognostic (7.24e-2)"	"prognostic unfavorable (3.73e-5)"	"unprognostic (7.51e-2)"	"unprognostic (6.06e-3)"	"unprognostic (3.14e-2)"	"unprognostic (1.08e-3)"	"unprognostic (2.37e-1)"	"prognostic unfavorable (1.87e-6)"	"unprognostic (2.08e-2)"	"unprognostic (4.14e-2)"	"unprognostic (2.44e-2)"	"unprognostic (6.41e-2)"	17.7	8.9	2.5	23.0	4.0	55.3	14.3	1.1	5.2	21.7	15.9	12.9	0.5	12.9	56.9	18.5	11.6	19.1	27.1	16.4	3.0	2.4	10.7	15.5	30.3	41.1	6.3	3.2	10.7	16.2	2.4	3.3	18.2	5.9	11.3	9.0	6.9	17.0	3.6	12.5	6.0	22.2	36.2	4.2	56.9	15.0	6.9	4.9	24.3	8.6	3.7	22.5	34.7	12.4	3.9	13.3	95.3	43.2	22.8	25.8	23.3	30.8	21.9	0.2	21.0	9.3	15.3	3.3	21.4	34.5	15.4	16.9	6.2	31.3	3.5	21.7	27.5	22.0	7.3	5.7	10.4	6.9	19.2	6.4	6.9	32.5	2.7	11.5	14.9	32.3	6.7	0.3	15.7	5.4	5.0	1.5	6.1	9.0	27.7	16.8	6.9	0.9	20.0	0.6	24.5	27.3	2.0	9.2	16.1	5.2	2.7	0.2	0.7	12.2	17.5	15.2	0.5	4.5	13.8	3.7	5.2	8.7	21.7	35.2	0.0	0.1	0.2	18.7	26.7	19.5	42.0	18.6	95.3	25.8	36.7	17.3	3.9	13.1	17.8	13.3	2.6	9.4	12.8	82.7	22.8	43.2	6.4	9.0	23.3	2.5	4.0	1.1	5.2	3.0	2.4	6.3	3.2	5.9	4.9	32.8	102.4	15.9	7.4	0.0	0.2	3.1	12.7	50.9	31.8	0.0	0.0	2.7	0.0	15.1	0.0	4.5	10.2	23.3	19.1	36.8	4.8	9.8	70.9	1.5	47.0	0.0	4.7	26.4	83.8	1.0	6.1	50.6	0.0	2.8	34.7	2.3	17.9	21.0	4.6	0.7	1.2	25.8	17.2	0.5	5.7	0.0	6.6	152.3	31.8	14.1
ALCAM	"CD166, MEMD"	ENSG00000170017	"Activated leukocyte cell adhesion molecule"	Q13740	3	105366909-105576900	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Adaptive immunity, Cell adhesion, Immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 122.5"	"Cell type enhanced"	"Detected in many"	14	"Alveolar cells type 1: 684.9;Ciliated cells: 364.1;Club cells: 315.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"myeloid DC: 20.7"	"Lineage enriched"	"Detected in many"	6	"dendritic cells: 20.7"	"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 64.5;U-138 MG: 77.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002148, HPA010926"	Enhanced				"Intracellular and membrane"	NA	NA		1800000000			"CAB002148: AB_442053, HPA010926: AB_1078449"	"unprognostic (6.82e-2)"	"unprognostic (2.66e-1)"	"unprognostic (2.13e-1)"	"unprognostic (2.19e-1)"	"unprognostic (9.48e-3)"	"unprognostic (2.08e-2)"	"unprognostic (1.63e-3)"	"unprognostic (3.89e-2)"	"unprognostic (1.75e-1)"	"unprognostic (4.01e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.07e-1)"	"prognostic favorable (3.15e-4)"	"unprognostic (3.15e-1)"	"unprognostic (4.47e-2)"	"unprognostic (9.57e-2)"	"unprognostic (7.76e-2)"	16.6	14.1	23.6	5.2	31.1	4.2	34.2	4.2	25.3	12.9	8.2	25.0	13.9	7.2	7.0	15.4	4.0	20.6	9.9	4.7	23.2	24.3	9.6	19.4	29.6	4.2	45.1	19.7	24.6	15.3	122.5	11.9	5.3	31.5	14.0	6.6	3.0	17.9	17.5	0.9	5.9	7.3	10.8	35.3	3.0	14.2	2.3	43.8	2.2	25.6	2.7	6.2	9.9	5.5	3.5	20.7	3.7	3.2	0.4	1.6	2.0	38.3	14.8	10.6	5.4	16.2	7.1	0.1	31.4	18.4	20.3	28.5	0.1	8.0	2.7	13.1	44.2	11.2	29.8	1.7	25.0	60.1	2.5	2.6	0.3	11.3	0.7	18.2	15.6	0.1	12.6	18.6	25.9	64.5	56.7	22.2	2.8	0.0	4.6	26.6	2.6	2.2	5.7	2.2	12.4	16.8	1.4	0.9	0.1	30.8	4.3	7.7	21.5	3.2	3.1	2.0	4.4	6.0	10.3	46.1	77.7	26.5	3.3	37.2	0.0	0.0	0.2	17.7	3.3	33.2	0.0	3.2	2.4	0.4	1.5	1.4	3.5	1.1	0.7	20.7	2.2	0.2	0.2	3.7	0.4	0.8	7.4	1.6	2.0	23.6	31.1	4.2	24.6	23.2	24.3	45.1	19.7	31.5	43.8	684.9	108.8	7.2	17.0	10.8	3.0	5.6	61.1	364.1	315.1	15.7	2.0	0.6	1.7	16.4	49.7	10.5	7.5	0.0	36.7	0.6	27.3	97.5	10.5	40.4	60.4	1.6	16.1	3.7	38.7	47.9	3.4	105.6	23.6	140.7	15.0	1.3	39.9	5.8	6.0	23.3	0.5	0.0	19.6	2.1	3.4	17.7	0.7	3.2	9.8	69.3
ALK	CD246	ENSG00000171094	"ALK receptor tyrosine kinase"	Q9UM73	2	29192774-29921566	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 8.1;pituitary gland: 17.9"	"Group enriched"	"Detected in some"	12	"Early spermatids: 36.6;Late spermatids: 30.9"	"Group enriched"	"Detected in some"	5	"glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	6	"SH-SY5Y: 27.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA010694	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA010694: AB_1078133"	"unprognostic (4.96e-2)"	"unprognostic (1.11e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.56e-7)"	"unprognostic (7.17e-2)"	"unprognostic (1.71e-1)"	"unprognostic (9.07e-3)"	"unprognostic (6.29e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.01e-1)"	"unprognostic (2.67e-4)"	"unprognostic (3.70e-2)"	"unprognostic (2.06e-2)"	"unprognostic (7.15e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.38e-1)"	"unprognostic (3.61e-2)"	1.8	3.1	3.6	1.2	4.4	0.3	1.1	0.5	8.1	0.7	2.1	2.0	0.0	0.7	0.5	0.5	0.6	0.5	1.2	0.4	3.4	4.9	0.4	0.5	1.1	0.5	2.7	4.2	0.6	0.4	0.4	17.9	0.5	5.5	0.5	1.2	2.4	0.9	0.8	0.3	0.9	1.5	0.9	2.1	0.5	0.8	4.9	0.9	0.0	1.6	0.0	0.3	0.6	1.2	0.0	0.0	0.0	0.2	0.0	0.7	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	3.6	0.0	0.0	0.1	0.3	27.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	3.2	0.0	4.1	0.0	0.1	0.0	0.7	0.0	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	3.6	4.4	0.5	5.9	3.4	4.9	2.7	4.2	5.5	0.9	0.0	0.0	0.0	0.0	0.0	1.5	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	30.9	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.9	0.2	0.0	0.0	0.0	0.0	0.0
ANPEP	"CD13, gp150, LAP1, p150, PEPN"	ENSG00000166825	"Alanyl aminopeptidase, membrane"	P15144	15	89784889-89815401	"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins"	"Angiogenesis, Differentiation, Host-virus interaction"	"Aminopeptidase, Developmental protein, Host cell receptor for virus entry, Hydrolase, Metalloprotease, Protease, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 195.3;kidney: 78.7;pancreas: 93.9"	"Cell type enhanced"	"Detected in many"	16	"Cholangiocytes: 372.0;Enterocytes: 993.7;Exocrine glandular cells: 328.5;Proximal tubular cells: 388.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in many"	5	"neutrophil: 59.4"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 59.4"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 78.5;BJ: 78.2;BJ hTERT+: 111.8;fHDF/TERT166: 67.0;HMC-1: 71.1;HSkMC: 68.7;HUVEC TERT2: 87.5;TIME: 87.4;U-2197: 95.3"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"CAB002417, HPA004625"	Enhanced		Supported	"Plasma membrane"		NA	NA		1500000000	"Plasma membrane"		"CAB002417: AB_563491, HPA004625: AB_2667199"	"unprognostic (6.31e-2)"	"unprognostic (7.94e-3)"	"unprognostic (6.91e-2)"	"unprognostic (2.16e-1)"	"unprognostic (2.50e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.23e-2)"	"unprognostic (1.89e-1)"	"unprognostic (2.50e-1)"	"unprognostic (7.73e-2)"	"unprognostic (5.28e-3)"	"unprognostic (3.96e-1)"	"unprognostic (4.04e-3)"	"unprognostic (3.20e-2)"	"unprognostic (2.01e-2)"	"unprognostic (4.61e-3)"	"unprognostic (1.99e-2)"	21.3	1.1	0.6	2.9	0.8	9.5	17.0	1.0	1.3	8.2	21.2	0.8	0.5	195.3	1.4	8.4	3.6	1.4	27.7	3.7	0.4	0.3	78.7	37.7	9.7	9.3	0.9	0.9	1.8	93.9	0.0	0.7	14.7	1.3	8.6	4.7	4.0	6.6	1.8	1.6	4.9	155.8	4.3	1.2	7.2	0.8	4.7	0.2	5.6	1.5	4.2	3.8	4.7	3.0	0.0	6.9	59.4	12.8	0.0	0.0	5.5	0.0	5.0	0.0	0.0	61.3	78.5	0.5	78.2	111.8	9.6	8.5	0.5	0.0	0.0	0.9	67.0	0.0	0.0	0.6	0.0	3.8	0.0	0.0	14.7	0.4	11.7	36.1	1.0	71.1	68.7	0.1	30.2	0.0	0.4	87.5	0.0	0.4	0.1	3.7	0.0	0.0	34.7	0.2	0.0	5.3	0.0	0.0	0.8	43.7	0.0	0.1	0.7	0.0	0.1	0.0	0.1	0.0	6.8	87.4	42.2	0.0	95.3	0.0	0.0	0.0	0.0	0.1	0.0	2.2	5.7	12.8	10.4	0.0	7.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	59.4	0.0	12.0	0.1	0.0	5.5	0.6	0.8	1.0	1.3	0.4	0.3	0.9	0.9	1.3	0.2	0.0	4.8	8.2	3.1	8.9	0.0	0.8	372.0	2.7	20.5	19.2	0.0	9.7	36.5	10.6	0.1	1.8	993.7	0.0	328.5	12.0	36.3	18.0	24.2	144.7	39.4	0.0	2.9	101.9	51.7	0.0	2.6	46.4	3.3	39.7	10.5	0.0	120.5	201.5	1.4	388.5	0.0	25.8	5.0	0.4	0.1	5.1	5.4	1.0	18.3	1.3
ART1	"ART2, CD296"	ENSG00000129744	"ADP-ribosyltransferase 1"	P52961	11	3645128-3664416	"CD markers, Enzymes, Predicted membrane proteins"		"Glycosyltransferase, Transferase"		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Group enriched"	"Detected in some"	20	"skeletal muscle: 50.9;tongue: 13.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA051148	Uncertain					NA	NA					"HPA051148: AB_2681363"	"unprognostic (3.73e-1)"							"unprognostic (4.58e-2)"		"unprognostic (3.12e-2)"	"unprognostic (1.35e-1)"	"unprognostic (3.01e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.06e-1)"		"unprognostic (1.73e-1)"		1.5	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.6	0.1	0.0	0.2	0.1	0.1	0.4	0.0	0.3	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.0	0.3	0.2	0.1	50.9	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	13.7	0.5	0.0	0.0	0.5	0.0	0.6	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.3	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.5	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.4	0.1	0.1	0.1	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ART4	"CD297, DO, DOK1"	ENSG00000111339	"ADP-ribosyltransferase 4 (Dombrock blood group)"	Q93070	12	14825569-14843533	"Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins"		"Blood group antigen, Glycosyltransferase, Transferase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 33.7;lymphoid tissue: 17.8;placenta: 17.8"	"Cell type enhanced"	"Detected in many"	20	"Erythroid cells: 93.5;Hepatocytes: 21.3;Ito cells: 55.3"	"Cancer enhanced"	"Detected in some"		"liver cancer: 3.8"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"AN3-CA: 5.2;HEL: 10.3;Hep G2: 6.1;HUVEC TERT2: 23.4"	"Region enhanced"	"Detected in single"		"olfactory region: 2.2"	"Low region specificity"	"Detected in single"			HPA075664			Approved	"Rods & Rings"	"Secreted to blood"	NA	NA		11000000	"Rods & Rings"		"HPA075664: "	"unprognostic (2.50e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.18e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.37e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.90e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.64e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.90e-2)"	"unprognostic (2.62e-3)"	"unprognostic (4.33e-3)"	"unprognostic (1.25e-3)"	"unprognostic (1.05e-1)"	"unprognostic (1.71e-1)"	2.7	2.0	0.2	1.7	0.2	2.4	2.1	0.2	0.2	1.4	1.3	0.1	1.9	0.0	1.1	3.7	3.1	1.9	6.1	10.1	0.2	0.2	6.6	33.7	2.1	17.0	0.2	0.0	1.3	1.9	0.0	0.4	17.8	0.3	0.8	0.2	0.0	0.7	0.4	1.9	0.5	0.8	1.5	0.2	17.8	0.5	1.4	0.0	0.1	4.6	1.3	1.3	1.3	1.2	0.6	0.6	1.4	0.4	0.6	1.3	0.3	0.0	0.0	0.2	5.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.3	0.0	6.1	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.6	0.1	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.4	0.4	0.5	0.3	0.4	0.5	0.3	0.3	0.2	0.6	0.5	1.3	1.4	0.6	0.2	0.6	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.3	0.0	0.0	0.6	0.0	0.8	0.2	1.8	1.4	12.7	0.0	0.0	1.8	11.8	0.1	0.0	0.7	0.4	2.8	0.0	93.5	1.8	1.4	1.9	0.1	0.0	21.3	0.1	0.0	0.0	55.3	7.5	0.0	1.7	0.6	1.7	0.0	0.0	0.2	0.3	0.0	0.0	0.0	12.6	6.5	0.8	0.0	0.0	0.1	0.2	0.0	0.0	0.3
ATP1B3	"CD298, FLJ29027"	ENSG00000069849	"ATPase Na+/K+ transporting subunit beta 3"	P54709	3	141876124-141926514	"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Late spermatids: 712.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB020697, HPA048963"	Enhanced		Supported	"Plasma membrane"		NA	NA		100000	"Plasma membrane"		"CAB020697: , HPA048963: AB_2680574"	"unprognostic (2.31e-1)"	"unprognostic (1.11e-3)"	"unprognostic (2.75e-1)"	"prognostic favorable (5.19e-5)"	"unprognostic (2.60e-2)"	"unprognostic (3.31e-2)"	"prognostic unfavorable (6.32e-6)"	"unprognostic (8.11e-3)"	"unprognostic (6.99e-2)"	"unprognostic (5.37e-3)"	"unprognostic (1.48e-2)"	"unprognostic (1.43e-1)"	"prognostic unfavorable (1.29e-5)"	"unprognostic (5.14e-2)"	"unprognostic (2.04e-1)"	"unprognostic (7.19e-3)"	"unprognostic (6.15e-2)"	50.5	79.9	12.7	26.3	23.3	17.5	105.9	25.7	35.1	17.7	48.2	9.1	16.8	37.3	17.9	14.6	36.9	20.0	47.8	44.0	16.0	18.9	24.9	7.7	44.9	43.4	21.3	12.8	34.7	11.5	6.3	33.8	32.6	43.3	20.5	58.1	23.9	18.4	24.8	7.4	85.4	57.3	24.3	28.4	16.5	13.5	21.1	13.6	14.5	15.6	41.4	18.4	21.9	31.5	10.4	26.8	13.6	60.9	7.8	20.0	22.5	46.4	28.9	27.2	25.5	73.0	21.3	62.3	54.5	49.6	39.7	45.0	44.9	23.4	37.9	49.3	41.4	57.5	102.0	26.9	26.0	45.2	20.6	34.2	33.1	32.5	29.1	28.9	27.2	26.0	22.5	62.3	31.1	30.1	28.4	42.3	26.6	22.7	33.7	40.6	21.1	27.6	45.6	37.8	64.7	13.9	38.0	20.4	38.6	33.3	35.9	22.4	15.3	71.2	33.1	73.1	49.4	25.2	33.2	29.4	34.9	13.4	52.1	31.7	25.1	32.3	61.1	45.5	29.6	28.6	13.6	27.1	8.9	19.2	44.5	14.1	10.4	15.6	20.0	26.8	7.5	9.2	16.7	1.9	7.8	60.9	16.4	16.9	22.5	12.7	23.3	25.7	35.1	16.0	18.9	21.3	12.8	43.3	13.6	53.6	46.5	109.5	333.7	437.8	35.4	16.7	20.4	10.7	43.3	209.3	23.6	255.9	34.9	71.5	391.5	178.3	384.3	140.2	52.8	199.5	109.5	121.1	129.2	6.0	276.1	23.8	53.9	79.8	137.2	712.2	78.6	209.3	210.9	518.4	67.0	42.5	54.6	123.0	64.3	29.8	25.4	122.9	189.2	42.4	191.3	362.3	327.4	66.0	109.6	362.4
BCAM	"CD239, LU"	ENSG00000187244	"Basal cell adhesion molecule (Lutheran blood group)"	P50895	19	44809059-44821421	"Blood group antigen proteins, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Blood group antigen, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 101.8"	"Cell type enhanced"	"Detected in many"	10	"Collecting duct cells: 519.9;Cytotrophoblasts: 537.1;Syncytiotrophoblasts: 362.4"	"Cancer enhanced"	"Detected in all"		"ovarian cancer: 493.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BEWO: 31.4;HaCaT: 64.1;SK-BR-3: 60.2;T-47d: 34.1;U-2 OS: 29.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005654	Enhanced		Approved	"Nucleoli fibrillar center"		NA	NA		16000000	"Nucleoli fibrillar center"		"HPA005654: AB_2667378"	"unprognostic (5.63e-2)"	"unprognostic (2.98e-2)"	"prognostic unfavorable (2.31e-4)"	"prognostic unfavorable (1.24e-5)"	"unprognostic (1.60e-2)"	"unprognostic (1.23e-3)"	"unprognostic (2.01e-1)"	"unprognostic (2.25e-2)"	"unprognostic (1.60e-1)"	"unprognostic (6.17e-2)"	"unprognostic (2.61e-3)"	"unprognostic (1.41e-1)"	"prognostic favorable (5.94e-6)"	"unprognostic (1.83e-2)"	"unprognostic (5.74e-2)"	"unprognostic (2.14e-2)"	"unprognostic (9.97e-3)"	28.9	7.2	4.9	8.1	5.4	1.4	33.1	3.4	8.7	33.5	8.5	4.4	17.8	5.7	24.8	26.5	15.6	46.3	23.2	23.8	4.5	4.2	101.8	13.2	41.6	5.8	4.4	6.5	30.4	17.8	5.8	9.8	28.7	7.0	42.7	2.4	21.4	17.8	27.3	16.7	12.7	7.4	12.5	3.8	14.2	9.6	13.6	2.6	5.7	93.0	23.7	8.5	14.2	30.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	7.2	9.4	0.2	26.2	0.1	0.1	31.4	2.8	1.3	2.3	1.5	14.1	18.0	0.0	14.5	0.3	0.1	64.1	2.3	16.0	0.7	0.0	1.6	0.0	1.9	19.5	5.3	0.0	3.5	2.6	6.2	0.8	0.9	7.5	1.4	0.0	1.5	0.1	0.3	3.7	0.1	0.2	2.9	2.1	3.3	0.1	3.1	0.7	19.6	4.6	0.0	0.1	11.6	60.2	0.7	3.0	34.1	1.0	3.8	0.6	29.5	0.7	1.3	0.1	0.3	0.0	0.2	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	4.9	5.4	3.4	8.7	4.5	4.2	4.4	6.5	7.0	2.6	6.0	10.5	0.5	101.3	36.1	0.6	9.0	38.2	2.7	18.2	519.9	0.0	537.1	69.6	23.4	0.8	63.2	5.1	0.0	3.5	27.0	13.6	65.7	0.0	27.0	38.8	0.0	50.0	39.9	5.9	0.8	27.3	8.0	15.1	0.0	4.7	26.3	14.4	17.5	14.2	123.1	0.5	155.2	124.6	2.2	14.9	21.5	362.4	0.0	10.5	34.4
BMPR1A	"ACVRLK3, ALK3, CD292"	ENSG00000107779	"Bone morphogenetic protein receptor type 1A"	P36894	10	86756601-86932838	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB019398	Approved		Approved	Cytosol		NA	NA			Cytosol		"CAB019398: "	"unprognostic (1.36e-1)"	"unprognostic (2.46e-1)"	"unprognostic (3.34e-1)"	"unprognostic (9.61e-2)"	"unprognostic (1.05e-3)"	"unprognostic (9.34e-2)"	"prognostic unfavorable (8.93e-4)"	"unprognostic (3.64e-1)"	"unprognostic (2.38e-2)"	"unprognostic (1.53e-1)"	"unprognostic (9.24e-2)"	"unprognostic (9.42e-2)"	"unprognostic (4.32e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.01e-2)"	"unprognostic (1.07e-1)"	8.9	7.0	9.4	7.9	12.4	0.9	10.7	14.1	9.2	19.4	20.6	10.9	7.7	6.2	16.3	12.3	8.4	10.9	10.8	11.0	7.7	6.1	8.2	4.6	7.4	2.9	7.3	7.6	16.1	10.6	10.0	14.0	7.4	8.5	12.8	9.3	10.9	12.6	14.2	8.4	11.3	9.8	16.5	12.2	3.4	12.1	7.8	9.2	0.3	19.4	7.8	5.7	16.0	11.4	1.8	1.1	3.6	0.8	0.9	1.4	0.3	7.3	3.7	14.3	12.1	7.5	4.8	2.5	7.4	7.7	4.3	5.1	6.2	6.4	2.2	3.4	9.4	3.1	7.8	6.3	8.0	6.4	2.4	3.6	2.8	3.5	10.3	4.0	3.8	19.7	4.2	3.4	5.8	4.3	6.4	0.0	4.1	4.4	1.5	5.0	3.1	2.6	3.1	7.7	2.6	1.7	0.0	5.6	0.0	8.9	6.9	1.4	4.6	8.2	4.2	4.9	18.2	7.1	1.9	3.7	3.1	5.0	6.4	6.8	0.4	6.8	2.8	2.7	2.6	2.5	2.0	0.8	0.6	1.4	0.5	0.9	1.8	1.4	1.2	0.3	1.5	1.0	1.1	3.6	0.9	0.6	1.1	0.7	0.3	9.4	12.4	14.1	9.2	7.7	6.1	7.3	7.6	8.5	9.2	32.8	24.8	0.0	6.7	10.8	6.0	19.0	10.2	13.4	9.1	10.4	19.6	10.0	1.7	9.8	0.6	2.1	9.0	0.0	8.1	0.7	13.3	12.9	15.0	7.2	2.7	11.1	17.3	8.0	4.0	1.7	31.1	3.5	8.5	1.0	13.6	12.9	7.7	3.5	29.4	4.7	19.0	6.5	14.1	2.3	3.6	8.5	4.2	0.0	10.0	4.2
BMPR1B	"ALK6, CDw293"	ENSG00000138696	"Bone morphogenetic protein receptor type 1B"	O00238	4	94757968-95158448	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Chondrogenesis	"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 28.0;ductus deferens: 25.1;prostate: 25.3;seminal vesicle: 32.0"	"Group enriched"	"Detected in many"	5	"Ciliated cells: 14.7;Club cells: 22.7;Collecting duct cells: 57.6;Glandular cells: 28.8;Intestinal endocrine cells: 17.6;Melanocytes: 27.0;Muller glia cells: 44.8"	"Cancer enhanced"	"Detected in many"		"breast cancer: 32.4;prostate cancer: 24.7"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A549: 18.7;MCF7: 9.4;SH-SY5Y: 15.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (2.25e-1)"	"unprognostic (1.80e-2)"	"unprognostic (1.40e-3)"	"prognostic favorable (2.84e-4)"	"unprognostic (1.57e-1)"	"unprognostic (4.22e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.86e-2)"	"unprognostic (2.95e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.97e-2)"	"unprognostic (3.93e-1)"	"unprognostic (1.62e-3)"	"unprognostic (7.89e-4)"	"unprognostic (6.22e-2)"	"unprognostic (3.81e-3)"	"unprognostic (2.63e-2)"	1.1	5.6	12.7	0.8	15.0	0.7	1.7	11.6	12.7	28.0	1.2	5.5	25.1	0.7	5.3	3.2	1.1	14.3	3.4	1.3	13.4	5.9	9.3	1.4	2.4	0.5	5.4	8.6	7.6	1.7	0.6	2.4	1.2	12.1	25.3	0.8	0.7	1.4	32.0	3.3	1.4	0.6	1.2	7.5	1.4	2.8	4.3	11.2	10.8	0.8	0.1	0.6	0.7	0.7	0.4	0.5	1.9	0.9	0.8	1.6	0.3	0.0	18.7	5.0	0.0	2.0	4.6	0.1	0.1	0.0	0.1	0.4	0.0	0.1	0.0	0.2	0.8	0.0	1.0	2.9	6.9	0.0	0.0	4.6	0.0	1.1	0.0	0.5	0.4	0.0	2.8	7.6	2.8	5.7	0.3	0.0	0.0	0.0	0.0	7.2	9.4	0.6	0.1	1.8	0.1	3.2	0.1	2.8	0.1	3.6	0.1	0.2	15.6	0.2	2.5	2.5	0.7	1.9	0.0	0.0	4.0	3.2	0.1	3.4	0.0	0.0	0.0	1.5	0.0	0.4	1.9	0.3	0.5	0.4	0.5	0.7	0.4	0.6	0.3	0.3	0.3	0.5	0.5	0.8	0.8	0.9	0.5	1.6	0.3	12.7	15.0	11.6	11.8	13.4	5.9	5.4	8.6	12.1	11.2	6.0	0.0	0.0	1.3	2.4	0.2	3.6	5.1	14.7	22.7	57.6	0.0	0.0	1.7	2.9	1.1	0.3	0.0	0.0	0.3	0.2	1.4	28.8	0.0	0.0	0.1	0.0	17.6	4.9	0.0	1.6	2.8	0.3	27.0	0.0	0.0	44.8	0.7	0.0	3.5	0.0	1.2	0.0	1.4	1.6	1.3	1.9	0.0	0.0	0.0	1.0
BSG	"CD147, EMMPRIN, OK"	ENSG00000172270	"Basigin (Ok blood group)"	P35613	19	571277-583493	"Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"Blood group antigen"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Cytotrophoblasts: 1238.9;Syncytiotrophoblasts: 1384.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB002427, HPA036048, HPA074870"	Enhanced		Approved	Vesicles		NA	NA		3400000	Vesicles		"CAB002427: AB_563501, HPA036048: AB_2674917, HPA074870: AB_2686719"	"unprognostic (1.88e-1)"	"unprognostic (4.85e-2)"	"unprognostic (9.53e-3)"	"prognostic favorable (2.59e-4)"	"unprognostic (3.34e-1)"	"unprognostic (1.38e-2)"	"prognostic unfavorable (5.48e-6)"	"unprognostic (1.54e-3)"	"unprognostic (1.55e-1)"	"unprognostic (9.46e-2)"	"unprognostic (4.48e-3)"	"unprognostic (2.61e-2)"	"prognostic favorable (1.95e-6)"	"unprognostic (1.22e-1)"	"unprognostic (1.03e-1)"	"unprognostic (7.30e-2)"	"unprognostic (3.22e-1)"	53.0	74.8	60.0	33.3	73.0	86.3	42.3	36.2	103.0	41.7	93.4	57.8	37.3	50.1	56.0	62.2	35.1	48.8	52.0	205.8	58.5	45.9	78.5	39.1	36.1	22.6	57.6	44.0	51.3	64.2	28.2	48.2	96.2	57.9	49.5	39.6	109.4	44.0	48.4	97.4	38.1	45.5	52.9	34.9	28.3	63.9	76.8	30.4	31.8	61.9	45.9	31.2	48.5	31.5	22.0	43.8	89.4	58.7	30.9	44.5	65.5	63.3	85.6	40.8	91.7	121.6	52.3	86.8	52.8	66.0	63.7	55.5	68.2	68.7	22.7	61.3	47.7	17.4	103.5	41.4	64.1	22.1	47.7	88.7	15.6	72.4	92.2	76.9	37.7	73.6	54.4	65.1	36.6	40.9	76.8	45.7	21.3	73.5	107.6	37.4	113.8	27.4	72.3	95.8	41.1	43.8	55.2	33.4	74.9	75.3	47.6	63.4	57.6	109.6	44.2	78.3	38.1	46.4	116.6	50.2	61.2	38.9	101.3	79.6	69.4	69.8	21.6	116.0	52.3	75.7	32.0	58.7	62.0	44.5	45.2	39.5	22.0	30.2	42.6	39.9	18.3	23.1	29.1	89.4	30.9	48.3	43.8	35.1	65.5	60.0	73.0	36.2	103.0	58.5	45.9	57.6	44.0	57.9	30.4	20.8	26.9	96.8	148.3	185.3	141.6	73.6	104.4	61.6	43.3	272.2	192.4	1238.9	124.3	507.3	196.9	200.0	714.8	607.3	327.4	909.7	249.5	169.5	116.3	84.7	379.2	131.9	245.0	132.0	136.1	473.6	278.2	146.3	480.8	346.3	224.4	452.0	369.5	480.7	316.4	241.2	167.7	200.5	269.3	259.3	553.8	137.0	1384.0	132.0	328.6	155.8
BST1	CD157	ENSG00000109743	"Bone marrow stromal cell antigen 1"	Q10588	4	15702950-15738313	"CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Hydrolase, Transferase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 59.5;bone marrow: 54.9;intestine: 61.3"	"Cell type enhanced"	"Detected in many"	6	"Hofbauer cells: 39.0;Kupffer cells: 36.4;Macrophages: 29.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 52.7;neutrophil: 59.5"	"Group enriched"	"Detected in many"	105	"dendritic cells: 16.6;granulocytes: 59.5;monocytes: 52.7"	"Cell line enhanced"	"Detected in many"		"THP-1: 37.1;TIME: 20.4;U-937: 24.2;WM-115: 22.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA050121	Uncertain				"Intracellular and membrane"	NA	NA		170000000			"HPA050121: AB_2681025"	"unprognostic (2.95e-1)"	"unprognostic (3.61e-1)"	"unprognostic (1.27e-1)"	"unprognostic (4.00e-2)"	"unprognostic (7.49e-2)"	"unprognostic (2.89e-1)"	"unprognostic (4.55e-2)"	"unprognostic (2.70e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.08e-1)"	"unprognostic (4.06e-2)"	"unprognostic (4.83e-3)"	"unprognostic (1.94e-3)"	"unprognostic (3.11e-1)"	"unprognostic (1.57e-2)"	"unprognostic (1.95e-1)"	14.3	2.0	1.1	5.6	2.0	54.9	6.6	0.8	1.5	7.2	33.8	1.5	2.1	20.4	6.4	7.0	4.6	5.6	10.3	14.5	1.8	0.8	6.6	3.7	9.4	9.6	1.3	1.9	5.5	1.0	0.4	1.3	8.0	1.3	7.5	4.0	5.4	2.8	2.2	3.4	3.5	61.3	7.9	1.5	13.6	2.4	2.4	1.2	2.8	3.5	2.9	1.8	7.5	16.1	0.4	16.6	59.5	52.7	0.1	0.3	19.6	0.2	5.5	0.5	0.4	13.5	3.2	0.7	10.5	1.0	9.6	10.8	0.1	5.7	0.3	0.9	5.3	0.2	0.1	1.5	0.2	8.2	0.3	0.2	2.5	0.3	0.2	3.4	3.3	7.3	2.7	0.7	6.1	0.5	0.4	1.5	2.3	0.3	0.2	5.6	0.1	1.0	1.9	1.2	0.4	1.1	0.3	0.7	0.2	0.3	0.3	0.7	2.1	0.2	0.3	7.0	0.5	0.2	37.1	20.4	0.3	0.5	3.7	0.4	0.2	0.0	0.3	1.3	24.2	22.1	7.6	52.7	3.9	0.2	19.8	0.3	0.4	0.1	0.1	16.6	0.2	0.2	0.1	59.5	0.1	13.6	5.5	0.2	19.6	1.1	2.0	0.8	1.5	1.8	0.8	1.3	1.9	1.3	1.2	3.0	3.0	0.0	0.8	4.0	0.2	0.8	5.1	2.7	1.2	1.8	0.0	14.0	1.7	4.1	2.7	2.1	3.2	0.0	2.3	18.7	18.6	0.5	16.1	1.8	39.0	0.0	1.2	3.7	36.4	0.7	2.8	29.9	13.5	0.0	7.0	0.3	0.8	7.0	2.1	6.7	0.0	6.5	10.8	2.3	1.2	2.6	5.9	0.0	16.6	2.7
BST2	"CD317, tetherin"	ENSG00000130303	"Bone marrow stromal cell antigen 2"	Q10589	19	17402939-17405648	"CD markers, Plasma proteins, Predicted membrane proteins"	"Antiviral defense, B-cell activation, Immunity, Innate immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ovary: 101.0"	"Cell type enhanced"	"Detected in many"	5	"Hofbauer cells: 338.9;Ito cells: 362.2;Leydig cells: 321.0;Peritubular cells: 394.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+ SV40 Large T+ RasG12V: 79.0;Karpas-707: 76.6"									HPA017060	Enhanced		Supported	"Golgi apparatus,Plasma membrane,Cytosol"		NA	NA			"Golgi apparatus, Plasma membrane, Cytosol"		"HPA017060: AB_1845467"	"prognostic favorable (6.69e-4)"	"unprognostic (1.75e-1)"	"unprognostic (8.42e-3)"	"unprognostic (8.93e-3)"	"unprognostic (4.87e-2)"	"unprognostic (2.25e-1)"	"unprognostic (2.26e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.25e-1)"	"unprognostic (6.46e-2)"	"unprognostic (6.56e-3)"	"unprognostic (1.64e-1)"	"prognostic unfavorable (3.56e-9)"	"unprognostic (1.05e-1)"	"prognostic unfavorable (4.22e-4)"	"unprognostic (1.08e-1)"	"unprognostic (2.46e-2)"	29.6	72.2	8.4	31.1	9.8	13.6	27.9	2.5	7.6	14.4	12.0	5.6	24.8	6.9	13.4	36.7	8.6	26.8	30.1	13.9	7.9	4.9	24.7	30.8	44.9	16.6	10.0	5.2	101.0	6.9	0.3	8.6	31.5	8.8	15.6	4.8	8.4	11.4	17.5	6.0	3.2	14.0	11.3	9.0	32.9	12.3	8.5	9.4	10.3	10.3	5.9	12.3	14.0	42.4	26.2	74.1	35.8	66.4	57.9	32.6	54.5	39.6	0.0	0.1	18.3	0.0	0.1	6.3	0.1	3.1	58.6	79.0	18.6	35.8	30.8	43.3	24.4	1.8	0.1	26.7	2.9	1.8	33.9	0.2	0.4	64.3	18.1	33.6	14.5	39.0	0.1	0.0	19.4	0.0	0.5	14.9	0.7	17.5	76.6	0.0	10.9	6.9	25.4	20.1	0.0	51.4	12.9	0.1	64.2	13.9	0.1	0.0	0.1	40.5	1.5	48.8	1.6	30.7	20.5	0.1	0.2	1.4	0.0	0.4	39.6	51.6	20.4	0.1	57.4	0.2	35.8	61.6	21.0	32.6	66.4	30.8	21.0	27.5	30.2	50.7	26.2	22.5	25.6	20.3	57.9	59.3	74.1	24.8	54.5	8.4	9.8	2.5	7.6	7.9	4.9	10.0	5.2	8.8	9.4	53.6	16.5	81.0	13.1	29.5	0.0	4.5	50.9	14.7	38.7	47.1	0.0	7.1	31.5	19.8	9.9	239.7	1.6	0.0	1.0	55.9	84.0	7.2	225.9	155.9	338.9	0.0	1.2	362.2	153.7	4.5	321.0	191.2	70.9	239.0	1.4	1.3	2.2	3.5	394.2	0.7	1.9	161.7	150.2	1.4	1.2	22.8	11.0	126.9	2.6	30.3
BTLA	"BTLA1, CD272"	ENSG00000186265	"B and T lymphocyte associated"	Q7Z6A9	3	112463968-112499561	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 37.2;lymphoid tissue: 30.9"	"Cell type enhanced"	"Detected in some"	26	"B-cells: 26.7;Melanocytes: 6.8;T-cells: 5.3"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 22.6;naive B-cell: 37.2"	"Lineage enriched"	"Detected in many"	4	"B-cells: 37.2"	"Cell line enhanced"	"Detected in some"		"ASC diff: 2.5;Daudi: 2.0;JURKAT: 1.3;U-698: 6.3"	"Not detected"	"Not detected"							"HPA047211, HPA062029"	Enhanced					NA	NA					"HPA047211: AB_2679983, HPA062029: AB_2684665"	"unprognostic (1.13e-3)"	"unprognostic (2.13e-3)"	"unprognostic (5.79e-4)"	"unprognostic (1.01e-4)"	"unprognostic (7.08e-2)"	"unprognostic (7.74e-6)"	"unprognostic (6.20e-3)"	"unprognostic (7.59e-3)"	"unprognostic (5.98e-2)"	"unprognostic (1.53e-5)"	"unprognostic (2.33e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.57e-5)"	"unprognostic (2.57e-1)"	"unprognostic (2.46e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.42e-2)"	0.6	0.3	0.3	20.3	0.4	1.2	1.1	0.4	0.3	0.5	1.2	0.1	0.0	0.9	0.4	0.1	2.3	0.5	1.0	0.4	0.3	0.3	1.0	0.5	1.2	30.9	0.3	0.0	0.4	0.3	0.0	0.4	0.3	0.1	0.5	0.9	0.2	5.7	0.4	0.3	0.5	6.0	0.2	0.4	18.6	1.7	0.6	0.0	14.6	0.9	1.1	19.4	2.8	0.5	37.2	8.6	0.1	0.0	0.1	5.1	2.4	0.0	0.0	0.0	0.3	2.5	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	2.0	0.1	0.1	0.1	0.0	0.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.3	0.0	0.0	0.7	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.4	0.4	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	6.3	0.1	0.0	0.0	0.0	0.0	0.0	4.1	0.0	3.1	22.6	5.1	2.4	1.5	37.2	4.8	4.7	0.1	0.1	0.0	8.6	1.1	2.4	0.3	0.4	0.4	0.3	0.3	0.3	0.3	0.0	0.1	0.0	0.0	0.3	26.7	0.0	0.1	0.0	0.1	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.1	0.0	0.1	0.0	0.0	0.6	1.3	3.0	0.0	1.1	6.8	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.3	0.1	5.3	0.0	0.0
BTN3A1	"BT3.1, BTF5, BTN3.1, CD277"	ENSG00000026950	"Butyrophilin subfamily 3 member A1"	O00481	6	26402237-26415216	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"granulocytes: 24.4;T-cells: 37.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"											HPA012565	Approved		Uncertain	Vesicles		NA	NA			Vesicles		"HPA012565: AB_1845494"	"unprognostic (2.82e-2)"	"unprognostic (6.43e-2)"	"unprognostic (1.45e-3)"	"unprognostic (4.72e-3)"	"unprognostic (1.41e-2)"	"unprognostic (1.42e-1)"	"unprognostic (3.10e-2)"	"unprognostic (9.31e-2)"	"unprognostic (9.81e-2)"	"unprognostic (8.60e-3)"	"unprognostic (1.19e-1)"	"unprognostic (2.41e-1)"	"prognostic unfavorable (4.15e-5)"	"unprognostic (2.45e-1)"	"unprognostic (5.02e-2)"	"unprognostic (3.26e-2)"	"prognostic favorable (4.81e-4)"	11.3	14.3	6.7	33.5	5.4	10.3	10.2	10.7	5.9	18.5	14.9	10.0	10.1	11.5	22.3	14.1	13.1	9.6	16.5	9.0	5.3	6.1	9.7	11.4	29.9	24.1	7.1	5.4	15.5	9.4	5.6	11.2	8.5	7.8	17.9	12.1	12.3	16.7	10.0	4.8	9.7	20.6	10.2	9.0	45.2	12.5	4.9	6.7	16.5	8.5	9.8	32.9	11.6	12.9	9.8	4.4	17.4	5.9	18.4	23.4	12.1	3.7	3.2	4.7	4.8	13.6	14.5	0.5	3.0	12.0	6.9	20.3	0.1	8.1	9.7	10.6	5.5	10.8	2.5	1.5	4.8	4.0	9.5	3.3	5.1	3.9	2.2	6.1	4.7	4.7	7.8	2.7	6.0	2.7	10.5	9.7	15.7	1.2	12.7	2.8	0.3	8.5	2.9	0.5	1.6	1.0	11.8	2.1	22.0	4.2	4.7	2.5	5.0	1.7	3.6	6.8	0.7	3.3	1.9	2.4	5.3	1.3	1.5	2.9	21.7	22.1	3.5	8.1	10.6	4.0	17.4	5.3	13.5	23.4	5.7	20.9	9.8	14.6	21.7	4.4	5.3	12.7	16.8	11.9	18.4	5.9	2.1	16.9	12.1	6.7	5.4	10.7	5.9	5.3	6.1	7.1	5.4	7.8	6.7	14.9	6.2	15.4	3.5	3.8	4.3	3.5	7.6	5.3	11.4	5.2	0.0	4.5	0.0	5.4	0.1	11.3	9.1	0.0	2.9	3.6	6.6	5.3	24.4	3.4	6.9	0.0	4.6	10.4	11.8	0.4	3.4	8.3	1.7	2.8	14.6	2.9	2.4	7.0	2.5	1.2	0.4	0.0	3.3	0.0	0.1	2.9	1.3	37.4	6.8	4.2
C5AR1	"C5A, C5AR, C5R1, CD88"	ENSG00000197405	"Complement C5a receptor 1"	P21730	19	47290023-47322066	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	Chemotaxis	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 75.8"	"Cell type enhanced"	"Detected in many"	15	"Hofbauer cells: 131.1;Kupffer cells: 223.6;Macrophages: 162.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 75.8"	"Group enriched"	"Detected in many"	42	"granulocytes: 75.8;monocytes: 20.5"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 6.0;HMC-1: 7.5;U-87 MG: 9.0;U-937: 9.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002720, HPA014520, HPA048012"	Approved		Approved	"Golgi apparatus,Vesicles"		NA	NA			"Golgi apparatus"	Vesicles	"CAB002720: , HPA014520: AB_1846337, HPA048012: "	"unprognostic (5.95e-2)"	"prognostic favorable (4.71e-4)"	"unprognostic (1.70e-2)"	"unprognostic (1.25e-1)"	"unprognostic (4.08e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.80e-2)"	"unprognostic (4.41e-2)"	"unprognostic (5.45e-2)"	"prognostic unfavorable (9.55e-4)"	"unprognostic (2.02e-1)"	"unprognostic (9.56e-2)"	"prognostic unfavorable (1.16e-4)"	"unprognostic (1.96e-3)"	"prognostic unfavorable (7.99e-4)"	"unprognostic (1.82e-2)"	"unprognostic (6.54e-2)"	33.7	8.0	1.9	34.9	7.0	46.2	8.7	0.7	3.0	5.6	6.0	3.7	1.6	1.0	4.1	4.9	3.5	14.3	16.5	11.7	7.6	3.2	5.3	9.1	38.1	26.9	3.8	1.2	7.6	3.6	1.3	27.9	12.8	10.9	4.2	1.9	7.8	2.9	1.1	7.0	1.1	3.0	11.4	11.2	48.8	4.2	6.3	1.3	2.3	2.5	1.7	3.4	12.2	2.7	0.1	1.1	75.8	20.5	0.1	0.1	2.6	1.4	5.4	0.3	0.5	1.0	0.4	1.1	1.0	0.6	0.3	0.1	0.2	6.0	0.5	1.1	1.2	0.7	2.0	0.7	0.8	0.2	1.0	0.7	0.2	5.0	0.8	0.7	2.7	7.5	0.8	3.0	0.6	0.9	0.9	0.0	0.3	0.3	2.6	0.2	1.5	0.3	3.4	1.9	0.3	0.9	0.3	0.2	0.4	1.8	1.3	0.0	0.1	0.5	0.6	0.8	0.9	0.4	3.1	0.0	0.1	3.2	0.4	0.3	0.4	0.4	0.3	9.0	9.1	0.3	7.0	8.9	6.9	0.1	15.1	0.0	0.0	0.0	0.0	1.1	0.1	0.0	0.0	75.8	0.1	20.5	0.2	0.0	2.6	1.9	7.0	0.7	3.0	7.6	3.2	3.8	1.2	10.9	1.3	3.0	33.4	11.3	0.6	4.5	0.8	2.0	2.5	52.2	26.1	1.8	2.0	0.8	3.3	0.0	0.6	1.7	1.1	0.0	0.0	0.9	2.6	0.5	23.3	3.4	131.1	0.0	0.0	3.1	223.6	0.0	0.6	162.7	5.0	14.4	0.7	0.4	0.1	0.0	0.0	1.1	4.2	12.9	1.7	0.5	1.1	2.6	1.3	0.0	0.9	0.3
CCR1	"CD191, CKR-1, CMKBR1, MIP1aR, SCYAR1"	ENSG00000163823	"C-C motif chemokine receptor 1"	P32246	3	46201709-46208396	"CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 34.0;lymphoid tissue: 40.2"	"Group enriched"	"Detected in many"	17	"Extravillous trophoblasts: 72.1;Hofbauer cells: 97.6;Kupffer cells: 150.1;Macrophages: 66.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Karpas-707: 78.3;RPMI-8226: 36.0;U-266/70: 13.8;U-266/84: 40.5"					"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (3.95e-1)"	"unprognostic (2.17e-1)"	"unprognostic (1.20e-1)"	"unprognostic (2.16e-1)"	"unprognostic (1.05e-1)"	"unprognostic (6.66e-2)"	"unprognostic (1.16e-1)"	"unprognostic (8.82e-2)"	"unprognostic (4.91e-3)"	"unprognostic (2.20e-3)"	"unprognostic (1.09e-1)"	"unprognostic (9.60e-2)"	"prognostic unfavorable (1.01e-4)"	"unprognostic (1.08e-1)"	"unprognostic (5.52e-3)"	"unprognostic (1.47e-1)"	"unprognostic (2.38e-1)"	21.2	6.0	5.1	23.8	8.4	11.2	4.9	1.0	3.7	1.9	2.9	7.2	0.5	3.9	2.0	5.1	2.0	4.5	6.7	4.1	5.4	3.2	4.4	9.6	11.6	26.3	9.0	1.6	2.8	2.3	1.0	2.6	14.9	6.9	2.3	4.1	2.9	3.3	1.3	1.4	1.4	4.5	8.5	11.6	40.2	2.9	1.2	8.7	2.2	1.8	1.0	5.5	6.9	1.5	0.9	15.3	32.5	34.0	22.1	15.3	11.8	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	78.3	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	36.0	0.0	1.3	0.0	0.0	0.0	0.1	0.3	0.2	0.0	8.2	0.0	0.2	0.0	0.0	0.0	13.8	40.5	0.0	7.0	6.1	0.1	21.5	34.0	6.8	3.1	21.4	15.3	0.9	0.0	2.5	15.3	0.0	0.0	0.4	32.5	22.1	13.1	5.5	0.0	11.8	5.1	8.4	1.0	3.3	5.4	3.2	9.0	1.6	6.9	8.7	3.0	4.0	5.4	0.0	0.8	0.0	0.4	0.0	2.7	2.3	0.0	0.0	0.6	1.7	0.0	0.2	0.5	0.0	0.0	0.0	72.1	1.5	0.0	3.5	0.8	97.6	0.0	0.0	2.5	150.1	0.0	0.0	66.6	5.0	0.0	0.0	0.4	0.1	0.0	0.0	2.4	0.0	0.0	0.3	0.0	0.0	1.5	2.4	5.7	0.0	0.0
CCR2	"CC-CKR-2, CD192, CKR2, CMKBR2, FLJ78302, MCP-1-R"	ENSG00000121807	"C-C motif chemokine receptor 2"	P41597	3	46353734-46360928	"CD markers, G-protein coupled receptors, Predicted membrane proteins"	"Host-virus interaction, Inflammatory response"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 96.3;lymphoid tissue: 36.1"	"Cell type enriched"	"Detected in some"	6	"Kupffer cells: 61.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in many"		"basophil: 96.3"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Karpas-707: 48.6;THP-1: 23.0;U-266/70: 111.8;U-266/84: 44.5"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in single"			CAB003793	Approved					NA	NA					"CAB003793: AB_344889"	"unprognostic (1.09e-2)"	"unprognostic (6.28e-4)"	"unprognostic (3.49e-2)"	"unprognostic (6.35e-4)"	"unprognostic (1.89e-2)"	"unprognostic (4.16e-4)"	"unprognostic (8.06e-2)"	"prognostic favorable (5.87e-4)"	"unprognostic (6.33e-2)"	"unprognostic (3.27e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.56e-1)"	"unprognostic (5.52e-3)"	"unprognostic (1.29e-1)"	"unprognostic (3.35e-2)"	"unprognostic (4.88e-2)"	"unprognostic (4.19e-1)"	2.5	1.3	0.6	20.7	0.8	0.9	1.9	0.5	0.8	4.3	5.8	0.5	1.5	5.6	2.6	2.4	6.1	2.2	2.5	1.8	0.6	0.6	3.7	1.8	8.6	30.1	1.6	0.1	1.7	1.7	0.0	0.8	2.1	1.8	3.7	4.0	2.6	10.2	3.5	0.8	1.3	7.3	5.6	1.5	36.1	3.7	1.5	0.5	3.6	2.0	3.5	5.9	5.8	1.7	1.6	29.0	96.3	28.4	2.5	19.3	13.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	48.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	23.0	0.0	0.0	0.0	0.0	0.0	111.8	44.5	0.0	0.0	0.8	0.0	96.3	28.4	0.4	2.5	2.6	19.3	1.6	5.2	4.2	29.0	0.3	0.1	0.1	0.7	2.5	0.0	23.0	2.3	13.5	0.6	0.8	0.5	0.8	0.6	0.6	1.6	0.1	1.8	0.5	0.0	2.2	7.8	0.0	0.2	0.0	0.3	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.8	0.0	0.0	3.1	61.3	0.4	0.0	10.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0
CCR3	"CC-CKR-3, CD193, CKR3, CMKBR3"	ENSG00000183625	"C-C motif chemokine receptor 3"	P51677	3	46163604-46266706	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	"Host-virus interaction"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	25	"blood: 175.9"	"Cell type enhanced"	"Detected in some"	17	"granulocytes: 1.1;Melanocytes: 1.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	22	"basophil: 175.9;eosinophil: 152.0"	"Lineage enriched"	"Detected in many"	92	"granulocytes: 175.9"	"Cell line enriched"	"Detected in some"	9	"RPMI-8226: 25.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB003795, HPA069514"	Uncertain		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB003795: AB_562259, HPA069514: "	"unprognostic (1.56e-2)"	"unprognostic (6.65e-3)"	"unprognostic (1.01e-1)"	"unprognostic (3.98e-2)"	"unprognostic (1.41e-1)"	"unprognostic (3.25e-3)"	"unprognostic (3.11e-7)"	"unprognostic (4.36e-2)"	"unprognostic (3.35e-2)"	"unprognostic (3.43e-2)"	"unprognostic (4.81e-2)"	"unprognostic (3.94e-2)"	"unprognostic (3.17e-6)"	"unprognostic (1.35e-2)"	"unprognostic (1.72e-2)"	"unprognostic (2.41e-1)"	"unprognostic (9.81e-2)"	0.6	0.2	0.3	2.9	1.1	0.4	0.3	0.2	0.8	0.3	1.3	0.2	0.2	2.9	0.8	0.2	0.4	0.5	1.3	0.3	0.2	0.2	0.5	1.2	5.8	0.6	0.3	0.2	0.2	0.3	0.0	0.3	7.0	0.7	1.0	1.4	0.9	2.4	0.2	3.2	3.6	5.1	1.6	0.5	2.7	2.2	0.4	0.2	0.6	1.8	2.8	0.6	4.0	0.3	0.0	0.2	175.9	0.0	0.0	1.9	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.7	2.3	0.0	0.7	0.0	0.8	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.4	0.1	0.3	0.1	0.0	0.0	0.2	0.0	25.5	0.0	2.1	0.1	0.0	0.0	0.7	0.0	0.8	0.0	0.6	0.0	0.1	0.2	0.0	0.1	2.8	2.2	0.0	0.0	0.5	0.0	175.9	0.0	152.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.2	1.9	0.3	0.3	1.1	0.2	0.8	0.2	0.2	0.3	0.2	0.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	1.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0
CCR4	"CC-CKR-4, CD194, ChemR13, CKR4, CMKBR4, k5-5"	ENSG00000183813	"C-C motif chemokine receptor 4"	P51679	3	32951574-32956349	"CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	5	"blood: 28.9;lymphoid tissue: 57.1"	"Cell type enhanced"	"Detected in some"	15	"Ciliated cells: 1.4;granulocytes: 2.3;Horizontal cells: 4.8;T-cells: 2.2"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	5	"T-reg: 28.9"	"Lineage enriched"	"Detected in single"	48	"T-cells: 28.9"	"Cell line enriched"	"Detected in some"	17	"HDLM-2: 67.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA031613	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA031613: AB_10601096"	"unprognostic (4.63e-3)"	"unprognostic (8.70e-3)"	"unprognostic (2.82e-3)"	"unprognostic (2.64e-3)"	"unprognostic (1.18e-1)"	"unprognostic (4.59e-7)"	"unprognostic (3.02e-1)"	"unprognostic (5.05e-3)"	"unprognostic (1.53e-2)"	"unprognostic (1.69e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.17e-1)"	"unprognostic (9.88e-3)"	"unprognostic (2.04e-1)"	"unprognostic (5.53e-4)"	"unprognostic (1.54e-1)"	"unprognostic (1.40e-1)"	1.5	0.6	0.3	12.6	0.4	1.5	1.1	0.3	0.3	1.1	1.1	0.1	0.7	0.4	1.0	0.6	1.6	0.8	3.8	0.8	0.3	0.3	1.8	0.9	6.0	24.1	0.3	0.0	0.5	0.5	0.5	0.5	0.1	0.1	1.5	1.2	0.8	4.3	0.2	1.8	2.2	5.0	0.4	0.4	10.2	1.3	2.7	0.0	57.1	1.3	2.8	29.7	8.6	1.1	0.2	0.2	0.5	0.1	0.1	28.9	0.8	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	67.1	0.0	4.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	1.9	1.0	0.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.1	0.1	0.2	0.1	0.2	0.1	6.0	1.8	0.0	0.2	0.1	0.1	0.5	0.1	0.1	0.2	28.9	0.8	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.0	0.1	0.0	0.0	1.1	0.0	0.5	0.3	0.1	0.3	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.5	2.3	0.0	0.1	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.0	1.0	0.1	0.0	2.2	0.0	0.4
CCR5	"CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22"	ENSG00000160791	"C-C motif chemokine receptor 5 (gene/pseudogene)"	P51681	3	46370854-46376206	"CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"	"Host-virus interaction"	"G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer"	"Diabetes mellitus, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 24.5"	"Cell type enhanced"	"Detected in some"	17	"Hofbauer cells: 4.9;Kupffer cells: 4.1;Macrophages: 16.2;T-cells: 13.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 24.5"	"Lineage enriched"	"Detected in many"	4	"T-cells: 24.5"	"Cell line enhanced"	"Detected in some"		"JURKAT: 2.5;Karpas-707: 12.0;U-266/84: 5.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (4.32e-3)"	"unprognostic (1.94e-3)"	"unprognostic (1.89e-3)"	"prognostic favorable (7.42e-5)"	"unprognostic (1.80e-2)"	"prognostic favorable (9.33e-5)"	"unprognostic (3.38e-3)"	"unprognostic (9.90e-3)"	"unprognostic (7.65e-2)"	"unprognostic (6.22e-2)"	"unprognostic (1.36e-1)"	"unprognostic (5.34e-2)"	"unprognostic (1.14e-3)"	"unprognostic (8.34e-2)"	"unprognostic (4.69e-2)"	"unprognostic (3.14e-2)"	"unprognostic (2.42e-2)"	7.1	2.3	3.4	13.8	6.1	0.8	2.1	0.8	2.5	2.3	3.0	3.0	0.8	3.8	3.7	4.0	2.6	2.6	5.0	3.6	1.6	2.0	2.7	3.0	9.3	11.9	8.1	0.5	3.0	2.1	0.4	1.9	1.2	4.0	2.8	3.8	3.5	4.4	2.5	0.8	1.1	7.2	2.9	6.1	14.6	6.0	0.9	5.9	2.0	2.6	1.5	13.9	5.7	2.0	0.3	5.5	5.6	2.1	3.2	24.5	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	12.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.2	0.0	0.0	0.0	0.0	0.4	5.1	0.0	0.0	0.3	0.0	5.6	1.1	0.0	6.7	2.1	24.5	0.3	2.9	9.7	5.5	0.0	0.3	2.6	0.3	3.2	0.0	5.2	4.5	1.5	3.4	6.1	0.8	2.5	1.6	2.0	8.1	0.5	4.0	5.9	0.0	1.7	0.9	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.1	0.2	4.9	0.0	0.0	1.3	4.1	0.0	0.0	16.2	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	13.1	0.0	0.0
CCR6	"BN-1, CD196, CKR-L3, CMKBR6, DCR2, DRY-6, GPR-CY4, GPR29, STRL22"	ENSG00000112486	"C-C motif chemokine receptor 6"	P51684	6	167111807-167139696	"CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 30.7;intestine: 9.9;lymphoid tissue: 33.7"	"Cell type enhanced"	"Detected in many"	11	"B-cells: 21.0;Late spermatids: 20.6;T-cells: 11.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	4	"MAIT T-cell: 30.7;memory B-cell: 23.8;memory CD4 T-cell: 11.9;naive B-cell: 28.2;T-reg: 20.9"	"Group enriched"	"Detected in many"	5	"B-cells: 28.2;T-cells: 30.7"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 2.6;Hep G2: 14.1;OE19: 4.9"	"Region enriched"	"Detected in single"	8	"basal ganglia: 0.9"	"Not detected"	"Not detected"			"CAB006820, HPA014488"	Approved					NA	NA					"CAB006820: , HPA014488: AB_1846639"	"unprognostic (1.12e-2)"	"unprognostic (2.92e-2)"	"unprognostic (2.07e-3)"	"unprognostic (2.08e-1)"	"unprognostic (8.43e-2)"	"unprognostic (2.05e-4)"	"unprognostic (2.39e-1)"	"unprognostic (4.98e-3)"	"unprognostic (1.29e-1)"	"unprognostic (1.40e-1)"	"unprognostic (4.19e-2)"	"unprognostic (4.26e-2)"	"unprognostic (2.68e-4)"	"unprognostic (3.74e-2)"	"unprognostic (7.96e-2)"	"unprognostic (2.26e-1)"	"unprognostic (1.77e-1)"	0.5	0.3	1.0	24.4	1.5	1.3	1.1	0.3	1.1	0.6	3.0	0.1	0.0	1.4	0.3	0.8	2.1	0.5	3.1	0.3	0.9	0.9	1.0	0.5	3.3	27.3	0.6	0.0	0.3	0.3	0.0	0.4	0.5	0.2	0.5	1.2	0.3	5.0	0.8	0.3	1.1	9.9	0.0	0.4	23.4	2.2	2.7	0.1	3.7	0.6	2.1	33.7	4.8	0.4	28.2	5.4	0.2	0.0	0.4	30.7	2.5	0.1	0.2	0.2	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.5	0.2	1.3	0.3	0.0	0.0	0.0	0.3	0.2	0.1	2.6	0.7	0.1	0.3	14.1	0.0	0.7	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.1	0.3	0.0	0.0	0.1	0.2	0.1	4.9	0.0	0.2	0.2	0.2	0.4	0.0	0.8	0.4	0.0	0.0	0.1	0.4	0.0	0.1	0.0	0.0	0.8	0.1	0.3	0.5	0.3	0.4	0.0	0.2	0.6	0.0	0.0	0.1	1.6	0.0	30.7	23.8	11.9	4.7	5.4	28.2	0.1	0.0	0.2	0.4	0.0	0.6	20.9	2.5	1.0	1.5	0.3	1.1	0.9	0.9	0.6	0.0	0.2	0.1	0.0	6.2	21.0	0.3	0.9	0.9	0.0	0.0	1.4	3.4	0.0	2.0	0.0	1.7	0.1	5.7	0.0	0.0	0.0	0.2	0.0	0.7	0.1	2.3	0.8	0.1	0.0	0.0	1.3	0.0	20.6	0.0	5.1	1.7	4.6	0.3	0.4	0.1	0.0	0.4	0.3	3.8	0.0	0.1	2.3	0.4	0.4	0.1	11.4	0.0	0.1
CCR7	"BLR2, CD197, CDw197, CMKBR7, EBI1"	ENSG00000126353	"C-C motif chemokine receptor 7"	P32248	17	40553769-40565472	"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	11	"blood: 252.3;lymphoid tissue: 110.6"	"Cell type enriched"	"Detected in many"	6	"monocytes: 2758.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 252.3"	"Lineage enriched"	"Detected in many"	4	"T-cells: 252.3"	"Cell line enriched"	"Detected in some"	79	"HDLM-2: 175.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB003796, HPA031383, HPA074467"	Enhanced		Enhanced	Mitochondria		NA	NA			Mitochondria		"CAB003796: AB_562261, HPA031383: AB_2673854, HPA074467: AB_2686693"	"prognostic favorable (3.84e-4)"	"prognostic favorable (8.03e-6)"	"unprognostic (2.26e-3)"	"unprognostic (1.32e-3)"	"unprognostic (2.35e-3)"	"prognostic favorable (7.61e-7)"	"unprognostic (2.71e-4)"	"unprognostic (2.58e-2)"	"unprognostic (4.48e-2)"	"unprognostic (4.68e-4)"	"unprognostic (1.10e-2)"	"unprognostic (3.11e-1)"	"unprognostic (1.08e-3)"	"unprognostic (3.12e-1)"	"prognostic unfavorable (7.72e-4)"	"unprognostic (1.02e-1)"	"unprognostic (7.95e-2)"	2.8	0.4	0.2	26.0	0.2	5.2	1.7	0.2	0.3	2.2	1.2	0.3	0.8	0.3	1.2	0.5	1.4	2.3	2.0	1.9	0.2	0.2	1.5	1.7	3.4	110.6	0.3	0.2	1.5	0.3	0.0	1.0	1.0	0.4	1.3	2.1	0.7	8.4	0.2	0.2	1.1	16.2	0.2	0.4	20.3	1.8	1.2	0.3	57.1	2.0	1.2	53.8	4.2	1.3	58.8	2.9	2.3	0.3	44.1	252.3	109.3	0.0	0.1	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	175.7	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.2	0.0	1.0	0.1	1.1	0.2	0.0	0.0	1.1	0.3	0.2	3.1	0.1	3.6	37.2	53.3	15.3	0.2	58.8	252.3	133.9	2.3	44.1	0.2	2.9	30.3	109.3	0.2	0.2	0.2	0.3	0.2	0.2	0.3	0.2	0.4	0.3	0.0	5.9	116.5	1.4	4.4	0.0	0.3	0.0	0.0	2.3	1.8	0.0	111.5	0.0	0.4	0.1	0.1	0.0	0.0	6.9	6.3	3.3	0.0	2.3	0.0	11.3	0.0	0.0	0.0	0.0	0.0	0.0	12.9	15.1	2758.4	0.0	0.7	0.7	0.0	0.0	0.1	0.0	0.0	3.9	0.2	0.5	3.9	432.7	16.2	0.0	3.3
CCR8	"CDw198, CKR-L1, CMKBR8, CMKBRL2, CY6, GPR-CY6, TER1"	ENSG00000179934	"C-C motif chemokine receptor 8"	P51685	3	39329706-39333511	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	7	"blood: 19.8;lymphoid tissue: 19.3;urinary bladder: 5.3"	"Cell type enriched"	"Detected in single"	11	"Alveolar cells type 2: 1.1"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	5	"T-reg: 19.8"	"Lineage enriched"	"Detected in single"	30	"T-cells: 19.8"	"Cell line enriched"	"Detected in some"	22	"HDLM-2: 50.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA042383	Enhanced					NA	NA					"HPA042383: AB_2732497"	"unprognostic (2.16e-1)"	"unprognostic (2.12e-2)"	"unprognostic (2.91e-2)"	"unprognostic (1.04e-1)"	"unprognostic (2.38e-2)"	"unprognostic (7.63e-4)"	"unprognostic (3.31e-1)"	"unprognostic (1.27e-1)"	"unprognostic (2.30e-3)"	"unprognostic (3.37e-2)"	"unprognostic (7.40e-2)"	"unprognostic (2.99e-1)"	"unprognostic (4.65e-8)"	"unprognostic (7.96e-2)"	"unprognostic (2.24e-2)"	"unprognostic (2.56e-1)"	"unprognostic (4.14e-1)"	0.3	0.2	0.2	3.1	0.2	0.0	0.3	0.2	0.2	0.3	0.5	0.1	0.1	0.0	0.3	0.1	0.8	0.1	2.1	0.2	0.2	0.2	0.5	0.3	1.4	2.8	0.1	0.1	0.2	0.3	0.0	0.2	0.1	0.1	0.4	1.3	0.1	0.5	0.1	0.2	1.0	1.2	0.1	0.4	1.7	0.8	0.3	0.1	19.3	0.4	1.2	3.5	5.3	0.3	0.0	0.0	0.0	0.0	0.6	19.8	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.1	1.3	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	1.8	0.0	0.0	0.2	0.0	0.0	0.6	0.0	0.0	19.8	0.6	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CCR9	"CDw199, GPR-9-6, GPR28"	ENSG00000173585	"C-C motif chemokine receptor 9"	P51686	3	45886504-45903177	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	"Host-virus interaction"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	7	"lymphoid tissue: 130.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"memory B-cell: 17.5;naive B-cell: 9.2;T-reg: 5.7"	"Group enriched"	"Detected in many"	42	"B-cells: 17.5;T-cells: 5.7"	"Cell line enriched"	"Detected in single"	50	"MOLT-4: 49.8"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			CAB006839	Uncertain					NA	NA					"CAB006839: "	"unprognostic (3.08e-3)"	"unprognostic (3.37e-1)"	"unprognostic (5.56e-2)"	"unprognostic (1.78e-1)"	"unprognostic (8.65e-3)"	"unprognostic (7.88e-3)"	"unprognostic (4.54e-1)"	"unprognostic (2.94e-2)"	"unprognostic (3.00e-1)"	"unprognostic (1.77e-1)"	"unprognostic (8.06e-2)"	"unprognostic (1.16e-1)"	"unprognostic (2.59e-2)"	"unprognostic (1.88e-1)"	"unprognostic (4.34e-1)"	"unprognostic (2.27e-1)"	"unprognostic (7.20e-3)"	0.1	0.1	0.1	1.8	0.1	0.7	0.1	0.1	0.3	0.1	2.2	0.1	0.1	7.0	0.2	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.4	0.2	0.2	0.8	0.1	0.1	0.1	0.1	0.0	0.2	0.1	0.1	0.1	0.3	0.1	0.1	0.2	0.2	0.1	10.7	0.1	0.2	2.2	0.3	0.1	0.1	130.2	0.1	0.1	0.7	0.1	0.1	17.5	0.2	0.0	0.0	0.0	5.7	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	49.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	17.5	2.2	1.8	0.2	9.2	0.3	0.1	0.0	0.0	0.0	0.2	5.7	1.8	0.1	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
CD101	"IGSF2, V7"	ENSG00000134256	"CD101 molecule"	Q93033	1	117001750-117036476	"CD markers, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 33.7;lung: 17.5"	"Cell type enhanced"	"Detected in some"	9	"Kupffer cells: 6.2;Macrophages: 7.2;Sertoli cells: 6.5;T-cells: 4.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"eosinophil: 33.7"	"Group enriched"	"Detected in many"	17	"dendritic cells: 12.2;granulocytes: 33.7;monocytes: 17.4"	"Cell line enriched"	"Detected in some"	9	"HMC-1: 25.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"HPA049527, HPA057763"	Approved		Uncertain	Mitochondria		NA	NA		42000	Mitochondria		"HPA049527: , HPA057763: AB_2683519"	"unprognostic (1.25e-1)"	"unprognostic (7.95e-3)"	"unprognostic (5.40e-3)"	"unprognostic (4.10e-3)"	"unprognostic (2.62e-1)"	"unprognostic (4.00e-2)"	"unprognostic (3.03e-2)"	"unprognostic (3.58e-3)"	"unprognostic (3.57e-2)"	"unprognostic (7.29e-3)"	"unprognostic (3.15e-1)"	"unprognostic (4.54e-2)"	"unprognostic (7.15e-6)"	"unprognostic (7.00e-2)"	"unprognostic (8.07e-2)"	"unprognostic (5.05e-2)"	"unprognostic (5.28e-2)"	0.9	1.7	0.8	11.3	1.1	5.7	0.8	0.2	1.1	1.3	5.0	0.6	1.2	4.6	1.7	0.4	1.8	1.5	1.4	2.6	1.1	0.5	1.3	0.8	17.5	4.0	1.3	0.2	1.0	2.3	0.0	0.8	0.5	1.1	1.6	3.2	0.7	2.1	1.3	0.5	1.8	10.9	1.6	2.0	7.8	1.8	0.9	1.2	6.4	0.9	2.4	7.4	2.4	1.8	0.1	12.2	33.7	17.4	0.0	1.2	2.5	0.4	0.0	0.9	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.1	1.2	1.9	0.1	0.0	0.0	1.1	0.1	0.8	0.0	0.0	0.1	25.3	0.3	1.3	0.0	0.1	0.2	0.2	0.5	0.1	0.6	0.1	1.5	0.0	2.9	0.8	0.0	0.0	0.0	0.5	0.0	0.6	0.7	0.4	0.6	0.4	0.5	0.3	0.6	0.9	0.6	0.5	0.1	0.4	0.5	0.2	0.2	0.1	0.0	0.7	1.9	1.5	0.0	7.6	33.7	0.1	10.0	0.7	0.1	0.2	1.2	12.2	0.0	0.3	1.2	0.3	0.0	17.4	0.0	1.1	2.5	0.8	1.1	0.2	1.1	1.1	0.5	1.3	0.2	1.1	1.2	0.0	1.4	0.5	0.1	1.1	0.0	0.6	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.3	1.5	0.0	0.0	0.0	0.5	0.0	0.2	0.1	1.1	0.4	0.7	0.0	1.7	0.0	6.2	1.3	0.3	7.2	0.0	0.0	0.0	0.0	0.1	0.0	1.1	0.0	0.0	6.5	0.2	0.0	0.0	1.4	0.0	4.6	0.1	0.1
CD109	"CPAMD7, DKFZp762L1111, FLJ38569"	ENSG00000156535	"CD109 molecule"	Q6YHK3	6	73695785-73828316	"CD markers, Plasma proteins, Predicted membrane proteins"		"Protease inhibitor, Serine protease inhibitor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"parathyroid gland: 203.4"	"Cell type enhanced"	"Detected in many"	6	"Basal keratinocytes: 36.9;Endothelial cells: 28.0;Hofbauer cells: 36.5;Suprabasal keratinocytes: 38.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"myeloid DC: 2.6"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 62.8;BJ hTERT+: 38.5"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA008992, HPA015723"	Enhanced		Supported	"Plasma membrane,Cytosol"		NA	NA		120000000	"Plasma membrane"	Cytosol	"HPA008992: , HPA015723: AB_2732415"	"unprognostic (2.28e-1)"	"unprognostic (1.03e-1)"	"unprognostic (7.76e-2)"	"unprognostic (1.52e-2)"	"unprognostic (9.17e-3)"	"unprognostic (1.36e-1)"	"unprognostic (1.03e-3)"	"unprognostic (1.23e-3)"	"unprognostic (7.49e-2)"	"unprognostic (2.47e-1)"	"unprognostic (1.15e-3)"	"unprognostic (8.81e-2)"	"prognostic unfavorable (2.65e-4)"	"prognostic unfavorable (7.96e-5)"	"unprognostic (9.50e-2)"	"unprognostic (2.02e-1)"	"prognostic unfavorable (4.68e-4)"	27.4	1.5	1.6	1.9	2.2	1.9	6.5	0.4	1.9	15.0	7.1	3.4	2.0	1.5	22.5	8.5	22.4	3.4	2.4	8.2	1.8	1.4	3.5	1.4	14.5	1.4	1.7	1.4	2.8	1.2	203.4	0.6	5.0	3.0	7.1	2.1	0.6	4.2	2.2	4.1	12.4	2.4	12.6	4.5	1.7	1.5	3.3	2.8	6.3	1.7	16.8	4.7	8.7	8.0	0.3	2.6	1.4	0.4	0.6	0.4	0.3	9.4	8.5	0.5	0.0	12.9	62.8	0.0	8.6	38.5	2.8	6.2	0.0	5.5	0.0	5.3	17.7	6.2	26.6	0.9	17.2	3.8	2.6	1.5	3.3	6.9	1.4	2.7	0.0	0.0	17.3	13.7	5.3	21.5	9.9	20.3	1.0	0.0	0.0	12.9	0.2	0.2	0.0	0.6	0.0	5.5	0.7	2.4	11.6	1.2	1.1	0.0	0.0	19.5	0.1	8.4	0.4	0.2	1.5	18.8	26.9	3.7	4.8	7.4	0.1	5.3	0.0	10.8	0.0	23.8	0.6	0.4	0.3	0.2	0.2	0.1	0.2	0.3	0.2	2.6	0.3	0.4	0.2	1.4	0.6	0.2	1.4	0.1	0.3	1.6	2.2	0.4	1.9	1.8	1.4	1.7	1.4	3.0	2.8	3.0	1.7	0.8	6.2	36.9	0.3	11.1	0.0	2.7	12.5	0.0	0.0	0.3	1.7	0.1	18.2	28.0	0.0	0.0	0.0	0.4	7.8	5.8	2.3	0.4	36.5	0.0	0.0	19.0	2.8	17.2	0.6	15.3	21.9	4.6	0.0	0.0	0.3	0.0	0.0	15.9	0.1	0.0	14.6	0.7	3.2	38.1	1.1	2.2	0.0	6.4
CD14		ENSG00000170458	"CD14 molecule"	P08571	5	140631728-140633701	"Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins"	"Immunity, Inflammatory response, Innate immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	4	"blood: 189.4;liver: 165.8"	"Cell type enhanced"	"Detected in many"	25	"Hofbauer cells: 2162.9;Ito cells: 448.7;Kupffer cells: 633.7;Macrophages: 438.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 189.4"	"Group enriched"	"Detected in many"	5	"granulocytes: 52.3;monocytes: 189.4"	"Cell line enhanced"	"Detected in many"		"A549: 9.1;CACO-2: 13.9;SiHa: 16.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001887, HPA002127, CAB033631, CAB072865, CAB072866"	Enhanced		Approved	Vesicles	"Secreted to blood"	NA	NA	2750000000	15000000000	Vesicles		"CAB033631: AB_781932, CAB072865: AB_2665714, CAB072866: AB_2665715, HPA001887: AB_1078442, HPA002127: AB_1078440"	"unprognostic (1.92e-1)"	"unprognostic (1.68e-1)"	"unprognostic (3.42e-3)"	"unprognostic (3.89e-2)"	"unprognostic (3.29e-2)"	"unprognostic (1.54e-1)"	"unprognostic (4.71e-3)"	"unprognostic (4.88e-2)"	"unprognostic (2.16e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.83e-1)"	"unprognostic (2.43e-1)"	"prognostic unfavorable (6.80e-5)"	"unprognostic (1.20e-2)"	"unprognostic (6.87e-3)"	"unprognostic (8.12e-2)"	"unprognostic (6.92e-2)"	27.9	44.1	9.0	42.7	25.2	9.8	11.7	3.5	8.9	5.6	10.0	6.0	1.8	5.4	5.6	24.0	4.5	12.0	14.6	18.9	11.7	7.4	12.7	165.8	23.8	34.7	21.6	2.9	14.2	5.3	4.3	10.1	37.3	18.9	8.5	9.2	14.6	28.5	5.8	10.2	3.5	12.1	21.4	18.2	35.5	6.6	6.5	17.3	2.2	7.9	5.8	6.6	15.9	3.8	0.5	23.6	52.3	189.4	0.2	0.4	124.2	0.1	9.1	0.1	0.6	1.3	0.3	0.5	0.9	4.2	1.3	1.6	13.9	2.2	0.4	0.7	5.0	1.1	3.9	0.0	1.7	0.2	0.1	0.9	0.3	0.5	1.8	4.9	1.0	0.4	4.0	0.2	0.2	1.3	0.4	0.0	0.2	0.2	0.2	1.3	0.3	0.0	0.6	0.2	0.2	0.3	0.3	0.4	1.1	0.2	0.0	2.4	1.0	16.7	0.4	0.5	0.2	0.3	1.7	0.6	0.2	0.3	1.5	1.3	0.7	0.9	0.5	0.4	0.4	0.1	0.4	189.4	1.0	0.3	36.6	0.4	0.5	0.2	0.2	23.6	0.1	0.3	0.2	52.3	0.2	4.8	1.3	0.1	124.2	9.0	25.2	3.5	8.9	11.7	7.4	21.6	2.9	18.9	17.3	8.9	44.2	23.9	3.1	4.5	9.5	2.5	28.1	6.7	6.8	1.8	0.0	15.3	1.7	3.3	1.3	13.8	7.9	0.0	1.6	12.6	12.3	2.2	8.1	323.7	2162.9	31.8	6.9	448.7	633.7	3.2	4.6	438.8	8.5	0.0	4.5	36.9	2.3	8.5	4.9	5.4	3.5	32.3	9.2	0.7	0.9	3.8	38.6	5.9	5.1	3.0
CD151	"PETA-3, RAPH, SFA-1, TSPAN24"	ENSG00000177697	"CD151 molecule (Raph blood group)"	P48509	11	832843-839831	"Blood group antigen proteins, CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	"Host-virus interaction"	"Blood group antigen"	"Deafness, Epidermolysis bullosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 112.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002428, HPA011906"	Supported					NA	NA		680000			"CAB002428: AB_564129, HPA011906: AB_1846245"	"unprognostic (1.50e-1)"	"unprognostic (1.12e-2)"	"unprognostic (5.47e-2)"	"unprognostic (5.45e-3)"	"unprognostic (4.10e-3)"	"unprognostic (2.45e-2)"	"prognostic unfavorable (5.58e-4)"	"prognostic unfavorable (9.46e-4)"	"unprognostic (5.47e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.02e-3)"	"unprognostic (3.31e-1)"	"unprognostic (4.39e-2)"	"unprognostic (6.23e-3)"	"unprognostic (3.24e-1)"	"prognostic favorable (6.92e-4)"	"unprognostic (7.83e-2)"	63.1	28.1	7.4	19.1	8.1	3.4	133.2	7.9	11.3	39.8	36.0	9.5	37.8	23.2	55.7	45.3	43.1	29.3	63.0	85.2	7.3	7.9	52.8	47.2	45.8	16.3	7.5	10.3	29.8	82.7	27.8	14.1	58.6	10.7	52.0	16.5	31.2	62.9	41.1	19.2	17.1	46.0	62.4	6.7	15.8	31.7	20.8	5.5	2.4	43.2	27.1	16.1	35.9	34.9	2.1	8.1	14.9	14.3	5.2	4.8	6.5	38.1	52.9	7.6	22.8	109.5	45.6	11.9	59.8	40.9	30.2	25.6	27.5	54.6	0.0	24.0	89.4	40.3	34.9	6.7	52.8	7.6	14.3	26.0	10.5	16.3	21.0	41.7	8.5	14.7	44.0	35.3	17.7	31.2	112.1	35.6	1.7	12.9	5.0	45.0	21.4	0.2	10.1	5.0	21.6	63.5	1.9	15.8	8.2	67.2	11.1	10.5	11.8	55.4	30.9	10.4	7.9	12.4	10.3	60.9	41.1	20.4	13.2	33.1	6.6	6.8	0.4	40.5	8.9	22.7	14.9	12.0	9.6	4.2	12.6	4.8	2.1	3.5	3.6	8.1	1.5	1.5	2.2	5.7	5.2	14.3	1.3	2.1	6.5	7.4	8.1	7.9	11.3	7.3	7.9	7.5	10.3	10.7	5.5	193.5	73.9	15.2	121.9	62.7	15.1	156.1	160.5	32.1	73.9	235.5	3.9	213.2	16.6	600.9	2.2	178.4	409.1	0.0	557.1	348.4	135.3	228.7	81.7	50.8	127.0	35.0	122.5	247.9	64.9	8.8	114.5	96.8	121.4	92.8	320.3	85.6	610.0	308.6	266.2	116.1	12.3	207.0	270.6	1.4	13.0	47.6	155.3	44.9	214.1	153.3
CD160	"BY55, NK1, NK28"	ENSG00000117281	"CD160 molecule"	O95971	1	145719471-145739288	"CD markers, Predicted intracellular proteins"	"Adaptive immunity, Angiogenesis, Immunity, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 33.9;brain: 15.2;intestine: 19.9;lymphoid tissue: 17.4"	"Cell type enriched"	"Detected in some"	5	"T-cells: 48.4"	"Not detected"	"Not detected"			"Region enriched"	"Detected in many"	5	"cerebellum: 15.2"	"Group enriched"	"Detected in many"	9	"gdT-cell: 33.9;MAIT T-cell: 14.4;memory CD8 T-cell: 22.9;naive CD8 T-cell: 27.3;NK-cell: 23.2"	"Group enriched"	"Detected in many"	11	"NK-cells: 23.2;T-cells: 33.9"	"Cell line enhanced"	"Detected in many"		"HeLa: 4.7"	"Not detected"	"Not detected"												"Intracellular and membrane"	NA	NA						"unprognostic (6.54e-4)"	"unprognostic (1.06e-1)"	"unprognostic (4.25e-2)"	"unprognostic (6.91e-2)"	"unprognostic (3.33e-1)"	"unprognostic (3.40e-2)"	"unprognostic (1.35e-1)"	"unprognostic (8.25e-3)"	"unprognostic (5.76e-2)"	"unprognostic (2.68e-1)"	"unprognostic (2.24e-2)"	"unprognostic (7.49e-3)"	"unprognostic (3.48e-5)"	"unprognostic (4.05e-2)"	"unprognostic (2.03e-1)"	"unprognostic (2.89e-2)"	"unprognostic (2.92e-4)"	0.6	0.2	2.2	3.6	2.6	5.1	0.6	15.2	3.1	0.8	9.3	0.4	0.3	5.6	0.8	1.4	0.9	0.6	1.2	0.6	1.6	2.2	0.5	5.9	3.8	6.0	1.6	0.3	1.1	2.2	0.0	0.4	1.8	0.6	1.3	1.0	0.9	3.0	0.4	1.0	1.1	19.9	1.4	1.0	17.4	0.8	0.8	0.3	2.9	0.4	0.3	3.1	0.7	0.3	0.2	0.3	2.7	0.4	23.2	33.9	20.2	1.4	1.0	1.6	0.9	0.0	0.3	0.3	0.1	0.0	0.2	0.1	0.6	0.1	1.7	1.3	0.2	0.1	1.7	0.2	0.2	0.1	3.5	1.7	3.1	4.7	1.3	0.1	2.1	3.2	0.2	0.4	0.1	0.3	0.7	0.0	1.7	0.8	1.5	0.1	1.5	1.2	4.0	1.2	0.8	2.9	0.3	0.2	1.1	0.0	0.6	1.2	1.6	0.9	1.3	0.6	1.2	1.5	2.0	1.8	1.4	0.6	0.8	3.0	2.4	1.6	0.6	0.7	2.4	0.2	2.7	0.1	0.1	33.9	0.1	14.4	0.2	0.4	22.9	0.0	0.2	0.2	27.3	1.7	23.2	0.4	0.3	0.0	20.2	2.2	2.6	15.2	3.1	1.6	2.2	1.6	0.3	0.6	0.3	0.0	0.0	0.0	0.2	0.1	2.1	0.2	0.0	0.0	0.0	0.0	9.8	0.1	0.0	0.0	2.8	0.1	0.5	0.0	0.4	0.0	0.0	0.3	2.3	0.5	0.0	6.4	0.0	1.8	3.1	6.7	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.1	2.6	0.0	0.2	0.0	0.1	0.1	0.1	48.4	0.0	0.1
CD163	"M130, MM130, SCARI1"	ENSG00000177575	"CD163 molecule"	Q86VB7	12	7470813-7503893	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Acute phase, Inflammatory response"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 113.6"	"Cell type enriched"	"Detected in many"	7	"Kupffer cells: 1509.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	10	"classical monocyte: 28.2;myeloid DC: 25.3"	"Group enriched"	"Detected in many"	40	"dendritic cells: 25.3;monocytes: 28.2"	"Cell line enhanced"	"Detected in some"		"ASC diff: 1.8;CACO-2: 1.7;GAMG: 5.4;HSkMC: 5.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"CAB002432, HPA046404, HPA051974"	Enhanced		Supported	"Plasma membrane"	"Secreted to blood"	NA	NA	903000000	1600000000	"Plasma membrane"		"CAB002432: AB_563510, HPA046404: AB_2679655, HPA051974: AB_2681678"	"unprognostic (1.13e-1)"	"unprognostic (2.13e-1)"	"unprognostic (5.02e-3)"	"unprognostic (2.72e-1)"	"unprognostic (6.17e-3)"	"unprognostic (2.09e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.21e-1)"	"unprognostic (2.78e-1)"	"prognostic unfavorable (7.27e-4)"	"unprognostic (1.04e-1)"	"unprognostic (6.50e-2)"	"unprognostic (1.84e-2)"	"unprognostic (8.77e-2)"	"unprognostic (4.95e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.20e-2)"	66.7	23.8	2.1	44.6	7.2	4.1	23.2	2.8	4.9	11.3	25.3	1.6	1.4	3.5	7.2	16.8	11.3	20.1	13.2	15.7	2.8	1.8	43.9	38.9	81.0	99.8	6.9	0.5	10.3	6.7	3.1	11.7	31.9	9.9	6.8	6.5	9.8	8.6	2.2	15.2	4.0	12.5	37.2	5.7	113.6	10.2	19.6	4.3	3.4	15.5	2.9	3.5	20.1	8.3	0.0	25.3	0.6	28.2	0.0	0.0	6.3	0.0	0.0	0.0	0.0	1.8	1.0	0.4	0.0	0.1	0.0	0.0	1.7	0.0	0.0	0.0	0.0	5.4	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.5	0.3	5.3	0.0	0.3	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.6	0.5	0.1	0.0	0.1	0.9	0.1	0.0	0.0	0.2	0.5	0.1	0.1	0.0	0.5	0.0	0.3	0.0	0.9	0.3	0.2	0.0	0.3	0.0	0.0	0.2	0.0	0.1	0.5	28.2	0.1	0.0	2.5	0.0	0.0	0.0	0.0	25.3	0.0	0.0	0.0	0.6	0.0	0.0	0.3	0.0	6.3	2.1	7.2	2.8	2.4	2.8	1.8	6.9	0.5	9.9	4.3	3.0	8.8	9.3	0.2	1.3	0.0	3.4	10.2	2.7	9.1	0.0	2.0	1.3	0.0	0.0	2.5	1.9	0.0	0.0	0.0	1.5	1.6	0.1	4.7	5.9	221.9	0.0	0.0	28.3	1509.4	3.9	4.6	104.2	0.0	0.0	0.0	0.8	0.0	0.0	1.1	0.0	0.1	116.4	0.3	3.9	1.7	0.9	2.5	5.0	0.0	0.0
CD163L1	"CD163B, M160, SCARI2, WC1"	ENSG00000177675	"CD163 molecule like 1"	Q9NR16	12	7346685-7479897	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 18.4;lymphoid tissue: 31.2"	"Cell type enhanced"	"Detected in many"	12	"Hofbauer cells: 6.9;Melanocytes: 13.5;Sertoli cells: 19.4;Smooth muscle cells: 8.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"GAMG: 9.2;HDLM-2: 8.2;HUVEC TERT2: 8.9;TIME: 8.3;U-87 MG: 19.4"									HPA015663	Enhanced		Approved	Nucleoplasm,Centrosome,Cytosol	"Intracellular and membrane"	NA	NA		170000	"Centrosome, Cytosol"	Nucleoplasm	"HPA015663: AB_2072575"	"unprognostic (1.25e-3)"	"unprognostic (1.77e-1)"	"unprognostic (1.42e-2)"	"unprognostic (7.46e-3)"	"unprognostic (2.29e-2)"	"unprognostic (7.79e-2)"	"unprognostic (9.39e-2)"	"unprognostic (4.44e-3)"	"unprognostic (1.07e-1)"	"unprognostic (8.35e-2)"	"unprognostic (1.08e-1)"	"unprognostic (3.08e-1)"	"unprognostic (1.26e-6)"	"unprognostic (8.59e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.69e-1)"	5.0	1.7	1.2	19.1	1.2	0.0	2.5	0.8	1.6	1.4	9.2	0.3	1.0	5.5	1.2	8.5	1.8	1.3	2.6	3.2	1.2	1.0	1.7	1.5	2.8	14.6	1.1	0.7	1.0	1.0	0.1	1.4	6.8	3.3	1.4	15.1	2.7	2.5	1.4	1.1	1.4	18.4	1.8	1.0	31.2	2.6	4.6	0.2	9.5	1.7	6.4	12.9	4.3	1.2	0.2	0.7	0.7	0.8	0.0	0.0	0.2	0.2	0.4	0.2	0.0	1.0	0.3	0.0	0.8	1.8	0.2	0.8	0.0	1.4	0.0	0.3	0.8	9.2	0.0	0.0	1.1	1.4	8.2	0.0	0.0	0.4	1.2	0.0	0.5	0.0	0.3	0.0	0.2	3.3	0.6	8.9	0.0	0.1	4.7	5.2	0.0	0.0	6.6	0.2	0.0	0.0	1.5	1.5	1.8	0.0	0.0	1.2	5.6	4.3	6.8	0.0	0.3	0.0	5.5	8.3	3.0	2.7	0.3	0.0	0.1	0.1	0.0	19.4	0.4	5.7	0.0	0.8	0.7	0.0	0.8	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.2	1.2	0.8	1.6	1.2	1.0	1.1	0.7	3.3	0.2	0.0	0.0	0.0	0.0	1.1	2.9	0.7	0.0	0.0	0.0	0.0	3.9	0.1	0.0	0.0	2.2	0.7	0.0	0.0	1.2	0.3	0.5	0.1	0.0	0.4	6.9	0.0	0.0	0.0	4.1	1.1	0.0	3.3	13.5	0.0	0.0	1.0	2.0	1.1	0.0	0.0	1.7	19.4	8.0	3.4	0.7	1.1	0.2	0.0	0.0	0.1
CD164	"DFNA66, MGC-24, MUC-24"	ENSG00000135535	"CD164 molecule"	Q04900	6	109366514-109382812	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Myogenesis"		"Deafness, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA010636	Uncertain				"Intracellular and membrane"	NA	NA					"HPA010636: AB_1078447"	"unprognostic (1.23e-2)"	"unprognostic (1.61e-2)"	"unprognostic (3.89e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.04e-2)"	"unprognostic (1.97e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.09e-1)"	"unprognostic (8.88e-2)"	"unprognostic (1.38e-1)"	"unprognostic (7.11e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.84e-1)"	"unprognostic (3.01e-1)"	"unprognostic (1.51e-1)"	85.0	37.6	17.1	37.2	28.5	38.0	72.9	11.2	19.2	34.2	55.2	31.1	57.4	50.5	35.6	44.4	29.6	31.7	58.1	32.0	18.6	22.6	67.4	66.1	52.5	60.9	45.2	16.7	38.0	49.2	30.4	55.0	106.6	28.2	33.4	57.4	44.1	75.1	49.6	38.5	30.6	100.2	41.5	42.8	43.2	55.8	38.1	30.2	50.7	73.3	25.0	34.7	40.3	37.2	32.6	54.2	66.1	48.9	61.1	46.7	83.2	20.5	11.5	6.1	38.6	88.3	85.3	37.4	38.6	48.7	34.7	50.1	23.0	31.4	16.6	37.4	41.8	34.9	20.3	22.9	24.7	53.7	34.0	22.9	28.2	12.3	27.7	52.4	33.2	67.3	66.8	49.0	34.3	31.4	48.7	32.1	14.7	26.9	44.3	47.9	21.5	31.3	41.5	9.1	46.7	18.8	20.6	18.0	20.9	51.2	27.7	6.5	13.2	23.5	31.5	56.3	31.1	27.5	44.1	32.4	22.7	16.6	32.5	30.5	16.8	23.6	19.1	40.9	39.0	23.3	66.1	47.6	39.9	44.7	48.9	46.4	32.6	36.5	40.9	47.1	28.8	38.3	40.7	32.7	61.1	45.5	54.2	46.7	83.2	17.1	28.5	11.2	19.2	18.6	22.6	45.2	16.7	28.2	30.2	151.8	62.8	154.7	162.8	177.7	29.5	60.1	211.5	374.8	95.5	266.9	23.6	193.9	79.6	146.9	73.7	93.1	381.3	23.3	120.3	352.8	194.4	248.6	124.8	160.3	277.6	31.8	159.9	106.2	314.8	72.5	147.0	269.8	234.5	92.8	363.1	107.0	148.8	273.5	171.1	307.5	42.7	122.9	177.2	153.3	160.8	202.0	564.1	162.5	216.7	229.5
CD180	"LY64, Ly78, RP105"	ENSG00000134061	"CD180 molecule"	Q99467	5	67179613-67196799	"CD markers, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 29.2;lymphoid tissue: 38.7"	"Cell type enhanced"	"Detected in some"	20	"B-cells: 49.6;Hofbauer cells: 63.1;Kupffer cells: 16.8;monocytes: 13.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 28.7;naive B-cell: 29.2"	"Group enriched"	"Detected in many"	23	"B-cells: 29.2;dendritic cells: 8.5;monocytes: 11.6"	"Group enriched"	"Detected in some"	10	"Daudi: 23.3;Karpas-707: 21.9;U-266/70: 17.8;U-266/84: 24.7;U-698: 6.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA003740	Enhanced					NA	NA					"HPA003740: AB_1078450"	"unprognostic (9.33e-2)"	"unprognostic (4.58e-2)"	"unprognostic (2.81e-3)"	"unprognostic (5.85e-3)"	"unprognostic (2.25e-2)"	"unprognostic (4.04e-3)"	"unprognostic (1.09e-1)"	"unprognostic (4.95e-2)"	"unprognostic (5.83e-2)"	"unprognostic (3.71e-1)"	"unprognostic (2.16e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.09e-1)"	"unprognostic (1.16e-1)"	"unprognostic (3.70e-2)"	"unprognostic (1.21e-1)"	"unprognostic (2.18e-2)"	9.6	1.6	1.4	24.3	3.2	1.9	5.7	0.6	1.3	1.0	2.1	1.6	0.0	1.8	0.9	1.0	1.7	1.3	1.5	4.6	1.2	1.1	2.5	2.7	3.0	30.4	4.1	0.6	1.5	1.0	0.2	1.1	2.9	2.2	1.5	2.5	0.4	3.1	0.4	0.6	0.7	8.4	1.6	3.5	38.7	1.9	0.8	2.8	1.9	1.2	0.2	31.3	4.1	0.8	29.2	8.5	0.3	11.6	0.7	0.0	2.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.3	0.1	17.8	24.7	6.5	0.0	1.4	0.0	0.0	4.1	0.3	0.0	7.4	0.0	28.7	0.0	0.0	8.0	29.2	0.0	0.0	0.3	0.7	11.6	8.5	0.0	2.8	1.4	3.2	0.6	1.3	1.2	1.1	4.1	0.6	2.2	2.8	0.0	0.3	49.6	0.1	0.3	0.0	0.3	0.0	1.4	0.0	0.0	0.0	0.4	0.0	0.0	2.2	0.3	0.0	0.0	0.2	0.2	0.4	0.0	2.3	0.0	63.1	0.0	0.0	0.0	16.8	1.0	0.0	9.7	0.0	13.6	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.6	0.0	0.0	0.1
CD19		ENSG00000177455	"CD19 molecule"	P15391	16	28931939-28939346	"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"blood: 47.6;intestine: 16.7;lymphoid tissue: 40.3"	"Cell type enriched"	"Detected in some"	6	"B-cells: 94.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	93	"memory B-cell: 36.0;naive B-cell: 47.6"	"Lineage enriched"	"Detected in single"	106	"B-cells: 47.6"	"Cell line enhanced"	"Detected in some"		"Daudi: 53.4;REH: 28.3;U-698: 12.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			CAB016110	Enhanced					NA	NA					"CAB016110: AB_626952"	"unprognostic (3.27e-3)"	"unprognostic (1.19e-3)"	"unprognostic (6.63e-2)"	"unprognostic (1.09e-2)"	"unprognostic (8.68e-3)"	"unprognostic (3.11e-5)"	"unprognostic (2.61e-1)"	"unprognostic (6.96e-3)"	"unprognostic (1.29e-2)"	"unprognostic (4.29e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.30e-1)"	"unprognostic (5.41e-6)"	"unprognostic (2.06e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.36e-1)"	"unprognostic (2.07e-1)"	0.4	0.2	0.2	37.0	0.2	2.3	0.2	0.1	0.2	0.2	0.9	0.1	0.0	0.2	0.2	0.1	1.4	0.3	0.2	0.2	0.2	0.2	0.7	0.3	1.4	32.0	0.2	0.0	0.3	0.2	0.0	0.2	0.0	0.0	0.4	0.5	0.1	5.9	0.0	0.1	0.1	16.7	0.0	0.2	40.3	1.3	1.9	0.0	2.4	0.7	0.2	38.7	1.8	0.3	47.6	0.0	0.4	0.1	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	53.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	28.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.1	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	36.0	0.0	0.0	0.0	47.6	0.1	0.0	0.3	0.0	0.1	0.0	0.0	1.8	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.0	1.1	94.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	16.9	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	1.4	0.0	0.0	1.8	0.6	3.6	0.3	0.4	3.3	0.0	0.0	0.3	0.2	0.0	0.7	0.0	0.0	0.0	0.0	6.1	3.0	0.0	0.6	0.0	0.4	0.0
CD1A	CD1	ENSG00000158477	"CD1a molecule"	P06126	1	158254137-158258269	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"lymphoid tissue: 105.1"	"Cell type enhanced"	"Detected in some"	17	"Basal keratinocytes: 6.5;Kupffer cells: 1.6;Macrophages: 2.9;Melanocytes: 1.7;Suprabasal keratinocytes: 6.0"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	23	"classical monocyte: 5.9;intermediate monocyte: 3.7;memory B-cell: 6.8;myeloid DC: 10.2;naive B-cell: 5.4"	"Group enriched"	"Detected in many"	35	"B-cells: 6.8;dendritic cells: 10.2;monocytes: 5.9"	"Group enriched"	"Detected in some"	86	"JURKAT: 21.2;MOLT-4: 33.8"									"CAB000009, HPA010734"	Enhanced					NA	NA					"CAB000009: AB_2073290, HPA010734: AB_1078452"	"unprognostic (7.21e-5)"	"prognostic favorable (6.37e-4)"	"unprognostic (1.37e-5)"	"unprognostic (2.55e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.16e-2)"	"unprognostic (9.93e-4)"	"unprognostic (1.49e-2)"	"unprognostic (3.12e-1)"	"unprognostic (3.86e-2)"	"unprognostic (6.99e-2)"	"unprognostic (5.12e-2)"	"unprognostic (5.49e-5)"	"unprognostic (5.58e-2)"	"unprognostic (1.72e-1)"	"unprognostic (1.76e-1)"	"unprognostic (8.81e-2)"	0.1	0.0	0.1	0.9	0.1	0.0	1.0	0.1	0.1	0.9	0.1	0.1	0.1	0.0	0.2	0.1	8.0	0.0	0.6	0.1	0.1	0.0	0.2	0.1	1.8	1.9	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	1.2	0.1	0.9	0.1	0.1	20.9	0.3	0.1	0.1	1.4	0.3	0.2	0.1	105.1	0.1	1.0	2.7	0.4	1.1	6.8	10.2	0.0	5.9	0.0	0.2	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	21.2	0.0	0.0	0.0	0.0	33.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	5.9	0.0	0.0	3.7	0.2	6.8	0.0	0.0	10.2	5.4	0.1	0.0	0.0	0.0	0.2	0.2	0.0	1.5	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.6	0.0	0.0	2.9	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	6.0	0.0	0.0	0.0	0.0
CD1B	CD1	ENSG00000158485	"CD1b molecule"	P29016	1	158327951-158331531	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	12	"lymphoid tissue: 188.8"	"Cell type enriched"	"Detected in some"	6	"Macrophages: 17.4"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	6	"myeloid DC: 16.3"	"Lineage enriched"	"Detected in many"	6	"dendritic cells: 16.3"	"Cell line enriched"	"Detected in some"	5	"MOLT-4: 112.0"									HPA021824	Approved		Approved	"Golgi apparatus,Vesicles,Cytosol"		NA	NA			"Golgi apparatus, Vesicles"	Cytosol	"HPA021824: AB_1846262"	"unprognostic (7.72e-3)"	"unprognostic (1.55e-4)"	"unprognostic (1.66e-5)"	"unprognostic (1.04e-2)"		"unprognostic (1.06e-3)"	"unprognostic (1.81e-1)"	"unprognostic (2.89e-4)"	"unprognostic (2.27e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.33e-1)"	"unprognostic (9.53e-2)"	"unprognostic (3.23e-1)"	"unprognostic (3.52e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.89e-1)"	"unprognostic (3.53e-2)"	0.8	0.1	0.2	1.9	0.2	0.0	0.6	0.2	0.2	0.8	0.6	0.3	0.2	0.0	0.3	0.2	0.9	0.7	1.3	0.2	0.2	0.0	0.6	0.3	1.7	4.0	0.2	0.2	0.3	0.3	0.0	0.2	0.2	0.2	0.2	5.6	0.2	0.6	0.2	0.2	6.2	0.8	0.3	0.2	1.9	0.9	0.2	0.2	188.8	0.4	0.4	2.4	0.5	0.8	0.0	16.3	0.0	2.9	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.6	0.0	0.0	0.0	0.0	112.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	2.3	0.0	0.0	0.0	0.0	16.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	2.7	0.0	0.0	17.4	1.7	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0
CD1C	CD1	ENSG00000158481	"CD1c molecule"	P29017	1	158289786-158293630	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"blood: 70.8;lymphoid tissue: 111.4"	"Cell type enhanced"	"Detected in some"	21	"B-cells: 37.2;Macrophages: 73.3;Melanocytes: 18.6"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"memory B-cell: 18.6;myeloid DC: 70.8"	"Group enriched"	"Detected in many"	8	"B-cells: 18.6;dendritic cells: 70.8"	"Group enriched"	"Detected in some"	9	"JURKAT: 11.0;MOLT-4: 34.8"															NA	NA		240000				"unprognostic (2.55e-3)"	"prognostic favorable (1.79e-5)"	"unprognostic (1.75e-5)"	"unprognostic (3.09e-5)"	"unprognostic (3.12e-2)"	"unprognostic (8.13e-3)"	"unprognostic (2.01e-1)"	"unprognostic (3.80e-3)"	"unprognostic (7.11e-3)"	"unprognostic (1.87e-1)"	"unprognostic (7.41e-2)"	"unprognostic (1.93e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.67e-1)"	"unprognostic (8.05e-2)"	"unprognostic (1.99e-1)"	1.8	0.4	0.5	8.2	0.6	0.0	2.2	0.5	0.5	1.1	1.2	0.5	1.3	0.4	1.4	1.2	1.8	1.6	5.1	0.6	0.5	0.3	1.6	1.5	2.8	13.2	0.6	0.5	0.7	0.7	0.0	0.6	0.7	0.6	1.0	4.8	0.9	3.0	1.0	0.6	5.5	11.7	1.3	0.5	24.6	1.2	0.8	0.5	111.4	1.0	2.4	20.5	1.4	1.3	18.6	70.8	0.2	5.9	0.9	0.1	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.0	0.0	0.0	0.0	0.0	34.8	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.6	0.0	0.1	5.9	0.0	0.0	5.1	0.0	18.6	0.0	0.0	70.8	9.3	0.0	0.0	0.2	0.9	0.6	0.3	0.1	3.3	0.5	0.6	0.5	0.5	0.5	0.3	0.6	0.5	0.6	0.5	0.0	6.9	37.2	0.0	11.6	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.2	0.0	0.0	0.0	0.1	2.3	0.0	3.5	0.0	4.0	0.0	0.0	0.0	5.9	3.3	0.0	73.3	18.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	6.5	0.0	0.0	0.0	0.0
CD1D		ENSG00000158473	"CD1d molecule"	P15813	1	158179947-158184896	"Cancer-related genes, CD markers, Predicted membrane proteins"	"Immunity, Innate immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 49.5;lymphoid tissue: 17.8"	"Cell type enhanced"	"Detected in many"	15	"B-cells: 27.5;Kupffer cells: 52.9;Macrophages: 34.3"	"Low cancer specificity"	"Detected in many"							"Group enriched"	"Detected in many"	6	"classical monocyte: 49.5;intermediate monocyte: 22.4;myeloid DC: 49.5"	"Group enriched"	"Detected in many"	8	"dendritic cells: 49.5;monocytes: 49.5"	"Cell line enriched"	"Detected in some"	4	"JURKAT: 45.7"					"Low region specificity"	"Detected in all"			"CAB016107, HPA072662"	Enhanced		Supported	"Endoplasmic reticulum"		NA	NA		720000	"Endoplasmic reticulum"		"CAB016107: AB_626960, HPA072662: AB_2686545"	"unprognostic (8.67e-2)"	"unprognostic (6.99e-2)"	"unprognostic (2.48e-1)"	"unprognostic (1.48e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.85e-1)"	"unprognostic (9.67e-3)"	"unprognostic (2.37e-1)"	"unprognostic (3.52e-1)"	"unprognostic (2.23e-2)"	"unprognostic (4.46e-2)"	"prognostic unfavorable (2.12e-5)"	"unprognostic (9.31e-3)"	"unprognostic (2.35e-1)"	"unprognostic (2.32e-2)"	"unprognostic (3.38e-1)"	1.5	1.2	0.0	8.6	0.0	2.6	1.2	0.0	0.0	0.8	2.5			9.5	1.5	0.0	0.4	1.4	2.0	1.4	0.0	0.1	1.6	10.5	2.3	5.5	0.2		0.3	0.7	0.0	0.6	0.0		1.4	3.7		0.7	0.3	0.6	0.0	12.2	2.2	0.4	17.8	1.4	1.4			1.8		3.4	1.6	0.5	6.3	49.5	2.5	49.5	0.1	0.1	23.5	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.9	0.0	0.0	2.9	0.0	5.5	0.0	0.0	0.0	0.1	0.0	0.0	8.5	0.1	0.0	3.2	0.4	0.0	0.6	0.0	0.0	45.7	0.0	0.0	0.0	0.0	11.2	1.1	0.5	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	1.7	0.0	0.0	0.3	0.0	0.3	0.0	3.1	0.4	0.0	49.5	0.1	0.0	22.4	0.1	6.3	0.0	0.0	49.5	4.7	0.0	0.0	2.5	0.1	3.6	0.5	0.0	23.5											0.0	5.1	27.5	0.4	0.2	0.4	0.8	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	4.5	1.2	2.2	0.0	0.0	0.1	0.2	0.0	1.1	5.3	11.3	1.6	2.4	4.3	52.9	0.9	0.0	34.3	0.0	10.0	2.0	0.3	0.0	3.7	0.0	0.0	0.1	0.0	0.5	0.5	0.9	0.1	0.1	0.0	3.9	0.0
CD1E		ENSG00000158488	"CD1e molecule"	P15812	1	158353696-158357553	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	10	"lymphoid tissue: 308.0"	"Cell type enriched"	"Detected in some"	9	"Macrophages: 75.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	13	"myeloid DC: 29.7"	"Lineage enriched"	"Detected in many"	13	"dendritic cells: 29.7"	"Cell line enriched"	"Detected in some"	42	"MOLT-4: 171.9"					"Not detected"	"Not detected"			HPA057769	Uncertain				"Intracellular and membrane"	NA	NA					"HPA057769: AB_2683522"	"unprognostic (7.94e-3)"	"unprognostic (1.85e-5)"	"unprognostic (1.47e-2)"	"unprognostic (1.64e-2)"	"unprognostic (1.76e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.33e-1)"	"unprognostic (1.54e-3)"	"unprognostic (1.24e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.60e-1)"	"unprognostic (8.55e-2)"	"unprognostic (1.69e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.49e-1)"	"unprognostic (8.50e-2)"	"unprognostic (2.45e-1)"	1.0	0.2	0.7	2.8	0.7	0.0	1.1	0.7	0.7	1.5	1.0	0.7	0.7	1.2	0.9	0.7	7.0	1.9	3.9	0.7	0.7	0.2	2.0	0.7	2.4	4.7	0.7	0.7	0.7	0.8	0.0	0.7	0.7	0.7	1.8	4.8	0.8	1.9	0.8	0.8	11.5	2.1	0.8	0.7	3.8	3.1	0.9	0.7	308.0	1.0	1.3	8.1	2.4	2.7	0.0	29.7	0.0	2.2	0.0	0.1	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	0.0	0.0	0.0	171.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	1.1	0.1	0.0	0.0	0.0	29.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.7	0.7	0.7	0.7	0.7	0.2	0.7	0.7	0.7	0.7	3.0	0.3	0.0	0.0	7.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.1	0.0	1.6	0.0	0.0	0.0	6.4	0.0	0.0	75.9	8.5	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2	6.1	0.1	0.0	0.0	0.0
CD2	SRBC	ENSG00000116824	"CD2 molecule"	P06729	1	116754385-116769228	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"blood: 101.7;lymphoid tissue: 164.4"	"Cell type enriched"	"Detected in many"	11	"T-cells: 299.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	6	"gdT-cell: 44.4;MAIT T-cell: 42.5;memory CD4 T-cell: 65.3;memory CD8 T-cell: 74.2;naive CD4 T-cell: 34.2;naive CD8 T-cell: 52.4;NK-cell: 101.7;T-reg: 62.3"	"Group enriched"	"Detected in many"	9	"NK-cells: 101.7;T-cells: 74.2"	"Group enriched"	"Detected in some"	24	"HDLM-2: 58.9;JURKAT: 39.9;MOLT-4: 43.3"	"Region enhanced"	"Detected in single"		"basal ganglia: 0.3"	"Low region specificity"	"Detected in some"			"CAB002430, HPA003883"	Enhanced					NA	NA					"CAB002430: AB_442057, HPA003883: AB_1846263"	"prognostic favorable (4.36e-4)"	"prognostic favorable (1.47e-4)"	"unprognostic (3.34e-3)"	"prognostic favorable (1.69e-5)"	"unprognostic (1.52e-1)"	"prognostic favorable (7.46e-5)"	"unprognostic (9.32e-3)"	"unprognostic (1.61e-2)"	"prognostic favorable (3.97e-5)"	"prognostic favorable (7.72e-4)"	"unprognostic (4.18e-2)"	"unprognostic (3.31e-1)"	"prognostic unfavorable (4.82e-6)"	"unprognostic (6.16e-2)"	"unprognostic (6.61e-2)"	"unprognostic (2.73e-2)"	"unprognostic (7.63e-3)"	3.0	1.1	0.6	14.5	0.5	2.4	1.7	0.5	0.6	2.9	6.0	0.6	0.6	4.8	1.7	2.1	3.8	3.1	4.8	1.4	0.6	0.6	3.3	2.5	8.1	33.0	1.2	0.6	1.9	1.6	0.0	1.0	1.0	1.0	2.9	4.7	2.3	4.1	1.3	1.0	1.2	18.8	0.9	1.8	28.8	6.5	1.1	0.8	164.4	3.5	3.4	30.8	7.7	2.7	0.3	9.3	1.4	0.5	101.7	74.2	45.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	58.9	0.0	0.1	0.0	0.0	0.0	0.1	2.0	0.0	0.0	0.0	0.0	0.0	0.0	39.9	0.0	0.1	0.0	0.0	43.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.7	0.5	0.1	44.4	0.3	42.5	0.3	65.3	74.2	9.3	0.2	34.2	52.4	1.4	101.7	0.2	2.0	62.3	45.9	0.6	0.5	0.5	0.6	0.6	0.6	1.2	0.6	1.0	0.8	3.0	27.0	1.5	0.4	4.4	0.0	0.8	0.0	0.0	4.5	3.5	0.0	0.0	0.0	0.0	13.2	2.4	0.0	0.0	0.0	0.0	2.1	0.1	4.7	0.9	0.7	0.0	2.9	9.8	7.0	4.0	0.6	8.7	1.7	0.0	0.0	0.0	0.0	0.0	0.4	1.3	0.0	0.0	4.7	0.2	0.2	3.1	0.0	299.5	0.1	0.1
CD200	"MOX1, MOX2, MRC, OX-2"	ENSG00000091972	"CD200 molecule"	P41217	3	112332347-112362812	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 63.5"	"Cell type enhanced"	"Detected in many"	10	"Endothelial cells: 82.9;Intestinal endocrine cells: 36.9;Syncytiotrophoblasts: 63.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	16	"memory B-cell: 9.9;naive B-cell: 36.4"	"Lineage enriched"	"Detected in many"	25	"B-cells: 36.4"	"Cell line enhanced"	"Detected in some"		"AF22: 31.9;HHSteC: 11.7;NTERA-2: 19.9;REH: 17.0;SH-SY5Y: 9.8;SK-MEL-30: 11.7;WM-115: 34.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA031149	Approved					NA	NA					"HPA031149: AB_10600694"	"unprognostic (1.84e-1)"	"unprognostic (5.08e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.03e-3)"	"unprognostic (4.97e-1)"	"unprognostic (1.21e-2)"	"unprognostic (9.29e-2)"	"unprognostic (2.25e-2)"	"unprognostic (3.06e-1)"	"unprognostic (3.14e-2)"	"unprognostic (1.21e-2)"	"unprognostic (1.27e-1)"	"unprognostic (8.97e-2)"	"unprognostic (1.06e-2)"	"unprognostic (2.80e-1)"	"unprognostic (4.49e-2)"	"unprognostic (1.22e-2)"	12.8	9.5	18.1	10.9	34.3	1.8	7.1	20.9	38.3	16.0	4.5	11.0	1.5	2.6	21.4	5.7	7.0	20.3	10.1	5.8	17.3	42.4	4.9	1.0	7.2	17.7	12.7	19.3	9.3	3.8	10.9	27.9	63.5	19.6	9.7	6.5	7.5	5.4	13.0	1.4	2.8	4.3	13.9	8.4	4.4	3.4	2.3	6.7	12.7	12.4	1.6	17.6	13.9	3.9	36.4	1.1	1.2	0.1	0.6	1.4	1.3	0.0	0.0	31.9	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	1.7	0.0	0.4	0.0	3.4	0.1	0.1	0.1	0.3	0.0	0.1	0.2	11.7	0.0	0.0	0.2	0.1	0.6	0.0	0.1	4.5	0.0	0.0	0.3	0.0	0.0	0.4	0.1	19.9	0.0	0.0	17.0	0.0	0.2	0.2	0.0	8.4	9.8	0.0	0.1	11.7	6.2	0.0	0.1	0.0	0.1	1.1	0.0	0.1	0.0	0.1	0.0	0.3	0.1	34.7	1.2	0.1	0.1	0.1	0.0	1.4	9.9	0.8	0.2	0.5	36.4	0.9	0.5	0.7	0.6	0.1	1.1	0.4	1.3	18.1	34.3	20.9	38.3	17.3	42.4	12.7	19.3	19.6	6.7	3.0	14.5	33.0	11.5	3.8	24.4	0.4	0.0	4.0	2.3	1.8	0.0	2.3	0.0	0.3	20.1	82.9	0.7	0.0	0.0	7.3	5.6	4.6	2.3	0.0	0.8	3.2	36.9	1.8	0.0	21.1	0.3	1.9	8.5	24.4	5.5	5.6	0.3	2.9	0.0	0.0	2.5	0.0	4.1	0.5	0.2	2.9	63.5	0.7	5.8	17.2
CD207	"CLEC4K, Langerin"	ENSG00000116031	"CD207 molecule"	Q9UJ71	2	70830214-70835822	"CD markers, Disease related genes, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 16.5;skin 1: 42.3"	"Cell type enhanced"	"Detected in some"	14	"Basal keratinocytes: 3.5;Macrophages: 1.5;Melanocytes: 5.0;monocytes: 2.8;Suprabasal keratinocytes: 4.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	18	"myeloid DC: 4.0"	"Lineage enriched"	"Detected in single"	18	"dendritic cells: 4.0"	"Cell line enriched"	"Detected in some"	4	"AN3-CA: 14.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB002222, HPA011216"	Enhanced		Uncertain	Cytosol		No	NA			Cytosol		"CAB002222: AB_563850, HPA011216: AB_1078453"	"unprognostic (1.45e-2)"	"unprognostic (8.28e-3)"	"unprognostic (9.34e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.23e-1)"	"unprognostic (3.02e-1)"	"unprognostic (1.27e-3)"	"unprognostic (1.05e-1)"	"unprognostic (4.86e-2)"	"unprognostic (3.45e-1)"	"unprognostic (1.63e-1)"	"unprognostic (7.92e-4)"	"unprognostic (2.13e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.98e-1)"	"unprognostic (2.46e-2)"	0.5	0.1	0.1	1.8	0.1	0.0	1.4	0.1	0.1	2.4	1.7	0.1	0.1	1.6	1.1	0.4	9.7	0.3	2.9	0.3	0.1	0.1	0.2	0.9	3.7	0.2	0.1	0.1	0.2	0.2	0.0	1.1	0.1	0.1	1.0	1.1	0.4	1.2	0.2	0.1	42.3	2.6	0.1	0.1	1.5	0.4	0.4	0.1	3.3	0.2	11.3	16.5	0.3	1.9	0.0	4.0	0.0	0.2	0.0	0.0	0.5	0.0	0.0	0.0	14.1	0.1	0.0	0.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	3.4	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.1	1.9	0.0	0.0	0.0	0.3	2.5	0.0	0.5	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	1.1	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	5.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.0
CD209	"CDSIGN, CLEC4L, DC-SIGN, DC-SIGN1"	ENSG00000090659	"CD209 molecule"	Q9NNX6	19	7739994-7747564	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Cell adhesion, Endocytosis, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 47.9"	"Cell type enhanced"	"Detected in some"	25	"Hofbauer cells: 3.0;Kupffer cells: 14.6;Macrophages: 5.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 3.7;intermediate monocyte: 3.5;myeloid DC: 3.4"	"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in single"	14	"THP-1: 8.8"									"CAB032436, CAB033831"	Supported				"Intracellular and membrane"	NA	NA		970000			"CAB032436: AB_639039, CAB033831: AB_1121347"	"unprognostic (2.76e-1)"	"unprognostic (1.15e-2)"	"unprognostic (5.36e-3)"	"unprognostic (1.25e-1)"	"unprognostic (4.43e-2)"	"unprognostic (1.40e-1)"	"unprognostic (5.45e-2)"	"unprognostic (3.83e-2)"	"unprognostic (2.10e-2)"	"unprognostic (1.24e-1)"	"unprognostic (9.65e-2)"	"unprognostic (1.39e-1)"	"prognostic unfavorable (1.15e-5)"	"unprognostic (1.70e-1)"	"unprognostic (5.51e-2)"	"unprognostic (6.17e-2)"	"unprognostic (1.09e-1)"	20.3	4.5	0.5	4.1	1.8	0.0	6.8	4.5	0.9	2.0	5.6	0.7	0.3	7.2	1.1	7.3	2.4	3.3	4.4	7.8	0.4	0.7	2.2	5.0	3.7	47.9	1.1	0.5	1.8	3.8	0.4	1.0	12.1	1.8	3.6	7.4	3.2	3.0	0.7	3.5	1.6	10.1	5.2	0.9	1.4	2.6	2.1	0.3	2.3	2.1	2.1	1.3	6.8	1.6	0.3	3.4	0.9	3.7	0.3	0.2	1.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.6	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.2	0.2	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.2	0.1	0.1	0.2	0.6	0.0	0.1	0.0	0.1	0.2	8.8	0.1	0.1	0.0	0.2	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.5	3.7	0.2	0.2	3.5	0.1	0.2	0.1	0.1	3.4	0.3	0.1	0.2	0.9	0.3	0.1	0.3	0.1	1.0	0.5	1.8	4.5	0.9	0.4	0.7	1.1	0.5	1.8	0.3	0.0	0.0	0.5	0.1	0.5	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.1	0.0	3.0	0.0	0.0	0.0	14.6	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.3	0.0	0.0	0.6	0.1	0.0	0.0	0.1
CD22	"SIGLEC-2, SIGLEC2"	ENSG00000012124	"CD22 molecule"	P20273	19	35319261-35347355	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 39.3;lymphoid tissue: 77.8;ovary: 35.4"	"Group enriched"	"Detected in some"	12	"B-cells: 68.1;granulocytes: 94.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	25	"memory B-cell: 29.8;naive B-cell: 39.3"	"Lineage enriched"	"Detected in many"	28	"B-cells: 39.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 69.8;REH: 20.6;U-698: 55.5;WM-115: 12.7"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"CAB002418, HPA024353"	Enhanced					NA	NA					"CAB002418: AB_563529, HPA024353: AB_10600695"	"unprognostic (2.80e-3)"	"unprognostic (3.99e-2)"	"unprognostic (6.79e-3)"	"unprognostic (9.17e-2)"	"unprognostic (3.07e-1)"	"unprognostic (6.45e-3)"	"unprognostic (3.79e-1)"	"unprognostic (3.32e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.47e-1)"	"unprognostic (1.75e-3)"	"unprognostic (1.98e-2)"	"unprognostic (1.48e-2)"	"unprognostic (9.05e-2)"	"unprognostic (3.04e-1)"	"unprognostic (2.35e-2)"	"unprognostic (1.48e-1)"	2.1	1.0	5.5	57.9	6.8	3.1	0.5	0.7	3.2	1.4	1.0	0.9	0.5	0.4	1.4	0.9	4.4	7.9	2.9	0.8	9.9	4.2	1.4	0.6	5.5	52.6	9.8	0.5	35.4	0.5	0.0	0.7	1.0	0.9	2.8	1.5	1.1	5.9	1.1	0.5	0.0	11.6	2.0	13.5	64.1	1.4	1.2	0.6	5.0	1.1	2.3	77.8	4.3	0.9	39.3	1.3	0.3	0.3	0.0	0.0	1.4	0.2	0.4	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.1	0.0	1.3	69.8	1.4	0.0	3.9	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.5	0.0	0.0	3.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.3	0.0	0.6	0.1	0.0	0.0	0.0	0.1	0.1	20.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.7	0.0	0.1	0.0	0.0	0.6	0.4	0.0	0.0	0.0	0.0	55.5	0.5	0.2	12.7	0.0	0.0	0.0	0.0	0.3	0.0	29.8	0.0	0.0	1.3	39.3	0.0	0.0	0.3	0.0	0.2	1.1	0.0	1.4	5.5	6.8	0.7	3.2	9.9	4.2	9.8	0.5	0.9	0.6	3.0	4.8	68.1	0.4	0.2	0.0	0.6	0.0	0.0	1.2	0.0	0.0	0.1	0.0	0.0	0.3	0.5	0.0	0.0	0.2	0.4	0.6	0.4	94.6	0.0	7.0	0.0	0.0	1.8	6.4	0.0	3.4	2.3	1.7	0.0	0.0	0.0	0.3	0.0	0.7	0.0	0.0	0.0	0.0	0.2	0.9	0.4	0.1	0.5	0.0	0.0
CD226	"DNAM-1, DNAM1, PTA1, TLiSA1"	ENSG00000150637	"CD226 molecule"	Q15762	18	69831158-69961803	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 31.9;parathyroid gland: 82.5"	"Cell type enhanced"	"Detected in many"	10	"granulocytes: 12.8;Kupffer cells: 11.2;monocytes: 21.6;T-cells: 25.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	8	"gdT-cell: 19.4;MAIT T-cell: 7.3;memory CD4 T-cell: 16.1;memory CD8 T-cell: 11.8;naive CD4 T-cell: 9.0;naive CD8 T-cell: 9.7;NK-cell: 14.0;T-reg: 5.5"	"Group enriched"	"Detected in many"	11	"NK-cells: 14.0;T-cells: 19.4"	"Group enriched"	"Detected in some"	6	"HEL: 45.3;HMC-1: 20.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA015715, HPA015865"	Supported		Supported	"Nucleoplasm,Plasma membrane,Centriolar satellite"		NA	No		27000000	"Plasma membrane"	"Nucleoplasm, Centriolar satellite"	"HPA015715: AB_1846278, HPA015865: "	"unprognostic (1.42e-4)"	"unprognostic (1.30e-3)"	"unprognostic (9.01e-3)"	"unprognostic (3.49e-5)"	"unprognostic (4.15e-1)"	"unprognostic (9.52e-4)"	"unprognostic (3.68e-3)"	"unprognostic (2.93e-2)"	"unprognostic (3.43e-1)"	"unprognostic (3.31e-3)"	"unprognostic (8.36e-2)"	"unprognostic (1.43e-1)"	"unprognostic (2.72e-3)"	"unprognostic (2.20e-1)"	"unprognostic (3.91e-2)"	"unprognostic (2.27e-1)"	"unprognostic (3.58e-2)"	1.2	0.6	1.0	7.5	2.0	1.7	0.8	0.7	0.9	1.5	2.9	0.3	0.1	1.1	1.0	1.4	0.8	0.8	1.4	0.9	1.9	1.3	1.3	3.1	5.2	14.0	1.7	0.0	1.0	0.6	82.5	2.4	0.6	1.3	0.9	1.2	2.4	5.4	0.6	1.1	0.4	6.0	1.3	4.2	31.9	1.4	1.8	0.5	6.4	1.8	2.6	10.1	2.0	1.6	0.4	1.5	0.9	0.6	14.0	19.4	6.6	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.1	2.4	0.0	45.3	0.1	0.0	0.0	0.3	20.2	0.0	0.5	0.1	0.3	0.0	0.0	0.4	0.1	4.7	0.2	0.0	0.3	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.3	0.1	0.0	0.1	5.5	0.1	0.0	0.1	0.0	0.2	0.1	0.0	0.5	19.4	0.4	7.3	0.4	16.1	11.8	1.5	0.1	9.0	9.7	0.9	14.0	0.6	0.1	5.5	6.6	1.0	2.0	0.7	0.9	1.9	1.3	1.7	0.0	1.3	0.5	3.0	5.1	0.8	0.3	0.0	2.4	1.6	0.0	2.7	1.2	0.0	0.0	0.1	0.0	0.0	6.6	0.1	0.0	0.0	0.3	0.0	0.4	0.2	12.8	0.5	1.4	0.0	0.0	2.5	11.2	7.5	0.9	7.8	0.0	21.6	0.0	1.4	0.2	0.0	0.7	0.0	3.7	0.0	0.3	0.3	0.5	0.4	0.0	25.4	0.0	0.1
CD244	"2B4, NAIL, NKR2B4, Nmrk, SLAMF4"	ENSG00000122223	"CD244 molecule"	Q9BZW8	1	160830160-160862855	"CD markers, Plasma proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 75.8;lymphoid tissue: 22.1"	"Cell type enhanced"	"Detected in some"	15	"Alveolar cells type 2: 9.6;Kupffer cells: 15.1;T-cells: 19.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in many"		"basophil: 75.8"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 75.8"	"Cell line enhanced"	"Detected in some"		"HEL: 10.9;HMC-1: 38.3;NB-4: 7.5;U-937: 15.3"					"Not detected"	"Not detected"									NA	NA						"unprognostic (6.11e-3)"	"unprognostic (1.54e-2)"	"unprognostic (1.85e-2)"	"unprognostic (6.95e-6)"	"unprognostic (5.79e-2)"	"unprognostic (1.43e-4)"	"unprognostic (1.93e-2)"	"unprognostic (7.36e-2)"	"unprognostic (3.36e-1)"	"unprognostic (2.85e-1)"	"unprognostic (1.60e-1)"	"unprognostic (2.32e-1)"	"unprognostic (5.40e-4)"	"unprognostic (1.71e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.87e-1)"	"unprognostic (1.79e-1)"	2.9	0.4	0.5	3.3	0.5	8.6	0.6	0.3	0.7	0.9	3.1	0.4	1.6	2.8	1.4	0.7	1.0	0.7	1.7	2.0	0.5	0.5	0.7	4.1	5.3	7.4	1.7	0.0	1.6	0.5	0.0	0.5	1.8	1.1	1.6	1.2	1.0	1.6	0.9	1.1	0.5	6.0	2.6	1.5	22.1	0.8	2.8	0.6	0.7	0.6	0.0	4.0	1.5	0.8	0.0	7.9	75.8	13.2	14.0	14.8	11.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.9	0.0	0.0	0.2	3.5	38.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	1.0	7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	0.0	0.0	0.0	0.0	1.4	0.5	0.0	0.0	15.3	0.0	75.8	8.2	20.1	14.8	11.2	7.3	0.0	0.8	8.1	7.9	0.0	1.1	7.8	0.6	14.0	13.2	0.4	0.0	11.3	0.5	0.5	0.3	0.7	0.5	0.5	1.7	0.0	1.1	0.6	3.0	9.6	0.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	1.6	0.0	0.2	0.0	3.5	0.0	0.6	0.0	0.0	0.0	15.1	1.9	1.7	3.5	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	19.8	0.0	0.0
CD247	"CD3H, CD3Q, CD3Z"	ENSG00000198821	"CD247 molecule"	P20963	1	167430640-167518610	"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 62.8;lymphoid tissue: 129.5"	"Cell type enriched"	"Detected in many"	10	"T-cells: 248.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	26	"gdT-cell: 62.8;MAIT T-cell: 35.4;memory CD4 T-cell: 32.4;memory CD8 T-cell: 36.7;naive CD4 T-cell: 41.3;naive CD8 T-cell: 33.5;NK-cell: 33.4;T-reg: 39.0"	"Group enriched"	"Detected in many"	31	"NK-cells: 33.4;T-cells: 62.8"	"Group enriched"	"Detected in some"	25	"HDLM-2: 46.4;JURKAT: 34.6;MOLT-4: 48.9"	"Region enhanced"	"Detected in single"		"thalamus: 0.7"	"Low region specificity"	"Detected in all"			"CAB004651, HPA008750"	Enhanced					NA	NA					"CAB004651: AB_425347, HPA008750: AB_1857863"	"prognostic favorable (9.12e-4)"	"unprognostic (3.21e-3)"	"unprognostic (7.09e-3)"	"prognostic favorable (8.63e-6)"	"unprognostic (1.99e-2)"	"prognostic favorable (3.98e-4)"	"unprognostic (1.79e-2)"	"unprognostic (1.11e-2)"	"unprognostic (5.46e-3)"	"unprognostic (9.73e-3)"	"unprognostic (1.33e-2)"	"unprognostic (2.50e-1)"	"prognostic unfavorable (9.94e-6)"	"unprognostic (1.60e-1)"	"unprognostic (5.33e-2)"	"unprognostic (4.02e-2)"	"unprognostic (5.94e-3)"	2.3	0.5	0.9	13.5	2.1	17.8	1.3	1.2	1.1	1.4	4.4	0.7	0.7	2.9	1.5	1.6	1.4	1.2	2.9	1.0	0.8	1.4	1.9	3.2	7.3	24.3	1.0	0.5	1.0	0.5	0.0	0.6	1.3	0.7	2.0	1.8	1.7	3.3	0.4	1.4	0.6	9.8	0.8	0.9	28.6	2.7	0.9	0.5	129.5	1.8	0.9	18.1	3.5	1.4	1.5	0.4	1.4	0.2	33.4	62.8	31.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.4	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	34.6	0.0	0.0	0.0	0.0	48.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	1.0	0.1	0.0	62.8	0.2	35.4	1.5	32.4	36.7	0.2	0.5	41.3	33.5	1.4	33.4	0.1	0.4	39.0	31.4	0.9	2.1	1.2	1.1	0.8	1.4	1.0	0.5	0.7	0.5	3.0	26.0	2.2	0.1	1.3	0.2	0.4	2.5	4.0	2.3	0.0	0.0	0.0	0.0	0.0	0.2	1.6	0.0	0.0	0.0	0.1	0.7	0.1	5.8	0.6	0.3	3.2	0.0	5.5	5.9	0.0	0.0	1.2	3.3	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.3	0.1	1.5	0.5	0.1	248.3	0.0	0.0
CD248	"CD164L1, TEM1"	ENSG00000174807	"CD248 molecule"	Q9HCU0	11	66314487-66317044	"CD markers, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 71.0"	"Cell type enhanced"	"Detected in many"	14	"Fibroblasts: 70.0;Leydig cells: 69.3;Sertoli cells: 32.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	6	"naive CD8 T-cell: 17.8"	"Lineage enriched"	"Detected in single"	122	"T-cells: 17.8"	"Cell line enhanced"	"Detected in some"		"ASC diff: 68.1;ASC TERT1: 67.2;BJ: 29.4;BJ hTERT+: 44.3;fHDF/TERT166: 59.3;HSkMC: 71.6;U-2197: 107.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			HPA051856	Enhanced		Approved	"Nucleoplasm,Plasma membrane"		NA	NA		27000000	"Plasma membrane"	Nucleoplasm	"HPA051856: AB_2681640"	"unprognostic (2.26e-1)"	"unprognostic (1.72e-1)"	"unprognostic (8.95e-2)"	"unprognostic (2.77e-2)"	"unprognostic (1.14e-2)"	"unprognostic (2.61e-1)"	"unprognostic (7.21e-3)"	"unprognostic (1.36e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.82e-2)"	"unprognostic (6.31e-2)"	"unprognostic (4.77e-2)"	"prognostic unfavorable (2.69e-7)"	"unprognostic (1.90e-2)"	"unprognostic (2.92e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.30e-2)"	59.2	3.5	0.8	14.4	2.5	0.0	55.2	0.6	2.2	21.2	7.6	1.9	6.3	2.7	14.1	22.9	14.8	17.7	12.3	18.2	1.2	0.5	5.3	1.7	9.3	16.2	1.3	1.6	15.6	4.9	1.4	2.3	71.0	2.1	10.6	2.7	11.5	4.6	8.0	6.7	13.3	7.5	27.6	1.2	1.9	7.5	8.0	0.7	4.1	9.4	6.6	4.5	19.5	17.6	0.1	0.0	0.0	0.0	0.0	17.8	1.9	0.0	0.0	0.6	0.0	68.1	67.2	0.0	29.4	44.3	2.2	2.0	0.0	0.0	0.0	0.7	59.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.4	13.5	0.0	0.0	71.6	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.3	0.0	0.1	1.2	0.0	0.0	0.0	0.0	0.3	1.0	0.0	0.1	0.0	1.9	0.0	0.0	0.0	0.0	0.1	107.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.8	0.0	0.0	2.3	0.0	0.1	2.8	17.8	0.0	0.0	0.0	0.0	0.0	1.9	0.8	2.5	0.6	2.2	1.2	0.5	1.3	1.6	2.1	0.7	0.0	0.0	0.0	0.0	11.1	0.0	2.1	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.2	0.3	2.5	0.0	0.0	0.0	2.5	70.0	0.0	0.0	0.0	5.5	0.0	0.0	4.3	0.0	0.4	69.3	0.0	11.8	1.0	0.0	3.6	0.4	0.0	19.1	0.0	0.0	32.3	12.2	0.1	0.0	7.2	3.7	0.0	0.0	0.0
CD27	"S152, TNFRSF7, Tp55"	ENSG00000139193	"CD27 molecule"	P26842	12	6444867-6451718	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 82.3;lymphoid tissue: 60.4"	"Group enriched"	"Detected in some"	10	"B-cells: 95.4;Erythroid cells: 70.0;Melanocytes: 92.8;T-cells: 73.4"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"T-reg: 82.3"	"Group enriched"	"Detected in many"	7	"B-cells: 41.8;T-cells: 82.3"	"Group enriched"	"Detected in some"	141	"Daudi: 65.2;U-698: 36.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"CAB002420, HPA038936"	Enhanced					NA	NA		28000			"CAB002420: AB_563539, HPA038936: AB_2676278"	"unprognostic (2.75e-3)"	"prognostic favorable (3.77e-5)"	"unprognostic (8.87e-3)"	"prognostic favorable (2.90e-4)"	"unprognostic (2.35e-1)"	"prognostic favorable (6.65e-7)"	"unprognostic (3.56e-2)"	"unprognostic (9.37e-2)"	"prognostic favorable (5.50e-4)"	"unprognostic (1.31e-3)"	"unprognostic (4.32e-2)"	"unprognostic (2.74e-1)"	"prognostic unfavorable (1.19e-6)"	"unprognostic (2.80e-1)"	"unprognostic (3.15e-1)"	"unprognostic (1.28e-1)"	"unprognostic (7.35e-2)"	1.1	0.6	0.4	40.8	0.5	2.0	1.2	0.4	0.4	1.7	10.0	0.2	0.5	5.3	0.8	0.6	4.9	1.6	3.7	0.9	0.4	0.4	1.7	1.0	2.9	49.5	0.4	0.1	1.0	0.5	0.0	0.6	0.4	0.2	1.3	2.9	1.2	10.7	1.4	0.4	0.6	19.4	0.2	0.6	45.7	3.7	0.5	0.1	33.5	3.1	2.3	60.4	9.1	1.2	41.8	0.3	0.8	0.1	8.3	82.3	22.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	65.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	36.1	0.0	0.0	0.0	0.8	0.1	0.1	16.7	0.1	28.7	41.8	40.1	37.5	0.1	10.5	55.6	39.1	0.8	8.3	0.1	0.3	82.3	22.1	0.4	0.5	0.4	0.4	0.4	0.4	0.4	0.1	0.2	0.1	0.0	8.2	95.4	0.1	2.1	1.0	0.0	0.0	1.4	1.2	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	70.0	0.0	0.0	1.9	0.2	1.1	1.0	0.2	0.0	1.2	1.3	2.5	0.0	0.3	0.2	92.8	0.0	0.0	0.3	0.0	0.0	0.4	0.4	1.3	0.0	0.2	0.1	0.0	2.8	0.2	73.4	0.0	0.0
CD274	"B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1"	ENSG00000120217	"CD274 molecule"	Q9NZQ7	9	5450503-5470566	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lung: 23.9;placenta: 56.0"	"Cell type enhanced"	"Detected in many"	14	"granulocytes: 26.7;monocytes: 73.9;Syncytiotrophoblasts: 37.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 8.4"	"Group enriched"	"Detected in many"	6	"granulocytes: 8.4;T-cells: 2.4"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 34.2;HHSteC: 22.8;U-251 MG: 37.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA003528, CAB076385"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Actin filaments"		NA	NA			"Plasma membrane, Actin filaments"	Nucleoplasm	"CAB076385: AB_2687655, HPA003528: "	"prognostic favorable (8.89e-4)"	"unprognostic (4.54e-2)"	"prognostic favorable (1.64e-5)"	"unprognostic (1.27e-2)"	"unprognostic (2.96e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.61e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.68e-2)"	"unprognostic (5.67e-4)"	"unprognostic (7.39e-3)"	"unprognostic (1.69e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.49e-2)"	"unprognostic (2.67e-1)"	"unprognostic (9.02e-2)"	3.4	2.1	1.7	10.8	3.2	1.4	2.2	2.5	3.3	2.0	2.3	2.5	2.8	2.6	1.7	2.4	3.0	1.9	4.3	9.5	1.4	3.7	3.0	3.6	23.9	6.4	2.3	0.7	1.7	2.7	3.8	7.4	56.0	3.2	2.9	2.2	3.3	1.7	1.6	4.3	1.3	2.7	2.3	2.4	12.8	1.9	1.2	1.0	11.6	3.7	2.1	5.8	3.1	1.9	0.9	0.0	8.4	0.1	0.4	2.4	0.7	5.9	0.1	0.0	0.2	0.0	0.0	0.0	11.9	10.1	3.0	4.2	0.0	1.9	0.0	0.2	0.3	1.5	0.2	0.0	5.2	9.9	34.2	0.0	3.4	0.1	0.0	22.8	0.0	0.0	0.2	0.0	6.3	9.3	3.1	5.9	0.3	0.0	1.1	9.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	1.7	0.3	0.6	0.1	0.0	0.1	0.1	0.9	0.7	0.9	0.0	0.1	10.9	6.5	2.0	0.2	37.9	0.2	0.1	0.1	2.1	0.1	0.0	8.4	0.1	0.3	1.2	0.1	2.1	0.9	2.4	1.8	0.0	0.2	1.3	0.7	5.7	0.4	0.0	0.0	1.1	0.7	1.7	3.2	2.5	3.3	1.4	3.7	2.3	0.7	3.2	1.0	11.9	10.7	0.5	1.2	4.0	1.4	6.5	0.0	4.0	3.4	0.0	0.0	4.9	0.0	6.4	0.2	6.3	0.8	0.0	3.7	20.2	1.9	0.9	26.7	1.0	4.9	0.0	0.0	10.4	1.9	0.0	0.3	7.7	3.3	73.9	0.1	0.6	12.0	0.0	0.4	0.4	0.1	0.0	0.9	0.5	0.7	2.3	37.2	1.3	0.2	2.2
CD276	"B7-H3, B7H3, B7RP-2"	ENSG00000103855	"CD276 molecule"	Q5ZPR3	15	73683966-73714518	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	11	"Extravillous trophoblasts: 186.5;Hofbauer cells: 70.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	4	"neutrophil: 4.0"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 4.0"	"Cell line enhanced"	"Detected in many"		"HaCaT: 42.2;U-2197: 55.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA009285, HPA017139, CAB017826"	Enhanced		Approved	Vesicles		NA	NA		8900000	Vesicles		"CAB017826: , HPA009285: AB_1078258, HPA017139: AB_1845246"	"unprognostic (1.05e-1)"	"unprognostic (4.74e-3)"	"unprognostic (4.57e-3)"	"unprognostic (9.62e-2)"	"unprognostic (1.26e-2)"	"unprognostic (5.50e-3)"	"prognostic unfavorable (9.81e-4)"	"unprognostic (2.57e-3)"	"unprognostic (1.89e-1)"	"unprognostic (3.75e-2)"	"unprognostic (1.54e-2)"	"unprognostic (3.29e-2)"	"prognostic unfavorable (6.31e-5)"	"unprognostic (1.17e-1)"	"unprognostic (9.22e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.34e-3)"	32.3	16.6	5.8	9.2	3.9	0.6	17.1	3.6	5.3	19.4	8.3	5.1	4.2	8.8	17.2	17.9	6.3	8.1	14.3	12.3	5.6	3.6	7.2	22.9	9.3	6.7	4.6	3.8	16.8	14.3	3.5	5.3	27.7	7.9	16.5	4.2	20.5	12.8	7.8	7.1	12.6	7.0	13.8	4.4	7.4	8.4	9.9	3.9	1.2	7.8	8.3	4.7	12.4	13.6	0.4	0.5	4.0	0.6	0.8	0.2	0.0	9.8	12.2	8.4	18.4	15.4	9.3	25.7	11.5	9.5	7.6	6.9	21.5	20.7	0.1	18.8	10.9	14.6	42.2	9.0	10.3	1.3	7.5	20.4	0.8	12.8	10.3	4.7	0.2	12.3	7.4	5.0	6.9	4.5	5.3	10.0	0.0	3.2	0.2	1.7	15.3	0.1	0.5	20.4	1.9	8.9	0.1	12.3	1.6	6.6	13.7	5.8	14.0	10.7	5.3	20.8	7.1	8.8	5.3	11.5	16.8	15.1	55.2	11.6	0.2	0.2	0.2	27.9	0.9	11.5	0.9	0.3	0.5	0.1	0.6	0.2	0.2	0.1	0.2	0.2	0.4	0.2	0.1	4.0	0.8	0.3	0.5	0.1	0.0	5.8	3.9	3.6	5.2	5.6	3.6	4.6	3.8	7.9	3.9	17.9	7.2	0.5	9.2	13.4	21.2	7.0	5.1	5.3	18.2	10.4	29.5	8.8	1.7	42.7	0.7	8.9	4.0	0.0	16.3	186.5	42.4	15.5	14.9	13.9	70.5	9.5	8.6	5.5	5.8	0.7	9.2	20.9	23.6	7.2	12.1	8.9	22.2	17.3	16.3	2.4	27.5	12.9	41.2	1.2	2.8	8.9	10.3	0.5	8.7	6.5
CD28		ENSG00000178562	"CD28 molecule"	P10747	2	203706475-203738912	"CD markers, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 32.7;lymphoid tissue: 48.6"	"Group enriched"	"Detected in some"	8	"Hofbauer cells: 25.7;T-cells: 16.6"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"T-reg: 32.7"	"Lineage enriched"	"Detected in many"	6	"T-cells: 32.7"	"Group enriched"	"Detected in some"	14	"Karpas-707: 73.8;RPMI-8226: 33.8;U-266/70: 60.7;U-266/84: 54.2"	"Region enhanced"	"Detected in single"		"olfactory region: 1.3"	"Low region specificity"	"Detected in all"			HPA070003	Enhanced					NA	NA					"HPA070003: AB_2686226"	"unprognostic (5.54e-2)"	"unprognostic (2.16e-4)"	"unprognostic (1.90e-3)"	"unprognostic (2.49e-3)"	"unprognostic (3.44e-2)"	"unprognostic (6.07e-5)"	"unprognostic (9.09e-2)"	"unprognostic (4.66e-2)"	"unprognostic (3.40e-1)"	"unprognostic (1.15e-1)"	"unprognostic (2.65e-1)"	"unprognostic (1.68e-1)"	"unprognostic (5.78e-5)"	"unprognostic (4.77e-2)"	"unprognostic (2.93e-2)"	"unprognostic (7.79e-2)"	"unprognostic (8.96e-2)"	5.1	0.6	0.4	14.2	0.5	1.9	3.3	0.3	0.4	1.1	1.6	0.4	0.2	0.6	1.1	2.3	1.5	2.1	3.0	4.5	0.4	0.5	1.7	1.5	3.8	23.3	0.5	0.2	1.4	0.6	0.0	0.6	11.0	0.2	1.2	1.3	1.2	3.1	0.8	0.7	1.0	7.2	0.9	0.8	9.0	1.6	0.9	0.0	48.6	1.5	0.8	29.9	4.5	1.4	0.1	0.0	5.1	0.2	0.0	32.7	4.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	73.8	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	33.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	60.7	54.2	0.5	0.0	0.0	0.0	0.5	0.2	0.3	3.0	0.1	18.2	0.1	19.4	9.5	0.0	0.1	17.0	6.5	5.1	0.0	0.1	0.0	32.7	4.7	0.4	0.5	0.3	0.4	0.4	0.5	0.5	0.2	0.2	0.0	0.0	2.2	2.2	0.0	2.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.8	0.0	1.1	0.0	25.7	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.4	0.1	16.6	0.0	0.0
CD300A	"CMRF-35-H9, CMRF35H, IGSF12, IRC1, IRC2, Irp60"	ENSG00000167851	"CD300a molecule"	Q9UGN4	17	74466416-74484796	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 81.1;brain: 28.7;lymphoid tissue: 57.8"	"Group enriched"	"Detected in some"	4	"granulocytes: 57.8;Hofbauer cells: 101.1;Kupffer cells: 71.3;Macrophages: 86.9;T-cells: 25.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"HMC-1: 42.2;NB-4: 17.2;RPMI-8226: 33.2"									"HPA010971, HPA011645"	Approved		Approved	"Vesicles,Plasma membrane,Cytosol"	"Intracellular and membrane"	NA	NA		2800000	"Plasma membrane"	"Vesicles, Cytosol"	"HPA010971: , HPA011645: AB_1846988"	"unprognostic (1.99e-1)"	"unprognostic (4.60e-2)"	"unprognostic (3.88e-2)"	"unprognostic (3.30e-2)"	"unprognostic (2.73e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.04e-2)"	"unprognostic (2.63e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.17e-2)"	"unprognostic (7.87e-2)"	"unprognostic (1.07e-1)"	"prognostic unfavorable (1.91e-5)"	"unprognostic (5.97e-2)"	"unprognostic (5.45e-3)"	"unprognostic (1.36e-1)"	"unprognostic (5.72e-2)"	8.6	4.5	9.8	16.0	17.7	11.9	4.4	2.2	11.5	2.0	4.8	3.7	0.0	6.0	1.9	1.3	2.1	2.1	7.7	3.4	7.3	4.2	3.0	7.5	10.6	19.0	20.1	0.3	1.5	2.1	0.3	3.0	6.9	12.6	2.8	4.7	2.3	3.0	1.3	1.1	2.3	7.4	6.0	28.7	57.8	2.4	1.5	17.4	4.1	1.9	0.5	6.0	5.4	2.1	2.2	19.4	81.1	45.7	52.1	29.5	19.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	2.0	42.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.5	17.2	0.0	0.0	0.0	0.0	0.0	33.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	6.4	0.0	81.1	20.4	57.3	29.5	45.7	6.2	2.2	6.1	8.7	19.4	0.6	2.3	7.1	71.6	52.1	44.2	18.1	0.3	19.2	9.8	17.7	2.2	11.5	7.3	4.2	20.1	0.3	12.6	17.4	0.0	11.9	15.7	0.0	0.8	0.0	0.4	2.5	0.0	1.2	0.0	0.0	0.7	0.0	0.1	0.0	0.5	0.0	0.0	0.0	1.0	0.5	0.1	57.8	0.8	101.1	0.0	0.0	3.1	71.3	0.0	0.0	86.9	3.3	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.2	0.0	0.5	0.5	1.3	25.9	0.0	0.1
CD300C	"CMRF-35A, CMRF35, CMRF35A, IGSF16, LIR"	ENSG00000167850	"CD300c molecule"	Q08708	17	74541108-74546143	"CD markers, Predicted membrane proteins"	Immunity	Receptor		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"blood: 46.8"	"Group enriched"	"Detected in some"	12	"granulocytes: 15.0;Hofbauer cells: 29.5;Kupffer cells: 28.1;Macrophages: 33.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"classical monocyte: 28.6;intermediate monocyte: 46.8;myeloid DC: 32.5;non-classical monocyte: 46.4"	"Group enriched"	"Detected in many"	5	"dendritic cells: 32.5;monocytes: 46.8"	"Cell line enhanced"	"Detected in some"		"HEL: 5.3;HMC-1: 26.2;THP-1: 4.9;U-937: 12.4"									"HPA014523, HPA060349"	Approved		Uncertain	"Golgi apparatus,Vesicles,Mitochondria"		NA	NA			"Golgi apparatus"	"Vesicles, Mitochondria"	"HPA014523: AB_1846293, HPA060349: "	"unprognostic (1.55e-2)"	"unprognostic (2.60e-1)"	"unprognostic (9.99e-3)"	"unprognostic (3.79e-1)"	"unprognostic (1.21e-1)"	"unprognostic (3.47e-2)"	"unprognostic (3.81e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.68e-2)"	"unprognostic (7.51e-2)"	"unprognostic (6.51e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.37e-3)"	"unprognostic (6.27e-2)"	"prognostic unfavorable (8.53e-5)"	"unprognostic (1.16e-2)"	"unprognostic (1.09e-1)"	9.8	2.8	3.6	9.0	4.6	10.9	1.8	0.4	2.9	1.2	1.7	2.9	0.0	1.5	1.4	1.9	1.0	1.9	2.8	3.4	2.0	1.7	1.9	2.1	11.2	12.3	5.3	1.3	1.1	1.3	0.5	1.2	3.8	3.9	1.9	1.8	1.8	1.8	0.7	1.1	0.9	2.3	4.1	7.1	14.2	1.6	0.9	2.7	0.1	1.6	0.1	1.4	3.5	1.1	0.4	32.5	8.4	46.8	8.6	0.1	10.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	2.4	26.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	2.7	0.0	0.0	0.1	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	4.9	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.7	12.4	0.0	8.4	28.6	1.4	0.1	46.8	0.1	0.4	0.0	0.0	32.5	0.3	0.0	0.0	1.0	8.6	46.4	2.1	0.0	10.7	3.6	4.6	0.4	2.9	2.0	1.7	5.3	1.3	3.9	2.7	0.0	2.2	0.0	0.0	0.3	0.0	0.0	0.0	1.4	1.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0	15.0	0.0	29.5	0.0	0.0	0.0	28.1	0.0	0.0	33.8	1.7	1.8	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0
CD300E	"CD300LE, CLM2, IREM2"	ENSG00000186407	"CD300e molecule"	Q496F6	17	74609887-74623738	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 36.5;bone marrow: 22.5;lymphoid tissue: 21.0"	"Cell type enhanced"	"Detected in some"	23	"Alveolar cells type 2: 25.2;Club cells: 15.9;Kupffer cells: 69.4;Macrophages: 16.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	5	"classical monocyte: 22.7;intermediate monocyte: 36.5;non-classical monocyte: 36.3"	"Lineage enriched"	"Detected in many"	6	"monocytes: 36.5"	"Cell line enhanced"	"Detected in some"		"HeLa: 1.7;SCLC-21H: 1.5"	"Low region specificity"	"Detected in single"							HPA015570	Uncertain					NA	NA					"HPA015570: AB_1846294"	"unprognostic (1.70e-1)"	"unprognostic (6.82e-2)"	"unprognostic (1.76e-1)"	"unprognostic (2.63e-2)"	"unprognostic (1.42e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.68e-2)"	"unprognostic (7.80e-3)"	"unprognostic (4.51e-1)"	"unprognostic (1.53e-1)"	"unprognostic (2.69e-2)"	"unprognostic (5.15e-2)"	"unprognostic (4.19e-7)"	"unprognostic (1.90e-2)"	"unprognostic (2.00e-4)"	"unprognostic (7.38e-3)"	"unprognostic (1.19e-1)"	8.5	0.7	0.5	21.0	0.6	22.5	0.7	1.2	1.0	0.5	1.2	0.3	0.0	0.0	0.7	3.0	0.9	1.5	1.9	2.0	0.5	0.5	2.5	1.1	14.3	9.4	0.5	0.2	1.0	0.8	0.0	0.5	1.7	0.7	0.6	0.2	1.1	0.6	1.6	1.6	0.6	0.7	5.3	0.9	14.3	0.8	0.7	0.3	0.2	1.2	0.8	0.8	1.8	0.6	0.0	5.9	0.5	36.5	0.0	0.0	11.6	0.2	0.0	1.1	0.1	0.0	0.1	0.2	0.2	0.2	0.0	0.1	1.1	0.0	0.5	0.2	0.3	0.3	0.2	0.0	0.1	0.0	0.1	0.1	0.0	1.7	0.8	0.0	0.9	0.3	0.1	0.3	0.0	0.0	0.5	0.0	0.5	0.2	0.5	0.0	0.9	0.2	0.8	0.5	0.2	0.4	0.2	0.0	0.2	0.1	0.6	1.5	0.5	0.3	0.0	0.1	1.2	0.6	0.0	0.0	0.5	0.7	0.7	0.2	0.9	0.0	0.1	0.0	0.7	0.5	0.0	22.7	0.1	0.0	36.5	0.0	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.5	0.0	36.3	0.1	0.0	11.6	0.5	0.6	1.2	1.0	0.5	0.5	0.5	0.2	0.7	0.3	6.0	25.2	1.4	0.0	0.6	0.2	0.3	0.0	2.7	15.9	1.8	0.0	0.1	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	3.5	0.2	4.1	0.0	0.0	0.6	69.4	0.0	0.0	16.8	1.7	1.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.3	0.0	0.0	0.0
CD300LB	"CLM7, TREM5"	ENSG00000178789	"CD300 molecule like family member b"	A8K4G0	17	74521174-74531474	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	4	"adipose tissue: 20.7;blood: 30.7;bone marrow: 8.8;lymphoid tissue: 10.9"	"Group enriched"	"Detected in some"	8	"Hofbauer cells: 6.5;Kupffer cells: 10.1;Macrophages: 10.7"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in many"		"eosinophil: 30.7"	"Group enriched"	"Detected in many"	52	"dendritic cells: 10.5;granulocytes: 30.7;monocytes: 13.0"	"Group enriched"	"Detected in some"	6	"HL-60: 4.6;NB-4: 6.0;THP-1: 4.7;U-937: 2.8"									HPA060449			Approved	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA060449: "	"unprognostic (1.39e-1)"	"unprognostic (2.44e-2)"	"unprognostic (1.37e-1)"	"unprognostic (4.39e-2)"	"unprognostic (3.59e-2)"	"unprognostic (1.15e-1)"	"unprognostic (6.41e-2)"	"unprognostic (7.69e-2)"	"unprognostic (2.05e-1)"	"unprognostic (2.95e-2)"	"unprognostic (6.24e-2)"	"unprognostic (3.32e-1)"	"unprognostic (2.49e-4)"	"unprognostic (2.92e-2)"	"unprognostic (1.79e-2)"	"unprognostic (7.08e-2)"	"unprognostic (4.01e-2)"	20.7	0.9	0.2	10.9	0.5	8.8	2.0	0.4	0.5	0.6	0.8	0.3	0.1	0.7	0.7	1.0	1.1	1.2	2.8	1.6	1.5	0.4	1.2	1.0	4.4	6.5	1.2	0.1	2.0	2.3	0.0	0.7	1.1	1.0	0.8	1.1	1.6	1.2	0.1	0.3	0.4	2.0	2.2	0.6	6.6	0.7	0.7	0.1	0.9	0.6	0.1	2.2	2.6	0.7	0.0	10.5	30.7	13.0	0.3	0.1	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.4	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.7	2.8	0.0	0.6	13.0	30.7	0.0	5.6	0.1	0.0	0.0	0.0	10.5	0.0	0.0	0.1	13.8	0.3	0.7	6.6	0.0	4.2	0.2	0.5	0.4	0.5	1.5	0.4	1.2	0.1	1.0	0.1	0.0	0.0	0.5	0.0	0.1	0.0	0.3	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	6.5	0.0	0.0	0.6	10.1	0.0	0.0	10.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
CD300LD	"CD300D, CMRF35A4"	ENSG00000204345	"CD300 molecule like family member d"	Q6UXZ3	17	74579365-74592283	"CD markers, Predicted membrane proteins"	Immunity	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"blood: 8.5;bone marrow: 3.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Cell type enriched"	"Detected in some"	7	"neutrophil: 8.5"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 8.5"	"Cell line enhanced"	"Detected in some"		"HMC-1: 4.5;RPMI-8226: 2.7"									HPA027756	Uncertain					NA	NA					"HPA027756: AB_10601097"			"unprognostic (8.03e-2)"											"unprognostic (3.30e-1)"				0.3	0.2	0.1	2.2	0.1	3.2	0.2	0.2	0.3	0.4	0.2			0.0	0.2	0.0	0.2	0.4	0.3	0.3	0.1	0.1	0.1	0.2	0.9	0.7	0.1		0.1	0.1	0.0	0.1	0.1		0.1	0.0		1.1	0.0	0.1	1.6	0.9	0.1	0.1	1.4	0.2	1.7			0.1		0.6	0.4	0.1	0.5	0.7	8.5	0.7	0.8	1.3	0.2	0.4	0.3	0.5	1.1	0.6	0.0	0.3	0.0	0.0	0.0	0.1	0.3	0.4	0.6	0.3	0.5	0.6	0.5	0.3	0.5	0.0	0.5	0.2	0.2	1.6	0.7	0.0	1.2	4.5	0.6	0.4	0.3	0.5	0.6	0.0	0.5	0.5	1.8	0.2	1.4	0.2	0.6	0.5	0.0	0.6	0.4	0.6	2.7	0.5	0.8	0.5	0.5	0.7	0.5	0.0	0.6	0.6	0.1	0.5	0.6	0.5	1.1	0.0	0.9	0.3	0.6	0.2	0.3	0.4	0.8	0.4	0.4	0.4	0.7	0.2	0.3	0.3	0.2	0.7	0.5	0.5	0.4	8.5	0.8	0.4	0.5	1.3	0.2											0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CD300LF	"CD300f, CLM1, IGSF13, IREM1, NKIR"	ENSG00000186074	"CD300 molecule like family member f"	Q8TDQ1	17	74694311-74712978	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 47.8;bone marrow: 18.2;lung: 24.1;lymphoid tissue: 29.1"	"Cell type enhanced"	"Detected in some"	13	"granulocytes: 22.0;Hofbauer cells: 21.0;Kupffer cells: 28.8;Macrophages: 32.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"eosinophil: 47.8"	"Group enriched"	"Detected in many"	46	"dendritic cells: 13.5;granulocytes: 47.8;monocytes: 38.1"	"Group enriched"	"Detected in some"	6	"THP-1: 16.0;U-937: 30.9"									HPA013712	Supported					NA	NA					"HPA013712: AB_2668874"	"unprognostic (6.51e-2)"	"unprognostic (1.49e-3)"	"unprognostic (3.81e-2)"	"unprognostic (4.00e-2)"	"unprognostic (8.51e-2)"	"unprognostic (6.74e-2)"	"unprognostic (1.79e-1)"	"unprognostic (3.17e-3)"	"unprognostic (1.53e-2)"	"unprognostic (1.77e-1)"	"unprognostic (9.81e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.95e-1)"	"unprognostic (9.60e-2)"	"unprognostic (4.14e-2)"	"unprognostic (7.75e-2)"	"unprognostic (4.79e-2)"	3.3	1.0	1.2	9.8	3.1	18.2	0.9	1.5	1.3	0.8	2.3	3.1	0.0	2.7	0.7	0.7	0.9	1.1	1.9	2.4	1.3	1.2	1.1	1.5	24.1	15.6	3.8	0.5	0.9	0.9	0.0	1.0	2.1	2.6	1.4	2.6	0.8	1.9	0.3	0.5	0.5	3.4	2.3	5.8	29.1	1.0	0.7	2.4	1.1	0.8	0.0	4.2	2.8	0.8	0.0	13.5	47.8	38.1	0.7	0.1	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.6	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	1.4	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	30.9	0.0	8.4	20.2	47.8	0.0	34.4	0.1	0.0	0.0	0.0	13.5	0.0	0.0	0.0	15.9	0.7	38.1	1.4	0.0	8.2	1.2	3.1	1.5	1.3	1.3	1.2	3.8	0.5	2.6	2.4	0.0	8.3	0.0	0.0	0.1	0.2	0.1	2.5	0.0	5.7	0.0	2.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	22.0	0.0	21.0	0.0	0.0	1.3	28.8	0.0	0.0	32.3	0.0	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
CD300LG	"CLM9, Trem4"	ENSG00000161649	"CD300 molecule like family member g"	Q6UXG3	17	43847148-43863629	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 76.1;breast: 45.4"	"Cell type enhanced"	"Detected in some"	19	"Ito cells: 6.7;Leydig cells: 12.0;Peritubular cells: 29.0;Sertoli cells: 12.9"	"Low cancer specificity"	"Detected in single"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 2.4"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BEWO: 2.0;NB-4: 1.1"															NA	NA		870000				"unprognostic (2.38e-2)"	"unprognostic (2.06e-3)"	"unprognostic (2.63e-1)"	"unprognostic (2.72e-1)"	"unprognostic (3.18e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.40e-4)"	"unprognostic (1.77e-1)"	"unprognostic (1.33e-1)"	"unprognostic (2.01e-2)"	"unprognostic (4.08e-3)"	"unprognostic (8.69e-4)"	"unprognostic (2.12e-5)"	"unprognostic (1.30e-3)"	"unprognostic (1.45e-1)"	"unprognostic (1.76e-2)"	"unprognostic (1.57e-1)"	76.1	0.9	0.1	2.8	0.2	0.0	45.4	0.1	0.5	2.2	6.1	0.1	1.2	0.0	1.7	5.4	1.5	1.8	1.7	10.5	0.1	0.0	1.9	1.4	4.6	0.5	0.1	0.2	0.8	1.1	0.2	0.1	25.2	0.2	2.6	0.1	1.4	1.7	0.8	8.2	3.1	0.9	0.3	0.1	1.1	1.0	16.0	0.1	2.1	1.2	1.7	0.2	1.5	7.8	0.5	1.6	2.4	0.2	0.6	0.2	0.1	0.1	0.0	0.1	0.3	0.0	0.0	2.0	0.3	0.0	0.6	0.2	0.0	0.2	0.0	1.0	0.0	0.7	0.1	0.0	0.4	0.3	0.4	0.0	0.5	1.0	0.4	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.1	0.0	1.1	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.3	0.7	0.0	0.1	0.2	0.8	0.2	0.1	0.0	0.2	0.6	0.4	0.3	0.1	0.6	0.3	0.4	0.1	0.1	2.4	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0.2	1.6	0.5	0.2	0.2	1.2	0.6	0.1	0.4	0.1	0.1	0.1	0.2	0.1	0.4	0.1	0.0	0.1	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	2.8	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.5	5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	6.7	0.3	1.5	12.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	29.0	0.0	0.0	12.9	0.0	0.4	0.6	0.4	0.0	0.0	0.0	0.0
CD302	"BIMLEC, CLEC13A, DCL-1, KIAA0022"	ENSG00000241399	"CD302 molecule"	Q8IX05	2	159768630-159798255	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in all"		"liver: 113.8"	"Cell type enhanced"	"Detected in many"	11	"Hepatocytes: 257.0;Kupffer cells: 378.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	190	"dendritic cells: 17.0;granulocytes: 19.1;monocytes: 20.8"	"Cell line enriched"	"Detected in many"	5	"ASC diff: 77.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA		16000				"unprognostic (2.52e-1)"	"unprognostic (5.44e-2)"	"unprognostic (1.19e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.03e-1)"	"unprognostic (6.88e-2)"	"unprognostic (1.68e-2)"	"unprognostic (9.12e-3)"	"unprognostic (5.29e-3)"	"unprognostic (2.37e-2)"	"unprognostic (4.38e-2)"	"unprognostic (2.14e-1)"	"unprognostic (4.67e-3)"	"unprognostic (1.75e-2)"	"unprognostic (6.61e-2)"	"unprognostic (7.45e-2)"	"unprognostic (3.61e-3)"	27.1	9.4	5.0	6.1	5.9	10.1	28.6	3.3	4.3	13.8	13.8	4.0	2.6	8.7	11.4	11.0	7.9	9.7	11.7	13.7	5.6	3.3	9.3	113.8	22.9	23.3	5.9	2.7	16.3	9.0	4.7	4.0	7.0	6.3	11.5	7.7	13.7	7.7	7.8	6.1	4.9	13.9	12.1	8.7	18.9	8.5	9.2	5.9	0.7	26.6	6.3	3.4	12.4	23.8	0.0	17.0	19.1	20.8	0.0	0.0	7.5	0.0	0.5	0.4	0.0	77.9	16.3	0.0	1.9	7.8	2.3	3.4	0.6	0.7	0.1	0.8	4.1	2.5	0.0	1.6	0.8	3.1	0.5	2.6	3.0	0.5	1.1	3.9	5.8	2.1	12.9	0.4	2.5	0.0	1.9	5.7	0.0	0.2	2.7	2.8	0.2	0.0	4.2	0.7	0.0	2.3	0.0	0.6	0.0	0.4	0.2	0.9	1.0	0.6	1.8	1.8	1.3	1.5	5.6	2.0	4.5	0.0	0.1	1.2	0.3	0.0	0.0	3.1	0.5	1.0	6.2	20.8	19.1	0.0	16.4	0.0	0.0	0.0	0.0	17.0	0.0	0.0	0.0	19.1	0.0	15.6	4.5	0.0	7.5	5.0	5.9	3.3	4.3	5.6	3.3	5.9	2.7	6.3	5.9	41.7	80.3	9.3	14.0	6.0	3.3	3.7	30.6	26.8	45.5	3.5	0.0	2.0	0.0	3.0	26.4	18.4	5.6	0.0	3.1	7.4	29.6	22.5	29.0	257.0	40.0	3.2	9.2	67.5	378.3	12.0	113.6	127.8	18.6	4.6	23.7	1.5	3.1	13.3	88.1	3.3	2.2	64.7	17.5	21.4	11.6	3.9	2.3	7.5	18.6	8.6
CD320	"8D6, 8D6A"	ENSG00000167775	"CD320 molecule"	Q9NPF0	19	8302127-8308356	"CD markers, Disease related genes, Predicted membrane proteins"		"Growth factor"	"Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Spermatocytes: 119.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"NB-4: 76.2;RPMI-8226: 69.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA014500, HPA073489"	Approved		Approved	Cytosol		NA	NA		400000	Cytosol		"HPA014500: AB_1846295, HPA073489: AB_2686609"	"unprognostic (9.97e-2)"	"unprognostic (2.62e-1)"	"unprognostic (3.51e-1)"	"unprognostic (2.54e-3)"	"unprognostic (2.17e-1)"	"unprognostic (2.39e-2)"	"prognostic unfavorable (4.02e-4)"	"unprognostic (4.19e-2)"	"unprognostic (7.13e-2)"	"unprognostic (1.31e-1)"	"unprognostic (9.35e-3)"	"unprognostic (1.25e-1)"	"unprognostic (2.03e-1)"	"unprognostic (1.07e-1)"	"unprognostic (8.92e-2)"	"unprognostic (3.14e-1)"	"unprognostic (9.90e-2)"	23.1	20.1	13.1	13.4	14.9	6.3	39.0	12.6	19.1	12.0	23.2	9.7	10.5	16.6	15.8	58.1	11.4	14.9	28.9	20.7	13.2	18.7	15.2	16.3	15.1	18.0	18.0	8.5	14.0	27.6	7.6	11.9	38.0	19.9	19.7	14.2	18.6	16.5	12.8	14.0	6.4	17.4	11.9	11.9	32.8	21.3	23.7	9.3	14.3	22.4	9.3	8.6	12.1	19.6	10.3	25.0	0.8	0.6	18.0	51.3	15.0	12.9	13.3	2.9	38.0	9.6	5.0	6.9	6.8	9.2	13.7	10.5	14.2	7.8	11.7	21.3	5.0	10.2	8.3	0.0	10.8	2.6	16.4	40.7	5.6	11.4	20.2	6.4	10.7	14.2	4.7	2.5	7.9	6.6	6.1	13.3	7.9	17.1	40.3	5.3	12.2	11.3	76.2	20.7	11.4	55.5	14.0	4.0	69.2	10.2	0.3	27.5	11.9	14.1	6.0	17.2	2.2	0.4	4.8	7.5	15.7	11.6	23.4	21.4	38.4	24.0	12.7	11.2	39.3	17.0	0.0	0.6	0.0	51.3	0.6	29.2	10.3	34.0	27.4	1.1	9.9	23.1	26.0	0.8	18.0	0.4	25.0	21.7	15.0	13.1	14.9	12.6	19.1	13.2	18.7	18.0	8.5	19.9	9.3	11.9	19.7	29.0	24.5	16.5	50.8	27.1	10.2	12.0	10.3	17.4	31.4	32.9	11.6	46.3	20.5	85.7	13.4	0.0	15.8	39.7	26.8	49.2	11.5	17.1	23.7	20.6	48.9	51.0	3.8	41.6	20.1	5.8	37.1	6.4	31.5	18.4	22.6	66.2	15.9	39.0	37.7	12.9	31.4	119.7	28.0	12.3	29.6	35.5	88.5	19.2
CD33	"FLJ00391, p67, SIGLEC-3, SIGLEC3"	ENSG00000105383	"CD33 molecule"	P20138	19	51225064-51243860	"CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 49.3;lymphoid tissue: 45.4"	"Group enriched"	"Detected in many"	7	"granulocytes: 73.9;Hofbauer cells: 67.4;Kupffer cells: 119.1;Macrophages: 56.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	7	"classical monocyte: 37.6;intermediate monocyte: 27.3;myeloid DC: 49.3;non-classical monocyte: 12.6"	"Group enriched"	"Detected in many"	9	"dendritic cells: 49.3;monocytes: 37.6"	"Cell line enhanced"	"Detected in some"		"HEL: 28.5;HL-60: 37.9;HMC-1: 28.4;NB-4: 18.1;RPMI-8226: 20.5;THP-1: 22.2;U-937: 28.0"									"CAB011442, HPA035832, HPA064807"	Approved		Approved	"Nucleoplasm,Plasma membrane"		NA	NA		1400000	"Nucleoplasm, Plasma membrane"		"CAB011442: , HPA035832: AB_2674808, HPA064807: AB_2685356"	"unprognostic (1.18e-2)"	"unprognostic (1.45e-2)"	"unprognostic (2.80e-2)"	"unprognostic (7.14e-2)"	"unprognostic (3.71e-1)"	"unprognostic (9.43e-2)"	"unprognostic (2.59e-1)"	"unprognostic (5.90e-3)"	"unprognostic (1.76e-1)"	"unprognostic (1.56e-1)"	"unprognostic (2.53e-1)"	"unprognostic (6.28e-2)"	"unprognostic (6.88e-4)"	"unprognostic (7.79e-2)"	"unprognostic (3.35e-2)"	"unprognostic (6.49e-2)"	"unprognostic (1.67e-1)"	10.2	4.3	3.6	8.4	6.0	23.0	6.5	0.8	3.5	2.6	2.7	4.4	0.3	2.5	2.3	5.2	1.7	3.9	5.3	7.5	3.1	2.5	4.1	6.4	11.6	45.4	6.4	1.8	1.9	1.9	0.5	1.7	5.4	5.2	2.6	3.4	2.6	2.9	2.1	1.2	2.5	4.0	5.6	9.9	31.6	2.8	1.5	5.8	2.5	1.7	0.2	2.7	4.7	2.3	0.1	49.3	4.6	37.6	3.3	0.2	14.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	1.7	0.1	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	28.5	0.1	0.0	0.0	37.9	28.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	5.2	7.2	0.0	0.0	0.0	18.1	0.0	0.0	8.7	0.0	1.5	20.5	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	22.2	0.2	4.9	0.4	0.6	0.0	0.1	2.4	0.0	3.3	28.0	0.1	3.3	37.6	2.3	0.0	27.3	0.1	0.0	0.0	0.1	49.3	0.1	0.0	0.0	4.6	3.3	12.6	1.4	0.2	14.7	3.6	6.0	0.8	3.5	3.1	2.5	6.4	1.8	5.2	5.8	0.0	10.7	1.4	0.5	1.5	0.1	0.6	0.0	1.4	1.2	0.0	0.0	0.7	0.0	0.0	0.4	1.5	0.0	0.0	0.0	0.4	1.5	0.3	73.9	0.8	67.4	0.0	0.0	8.6	119.1	1.3	0.3	56.4	1.7	2.8	0.0	0.2	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.7	0.5	0.9	0.7	1.7	0.0	0.3
CD34		ENSG00000174059	"CD34 molecule"	P28906	1	207880972-207911402	"CD markers, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"Endothelial cells: 214.1;Ito cells: 81.0;Leydig cells: 135.4;Peritubular cells: 115.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	6	"HUVEC TERT2: 32.6;MOLT-4: 32.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000018, HPA036722, HPA036723"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Cell Junctions"		NA	NA		69000000	"Plasma membrane, Cell Junctions"	Nucleoplasm	"CAB000018: AB_2063006, HPA036722: AB_2675271, HPA036723: AB_2675272"	"unprognostic (3.82e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.04e-1)"	"unprognostic (3.09e-1)"	"unprognostic (1.24e-1)"	"prognostic favorable (5.93e-5)"	"unprognostic (1.25e-2)"	"unprognostic (7.74e-2)"	"unprognostic (7.65e-2)"	"unprognostic (3.53e-1)"	"unprognostic (1.37e-3)"	"unprognostic (6.95e-2)"	"prognostic unfavorable (8.47e-4)"	"unprognostic (1.51e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.01e-2)"	61.9	8.8	4.6	12.8	7.6	1.9	37.5	3.1	6.7	38.3	15.9	5.2	20.5	5.0	41.4	40.3	33.8	22.3	20.6	51.2	5.4	4.9	18.8	2.2	25.0	11.9	8.1	6.7	20.7	8.6	7.8	3.6	78.9	6.3	21.0	7.4	12.8	12.4	20.5	39.7	21.2	12.1	42.3	4.7	9.2	11.3	23.1	4.7	3.5	25.8	35.9	11.0	33.6	33.1	0.6	1.7	1.6	0.3	0.6	0.5	1.5	0.0	0.0	0.1	0.0	1.6	0.1	0.1	0.2	1.2	0.3	0.9	0.0	0.0	0.0	3.2	0.3	0.1	0.0	0.0	0.0	0.3	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.4	32.6	0.5	0.0	0.0	0.8	0.0	32.1	0.1	0.2	0.0	0.0	0.0	1.9	0.0	0.1	0.0	0.0	0.1	0.0	0.3	0.0	0.2	1.1	0.0	4.9	0.1	1.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	1.6	0.2	0.3	0.5	0.2	0.5	0.3	0.3	0.2	0.2	0.6	0.3	0.3	1.1	0.6	0.3	1.7	0.2	1.5	4.6	7.6	3.1	6.7	5.4	4.9	8.1	6.7	6.3	4.7	3.0	8.5	0.0	0.1	14.8	0.4	12.3	2.5	0.0	0.0	3.5	2.0	0.2	0.0	0.2	10.9	214.1	0.0	0.0	0.2	0.3	22.6	0.2	1.1	0.5	0.3	0.0	0.0	81.0	0.3	4.2	135.4	2.2	16.9	0.0	0.0	0.3	0.2	0.0	115.6	0.0	0.0	6.5	4.1	0.7	0.5	11.3	0.1	0.0	0.0	0.3
CD36	"FAT, GP3B, GP4, GPIV, SCARB3"	ENSG00000135218	"CD36 molecule"	P16671	7	80369575-80679277	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	"Cell adhesion, Transport"	Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 464.3;breast: 156.1"	"Cell type enhanced"	"Detected in many"	16	"Cardiomyocytes: 491.8;Hofbauer cells: 1111.0;Ito cells: 465.9;Sertoli cells: 685.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"classical monocyte: 104.4;intermediate monocyte: 30.4;myeloid DC: 56.9"	"Group enriched"	"Detected in many"	45	"dendritic cells: 56.9;monocytes: 104.4"	"Group enriched"	"Detected in some"	5	"ASC diff: 82.7;HEL: 39.3"	"Low region specificity"	"Detected in many"							"HPA002018, CAB025866, HPA071026"	Enhanced		Enhanced	"Golgi apparatus"		NA	NA		92000000	"Golgi apparatus"		"CAB025866: , HPA002018: AB_1078464, HPA071026: AB_2732170"	"unprognostic (7.16e-2)"	"unprognostic (1.80e-2)"	"unprognostic (1.06e-3)"	"unprognostic (6.52e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.28e-1)"	"unprognostic (2.63e-1)"	"unprognostic (9.35e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.23e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.84e-3)"	"prognostic unfavorable (4.47e-4)"	"unprognostic (7.05e-3)"	"unprognostic (4.87e-2)"	"unprognostic (2.73e-3)"	464.3	3.6	1.2	8.9	1.3	10.9	156.1	0.5	0.5	1.8	31.8	0.6	3.3	9.8	1.8	7.5	7.5	3.3	7.2	76.8	1.8	1.9	2.2	13.3	11.5	4.8	0.6	0.3	2.5	3.9	3.1	0.8	37.9	2.9	9.2	3.5	0.8	4.6	2.3	23.6	5.4	23.4	4.7	0.8	42.8	5.0	6.0	0.5	2.7	13.6	15.3	1.4	9.4	19.2	0.3	56.9	1.8	104.4	0.7	0.2	60.2	0.0	0.0	0.2	0.1	82.7	0.8	0.1	0.2	2.8	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	1.0	0.1	0.0	0.1	0.1	39.3	0.1	6.3	0.0	0.0	0.0	8.0	3.1	0.0	0.0	1.9	0.2	0.0	1.4	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.3	0.2	0.1	0.0	0.7	2.7	4.5	0.0	0.1	0.5	0.1	0.0	0.0	0.1	0.1	0.0	13.5	10.4	0.9	104.4	0.3	0.2	30.4	0.2	0.3	0.0	0.0	56.9	0.0	0.1	0.0	1.8	0.7	7.5	14.3	0.1	60.2	1.2	1.3	0.5	0.5	1.8	1.9	0.6	0.3	2.9	0.5	6.0	69.8	5.2	0.1	6.5	0.0	491.8	7.6	0.0	5.7	7.0	0.0	8.5	0.0	0.0	9.2	46.6	0.0	163.5	0.0	9.4	14.4	0.7	14.0	12.1	1111.0	0.0	0.0	465.9	196.7	2.3	0.6	68.0	15.1	0.0	0.1	0.0	0.1	0.0	0.0	0.3	0.3	685.6	31.5	4.7	0.7	4.1	15.3	1.3	0.0	0.1
CD37	TSPAN26	ENSG00000104894	"CD37 molecule"	P11049	19	49335171-49343335	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 163.4;lymphoid tissue: 109.6"	"Cell type enhanced"	"Detected in many"	18	"B-cells: 979.0;granulocytes: 262.7;Hofbauer cells: 303.3;Kupffer cells: 224.9;Macrophages: 253.6;T-cells: 359.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 67.2;HMC-1: 66.6;RPMI-8226: 23.9;THP-1: 23.9;U-698: 14.8;U-937: 17.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB002492, HPA032120, HPA032121"	Enhanced		Approved	"Golgi apparatus,Plasma membrane"		NA	NA			"Golgi apparatus"	"Plasma membrane"	"CAB002492: AB_563554, HPA032120: AB_2674162, HPA032121: AB_2674163"	"unprognostic (4.30e-3)"	"unprognostic (2.39e-3)"	"unprognostic (8.85e-2)"	"prognostic favorable (4.51e-4)"	"unprognostic (5.46e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.76e-1)"	"unprognostic (6.23e-2)"	"unprognostic (5.34e-2)"	"unprognostic (2.23e-1)"	"unprognostic (1.22e-1)"	"unprognostic (3.06e-1)"	"unprognostic (2.45e-3)"	"unprognostic (7.12e-2)"	"unprognostic (3.35e-2)"	"unprognostic (7.22e-2)"	"unprognostic (7.71e-2)"	7.3	3.1	3.4	62.9	4.8	48.7	3.7	1.0	3.1	1.9	4.2	8.5	0.0	3.2	2.0	2.2	5.9	2.9	5.2	10.4	3.8	3.8	4.3	2.7	25.3	109.6	6.9	1.7	2.5	1.6	0.5	1.9	5.4	4.7	3.5	1.7	2.7	10.7	1.4	1.1	2.0	39.3	1.7	14.5	88.1	5.1	2.9	5.0	47.9	3.4	1.7	86.8	10.2	2.4	163.4	53.7	84.4	62.8	27.9	43.5	58.8	0.0	0.1	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	67.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	10.7	0.0	11.8	0.0	0.1	0.0	2.0	66.6	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.6	3.7	0.0	0.0	0.1	1.2	0.0	0.0	0.0	0.6	0.0	23.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	23.9	0.1	0.0	0.2	0.0	0.0	0.0	0.0	14.8	0.0	17.8	0.0	42.8	58.2	71.7	34.3	53.4	34.7	137.2	41.8	36.4	41.1	163.4	43.5	36.3	84.4	27.9	62.8	53.7	40.9	58.8	3.4	4.8	1.0	3.1	3.8	3.8	6.9	1.7	4.7	5.0	8.9	20.5	979.0	1.1	10.4	12.4	1.2	2.5	1.4	4.5	1.8	5.9	1.6	0.0	0.3	98.9	4.3	0.4	0.0	0.0	1.5	5.4	0.5	262.7	2.5	303.3	0.0	1.2	14.1	224.9	158.6	2.6	253.6	27.0	43.3	0.5	1.1	0.0	5.3	0.7	2.5	5.2	0.0	0.5	1.1	0.9	10.3	2.4	359.8	0.4	0.9
CD38		ENSG00000004468	"CD38 molecule"	P28907	4	15778275-15853230	"Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins"		"Hydrolase, Receptor, Transferase"	"Cancer-related genes, Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"lymphoid tissue: 94.9;seminal vesicle: 104.1"	"Cell type enhanced"	"Detected in many"	8	"Ciliated cells: 49.5;Erythroid cells: 46.7;granulocytes: 39.1;Kupffer cells: 31.1;T-cells: 30.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"NK-cell: 15.3"	"Group enriched"	"Detected in all"	4	"B-cells: 9.0;dendritic cells: 5.1;NK-cells: 15.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 50.8;Karpas-707: 14.2;MOLT-4: 12.8;REH: 10.3;U-266/70: 11.0;U-698: 9.6"	"Low region specificity"	"Detected in all"							"CAB002493, HPA022132, CAB025255, HPA052381"	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB002493: AB_563556, CAB025255: , HPA022132: AB_1846300, HPA052381: AB_2681807"	"unprognostic (1.27e-2)"	"unprognostic (8.06e-3)"	"unprognostic (1.06e-2)"	"prognostic favorable (9.68e-4)"	"unprognostic (1.13e-1)"	"unprognostic (1.82e-3)"	"unprognostic (2.74e-1)"	"unprognostic (8.51e-2)"	"unprognostic (5.87e-2)"	"unprognostic (6.15e-6)"	"unprognostic (5.23e-1)"	"unprognostic (4.34e-1)"	"unprognostic (6.63e-6)"	"unprognostic (1.79e-1)"	"unprognostic (5.74e-2)"	"unprognostic (2.12e-2)"	"unprognostic (2.13e-1)"	4.1	3.3	3.8	17.6	8.5	9.3	2.6	0.7	12.0	1.0	3.2	10.4	14.6	4.3	0.7	0.9	2.3	2.4	1.5	5.0	4.0	4.2	1.2	5.4	4.7	16.1	4.9	3.1	0.6	0.7	0.0	2.5	0.6	3.1	10.8	2.7	4.4	2.8	104.1	14.2	0.5	6.2	0.9	1.8	20.6	2.0	0.7	2.5	94.9	2.8	2.0	13.2	7.6	0.9	9.0	5.1	1.3	2.2	15.3	2.3	3.7	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	50.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.1	14.2	0.0	0.0	12.8	3.1	0.0	0.0	0.0	10.3	0.0	8.0	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.1	0.0	2.2	0.2	0.0	0.0	0.0	0.0	11.0	0.1	9.6	0.1	2.4	0.1	0.0	1.7	0.0	1.1	2.2	0.3	9.0	1.4	1.2	4.1	6.6	2.3	1.8	1.3	15.3	1.4	5.1	2.1	3.7	3.8	8.5	0.7	6.2	4.0	4.2	4.9	3.1	3.1	2.5	3.0	10.8	23.4	0.4	0.0	0.0	0.8	0.0	49.5	18.2	0.0	9.8	0.2	0.0	0.0	1.6	0.1	0.0	46.7	0.0	0.0	0.5	10.7	39.1	1.3	4.6	0.0	0.0	3.1	31.1	0.0	0.0	10.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.9	0.0	2.2	1.4	0.0	0.5	30.5	0.7	0.1
CD3D	T3D	ENSG00000167286	"CD3d molecule"	P04234	11	118338954-118342744	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"blood: 108.7;lymphoid tissue: 181.4"	"Cell type enriched"	"Detected in many"	12	"T-cells: 532.0"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	53	"gdT-cell: 105.6;MAIT T-cell: 68.6;memory CD4 T-cell: 88.1;memory CD8 T-cell: 97.6;naive CD4 T-cell: 78.8;naive CD8 T-cell: 98.6;T-reg: 108.7"	"Lineage enriched"	"Detected in many"	63	"T-cells: 108.7"	"Cell line enhanced"	"Detected in some"		"JURKAT: 69.9;MOLT-4: 149.5;NB-4: 27.9"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"CAB013055, HPA071778"	Enhanced		Uncertain	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"CAB013055: , HPA071778: "	"prognostic favorable (3.00e-4)"	"prognostic favorable (8.46e-5)"	"unprognostic (1.05e-2)"	"prognostic favorable (1.73e-7)"	"unprognostic (6.00e-2)"	"prognostic favorable (1.70e-4)"	"unprognostic (3.82e-1)"	"unprognostic (2.40e-2)"	"unprognostic (2.24e-3)"	"unprognostic (1.01e-2)"	"unprognostic (5.69e-2)"	"unprognostic (2.55e-1)"	"prognostic unfavorable (3.07e-5)"	"unprognostic (9.00e-2)"	"unprognostic (2.02e-1)"	"unprognostic (3.66e-2)"	"prognostic favorable (6.16e-4)"	2.6	0.8	0.5	17.4	0.7	4.8	1.7	0.5	0.7	1.3	4.1	0.7	0.8	4.1	1.2	1.6	3.2	1.9	2.9	1.0	0.7	0.4	2.6	1.9	6.1	40.8	0.9	0.5	1.0	1.2	0.0	0.7	0.8	0.7	2.2	4.3	1.1	9.0	0.8	0.7	1.3	19.3	1.0	1.5	28.6	4.4	0.8	0.5	181.4	2.7	2.8	32.6	5.7	2.4	0.5	0.3	1.7	0.3	0.2	108.7	64.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	69.9	5.7	0.0	0.0	0.0	149.5	27.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.5	0.3	0.2	105.6	0.2	68.6	0.5	88.1	97.6	0.3	0.2	78.8	98.6	1.7	0.2	0.3	0.3	108.7	64.9	0.5	0.7	0.5	0.7	0.7	0.4	0.9	0.5	0.7	0.5	6.0	45.4	3.0	0.3	13.6	0.0	2.5	0.0	2.7	4.5	3.5	0.0	0.2	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	5.1	0.1	11.6	2.0	0.6	0.0	1.2	9.8	7.6	0.4	0.0	6.1	11.8	0.0	0.0	0.0	0.1	0.0	0.0	2.2	0.0	0.0	5.6	0.0	0.0	10.3	0.2	532.0	0.3	0.0
CD3E		ENSG00000198851	"CD3e molecule"	P07766	11	118304545-118316175	"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 294.2"	"Cell type enriched"	"Detected in some"	31	"T-cells: 377.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	36	"gdT-cell: 59.5;MAIT T-cell: 50.2;memory CD4 T-cell: 50.7;memory CD8 T-cell: 55.7;naive CD4 T-cell: 61.3;naive CD8 T-cell: 62.0;NK-cell: 21.8;T-reg: 46.8"	"Group enriched"	"Detected in many"	29	"NK-cells: 21.8;T-cells: 62.0"	"Group enriched"	"Detected in some"	67	"JURKAT: 80.1;MOLT-4: 108.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"CAB000010, HPA040957, HPA043955, CAB072863, CAB072864"	Enhanced		Supported	"Endoplasmic reticulum,Plasma membrane"		NA	NA			"Endoplasmic reticulum, Plasma membrane"		"CAB000010: AB_2631163, CAB072863: AB_2665707, CAB072864: AB_2665708, HPA040957: AB_2677222, HPA043955: AB_2678747"	"prognostic favorable (1.72e-4)"	"prognostic favorable (1.62e-4)"	"unprognostic (1.51e-2)"	"prognostic favorable (2.30e-6)"	"unprognostic (4.31e-2)"	"prognostic favorable (1.32e-4)"	"unprognostic (3.60e-3)"	"unprognostic (3.85e-2)"	"prognostic favorable (1.18e-4)"	"unprognostic (6.11e-3)"	"unprognostic (1.59e-1)"	"unprognostic (3.59e-1)"	"prognostic unfavorable (1.12e-5)"	"unprognostic (5.46e-2)"	"unprognostic (9.28e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.12e-2)"	3.9	1.0	0.5	16.7	0.7	6.8	1.9	0.5	0.7	2.1	4.7	0.9	0.7	4.4	2.0	1.4	3.3	3.0	4.0	1.4	0.5	0.5	3.3	2.6	7.3	40.9	1.3	0.6	1.5	1.3	0.0	0.9	1.2	0.9	2.6	3.9	1.9	6.4	1.1	0.8	1.3	21.1	1.1	1.9	34.5	4.6	1.2	0.5	294.2	3.4	2.1	37.8	6.3	3.0	0.2	0.9	1.4	0.2	21.8	62.0	32.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	80.1	0.1	0.3	0.0	0.0	108.8	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.1	1.4	0.0	0.1	0.0	1.3	0.2	0.2	59.5	0.1	50.2	0.1	50.7	55.7	0.1	0.2	61.3	62.0	1.4	21.8	0.2	0.9	46.8	32.9	0.5	0.7	0.5	0.7	0.5	0.5	1.3	0.6	0.9	0.5	0.0	11.3	4.5	0.3	4.6	0.0	0.2	0.0	0.0	1.2	1.8	0.0	0.0	0.0	0.1	6.5	0.2	0.0	0.0	0.0	0.0	1.0	0.1	7.0	0.8	0.3	0.0	0.0	12.3	7.3	0.0	0.0	2.5	11.8	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.5	0.0	0.0	4.6	0.2	377.3	0.2	0.3
CD3G		ENSG00000160654	"CD3g molecule"	P09693	11	118344344-118355161	"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 187.6"	"Cell type enriched"	"Detected in some"	18	"T-cells: 153.8"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	30	"gdT-cell: 43.5;MAIT T-cell: 25.6;memory CD4 T-cell: 36.1;memory CD8 T-cell: 37.1;naive CD4 T-cell: 37.6;naive CD8 T-cell: 46.7;T-reg: 34.2"	"Lineage enriched"	"Detected in many"	37	"T-cells: 46.7"	"Group enriched"	"Detected in some"	53	"JURKAT: 24.1;MOLT-4: 64.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB017520, HPA038494"	Enhanced		Supported	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"CAB017520: AB_831094, HPA038494: AB_2676044"	"prognostic favorable (6.33e-4)"	"prognostic favorable (2.61e-4)"	"unprognostic (4.58e-3)"	"unprognostic (3.12e-5)"	"unprognostic (6.30e-2)"	"prognostic favorable (3.00e-4)"	"unprognostic (1.98e-2)"	"unprognostic (1.54e-2)"	"unprognostic (8.25e-3)"	"unprognostic (1.08e-3)"	"unprognostic (1.54e-2)"	"unprognostic (2.19e-1)"	"prognostic unfavorable (9.33e-5)"	"unprognostic (1.60e-1)"	"unprognostic (2.37e-2)"	"unprognostic (4.13e-2)"	"unprognostic (2.10e-3)"	1.1	0.6	0.4	7.1	0.4	0.5	0.8	0.3	0.3	0.7	2.3	0.4	0.4	2.0	0.9	0.6	1.5	1.1	1.9	0.6	0.4	0.4	1.2	0.9	2.4	17.2	0.5	0.2	0.7	0.7	0.0	0.5	0.4	0.3	1.0	1.6	0.9	2.9	0.3	5.9	0.6	8.1	0.2	0.8	11.5	2.4	0.5	0.2	187.6	1.4	1.7	19.2	2.5	1.1	0.1	0.2	1.2	0.2	0.2	46.7	14.1	0.0	0.1	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	24.1	0.8	0.2	0.0	0.2	64.5	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.1	0.0	0.1	0.2	0.1	0.1	0.1	0.0	0.6	0.2	0.2	43.5	0.1	25.6	0.1	36.1	37.1	0.1	0.1	37.6	46.7	1.2	0.2	0.1	0.2	34.2	14.1	0.4	0.4	0.3	0.3	0.4	0.4	0.5	0.2	0.3	0.2	3.0	8.6	0.8	0.0	2.1	0.1	0.4	0.0	1.4	3.4	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.8	0.0	5.8	1.3	0.1	0.0	0.0	6.2	2.8	0.4	0.0	2.8	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.6	0.0	0.3	0.2	0.0	2.0	0.2	153.8	0.0	0.0
CD4		ENSG00000010610	"CD4 molecule"	P01730	12	6786858-6820808	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity"	"Host cell receptor for virus entry, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 111.5;parathyroid gland: 78.4"	"Cell type enhanced"	"Detected in many"	19	"Hofbauer cells: 121.3;Ito cells: 382.4;Kupffer cells: 192.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	17	"classical monocyte: 42.2;intermediate monocyte: 42.5;memory CD4 T-cell: 29.1;myeloid DC: 29.3;naive CD4 T-cell: 24.8;non-classical monocyte: 33.3;plasmacytoid DC: 46.7;T-reg: 26.4"	"Group enriched"	"Detected in many"	20	"dendritic cells: 46.7;monocytes: 42.5;T-cells: 29.1"	"Group enriched"	"Detected in some"	6	"HEL: 34.3;HL-60: 13.8;NB-4: 19.7;THP-1: 39.0;U-937: 36.7"	"Region enriched"	"Detected in single"	15	"basal ganglia: 41.4"	"Not detected"	"Not detected"			"CAB000011, HPA004252, HPA004472, CAB068180"	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB000011: AB_442062, CAB068180: AB_2665653, HPA004252: AB_1078466, HPA004472: AB_1078465"	"unprognostic (1.39e-2)"	"unprognostic (1.12e-2)"	"unprognostic (2.75e-2)"	"prognostic favorable (2.16e-4)"	"unprognostic (7.76e-2)"	"unprognostic (4.82e-3)"	"unprognostic (3.70e-2)"	"unprognostic (2.74e-2)"	"unprognostic (7.04e-2)"	"unprognostic (2.40e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.92e-1)"	"prognostic unfavorable (7.45e-4)"	"unprognostic (1.06e-1)"	"unprognostic (4.65e-3)"	"unprognostic (9.08e-3)"	"unprognostic (2.95e-1)"	13.8	5.4	6.1	16.0	5.8	4.4	5.6	1.2	4.3	4.5	5.1	8.6	1.8	3.6	3.5	8.3	3.0	5.5	7.3	5.4	4.9	4.4	6.1	32.2	24.0	30.8	6.3	3.1	3.0	3.1	78.4	3.4	10.9	6.2	4.1	6.5	5.7	5.4	3.9	1.9	3.5	9.5	5.2	10.2	49.1	3.9	2.8	5.7	111.5	3.9	4.1	18.6	8.6	3.2	0.1	46.7	1.9	42.5	0.3	29.1	33.6	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	34.3	0.0	0.2	3.8	13.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	19.7	0.3	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	39.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.7	0.0	0.1	42.2	0.3	0.3	42.5	1.1	0.0	29.1	0.1	29.3	0.1	24.8	0.1	1.9	0.3	33.3	46.7	26.4	33.6	6.1	5.8	1.2	4.3	4.9	4.4	6.3	3.1	6.2	5.7	0.0	6.9	8.2	0.2	3.1	1.5	1.6	15.3	26.8	3.4	3.5	0.0	0.8	5.0	0.0	0.0	2.8	0.0	0.0	0.3	0.9	5.4	0.1	7.0	7.8	121.3	4.8	0.0	382.4	192.9	0.0	15.5	72.7	5.0	39.7	0.0	14.3	0.0	0.0	14.2	1.1	0.1	12.9	4.2	0.0	0.1	1.9	1.0	28.4	0.0	0.3
CD40	"Bp50, p50, TNFRSF5"	ENSG00000101017	"CD40 molecule"	P25942	20	46118272-46129863	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	4	"monocytes: 413.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 36.1;naive B-cell: 41.3"	"Group enriched"	"Detected in many"	6	"B-cells: 41.3;monocytes: 10.8"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 27.3;EFO-21: 47.9;U-2 OS: 15.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002495, HPA031567, HPA031568, CAB072868"	Enhanced				"Secreted to blood"	NA	NA	705000	16000			"CAB002495: AB_563562, CAB072868: AB_2665719, HPA031567: AB_2673936, HPA031568: AB_2673937"	"unprognostic (6.41e-2)"	"unprognostic (1.55e-2)"	"unprognostic (7.08e-3)"	"unprognostic (6.21e-2)"	"unprognostic (4.23e-3)"	"unprognostic (1.25e-1)"	"unprognostic (7.64e-3)"	"unprognostic (1.34e-1)"	"unprognostic (4.15e-2)"	"unprognostic (7.16e-2)"	"unprognostic (2.48e-2)"	"unprognostic (7.04e-2)"	"prognostic unfavorable (4.48e-4)"	"unprognostic (1.22e-1)"	"unprognostic (4.95e-2)"	"unprognostic (1.60e-2)"	"unprognostic (2.28e-2)"	13.0	4.6	3.6	38.6	4.7	1.1	11.6	9.7	4.4	11.3	9.2	3.6	7.8	6.5	9.6	8.6	9.9	9.7	8.6	9.5	4.5	2.6	10.0	10.0	18.8	34.7	3.3	3.2	14.8	14.0	12.1	5.9	6.5	5.4	14.7	5.2	13.7	13.0	11.6	7.5	9.0	11.8	10.0	4.6	30.1	8.4	4.4	4.4	11.5	16.5	6.7	46.0	12.5	13.8	41.3	4.1	1.0	10.8	0.6	1.4	4.8	9.2	1.4	0.0	4.6	1.7	1.0	1.8	1.7	0.5	1.4	1.3	0.0	27.3	14.8	47.9	0.3	6.8	1.1	0.8	5.8	1.4	9.9	0.0	3.5	0.0	2.5	13.7	0.0	4.7	6.1	2.2	5.6	0.0	0.0	10.3	0.0	1.2	0.0	0.2	0.0	0.0	0.0	0.6	3.2	0.0	0.3	0.3	1.5	12.0	0.1	0.0	0.0	8.1	4.5	0.0	0.0	0.9	4.9	0.0	0.0	15.3	0.0	0.0	0.0	0.0	10.1	3.4	1.8	0.0	1.0	7.7	0.1	1.3	10.8	0.9	36.1	0.7	0.5	4.1	41.3	1.4	1.0	0.7	0.6	7.5	2.1	1.0	4.8	3.6	4.7	9.7	4.4	4.5	2.6	3.3	3.2	5.4	4.4	11.9	15.9	94.5	51.6	38.7	1.0	3.6	40.8	2.7	23.9	14.0	0.0	0.2	0.0	50.8	9.8	40.9	2.4	0.0	26.1	1.1	18.2	33.2	3.5	13.5	37.2	0.0	1.2	39.3	11.9	9.1	23.9	46.8	27.0	413.8	5.3	8.2	33.6	3.6	21.2	4.4	0.0	32.3	36.1	0.9	5.1	29.7	0.3	5.0	5.7	54.0
CD40LG	"CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP"	ENSG00000102245	"CD40 ligand"	P29965	X	136648193-136660390	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 29.2;intestine: 8.7;lymphoid tissue: 33.7"	"Cell type enriched"	"Detected in some"	4	"T-cells: 24.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"gdT-cell: 9.4;MAIT T-cell: 22.9;memory CD4 T-cell: 29.2;naive CD4 T-cell: 28.1"	"Lineage enriched"	"Detected in single"	58	"T-cells: 29.2"	"Cell line enriched"	"Detected in some"	14	"MOLT-4: 22.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"HPA045827, HPA072480"	Enhanced				"Secreted to blood"	NA	NA	776000				"HPA045827: AB_10959606, HPA072480: "	"unprognostic (1.94e-5)"	"unprognostic (1.24e-2)"	"unprognostic (3.26e-1)"	"unprognostic (1.27e-3)"	"unprognostic (4.71e-2)"	"unprognostic (3.56e-5)"	"unprognostic (3.66e-2)"	"unprognostic (5.48e-3)"	"unprognostic (2.77e-1)"	"unprognostic (2.14e-4)"	"unprognostic (1.87e-1)"	"unprognostic (1.55e-1)"	"unprognostic (6.70e-4)"	"unprognostic (2.15e-1)"	"unprognostic (5.19e-2)"	"unprognostic (2.36e-3)"	"unprognostic (2.92e-2)"	2.0	0.5	0.3	22.4	0.3	1.4	1.2	0.3	0.3	2.0	3.3	0.1	0.0	1.7	1.5	1.3	1.6	1.6	2.6	1.1	0.4	0.4	1.6	1.1	4.0	14.6	0.4	0.0	0.7	0.6	0.0	0.4	0.2	0.3	1.0	3.1	1.0	4.9	1.3	0.4	1.1	8.7	0.5	0.6	9.9	1.7	0.6	0.1	33.7	1.4	2.0	26.1	3.0	1.4	0.0	0.0	0.5	0.0	0.2	29.2	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	22.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	9.4	0.0	22.9	0.0	29.2	4.1	0.0	0.0	28.1	0.2	0.5	0.2	0.0	0.0	3.3	4.7	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.0	0.3	0.1	0.0	3.7	0.0	0.0	1.1	0.0	0.3	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.0	0.0	0.0	0.6	5.5	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.1	0.0	0.0	1.8	0.0	24.5	0.0	0.0
CD44	"CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1"	ENSG00000026508	"CD44 molecule (Indian blood group)"	P16070	11	35138870-35232402	"Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion"	"Blood group antigen, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	4	"Basal keratinocytes: 888.0;Ductal cells: 858.7;Suprabasal keratinocytes: 895.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 139.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB000112, CAB000316, HPA005785"	Enhanced		Supported	"Golgi apparatus,Plasma membrane"	"Secreted - unknown location"	NA	NA		2400000000	"Plasma membrane"	"Golgi apparatus"	"CAB000112: , CAB000316: AB_2076596, HPA005785: AB_1078467"	"unprognostic (5.33e-2)"	"unprognostic (1.85e-1)"	"unprognostic (4.97e-2)"	"unprognostic (9.90e-3)"	"unprognostic (3.50e-3)"	"unprognostic (1.46e-2)"	"unprognostic (1.56e-2)"	"unprognostic (8.12e-2)"	"unprognostic (1.57e-1)"	"unprognostic (4.18e-2)"	"unprognostic (1.51e-3)"	"unprognostic (4.63e-2)"	"prognostic unfavorable (1.78e-8)"	"unprognostic (6.41e-2)"	"unprognostic (4.14e-2)"	"unprognostic (3.93e-2)"	"unprognostic (7.98e-2)"	45.5	9.0	10.5	42.5	21.7	53.0	35.6	4.7	13.4	43.2	19.5	26.3	8.3	10.6	80.5	20.3	66.5	18.6	48.0	11.7	14.9	9.3	12.4	9.1	43.4	48.4	31.5	6.1	12.8	83.9	0.8	3.8	19.4	40.7	30.1	24.5	30.2	148.2	22.4	15.9	107.7	18.9	44.5	100.5	30.9	19.9	7.2	20.3	17.9	20.6	53.9	53.7	55.0	54.2	22.7	41.0	19.1	65.2	54.6	53.1	59.9	39.7	35.9	0.3	0.0	21.7	60.0	0.1	77.9	60.9	43.4	24.2	2.4	12.5	0.0	10.4	110.3	89.3	68.5	0.8	84.7	59.6	8.5	0.4	1.4	17.7	0.0	21.4	20.2	93.5	27.0	66.8	58.3	47.4	139.4	15.1	0.0	0.3	13.0	41.6	0.2	1.8	13.3	0.7	0.7	10.6	0.1	7.4	0.6	63.6	11.5	0.1	0.1	14.7	0.4	35.2	3.4	2.1	1.2	43.5	54.1	9.8	66.3	80.0	22.5	24.3	0.2	82.1	11.4	78.6	19.1	65.2	6.0	26.2	45.7	37.0	22.7	39.8	34.9	41.0	16.2	34.5	28.7	16.4	54.6	59.3	14.2	53.1	59.9	10.5	21.7	4.7	13.4	14.9	9.3	31.5	6.1	40.7	20.3	89.3	339.9	168.9	263.7	888.0	0.0	4.0	25.5	18.7	135.4	19.2	2.0	4.0	1.7	858.7	30.1	53.0	5.0	23.3	741.5	3.7	143.9	293.1	733.4	2.5	234.7	0.0	96.2	20.3	427.0	13.8	20.8	611.7	573.6	514.0	84.8	26.6	787.6	8.6	0.4	0.6	1.6	155.2	254.2	0.4	0.4	895.8	15.0	244.8	66.1	304.0
CD46	"MCP, MGC26544, MIC10, TLX, TRA2.10"	ENSG00000117335	"CD46 molecule"	P15529	1	207752057-207795513	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	"Complement pathway, Fertilization, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, Disease mutation, Hemolytic uremic syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"basophil: 41.7;eosinophil: 63.7;neutrophil: 69.8"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 69.8"	"Low cell line specificity"	"Detected in all"											"CAB010401, HPA016903"	Enhanced		Approved	"Plasma membrane"		NA	NA		1000000	"Plasma membrane"		"CAB010401: AB_2291289, HPA016903: AB_1846309"	"unprognostic (1.42e-2)"	"prognostic unfavorable (8.54e-5)"	"unprognostic (3.94e-2)"	"unprognostic (2.14e-2)"	"unprognostic (3.28e-2)"	"unprognostic (6.30e-2)"	"unprognostic (1.91e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.25e-1)"	"unprognostic (2.74e-1)"	"unprognostic (8.79e-2)"	"unprognostic (2.50e-1)"	"unprognostic (6.78e-3)"	"prognostic favorable (2.38e-4)"	"unprognostic (1.76e-1)"	"unprognostic (8.23e-2)"	"unprognostic (1.49e-2)"	38.0	78.0	13.0	22.9	20.5	18.5	57.0	12.9	17.8	27.5	35.4	25.3	64.3	32.9	39.7	32.6	43.2	30.4	25.2	20.6	16.1	15.5	50.8	57.8	43.6	25.0	21.4	13.2	27.6	47.9	86.6	32.7	119.6	29.1	47.0	28.5	26.7	68.4	60.5	18.8	18.4	39.8	25.0	21.8	26.9	33.9	16.5	20.7	20.3	25.3	21.8	30.3	37.2	27.0	7.7	8.1	69.8	14.1	7.5	13.5	14.9	26.7	15.1	14.2	6.5	44.8	44.4	21.6	20.1	29.2	13.3	18.0	14.8	71.2	4.1	20.5	20.0	18.3	36.3	10.6	27.6	20.3	20.5	15.1	8.9	16.6	26.6	28.5	19.3	31.0	38.1	41.1	20.0	15.8	31.4	37.1	16.3	18.6	17.9	20.4	12.6	9.2	17.0	16.2	16.0	15.1	6.2	22.6	25.2	54.3	53.0	14.4	9.8	25.4	57.2	33.0	29.6	45.0	16.6	31.8	14.3	12.7	30.0	22.8	24.1	29.0	12.4	20.9	12.8	13.4	41.7	13.5	63.7	9.2	14.0	12.5	7.7	11.7	10.1	8.1	6.0	13.5	11.2	69.8	7.5	14.1	4.2	10.1	14.9	13.0	20.5	12.9	17.8	16.1	15.5	21.4	13.2	29.1	20.7	187.6	224.8	34.3	81.1	47.1	61.8	56.5	86.6	227.5	213.9	137.9	62.8	190.0	13.3	67.0	176.4	91.0	82.1	0.0	68.5	62.2	54.2	160.9	108.9	100.2	53.0	38.1	69.8	78.5	81.8	23.7	43.7	72.9	59.1	50.5	91.2	28.9	65.3	92.2	41.4	61.7	79.1	51.8	66.9	13.8	23.3	40.1	287.4	51.1	85.2	127.3
CD47	"IAP, MER6, OA3"	ENSG00000196776	"CD47 molecule"	Q08722	3	108043094-108091862	"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016055, HPA044659"	Approved		Supported	"Vesicles,Plasma membrane"		NA	NA		2000000	"Plasma membrane"	Vesicles	"CAB016055: AB_627086, HPA044659: AB_2679040"	"unprognostic (3.54e-2)"	"unprognostic (4.74e-2)"	"unprognostic (3.19e-2)"	"prognostic unfavorable (2.44e-4)"	"unprognostic (4.49e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.05e-3)"	"unprognostic (8.77e-3)"	"unprognostic (7.35e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.69e-2)"	"unprognostic (2.87e-1)"	"prognostic unfavorable (1.69e-4)"	"unprognostic (7.37e-2)"	"unprognostic (3.78e-1)"	"prognostic favorable (7.29e-5)"	"unprognostic (1.83e-1)"	16.2	24.3	23.0	28.8	46.5	58.0	29.0	44.0	55.5	20.5	25.7	42.5	13.4	19.8	16.2	30.4	46.7	31.7	26.0	26.7	24.1	24.4	19.1	22.1	49.6	35.1	27.4	28.8	16.2	25.7	11.5	34.8	23.3	43.6	40.2	29.0	15.7	43.8	18.9	18.1	19.3	21.2	21.0	37.7	29.0	33.4	20.6	25.0	34.4	30.1	22.0	42.5	25.1	29.1	40.1	35.6	44.1	64.4	45.1	65.3	51.7	45.7	8.2	16.6	9.4	23.8	25.6	21.9	17.3	27.1	13.5	23.1	0.4	25.9	21.0	28.1	16.6	31.0	31.4	9.2	17.5	17.6	12.4	6.3	53.5	7.7	0.7	13.8	38.1	72.3	16.4	10.7	12.9	10.4	21.0	13.3	21.8	12.6	50.0	20.0	23.5	46.3	14.3	6.9	42.7	21.0	24.6	12.2	29.7	34.2	18.3	12.6	7.8	10.3	20.5	17.5	8.8	37.1	12.5	12.8	35.0	6.4	19.6	11.7	19.4	13.1	29.5	25.5	19.1	9.6	31.7	24.7	44.1	40.2	48.1	35.0	40.1	47.0	42.0	35.6	39.2	35.4	38.3	30.1	45.1	64.4	27.7	65.3	51.7	23.0	46.5	44.0	55.5	24.1	24.4	27.4	28.8	43.6	25.0	342.4	135.6	141.2	259.6	146.8	90.6	37.8	109.5	58.9	102.4	89.0	90.3	137.8	13.3	418.5	33.5	71.3	35.8	23.3	357.7	75.9	79.2	245.6	56.6	30.2	163.7	116.0	61.4	82.9	78.2	40.6	31.7	105.3	111.3	90.2	60.0	47.2	337.0	107.2	45.6	11.9	214.8	64.7	72.9	25.2	13.2	122.5	101.4	137.1	79.7	264.1
CD48	"BCM1, BLAST, hCD48, mCD48, SLAMF2"	ENSG00000117091	"CD48 molecule"	P09326	1	160678746-160711851	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 81.3;lymphoid tissue: 86.3"	"Group enriched"	"Detected in many"	5	"B-cells: 233.4;granulocytes: 88.9;Hofbauer cells: 87.6;Kupffer cells: 195.5;Macrophages: 131.8;T-cells: 297.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 38.9;HMC-1: 43.5;U-266/70: 92.1;U-266/84: 61.5"									"CAB002497, HPA055146"	Enhanced		Supported	"Nucleoli fibrillar center,Plasma membrane,Cytosol"	"Intracellular and membrane"	NA	NA		2600000	"Plasma membrane"	"Nucleoli fibrillar center, Cytosol"	"CAB002497: AB_563586, HPA055146: AB_2682716"	"prognostic favorable (3.91e-4)"	"unprognostic (1.72e-3)"	"prognostic favorable (4.17e-4)"	"unprognostic (1.58e-3)"	"unprognostic (2.36e-1)"	"unprognostic (1.71e-3)"	"unprognostic (2.09e-2)"	"unprognostic (2.19e-2)"	"unprognostic (1.92e-1)"	"unprognostic (3.02e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.65e-1)"	"prognostic unfavorable (3.36e-4)"	"unprognostic (3.21e-1)"	"unprognostic (4.69e-2)"	"unprognostic (9.38e-2)"	"unprognostic (8.51e-2)"	5.5	1.4	1.0	44.6	0.9	23.1	2.8	0.6	0.7	3.2	5.0	0.5	1.1	3.2	1.9	2.5	7.3	2.1	4.8	1.8	1.0	1.0	3.6	3.1	15.4	86.3	1.6	0.3	2.3	1.5	0.0	1.3	2.2	0.8	2.8	5.7	2.4	13.9	1.5	1.3	1.2	21.2	1.7	3.8	66.6	5.0	1.3	0.2	50.8	2.9	3.6	58.0	8.6	2.6	34.6	53.6	35.8	74.1	24.9	57.9	81.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	38.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.0	0.0	0.3	0.0	0.0	0.0	4.6	43.5	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	14.2	0.0	0.0	13.5	6.7	0.0	0.0	0.0	0.8	0.0	5.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	92.1	61.5	15.8	0.0	11.7	0.0	28.2	52.2	35.8	42.4	74.1	57.9	34.6	48.3	48.8	53.6	27.9	49.7	52.5	13.4	24.9	73.5	9.4	36.4	81.3	1.0	0.9	0.6	0.7	1.0	1.0	1.6	0.3	0.8	0.2	0.0	14.8	233.4	0.5	4.8	0.0	0.8	5.1	4.0	2.3	3.5	0.0	0.7	1.7	0.1	0.0	0.7	0.0	23.3	0.2	0.7	3.1	0.2	88.9	1.8	87.6	0.0	1.2	8.6	195.5	0.4	1.7	131.8	37.1	8.2	0.0	0.0	0.1	0.0	0.4	1.5	0.0	0.0	0.7	0.4	0.1	2.6	0.3	297.5	0.0	0.3
CD5	"LEU1, T1"	ENSG00000110448	"CD5 molecule"	P06127	11	61102395-61127852	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 36.3;lymphoid tissue: 96.2"	"Group enriched"	"Detected in some"	4	"Muller glia cells: 9.6;T-cells: 18.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	20	"gdT-cell: 12.9;MAIT T-cell: 9.3;memory CD4 T-cell: 31.2;memory CD8 T-cell: 20.6;naive CD4 T-cell: 25.9;naive CD8 T-cell: 19.5;T-reg: 36.3"	"Lineage enriched"	"Detected in many"	32	"T-cells: 36.3"	"Group enriched"	"Detected in some"	65	"JURKAT: 12.0;MOLT-4: 38.5"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"CAB015392, CAB020308, HPA043416, HPA060839"	Enhanced					NA	NA					"CAB015392: AB_2075324, CAB020308: , HPA043416: AB_2678472, HPA060839: AB_2684376"	"prognostic favorable (4.05e-4)"	"prognostic favorable (9.16e-5)"	"unprognostic (2.33e-1)"	"prognostic favorable (9.00e-5)"	"unprognostic (1.02e-2)"	"prognostic favorable (7.41e-6)"	"unprognostic (2.45e-3)"	"unprognostic (1.37e-2)"	"prognostic favorable (3.93e-4)"	"unprognostic (1.25e-2)"	"unprognostic (5.00e-2)"	"unprognostic (2.14e-1)"	"prognostic unfavorable (8.94e-5)"	"unprognostic (4.78e-2)"	"unprognostic (1.02e-2)"	"unprognostic (2.38e-1)"	"unprognostic (1.06e-1)"	2.1	0.6	0.5	19.4	0.4	6.5	1.3	0.3	0.6	1.6	2.5	0.3	0.3	1.7	1.1	1.7	1.9	1.4	3.9	0.8	0.6	1.3	1.9	1.1	7.1	28.8	0.4	0.1	1.1	0.9	0.0	0.8	0.4	0.3	1.4	1.5	1.6	15.5	1.3	0.6	1.3	10.2	0.4	0.7	13.8	4.8	1.3	0.1	96.2	1.7	2.4	42.2	5.4	1.5	1.1	1.1	0.4	0.7	0.1	36.3	14.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.0	0.0	0.0	0.0	0.0	38.5	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	12.9	0.1	9.3	0.4	31.2	20.6	0.9	1.1	25.9	19.5	0.4	0.1	0.7	1.1	36.3	14.6	0.5	0.4	0.3	0.6	0.6	1.3	0.4	0.1	0.3	0.1	0.0	1.7	0.5	0.0	0.8	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.1	0.0	0.1	0.0	0.0	1.3	0.0	0.8	0.0	0.6	3.3	1.8	0.0	9.6	0.1	0.0	0.0	0.0	1.2	0.0	0.3	0.3	0.5	0.3	0.0	18.7	0.0	0.1
CD52	"CDW52, EDDM5, HE5"	ENSG00000169442	"CD52 molecule"	P31358	1	26317957-26320523	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins"			"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	7	"blood: 495.7;epididymis: 978.9"	"Cell type enhanced"	"Detected in many"	13	"B-cells: 1214.9;granulocytes: 550.2;Hofbauer cells: 593.7;Macrophages: 676.6;T-cells: 760.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in some"	9	"Daudi: 76.1;REH: 111.3;U-266/84: 111.2;U-698: 123.2"															NA	NA						"prognostic favorable (1.85e-5)"	"unprognostic (3.28e-3)"	"unprognostic (1.93e-2)"	"prognostic favorable (2.06e-4)"	"unprognostic (4.18e-2)"	"prognostic favorable (4.45e-4)"	"unprognostic (9.11e-2)"	"unprognostic (2.98e-2)"	"unprognostic (7.73e-3)"	"unprognostic (6.27e-2)"	"unprognostic (4.58e-1)"	"unprognostic (1.70e-1)"	"prognostic unfavorable (5.85e-4)"	"unprognostic (3.64e-1)"	"unprognostic (6.14e-2)"	"unprognostic (7.95e-2)"	"unprognostic (1.26e-1)"	9.5	0.9	0.8	23.0	1.4	5.7	4.7	0.3	0.8	0.9	3.7	0.3	93.2	1.0	1.1	978.9	2.9	1.5	2.2	1.5	0.6	0.2	3.5	3.2	43.4	54.6	0.8	0.6	0.8	1.0	0.0	0.7	0.7	0.7	1.7	2.5	1.3	5.7	2.9	0.4	1.9	39.6	1.1	1.2	98.7	2.7	5.3	0.4	24.7	3.2	2.1	30.4	4.3	1.7	292.0	87.6	258.4	194.6	94.3	308.1	495.7	0.2	0.0	0.0	0.0	0.0	0.1	1.6	0.0	0.1	0.0	0.0	0.0	0.0	76.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.1	0.0	0.7	11.9	0.0	0.0	0.0	0.0	0.0	0.0	4.9	2.5	0.1	0.0	0.5	0.8	6.8	0.3	0.0	0.0	111.3	0.1	1.7	0.0	0.0	0.2	1.0	0.0	0.1	0.1	1.0	0.0	1.3	0.1	0.0	0.2	0.0	0.1	0.3	111.2	123.2	0.0	1.9	0.0	12.4	126.8	258.4	194.7	194.6	155.1	292.0	244.1	190.3	87.6	273.7	166.6	171.2	9.6	94.3	167.6	28.6	308.1	495.7	0.8	1.4	0.3	0.8	0.6	0.2	0.8	0.6	0.7	0.4	62.5	287.6	1214.9	0.7	40.3	0.0	6.0	2.5	32.1	92.1	47.1	0.0	2.7	0.0	0.2	0.7	22.7	0.7	0.0	0.2	4.3	18.8	0.4	550.2	1.5	593.7	0.0	0.0	17.8	203.9	1.3	0.0	676.6	101.3	2.8	1.9	0.0	0.1	2.9	0.0	7.6	0.0	0.0	3.3	0.2	0.2	27.5	4.7	760.6	0.2	0.8
CD53	"MOX44, TSPAN25"	ENSG00000143119	"CD53 molecule"	P19397	1	110873154-110899928	"CD markers, Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 146.7;lymphoid tissue: 103.0"	"Group enriched"	"Detected in many"	7	"B-cells: 233.1;granulocytes: 158.2;Hofbauer cells: 322.4;Kupffer cells: 293.3;Macrophages: 340.3;T-cells: 289.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 87.2;HDLM-2: 37.5;HMC-1: 54.9;Karpas-707: 34.2;U-266/70: 47.3;U-698: 27.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA047216	Enhanced					NA	NA					"HPA047216: AB_2679986"	"unprognostic (2.93e-2)"	"unprognostic (1.25e-2)"	"unprognostic (7.45e-3)"	"unprognostic (1.02e-3)"	"unprognostic (8.88e-2)"	"unprognostic (3.78e-2)"	"unprognostic (2.96e-1)"	"unprognostic (6.07e-2)"	"unprognostic (2.83e-2)"	"unprognostic (2.03e-1)"	"unprognostic (5.09e-2)"	"unprognostic (1.62e-1)"	"prognostic unfavorable (2.60e-4)"	"unprognostic (9.58e-2)"	"unprognostic (4.95e-2)"	"unprognostic (1.33e-1)"	"unprognostic (7.72e-2)"	29.7	8.1	6.1	50.6	10.3	20.4	6.6	1.6	5.8	4.5	9.6	7.6	1.2	6.7	4.3	6.0	5.5	9.9	11.0	6.4	6.4	5.9	9.6	8.8	28.9	93.8	13.3	2.7	4.7	3.8	0.8	3.1	10.6	8.5	5.2	10.5	4.5	10.1	2.3	2.3	2.2	35.2	10.0	14.9	103.0	7.5	4.8	10.0	37.2	4.6	4.1	82.1	15.2	4.0	97.5	74.6	138.0	97.0	59.2	91.8	146.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	87.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	37.5	0.0	4.6	0.0	0.0	0.0	10.4	54.9	0.0	0.0	0.0	0.0	0.0	0.0	25.0	1.9	34.2	0.0	0.0	17.7	12.4	0.0	0.0	0.0	17.2	0.1	18.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	15.7	3.1	0.0	0.0	0.0	0.1	47.3	21.4	27.0	0.2	12.1	0.6	138.0	87.0	54.1	91.8	93.3	82.8	97.5	67.5	80.8	74.6	83.3	49.2	70.8	136.2	59.2	97.0	61.4	85.0	146.7	6.1	10.3	1.6	5.8	6.4	5.9	13.3	2.7	8.5	10.0	14.9	35.6	233.1	0.4	6.3	0.0	0.8	5.1	8.1	15.9	1.8	0.0	1.7	0.0	0.0	0.2	7.2	0.0	23.3	0.2	4.2	5.0	0.3	158.2	1.7	322.4	0.0	0.0	15.4	293.3	0.9	2.0	340.3	37.1	39.7	0.0	0.0	0.2	0.0	0.4	1.1	0.6	6.5	0.7	0.1	0.7	4.8	3.4	289.1	0.0	0.3
CD55	"CR, CROM, DAF, TC"	ENSG00000196352	"CD55 molecule (Cromer blood group)"	P08174	1	207321376-207386804	"Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Complement pathway, Host-virus interaction, Immunity, Innate immunity"	"Blood group antigen, Host cell receptor for virus entry, Receptor"	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	11	"Alveolar cells type 1: 2069.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 101.4"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HeLa: 79.2;HMC-1: 105.8;PC-3: 63.1;U-2197: 64.2"									"HPA002190, CAB010454, HPA024386"	Enhanced				"Secreted to blood"	NA	No	32300000	310000000			"CAB010454: AB_2075970, HPA002190: AB_1078472, HPA024386: AB_1846319"	"unprognostic (4.08e-2)"	"unprognostic (3.22e-1)"	"unprognostic (3.41e-1)"	"unprognostic (1.63e-1)"	"unprognostic (9.05e-2)"	"unprognostic (1.08e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.57e-2)"	"unprognostic (1.55e-2)"	"unprognostic (1.86e-1)"	"prognostic unfavorable (9.36e-4)"	"unprognostic (3.41e-2)"	"unprognostic (2.04e-1)"	"unprognostic (9.70e-2)"	"unprognostic (2.33e-2)"	21.8	63.2	5.8	27.2	20.2	31.9	17.9	4.6	10.5	34.0	14.8	13.8	7.8	12.8	16.3	11.9	36.1	10.4	18.0	32.0	7.5	10.1	9.6	16.7	114.6	41.1	16.7	4.7	31.3	9.1	8.1	12.8	107.0	11.9	9.7	12.4	8.2	82.3	12.8	108.8	37.5	26.0	23.5	11.4	30.4	17.7	10.2	18.8	4.2	13.2	31.4	19.1	39.3	19.1	18.6	18.3	101.4	31.6	19.0	16.9	20.3	4.8	6.6	0.0	2.2	8.5	9.1	34.6	9.2	16.2	5.3	5.7	20.8	6.9	9.4	7.7	5.4	19.8	2.8	10.6	2.0	4.9	4.3	3.9	12.2	79.2	3.4	27.6	7.4	105.8	4.3	25.0	6.5	28.7	21.0	27.3	1.5	13.1	4.5	3.0	5.2	0.7	5.1	6.7	11.4	63.1	1.1	6.6	7.4	8.8	4.7	2.6	0.0	49.8	10.1	8.0	15.5	8.6	6.3	11.9	2.7	5.1	64.2	3.5	3.7	4.4	6.3	7.2	2.9	12.1	39.3	26.9	35.9	5.5	26.3	8.2	16.9	7.4	5.8	18.3	18.6	16.9	16.4	101.4	19.0	31.6	9.8	5.0	20.3	5.8	20.2	4.6	10.5	7.5	10.1	16.7	4.7	11.9	18.8	2069.5	358.8	93.2	172.8	626.3	1.3	63.2	2.5	389.5	704.1	22.7	0.0	192.2	3.3	54.9	311.7	62.4	158.4	0.0	162.7	371.1	199.2	136.1	142.1	6.6	62.3	1.6	16.6	41.1	161.1	60.3	30.2	161.4	151.8	53.3	67.0	5.8	238.8	150.8	8.5	3.3	2.5	6.5	60.8	7.7	4.1	669.5	708.9	76.1	69.0	491.7
CD58	LFA3	ENSG00000116815	"CD58 molecule"	P19256	1	116514535-116571039	"CD markers, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Macrophages: 115.4;monocytes: 225.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Karpas-707: 46.3"															NA	NA		7100000				"unprognostic (4.48e-3)"	"unprognostic (3.20e-1)"	"unprognostic (2.95e-2)"	"unprognostic (4.03e-2)"	"unprognostic (8.45e-2)"	"unprognostic (1.95e-1)"	"prognostic unfavorable (2.32e-6)"	"unprognostic (9.84e-2)"	"unprognostic (7.17e-2)"	"unprognostic (4.72e-2)"	"prognostic unfavorable (5.60e-4)"	"unprognostic (2.82e-1)"	"unprognostic (1.66e-2)"	"unprognostic (1.86e-1)"	"unprognostic (3.68e-2)"	"unprognostic (2.17e-2)"	"unprognostic (9.66e-2)"	21.5	9.6	5.9	17.6	8.7	29.9	15.2	2.2	7.7	15.8	24.7	5.9	10.4	17.0	12.4	15.3	22.1	11.0	19.2	23.9	7.3	4.8	32.8	11.0	22.4	14.5	9.6	3.7	6.5	6.6	6.5	12.0	10.0	9.3	9.4	17.9	6.4	18.4	15.3	8.8	14.9	48.3	16.3	11.5	23.1	11.1	6.5	8.8	9.3	12.0	22.9	18.2	15.4	16.2	6.0	12.4	47.3	17.1	4.9	17.8	9.5	11.8	6.8	5.0	4.8	8.5	14.3	3.1	6.1	10.6	10.6	10.4	3.0	23.0	2.1	11.3	10.6	12.4	15.4	3.7	10.4	11.3	11.6	4.3	10.7	12.5	4.2	5.4	14.7	14.9	3.9	14.2	8.8	7.9	22.7	6.1	2.8	9.4	46.3	6.4	21.3	6.3	11.2	2.5	17.6	7.5	12.5	17.0	2.8	21.3	9.7	1.7	3.5	12.2	9.1	34.2	5.4	4.7	5.5	11.2	7.7	5.9	10.3	15.5	7.0	12.4	1.4	17.7	7.3	38.0	28.7	14.7	24.4	11.5	14.2	7.9	6.0	10.1	9.5	12.4	2.1	1.4	5.8	47.3	4.9	17.1	1.4	17.8	9.5	5.9	8.7	2.2	7.7	7.3	4.8	9.6	3.7	9.3	8.8	8.9	36.4	11.5	12.8	16.3	0.0	24.6	30.6	33.5	22.7	14.0	0.0	3.6	3.3	34.2	1.7	27.4	41.0	23.3	24.6	1.6	16.2	13.6	49.9	7.8	57.7	1.6	10.4	22.1	34.3	2.1	9.8	115.4	11.8	225.4	14.5	3.9	30.7	42.1	11.0	23.7	0.5	32.3	25.9	3.0	1.4	24.3	1.6	30.5	16.3	33.1
CD59	"16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20"	ENSG00000085063	"CD59 molecule (CD59 blood group)"	P13987	11	33703010-33736491	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes, Disease mutation, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 285.5"	"Cell type enhanced"	"Detected in all"	4	"Urothelial cells: 1502.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"TIME: 217.5;U-2197: 180.1"									"CAB001448, HPA026494"	Supported		Uncertain	"Golgi apparatus,Vesicles"	"Intracellular and membrane"	NA	NA		98000000	"Golgi apparatus, Vesicles"		"CAB001448: AB_563604, HPA026494: AB_1846321"	"unprognostic (2.07e-2)"	"prognostic unfavorable (3.81e-5)"	"unprognostic (7.40e-2)"	"unprognostic (1.14e-2)"	"unprognostic (2.11e-2)"	"prognostic unfavorable (3.10e-5)"	"unprognostic (5.65e-2)"	"unprognostic (1.46e-1)"	"unprognostic (4.47e-2)"	"unprognostic (2.98e-1)"	"prognostic unfavorable (2.92e-5)"	"unprognostic (1.66e-2)"	"prognostic favorable (1.39e-10)"	"prognostic unfavorable (9.03e-4)"	"unprognostic (1.31e-1)"	"unprognostic (1.03e-2)"	"unprognostic (3.09e-1)"	96.7	41.0	36.7	26.3	44.3	23.8	76.0	25.9	32.7	44.8	36.9	24.0	57.9	16.5	45.4	132.8	68.4	53.2	67.6	90.5	35.6	38.4	100.0	61.0	86.4	39.8	39.7	25.8	39.3	52.3	60.6	48.0	285.5	68.7	47.4	37.7	51.4	114.8	62.6	70.6	43.4	25.0	52.4	32.9	26.2	54.7	28.1	23.1	16.1	85.9	57.7	40.0	51.2	63.4	13.5	20.5	42.8	4.8	17.7	60.4	11.1	16.8	15.8	4.7	13.8	109.9	86.2	2.7	96.0	107.2	24.1	28.2	7.3	50.7	1.3	17.2	103.4	28.7	19.0	8.6	95.8	33.8	26.8	13.1	1.7	56.0	11.0	30.0	10.1	5.8	40.0	24.2	20.4	98.3	66.8	146.8	5.9	11.8	39.0	151.5	15.4	4.7	4.2	2.6	31.1	82.5	1.8	14.6	13.5	72.7	28.8	3.2	4.4	33.4	15.5	17.6	13.9	11.8	1.0	217.5	55.4	13.3	180.1	33.3	17.3	33.8	1.6	47.6	0.0	96.2	30.5	4.8	42.8	11.3	1.6	14.4	13.5	24.0	12.7	20.5	10.6	15.7	9.3	28.4	17.7	0.9	10.5	60.4	11.1	36.7	44.3	25.9	32.7	35.6	38.4	39.7	25.8	68.7	23.1	253.1	215.4	44.4	795.7	254.1	47.4	262.5	430.6	580.9	208.1	230.3	31.4	513.5	139.3	1251.4	102.0	802.4	90.2	140.2	547.4	330.2	284.0	787.9	136.2	175.7	400.2	44.5	160.2	566.0	129.7	49.4	219.8	141.1	1204.5	272.3	85.9	184.1	823.9	122.8	192.3	162.3	45.0	271.7	576.8	86.8	27.6	248.5	699.7	62.8	98.2	1502.4
CD6	Tp120	ENSG00000013725	"CD6 molecule"	P30203	11	60971680-61020377	"CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Adaptive immunity, Cell adhesion, Immunity, Innate immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 23.0;lymphoid tissue: 58.1"	"Group enriched"	"Detected in some"	5	"B-cells: 10.7;T-cells: 34.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	34	"gdT-cell: 12.4;MAIT T-cell: 11.1;memory CD4 T-cell: 23.0;memory CD8 T-cell: 21.4;naive CD4 T-cell: 15.5;naive CD8 T-cell: 11.1;T-reg: 10.1"	"Lineage enriched"	"Detected in single"	52	"T-cells: 23.0"	"Group enriched"	"Detected in some"	12	"JURKAT: 7.8;MOLT-4: 28.9"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"CAB002489, CAB016252"	Enhanced				"Secreted to blood"	NA	NA	5270000	110000			"CAB002489: AB_563605, CAB016252: AB_631163"	"prognostic favorable (1.95e-4)"	"prognostic favorable (1.57e-5)"	"unprognostic (4.47e-2)"	"prognostic favorable (2.41e-4)"	"unprognostic (2.06e-2)"	"prognostic favorable (5.10e-6)"	"unprognostic (8.45e-3)"	"unprognostic (8.21e-3)"	"unprognostic (2.87e-3)"	"unprognostic (5.32e-3)"	"unprognostic (2.07e-1)"	"unprognostic (5.35e-1)"	"prognostic unfavorable (1.82e-4)"	"unprognostic (1.77e-1)"	"unprognostic (4.95e-2)"	"unprognostic (6.19e-2)"	"unprognostic (5.96e-2)"	1.5	0.5	0.8	26.4	0.4	5.5	0.9	0.5	1.4	1.3	3.3	0.6	0.8	2.2	1.4	1.5	1.9	1.3	5.0	1.3	0.7	1.8	1.6	1.1	6.9	25.6	1.7	0.5	0.7	0.8	0.0	0.6	0.6	0.4	1.2	1.6	1.2	7.0	0.3	0.3	0.9	13.0	0.7	0.9	18.4	3.4	0.9	0.1	58.1	1.6	1.9	42.0	3.7	1.3	0.4	0.1	0.3	0.0	0.0	23.0	5.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	7.8	0.1	0.0	0.0	0.0	28.9	0.0	0.1	0.1	0.1	0.1	0.0	0.6	0.0	0.1	0.1	0.2	0.0	0.3	0.0	0.3	0.2	0.3	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	12.4	0.0	11.1	0.4	23.0	21.4	0.1	0.4	15.5	11.1	0.3	0.0	0.0	0.0	10.1	5.1	0.8	0.4	0.5	1.4	0.7	1.8	1.7	0.5	0.4	0.1	0.0	4.5	10.7	0.2	1.8	1.4	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.8	0.4	0.0	0.0	0.6	0.1	0.3	0.1	0.0	0.9	2.1	1.6	0.0	1.3	1.2	0.0	0.3	2.0	3.3	1.0	0.0	0.0	0.7	0.0	0.0	0.1	0.2	0.0	0.9	0.3	0.8	1.3	0.2	34.6	0.1	0.3
CD63	"ME491, MLA1, TSPAN30"	ENSG00000135404	"CD63 molecule"	P08962	12	55725323-55729707	"CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"ASC diff: 276.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010088, CAB026356, HPA073506"	Supported		Supported	Vesicles	"Intracellular and membrane"	NA	NA			Vesicles		"CAB026356: AB_629864, HPA010088: AB_1846323, HPA073506: "	"unprognostic (8.76e-3)"	"unprognostic (8.81e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.28e-3)"	"unprognostic (9.48e-2)"	"unprognostic (3.66e-3)"	"prognostic unfavorable (1.37e-4)"	"unprognostic (1.11e-1)"	"unprognostic (6.50e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.66e-2)"	"unprognostic (3.10e-1)"	"unprognostic (2.70e-2)"	"unprognostic (4.82e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.85e-3)"	"unprognostic (9.02e-2)"	115.3	88.2	42.5	44.9	37.2	67.4	106.3	13.7	33.1	80.6	84.7	34.4	71.5	39.9	99.7	177.9	70.9	60.4	102.7	154.4	36.9	39.0	106.6	92.5	109.6	113.8	49.8	27.2	93.8	187.1	33.3	49.3	176.9	50.8	82.9	81.8	102.1	105.0	83.7	92.7	38.5	72.4	88.2	43.6	107.7	74.8	52.1	30.5	17.6	108.1	50.7	47.4	96.3	82.2	9.6	40.3	147.4	50.8	58.4	29.8	56.6	22.2	38.8	21.3	20.7	276.2	173.2	28.1	90.7	166.3	53.7	58.5	43.3	44.9	6.4	28.9	134.9	38.3	20.7	15.4	37.5	69.1	18.1	14.5	35.0	30.3	23.9	109.9	15.5	83.4	127.4	37.4	59.6	54.7	111.7	59.1	3.2	19.7	44.8	170.8	35.6	3.1	21.1	19.4	49.2	45.2	7.0	46.8	16.0	90.8	75.9	8.3	21.3	24.8	18.8	162.9	32.5	26.5	51.9	43.9	34.8	25.4	47.9	30.3	18.4	11.3	4.4	99.6	10.0	63.4	89.6	50.8	147.4	29.8	38.5	21.8	9.6	11.9	23.7	40.3	6.5	5.3	18.1	55.7	58.4	26.1	27.0	10.0	56.6	42.5	37.2	13.7	33.1	36.9	39.0	49.8	27.2	50.8	30.5	476.4	590.3	176.4	1219.6	503.8	174.4	555.7	917.2	377.4	564.1	830.5	143.3	558.0	197.3	2170.1	13.3	768.7	766.8	0.0	3001.1	2390.1	1497.1	1539.2	986.0	374.3	3024.5	31.8	557.9	750.1	794.3	26.6	1599.3	1215.7	1891.2	756.6	1108.9	851.5	2709.4	1083.7	1087.6	631.9	181.5	1235.3	1556.4	33.0	71.8	350.0	2264.8	339.0	575.6	1313.8
CD68	"DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1"	ENSG00000129226	"CD68 molecule"	P34810	17	7579467-7582113	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 179.1;lymphoid tissue: 139.1"	"Group enriched"	"Detected in many"	6	"Hofbauer cells: 1656.8;Kupffer cells: 486.8;Macrophages: 440.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 155.1;intermediate monocyte: 179.1;non-classical monocyte: 170.1"	"Group enriched"	"Detected in many"	11	"dendritic cells: 68.4;monocytes: 179.1"	"Cell line enhanced"	"Detected in many"		"ASC diff: 74.5;U-87 MG: 117.4"	"Low region specificity"	"Detected in all"							"CAB000051, CAB000066, HPA048982, CAB072861, CAB072862"	Enhanced		Supported	"Golgi apparatus,Vesicles"		NA	NA			"Golgi apparatus, Vesicles"		"CAB000051: AB_2314148, CAB000066: AB_2074844, CAB072861: AB_2665705, CAB072862: AB_2665706, HPA048982: AB_2680587"	"unprognostic (2.16e-2)"	"unprognostic (1.47e-2)"	"unprognostic (6.46e-2)"	"unprognostic (1.49e-3)"	"unprognostic (1.78e-2)"	"unprognostic (1.97e-1)"	"unprognostic (4.75e-4)"	"unprognostic (2.83e-2)"	"unprognostic (1.31e-1)"	"unprognostic (6.85e-2)"	"unprognostic (1.04e-1)"	"unprognostic (2.59e-1)"	"prognostic unfavorable (1.14e-5)"	"unprognostic (1.58e-1)"	"unprognostic (8.91e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.65e-2)"	118.4	28.5	12.5	46.8	21.6	46.8	40.9	2.9	11.2	27.1	38.1	15.5	2.1	57.0	9.6	24.1	26.9	17.3	33.7	39.0	10.1	6.9	20.9	43.1	84.4	102.5	21.1	4.4	15.8	7.5	2.1	8.5	34.7	15.7	12.1	18.5	12.8	22.2	4.4	16.1	9.4	58.3	15.6	26.0	139.1	17.6	9.4	16.3	13.3	8.8	12.3	21.1	31.4	19.1	3.7	68.4	11.0	179.1	0.9	0.5	125.6	35.7	7.3	0.4	0.5	74.5	28.4	0.3	11.4	31.2	15.2	17.7	1.5	10.8	0.4	13.0	33.1	27.0	1.6	0.1	7.2	10.3	0.3	1.3	5.7	1.8	8.6	6.3	2.8	32.2	9.0	1.5	31.7	23.4	25.1	3.9	0.6	2.2	3.7	14.6	0.2	0.2	2.5	0.4	9.3	5.3	0.4	0.6	21.1	3.1	1.6	0.2	0.4	9.5	4.8	11.1	0.3	0.2	21.9	12.4	19.3	1.2	19.3	14.9	0.2	0.3	0.2	117.4	7.0	9.7	10.1	155.1	0.9	0.4	179.1	0.5	3.7	0.2	0.3	40.9	2.0	0.3	0.2	11.0	0.9	170.1	68.4	0.3	125.6	12.5	21.6	2.9	11.2	10.1	6.9	21.1	4.4	15.7	16.3	0.0	22.4	23.8	26.4	14.0	0.0	0.0	7.6	9.4	13.6	5.2	0.0	7.2	5.0	60.6	0.6	16.8	36.0	0.0	137.4	51.8	33.7	27.3	40.6	16.3	1656.8	0.0	4.7	13.5	486.8	1.1	6.1	440.3	37.1	60.5	7.1	0.2	92.4	25.9	1.8	31.1	1.2	25.8	13.3	0.3	0.2	12.5	27.9	12.5	10.2	68.9
CD69	CLEC2C	ENSG00000110848	"CD69 molecule"	Q07108	12	9752486-9760901	"CD markers, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 52.1;lymphoid tissue: 56.4"	"Cell type enhanced"	"Detected in many"	27	"B-cells: 256.7;granulocytes: 1372.7;T-cells: 467.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"NK-cells: 14.8;T-cells: 18.3"	"Cell line enhanced"	"Detected in some"		"HL-60: 12.7;JURKAT: 8.5;K-562: 24.5;MOLT-4: 8.7;U-266/70: 10.0;U-698: 11.3;U-937: 41.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB002503, HPA050525"	Enhanced					NA	NA					"CAB002503: AB_563625, HPA050525: AB_2681157"	"prognostic favorable (3.31e-5)"	"unprognostic (1.84e-2)"	"unprognostic (1.80e-2)"	"unprognostic (1.73e-2)"	"unprognostic (1.66e-1)"	"unprognostic (7.10e-3)"	"unprognostic (4.76e-3)"	"unprognostic (9.53e-3)"	"unprognostic (9.73e-3)"	"unprognostic (1.64e-2)"	"unprognostic (1.96e-2)"	"unprognostic (1.75e-1)"	"prognostic unfavorable (7.87e-5)"	"unprognostic (2.88e-2)"	"unprognostic (3.32e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.65e-1)"	10.1	2.2	1.3	19.9	1.4	52.1	7.0	0.5	0.9	9.0	9.6	4.6	0.8	2.8	5.1	5.1	10.6	6.4	13.6	3.1	2.0	2.2	4.7	6.2	27.0	31.6	4.5	0.6	3.4	1.4	0.9	3.4	1.9	3.5	7.4	8.0	3.3	6.0	2.0	1.5	3.3	14.3	5.0	8.3	43.3	4.3	4.5	1.6	56.4	5.5	6.1	26.7	27.4	5.9	3.9	0.0	3.1	0.1	14.8	18.3	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.5	0.0	0.6	0.0	0.0	0.0	0.0	5.2	0.0	0.0	0.7	12.7	0.6	0.0	0.0	0.0	0.0	0.0	0.2	8.5	24.5	0.0	0.0	0.0	8.7	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3	3.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.0	1.1	11.3	0.0	41.9	0.0	0.7	0.1	3.1	13.7	0.0	18.3	3.3	8.7	9.9	0.0	3.9	12.6	9.2	0.2	14.8	0.0	0.0	4.3	3.8	1.3	1.4	0.5	0.9	2.0	2.2	4.5	0.6	3.5	1.6	38.7	196.1	256.7	1.7	16.5	0.0	0.8	0.0	2.7	9.1	1.8	0.0	0.5	0.0	0.0	0.2	3.9	0.3	23.3	0.0	0.2	14.6	1.2	1372.7	1.0	17.1	0.0	0.0	6.7	6.0	0.0	0.0	57.6	32.1	2.8	0.0	0.0	0.0	0.0	0.0	1.3	0.4	0.0	2.0	0.0	0.2	15.8	1.6	467.3	0.0	1.3
CD7	"GP40, LEU-9, Tp40, TP41"	ENSG00000173762	"CD7 molecule"	P09564	17	82314868-82317602	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 54.1;lymphoid tissue: 127.6"	"Cell type enriched"	"Detected in many"	29	"T-cells: 440.5"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"NK-cell: 54.1"	"Group enriched"	"Detected in many"	21	"NK-cells: 54.1;T-cells: 19.0"	"Cell line enhanced"	"Detected in some"		"BEWO: 5.6;Hep G2: 21.4;JURKAT: 11.4;MOLT-4: 48.7"									"CAB002594, HPA039079"	Enhanced					NA	NA					"CAB002594: , HPA039079: AB_2676337"	"unprognostic (3.14e-3)"	"prognostic favorable (5.51e-4)"	"unprognostic (1.89e-2)"	"prognostic favorable (2.03e-5)"	"unprognostic (7.69e-3)"	"unprognostic (1.09e-3)"	"unprognostic (3.28e-2)"	"unprognostic (1.34e-1)"	"prognostic favorable (2.69e-4)"	"unprognostic (3.16e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.24e-1)"	"prognostic unfavorable (7.75e-11)"	"unprognostic (4.69e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.97e-1)"	"unprognostic (1.55e-3)"	4.7	0.7	0.5	23.4	0.4	14.5	1.7	0.4	0.3	1.9	8.0	0.3	0.5	7.7	1.8	1.9	3.4	2.4	3.5	1.4	0.5	0.6	2.8	4.1	9.5	50.2	0.9	0.0	1.6	1.0	0.0	1.0	4.0	0.4	2.7	1.0	1.8	6.0	1.1	0.5	1.0	17.5	0.5	1.6	33.0	4.6	0.9	0.1	127.6	2.2	1.0	33.3	4.6	2.2	0.1	1.7	0.6	0.1	54.1	19.0	7.1	0.0	0.0	0.0	0.0	0.0	0.1	5.6	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.3	21.4	0.2	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	11.4	0.0	0.0	0.0	0.0	48.7	0.0	0.0	0.0	0.1	0.0	0.0	0.9	0.1	0.0	0.1	0.1	0.7	0.5	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.4	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	17.6	0.0	15.1	0.1	7.9	12.8	0.0	0.0	19.0	18.9	0.6	54.1	0.1	1.7	6.8	7.1	0.5	0.4	0.4	0.3	0.5	0.6	0.9	0.0	0.4	0.1	0.0	0.0	5.6	0.5	6.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.3	0.0	0.9	4.2	0.0	0.5	5.2	6.4	1.7	8.1	2.4	3.2	1.6	0.0	12.9	15.2	0.0	0.0	5.8	11.8	0.0	0.6	0.0	0.2	0.8	0.0	0.6	0.0	0.0	2.2	0.0	0.4	3.9	1.6	440.5	0.9	1.7
CD70	"CD27L, CD27LG, TNFSF7"	ENSG00000125726	"CD70 molecule"	P32970	19	6583183-6604103	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Cytokine	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 23.3;lymphoid tissue: 12.7"	"Cell type enriched"	"Detected in some"	23	"monocytes: 417.4"	"Cancer enhanced"	"Detected in many"		"renal cancer: 24.7"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 13.9;T-reg: 23.3"	"Group enriched"	"Detected in many"	38	"B-cells: 13.9;T-cells: 23.3"	"Cell line enhanced"	"Detected in many"		"SiHa: 36.8;THP-1: 30.2;U-251 MG: 44.7;U-266/70: 79.5;U-266/84: 57.5"									HPA046582			Uncertain	Nucleoplasm		NA	NA			Nucleoplasm		"HPA046582: "	"unprognostic (8.71e-2)"	"unprognostic (9.91e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.33e-4)"	"unprognostic (1.73e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.61e-1)"	"prognostic unfavorable (6.29e-4)"	"unprognostic (1.36e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.92e-1)"	"unprognostic (1.72e-1)"	"prognostic unfavorable (3.22e-4)"	"unprognostic (2.57e-2)"	"unprognostic (1.40e-1)"	"unprognostic (2.27e-1)"	"unprognostic (2.08e-1)"	5.3	0.2	0.2	9.3	0.2	1.4	2.2	0.9	0.9	1.4	4.1	0.2	0.1	1.0	0.4	1.8	4.0	0.7	0.8	0.4	0.2	0.2	1.7	0.4	1.9	6.1	0.4	0.1	0.3	0.4	0.0	0.3	0.3	0.2	0.9	3.1	0.2	3.1	1.2	1.2	3.3	5.2	0.7	0.5	11.8	1.7	1.9	0.1	3.2	0.8	1.8	12.7	3.1	1.1	13.9	0.1	0.2	0.0	0.4	23.3	0.9	0.2	7.5	0.0	14.8	0.3	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.1	14.2	0.8	0.0	16.3	10.4	9.1	0.7	0.0	0.0	0.3	0.0	11.2	0.0	0.0	0.0	0.4	0.1	0.0	8.7	6.2	2.4	0.0	0.0	0.2	0.4	0.2	0.0	0.2	17.8	0.1	0.0	13.7	3.8	0.0	3.0	4.8	0.0	0.0	0.0	36.8	0.0	0.1	0.0	0.1	30.2	0.2	0.1	6.6	0.0	44.7	79.5	57.5	25.6	8.2	4.5	2.8	0.2	0.0	0.0	1.9	0.0	4.8	13.9	3.2	5.0	0.0	4.0	0.4	1.3	0.1	0.4	0.0	0.1	23.3	0.9	0.2	0.2	0.9	0.9	0.2	0.2	0.4	0.1	0.2	0.1	0.0	0.0	18.2	0.1	5.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.6	0.0	0.6	0.1	1.1	0.0	0.3	0.0	1.7	1.3	0.0	0.0	0.0	1.7	3.3	417.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.3	0.2	4.6	0.0	10.2	0.0	0.0
CD72	"CD72b, LYB2"	ENSG00000137101	"CD72 molecule"	P21854	9	35609533-35646810	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	13	"blood: 75.5;lymphoid tissue: 59.7"	"Cell type enriched"	"Detected in some"	4	"B-cells: 82.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	16	"memory B-cell: 34.3;naive B-cell: 75.5"	"Lineage enriched"	"Detected in many"	22	"B-cells: 75.5"	"Cell line enhanced"	"Detected in some"		"Daudi: 12.7;Karpas-707: 8.2;REH: 5.3;U-698: 28.3"	"Region enriched"	"Detected in single"	7	"basal ganglia: 3.6"	"Low region specificity"	"Detected in single"			"CAB002505, HPA044658"	Enhanced		Approved	Nucleoplasm,Mitochondria		NA	NA			"Nucleoplasm, Mitochondria"		"CAB002505: AB_563629, HPA044658: AB_2679039"	"unprognostic (1.13e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.21e-2)"	"unprognostic (8.82e-2)"	"unprognostic (1.87e-2)"	"unprognostic (7.81e-2)"	"unprognostic (7.11e-2)"	"unprognostic (2.95e-1)"	"unprognostic (3.29e-2)"	"unprognostic (2.02e-2)"	"unprognostic (1.95e-1)"	"unprognostic (2.89e-1)"	"prognostic unfavorable (2.49e-8)"	"unprognostic (1.42e-1)"	"unprognostic (2.32e-2)"	"unprognostic (1.23e-1)"	"unprognostic (3.59e-2)"	1.9	1.2	0.8	16.6	1.1	2.6	1.3	0.6	0.6	0.7	0.9	0.2	0.5	0.3	0.8	2.1	0.8	0.7	1.6	0.6	0.8	0.7	1.5	2.3	2.2	26.8	0.8	0.1	0.5	1.4	0.5	1.6	1.5	1.1	0.9	0.3	1.1	3.4	0.1	0.5	0.8	5.2	0.6	1.8	59.7	0.8	0.8	0.2	1.5	1.4	0.3	22.2	4.9	0.6	75.5	3.4	0.2	0.6	1.7	0.7	2.5	0.1	0.0	0.4	0.2	0.7	3.9	0.1	0.2	0.1	0.3	0.5	0.0	0.1	12.7	0.0	0.2	0.1	0.0	0.0	0.1	0.4	1.2	0.3	0.4	0.0	0.0	0.4	0.2	2.8	1.1	0.0	0.2	0.3	0.6	0.0	2.8	0.0	8.2	0.7	0.0	0.2	1.7	0.1	0.0	0.1	5.3	0.0	3.8	0.0	0.0	0.2	0.4	0.0	0.1	0.0	0.2	0.1	0.1	0.0	0.5	0.1	0.2	0.0	0.1	0.2	28.3	0.5	0.4	0.0	0.0	0.3	0.0	0.5	0.6	0.7	34.3	0.2	0.3	3.4	75.5	0.1	0.4	0.2	1.7	0.0	1.8	0.3	2.5	0.8	1.1	0.6	0.6	0.8	0.7	0.8	0.1	1.1	0.2	0.0	1.1	82.7	0.3	0.9	0.0	0.6	2.5	1.4	0.0	3.5	0.0	0.1	0.0	0.6	0.1	0.5	0.5	0.0	0.6	0.2	0.6	0.4	0.0	0.0	19.7	0.0	1.7	0.6	16.7	0.0	0.9	8.0	0.0	1.8	0.0	0.5	1.2	0.0	0.4	0.3	0.7	0.0	0.8	0.2	1.2	1.0	0.2	4.9	0.3	0.1
CD74	DHLAG	ENSG00000019582	"CD74 molecule"	P04233	5	150401637-150412929	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 504.7"	"Cell type enhanced"	"Detected in many"	16	"Hofbauer cells: 4588.2;Macrophages: 7133.7;monocytes: 15196.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"classical monocyte: 191.6;intermediate monocyte: 303.5;memory B-cell: 467.7;myeloid DC: 437.9;naive B-cell: 504.7;non-classical monocyte: 140.0;plasmacytoid DC: 303.2"	"Group enriched"	"Detected in all"	5	"B-cells: 504.7;dendritic cells: 437.9;monocytes: 303.5"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 118.2;Daudi: 181.9;HDLM-2: 261.1;REH: 157.4;RPMI-8226: 107.2;U-266/70: 87.7;U-698: 100.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002506, HPA010592"	Enhanced		Supported	"Golgi apparatus"		NA	NA		90000	"Golgi apparatus"		"CAB002506: AB_563630, HPA010592: AB_1078482"	"prognostic favorable (1.06e-4)"	"unprognostic (1.48e-2)"	"unprognostic (4.80e-3)"	"prognostic favorable (6.53e-6)"	"unprognostic (1.41e-1)"	"unprognostic (4.53e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.69e-3)"	"unprognostic (1.54e-2)"	"unprognostic (3.48e-2)"	"unprognostic (2.20e-2)"	"unprognostic (2.64e-1)"	"unprognostic (5.44e-3)"	"unprognostic (1.73e-1)"	"unprognostic (4.95e-2)"	"unprognostic (2.05e-1)"	"unprognostic (4.24e-2)"	137.8	95.7	53.2	177.0	81.4	40.7	104.2	8.4	43.5	89.6	68.2	79.0	30.0	98.3	60.0	73.9	43.6	68.1	81.3	104.1	46.9	43.5	168.3	60.1	222.5	310.1	78.3	23.1	53.4	34.1	15.1	51.0	27.9	79.8	72.6	63.6	72.9	123.0	55.4	40.5	56.6	182.8	55.1	123.1	372.1	77.3	23.7	68.1	201.1	83.4	45.6	288.2	91.7	47.0	504.7	437.9	76.1	303.5	42.2	41.2	238.1	1.9	0.0	0.0	0.1	0.1	0.1	0.7	0.0	0.0	0.0	0.0	23.6	118.2	181.9	7.3	0.0	0.5	0.5	0.0	0.0	0.0	261.1	0.0	5.9	0.1	14.4	0.3	0.4	0.3	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.4	72.4	0.0	0.0	0.2	0.8	0.3	0.0	0.0	157.4	0.2	107.2	0.5	7.7	0.3	0.5	0.3	0.2	5.2	1.2	4.8	21.8	0.2	0.6	0.5	0.5	0.2	87.7	9.4	100.8	42.2	8.2	38.5	6.3	191.6	76.1	16.8	303.5	18.7	467.7	14.8	24.8	437.9	504.7	7.8	13.5	16.8	42.2	140.0	303.2	41.2	238.1	53.2	81.4	8.4	43.5	46.9	43.5	78.3	23.1	79.8	68.1	390.1	2012.6	3694.0	133.2	635.9	0.3	57.9	405.1	591.6	683.6	476.3	0.0	29.1	99.5	571.4	6.9	1116.8	170.9	23.3	476.1	19.5	234.4	182.3	395.1	56.2	4588.2	1.6	233.2	353.6	3259.2	11.0	108.4	7133.7	1135.4	15196.0	331.4	14.5	306.9	131.5	16.6	759.6	8.0	161.7	171.2	2.3	7.6	503.4	34.8	370.6	168.2	195.9
CD79A	"IGA, MB-1"	ENSG00000105369	"CD79a molecule"	P11912	19	41877120-41881372	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"blood: 125.3;intestine: 43.5;lymphoid tissue: 119.2"	"Cell type enriched"	"Detected in some"	6	"B-cells: 739.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	38	"memory B-cell: 106.4;naive B-cell: 125.3"	"Lineage enriched"	"Detected in many"	41	"B-cells: 125.3"	"Group enriched"	"Detected in some"	24	"Daudi: 159.2;REH: 49.5;U-698: 138.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			CAB000019	Enhanced					NA	NA					"CAB000019: AB_2244527"	"prognostic favorable (8.45e-5)"	"unprognostic (1.63e-3)"	"unprognostic (4.13e-3)"	"unprognostic (1.31e-3)"	"unprognostic (2.02e-1)"	"prognostic favorable (1.18e-5)"	"unprognostic (1.23e-2)"	"unprognostic (8.11e-3)"	"unprognostic (9.41e-3)"	"unprognostic (1.12e-2)"	"unprognostic (2.53e-1)"	"unprognostic (2.32e-1)"	"prognostic unfavorable (2.15e-5)"	"unprognostic (6.08e-2)"	"unprognostic (3.39e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.46e-1)"	1.3	0.6	0.5	103.8	0.5	5.4	1.3	0.5	0.5	1.8	6.3	0.1	0.1	4.9	0.6	0.2	4.4	1.0	2.3	0.8	0.5	0.5	2.3	0.9	4.3	114.9	0.5	0.1	0.6	0.6	0.0	0.5	0.5	0.1	1.0	3.4	1.8	13.6	1.2	0.5	0.5	43.5	0.2	0.5	108.1	9.7	0.8	0.1	32.0	2.4	1.9	119.2	6.8	1.0	125.3	3.0	0.7	0.3	0.2	2.3	4.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	159.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.3	0.0	0.0	0.1	0.1	0.9	0.0	0.0	0.0	49.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.1	0.0	0.4	0.0	0.0	0.8	0.1	138.6	0.0	4.7	0.0	0.7	0.1	0.5	0.1	0.1	0.0	106.4	0.3	0.1	0.2	125.3	0.4	2.3	0.4	0.2	0.3	3.0	0.8	4.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.1	0.1	0.1	0.0	3.7	739.3	0.4	1.5	0.0	0.2	2.5	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.2	0.0	0.0	0.0	22.3	0.2	0.6	0.2	0.0	0.0	0.8	0.0	0.0	1.8	3.1	0.0	0.3	1.7	131.6	2.8	0.3	0.0	105.8	0.0	0.4	0.6	0.0	0.0	0.4	0.0	0.6	1.3	0.1	6.5	0.6	0.1
CD79B	"B29, IGB"	ENSG00000007312	"CD79b molecule"	P40259	17	63928740-63932354	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 138.8;lymphoid tissue: 56.6"	"Cell type enriched"	"Detected in many"	8	"B-cells: 486.9"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"memory B-cell: 100.6;naive B-cell: 138.8"	"Lineage enriched"	"Detected in many"	6	"B-cells: 138.8"	"Cell line enhanced"	"Detected in some"		"Daudi: 117.7;REH: 38.7;U-698: 161.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA009178, CAB009751, HPA044107"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	"Nucleoplasm, Cytosol"	"CAB009751: AB_2275844, HPA009178: AB_1078483, HPA044107: "	"unprognostic (3.90e-3)"	"unprognostic (1.61e-3)"	"unprognostic (5.21e-2)"	"unprognostic (3.45e-3)"	"unprognostic (4.22e-3)"	"prognostic favorable (2.35e-4)"	"unprognostic (1.82e-1)"	"unprognostic (9.25e-3)"	"unprognostic (3.89e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.87e-2)"	"unprognostic (2.50e-3)"	"unprognostic (1.89e-1)"	"unprognostic (1.44e-1)"	"unprognostic (4.28e-2)"	"unprognostic (2.75e-1)"	1.7	0.7	0.4	50.6	0.4	11.1	1.2	0.3	0.4	0.6	1.7	0.3	0.3	0.7	0.6	0.5	2.6	0.6	1.4	3.4	0.4	0.2	2.3	1.7	1.3	56.6	0.4	0.3	0.6	1.6	0.0	9.0	0.5	0.3	1.0	1.3	0.8	8.9	0.9	1.2	0.9	22.4	0.5	0.4	56.0	1.8	0.6	0.3	3.7	1.4	1.7	46.6	4.5	0.9	138.8	4.2	0.5	25.0	3.4	9.2	9.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.7	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	6.5	0.0	0.0	0.0	2.5	0.0	0.0	0.0	38.7	0.1	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.7	0.0	1.8	0.1	0.0	0.4	0.0	0.0	5.9	5.7	161.1	0.0	0.2	0.0	0.5	1.1	0.0	4.2	16.5	4.8	100.6	5.4	2.8	4.2	138.8	3.7	2.2	0.5	3.4	25.0	0.6	9.2	9.0	0.4	0.4	0.3	0.4	0.4	0.2	0.4	0.3	0.3	0.3	0.0	2.2	486.9	0.3	3.9	0.0	0.8	2.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	7.1	0.0	23.3	0.0	0.4	4.3	0.3	15.0	0.5	4.7	0.0	1.2	62.0	14.1	1.1	1.1	3.5	20.3	1.0	0.0	0.0	0.0	0.0	1.8	0.8	0.0	0.0	3.3	0.7	0.1	2.8	0.3	34.6	0.0	0.1
CD80	"B7-1, B7.1, CD28LG, CD28LG1"	ENSG00000121594	"CD80 molecule"	P33681	3	119524293-119559602	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 17.5"	"Cell type enriched"	"Detected in some"	22	"monocytes: 113.6"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"memory B-cell: 4.3;non-classical monocyte: 1.1;T-reg: 3.3"	"Group enriched"	"Detected in many"	24	"B-cells: 4.3;monocytes: 1.1;T-cells: 3.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 8.2;HDLM-2: 29.0;Karpas-707: 12.1;U-266/70: 5.2"					"Low region specificity"	"Detected in all"			"CAB025368, HPA050092"	Enhanced				"Intracellular and membrane"	NA	NA					"CAB025368: , HPA050092: AB_2681012"	"unprognostic (2.36e-1)"	"unprognostic (1.55e-2)"	"unprognostic (5.91e-2)"	"unprognostic (1.24e-1)"	"unprognostic (3.14e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.86e-2)"	"unprognostic (4.14e-3)"	"unprognostic (1.02e-2)"	"unprognostic (4.96e-3)"	"unprognostic (1.16e-2)"	"unprognostic (1.15e-1)"	"unprognostic (9.03e-8)"	"unprognostic (3.20e-1)"	"unprognostic (3.65e-2)"	"unprognostic (7.81e-3)"	"unprognostic (1.94e-2)"	0.7	0.6	0.4	11.7	0.3	1.5	1.2	0.3	0.3	0.6	0.7	0.3	0.7	1.3	0.4	0.6	0.7	0.3	1.0	0.5	0.9	0.3	0.7	2.0	6.2	7.4	0.4	0.0	0.3	0.9	0.0	1.1	0.7	0.6	0.6	1.7	0.8	3.9	0.2	0.5	0.4	2.4	0.2	0.8	17.5	0.6	0.4	0.0	5.6	1.6	0.8	17.2	1.8	0.4	4.3	0.1	0.0	1.1	0.0	3.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	12.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	5.2	0.2	1.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	4.3	0.5	0.3	0.1	0.6	0.0	0.0	0.0	0.0	1.1	0.0	3.3	0.2	0.4	0.3	0.3	0.3	0.9	0.3	0.4	0.0	0.6	0.0	0.0	1.0	0.5	0.0	0.6	0.0	0.6	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.3	0.0	0.0	0.0	3.9	0.0	0.0	5.2	0.0	113.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.2	0.0	0.0	0.0
CD81	"TAPA-1, TAPA1, TSPAN28"	ENSG00000110651	"CD81 molecule"	P60033	11	2376177-2397419	"CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	"Adaptive immunity, Host-virus interaction, Immunity"	"Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	6	"Muller glia cells: 752.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 41.4;naive B-cell: 37.6"	"Lineage enriched"	"Detected in all"	4	"B-cells: 41.4"	"Cell line enhanced"	"Detected in many"		"ASC diff: 236.1;ASC TERT1: 134.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002507, HPA007234"	Supported		Supported	"Plasma membrane"		NA	NA		1900000	"Plasma membrane"		"CAB002507: AB_563639, HPA007234: AB_1846333"	"unprognostic (2.96e-1)"	"unprognostic (3.40e-1)"	"prognostic unfavorable (7.56e-4)"	"unprognostic (1.84e-2)"	"prognostic unfavorable (8.21e-5)"	"unprognostic (6.03e-2)"	"unprognostic (1.75e-1)"	"unprognostic (1.31e-1)"	"unprognostic (2.09e-1)"	"unprognostic (1.24e-1)"	"prognostic favorable (3.86e-4)"	"unprognostic (3.07e-3)"	"unprognostic (2.08e-1)"	"unprognostic (3.55e-2)"	"unprognostic (1.67e-1)"	"unprognostic (2.06e-1)"	"unprognostic (2.06e-1)"	102.5	43.7	52.8	40.1	57.0	9.6	79.3	31.7	63.2	124.7	88.9	75.8	261.4	21.1	143.5	141.5	56.8	123.1	86.8	101.2	46.6	52.8	65.5	123.9	107.4	82.4	70.4	51.3	77.9	62.4	41.4	42.9	61.2	63.0	89.3	34.0	46.6	59.7	263.3	22.6	59.6	39.7	138.9	59.3	64.5	52.1	57.6	53.3	25.3	66.3	38.5	37.9	93.5	80.2	41.4	2.1	5.7	1.8	3.5	9.9	2.7	25.0	26.1	20.9	31.9	236.1	134.3	17.5	47.4	105.1	38.4	38.8	24.4	0.1	21.4	17.1	132.9	24.5	33.0	12.9	33.7	15.8	10.1	39.7	3.2	9.9	0.0	78.1	13.9	28.2	97.5	48.3	15.6	23.8	59.6	36.7	15.6	14.6	37.6	53.6	19.2	11.7	17.7	25.1	22.9	21.1	24.2	10.5	13.6	41.2	16.9	22.6	25.0	15.1	39.8	28.6	17.5	13.2	25.4	48.8	19.6	14.4	36.6	16.2	27.9	6.3	39.1	28.4	8.3	33.4	0.2	0.9	5.7	6.0	1.4	9.9	41.4	4.3	9.4	0.6	37.6	2.6	5.0	0.3	3.5	1.8	2.1	3.0	2.7	52.8	57.0	31.7	63.2	46.6	52.8	70.4	51.3	63.0	53.3	226.3	220.8	55.9	245.9	159.7	80.4	246.3	147.7	72.3	130.8	197.1	25.5	19.0	29.9	103.9	13.1	213.4	6.4	46.7	46.5	23.9	217.2	129.6	79.7	450.6	229.2	139.8	69.1	262.8	169.7	26.3	360.5	166.2	143.4	23.4	40.0	752.2	58.2	11.5	236.2	26.2	63.6	116.4	236.9	12.0	13.4	144.2	16.8	56.5	36.6	204.6
CD82	"IA4, KAI1, R2, ST6, TSPAN27"	ENSG00000085117	"CD82 molecule"	P27701	11	44564427-44620363	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	7	"granulocytes: 269.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 80.5"	"Group enriched"	"Detected in all"	6	"B-cells: 51.1;granulocytes: 80.5;T-cells: 25.6"	"Cell line enhanced"	"Detected in many"		"HMC-1: 78.9;LHCN-M2: 46.6;U-87 MG: 55.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002508, HPA028900, HPA061418"	Supported		Approved	Vesicles		NA	NA			Vesicles		"CAB002508: AB_563640, HPA028900: AB_10603558, HPA061418: AB_2684510"	"unprognostic (5.31e-2)"	"unprognostic (4.62e-1)"	"unprognostic (2.38e-2)"	"unprognostic (1.33e-1)"	"unprognostic (2.79e-1)"	"unprognostic (1.37e-2)"	"unprognostic (1.78e-1)"	"unprognostic (7.29e-2)"	"unprognostic (3.48e-1)"	"unprognostic (2.97e-1)"	"unprognostic (2.58e-2)"	"unprognostic (1.58e-1)"	"unprognostic (3.48e-3)"	"unprognostic (1.86e-3)"	"unprognostic (2.33e-2)"	"unprognostic (2.88e-2)"	"unprognostic (6.30e-2)"	14.7	4.9	16.3	21.6	23.1	43.6	13.8	6.3	13.6	17.5	20.7	23.0	53.0	25.9	4.8	13.5	58.3	19.8	21.7	12.7	16.9	13.3	10.2	18.8	38.8	22.8	17.9	9.2	9.0	11.6	2.8	3.9	20.7	14.0	14.3	6.8	18.6	29.8	55.2	10.5	34.6	36.0	8.9	10.2	21.9	22.5	4.5	12.6	23.9	8.3	23.5	33.5	16.3	28.1	51.1	6.7	80.5	9.1	7.2	25.6	9.5	5.1	0.7	6.8	1.3	4.6	17.6	0.2	2.9	24.1	5.2	13.3	0.3	3.5	5.3	3.6	1.5	11.0	19.6	0.9	15.3	12.0	23.7	0.4	33.1	1.6	0.1	3.4	9.1	78.9	24.2	17.9	21.9	11.7	13.4	9.2	4.5	0.2	1.6	46.6	3.7	8.8	17.1	0.2	18.7	0.3	0.2	28.2	7.4	3.1	5.0	0.2	0.3	1.8	28.1	3.9	0.9	26.9	9.0	5.1	16.5	2.2	0.3	28.0	0.6	0.0	0.1	55.8	5.0	8.8	48.4	9.1	16.0	4.9	4.8	8.5	51.1	24.9	11.6	2.2	30.9	8.6	3.8	80.5	7.2	3.4	6.7	25.6	9.5	16.3	23.1	6.3	13.6	16.9	13.3	17.9	9.2	14.0	12.6	44.7	44.6	74.3	91.2	48.9	1.8	6.5	45.9	54.9	87.6	150.1	2.0	1.2	10.0	68.4	1.9	26.6	44.6	46.7	58.6	1.0	26.5	41.9	269.5	23.3	60.0	1.6	12.7	43.0	26.7	1.3	37.4	30.2	60.8	10.0	21.4	35.9	63.0	30.0	7.8	2.0	1.9	12.9	28.8	1.8	4.7	58.7	1.1	35.1	29.6	115.3
CD83	"BL11, HB15"	ENSG00000112149	"CD83 molecule"	Q01151	6	14117256-14136918	"CD markers, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 70.0;lymphoid tissue: 64.5"	"Cell type enhanced"	"Detected in many"	22	"granulocytes: 239.5;Macrophages: 184.4;monocytes: 891.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 29.2;HDLM-2: 26.2;U-698: 44.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002509, HPA041454"	Enhanced					NA	NA					"CAB002509: AB_563641, HPA041454: AB_2677489"	"unprognostic (2.22e-3)"	"unprognostic (1.92e-2)"	"unprognostic (1.22e-1)"	"unprognostic (6.39e-2)"	"unprognostic (5.83e-2)"	"unprognostic (3.02e-2)"	"unprognostic (1.00e-2)"	"unprognostic (9.05e-3)"	"unprognostic (9.05e-2)"	"unprognostic (3.91e-2)"	"unprognostic (7.37e-2)"	"unprognostic (6.68e-2)"	"prognostic favorable (3.49e-4)"	"unprognostic (2.30e-1)"	"unprognostic (7.07e-2)"	"unprognostic (1.40e-2)"	"unprognostic (2.46e-2)"	14.0	8.3	6.1	64.5	5.7	70.0	7.5	14.2	11.8	17.0	2.0	24.7	3.4	1.8	3.7	8.3	3.6	1.8	9.9	2.6	7.3	12.7	9.7	6.0	29.0	19.5	7.8	2.2	9.7	1.6	2.2	4.1	3.4	10.8	5.2	3.8	3.5	16.4	7.8	1.8	2.6	6.9	2.7	11.1	16.5	2.2	4.0	2.8	33.8	2.3	6.2	57.5	16.4	9.8	19.1	5.2	1.3	15.4	2.6	3.6	2.3	6.6	0.3	5.0	6.9	7.3	1.7	0.1	1.8	6.8	3.2	5.7	0.5	4.4	29.2	5.6	0.5	6.7	0.7	1.9	2.1	10.8	26.2	2.8	4.0	8.6	0.8	0.2	5.8	6.4	1.9	0.9	3.1	1.0	1.0	0.1	10.1	0.8	0.0	0.3	2.4	4.6	11.0	2.0	1.2	1.3	4.5	10.9	4.1	2.3	6.6	1.1	2.0	0.4	0.2	5.0	3.0	1.2	4.7	0.1	5.0	3.1	0.7	4.5	0.3	0.0	44.9	1.1	8.0	7.5	0.0	1.7	1.1	2.7	10.7	2.9	11.5	2.5	2.2	5.2	19.1	1.8	2.1	1.3	2.6	15.4	1.8	3.6	2.3	6.1	5.7	14.2	11.8	7.3	12.7	7.8	2.2	10.8	2.8	17.9	74.6	42.7	9.5	44.0	3.5	25.4	2.5	5.3	9.1	10.4	5.9	1.4	3.3	0.6	0.4	16.9	2.6	0.0	1.3	2.2	18.7	12.7	239.5	0.8	140.3	1.6	23.1	3.1	66.8	1.1	0.3	184.4	42.2	891.9	3.3	3.1	1.6	0.0	0.0	15.8	2.6	0.0	26.8	0.9	12.1	33.6	2.3	13.8	3.5	2.8
CD84	"hCD84, mCD84, SLAMF5"	ENSG00000066294	"CD84 molecule"	Q9UIB8	1	160541095-160579516	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Autophagy, Cell adhesion, Immunity, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 26.0"	"Cell type enhanced"	"Detected in many"	14	"granulocytes: 177.3;Hofbauer cells: 84.2;Kupffer cells: 123.8;Macrophages: 52.0;monocytes: 78.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 12.6;HEL: 24.3;HL-60: 6.8;HMC-1: 27.7;MOLT-4: 6.7;U-698: 17.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA063316, HPA068020, HPA070502"	Enhanced		Enhanced	"Vesicles,Plasma membrane"		NA	NA		36000000	"Plasma membrane"	Vesicles	"HPA063316: , HPA068020: , HPA070502: AB_2686274"	"unprognostic (4.38e-2)"	"unprognostic (6.16e-3)"	"unprognostic (1.00e-2)"	"unprognostic (8.16e-2)"	"unprognostic (2.35e-1)"	"unprognostic (2.00e-2)"	"unprognostic (3.84e-1)"	"unprognostic (2.54e-2)"	"unprognostic (8.60e-2)"	"unprognostic (1.80e-1)"	"unprognostic (8.26e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.30e-2)"	"unprognostic (2.15e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.08e-1)"	15.9	4.8	3.8	18.5	4.5	6.7	3.7	1.3	3.4	3.3	3.2	7.9	7.7	2.5	2.5	4.3	2.7	3.1	6.4	5.0	3.8	3.0	3.1	5.1	9.2	26.0	6.0	2.2	1.8	4.3	0.9	1.9	7.1	5.3	3.7	4.7	2.4	4.3	9.8	1.6	2.7	9.6	4.1	11.1	25.6	3.5	2.8	5.9	13.8	2.9	2.3	16.3	5.8	2.7	5.1	5.4	21.0	7.3	1.0	8.2	6.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.3	0.0	0.0	0.0	6.8	27.7	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.4	0.1	0.0	0.0	6.7	5.1	0.0	0.0	0.0	0.2	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.1	0.0	1.5	0.0	21.0	7.3	11.0	6.9	6.3	5.2	5.1	5.9	8.2	5.4	4.7	3.5	6.3	1.0	1.0	2.4	3.2	7.9	6.1	3.8	4.5	1.3	3.4	3.8	3.0	6.0	2.2	5.3	5.9	0.0	8.3	23.1	0.7	2.2	0.2	1.2	5.1	1.4	2.3	0.0	0.0	0.4	0.0	0.0	0.6	2.6	0.0	0.0	0.2	0.3	0.8	0.6	177.3	0.9	84.2	0.0	0.0	5.5	123.8	0.5	0.6	52.0	5.0	78.5	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	1.0	0.0	0.0	2.0	0.8	42.4	0.0	0.7
CD86	"B7-2, B7.2, CD28LG2"	ENSG00000114013	"CD86 molecule"	P42081	3	122055366-122121139	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity"	"Host cell receptor for virus entry, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 27.0;brain: 26.1"	"Cell type enriched"	"Detected in many"	5	"monocytes: 760.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	8	"classical monocyte: 25.6;intermediate monocyte: 26.4;memory B-cell: 13.6;myeloid DC: 25.9;naive B-cell: 8.0;non-classical monocyte: 27.0"	"Group enriched"	"Detected in many"	17	"B-cells: 13.6;dendritic cells: 25.9;monocytes: 27.0"	"Cell line enriched"	"Detected in some"	7	"HDLM-2: 80.7"					"Low region specificity"	"Detected in all"			"CAB004319, HPA026802"	Approved		Supported	"Plasma membrane"		NA	NA		220000	"Plasma membrane"		"CAB004319: AB_627200, HPA026802: "	"unprognostic (1.81e-1)"	"unprognostic (3.78e-3)"	"unprognostic (3.04e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.36e-1)"	"unprognostic (2.79e-1)"	"unprognostic (1.15e-1)"	"unprognostic (8.56e-2)"	"unprognostic (7.72e-3)"	"unprognostic (1.21e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.98e-1)"	"prognostic unfavorable (9.83e-5)"	"unprognostic (9.72e-2)"	"unprognostic (1.70e-2)"	"unprognostic (9.78e-2)"	"unprognostic (8.67e-2)"	10.5	4.7	7.1	23.6	9.5	6.0	3.6	1.5	6.3	2.9	4.3	9.8	0.6	2.5	2.6	5.2	2.8	3.3	10.4	3.5	7.3	6.0	4.0	7.8	13.0	17.8	11.7	3.0	2.5	2.3	2.1	2.6	10.3	8.1	3.1	5.6	3.0	3.6	1.8	1.3	2.4	6.9	5.1	26.1	22.5	3.4	2.4	10.3	7.7	2.3	2.1	15.0	9.2	2.2	13.6	25.9	0.3	27.0	1.2	0.4	9.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	80.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	8.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.0	4.3	0.1	9.6	0.0	0.2	0.0	0.0	25.6	0.2	0.0	26.4	0.0	13.6	0.1	0.1	25.9	8.0	0.0	0.0	0.3	1.2	27.0	2.6	0.4	9.3	7.1	9.5	1.5	6.3	7.3	6.0	11.7	3.0	8.1	10.3	0.0	10.6	25.1	0.0	3.2	0.0	0.2	0.0	0.0	4.5	1.8	0.0	1.6	0.0	0.2	3.0	0.2	0.0	0.0	2.9	0.5	1.7	0.3	2.3	0.8	106.9	0.0	0.0	1.8	111.1	1.3	0.0	155.5	6.8	760.2	0.0	0.0	0.4	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.1	3.4	1.6	0.0	0.0	0.3
CD8A	CD8	ENSG00000153563	"CD8a molecule"	P01732	2	86784610-86808396	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	14	"blood: 82.2;lymphoid tissue: 262.3"	"Cell type enriched"	"Detected in some"	11	"T-cells: 65.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	13	"MAIT T-cell: 36.7;memory CD8 T-cell: 82.2;naive CD8 T-cell: 77.8"	"Lineage enriched"	"Detected in many"	20	"T-cells: 82.2"	"Cell line enhanced"	"Detected in some"		"JURKAT: 5.0;MOLT-4: 17.5;RPMI-8226: 4.0"					"Low region specificity"	"Detected in many"			"CAB000012, HPA037756, CAB075722"	Enhanced		Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA		500000	"Plasma membrane"		"CAB000012: AB_2075537, CAB075722: AB_2665709, HPA037756: AB_2675648"	"unprognostic (1.29e-3)"	"prognostic favorable (4.54e-4)"	"unprognostic (9.26e-3)"	"prognostic favorable (6.15e-6)"	"unprognostic (7.28e-2)"	"unprognostic (2.79e-3)"	"unprognostic (1.03e-2)"	"unprognostic (2.00e-2)"	"unprognostic (1.35e-2)"	"unprognostic (4.50e-3)"	"unprognostic (1.09e-1)"	"unprognostic (1.14e-1)"	"prognostic unfavorable (1.91e-5)"	"unprognostic (1.36e-1)"	"unprognostic (1.48e-1)"	"unprognostic (6.74e-2)"	"unprognostic (1.56e-2)"	2.4	1.4	1.4	7.4	2.8	6.8	1.5	1.4	1.2	2.1	5.3	0.8	0.8	4.2	1.5	2.1	2.0	2.1	4.5	1.6	1.2	1.6	1.3	2.1	6.0	23.8	1.0	0.5	1.7	1.2	0.0	0.9	0.6	0.7	2.3	1.9	1.8	3.0	1.1	0.8	0.7	12.2	0.7	1.7	46.4	5.4	1.0	0.5	262.3	2.2	1.6	8.1	3.8	1.9	0.0	0.1	0.6	0.1	4.0	82.2	17.4	0.3	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.4	0.0	1.8	0.0	0.7	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	5.0	0.0	0.3	0.0	0.8	17.5	1.1	0.6	0.2	0.3	0.1	0.9	4.0	0.0	0.4	0.9	2.4	0.2	0.1	0.0	0.0	0.4	0.5	0.0	0.0	0.6	0.1	0.0	0.1	0.3	0.9	0.0	0.0	0.1	0.1	0.1	0.0	4.8	0.0	36.7	0.0	0.3	82.2	0.0	0.0	0.3	77.8	0.6	4.0	0.1	0.1	0.1	17.4	1.4	2.8	1.4	1.2	1.2	1.6	1.0	0.5	0.7	0.5	0.0	5.8	1.5	0.2	1.8	0.1	2.9	0.0	2.7	1.2	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	0.0	0.0	0.0	0.5	0.2	2.3	0.8	0.1	0.0	0.0	5.5	1.3	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.9	0.5	0.4	1.6	0.1	65.4	0.0	0.1
CD8B	CD8B1	ENSG00000172116	"CD8b molecule"	P10966	2	86815339-86861924	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 132.1;lymphoid tissue: 61.5"	"Cell type enriched"	"Detected in some"	7	"T-cells: 61.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	10	"memory CD8 T-cell: 73.5;naive CD8 T-cell: 132.1"	"Lineage enriched"	"Detected in many"	40	"T-cells: 132.1"	"Cell line enriched"	"Detected in some"	55	"RPMI-8226: 158.6"									"CAB004353, HPA029164"	Enhanced		Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"		"CAB004353: AB_627211, HPA029164: AB_2672936"	"unprognostic (1.83e-3)"	"unprognostic (1.98e-3)"	"unprognostic (2.22e-2)"	"prognostic favorable (7.88e-7)"	"unprognostic (6.23e-2)"	"unprognostic (7.05e-3)"	"unprognostic (1.11e-2)"	"unprognostic (2.59e-2)"	"unprognostic (5.50e-3)"	"unprognostic (5.91e-2)"	"unprognostic (9.25e-2)"	"unprognostic (4.60e-1)"	"prognostic unfavorable (7.11e-6)"	"unprognostic (7.84e-2)"	"unprognostic (3.00e-1)"	"unprognostic (1.86e-2)"	"unprognostic (4.33e-2)"	1.2	0.7	1.0	5.3	1.0	3.9	1.0	1.3	1.3	21.2	1.1	1.0	1.0	2.5	1.2	1.0	1.0	1.1	1.8	1.0	1.0	1.8	1.0	1.0	2.7	14.4	1.7	1.0	1.3	1.0	6.4	7.4	1.0	2.2	1.3	1.3	1.0	1.0	1.0	1.0	0.9	11.4	1.0	1.5	12.7	2.3	1.0	1.0	61.5	1.5	1.0	8.1	1.8	1.3	0.1	0.1	3.2	0.1	0.1	132.1	36.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	158.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	3.2	0.1	0.0	2.0	0.1	10.0	0.0	0.2	73.5	0.0	0.1	0.5	132.1	0.7	0.1	0.1	0.1	0.2	36.3	1.0	1.0	1.3	1.3	1.0	1.8	1.7	1.0	2.2	1.0	6.0	8.5	0.8	1.7	3.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.7	0.6	0.0	0.2	0.1	0.0	0.0	0.6	1.0	0.0	0.0	1.3	5.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.1	2.5	0.0	61.8	1.2	0.1
CD9	"BA2, MIC3, MRP-1, P24, TSPAN29"	ENSG00000010278	"CD9 molecule"	P21926	12	6199715-6238271	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Fertilization"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Urothelial cells: 2399.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	21	"basophil: 137.8;eosinophil: 98.3"	"Lineage enriched"	"Detected in many"	24	"granulocytes: 137.8"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 129.4;RT4: 95.9;TIME: 191.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB002490	Supported		Supported	"Plasma membrane"		NA	NA		68000000	"Plasma membrane"		"CAB002490: AB_563643"	"unprognostic (1.38e-1)"	"unprognostic (6.36e-3)"	"unprognostic (8.27e-3)"	"unprognostic (6.98e-3)"	"unprognostic (3.89e-1)"	"unprognostic (2.81e-1)"	"unprognostic (1.32e-1)"	"unprognostic (2.08e-2)"	"unprognostic (2.90e-1)"	"unprognostic (2.60e-2)"	"prognostic unfavorable (1.59e-4)"	"unprognostic (2.30e-1)"	"prognostic favorable (6.49e-5)"	"unprognostic (6.10e-2)"	"unprognostic (1.77e-1)"	"prognostic favorable (8.93e-5)"	"unprognostic (9.26e-2)"	38.1	44.5	20.0	24.1	36.2	3.1	48.2	6.8	29.6	55.0	68.3	63.1	151.6	19.5	36.2	43.4	139.8	38.4	23.2	39.2	30.3	15.6	39.9	12.2	61.1	8.2	43.3	23.3	14.1	23.3	89.5	15.2	13.0	28.7	77.9	73.5	25.5	91.6	180.4	11.3	60.1	29.6	62.2	48.9	12.2	27.7	10.4	47.7	6.0	63.6	112.3	85.8	54.5	76.0	1.9	0.9	137.8	5.6	0.2	1.1	5.6	34.3	15.1	0.3	9.3	14.8	15.3	13.1	20.4	40.7	7.0	10.7	11.1	129.4	0.1	5.1	4.3	20.8	75.4	7.9	40.7	5.4	1.7	5.5	0.1	11.5	2.4	6.4	0.1	43.3	0.0	30.3	12.8	11.0	19.7	83.6	2.5	1.6	0.1	4.4	49.2	0.1	3.7	11.7	41.8	15.2	0.3	24.9	43.8	68.4	95.9	0.0	2.9	20.3	16.8	17.5	71.5	7.8	3.5	191.3	0.7	19.1	0.7	2.4	0.1	0.1	5.2	11.9	0.0	18.8	137.8	5.6	98.3	0.1	1.8	0.2	0.5	0.1	0.1	0.9	1.9	0.4	1.1	2.6	0.2	0.0	0.3	0.0	5.6	20.0	36.2	6.8	29.6	30.3	15.6	43.3	23.3	28.7	47.7	738.4	321.6	28.1	1345.7	921.9	3.7	14.2	76.5	519.3	651.7	1020.6	0.0	8.4	116.0	478.4	2.3	477.7	411.2	0.0	155.9	225.1	473.0	1465.7	638.5	36.4	653.0	0.0	166.1	406.4	33.8	7.3	29.7	438.3	892.5	256.1	636.4	386.7	257.1	669.9	66.4	14.0	13.1	653.2	455.3	7.0	76.5	1118.7	45.2	23.0	620.5	2399.6
CD93	"C1qR(P), C1QR1, C1qRP, CDw93, dJ737E23.1, ECSM3, MXRA4"	ENSG00000125810	"CD93 molecule"	Q9NPY3	20	23079349-23086340	"CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"Endothelial cells: 232.0;Ito cells: 170.6;Kupffer cells: 149.3;Macrophages: 59.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 14.4;neutrophil: 17.4"	"Group enriched"	"Detected in many"	40	"dendritic cells: 5.5;granulocytes: 17.4;monocytes: 14.4"	"Group enriched"	"Detected in some"	4	"HUVEC TERT2: 58.4;TIME: 73.9;U-937: 98.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA009300, HPA012368"	Enhanced		Approved	"Vesicles,Plasma membrane"		NA	NA		440000000	"Vesicles, Plasma membrane"		"HPA009300: AB_1846342, HPA012368: AB_1846341"	"unprognostic (2.05e-1)"	"unprognostic (2.85e-1)"	"unprognostic (1.07e-1)"	"unprognostic (4.83e-2)"	"unprognostic (2.31e-1)"	"unprognostic (2.66e-2)"	"unprognostic (6.45e-2)"	"unprognostic (2.77e-1)"	"unprognostic (4.51e-1)"	"unprognostic (3.74e-2)"	"unprognostic (2.61e-1)"	"unprognostic (1.81e-1)"	"prognostic unfavorable (2.74e-4)"	"unprognostic (8.81e-3)"	"unprognostic (6.13e-2)"	"unprognostic (4.49e-2)"	"unprognostic (3.11e-2)"	50.5	6.1	2.4	15.0	3.4	4.7	31.4	1.0	3.0	13.6	8.1	1.7	3.9	3.2	14.3	12.5	10.0	13.6	14.2	33.3	2.4	2.2	10.8	10.9	34.8	25.3	4.1	1.2	11.6	5.9	5.1	4.3	48.9	5.3	9.7	4.3	4.9	5.9	3.9	16.2	6.8	7.7	15.4	4.3	17.5	7.5	6.9	3.3	6.9	12.3	9.3	4.5	15.6	12.2	0.0	5.5	17.4	14.4	0.0	0.3	4.7	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	58.4	0.0	0.1	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.1	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.4	73.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	98.9	0.0	0.0	14.4	0.2	0.2	10.3	0.0	0.0	0.1	0.0	5.5	0.0	0.0	0.0	17.4	0.0	4.2	0.7	0.3	4.7	2.4	3.4	1.0	3.0	2.4	2.2	4.1	1.2	5.3	3.3	3.0	11.9	3.7	0.6	13.4	0.0	7.3	10.2	5.3	6.8	0.0	0.0	0.2	0.0	0.2	0.4	232.0	0.0	0.0	0.0	0.4	6.5	2.9	4.7	1.3	16.2	0.0	0.0	170.6	149.3	0.2	1.7	59.8	8.5	0.0	0.0	0.1	0.1	0.0	26.2	0.2	0.0	19.4	15.3	0.0	0.2	8.8	0.3	2.9	0.0	0.9
CD96	TACTILE	ENSG00000153283	"CD96 molecule"	P40200	3	111292719-111665750	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Craniosynostosis, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 32.0;lymphoid tissue: 82.4"	"Cell type enriched"	"Detected in many"	6	"T-cells: 148.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"NK-cells: 20.0;T-cells: 32.0"	"Cell line enhanced"	"Detected in some"		"HEL: 6.8;JURKAT: 7.7;MOLT-4: 29.8;RT4: 27.6;U-937: 24.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA066754	Enhanced					NA	NA		37000			"HPA066754: AB_2685714"	"unprognostic (1.06e-3)"	"unprognostic (3.95e-3)"	"unprognostic (4.16e-3)"	"unprognostic (1.91e-5)"	"unprognostic (4.72e-3)"	"prognostic favorable (5.52e-4)"	"unprognostic (2.12e-2)"	"unprognostic (3.48e-2)"	"unprognostic (6.06e-2)"	"unprognostic (4.84e-3)"	"unprognostic (2.44e-2)"	"unprognostic (2.77e-1)"	"prognostic unfavorable (2.02e-6)"	"unprognostic (3.12e-1)"	"unprognostic (4.42e-2)"	"unprognostic (3.90e-2)"	"prognostic favorable (5.23e-5)"	5.7	0.9	0.4	18.6	0.5	8.6	3.1	0.6	0.4	2.2	7.1	0.6	0.5	3.6	1.7	1.8	3.4	2.1	3.5	1.3	0.4	0.5	2.3	2.7	9.7	21.9	1.5	0.2	1.4	0.8	0.0	1.1	1.1	1.0	2.6	3.7	2.5	4.0	1.6	0.6	1.3	13.4	1.4	2.0	14.2	3.5	1.0	0.4	82.4	4.8	2.3	23.9	9.9	3.2	5.5	0.1	3.8	0.2	20.0	32.0	11.2	0.0	0.0	0.1	0.1	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.8	0.1	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	6.8	0.1	0.1	0.0	0.3	0.6	0.0	0.0	0.0	0.1	0.6	0.0	7.7	0.1	0.9	0.0	0.0	29.8	0.1	0.3	0.0	0.0	0.0	0.9	0.2	0.2	27.6	0.0	0.0	0.1	0.4	0.0	0.1	0.1	0.1	0.0	0.1	0.5	0.1	0.0	2.7	0.8	0.0	0.1	24.7	5.3	0.5	0.1	3.8	20.2	0.0	32.0	2.8	18.6	23.5	0.1	5.5	19.4	23.6	0.8	20.0	0.2	0.1	11.8	11.2	0.4	0.5	0.6	0.4	0.4	0.5	1.5	0.2	1.0	0.4	17.9	24.2	7.5	0.6	2.9	1.6	0.8	0.0	2.7	17.0	1.8	0.0	0.5	0.0	0.0	0.4	0.7	0.0	0.0	0.0	0.1	2.8	0.3	15.1	0.8	0.2	0.0	0.0	0.6	5.1	0.0	0.3	2.5	3.3	0.0	0.0	0.2	0.0	0.2	0.0	0.5	2.2	0.0	0.9	0.5	0.4	2.8	1.6	148.1	0.0	0.4
CD99	MIC2	ENSG00000002586	"CD99 molecule (Xg blood group)"	P14209	X	2691133-2741309	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 359.1;breast: 433.0;heart muscle: 347.0"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 124.8"					"Low region specificity"	"Detected in all"			"CAB000020, HPA035304"	Supported		Approved	"Golgi apparatus"		NA	NA		34000000	"Golgi apparatus"		"CAB000020: AB_2076419, HPA035304: AB_10672861"	"unprognostic (3.71e-3)"	"unprognostic (2.90e-1)"	"unprognostic (5.97e-3)"	"unprognostic (7.01e-3)"	"unprognostic (2.14e-2)"	"unprognostic (6.98e-3)"	"unprognostic (3.89e-3)"	"unprognostic (1.54e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.59e-2)"	"unprognostic (1.87e-1)"	"prognostic unfavorable (5.87e-7)"	"unprognostic (2.11e-2)"	"unprognostic (2.18e-1)"	"unprognostic (5.37e-2)"	"unprognostic (3.61e-2)"	45.7	14.1	85.8	14.4	100.5	11.1	433.0	45.7	60.9	243.9	31.8	4.5	4.5	19.9	258.4	18.3	26.1	22.2	35.2	347.0	103.4	14.7	66.4	24.6	24.5	16.6	161.0	56.6	187.4	28.9	3.3	67.0	138.7	185.5	30.5	20.6	4.5	18.1	37.7	18.9	28.0	23.8	31.1	359.1	18.5	21.7	23.3	101.3	4.5	15.2	4.5	16.1	24.7	208.8	32.7	62.6	4.3	47.1	32.1	107.1	103.6	23.9	27.5	30.8	41.6	124.8	94.6	18.5	64.2	100.7	40.4	58.9	39.7	16.9	1.6	12.6	89.1	22.5	9.4	12.3	16.1	33.6	32.6	31.0	4.6	19.2	34.5	39.6	7.3	36.7	58.8	20.0	22.1	15.6	28.0	73.6	25.3	5.7	0.0	38.1	18.8	63.9	25.0	10.0	2.7	30.0	10.8	25.7	45.4	23.3	16.4	0.1	13.6	15.4	13.9	38.6	81.3	12.3	22.9	67.9	49.8	8.4	47.6	21.6	0.1	0.0	10.5	33.3	18.4	31.1	1.8	47.1	1.5	107.1	11.6	60.4	32.7	72.6	94.6	44.6	20.2	26.8	57.1	4.3	32.1	2.6	62.6	74.3	103.6	85.8	100.5	45.7	60.9	103.4	14.7	161.0	56.6	185.5	101.3	59.6	70.1	119.1	149.0	222.5	0.9	77.6	76.5	73.6	67.1	68.0	0.0	181.3	11.6	139.8	5.6	366.2	95.9	70.0	121.0	161.2	556.7	292.3	222.0	87.0	661.4	0.0	77.6	437.1	220.0	13.6	597.5	294.4	656.3	138.9	114.0	38.7	162.8	176.3	480.5	50.9	3.0	336.3	416.7	17.9	45.6	194.8	102.9	472.0	184.3	245.6
CDCP1	"CD318, SIMA135"	ENSG00000163814	"CUB domain containing protein 1"	Q9H5V8	3	45082278-45146422	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Basal keratinocytes: 107.6;Ductal cells: 84.9;Pancreatic endocrine cells: 100.0;Urothelial cells: 90.5"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in some"	5	"pons and medulla: 5.5"	"Group enriched"	"Detected in some"	5	"myeloid DC: 4.0;neutrophil: 1.8;NK-cell: 7.1"	"Group enriched"	"Detected in many"	5	"dendritic cells: 4.0;granulocytes: 1.8;NK-cells: 7.1"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 23.8;HBEC3-KT: 27.2;hTEC/SVTERT24-B: 67.5;hTERT-HME1: 45.8;PC-3: 21.1;RPTEC TERT1: 20.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA010978, HPA010979, CAB025637"	Enhanced				"Intracellular and membrane"	NA	NA					"CAB025637: , HPA010978: AB_1846403, HPA010979: AB_1846401"	"unprognostic (9.31e-2)"	"unprognostic (4.50e-2)"	"unprognostic (1.67e-2)"	"unprognostic (2.66e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.51e-3)"	"unprognostic (2.94e-2)"	"prognostic unfavorable (1.41e-5)"	"unprognostic (2.15e-1)"	"unprognostic (1.00e-1)"	"prognostic unfavorable (1.48e-4)"	"unprognostic (2.14e-2)"	"unprognostic (9.98e-3)"	"unprognostic (3.59e-2)"	"unprognostic (2.99e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.34e-1)"	2.3	0.7	0.5	5.6	1.0	0.2	4.4	0.3	0.7	6.9	17.4	1.1	10.1	11.4	3.2	11.1	28.6	2.4	9.8	0.8	1.0	0.5	4.4	0.8	7.1	1.4	0.6	0.3	1.6	13.9	0.0	2.3	4.0	5.5	5.2	11.3	0.5	11.4	13.0	0.6	15.2	29.8	1.8	1.3	0.8	10.8	1.3	0.5	1.0	21.8	19.2	19.1	7.3	11.7	0.2	4.0	1.8	0.9	7.1	0.3	0.3	12.3	3.7	0.0	0.0	0.0	0.6	3.0	2.2	0.4	1.1	1.0	5.2	23.8	0.0	2.8	0.7	0.6	10.0	0.0	27.2	2.3	0.0	0.0	0.0	4.2	0.0	2.0	0.0	0.9	0.9	14.3	67.5	45.8	4.1	0.2	0.0	7.2	0.0	3.4	0.0	0.0	0.2	1.8	6.0	21.1	0.0	0.0	2.1	20.8	10.0	0.8	0.0	4.6	1.2	0.0	1.2	5.8	0.1	1.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.3	0.2	0.2	0.4	0.9	0.1	0.1	0.1	0.0	0.1	0.3	0.1	4.0	0.2	0.2	0.1	1.8	7.1	0.0	0.1	0.0	0.3	0.5	1.0	0.3	0.7	1.0	0.5	0.6	0.3	5.5	0.5	3.0	13.3	0.0	52.1	107.6	0.0	0.4	12.7	26.8	18.2	8.7	0.0	4.5	0.0	84.9	0.0	0.6	30.4	0.0	61.1	6.7	5.8	52.2	8.1	0.0	10.2	0.0	36.0	0.0	4.8	0.0	2.8	26.8	3.3	18.0	34.1	0.0	100.0	28.8	0.0	0.0	0.0	0.0	3.3	0.0	0.4	65.6	2.7	0.0	22.5	90.5
CDH1	"CD324, UVO, uvomorulin"	ENSG00000039068	"Cadherin 1"	P12830	16	68737225-68835548	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes, Disease mutation, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 125.5"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	12	"myeloid DC: 2.8;plasmacytoid DC: 8.5"	"Lineage enriched"	"Detected in single"	18	"dendritic cells: 8.5"	"Cell line enhanced"	"Detected in some"		"BEWO: 107.1;CACO-2: 36.0;CAPAN-2: 50.3;HaCaT: 48.6;hTCEpi: 34.3;MCF7: 29.7;OE19: 31.7;RT4: 37.0;T-47d: 32.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857"	Enhanced		Supported	"Golgi apparatus,Plasma membrane,Cell Junctions"		NA	NA		22000000	"Plasma membrane, Cell Junctions"	"Golgi apparatus"	"CAB000087: AB_2533003, CAB028364: AB_2076812, CAB072855: AB_2665698, CAB072856: AB_2665699, CAB072857: AB_2665700, HPA004812: AB_1078369"	"unprognostic (3.95e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.12e-3)"	"unprognostic (1.13e-1)"	"unprognostic (1.42e-1)"	"unprognostic (2.78e-1)"	"unprognostic (5.04e-3)"	"unprognostic (1.63e-1)"	"unprognostic (5.47e-2)"	"unprognostic (2.85e-1)"	"unprognostic (1.19e-2)"	"unprognostic (3.61e-1)"	"prognostic favorable (2.06e-4)"	"unprognostic (1.21e-1)"	"unprognostic (2.62e-1)"	"unprognostic (2.51e-1)"	"unprognostic (5.92e-2)"	1.1	0.7	1.3	14.8	1.5	0.5	15.3	0.8	1.1	14.4	63.8	1.8	42.4	25.5	4.7	18.6	48.5	9.7	48.9	0.8	1.5	1.0	24.2	64.9	24.4	0.5	1.8	0.9	5.6	71.5	62.2	13.2	55.2	2.8	28.9	25.9	11.8	66.6	43.7	0.8	30.5	125.5	1.5	1.1	3.5	21.6	2.1	1.8	11.7	83.0	26.2	32.6	16.8	21.7	0.0	8.5	0.0	0.0	0.3	0.4	0.1	21.6	2.2	0.0	0.0	0.0	0.0	107.1	0.0	0.0	0.0	0.0	36.0	50.3	0.0	0.4	0.0	0.0	48.6	0.0	24.1	0.0	4.2	0.6	0.0	0.1	7.7	0.0	0.0	0.2	0.0	34.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.7	0.0	0.1	0.8	31.7	0.1	0.0	0.0	0.3	8.8	37.0	1.3	0.1	0.2	0.0	9.1	15.2	32.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	2.8	0.0	0.0	0.0	0.0	0.3	0.0	8.5	0.1	0.1	1.3	1.5	0.8	1.1	1.5	1.0	1.8	0.9	2.8	1.8	122.1	58.7	0.9	101.9	83.6	0.0	0.8	152.8	73.6	64.8	155.3	0.0	97.3	1.7	107.7	0.0	1.2	202.1	0.0	98.3	22.3	4.1	170.0	1.1	44.7	10.1	0.0	83.2	0.6	1.5	0.0	0.3	6.3	50.6	5.4	180.9	0.0	193.9	160.9	0.4	3.3	0.0	0.0	4.7	0.0	0.1	114.9	42.2	0.0	125.1	204.2
CDH2	"CD325, CDHN, NCAD"	ENSG00000170558	"Cadherin 2"	P19022	18	27950966-28177446	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 77.6;parathyroid gland: 35.4"	"Cell type enhanced"	"Detected in many"	15	"Cardiomyocytes: 330.4;Cone photoreceptor cells: 141.4;Hepatocytes: 98.3;Muller glia cells: 175.2;Rod photoreceptor cells: 92.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"basophil: 4.4;neutrophil: 4.1"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 4.4"	"Cell line enhanced"	"Detected in many"		"AF22: 56.7;BJ: 40.9;fHDF/TERT166: 84.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000141, CAB018580, HPA058574, CAB078686"	Enhanced		Supported	"Plasma membrane,Cell Junctions"		NA	NA		160000000	"Plasma membrane, Cell Junctions"		"CAB000141: , CAB018580: AB_626778, CAB078686: AB_2665849, HPA058574: AB_2683760"	"unprognostic (9.42e-2)"	"unprognostic (2.69e-3)"	"unprognostic (9.07e-3)"	"unprognostic (5.45e-2)"	"unprognostic (1.14e-1)"	"unprognostic (9.30e-2)"	"unprognostic (3.97e-2)"	"unprognostic (2.53e-3)"	"unprognostic (6.70e-3)"	"unprognostic (1.00e-2)"	"unprognostic (7.53e-2)"	"unprognostic (3.51e-2)"	"unprognostic (3.02e-2)"	"unprognostic (1.93e-3)"	"unprognostic (6.69e-2)"	"unprognostic (1.33e-1)"	"unprognostic (2.59e-3)"	0.6	29.6	9.8	1.5	9.4	0.5	0.5	5.7	16.1	3.2	2.0	8.0	0.2	0.8	3.1	1.9	0.6	4.7	1.7	77.6	9.9	9.6	9.2	23.3	0.7	1.1	6.0	9.1	3.4	0.7	35.4	5.4	0.5	5.9	1.4	0.8	6.8	0.5	4.6	0.4	0.5	0.9	3.2	6.7	5.9	2.5	19.6	7.4	0.9	2.8	0.0	1.0	1.0	1.3	0.0	0.0	4.4	0.0	0.7	0.9	0.0	0.0	4.5	56.7	0.0	9.0	1.8	0.0	40.9	12.4	16.7	15.3	0.0	0.0	0.0	22.0	84.6	8.0	6.0	9.3	0.0	23.7	0.1	5.9	0.0	15.3	14.0	8.6	0.0	0.0	0.8	0.1	38.3	6.7	38.6	14.6	2.5	0.0	0.0	13.0	0.0	10.3	0.0	7.6	0.0	4.9	0.0	6.7	7.8	0.0	1.8	14.8	25.6	0.0	0.0	4.5	23.2	0.0	0.0	2.3	36.2	11.5	0.5	29.6	0.0	0.0	0.0	6.9	0.0	27.8	4.4	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	4.1	0.7	0.0	0.0	0.0	0.0	9.8	9.4	5.7	10.1	9.9	9.6	6.0	9.1	5.9	7.4	0.0	1.1	5.0	0.0	0.2	23.9	330.4	58.6	2.7	1.2	10.4	141.4	0.2	0.0	5.6	31.9	3.6	0.0	0.0	0.3	0.0	1.2	0.0	0.0	98.3	0.3	3.2	0.0	18.4	1.9	11.0	2.0	0.4	3.3	0.0	0.0	175.2	12.4	0.0	12.0	40.6	92.8	6.5	5.3	3.3	28.8	0.0	0.2	0.0	0.0	0.1
CDH5	"7B4, CD144"	ENSG00000179776	"Cadherin 5"	P33151	16	66366622-66404786	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 96.6"	"Cell type enhanced"	"Detected in many"	15	"Endothelial cells: 155.1;Ito cells: 190.9;Syncytiotrophoblasts: 67.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"HUVEC TERT2: 113.8;TIME: 97.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB028366, HPA075875"	Approved		Supported	"Nucleoplasm,Nuclear membrane,Plasma membrane"		NA	NA		1000000000	"Plasma membrane"	"Nucleoplasm, Nuclear membrane"	"CAB028366: AB_2276033, HPA075875: "	"unprognostic (1.05e-1)"	"unprognostic (8.13e-2)"	"unprognostic (6.11e-2)"	"unprognostic (4.89e-2)"	"unprognostic (4.96e-2)"	"unprognostic (5.50e-3)"	"unprognostic (9.38e-2)"	"unprognostic (5.28e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.33e-2)"	"unprognostic (2.32e-1)"	"prognostic unfavorable (5.14e-4)"	"unprognostic (9.49e-3)"	"unprognostic (3.01e-2)"	"unprognostic (2.22e-1)"	"unprognostic (3.15e-2)"	48.7	5.6	4.0	6.2	5.8	0.6	28.1	2.6	4.8	11.1	6.6	3.4	5.5	3.7	18.7	11.2	8.4	7.2	12.6	21.7	4.5	4.3	7.8	12.7	43.7	9.7	6.5	2.8	7.7	3.6	5.0	3.5	96.6	7.6	9.0	4.8	8.5	5.2	4.4	19.0	7.0	6.8	12.1	5.4	10.8	5.7	6.7	3.3	1.2	16.6	15.7	4.5	11.7	11.3	0.0	0.6	0.4	0.8	0.1	0.1	1.1	0.0	0.0	0.7	0.0	0.0	0.0	7.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	113.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	2.4	0.0	0.3	0.0	0.0	97.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.4	0.0	0.1	0.0	0.4	0.1	0.0	0.6	0.1	1.1	4.0	5.8	2.6	4.8	4.5	4.3	6.5	2.8	7.6	3.3	0.0	10.4	0.0	0.0	3.7	0.0	14.6	7.6	0.0	1.2	1.8	0.0	3.3	0.0	0.1	33.0	155.1	0.0	0.0	0.0	40.7	3.1	0.1	3.5	1.5	2.1	0.0	0.0	190.9	29.5	47.7	5.8	2.3	11.8	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	3.1	13.4	0.2	2.6	67.5	0.0	0.0	0.0
CEACAM1	"BGP, BGP1, CD66a"	ENSG00000079385	"Carcinoembryonic antigen related cell adhesion molecule 1"	P13688	19	42507304-42561234	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 58.7;liver: 46.1;lymphoid tissue: 46.5"	"Cell type enhanced"	"Detected in many"	16	"Basal glandular cells: 234.8;Enterocytes: 131.5;Glandular cells: 256.0;Urothelial cells: 472.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	9	"eosinophil: 20.6;neutrophil: 12.7"	"Lineage enriched"	"Detected in many"	11	"granulocytes: 20.6"	"Group enriched"	"Detected in some"	4	"CAPAN-2: 11.7;Hep G2: 33.3;OE19: 32.1;RT4: 21.9;SK-MEL-30: 24.6"									"CAB002146, HPA011041"	Enhanced				"Intracellular and membrane"	NA	NA		180000000			"CAB002146: AB_563614, HPA011041: AB_1078481"	"unprognostic (7.13e-3)"	"unprognostic (2.15e-1)"	"unprognostic (2.67e-2)"	"prognostic favorable (6.32e-7)"	"unprognostic (3.04e-1)"	"unprognostic (1.80e-3)"	"unprognostic (1.21e-1)"	"unprognostic (4.45e-2)"	"unprognostic (4.43e-1)"	"unprognostic (5.46e-3)"	"unprognostic (4.87e-2)"	"unprognostic (4.03e-1)"	"unprognostic (1.92e-2)"	"unprognostic (1.88e-1)"	"unprognostic (1.06e-1)"	"unprognostic (7.55e-2)"	"unprognostic (5.52e-3)"	5.3	5.0	0.4	30.2	0.7	15.8	5.3	0.5	0.5	7.7	58.7	0.9	2.5	11.8	3.5	1.5	35.6	1.7	4.3	3.8	0.5	0.5	24.0	46.1	5.4	8.6	1.8	0.0	2.5	1.0	0.0	3.7	16.8	1.0	8.8	35.6	1.7	20.7	5.4	0.9	1.7	54.9	3.0	1.5	5.5	3.6	1.3	0.7	1.2	2.3	18.5	46.5	7.8	12.7	1.9	0.1	20.6	1.8	0.0	1.5	0.3	0.1	2.2	0.1	0.1	0.0	0.0	5.6	0.0	0.1	0.4	0.2	0.9	11.7	0.7	4.7	0.0	1.2	0.3	0.0	3.1	0.1	0.0	0.2	0.1	0.1	33.3	0.7	0.0	4.8	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	1.5	0.0	0.4	0.1	0.0	0.1	32.1	0.6	0.6	0.0	0.5	0.2	21.9	0.1	0.0	0.0	0.0	24.6	3.2	0.1	0.0	0.8	0.1	0.2	0.1	0.1	0.7	0.0	1.3	0.0	0.1	0.1	0.4	0.0	20.6	0.0	0.9	0.2	1.9	0.5	0.2	0.1	0.3	0.4	0.1	12.7	0.0	1.8	0.0	1.5	0.3	0.4	0.7	0.5	0.5	0.5	0.5	1.8	0.0	1.0	0.7	6.0	10.9	15.9	234.8	1.1	5.7	1.6	7.6	4.0	7.9	0.0	3.9	0.8	0.0	16.9	2.1	7.1	131.5	0.0	13.8	7.8	1.7	256.0	9.2	32.6	1.1	4.8	16.6	51.5	6.5	0.0	0.0	3.0	6.8	1.0	22.4	1.4	43.2	84.3	0.7	10.5	6.6	0.0	1.8	4.3	2.8	0.9	0.6	4.9	9.8	472.9
CEACAM3	"CD66d, CGM1"	ENSG00000170956	"Carcinoembryonic antigen related cell adhesion molecule 3"	P40198	19	41796437-41811553	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 60.0;bone marrow: 35.4"	"Cell type enriched"	"Detected in some"	12	"Paneth cells: 35.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in some"	7	"neutrophil: 60.0"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 60.0"	"Cell line enhanced"	"Detected in some"		"CACO-2: 1.0;PC-3: 3.8"									HPA011041	Approved					NA	NA					"HPA011041: AB_1078481"	"unprognostic (1.60e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.23e-2)"	"unprognostic (2.95e-2)"	"unprognostic (2.19e-1)"	"unprognostic (8.09e-3)"	"unprognostic (1.44e-1)"	"unprognostic (2.85e-1)"	"unprognostic (1.49e-1)"	"unprognostic (3.19e-2)"	"unprognostic (1.62e-1)"	"unprognostic (8.07e-2)"	"unprognostic (1.32e-2)"	"unprognostic (1.32e-1)"	"unprognostic (4.68e-2)"	"unprognostic (8.44e-2)"	"unprognostic (2.83e-1)"	0.9	0.3	0.3	3.6	0.8	35.4	0.7	0.2	0.8	0.6	1.0	0.0	0.0	0.2	0.4	0.2	1.2	0.7	0.4	5.1	0.4	0.3	0.4	1.1	14.0	11.5	1.8	0.1	0.7	1.0	0.2	0.3	4.6	0.5	0.3	0.3	1.4	0.8	0.2	1.5	0.2	0.6	0.4	0.3	10.7	0.4	0.9	0.2	1.6	0.5	0.3	2.7	0.8	0.6	0.0	0.8	60.0	8.9	0.0	0.0	0.6	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.8	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	60.0	0.0	8.9	0.0	0.0	0.6	0.3	0.8	0.2	0.8	0.4	0.3	1.8	0.1	0.5	0.2	3.0	1.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.8	0.0	0.0	0.0	0.0	0.3	1.1	0.0	0.8	0.0	0.0	0.0	1.2	0.9	0.0	1.7	0.0	0.0	0.0	0.0	0.1	35.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CEACAM5	"CD66e, CEA"	ENSG00000105388	"Carcinoembryonic antigen related cell adhesion molecule 5"	P06731	19	41708585-41729798	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Cell adhesion"		"Cancer-related genes, Oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 103.5;intestine: 118.2;lymphoid tissue: 100.6"	"Cell type enhanced"	"Detected in some"	19	"Enterocytes: 233.4;Mucus-secreting cells: 290.9;Paneth cells: 482.9;Undifferentiated cells: 102.6"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 1007.1"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	4	"OE19: 35.9"									"CAB000021, CAB000022, HPA011041, HPA019758"	Enhanced		Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA		19000000	"Plasma membrane"		"CAB000021: , CAB000022: AB_2335697, HPA011041: AB_1078481, HPA019758: AB_1846326"	"unprognostic (1.54e-2)"	"unprognostic (7.59e-2)"	"unprognostic (5.49e-3)"	"unprognostic (1.80e-1)"		"unprognostic (1.38e-2)"		"unprognostic (2.22e-1)"	"unprognostic (3.49e-1)"	"unprognostic (2.11e-1)"	"unprognostic (2.19e-2)"	"unprognostic (2.89e-1)"	"unprognostic (8.67e-9)"	"unprognostic (2.92e-1)"	"unprognostic (2.71e-2)"	"unprognostic (6.31e-2)"	"unprognostic (1.85e-1)"	0.1	0.1	0.1	78.8	0.1	0.0	0.1	0.1	0.2	12.5	117.1	0.2	0.1	2.5	0.9	0.1	103.5	0.3	1.2	0.1	0.1	0.1	0.1	0.1	3.3	0.1	0.1	0.1	0.2	0.2	0.0	0.2	0.5	0.1	0.3	118.2	0.2	6.8	0.1	0.1	0.6	12.8	3.3	0.1	0.1	20.1	0.2	0.1	0.6	0.2	29.4	100.6	2.0	14.1	0.6	0.6	1.8	0.7	0.6	0.5	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	1.3	0.0	0.0	0.0	0.0	8.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.2	35.9	0.7	0.1	0.0	0.0	0.0	0.2	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.1	1.2	0.3	0.8	0.3	0.2	0.1	0.5	0.2	0.3	0.6	0.6	0.4	0.5	1.8	0.6	0.7	0.5	0.3	0.3	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	29.8	2.6	0.0	0.6	0.0	0.0	0.3	0.0	1.4	5.7	0.0	0.0	0.0	0.0	0.3	0.3	0.0	233.4	0.0	0.8	0.0	0.0	7.8	4.6	0.0	0.0	0.0	63.1	0.0	0.0	0.0	0.0	0.0	5.0	0.0	290.9	0.0	12.4	482.9	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	102.6	36.7
CEACAM6	"CD66c, NCA"	ENSG00000086548	"Carcinoembryonic antigen related cell adhesion molecule 6"	P40199	19	41750977-41772208	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Cell adhesion"		"Cancer-related genes, Oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 81.4;gallbladder: 75.7;lung: 129.1"	"Group enriched"	"Detected in many"	4	"Alveolar cells type 1: 875.4;Club cells: 255.9;Paneth cells: 283.7"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.6"	"Group enriched"	"Detected in many"	6	"granulocytes: 2.6;monocytes: 1.3"	"Cell line enriched"	"Detected in some"	11	"OE19: 196.2"									"CAB008370, HPA011041"	Enhanced					NA	NA		79000000			"CAB008370: AB_592067, HPA011041: AB_1078481"	"unprognostic (1.00e-2)"	"unprognostic (2.05e-1)"	"unprognostic (2.62e-2)"	"unprognostic (8.22e-2)"	"unprognostic (1.39e-1)"	"unprognostic (9.06e-3)"	"unprognostic (2.32e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.49e-1)"	"unprognostic (5.22e-2)"	"unprognostic (3.70e-3)"	"unprognostic (1.93e-1)"	"unprognostic (2.42e-4)"	"unprognostic (4.08e-1)"	"unprognostic (8.71e-3)"	"unprognostic (2.85e-1)"	"unprognostic (7.68e-2)"	0.3	0.3	0.3	7.4	0.3	29.7	0.3	0.3	0.3	16.8	35.3	0.2	0.1	5.8	0.9	0.2	81.4	1.1	75.7	2.3	0.3	0.3	0.3	0.8	129.1	0.1	0.3	0.1	0.3	1.7	0.0	0.3	32.1	0.2	0.9	43.1	0.2	50.1	0.1	0.3	2.1	12.8	0.9	0.3	0.8	2.6	0.3	0.1	1.0	0.3	25.3	58.1	2.3	21.0	0.1	0.3	2.6	1.3	0.1	0.3	5.2	0.0	17.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.5	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	196.2	0.5	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.3	1.3	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	2.6	0.1	0.5	0.3	0.0	5.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.1	0.2	0.1	875.4	62.6	0.0	2.8	0.0	0.0	0.0	81.5	95.0	255.9	0.0	0.0	0.0	0.0	44.8	0.0	0.0	46.4	0.0	13.9	0.0	0.0	19.2	6.9	0.0	0.0	0.0	5.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	67.1	0.0	93.7	283.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	11.8	105.5
CEACAM8	"CD66b, CGM6"	ENSG00000124469	"Carcinoembryonic antigen related cell adhesion molecule 8"	P31997	19	42580241-42595055	"CD markers, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"bone marrow: 71.0;placenta: 35.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"neutrophil: 4.2;non-classical monocyte: 3.0"	"Group enriched"	"Detected in many"	6	"granulocytes: 4.2;monocytes: 3.0"	"Low cell line specificity"	"Detected in some"											CAB033676	Approved				"Intracellular and membrane"	NA	NA		15000000			"CAB033676: AB_1125678"		"unprognostic (2.01e-1)"	"unprognostic (4.52e-2)"		"unprognostic (3.31e-1)"			"unprognostic (6.30e-2)"		"unprognostic (2.68e-1)"	"unprognostic (1.62e-1)"		"unprognostic (1.71e-2)"	"unprognostic (7.77e-2)"		"unprognostic (9.62e-2)"		0.2	0.0	0.1	0.0	0.1	71.0	0.1	0.1	0.4	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	6.6	0.1	0.1	0.1	0.4	4.0	0.1	0.1	0.0	0.0	0.1	0.0	0.1	35.6	0.1	0.0	0.1	0.0	0.1	0.0	0.7	0.2	0.0	0.0	0.1	10.1	0.0	0.1	0.1	1.9	0.1	0.0	0.0	0.0	0.7	0.5	0.1	4.2	3.0	0.6	0.4	4.1	0.9	0.3	1.2	2.1	0.0	0.5	0.3	1.4	0.0	0.0	0.1	0.2	0.4	1.2	0.3	0.5	0.6	0.5	0.0	0.3	0.0	0.2	0.3	0.5	0.7	0.7	0.1	0.8	0.7	0.0	0.1	0.1	0.1	0.3	0.0	0.8	0.7	1.6	0.0	0.3	0.4	0.9	0.6	0.3	0.1	0.5	0.5	1.3	0.4	0.5	0.8	0.8	0.1	0.3	1.2	0.5	1.3	0.9	0.8	1.4	0.3	1.5	0.5	1.5	1.4	0.8	0.8	1.3	0.7	0.6	0.5	0.5	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.5	0.3	0.4	4.2	0.6	3.0	0.1	0.1	4.1	0.1	0.1	0.1	0.4	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CLEC10A	"CD301, CLECSF13, CLECSF14, HML, HML2"	ENSG00000132514	"C-type lectin domain containing 10A"	Q8IUN9	17	7074537-7080307	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Endocytosis, Immunity, Innate immunity"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 81.1;lymphoid tissue: 49.3"	"Group enriched"	"Detected in some"	6	"Kupffer cells: 53.6;Macrophages: 176.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in some"	12	"myeloid DC: 81.1"	"Lineage enriched"	"Detected in many"	12	"dendritic cells: 81.1"	"Cell line enhanced"	"Detected in some"		"HUVEC TERT2: 1.6;NB-4: 4.0"									HPA021937	Approved					NA	NA					"HPA021937: AB_1846905"	"unprognostic (3.96e-3)"	"unprognostic (1.71e-3)"	"unprognostic (2.95e-2)"	"unprognostic (2.04e-3)"	"unprognostic (4.54e-2)"	"prognostic favorable (1.26e-5)"	"unprognostic (1.07e-1)"	"prognostic favorable (9.24e-4)"	"unprognostic (2.70e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.12e-1)"	"unprognostic (2.30e-1)"	"unprognostic (6.12e-2)"	"unprognostic (1.43e-1)"	"prognostic unfavorable (4.22e-4)"	"unprognostic (3.23e-1)"	"unprognostic (3.65e-1)"	12.7	4.0	0.4	14.3	0.5	0.6	6.6	0.4	0.6	4.9	9.7	0.8	1.7	7.9	6.4	31.3	6.9	6.1	12.2	17.5	0.4	0.4	4.4	6.2	22.0	49.3	0.6	0.6	4.1	3.3	0.4	2.0	1.3	2.0	7.2	9.7	3.8	5.0	5.9	6.1	5.1	14.3	9.6	0.9	10.2	4.4	3.7	0.5	5.4	4.7	9.9	10.4	9.8	4.6	0.0	81.1	0.3	6.6	0.3	0.0	3.3	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.3	0.3	0.0	0.0	0.0	4.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.3	0.3	0.6	0.0	0.0	0.1	0.0	0.1	0.0	5.5	0.0	0.0	6.6	0.0	0.0	0.0	0.0	81.1	0.0	0.0	0.0	0.3	0.3	0.0	1.6	0.0	3.3	0.4	0.5	0.4	0.6	0.4	0.4	0.6	0.6	2.0	0.5	3.0	3.8	2.2	0.0	11.7	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	1.5	0.0	1.1	0.9	17.9	0.0	0.0	0.6	53.6	0.7	0.3	176.8	20.3	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	6.5	3.9	0.0	2.1	10.3	0.1	0.0	0.0	0.0
CLEC4C	"BDCA2, CD303, CLECSF11, CLECSF7, DLEC, HECL"	ENSG00000198178	"C-type lectin domain family 4 member C"	Q8WTT0	12	7729415-7751605	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity, Innate immunity"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	8	"blood: 80.0"	"Cell type enriched"	"Detected in some"	5	"Spermatogonia: 5.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	16	"plasmacytoid DC: 80.0"	"Lineage enriched"	"Detected in many"	16	"dendritic cells: 80.0"	"Cell line enriched"	"Detected in some"	4	"HDLM-2: 6.6"									HPA029432	Approved					NA	NA					"HPA029432: AB_10601259"	"unprognostic (3.55e-3)"	"unprognostic (3.01e-2)"		"unprognostic (1.03e-1)"	"unprognostic (3.70e-2)"	"unprognostic (7.37e-5)"		"unprognostic (2.36e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.55e-2)"	"unprognostic (6.98e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.88e-3)"	"unprognostic (2.82e-2)"	"unprognostic (3.18e-3)"	"unprognostic (2.36e-2)"	"unprognostic (1.25e-1)"	0.3	0.2	0.2	1.6	0.2	1.8	2.0	0.2	0.6	0.2	0.2	0.1	0.1	0.0	0.2	0.1	0.3	0.5	1.2	0.3	0.2	0.2	0.5	0.3	1.5	7.0	0.2	0.1	0.4	0.2	0.0	0.2	0.1	0.1	0.2	0.0	0.4	0.3	2.0	0.2	0.3	0.3	0.1	0.2	4.6	0.3	9.9	0.1	6.7	0.3	0.1	7.1	1.9	0.3	0.5	80.0	4.9	0.1	0.5	0.0	0.5	0.2	0.0	0.3	0.3	0.5	0.0	0.4	0.0	0.0	0.1	0.0	0.5	0.6	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.2	6.6	0.2	0.3	0.7	0.2	0.0	0.6	1.3	0.4	0.3	0.0	0.0	0.1	0.1	0.0	0.2	1.0	0.0	0.1	0.1	0.8	1.5	0.0	0.2	0.1	0.0	0.1	0.1	0.4	0.2	0.2	0.1	0.2	0.0	0.4	0.9	0.1	0.4	0.4	0.2	0.1	0.1	0.6	0.2	1.4	0.1	0.3	0.3	0.9	0.1	4.9	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.5	0.0	0.0	2.6	0.5	0.0	80.0	0.0	0.5	0.2	0.2	0.2	0.6	0.2	0.2	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	5.3	0.3	0.0	0.0	0.0	0.0
CLEC4M	"CD209L, CD299, DC-SIGN2, DC-SIGNR, DCSIGNR, HP10347, LSIGN"	ENSG00000104938	"C-type lectin domain family 4 member M"	Q9H2X3	19	7763149-7769605	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Endocytosis, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"liver: 38.5;lymphoid tissue: 30.1"	"Cell type enriched"	"Detected in some"	17	"Ito cells: 378.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	7	"memory B-cell: 1.7"	"Lineage enriched"	"Detected in single"	18	"B-cells: 1.7"	"Group enriched"	"Detected in some"	7	"GAMG: 3.5;HUVEC TERT2: 2.3;K-562: 3.1;Karpas-707: 1.2;RPMI-8226: 1.6"									"CAB033689, CAB033691, HPA042661"	Supported				"Intracellular and membrane"	NA	NA		890000			"CAB033689: AB_831088, CAB033691: AB_2081354, HPA042661: AB_2678101"	"unprognostic (1.56e-1)"				"unprognostic (3.03e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.71e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.64e-1)"	"unprognostic (6.58e-2)"		"unprognostic (1.27e-1)"	"unprognostic (4.58e-3)"	"unprognostic (4.60e-2)"	"unprognostic (5.15e-2)"		"unprognostic (1.43e-1)"	0.9	0.9	0.1	0.5	0.1	0.0	0.1	0.2	0.1	0.1	0.3	0.1	0.1	0.0	0.3	0.1	1.2	0.6	0.1	0.1	0.1	0.0	0.1	38.5	2.5	30.1	0.1	0.1	2.7	0.1	0.0	0.1	4.8	0.2	0.1	0.0	0.1	0.8	0.1	0.1	0.0	0.5	0.1	0.1	0.2	0.0	1.4	0.1	0.1	0.2	0.1	0.2	0.1	0.1	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.3	0.0	3.1	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.3	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.8	0.5	0.0	0.0	378.7	22.4	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.2	0.0	0.0	0.1
CR1	"CD35, KN"	ENSG00000203710	"Complement C3b/C4b receptor 1 (Knops blood group)"	P17927	1	207496147-207641765	"Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins"	"Complement pathway, Host-virus interaction, Immunity, Innate immunity"	"Blood group antigen, Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 23.2;lymphoid tissue: 42.3"	"Group enriched"	"Detected in some"	4	"B-cells: 23.8;Erythroid cells: 46.7;Kupffer cells: 50.8;Macrophages: 12.9"	"Low cancer specificity"	"Detected in single"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	5	"basophil: 23.2;eosinophil: 9.4;neutrophil: 9.1"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 23.2"	"Group enriched"	"Detected in some"	9	"HL-60: 9.0;HMC-1: 21.1;NB-4: 8.4"									"CAB002491, CAB016271, HPA042455, HPA043579, HPA049348"	Enhanced					NA	NA		27000000			"CAB002491: AB_563553, CAB016271: AB_627040, HPA042455: AB_2678006, HPA043579: AB_2678564, HPA049348: AB_2680723"	"unprognostic (1.74e-1)"	"unprognostic (3.16e-2)"	"unprognostic (2.75e-2)"	"unprognostic (6.12e-2)"	"unprognostic (1.58e-2)"	"unprognostic (7.14e-2)"	"unprognostic (2.84e-1)"	"unprognostic (3.86e-2)"	"unprognostic (2.02e-1)"	"unprognostic (2.80e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.84e-1)"	"unprognostic (2.29e-3)"	"unprognostic (4.38e-2)"	"unprognostic (3.32e-2)"	"unprognostic (6.45e-2)"	"unprognostic (3.50e-3)"	9.0	1.1	0.6	17.0	0.6	5.8	1.5	0.4	0.5	0.6	1.7	0.2	0.0	0.5	0.7	5.6	1.4	2.2	1.1	8.0	0.6	0.5	2.3	3.8	4.0	42.3	0.6	0.0	1.7	1.2	0.0	0.6	5.5	1.0	1.7	0.7	0.5	1.9	0.0	0.8	0.5	5.1	3.6	0.7	42.0	1.1	0.9	0.1	1.3	0.7	0.0	11.1	3.2	1.3	2.8	0.2	23.2	2.3	0.0	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	9.0	21.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	8.4	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	23.2	2.3	9.4	0.0	1.4	0.4	2.8	0.6	0.3	0.2	1.4	0.1	0.1	9.1	0.0	1.2	0.0	0.0	0.6	0.6	0.6	0.4	0.5	0.6	0.5	0.6	0.0	1.0	0.1	0.0	6.2	23.8	0.0	0.0	0.0	0.8	0.0	1.4	2.3	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	46.7	0.0	0.1	0.2	0.0	1.1	0.0	8.0	0.0	0.0	0.0	50.8	0.0	0.0	12.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0
CR2	"C3DR, CD21"	ENSG00000117322	"Complement C3d receptor 2"	P20023	1	207454230-207489895	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Complement pathway, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"	"Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"lymphoid tissue: 97.2"	"Cell type enriched"	"Detected in some"	15	"B-cells: 25.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"memory B-cell: 13.3;naive B-cell: 16.2"	"Lineage enriched"	"Detected in many"	9	"B-cells: 16.2"	"Cell line enhanced"	"Detected in some"		"Daudi: 21.5;JURKAT: 3.7;MOLT-4: 11.8;RPMI-8226: 4.2"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"CAB002659, HPA052942, HPA060715"	Enhanced					NA	NA		150000000			"CAB002659: , HPA052942: AB_2681994, HPA060715: AB_2684349"	"prognostic favorable (6.90e-4)"	"unprognostic (1.22e-1)"	"unprognostic (9.95e-2)"	"unprognostic (3.64e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.27e-3)"	"unprognostic (1.18e-1)"	"unprognostic (6.62e-3)"	"unprognostic (1.91e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.20e-1)"	"unprognostic (7.95e-2)"	"unprognostic (2.14e-1)"	"unprognostic (1.12e-1)"	"unprognostic (2.19e-1)"	"unprognostic (2.09e-2)"	"unprognostic (3.35e-2)"	0.5	0.3	0.4	97.2	0.3	0.0	0.4	0.3	0.3	0.3	1.2	0.0	0.0	0.0	0.3	0.0	2.8	0.3	0.3	0.3	0.4	0.4	1.4	0.4	2.0	72.8	0.4	0.0	0.4	0.4	0.0	0.3	0.0	0.0	0.5	0.9	0.0	6.0	0.0	0.4	0.3	11.5	0.0	0.4	63.4	1.4	0.5	0.0	6.5	0.7	0.3	56.3	0.6	0.3	16.2	0.0	0.2	0.0	0.0	1.8	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	21.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.3	0.0	0.0	0.1	11.8	0.0	1.9	0.0	0.2	0.0	0.2	4.2	0.0	0.0	1.1	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.5	13.3	0.7	0.5	0.0	16.2	1.8	1.6	0.2	0.0	0.0	0.0	0.0	1.1	0.4	0.3	0.3	0.3	0.4	0.4	0.4	0.0	0.0	0.0	0.0	0.0	25.5	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0
CRTAM	CD355	ENSG00000109943	"Cytotoxic and regulatory T cell molecule"	O95727	11	122838500-122872639	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Cell adhesion, Immunity"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"brain: 140.8"	"Cell type enhanced"	"Detected in some"	25	"Hofbauer cells: 6.2;Kupffer cells: 9.1;Macrophages: 7.2;T-cells: 34.1"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in some"	24	"cerebellum: 140.8"	"Cell type enhanced"	"Detected in many"		"NK-cell: 25.7"	"Group enriched"	"Detected in many"	5	"NK-cells: 25.7;T-cells: 16.7"	"Cell line enriched"	"Detected in single"	34	"SCLC-21H: 17.4"	"Region enriched"	"Detected in single"	44	"cerebellum: 115.2"	"Low region specificity"	"Detected in all"									NA	NA		3200000				"unprognostic (3.51e-3)"	"unprognostic (6.73e-4)"	"unprognostic (1.33e-2)"	"unprognostic (3.73e-3)"	"unprognostic (2.40e-2)"	"unprognostic (5.25e-4)"	"unprognostic (1.25e-1)"	"unprognostic (3.66e-2)"	"unprognostic (5.27e-2)"	"unprognostic (1.71e-1)"	"unprognostic (5.49e-3)"	"unprognostic (2.32e-1)"	"unprognostic (1.83e-4)"	"unprognostic (6.01e-2)"	"unprognostic (4.26e-2)"	"unprognostic (3.87e-2)"	"unprognostic (6.59e-2)"	0.4	0.3	0.3	2.7	0.4	1.9	0.4	140.8	0.4	0.3	0.4	0.2	0.1	0.4	0.8	0.4	0.3	0.3	1.8	0.3	0.3	0.3	0.3	1.0	2.2	10.6	0.4	0.1	0.3	0.3	0.0	0.3	0.2	5.8	0.3	0.5	0.3	0.7	0.1	0.3	0.3	1.3	0.2	1.2	4.4	0.7	0.3	0.1	3.3	0.3	0.2	4.3	1.1	0.3	0.1	1.7	0.6	4.4	25.7	16.7	2.8	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.5	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.4	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	2.2	0.2	6.7	2.7	6.5	0.0	0.7	13.5	1.7	0.1	2.2	16.7	0.6	25.7	4.4	0.1	0.0	2.8	0.3	0.4	140.8	0.4	0.3	0.3	0.4	0.1	5.8	0.1	0.0	1.4	0.0	0.4	1.3	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.1	0.1	0.3	1.1	0.0	6.2	0.0	0.0	0.6	9.1	0.6	0.0	7.2	3.3	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.4	0.6	0.1	34.1	0.0	0.3
CSF1R	"C-FMS, CD115, CSFR, FMS"	ENSG00000182578	"Colony stimulating factor 1 receptor"	P07333	5	150053291-150113372	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Immunity, Inflammatory response, Innate immunity"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 82.5;lymphoid tissue: 82.6"	"Group enriched"	"Detected in many"	8	"Extravillous trophoblasts: 97.9;Hofbauer cells: 277.3;Kupffer cells: 200.7;Macrophages: 125.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 60.7;non-classical monocyte: 82.5"	"Lineage enriched"	"Detected in many"	4	"monocytes: 82.5"	"Group enriched"	"Detected in some"	5	"BEWO: 51.8;SK-BR-3: 19.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008970, HPA012323"	Uncertain		Supported	"Vesicles,Plasma membrane"	"Intracellular and membrane"	NA	NA		1500000000	"Vesicles, Plasma membrane"		"CAB008970: , HPA012323: AB_1848977"	"unprognostic (3.82e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.86e-3)"	"unprognostic (9.83e-2)"	"unprognostic (1.20e-1)"	"unprognostic (7.33e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.45e-1)"	"unprognostic (9.37e-2)"	"unprognostic (1.11e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.65e-1)"	"prognostic unfavorable (1.08e-4)"	"unprognostic (3.67e-2)"	"prognostic unfavorable (4.92e-4)"	"unprognostic (1.72e-2)"	"unprognostic (4.61e-2)"	20.9	12.4	18.2	28.1	18.9	1.8	7.7	2.8	13.5	9.3	8.3	25.4	1.1	9.2	5.9	13.1	8.4	7.9	16.1	8.7	16.4	13.7	7.8	15.1	13.7	25.4	21.3	6.0	5.3	5.2	5.9	6.4	52.1	17.1	8.5	8.4	16.8	8.0	8.7	3.0	5.8	14.5	16.2	25.8	82.6	9.0	4.9	23.0	3.1	4.2	2.9	8.2	16.4	4.7	0.0	19.1	2.9	82.5	0.0	0.1	13.9	1.7	0.0	0.0	0.0	0.8	0.2	51.8	0.1	0.0	0.0	0.0	1.5	0.0	2.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	1.1	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.0	0.0	0.1	0.0	19.8	0.0	0.8	0.0	7.4	0.0	0.3	0.0	0.0	1.3	0.0	0.1	0.0	2.6	0.9	0.0	0.4	18.1	0.5	0.1	60.7	0.0	0.0	0.0	0.0	19.1	0.0	0.0	0.0	2.9	0.0	82.5	1.4	0.0	13.9	18.2	18.9	2.8	13.4	16.4	13.7	21.3	6.0	17.1	23.0	0.0	6.7	0.5	0.0	2.5	0.0	2.8	5.1	1.4	0.0	0.0	0.0	2.9	0.0	0.0	3.7	2.2	0.0	0.0	0.0	97.9	3.3	0.0	2.3	0.8	277.3	0.0	0.0	4.9	200.7	3.5	1.7	125.7	3.3	1.8	0.0	0.0	0.1	0.0	0.0	0.0	0.4	12.9	1.3	0.5	0.2	1.1	22.1	2.2	0.0	0.0
CSF2RA	"alphaGMR, CD116, CSF2R"	ENSG00000198223	"Colony stimulating factor 2 receptor alpha subunit"	P15509	X	1268800-1310381	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 60.2;placenta: 79.5"	"Cell type enhanced"	"Detected in many"	26	"Cytotrophoblasts: 215.8;monocytes: 954.0;Syncytiotrophoblasts: 261.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 30.0;eosinophil: 36.0;intermediate monocyte: 17.7;myeloid DC: 31.9;neutrophil: 60.2;plasmacytoid DC: 30.5"	"Group enriched"	"Detected in many"	28	"dendritic cells: 31.9;granulocytes: 60.2;monocytes: 30.0"	"Group enriched"	"Detected in some"	7	"BEWO: 60.4;HMC-1: 18.2;SK-MEL-30: 42.3"									CAB016148	Uncertain				"Secreted to blood"	NA	NA		9400000			"CAB016148: AB_626868"	"unprognostic (4.19e-2)"	"prognostic favorable (2.38e-5)"	"unprognostic (5.47e-2)"	"unprognostic (4.33e-2)"	"unprognostic (4.88e-2)"	"prognostic favorable (2.81e-4)"	"unprognostic (8.24e-2)"	"unprognostic (2.17e-1)"	"unprognostic (5.55e-2)"	"unprognostic (8.48e-2)"	"unprognostic (8.89e-2)"	"unprognostic (3.80e-1)"	"unprognostic (2.89e-2)"	"unprognostic (8.91e-3)"	"prognostic unfavorable (5.53e-4)"	"unprognostic (3.60e-1)"	"unprognostic (9.44e-2)"	8.7	2.3	11.8	11.1	11.1	8.9	17.7	3.4	9.6	3.1	2.2	0.6	0.6	2.2	4.4	0.6	2.1	2.2	5.7	3.7	15.0	4.7	2.4	1.7	11.2	8.3	18.8	6.5	3.5	1.0	0.2	2.1	79.5	13.2	1.5	3.3	0.6	3.1	1.0	0.6	1.8	3.3	2.9	25.5	12.6	1.7	0.6	16.3	0.6	2.5	0.6	10.4	4.2	1.5	0.3	31.9	60.2	30.0	1.4	0.2	10.1	0.1	3.5	0.2	0.0	0.0	0.0	60.4	0.0	0.1	0.1	0.0	1.2	0.3	0.0	3.9	0.0	3.3	0.0	0.0	0.0	0.0	1.1	0.0	0.0	2.4	0.0	0.0	1.3	18.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.1	5.6	0.5	0.5	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.1	1.0	0.0	42.3	5.0	2.8	5.0	0.0	0.0	1.7	0.3	0.0	0.1	0.1	0.1	0.0	5.5	0.0	2.4	30.0	36.0	0.0	17.7	0.2	0.3	0.0	0.0	31.9	0.1	0.0	0.0	60.2	1.4	8.4	30.5	0.1	10.1	11.8	11.1	3.4	9.6	15.0	4.7	18.8	6.5	13.2	16.3	0.0	8.2	11.1	1.0	6.9	0.6	1.1	5.1	4.0	5.7	1.8	0.0	215.8	0.0	0.2	0.5	1.4	0.0	0.0	1.5	101.6	5.3	0.5	9.3	0.0	66.0	0.0	0.0	1.3	66.8	0.0	0.9	146.7	8.5	954.0	0.0	0.5	0.3	0.0	0.4	0.0	1.1	6.5	2.1	0.2	0.4	4.5	261.3	0.0	0.0	2.1
CSF2RB	"betaGMR, CD131, IL3RB, IL5RB"	ENSG00000100368	"Colony stimulating factor 2 receptor beta common subunit"	P32927	22	36913628-36940449	"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 53.1;placenta: 73.6"	"Cell type enhanced"	"Detected in many"	12	"Extravillous trophoblasts: 32.6;granulocytes: 87.9;Macrophages: 41.6;monocytes: 29.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"basophil: 53.1;neutrophil: 20.1"	"Lineage enriched"	"Detected in many"	14	"granulocytes: 53.1"	"Group enriched"	"Detected in some"	6	"HEL: 27.0;HMC-1: 84.6"					"Low region specificity"	"Detected in all"			HPA078677			Approved	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"HPA078677: AB_2732389"	"unprognostic (1.67e-2)"	"unprognostic (9.44e-3)"	"unprognostic (1.03e-2)"	"unprognostic (6.66e-3)"	"unprognostic (1.51e-1)"	"prognostic favorable (7.47e-5)"	"unprognostic (1.86e-1)"	"unprognostic (1.94e-2)"	"unprognostic (4.38e-1)"	"unprognostic (9.57e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.21e-1)"	"unprognostic (1.82e-3)"	"unprognostic (5.76e-2)"	"unprognostic (3.65e-2)"	"unprognostic (1.95e-1)"	"unprognostic (8.52e-2)"	8.5	1.8	1.5	28.9	1.5	21.7	6.0	0.6	1.0	3.0	5.9	2.0	0.4	4.5	2.2	2.8	4.0	3.6	5.5	4.2	1.4	1.4	2.4	3.5	12.6	34.1	2.9	0.2	2.5	1.9	0.3	1.2	73.6	2.4	3.5	3.8	2.8	9.7	1.0	2.6	3.8	10.2	3.0	2.9	25.2	3.9	2.1	1.9	8.2	3.4	4.8	30.5	8.2	4.3	0.4	3.8	53.1	2.1	0.0	0.6	1.8	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	6.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	27.0	0.0	0.0	0.0	0.4	84.6	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	3.2	0.0	0.0	0.0	2.8	0.0	0.0	0.0	2.7	0.0	10.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	2.4	0.1	0.2	0.0	0.0	0.0	0.4	0.2	1.7	0.0	3.9	0.0	53.1	1.9	5.8	0.0	2.1	0.0	0.4	0.0	0.0	1.2	0.3	0.0	0.0	20.1	0.0	1.7	3.8	0.6	1.8	1.5	1.5	0.6	1.0	1.4	1.4	2.9	0.2	2.4	1.9	0.0	14.5	8.2	0.0	6.4	0.0	0.8	5.1	5.3	3.4	0.0	0.0	2.2	0.0	0.0	11.1	9.0	0.0	0.0	0.2	32.6	4.1	0.0	87.9	0.0	16.8	0.0	0.0	4.3	26.0	26.5	0.0	41.6	11.8	29.7	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.5	0.0	0.0	5.5	13.8	1.3	0.0	0.0
CSF3R	"CD114, GCSFR"	ENSG00000119535	"Colony stimulating factor 3 receptor"	Q99062	1	36466043-36483278	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 167.3;bone marrow: 88.9;lymphoid tissue: 71.4;placenta: 152.7"	"Cell type enhanced"	"Detected in many"	27	"Alveolar cells type 2: 228.0;Cytotrophoblasts: 271.6;Syncytiotrophoblasts: 999.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	8	"neutrophil: 167.3"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 167.3"	"Group enriched"	"Detected in some"	18	"BEWO: 34.9;NB-4: 9.4;THP-1: 22.9;U-937: 22.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB017116, HPA048086"	Enhanced				"Intracellular and membrane"	NA	NA					"CAB017116: , HPA048086: AB_2680257"	"unprognostic (5.57e-3)"	"unprognostic (8.05e-2)"	"unprognostic (7.23e-2)"	"unprognostic (3.87e-2)"	"unprognostic (2.88e-1)"	"unprognostic (2.92e-2)"	"unprognostic (2.86e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.83e-1)"	"unprognostic (5.65e-2)"	"unprognostic (2.47e-1)"	"unprognostic (3.44e-1)"	"prognostic unfavorable (5.72e-4)"	"unprognostic (6.33e-2)"	"prognostic unfavorable (3.79e-4)"	"unprognostic (2.03e-1)"	"unprognostic (2.31e-2)"	8.5	1.5	2.9	39.5	3.2	88.9	2.4	0.7	2.9	1.1	1.1	4.2	0.4	0.6	0.7	1.1	1.2	6.9	4.3	5.6	2.6	2.0	1.7	4.5	26.9	27.5	7.2	1.1	1.1	1.3	0.3	1.1	152.7	3.8	1.3	0.5	2.1	1.6	0.5	0.6	0.3	1.6	3.1	7.1	71.4	2.2	1.4	3.3	1.1	1.0	0.4	0.9	4.6	3.9	0.0	8.2	167.3	22.1	0.2	0.0	10.3	0.0	0.0	0.0	0.0	0.0	0.0	34.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.9	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	9.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.7	0.0	22.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	22.1	0.0	0.0	22.1	0.6	0.0	4.8	0.0	0.0	0.0	0.0	8.2	0.0	0.0	0.0	167.3	0.2	1.8	0.2	0.0	10.3	2.9	3.2	0.7	2.9	2.6	2.0	7.2	1.1	3.8	3.3	23.8	228.0	2.4	0.6	0.9	0.0	1.4	0.0	12.0	18.2	0.0	0.0	271.6	0.0	0.0	0.4	1.9	0.0	0.0	0.0	49.1	3.0	0.2	17.4	0.8	60.8	0.0	0.0	3.7	146.3	0.4	0.3	62.6	0.0	3.6	0.0	0.2	0.1	0.0	0.0	0.4	0.2	0.0	0.3	0.0	0.2	0.1	999.2	0.5	0.0	2.2
CTLA4	"CD, CD152, CELIAC3, GSE, IDDM12"	ENSG00000163599	"Cytotoxic T-lymphocyte associated protein 4"	P16410	2	203867786-203873960	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Diabetes mellitus, Disease mutation, FDA approved drug targets, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 24.8;lymphoid tissue: 31.2"	"Cell type enhanced"	"Detected in some"	22	"Alveolar cells type 2: 5.6;granulocytes: 1.1;T-cells: 1.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in some"	6	"T-reg: 24.8"	"Lineage enriched"	"Detected in single"	248	"T-cells: 24.8"	"Cell line enhanced"	"Detected in some"		"SK-MEL-30: 3.9;U-266/70: 5.9;U-266/84: 16.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Intracellular and membrane"	NA	NA						"unprognostic (1.92e-2)"	"unprognostic (9.13e-3)"	"unprognostic (1.47e-3)"	"unprognostic (9.89e-6)"	"unprognostic (1.86e-1)"	"prognostic favorable (4.48e-5)"	"unprognostic (1.02e-1)"	"unprognostic (1.75e-2)"	"unprognostic (1.84e-3)"	"unprognostic (2.65e-3)"	"unprognostic (2.77e-1)"	"unprognostic (3.76e-1)"	"unprognostic (9.86e-10)"	"unprognostic (4.13e-2)"	"unprognostic (7.45e-2)"	"unprognostic (4.94e-2)"	"unprognostic (1.19e-2)"	1.6	0.2	0.2	24.1	0.3	2.9	1.3	0.2	0.6	0.8	1.6	0.1	0.6	0.2	1.1	0.1	2.0	1.2	3.6	0.5	0.3	0.5	1.6	0.6	5.8	27.9	0.3	0.3	0.7	0.3	0.1	0.6	0.1	1.7	1.1	1.7	0.8	1.4	0.6	0.2	1.0	10.3	0.3	1.5	6.7	1.2	1.7	0.1	14.2	1.9	3.3	31.2	4.6	1.3	0.0	0.0	0.0	0.0	0.0	24.8	0.4	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.3	0.0	0.5	0.1	0.3	0.0	5.9	16.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	4.0	0.4	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	24.8	0.4	0.2	0.3	0.2	0.6	0.3	0.5	0.3	0.3	1.7	0.1	0.0	5.6	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.1	1.1	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.6	0.1	1.9	0.0	0.0
CXCR1	"CD181, CDw128a, CKR-1, CMKAR1, IL8RA"	ENSG00000163464	"C-X-C motif chemokine receptor 1"	P25024	2	218162845-218166995	"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins"	Chemotaxis	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 144.6"	"Group enriched"	"Detected in some"	5	"Alveolar cells type 2: 9.0;granulocytes: 2.3"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in some"	16	"neutrophil: 144.6"	"Lineage enriched"	"Detected in many"	59	"granulocytes: 144.6"	"Cell line enriched"	"Detected in single"	26	"HMC-1: 11.6"	"Not detected"	"Not detected"							HPA031991	Uncertain					NA	NA					"HPA031991: AB_2674103"	"unprognostic (2.80e-1)"	"unprognostic (2.91e-2)"	"unprognostic (3.53e-2)"	"unprognostic (5.74e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.68e-1)"	"unprognostic (2.14e-2)"	"unprognostic (3.36e-2)"	"unprognostic (2.32e-1)"	"unprognostic (1.57e-1)"	"unprognostic (8.27e-2)"	"unprognostic (2.15e-2)"	"unprognostic (2.88e-1)"	"unprognostic (5.47e-2)"	"unprognostic (2.97e-1)"	"unprognostic (1.30e-1)"	"unprognostic (8.85e-2)"	11.5	0.4	0.8	21.1	0.7	7.3	0.6	0.9	2.6	0.6	0.6	0.2	0.0	0.0	0.5	0.1	1.3	2.8	3.6	3.8	0.9	0.6	0.7	2.9	20.3	33.4	5.9	0.0	1.7	1.2	0.0	0.8	2.1	2.3	0.9	0.1	1.4	0.6	0.0	1.0	0.5	0.6	1.4	3.4	33.7	1.0	1.4	0.7	0.1	0.9	0.6	0.4	4.5	4.1	0.0	0.0	144.6	0.2	0.1	2.4	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.6	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.7	0.2	0.2	2.4	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.9	144.6	0.1	0.2	0.0	0.0	0.7	0.8	0.7	0.9	2.6	0.9	0.6	5.9	0.0	2.3	0.7	0.0	9.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.0	0.0	0.0
CXCR2	"CD182, CMKAR2, IL8RB"	ENSG00000180871	"C-X-C motif chemokine receptor 2"	P25025	2	218125289-218137253	"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	Chemotaxis	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"blood: 216.1"	"Cell type enhanced"	"Detected in some"	21	"Alveolar cells type 2: 17.5;Club cells: 3.4;granulocytes: 5.8;Kupffer cells: 5.0;Macrophages: 4.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	59	"neutrophil: 216.1"	"Lineage enriched"	"Detected in many"	109	"granulocytes: 216.1"	"Group enriched"	"Detected in some"	11	"BEWO: 12.4;HL-60: 6.9;HMC-1: 14.4;THP-1: 13.1;U-937: 12.9"	"Low region specificity"	"Detected in single"							"CAB016268, HPA031999, HPA032017"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Microtubules,Mitotic spindle"		NA	NA			"Plasma membrane"	"Nucleoplasm, Microtubules, Mitotic spindle"	"CAB016268: AB_626893, HPA031999: AB_2674105, HPA032017: AB_2674112"	"unprognostic (4.89e-2)"	"unprognostic (2.01e-1)"	"unprognostic (5.63e-2)"	"unprognostic (1.10e-2)"	"unprognostic (1.58e-1)"	"unprognostic (3.13e-1)"	"unprognostic (1.33e-1)"	"unprognostic (2.13e-1)"	"unprognostic (5.96e-2)"	"unprognostic (1.22e-2)"	"unprognostic (5.67e-2)"	"unprognostic (1.41e-1)"	"unprognostic (7.54e-2)"	"unprognostic (1.04e-1)"	"unprognostic (7.23e-2)"	"unprognostic (8.18e-2)"	"unprognostic (5.48e-2)"	9.3	0.9	1.3	25.6	1.5	4.0	0.6	1.2	1.3	5.2	0.6	0.5	2.5	0.0	0.8	1.1	18.1	3.3	5.2	4.3	1.5	0.6	0.7	4.6	16.7	40.5	6.6	0.0	1.2	1.7	0.0	0.7	4.5	1.7	1.9	0.3	1.8	3.3	2.6	0.6	3.0	0.7	1.4	4.1	30.6	1.0	1.1	0.7	0.6	0.6	4.8	10.1	5.4	6.4	0.0	1.6	216.1	1.9	0.4	1.9	1.0	0.0	0.0	0.1	0.0	0.0	0.0	12.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	6.9	14.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.3	1.1	0.2	0.0	0.0	0.3	0.0	1.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.5	0.0	13.1	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	12.9	0.0	3.6	1.9	3.2	1.9	0.5	0.0	0.0	0.0	0.4	0.8	0.0	0.0	0.7	216.1	0.4	0.2	1.6	0.0	1.0	1.3	1.5	1.2	1.3	1.5	0.6	6.6	0.0	1.7	0.7	0.0	17.5	0.0	0.9	0.0	0.0	0.2	0.0	0.0	3.4	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.2	0.2	5.8	0.0	1.6	0.0	0.0	0.0	5.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	1.0	0.0	1.8
CXCR3	"CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR"	ENSG00000186810	"C-X-C motif chemokine receptor 3"	P49682	X	71615916-71618517	"CD markers, G-protein coupled receptors, Predicted membrane proteins"	"Angiogenesis, Apoptosis, Chemotaxis"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 61.7;lymphoid tissue: 24.5"	"Cell type enriched"	"Detected in some"	4	"T-cells: 31.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 61.7"	"Group enriched"	"Detected in many"	4	"dendritic cells: 61.7;NK-cells: 38.1;T-cells: 26.6"	"Cell line enriched"	"Detected in some"	15	"RPMI-8226: 32.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA045942	Enhanced					NA	NA					"HPA045942: AB_2679507"	"unprognostic (4.84e-3)"	"unprognostic (3.05e-3)"	"unprognostic (1.61e-1)"	"prognostic favorable (3.44e-6)"	"unprognostic (3.93e-2)"	"prognostic favorable (3.35e-4)"	"unprognostic (1.01e-2)"	"unprognostic (5.24e-2)"	"prognostic favorable (2.90e-4)"	"unprognostic (6.32e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.39e-1)"	"prognostic unfavorable (1.67e-6)"	"unprognostic (4.67e-2)"	"unprognostic (2.18e-1)"	"unprognostic (2.91e-2)"	"unprognostic (5.76e-2)"	0.9	0.9	0.4	9.0	0.4	6.0	0.6	0.3	0.3	1.9	2.4	0.4	0.5	5.4	3.3	1.4	1.3	1.1	2.6	2.4	0.3	0.4	1.9	0.8	4.5	19.0	0.4	0.1	1.6	0.8	0.0	0.6	0.7	0.5	2.9	0.8	1.5	3.9	1.0	0.4	0.5	9.1	0.3	0.7	13.9	2.6	0.6	0.0	14.0	1.9	1.7	24.5	1.7	1.8	9.8	61.7	0.4	0.0	38.1	26.6	6.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.0	32.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.1	0.0	0.0	0.0	0.0	17.3	0.0	8.9	9.8	19.6	26.6	1.6	1.8	1.2	11.1	0.4	38.1	0.0	61.7	17.8	6.3	0.4	0.4	0.3	0.3	0.3	0.4	0.4	0.1	0.5	0.0	0.0	0.0	7.5	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.2	0.0	0.0	0.0	1.1	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.0	1.0	1.7	1.8	1.1	0.0	0.1	5.8	0.0	0.3	0.0	0.0	0.2	0.0	0.1	0.5	0.1	31.9	1.7	0.0
CXCR4	"CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R"	ENSG00000121966	"C-X-C motif chemokine receptor 4"	P61073	2	136114349-136118165	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	"Host-virus interaction"	"G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 149.9;lymphoid tissue: 186.3"	"Cell type enhanced"	"Detected in many"	14	"B-cells: 772.9;Macrophages: 299.5;monocytes: 255.1;T-cells: 588.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 76.4;JURKAT: 43.5;Karpas-707: 41.0;MOLT-4: 69.2;REH: 36.7;U-266/70: 88.9;U-698: 89.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.19e-1)"	"unprognostic (1.46e-2)"	"unprognostic (2.69e-1)"	"unprognostic (5.97e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.12e-2)"	"unprognostic (4.99e-2)"	"unprognostic (9.25e-2)"	"unprognostic (6.06e-2)"	"prognostic favorable (2.05e-4)"	"unprognostic (1.23e-1)"	"unprognostic (2.66e-1)"	"prognostic unfavorable (1.41e-7)"	"prognostic unfavorable (5.67e-4)"	"unprognostic (1.57e-1)"	"unprognostic (3.47e-2)"	"unprognostic (9.33e-2)"	15.4	26.5	3.0	39.1	3.4	149.9	9.7	0.8	2.1	7.7	8.7	6.8	1.5	1.6	8.3	3.8	16.4	9.1	12.0	5.4	4.1	4.7	8.2	7.1	29.3	94.5	6.5	1.3	6.3	3.1	0.7	8.1	7.8	6.1	6.8	7.0	10.0	10.6	2.2	3.2	2.3	57.8	3.8	22.9	82.4	8.0	7.2	3.4	186.3	9.2	4.6	97.5	50.0	6.6	47.3	16.8	37.8	7.2	4.0	32.0	11.9	0.1	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	76.4	0.2	0.0	0.0	0.0	0.2	0.0	0.0	3.8	0.9	4.6	12.1	0.0	0.0	10.5	8.3	0.0	0.0	0.0	0.0	0.0	7.3	43.5	0.1	41.0	0.0	0.2	69.2	9.4	1.2	5.9	0.4	36.7	8.5	13.3	0.6	0.0	4.2	3.5	0.0	0.2	0.0	0.4	0.0	20.7	1.0	0.0	0.2	0.0	0.0	88.9	15.0	89.4	0.0	17.4	0.0	17.9	7.2	29.6	22.9	3.8	18.7	30.1	21.1	21.7	6.6	47.3	32.0	30.1	37.8	4.0	2.1	16.8	18.9	11.9	3.0	3.4	0.8	2.1	4.1	4.7	6.5	1.3	6.1	3.4	14.9	64.2	772.9	4.0	36.5	4.4	3.6	2.5	4.0	6.8	3.5	0.0	1.4	11.6	3.6	0.9	19.0	0.0	46.7	0.8	2.2	30.2	4.8	11.6	5.5	168.4	0.0	1.7	22.7	175.5	1.7	1.4	299.5	108.0	255.1	0.1	1.0	1.6	0.0	2.5	2.1	0.6	45.3	16.3	0.5	5.5	31.1	5.3	588.4	0.4	3.2
CXCR5	"BLR1, CD185, MDR15"	ENSG00000160683	"C-X-C motif chemokine receptor 5"	P32302	11	118883766-118897799	"CD markers, G-protein coupled receptors, Predicted membrane proteins"	"B-cell activation"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 35.5;lymphoid tissue: 45.6"	"Cell type enriched"	"Detected in some"	26	"B-cells: 71.5"	"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	4	"cerebellum: 4.0"	"Group enriched"	"Detected in some"	8	"memory B-cell: 24.2;naive B-cell: 35.5"	"Lineage enriched"	"Detected in many"	9	"B-cells: 35.5"	"Group enriched"	"Detected in some"	10	"Daudi: 10.6;U-698: 37.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB026149, HPA042432"	Enhanced					NA	NA					"CAB026149: , HPA042432: AB_2677995"	"unprognostic (8.51e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.19e-1)"		"unprognostic (4.02e-5)"		"unprognostic (2.08e-2)"	"unprognostic (3.23e-3)"	"unprognostic (1.19e-2)"	"unprognostic (3.66e-1)"	"unprognostic (2.41e-3)"	"unprognostic (1.52e-5)"	"unprognostic (4.21e-1)"	"unprognostic (2.03e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.90e-1)"	0.4	0.8	0.6	31.8	0.6	7.3	0.1	4.0	0.9	0.1	3.6	0.2	0.1	0.1	0.2	0.1	2.6	0.0	0.5	0.9	0.7	0.5	0.8	1.0	0.9	31.5	0.3	0.1	0.3	0.5	0.0	0.9	0.1	0.2	2.9	0.3	0.3	3.6	0.1	1.3	0.9	8.6	0.1	0.3	45.6	1.3	0.1	0.1	1.9	0.7	1.3	41.8	3.9	0.9	35.5	0.0	0.0	0.0	0.0	3.9	1.9	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	10.6	0.2	0.0	0.1	0.6	0.0	0.0	0.0	0.1	0.1	2.3	0.0	0.0	0.0	0.2	0.8	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.1	0.0	0.5	0.4	0.9	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.3	0.4	0.0	0.0	0.4	0.1	0.1	0.5	0.0	0.2	0.5	0.0	0.0	0.2	0.0	37.1	0.0	0.4	0.0	0.0	0.0	0.0	0.3	0.0	0.3	24.2	3.9	1.0	0.0	35.5	0.4	0.3	0.0	0.0	0.0	0.0	0.5	1.9	0.6	0.6	4.0	0.9	0.7	0.5	0.3	0.1	0.2	0.1	0.0	2.6	71.5	0.0	0.1	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.2	0.5	0.0	0.0
CXCR6	"BONZO, CD186, STRL33, TYMSTR"	ENSG00000172215	"C-X-C motif chemokine receptor 6"	O00574	3	45940933-45948353	"CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"blood: 81.3"	"Group enriched"	"Detected in some"	7	"Extravillous trophoblasts: 66.4;T-cells: 54.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in many"	4	"MAIT T-cell: 81.3"	"Lineage enriched"	"Detected in many"	6	"T-cells: 81.3"	"Cell line enhanced"	"Detected in some"		"BEWO: 4.1;CAPAN-2: 15.7;JURKAT: 3.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (2.05e-3)"	"prognostic favorable (4.92e-4)"	"unprognostic (1.77e-3)"	"prognostic favorable (6.74e-6)"	"unprognostic (6.67e-2)"	"prognostic favorable (2.16e-4)"	"unprognostic (2.09e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.93e-2)"	"unprognostic (3.65e-4)"	"unprognostic (8.57e-2)"	"unprognostic (1.07e-1)"	"prognostic unfavorable (2.42e-5)"	"unprognostic (2.25e-2)"	"unprognostic (4.42e-2)"	"unprognostic (3.46e-2)"	"unprognostic (1.57e-2)"	2.5	1.1	0.5	7.6	0.5	0.5	2.1	0.4	0.5	2.3	9.9	1.1	1.5	3.0	2.7	3.2	3.0	2.4	5.2	1.7	0.6	0.6	2.5	2.5	9.2	10.4	0.6	0.2	3.7	1.6	0.0	0.9	18.9	1.0	2.6	2.6	3.0	3.3	0.2	7.7	1.1	10.8	1.0	1.3	22.3	6.0	2.3	0.2	5.2	4.1	5.3	14.6	5.2	2.6	0.0	0.1	0.1	0.0	13.4	81.3	3.8	0.3	0.1	0.0	0.3	0.0	0.0	4.1	0.2	0.0	0.0	0.0	1.1	15.7	0.3	0.1	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.7	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	3.2	0.2	0.5	0.0	0.2	0.8	0.2	0.3	0.0	0.6	0.1	0.0	0.0	0.0	1.7	0.0	0.1	0.3	0.9	0.0	2.1	0.2	0.8	0.4	1.5	0.7	0.0	0.1	0.1	0.0	0.2	0.2	0.1	0.1	0.0	0.0	0.0	17.3	0.0	81.3	0.0	4.9	20.3	0.0	0.0	0.2	3.1	0.1	13.4	0.0	0.1	14.5	3.8	0.5	0.5	0.4	0.5	0.6	0.6	0.6	0.2	1.0	0.2	0.0	0.0	0.0	0.0	0.9	0.7	0.7	0.0	0.0	0.0	0.0	2.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.4	0.5	0.1	1.1	0.8	0.7	0.0	0.0	1.3	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	3.4	0.0	0.6	0.0	0.0	1.0	8.6	54.5	0.0	0.0
DDR1	"CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6"	ENSG00000204580	"Discoidin domain receptor tyrosine kinase 1"	Q08345	6	30876421-30900156	"CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Lactation, Pregnancy"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Muller glia cells: 145.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HaCaT: 31.8;HBEC3-KT: 24.5;RT4: 32.5;T-47d: 36.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010162, CAB025656, HPA057194"	Approved		Approved	"Nucleoplasm,Cell Junctions"	"Intracellular and membrane"	NA	NA		2100000	"Nucleoplasm, Cell Junctions"		"CAB010162: AB_2092090, CAB025656: , HPA057194: "	"unprognostic (2.11e-2)"	"unprognostic (9.31e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.09e-1)"	"unprognostic (2.07e-1)"	"unprognostic (7.75e-3)"	"unprognostic (6.43e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.50e-1)"	"unprognostic (4.41e-2)"	"prognostic favorable (3.31e-10)"	"unprognostic (1.42e-1)"	"unprognostic (2.53e-1)"	"unprognostic (5.49e-3)"	"unprognostic (4.09e-2)"	6.7	11.3	23.5	7.9	36.2	2.2	12.5	6.8	42.2	9.7	25.2	57.4	17.6	16.8	7.7	10.5	30.5	31.7	18.9	8.7	27.8	20.8	19.8	3.5	13.2	3.1	55.7	19.8	11.3	20.9	28.2	14.6	13.3	34.7	17.7	14.9	4.0	28.3	20.5	9.1	41.3	32.1	3.1	43.2	5.1	52.2	5.1	37.0	8.7	20.9	10.5	7.6	16.3	16.6	1.8	0.4	0.0	0.2	0.0	1.8	0.9	19.7	6.5	9.2	1.9	0.6	0.9	5.7	0.5	0.1	0.3	0.0	8.7	10.5	0.1	11.0	1.7	9.6	31.8	2.0	24.5	0.1	10.9	3.5	0.0	6.0	2.3	1.8	0.0	0.4	1.2	12.7	0.1	0.2	5.8	0.7	0.5	5.7	0.2	1.4	12.5	0.7	0.0	1.6	10.9	1.3	1.3	6.9	0.7	4.7	32.5	1.6	0.9	1.8	14.7	7.1	3.2	36.5	0.2	1.5	4.6	4.3	0.4	4.6	0.2	0.0	0.8	3.0	0.0	4.0	0.0	0.2	0.0	1.1	0.0	0.8	0.4	0.2	0.7	0.4	1.8	1.2	1.8	0.0	0.0	0.0	0.4	0.0	0.9	23.5	36.2	6.8	25.0	27.8	20.8	55.7	19.8	34.7	37.0	32.8	24.0	2.2	62.3	47.2	5.2	19.9	38.2	33.5	31.8	85.5	0.0	53.4	5.0	115.9	10.8	4.9	88.3	23.3	66.9	19.7	6.5	54.7	1.1	0.4	5.4	6.4	44.4	1.8	0.8	16.6	7.8	2.2	15.1	22.6	55.1	145.4	62.4	74.8	4.9	5.6	7.4	6.5	8.9	0.7	4.5	45.4	38.9	0.0	54.4	76.8
DDR2	"NTRKR3, TKT, TYRO10"	ENSG00000162733	"Discoidin domain receptor tyrosine kinase 2"	Q16832	1	162631373-162787400	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Osteogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Fibroblasts: 84.7;Leydig cells: 58.4;Peritubular cells: 83.1;Smooth muscle cells: 68.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 1.1;MAIT T-cell: 1.3"	"Lineage enriched"	"Detected in single"	5	"T-cells: 1.3"	"Cell line enhanced"	"Detected in many"		"ASC diff: 61.7;ASC TERT1: 61.0;BJ hTERT+: 45.1;fHDF/TERT166: 32.3;HSkMC: 43.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA070112			Supported	"Plasma membrane,Actin filaments"		Yes	No		850000	"Plasma membrane, Actin filaments"		"HPA070112: AB_2686229"	"unprognostic (4.12e-2)"	"unprognostic (2.73e-1)"	"unprognostic (6.97e-3)"	"unprognostic (4.52e-2)"	"unprognostic (1.17e-1)"	"unprognostic (8.16e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.19e-1)"	"unprognostic (6.62e-2)"	"unprognostic (2.24e-2)"	"unprognostic (1.00e-1)"	"unprognostic (1.15e-1)"	"prognostic unfavorable (1.73e-7)"	"unprognostic (1.56e-3)"	"unprognostic (8.26e-3)"	"unprognostic (7.57e-2)"	"unprognostic (4.10e-3)"	42.1	43.5	4.7	10.9	6.9	0.2	15.6	7.9	7.1	30.3	30.4	9.0	18.6	3.3	24.2	17.7	25.0	13.4	16.6	15.4	7.9	4.7	4.0	3.3	8.9	5.1	12.9	3.4	26.4	2.2	2.1	4.0	6.6	12.7	21.8	9.1	30.7	6.4	19.3	5.2	6.1	10.1	34.3	19.7	3.4	14.1	8.3	7.5	0.0	8.6	12.8	4.1	29.0	18.3	0.1	0.2	0.0	0.0	0.2	1.3	0.0	0.1	0.0	0.0	16.3	61.7	61.0	0.2	24.0	45.1	10.5	15.1	0.0	0.0	0.0	0.0	32.3	2.1	0.0	0.0	0.1	14.4	12.9	0.1	0.0	0.1	0.0	26.8	0.0	0.0	43.3	0.1	18.5	0.5	17.0	12.1	0.1	0.1	5.1	9.6	0.0	0.0	0.0	0.1	0.0	0.1	0.0	6.9	0.1	0.0	0.0	0.0	9.9	0.0	0.0	0.8	0.9	0.0	0.0	0.6	16.8	3.7	8.5	3.3	0.7	1.3	0.0	15.2	0.0	17.0	0.0	0.0	0.0	1.1	0.0	1.3	0.0	0.8	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	4.7	6.9	7.9	7.1	7.9	4.7	12.9	3.4	12.7	7.5	3.0	2.9	0.0	2.4	11.2	3.1	23.3	2.5	4.0	1.2	0.0	0.0	0.5	0.0	0.5	6.9	21.3	2.0	0.0	1.5	0.4	84.7	4.1	1.1	3.0	1.1	0.0	1.2	24.5	2.1	4.0	58.4	1.5	21.9	0.0	0.7	19.0	1.5	1.7	83.1	0.9	2.9	38.8	68.4	0.9	0.9	7.5	0.8	1.3	0.6	3.3
DPP4	"ADCP2, CD26, DPPIV"	ENSG00000197635	"Dipeptidyl peptidase 4"	P27487	2	161992241-162074542	"CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion"	"Aminopeptidase, Hydrolase, Protease, Receptor, Serine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 133.1;parathyroid gland: 75.5"	"Cell type enhanced"	"Detected in many"	9	"Cytotrophoblasts: 134.1;Proximal tubular cells: 80.1;Syncytiotrophoblasts: 143.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 26.7"	"Lineage enriched"	"Detected in many"	10	"T-cells: 26.7"	"Cell line enhanced"	"Detected in many"		"ASC diff: 42.8;ASC TERT1: 43.4;BJ hTERT+: 39.8;RPTEC TERT1: 58.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"CAB045970, HPA068778, HPA071236"	Enhanced				"Secreted in other tissues"	NA	NA		170000000			"CAB045970: AB_11140529, HPA068778: , HPA071236: "	"unprognostic (4.47e-2)"	"unprognostic (4.47e-2)"	"unprognostic (8.89e-2)"	"unprognostic (3.36e-1)"	"unprognostic (7.25e-2)"	"unprognostic (5.40e-2)"	"unprognostic (2.78e-1)"	"unprognostic (3.54e-2)"	"unprognostic (3.58e-1)"	"unprognostic (4.73e-1)"	"unprognostic (2.36e-1)"	"prognostic unfavorable (1.98e-4)"	"prognostic favorable (1.35e-6)"	"unprognostic (4.68e-2)"	"unprognostic (6.33e-2)"	"prognostic favorable (4.99e-4)"	"unprognostic (1.21e-2)"	9.5	2.9	0.3	3.2	0.5	0.0	5.0	0.3	1.4	2.2	50.0	0.2	36.9	19.1	2.2	3.5	1.2	1.2	5.2	2.1	0.4	0.3	29.1	12.2	5.4	2.1	0.4	0.2	2.7	1.8	75.5	0.3	24.0	0.2	21.1	2.8	0.6	46.9	38.8	2.4	4.4	133.1	0.9	0.8	5.0	1.2	0.6	0.1	6.2	1.0	1.4	1.1	1.0	2.6	0.1	2.1	0.3	0.0	2.6	26.7	2.5	0.0	0.0	0.1	0.0	42.8	43.4	0.1	7.9	39.8	2.2	7.7	8.0	0.2	0.0	3.0	13.7	7.4	0.2	0.1	0.0	1.3	2.5	0.1	0.0	0.0	11.9	17.4	0.0	0.0	4.9	0.0	13.4	0.1	2.0	1.3	0.1	0.0	0.0	0.7	0.0	0.7	0.1	0.4	0.3	16.4	0.0	0.0	0.1	58.0	0.0	0.0	0.1	0.0	0.0	0.0	0.9	0.0	0.0	7.1	4.6	0.2	0.2	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	3.2	0.0	26.7	0.1	8.3	5.2	0.6	0.0	8.3	3.3	0.3	2.6	0.0	2.1	0.9	2.5	0.3	0.5	0.3	1.4	0.4	0.3	0.4	0.2	0.2	0.1	6.0	17.5	0.0	0.3	3.7	1.7	4.0	12.7	4.0	4.5	14.0	9.8	134.1	1.7	3.1	13.0	3.9	21.3	0.0	0.0	52.7	45.7	38.3	12.8	39.9	12.7	0.0	53.0	12.3	1.6	6.2	0.0	4.6	5.0	1.0	11.0	0.0	0.9	11.4	0.0	80.1	0.0	0.0	1.0	2.1	0.8	3.6	143.8	11.4	12.8	0.3
ENG	"CD105, END, HHT1, ORW, ORW1"	ENSG00000106991	Endoglin	P17813	9	127815012-127854756	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	"Angiogenesis, Cell adhesion"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	17	"Endothelial cells: 336.5;Ito cells: 724.3;Leydig cells: 451.1;Peritubular cells: 1336.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 12.2;intermediate monocyte: 17.7;myeloid DC: 6.4;NK-cell: 4.6;non-classical monocyte: 13.0"	"Group enriched"	"Detected in many"	4	"dendritic cells: 6.4;monocytes: 17.7;NK-cells: 4.6"	"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 36.6;HUVEC TERT2: 68.4;TIME: 139.4;U-138 MG: 34.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000096, HPA011862, HPA067440, CAB072873"	Enhanced		Supported	"Nuclear bodies,Plasma membrane"		NA	NA		260000000	"Plasma membrane"	"Nuclear bodies"	"CAB000096: AB_563482, CAB072873: AB_2665725, HPA011862: AB_1846217, HPA067440: AB_2685840"	"unprognostic (2.28e-1)"	"unprognostic (1.13e-1)"	"unprognostic (3.87e-2)"	"unprognostic (2.96e-2)"	"unprognostic (1.77e-1)"	"prognostic favorable (6.61e-4)"	"prognostic favorable (5.62e-6)"	"unprognostic (2.15e-1)"	"unprognostic (4.06e-1)"	"unprognostic (3.87e-2)"	"unprognostic (2.20e-2)"	"unprognostic (8.98e-2)"	"prognostic unfavorable (4.26e-4)"	"unprognostic (3.33e-3)"	"unprognostic (7.35e-2)"	"unprognostic (2.84e-1)"	"unprognostic (1.27e-1)"	40.3	19.3	6.4	26.6	10.5	5.5	52.7	3.9	8.6	26.3	14.0	7.6	18.5	11.2	27.0	25.2	17.2	23.2	28.3	105.4	8.0	5.0	40.8	26.8	66.7	44.1	10.6	7.0	66.4	9.6	8.6	12.5	60.2	10.1	23.1	6.4	35.5	9.9	51.7	24.1	10.1	14.5	23.1	8.7	52.4	11.6	37.2	7.7	6.7	35.4	19.3	11.0	20.3	44.8	1.1	6.4	0.3	17.7	4.6	2.3	4.6	0.1	0.1	1.0	0.0	17.2	11.8	30.3	19.9	14.3	10.6	6.2	0.0	0.1	0.1	9.7	36.6	8.0	0.3	0.0	3.2	3.5	0.0	0.0	5.6	11.3	0.6	13.3	2.6	0.0	20.1	0.7	13.8	5.0	0.1	68.4	0.1	0.0	0.1	12.4	0.1	0.0	0.2	0.2	0.0	0.5	8.8	1.7	0.1	0.0	0.0	0.1	0.2	10.5	9.2	2.7	0.7	1.8	4.0	139.4	34.9	1.9	22.7	0.0	0.7	0.1	0.1	9.4	7.0	11.4	0.0	12.2	0.3	1.3	17.7	0.4	0.4	2.1	2.3	6.4	1.1	1.3	2.0	0.3	4.6	13.0	2.4	0.8	4.6	6.4	10.5	3.9	8.6	8.0	5.0	10.6	7.0	10.1	7.7	3.0	23.1	25.1	2.3	10.6	2.5	16.5	22.9	8.1	3.4	3.5	3.9	24.4	0.0	8.3	7.0	336.5	0.0	23.3	1.0	249.8	36.6	1.4	15.0	5.1	119.5	0.0	2.4	724.3	66.8	29.3	451.1	50.7	23.6	46.9	1.1	3.1	2.0	0.0	1336.5	0.0	4.1	71.1	20.8	3.7	4.9	7.3	314.8	5.7	0.2	1.1
ENPEP	"CD249, gp160"	ENSG00000138792	"Glutamyl aminopeptidase"	Q07075	4	110365733-110565285	"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins"		"Aminopeptidase, Hydrolase, Metalloprotease, Protease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 165.1;kidney: 63.8"	"Cell type enhanced"	"Detected in many"	14	"Proximal tubular cells: 153.4;Sertoli cells: 155.2;Smooth muscle cells: 60.8;Syncytiotrophoblasts: 49.0"	"Cancer enriched"	"Detected in many"	8	"renal cancer: 41.0"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 4.2;HEK 293: 11.4;MOLT-4: 2.7;SuSa: 8.6"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			HPA005128	Enhanced					NA	NA		37000000			"HPA005128: AB_1844795"	"unprognostic (2.73e-3)"	"unprognostic (2.84e-3)"	"unprognostic (5.16e-3)"	"unprognostic (3.48e-1)"	"unprognostic (2.90e-1)"	"unprognostic (8.74e-2)"	"unprognostic (3.34e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.35e-2)"	"unprognostic (1.22e-1)"	"unprognostic (1.93e-1)"	"unprognostic (9.47e-2)"	"unprognostic (4.49e-3)"	"unprognostic (3.43e-3)"	"unprognostic (1.52e-2)"	"unprognostic (8.46e-2)"	"unprognostic (2.49e-3)"	5.8	1.0	0.4	0.4	0.6	0.0	2.8	0.3	1.0	1.1	54.4	0.4	0.7	11.1	5.3	2.4	0.8	1.4	1.1	2.3	0.5	0.3	63.8	14.5	2.7	0.5	0.4	0.3	1.0	1.0	33.3	0.8	4.4	0.5	1.4	0.0	0.8	0.6	0.5	2.3	0.4	165.1	3.1	0.5	4.7	0.7	0.4	0.4	1.4	2.4	2.0	0.4	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.3	0.1	0.0	0.1	0.2	4.2	0.6	0.0	0.2	0.3	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.2	0.0	0.1	0.0	11.4	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	1.5	2.7	0.5	0.5	0.1	0.0	0.2	0.0	0.4	0.0	0.4	0.1	0.2	0.0	2.0	0.0	8.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.1	2.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.6	0.3	1.0	0.5	0.3	0.4	0.3	0.5	0.4	0.0	1.3	0.0	0.1	1.4	0.0	3.3	0.0	0.0	0.0	10.4	0.0	33.0	14.9	0.0	0.4	1.4	2.6	0.0	0.0	2.7	19.7	0.1	0.0	24.1	2.4	0.0	1.7	1.8	0.3	0.0	0.6	0.6	0.0	0.0	0.8	0.0	0.0	0.8	0.4	153.4	0.0	155.2	60.8	0.0	0.2	0.9	49.0	1.3	1.1	0.1
ENPP1	"M6S1, NPPS, PC-1, PCA1, PDNP1"	ENSG00000197594	"Ectonucleotide pyrophosphatase/phosphodiesterase 1"	P22413	6	131808016-131895155	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins"	Biomineralization	Hydrolase	"Diabetes mellitus, Disease mutation, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	12	"Hepatocytes: 80.9;Peritubular cells: 65.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in some"		"NK-cell: 4.6"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 23.1;LHCN-M2: 13.8;U-138 MG: 18.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB032904, HPA062066"	Enhanced				"Secreted - unknown location"	NA	NA		2500000			"CAB032904: AB_2099635, HPA062066: AB_2684674"	"unprognostic (1.47e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.15e-1)"	"unprognostic (1.60e-3)"	"unprognostic (2.40e-1)"	"unprognostic (1.11e-1)"	"unprognostic (2.00e-1)"	"unprognostic (1.60e-2)"	"unprognostic (7.22e-3)"	"unprognostic (8.96e-2)"	"unprognostic (1.95e-1)"	"unprognostic (3.00e-1)"	"unprognostic (2.61e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.84e-1)"	"unprognostic (3.28e-3)"	17.2	2.1	0.5	1.9	0.5	0.0	30.5	0.6	0.4	8.5	2.8	1.6	8.3	1.1	25.7	7.1	1.5	6.4	2.6	1.9	0.5	0.7	10.9	19.4	2.0	0.7	1.1	0.0	7.3	17.5	22.2	27.0	28.9	0.8	3.3	1.2	13.4	5.4	6.5	2.1	1.7	2.6	6.8	2.0	1.2	1.7	4.6	0.3	2.0	13.2	6.9	1.4	3.2	7.7	0.6	2.2	1.4	0.3	4.6	1.7	0.1	0.0	0.8	0.8	0.0	23.1	3.6	0.0	6.0	6.1	2.3	6.4	2.6	0.7	0.0	0.5	3.8	4.8	0.0	0.8	0.1	9.9	0.2	1.1	0.0	0.7	7.7	0.7	0.0	2.8	5.9	0.2	6.4	0.2	2.7	2.8	0.5	0.0	1.2	13.8	1.6	0.0	0.0	5.2	1.0	0.9	0.0	6.7	0.1	0.1	0.3	2.3	0.0	0.1	0.8	2.7	4.0	2.5	0.0	1.8	18.5	0.7	1.3	5.8	2.2	0.0	0.0	8.4	0.0	2.3	1.4	0.2	0.3	0.3	0.2	1.7	0.3	0.3	0.3	2.2	0.6	0.3	0.3	1.0	4.6	0.3	0.3	0.2	0.1	0.5	0.5	0.6	0.4	0.5	0.7	1.1	0.0	0.8	0.3	0.0	1.7	1.5	10.5	1.3	4.0	2.8	5.1	0.0	0.0	1.8	0.0	2.0	5.0	0.1	3.9	1.9	7.7	0.0	8.8	1.3	25.4	3.4	0.0	80.9	4.3	1.6	0.0	2.5	3.3	4.7	23.3	1.3	1.7	0.0	8.6	4.4	7.9	3.5	65.7	15.6	0.3	12.9	10.5	1.4	1.3	1.1	5.1	0.0	1.7	1.6
ENPP3	"B10, CD203c, gp130RB13-6, PD-IBETA, PDNP3"	ENSG00000154269	"Ectonucleotide pyrophosphatase/phosphodiesterase 3"	O14638	6	131628442-131747418	"CD markers, Enzymes, Predicted intracellular proteins, Predicted secreted proteins"		Hydrolase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ductus deferens: 29.0;intestine: 45.4;seminal vesicle: 70.7"	"Cell type enhanced"	"Detected in many"	20	"Enterocytes: 9.0;granulocytes: 33.7;Proximal tubular cells: 8.2"	"Cancer enriched"	"Detected in many"	8	"renal cancer: 49.6"	"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	74	"basophil: 18.2"	"Lineage enriched"	"Detected in single"	74	"granulocytes: 18.2"	"Group enriched"	"Detected in some"	18	"HEL: 5.2;Hep G2: 17.0;HMC-1: 7.6"	"Low region specificity"	"Detected in some"							HPA043772	Enhanced				"Secreted - unknown location"	NA	NA		480000			"HPA043772: AB_10795616"	"unprognostic (2.74e-1)"	"unprognostic (1.99e-2)"	"unprognostic (1.84e-1)"	"unprognostic (5.41e-3)"	"unprognostic (6.07e-2)"	"unprognostic (4.86e-5)"	"unprognostic (1.13e-1)"	"unprognostic (7.20e-3)"	"unprognostic (1.17e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.21e-3)"	"unprognostic (2.34e-1)"	"prognostic unfavorable (1.96e-4)"	"unprognostic (2.80e-2)"	"unprognostic (7.85e-2)"	"unprognostic (2.29e-1)"	"unprognostic (1.31e-3)"	0.8	7.9	0.5	2.0	0.5	0.0	4.0	2.1	0.4	19.0	18.5	0.2	29.0	9.3	6.2	7.2	0.5	2.3	1.8	0.2	0.4	0.7	11.9	2.7	1.7	0.2	0.5	0.2	0.9	0.2	0.0	0.5	0.4	0.2	3.7	4.8	0.6	14.9	70.7	0.2	0.8	45.4	1.9	0.4	0.5	0.7	1.0	0.2	4.1	0.5	1.2	0.5	0.9	1.2	0.0	0.0	18.2	0.0	0.2	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.1	5.2	0.0	17.0	0.0	0.1	7.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.2	0.1	0.0	0.0	18.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.5	2.1	0.4	0.4	0.7	0.5	0.2	0.2	0.2	0.0	1.4	0.0	2.8	0.0	0.0	0.2	0.0	2.7	1.2	0.0	0.0	0.0	1.7	0.0	1.3	0.3	9.0	0.0	0.0	0.0	0.5	4.6	33.7	1.7	0.1	0.0	0.0	0.6	0.6	0.0	1.1	0.2	1.7	0.0	1.1	0.0	0.0	2.3	0.7	8.2	0.0	0.0	0.0	1.8	0.8	0.5	0.1	0.5	5.2	1.1
ENTPD1	"ATPDase, CD39, NTPDase-1, SPG64"	ENSG00000138185	"Ectonucleoside triphosphate diphosphohydrolase 1"	P49961	10	95711779-95869695	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"		Hydrolase	"Disease mutation, Hereditary spastic paraplegia, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"endometrium 1: 59.4"	"Cell type enhanced"	"Detected in many"	8	"B-cells: 45.3;Endothelial cells: 46.6;Kupffer cells: 77.1;Macrophages: 80.4;monocytes: 46.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 37.4"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	7	"HDLM-2: 57.3;Karpas-707: 47.1"									"CAB002494, HPA014067"	Enhanced		Uncertain	Microtubules		NA	NA			Microtubules		"CAB002494: AB_563557, HPA014067: AB_1848178"	"unprognostic (1.14e-1)"	"unprognostic (1.01e-2)"	"unprognostic (3.11e-1)"	"unprognostic (5.67e-2)"	"unprognostic (9.68e-3)"	"unprognostic (3.45e-3)"	"unprognostic (6.31e-2)"	"unprognostic (5.26e-3)"	"unprognostic (2.73e-1)"	"unprognostic (1.28e-2)"	"unprognostic (6.40e-2)"	"unprognostic (1.41e-1)"	"prognostic unfavorable (5.33e-5)"	"unprognostic (9.79e-2)"	"unprognostic (2.30e-1)"	"prognostic favorable (7.89e-4)"	"unprognostic (5.09e-2)"	10.4	7.5	7.4	16.2	8.4	15.6	8.8	7.6	6.9	18.9	12.7	13.1	8.7	5.8	59.4	12.8	13.2	15.6	22.2	6.8	7.4	7.4	6.2	3.9	14.8	14.5	8.5	4.9	10.3	2.8	3.0	4.3	24.0	9.9	14.7	9.1	10.8	6.7	12.7	3.3	5.5	12.2	37.2	17.9	25.3	7.5	5.4	7.2	3.5	13.4	12.5	21.1	25.2	12.4	6.0	11.8	37.4	15.2	0.5	5.1	4.6	0.1	0.3	0.9	0.8	0.0	0.0	0.5	0.5	0.4	0.0	0.0	0.5	0.1	1.0	0.6	0.0	1.4	0.3	0.0	0.0	0.0	57.3	0.7	0.6	0.4	0.7	0.0	1.5	0.2	0.0	0.0	0.2	0.0	0.3	7.5	0.3	0.6	47.1	0.0	0.6	0.4	1.5	0.6	0.6	0.2	2.4	0.4	0.7	0.5	0.2	0.7	1.1	0.3	1.1	0.8	0.6	0.5	1.6	0.8	0.4	0.2	0.6	0.6	6.7	0.9	0.0	0.6	3.1	0.2	0.1	15.2	37.4	0.1	10.7	0.3	6.0	0.6	0.3	11.8	4.6	0.1	0.1	26.7	0.5	2.4	0.7	5.1	4.6	7.4	8.4	7.6	6.9	7.4	7.4	8.5	4.9	9.9	7.2	0.0	1.4	45.3	0.3	7.9	1.4	8.5	0.0	1.4	1.2	1.8	2.0	0.4	1.7	0.0	5.9	46.6	0.0	0.0	1.8	1.7	8.7	0.4	3.5	0.0	23.2	0.0	0.0	11.6	77.1	6.1	0.6	80.4	15.1	46.9	0.0	0.7	0.2	0.2	2.8	0.3	0.7	6.5	32.0	6.2	4.3	9.8	13.2	14.6	0.4	0.2
EPCAM	"17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1"	ENSG00000119888	"Epithelial cell adhesion molecule"	P16422	2	47345158-47387601	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Tumor antigen"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Hereditary nonpolyposis colorectal cancer"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 303.2"	"Cell type enhanced"	"Detected in many"	10	"Enterocytes: 1952.6;Mucus-secreting cells: 1256.8;Paneth cells: 2168.3;Undifferentiated cells: 1330.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"plasmacytoid DC: 1.9"	"Lineage enriched"	"Detected in single"	5	"dendritic cells: 1.9"	"Cell line enhanced"	"Detected in many"		"A-431: 55.5;CACO-2: 71.9;CAPAN-2: 101.2;OE19: 96.3;RPTEC TERT1: 43.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"CAB003809, HPA026761, CAB030012, CAB055098, HPA067463"	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB003809: AB_562285, CAB030012: AB_756075, CAB055098: AB_2335685, HPA026761: AB_1848198, HPA067463: AB_2685846"	"unprognostic (6.79e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.59e-2)"	"unprognostic (1.16e-2)"	"unprognostic (1.61e-1)"	"unprognostic (3.49e-2)"	"unprognostic (2.01e-1)"	"unprognostic (3.61e-2)"	"unprognostic (3.40e-1)"	"prognostic favorable (3.30e-4)"	"unprognostic (5.27e-2)"	"unprognostic (3.28e-2)"	"prognostic favorable (1.04e-6)"	"unprognostic (6.38e-3)"	"unprognostic (1.28e-1)"	"unprognostic (6.45e-3)"	"unprognostic (6.08e-2)"	0.4	2.1	1.8	49.8	3.0	0.2	8.9	0.6	1.0	10.8	155.8	0.7	31.5	66.8	4.4	35.2	2.8	10.2	41.6	0.4	1.7	2.7	60.2	1.2	22.6	0.4	1.2	0.4	3.8	54.1	19.8	38.7	2.2	0.9	9.0	70.5	0.7	47.2	25.0	0.5	2.0	303.2	1.7	1.4	0.5	15.3	5.5	0.9	1.7	83.6	4.2	4.1	4.1	2.1	0.2	1.9	0.4	0.2	0.0	0.0	0.6	55.5	0.6	0.0	0.1	0.0	0.0	35.2	0.0	0.0	0.0	0.0	71.9	101.2	0.0	15.6	0.1	0.0	26.2	0.5	6.6	0.2	0.0	6.4	0.0	0.3	28.2	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.1	0.0	16.6	0.0	0.0	28.3	0.0	2.6	18.2	96.3	3.6	0.0	0.0	14.1	43.2	24.5	39.1	0.3	0.4	20.7	0.0	15.5	17.4	0.1	0.0	0.0	0.7	0.2	0.1	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	1.9	0.0	0.6	1.8	3.0	0.6	1.0	1.7	2.7	1.2	0.4	0.9	0.9	288.8	113.7	7.2	161.4	8.2	0.1	1.7	236.9	180.7	188.8	425.7	0.0	14.0	64.6	814.0	5.0	2.3	1952.6	0.0	356.0	2.6	1.9	182.8	33.3	0.4	2.4	0.0	478.4	0.0	0.0	3.2	19.0	5.0	33.7	19.8	1256.8	11.8	505.0	2168.3	17.7	160.0	0.7	12.9	0.4	67.3	135.0	9.2	5.0	2.5	1330.8	202.8
ERBB2	"CD340, HER-2, HER2, NEU, NGL"	ENSG00000141736	"Erb-b2 receptor tyrosine kinase 2"	P04626	17	39687914-39730426	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	"Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Collecting duct cells: 129.1;Enterocytes: 93.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 8.8"	"Lineage enriched"	"Detected in many"	4	"T-cells: 8.8"	"Group enriched"	"Detected in many"	41	"OE19: 366.2;SK-BR-3: 179.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		NA	NA		430000	"Plasma membrane"	Cytosol	"CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: AB_2665610, HPA001060: AB_2666185, HPA001338: AB_2666279, HPA001383: AB_1078500"	"unprognostic (1.97e-1)"	"unprognostic (6.60e-3)"	"unprognostic (6.21e-2)"	"prognostic unfavorable (8.99e-8)"	"unprognostic (2.96e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.97e-2)"	"unprognostic (9.04e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.20e-3)"	"prognostic unfavorable (9.17e-4)"	"unprognostic (3.92e-1)"	"prognostic favorable (2.41e-14)"	"unprognostic (9.29e-2)"	"unprognostic (1.40e-1)"	"unprognostic (3.75e-2)"	"unprognostic (1.96e-1)"	5.8	2.4	5.2	10.4	7.0	0.1	20.1	4.2	7.0	19.1	46.5	9.1	55.2	21.6	14.9	18.7	40.9	22.7	26.6	24.8	6.3	3.1	37.5	21.5	17.6	3.7	5.1	5.6	19.3	16.2	27.7	8.1	60.8	7.5	23.6	16.6	15.9	28.7	58.1	8.9	35.3	47.2	10.9	4.5	4.0	17.1	6.5	3.7	2.8	35.7	20.8	22.9	19.7	20.3	1.3	0.3	2.1	0.4	0.9	8.8	2.2	2.1	2.5	2.9	1.8	3.5	2.4	3.9	1.5	2.5	3.3	2.8	1.9	5.8	0.1	3.1	3.5	1.8	6.7	0.1	3.4	1.5	0.2	2.2	0.1	2.0	3.1	2.0	0.0	0.0	2.4	3.2	2.0	1.2	3.2	1.3	0.1	0.3	0.1	2.4	3.3	0.3	0.1	5.2	366.2	0.6	0.2	1.1	0.3	3.4	6.7	0.5	0.1	2.9	179.8	0.9	3.7	5.0	0.1	0.1	1.7	2.2	2.1	0.9	0.3	0.1	0.1	0.1	0.0	5.6	1.6	0.4	0.8	8.8	0.3	0.7	0.9	0.5	2.5	0.3	1.3	1.0	2.5	2.1	0.9	0.2	0.2	0.4	2.2	5.2	7.0	4.2	7.0	6.3	3.1	5.1	5.6	7.5	3.7	38.7	34.4	1.3	21.0	12.5	4.3	13.5	30.6	10.7	15.9	129.1	11.8	9.7	6.6	27.1	0.3	4.6	93.2	0.0	22.3	75.4	11.0	33.4	0.0	10.4	3.5	6.4	15.0	12.3	2.4	0.7	17.0	1.8	10.1	1.0	56.6	30.9	26.2	42.1	21.5	20.7	5.9	0.0	10.3	7.1	5.3	16.6	19.0	2.2	63.0	28.1
EVI2B	"CD361, D17S376, EVDB"	ENSG00000185862	"Ecotropic viral integration site 2B"	P34910	17	31303766-31314112	"CD markers, Predicted membrane proteins"			Proto-oncogene	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 133.6;lymphoid tissue: 72.8"	"Cell type enhanced"	"Detected in many"	16	"B-cells: 217.4;Kupffer cells: 447.5;Macrophages: 274.7;T-cells: 178.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 133.6"	"Group enriched"	"Detected in all"	4	"granulocytes: 133.6;monocytes: 34.3"	"Cell line enhanced"	"Detected in many"		"Daudi: 24.2;HHSteC: 19.9;HL-60: 27.3;HMC-1: 38.5;Karpas-707: 27.3;NB-4: 21.6;RPMI-8226: 39.9;THP-1: 34.4"					"Low region specificity"	"Detected in all"			HPA007436	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		NA	NA			Nucleoplasm	"Plasma membrane, Focal adhesion sites"	"HPA007436: AB_1848307"	"unprognostic (1.07e-2)"	"unprognostic (1.20e-2)"	"unprognostic (5.97e-2)"	"unprognostic (4.09e-3)"	"unprognostic (2.99e-2)"	"unprognostic (1.41e-2)"	"unprognostic (3.06e-1)"	"unprognostic (3.36e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.78e-2)"	"unprognostic (2.34e-1)"	"prognostic unfavorable (2.05e-4)"	"unprognostic (1.56e-2)"	"unprognostic (3.32e-2)"	"unprognostic (8.64e-2)"	"unprognostic (2.73e-2)"	15.0	3.6	4.4	37.7	5.8	44.0	4.2	1.7	4.4	3.7	10.7	6.5	0.3	6.0	2.8	4.8	7.1	4.7	8.1	6.7	6.4	4.4	7.8	7.1	38.5	37.5	10.2	2.6	3.8	2.7	0.4	2.1	4.8	7.8	5.3	8.1	2.5	6.6	1.5	2.3	2.4	23.3	4.2	22.0	72.8	8.0	3.7	6.7	26.1	4.0	3.0	43.0	13.0	7.6	18.6	14.6	133.6	34.3	4.1	16.4	19.8	0.1	0.1	0.0	0.0	1.9	2.5	0.0	0.2	1.7	2.0	3.7	0.0	0.9	24.2	0.0	1.5	7.5	0.1	0.0	0.3	2.2	0.0	0.0	0.5	0.0	0.0	19.9	27.3	38.5	4.6	0.0	1.1	1.5	0.6	1.9	2.0	0.3	27.3	5.7	0.0	7.9	21.6	0.0	0.0	0.0	13.9	0.1	39.9	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	34.4	2.1	0.5	0.0	0.2	1.9	5.3	0.2	5.3	2.5	9.4	0.6	78.9	30.5	74.5	8.2	23.2	7.9	18.6	12.6	10.6	14.6	14.3	9.7	9.1	133.6	4.1	34.3	8.4	16.4	19.8	4.4	5.8	1.7	4.4	6.4	4.4	10.2	2.6	7.8	6.7	0.0	17.9	217.4	0.6	4.7	0.2	0.4	2.5	4.0	11.4	1.8	0.0	0.5	0.0	0.0	5.3	2.7	0.2	0.0	0.0	0.5	2.8	0.3	78.7	1.7	88.8	0.0	0.0	9.8	447.5	4.7	0.0	274.7	35.4	10.8	0.0	0.0	0.7	0.0	0.4	0.7	0.8	19.4	4.1	0.3	0.5	3.1	0.2	178.5	0.0	1.1
F11R	"CD321, JAM-1, JAM-A, JAM1, JAMA, JCAM, PAM-1"	ENSG00000158769	"F11 receptor"	Q9Y624	1	160995211-161021348	"CD markers, Plasma proteins, Predicted membrane proteins"	"Host-virus interaction"	"Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Alveolar cells type 1: 235.2;Urothelial cells: 227.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"eosinophil: 44.5;neutrophil: 32.2"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 44.5"	"Cell line enhanced"	"Detected in many"		"HaCaT: 45.8;OE19: 44.1;SuSa: 54.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB004671, HPA043616, HPA061700"	Enhanced		Supported	"Cell Junctions,Microtubules"		NA	NA		41000000	Microtubules	"Cell Junctions"	"CAB004671: AB_425964, HPA043616: , HPA061700: AB_2684589"	"unprognostic (1.60e-2)"	"unprognostic (5.78e-3)"	"unprognostic (1.78e-3)"	"unprognostic (2.24e-1)"	"unprognostic (4.99e-2)"	"unprognostic (4.89e-2)"	"unprognostic (2.28e-1)"	"unprognostic (2.55e-1)"	"unprognostic (6.35e-2)"	"unprognostic (1.98e-3)"	"unprognostic (1.87e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.78e-1)"	"unprognostic (2.50e-1)"	"unprognostic (1.59e-1)"	"unprognostic (9.72e-3)"	"unprognostic (5.01e-2)"	20.7	13.3	3.0	9.6	3.6	6.4	11.8	2.0	3.5	14.5	36.3	3.9	21.4	20.5	8.6	11.2	41.5	12.3	30.5	10.0	3.4	3.2	35.9	69.8	55.0	10.4	3.6	1.8	10.9	37.9	18.5	16.3	61.8	5.3	17.8	19.5	5.7	59.3	23.7	9.0	22.0	59.8	4.9	4.0	27.0	18.8	11.0	3.3	8.1	52.2	25.8	29.9	16.8	19.7	1.3	7.0	44.5	8.9	2.2	3.8	6.6	26.4	3.4	1.0	0.3	0.7	0.0	21.5	0.1	0.0	0.9	0.9	24.5	35.0	1.9	18.0	0.0	5.2	45.8	5.4	22.7	1.4	1.5	4.0	5.5	1.4	11.1	1.1	5.1	16.5	0.3	28.7	0.1	7.6	5.5	21.5	4.2	7.5	0.5	0.1	11.4	1.6	2.9	18.2	44.1	4.9	2.4	0.0	8.5	15.4	20.1	7.6	2.0	6.4	27.5	5.7	54.5	29.9	9.2	12.9	0.0	0.6	0.1	0.2	6.4	12.6	0.6	4.1	5.1	1.7	7.6	8.9	44.5	3.8	4.5	2.0	1.3	3.5	2.3	7.0	0.9	3.4	2.7	32.2	2.2	3.4	5.3	1.5	6.6	3.0	3.6	2.0	3.5	3.4	3.2	3.6	1.8	5.3	3.3	235.2	115.8	3.7	97.8	31.3	0.8	3.0	61.1	163.3	161.5	73.3	2.0	64.9	6.6	66.4	6.8	40.7	78.8	0.0	61.9	148.6	11.0	102.0	17.4	55.2	27.9	0.0	59.7	24.5	14.6	1.5	2.0	22.4	8.5	63.1	64.1	1.4	68.6	75.0	0.7	11.9	2.5	0.0	3.1	12.9	1.2	44.3	52.7	8.7	42.7	227.3
F3	"CD142, TF"	ENSG00000117525	"Coagulation factor III, tissue factor"	P13726	1	94529225-94541800	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"		"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	12	"Basal glandular cells: 636.0;Exocrine glandular cells: 410.4;Muller glia cells: 389.7;Pancreatic endocrine cells: 1078.7;Peritubular cells: 498.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.8"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"A-431: 117.4;HaCaT: 55.6;HBEC3-KT: 144.4;U-2197: 54.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009438, HPA049292, HPA069132"	Uncertain		Approved	Vesicles	"Secreted to blood"	NA	NA	603000		Vesicles		"CAB009438: AB_668005, HPA049292: AB_2680701, HPA069132: AB_2686092"	"unprognostic (3.86e-2)"	"unprognostic (1.19e-1)"	"unprognostic (8.04e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.23e-3)"	"unprognostic (4.93e-2)"	"unprognostic (8.00e-2)"	"unprognostic (5.88e-1)"	"unprognostic (1.35e-1)"	"prognostic unfavorable (1.07e-4)"	"unprognostic (1.25e-1)"	"prognostic unfavorable (2.02e-8)"	"unprognostic (4.84e-2)"	"unprognostic (4.08e-1)"	"unprognostic (1.23e-1)"	"unprognostic (1.08e-1)"	45.5	9.8	27.0	14.1	42.9	2.1	55.1	3.4	27.9	14.8	18.7	20.9	18.7	18.3	30.5	23.7	21.3	25.4	30.9	18.8	26.9	14.5	6.6	2.8	31.4	5.8	14.1	20.3	41.6	35.0	6.1	28.8	65.4	39.2	29.7	22.2	49.9	29.2	33.0	2.4	17.7	19.2	5.9	46.3	2.9	18.2	16.4	16.0	0.0	21.8	17.3	11.9	24.7	22.3	0.5	0.9	2.8	0.8	0.7	0.4	0.2	117.4	0.2	0.2	0.0	12.8	6.3	6.6	16.7	10.0	18.1	19.7	2.1	25.2	0.0	8.6	20.7	3.9	55.6	1.5	144.4	29.9	0.1	0.1	0.0	3.6	0.3	4.2	0.0	0.0	10.9	3.2	8.5	41.9	34.4	0.1	0.1	0.1	0.1	12.6	0.2	0.1	2.4	1.1	0.7	0.2	0.1	1.2	0.0	2.2	0.3	0.1	0.3	13.3	5.5	0.4	3.6	0.1	1.6	0.0	11.0	0.3	54.8	5.0	0.1	0.1	0.1	8.4	0.6	0.4	1.7	0.8	0.1	0.3	0.3	0.4	0.2	0.3	0.2	0.2	0.5	0.3	0.3	2.8	0.7	0.2	0.9	0.2	0.2	27.0	42.9	3.4	27.1	26.9	14.5	14.1	20.3	39.2	16.0	122.1	188.9	0.5	636.0	14.4	1.5	21.1	7.6	72.3	238.8	14.0	0.0	13.6	0.0	120.9	5.6	10.5	10.3	0.0	410.4	4.8	48.3	85.3	2.3	0.6	5.4	3.2	12.6	12.3	4.0	9.8	260.4	4.9	3.3	3.6	40.9	389.7	1078.7	11.0	498.9	0.3	13.3	6.5	7.2	1.1	3.4	6.6	6.4	0.8	9.5	358.5
FAS	"APO-1, APT1, CD95, FAS1, TNFRSF6"	ENSG00000026103	"Fas cell surface death receptor"	P25445	10	88990582-89015785	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	"Calmodulin-binding, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Basal glandular cells: 100.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 40.1"	"Group enriched"	"Detected in all"	5	"granulocytes: 40.1;T-cells: 30.9"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 28.0;Karpas-707: 44.7"					"Low region specificity"	"Detected in all"			HPA027444	Uncertain		Supported	"Nuclear bodies,Plasma membrane,Cytosol"	"Secreted to blood"	NA	NA	11900000	450000	"Plasma membrane"	"Nuclear bodies, Cytosol"	"HPA027444: AB_10601378"	"unprognostic (6.84e-2)"	"unprognostic (2.88e-3)"	"unprognostic (8.38e-3)"	"unprognostic (1.94e-1)"	"unprognostic (2.35e-2)"	"unprognostic (9.56e-2)"	"unprognostic (7.00e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.01e-1)"	"unprognostic (7.70e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.52e-3)"	"unprognostic (2.10e-1)"	"unprognostic (2.32e-2)"	"unprognostic (4.95e-3)"	"unprognostic (1.65e-1)"	13.5	26.3	6.1	17.3	7.7	12.4	10.6	2.1	7.2	15.6	14.2	6.1	7.0	5.9	15.7	16.6	14.1	14.2	14.5	8.9	8.2	2.7	11.7	21.9	28.6	15.6	6.0	3.9	24.7	4.1	4.5	4.6	9.0	7.5	22.3	21.3	4.4	7.1	8.5	4.3	9.6	16.3	12.5	10.2	15.3	5.0	7.3	5.1	12.5	10.0	15.8	14.4	14.8	21.4	3.0	4.0	40.1	6.8	1.2	30.9	3.9	8.7	3.4	1.8	5.6	14.5	21.4	0.0	19.2	19.5	0.7	3.8	0.0	9.5	1.7	7.4	18.0	3.2	1.4	0.3	16.2	1.3	28.0	2.8	0.1	1.8	5.7	13.9	0.9	0.4	26.5	14.5	12.0	26.0	9.4	1.7	6.4	0.0	44.7	19.6	0.8	2.8	1.4	0.2	0.0	0.9	0.2	0.1	1.8	27.1	2.8	0.1	0.1	2.8	0.0	0.3	2.8	6.1	0.3	4.2	6.2	3.4	5.7	4.4	17.5	1.8	0.1	5.1	3.5	1.8	11.3	3.2	9.4	3.3	3.9	4.8	3.0	10.4	7.2	4.0	0.7	1.2	3.4	40.1	1.2	6.8	0.0	30.9	3.9	6.1	7.7	2.1	7.2	8.2	2.7	6.0	3.9	7.5	5.1	53.6	14.4	3.7	100.3	40.8	0.0	1.2	15.3	21.4	21.6	8.7	0.0	0.4	0.0	6.7	5.4	8.4	12.0	0.0	3.8	0.2	34.9	22.7	3.5	15.3	5.0	1.6	8.1	2.5	6.9	3.5	17.5	12.7	11.8	20.8	15.0	17.1	4.3	0.0	13.1	11.5	0.7	6.5	33.4	4.8	1.3	38.3	0.3	37.9	23.2	22.7
FASLG	"APT1LG1, CD178, FasL, TNFSF6"	ENSG00000117560	"Fas ligand"	P48023	1	172659018-172666874	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Apoptosis, Transcription, Transcription regulation"	"Cytokine, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 25.6;lymphoid tissue: 13.4"	"Cell type enriched"	"Detected in some"	7	"T-cells: 30.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 25.6"	"Group enriched"	"Detected in many"	12	"NK-cells: 16.0;T-cells: 25.6"	"Cell line enhanced"	"Detected in some"		"ASC diff: 1.0;LHCN-M2: 2.5;NB-4: 1.2;RPTEC TERT1: 1.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA054959	Approved				"Secreted to blood"	NA	NA	73600				"HPA054959: AB_2682650"	"unprognostic (1.09e-3)"	"unprognostic (1.41e-2)"	"unprognostic (8.69e-2)"	"unprognostic (1.54e-7)"	"unprognostic (3.29e-1)"	"unprognostic (2.23e-3)"	"unprognostic (5.44e-2)"	"unprognostic (1.84e-2)"	"unprognostic (4.67e-2)"	"unprognostic (4.76e-2)"	"unprognostic (8.88e-2)"	"unprognostic (1.07e-1)"	"prognostic unfavorable (1.59e-6)"	"unprognostic (3.49e-2)"	"unprognostic (1.22e-1)"	"unprognostic (1.15e-2)"	"unprognostic (3.82e-3)"	0.9	1.1	0.5	1.9	0.7	3.6	1.8	0.5	0.8	0.7	2.6	0.6	0.0	3.0	3.9	1.2	1.0	0.8	1.6	1.2	0.5	0.5	1.2	2.2	6.8	7.7	1.4	0.0	1.5	0.6	0.0	0.7	2.4	0.6	4.7	1.2	2.8	1.9	0.3	0.4	0.5	3.8	1.9	1.7	13.4	2.1	0.4	0.0	1.2	1.1	0.0	10.1	1.4	0.9	0.0	0.0	1.6	0.0	16.0	25.6	5.5	0.0	0.0	0.3	0.1	1.0	0.0	0.5	0.2	0.0	0.0	0.1	0.0	0.5	0.5	0.1	0.0	0.0	0.8	0.0	0.3	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.2	0.1	0.0	0.2	0.4	0.7	0.1	0.0	0.1	0.3	0.6	2.5	0.0	0.0	1.2	0.4	0.2	0.0	0.0	0.0	0.1	1.0	0.2	0.0	0.1	0.0	0.1	0.0	0.6	0.1	0.0	0.0	0.1	0.1	0.3	0.3	0.8	0.0	0.0	0.0	0.1	0.1	1.6	0.0	0.0	25.6	0.0	15.8	0.0	5.4	13.7	0.0	0.0	1.1	11.7	0.8	16.0	0.0	0.0	0.1	5.5	0.5	0.7	0.5	0.8	0.5	0.5	1.4	0.0	0.6	0.0	0.0	4.5	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.2	1.7	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.0	30.5	0.0	0.0
FCAMR	"CD351, FCA/MR, FKSG87"	ENSG00000162897	"Fc fragment of IgA and IgM receptor"	Q8WWV6	1	206957965-206970625	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"kidney: 23.9;liver: 7.6;lymphoid tissue: 23.0"	"Cell type enriched"	"Detected in some"	8	"Proximal tubular cells: 26.5"	"Cancer enhanced"	"Detected in some"		"renal cancer: 5.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 1.9;HMC-1: 1.0"									HPA056505	Enhanced					NA	NA		3600000			"HPA056505: AB_2732604"	"unprognostic (2.94e-1)"	"unprognostic (1.06e-1)"	"unprognostic (8.53e-2)"	"unprognostic (2.92e-1)"	"unprognostic (7.44e-2)"	"unprognostic (4.55e-3)"	"unprognostic (2.69e-3)"	"unprognostic (1.08e-4)"	"unprognostic (3.61e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.82e-1)"	"unprognostic (1.23e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.29e-1)"	"unprognostic (3.88e-2)"	"unprognostic (2.08e-1)"	"unprognostic (1.26e-1)"	0.1	0.1	0.1	23.0	0.1	0.0	0.1	0.1	0.1	0.1	0.3	0.1	0.1	0.6	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	23.9	7.6	0.1	8.3	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	2.4	0.1	0.1	0.1	1.0	0.1	0.5	0.6	0.1	0.2	0.1	0.2	0.2	0.1	9.1	0.1	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	1.9	0.3	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.0	0.0	0.2	0.0	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.3	0.4	0.1	0.3	0.0	0.2	0.5	0.0	0.2	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	26.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0
FCAR	CD89	ENSG00000186431	"Fc fragment of IgA receptor"	P24071	19	54874248-54890472	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		"IgA-binding protein, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 28.1;lung: 19.5;lymphoid tissue: 15.9"	"Cell type enhanced"	"Detected in some"	15	"Alveolar cells type 2: 3.7;Cardiomyocytes: 1.4;Ciliated cells: 1.4;Kupffer cells: 5.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	6	"classical monocyte: 2.6;neutrophil: 6.1"	"Group enriched"	"Detected in many"	44	"granulocytes: 6.1;monocytes: 2.6"	"Cell line enhanced"	"Detected in single"		"THP-1: 1.7"					"Low region specificity"	"Detected in all"			HPA014050	Approved		Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"		"HPA014050: AB_1846338"	"unprognostic (1.46e-1)"	"unprognostic (5.74e-2)"	"unprognostic (1.30e-1)"	"unprognostic (4.71e-3)"	"unprognostic (3.46e-1)"	"unprognostic (2.02e-1)"	"unprognostic (7.99e-2)"	"unprognostic (1.54e-2)"	"unprognostic (1.59e-2)"	"unprognostic (4.70e-2)"	"unprognostic (1.41e-2)"	"unprognostic (7.05e-2)"	"unprognostic (4.19e-6)"	"unprognostic (9.23e-2)"	"unprognostic (8.10e-3)"	"unprognostic (8.04e-3)"	"unprognostic (9.81e-2)"	4.0	0.6	0.4	1.5	4.4	28.1	0.8	0.1	1.0	0.6	0.6	0.7	0.0	0.6	0.6	0.6	0.6	3.8	0.6	8.2	2.0	0.4	0.6	1.8	19.5	15.9	1.2	0.0	2.2	0.6	0.6	0.3	1.5	4.3	0.6	0.6	0.9	0.6	0.6	0.6	0.6	0.6	0.7	2.7	14.9	0.9	2.1	0.0	1.0	0.6	0.3	0.6	4.4	4.8	0.0	0.0	6.1	2.6	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.7	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.1	0.0	0.1	0.0	0.0	0.7	0.4	4.4	0.1	1.0	2.0	0.4	1.2	0.0	4.3	0.0	0.0	3.7	0.0	0.2	0.1	0.1	1.4	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.4	0.3	1.1	0.0	1.0	0.0	0.0	0.0	5.1	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.3	0.1	0.0	0.0	0.1
FCER2	"CD23, CD23A, CLEC4J, FCE2"	ENSG00000104921	"Fc fragment of IgE receptor II"	P06734	19	7688758-7702146	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgE-binding protein, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"blood: 87.2;lymphoid tissue: 38.4"	"Cell type enriched"	"Detected in some"	57	"B-cells: 110.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	23	"memory B-cell: 28.2;naive B-cell: 87.2"	"Lineage enriched"	"Detected in many"	34	"B-cells: 87.2"	"Cell line enriched"	"Detected in some"	14	"HDLM-2: 99.9"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"CAB002624, HPA008928, HPA067430"	Enhanced				"Secreted to blood"	NA	NA		59000			"CAB002624: , HPA008928: AB_1846285, HPA067430: "	"unprognostic (3.20e-4)"	"unprognostic (1.87e-3)"	"unprognostic (1.95e-2)"	"unprognostic (2.44e-2)"	"unprognostic (4.77e-2)"	"unprognostic (1.77e-3)"	"unprognostic (1.64e-1)"	"unprognostic (1.89e-3)"	"unprognostic (2.71e-1)"	"unprognostic (1.88e-1)"	"unprognostic (2.04e-2)"	"unprognostic (8.55e-2)"	"unprognostic (2.46e-4)"	"unprognostic (2.99e-1)"	"unprognostic (1.80e-1)"	"unprognostic (4.89e-2)"	"unprognostic (5.17e-2)"	2.4	0.3	0.5	17.1	0.5	2.3	1.2	0.3	1.1	0.3	1.0	0.1	0.4	1.3	0.3	2.3	1.0	0.4	0.5	0.8	0.3	0.3	0.6	0.6	0.8	21.1	0.3	0.0	0.4	0.3	0.0	0.3	0.3	0.1	0.3	0.8	0.0	7.5	0.7	0.4	0.6	7.7	0.4	0.3	38.4	0.8	0.5	0.0	6.3	0.7	0.0	33.8	2.0	0.5	87.2	0.7	0.2	2.5	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	99.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.5	0.0	0.0	2.5	0.0	28.2	0.0	0.0	0.7	87.2	0.0	0.0	0.2	0.0	0.7	0.1	0.0	3.0	0.5	0.5	0.3	0.3	0.3	0.3	0.3	0.0	0.1	0.0	0.0	1.1	110.4	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	1.3	0.6	0.0	0.0	1.9	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
FCGR1A	"CD64, CD64A"	ENSG00000150337	"Fc fragment of IgG receptor Ia"	P12314	1	149782671-149792518	"CD markers, FDA approved drug targets, Predicted membrane proteins"	"Immunity, Innate immunity"	"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 35.6;epididymis: 33.2"	"Cell type enhanced"	"Detected in many"	21	"Hofbauer cells: 235.7;Kupffer cells: 121.8;Late spermatids: 48.6;Macrophages: 101.0"	"Cancer enhanced"	"Detected in many"		"glioma: 10.3"					"Group enriched"	"Detected in some"	7	"classical monocyte: 35.6;intermediate monocyte: 14.0;myeloid DC: 9.5;neutrophil: 25.5"	"Group enriched"	"Detected in many"	80	"dendritic cells: 9.5;granulocytes: 25.5;monocytes: 35.6"	"Cell line enriched"	"Detected in some"	5	"THP-1: 61.0"									HPA026910			Uncertain	"Golgi apparatus,Vesicles,Plasma membrane"		NA	NA			Vesicles	"Golgi apparatus, Plasma membrane"	"HPA026910: "	"unprognostic (5.27e-2)"	"unprognostic (2.89e-2)"	"unprognostic (2.34e-2)"	"unprognostic (7.97e-2)"	"unprognostic (8.44e-3)"	"unprognostic (1.73e-1)"	"unprognostic (7.69e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.88e-2)"	"unprognostic (1.72e-1)"	"unprognostic (1.98e-2)"	"unprognostic (6.18e-2)"	"prognostic unfavorable (4.83e-8)"	"unprognostic (1.28e-1)"	"unprognostic (4.51e-2)"	"unprognostic (9.99e-2)"	"unprognostic (9.03e-2)"	3.9	2.4	6.7	14.1	4.4	5.0	0.7	0.3	3.5	1.1	0.3			0.0	0.1	33.2	0.3	0.7	2.4	0.7	5.3	4.9	1.0	1.1	8.9	3.4	10.1		0.3	1.0	0.5	1.2	10.8		0.4	0.3		0.7	0.2	0.0	0.0	0.1	5.5	14.3	7.0	0.3	0.9			0.3		0.0	3.3	0.0	0.2	9.5	25.5	35.6	0.0	0.2	11.2	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	12.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.4	61.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.5	35.6	0.4	0.0	14.0	0.2	0.2	0.0	0.1	9.5	0.0	0.0	0.0	25.5	0.0	2.8	0.2	0.1	11.2											0.0	1.9	3.5	0.0	0.1	1.5	1.2	2.5	1.4	2.3	0.0	2.0	2.1	0.0	0.0	28.2	0.1	0.0	0.0	0.0	1.1	0.6	0.0	0.0	0.0	235.7	0.0	0.0	1.3	121.8	48.6	0.3	101.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.7	6.5	0.0	0.7	0.4	0.0	3.4	0.0	0.0	0.0
FCGR2A	"CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2"	ENSG00000143226	"Fc fragment of IgG receptor IIa"	P12318	1	161505430-161524013	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 182.8"	"Cell type enhanced"	"Detected in many"	17	"Hofbauer cells: 145.9;Kupffer cells: 155.0;Macrophages: 311.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"neutrophil: 182.8"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 182.8"	"Cell line enhanced"	"Detected in some"		"HEL: 14.3;HMC-1: 28.9;K-562: 8.4;NB-4: 8.1;THP-1: 30.7;U-937: 13.2"									"HPA010718, HPA010776, HPA014730"	Enhanced		Supported	"Golgi apparatus,Plasma membrane"		NA	NA		55000000	"Plasma membrane"	"Golgi apparatus"	"HPA010718: AB_1078463, HPA010776: , HPA014730: AB_2669074"	"unprognostic (2.57e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.48e-2)"	"unprognostic (4.12e-2)"	"unprognostic (5.89e-2)"	"unprognostic (6.17e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.17e-1)"	"unprognostic (7.63e-2)"	"unprognostic (1.17e-3)"	"unprognostic (2.43e-2)"	"unprognostic (2.91e-1)"	"prognostic unfavorable (6.49e-7)"	"unprognostic (8.85e-3)"	"unprognostic (6.47e-3)"	"unprognostic (1.54e-1)"	"unprognostic (3.42e-2)"	36.8	12.6	13.2	44.6	19.2	18.6	8.2	2.2	10.1	9.1	7.1	10.0	0.0	3.8	4.7	6.6	5.5	11.6	17.0	11.3	17.0	8.9	11.5	7.1	44.1	50.0	25.9	1.7	8.0	5.8	2.8	6.1	47.5	19.6	7.0	9.9	10.8	8.3	4.8	7.3	3.0	7.3	17.6	30.9	43.4	5.9	4.8	19.2	3.2	6.3	2.5	4.4	19.3	4.5	0.2	7.0	182.8	27.2	0.0	0.0	10.6	0.0	0.0	0.0	1.2	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	14.3	0.2	0.0	0.3	4.1	28.9	0.3	0.0	0.0	0.0	0.4	0.0	0.0	8.4	0.2	0.0	0.0	0.2	8.1	0.0	0.0	0.6	0.1	0.6	3.9	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	30.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.2	13.2	3.6	0.1	27.2	31.6	0.0	20.7	0.0	0.2	0.0	0.0	7.0	0.1	0.0	0.0	182.8	0.0	16.7	0.2	0.0	10.6	13.2	19.2	2.2	10.1	17.0	8.9	25.9	1.7	19.6	19.2	20.8	63.3	13.7	0.4	7.7	0.0	1.2	5.1	6.7	21.6	0.0	0.0	0.8	8.3	0.2	37.5	2.6	0.0	0.0	0.5	1.1	5.8	0.3	29.0	0.8	145.9	0.0	0.0	4.3	155.0	35.2	1.4	311.2	16.9	1.8	0.0	0.3	0.7	0.0	0.0	7.9	0.1	6.5	5.8	0.3	0.4	6.8	1.4	4.1	0.0	0.3
FCGR2B	"CD32, CD32B, FCG2, FCGR2"	ENSG00000072694	"Fc fragment of IgG receptor IIb"	P31994	1	161663147-161678654	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Host-virus interaction"	"IgG-binding protein, Receptor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 53.3;placenta: 83.2"	"Group enriched"	"Detected in many"	5	"Ito cells: 479.4;Macrophages: 138.2"	"Low cancer specificity"	"Detected in many"							"Cell type enhanced"	"Detected in many"		"basophil: 53.3;memory B-cell: 42.2"	"Group enriched"	"Detected in many"	18	"B-cells: 42.2;dendritic cells: 14.5;granulocytes: 53.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 18.7;HMC-1: 23.5;NB-4: 5.2;RPMI-8226: 8.4"									"CAB007796, HPA014730"	Enhanced					NA	NA					"CAB007796: AB_562288, HPA014730: AB_2669074"	"unprognostic (1.58e-1)"	"unprognostic (5.14e-2)"	"unprognostic (3.32e-3)"	"unprognostic (3.12e-2)"	"unprognostic (6.79e-3)"	"unprognostic (4.05e-3)"	"unprognostic (1.27e-1)"	"unprognostic (4.65e-3)"	"unprognostic (1.91e-1)"	"unprognostic (4.72e-2)"	"unprognostic (2.89e-2)"	"unprognostic (3.49e-1)"	"prognostic unfavorable (8.82e-4)"	"unprognostic (3.51e-2)"	"unprognostic (6.36e-2)"	"unprognostic (4.31e-1)"	"unprognostic (3.37e-1)"	11.3	2.4	0.0	2.0	0.2	0.0	4.1	0.0	0.0	1.9	3.4			0.2	0.9	0.2	2.1	2.1	2.3	3.7	0.0	0.2	2.0	9.5	5.6	2.5	0.5		0.8	0.6	0.0	0.3	83.2		0.3	2.0		3.3	0.2	0.5	2.0	4.6	3.1	4.7	6.7	1.5	0.1			1.7		5.6	3.3	1.2	42.2	14.5	53.3	1.9	0.1	0.3	2.4	0.0	0.1	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	5.2	0.1	0.0	0.0	0.0	0.0	8.4	0.0	0.0	0.1	0.1	0.0	0.0	1.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	2.2	0.0	53.3	1.8	5.4	0.3	1.9	0.1	42.2	0.1	0.2	14.5	34.3	0.0	0.3	11.2	0.1	1.7	0.0	0.0	2.4											0.0	4.6	57.3	0.0	4.7	0.0	1.9	5.1	0.0	2.3	0.0	0.0	0.2	0.0	0.0	4.2	1.4	0.0	23.3	0.0	0.2	2.7	0.0	2.3	2.5	7.6	0.0	0.0	479.4	63.3	2.3	0.6	138.2	21.9	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.7	0.3	0.2	2.8	0.3	4.9	0.0	0.0
FCGR3A	"CD16, CD16a, FCG3, FCGR3"	ENSG00000203747	"Fc fragment of IgG receptor IIIa"	P08637	1	161541759-161550737	"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 223.6;lymphoid tissue: 60.8"	"Cell type enhanced"	"Detected in many"	22	"Hofbauer cells: 191.4;Kupffer cells: 556.1;Macrophages: 266.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 109.4;non-classical monocyte: 223.6"	"Group enriched"	"Detected in many"	4	"granulocytes: 73.0;monocytes: 223.6"	"Cell line enhanced"	"Detected in some"		"BEWO: 1.0;HaCaT: 1.7;SH-SY5Y: 1.3;U-2197: 1.1;U-266/70: 1.8"									"CAB032435, HPA055431"	Supported				"Secreted to blood"	NA	NA		2500000000			"CAB032435: AB_626925, HPA055431: AB_2682815"	"unprognostic (5.27e-2)"	"unprognostic (9.95e-2)"	"unprognostic (2.37e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.82e-1)"	"unprognostic (2.24e-2)"	"unprognostic (6.06e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.98e-2)"	"unprognostic (7.52e-2)"	"prognostic unfavorable (3.22e-6)"	"unprognostic (1.14e-1)"	"unprognostic (4.66e-2)"	"unprognostic (1.03e-2)"	"unprognostic (7.51e-2)"	11.9	9.7	7.5	20.5	12.4	4.4	4.1	1.6	7.0	1.9	2.1	5.5	0.8	0.8	1.1	2.4	1.0	2.4	5.1	6.4	6.3	7.3	2.6	22.5	43.2	8.0	12.7	1.9	1.4	2.9	1.8	3.9	14.6	6.8	2.6	2.3	2.2	2.7	1.3	1.3	0.3	1.2	14.3	25.7	60.8	1.3	1.2	8.0	1.4	1.8	1.3	1.3	6.3	2.3	0.1	11.7	73.0	223.6	7.9	33.9	35.8	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.5	1.7	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.3	0.8	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.3	0.5	0.5	0.0	0.0	0.8	0.5	0.4	0.0	0.0	0.5	1.3	0.4	0.2	0.0	0.5	0.0	0.1	0.0	0.0	0.1	1.1	0.0	1.8	0.0	0.4	0.0	0.0	0.0	0.3	1.6	0.5	33.9	109.4	0.3	0.1	0.3	13.2	11.7	0.0	0.2	12.2	73.0	7.9	223.6	0.2	0.1	35.8	7.5	12.4	1.6	7.0	6.3	7.3	12.7	1.9	6.8	8.0	20.8	30.6	13.0	0.0	0.5	0.1	0.4	7.6	10.7	19.4	3.5	2.0	1.1	0.0	0.0	0.9	0.8	0.0	0.0	0.0	1.1	0.3	0.0	17.4	3.4	191.4	0.0	0.0	9.2	556.1	1.5	0.3	266.3	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.6	1.3	19.4	0.0	0.0	0.5	0.0	1.7	99.7	0.0	0.1
FCGR3B	"CD16, CD16b, FCG3, FCGR3"	ENSG00000162747	"Fc fragment of IgG receptor IIIb"	O75015	1	161623196-161631963	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	8	"blood: 334.5"	"Cell type enhanced"	"Detected in some"	19	"Alveolar cells type 1: 3.0;Alveolar cells type 2: 11.1;Ciliated cells: 4.0;Club cells: 5.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	95	"neutrophil: 334.5"	"Lineage enriched"	"Detected in many"	95	"granulocytes: 334.5"	"Cell line enhanced"	"Detected in single"		"K-562: 1.5"														"Secreted to blood"	NA	NA						"unprognostic (1.60e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.59e-3)"	"unprognostic (4.16e-2)"	"unprognostic (1.15e-1)"	"unprognostic (6.52e-2)"	"unprognostic (3.97e-2)"	"unprognostic (6.96e-3)"	"unprognostic (2.53e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.07e-1)"	"unprognostic (8.67e-2)"	"unprognostic (5.16e-2)"	"unprognostic (1.35e-1)"	"unprognostic (8.37e-3)"	"unprognostic (2.28e-1)"	"unprognostic (9.24e-2)"	9.9	0.8	1.8	30.8	1.5	13.8	1.5	0.9	1.8	0.9	0.8	0.5	0.2	0.0	0.4	0.5	1.7	2.8	6.8	4.6	1.2	0.9	0.9	2.9	15.2	16.9	5.0	0.5	1.2	1.2	0.0	0.6	4.5	1.9	1.5	0.0	1.3	0.9	0.9	0.8	1.4	0.8	2.0	4.0	44.3	1.3	1.5	0.9	0.6	0.8	0.2	0.9	11.1	4.7	0.0	0.1	334.5	3.5	0.1	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.4	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.4	0.0	0.3	0.0	0.0	0.0	0.5	0.5	1.2	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.1	334.5	0.1	3.5	0.0	0.0	0.5	1.8	1.5	0.9	1.8	1.2	0.9	5.0	0.5	1.9	0.9	3.0	11.1	0.0	0.0	0.0	0.0	0.3	0.0	4.0	5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.8	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.0	0.0	0.0
FCRL1	"CD307a, FCRH1, IFGP1, IRTA5"	ENSG00000163534	"Fc receptor like 1"	Q96LA6	1	157794403-157820105	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"blood: 31.6;lymphoid tissue: 55.1"	"Cell type enriched"	"Detected in some"	60	"B-cells: 69.9"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	51	"memory B-cell: 16.8;naive B-cell: 31.6"	"Lineage enriched"	"Detected in single"	66	"B-cells: 31.6"	"Group enriched"	"Detected in some"	33	"Daudi: 5.7;U-698: 19.4"					"Low region specificity"	"Detected in all"			HPA013323	Enhanced					NA	NA		120000			"HPA013323: AB_1848480"	"unprognostic (6.52e-4)"	"unprognostic (3.49e-3)"	"unprognostic (8.68e-3)"	"unprognostic (8.08e-3)"	"unprognostic (1.31e-1)"	"unprognostic (1.01e-5)"	"unprognostic (1.47e-2)"	"unprognostic (5.48e-3)"	"unprognostic (1.40e-2)"	"unprognostic (4.30e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.85e-2)"	"unprognostic (1.44e-3)"	"unprognostic (1.96e-1)"	"unprognostic (1.65e-2)"	"unprognostic (4.80e-2)"	"unprognostic (6.74e-2)"	0.5	0.2	0.2	55.1	0.2	6.2	0.3	0.2	0.2	0.2	0.7	0.0	0.0	0.0	0.2	0.1	2.4	0.3	0.2	0.3	0.2	0.2	0.7	0.5	1.9	19.2	0.2	0.0	0.2	0.3	0.0	0.2	0.0	0.0	0.5	0.3	0.3	5.4	0.7	0.2	0.2	10.1	0.0	0.2	25.3	0.4	0.2	0.0	1.1	0.7	0.4	49.0	4.5	0.8	31.6	0.0	0.4	0.2	0.0	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	19.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	16.8	0.0	0.0	0.0	31.6	0.0	0.0	0.4	0.0	0.2	0.0	0.1	0.9	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.0	0.0	69.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCRL2	"CD307b, FCRH2, IRTA4, SPAP1"	ENSG00000132704	"Fc receptor like 2"	Q96LA5	1	157745733-157777132	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"blood: 20.2;intestine: 14.9;lymphoid tissue: 27.0"	"Cell type enriched"	"Detected in some"	17	"B-cells: 57.3"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	50	"memory B-cell: 20.2;naive B-cell: 10.8"	"Lineage enriched"	"Detected in single"	65	"B-cells: 20.2"	"Group enriched"	"Detected in some"	4	"Daudi: 15.0;U-698: 12.2"															NA	NA						"unprognostic (3.94e-3)"	"unprognostic (1.47e-3)"	"unprognostic (3.49e-2)"	"unprognostic (3.69e-3)"		"unprognostic (5.11e-5)"	"unprognostic (1.67e-2)"	"unprognostic (4.77e-3)"	"unprognostic (8.19e-2)"	"unprognostic (8.66e-3)"	"unprognostic (1.20e-2)"	"unprognostic (4.19e-2)"	"unprognostic (4.60e-7)"	"unprognostic (2.89e-1)"	"unprognostic (2.29e-1)"	"unprognostic (7.92e-2)"	"unprognostic (2.48e-1)"	0.4	0.2	0.2	22.6	0.2	1.5	0.2	0.1	0.2	0.2	1.3	0.1	0.1	1.2	0.3	0.1	1.4	0.2	0.4	0.2	0.2	0.2	0.5	0.9	0.7	15.6	0.3	0.1	0.5	0.2	0.0	0.2	0.1	0.2	0.4	1.7	0.6	2.8	0.7	0.1	0.2	14.9	0.1	0.2	27.0	0.8	0.2	0.1	0.3	0.5	0.1	23.3	1.4	0.2	20.2	0.0	0.3	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	15.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	3.2	0.0	12.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	20.2	0.0	0.0	0.0	10.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.2	0.1	0.2	0.2	0.2	0.3	0.1	0.2	0.1	0.0	1.4	57.3	0.4	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.3	1.1	0.4	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.6	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.1	0.0	0.0	0.3
FCRL3	"CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e"	ENSG00000160856	"Fc receptor like 3"	Q96P31	1	157674321-157700857	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 20.3;lymphoid tissue: 32.2"	"Cell type enhanced"	"Detected in some"	28	"B-cells: 38.7;Early spermatids: 7.0;Late spermatids: 7.6;T-cells: 14.6"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 20.3"	"Group enriched"	"Detected in many"	56	"B-cells: 20.3;NK-cells: 10.7;T-cells: 10.8"	"Cell line enriched"	"Detected in some"	7	"Daudi: 14.6"					"Low region specificity"	"Detected in single"			HPA048022	Enhanced					NA	NA					"HPA048022: AB_2732541"	"unprognostic (6.73e-3)"	"unprognostic (5.06e-4)"	"unprognostic (1.13e-2)"	"unprognostic (2.08e-4)"	"unprognostic (3.86e-1)"	"unprognostic (1.74e-5)"	"unprognostic (1.09e-2)"	"unprognostic (4.29e-3)"	"unprognostic (3.69e-3)"	"unprognostic (2.46e-4)"	"unprognostic (1.13e-1)"	"unprognostic (2.55e-2)"	"unprognostic (2.01e-4)"	"unprognostic (1.55e-1)"	"unprognostic (1.29e-1)"	"unprognostic (2.21e-1)"	"unprognostic (6.69e-2)"	0.4	0.2	0.2	29.4	0.2	0.4	0.3	0.2	0.2	0.3	0.6	0.0	0.0	0.0	0.5	0.2	1.5	0.3	0.6	0.3	0.2	0.2	0.5	0.6	0.9	26.4	0.4	0.0	0.2	0.2	0.0	0.3	0.0	0.0	0.5	0.6	0.2	5.6	0.0	0.4	0.2	8.7	0.1	0.2	22.4	0.6	0.2	0.0	5.2	0.6	0.6	32.2	1.2	0.3	20.3	0.0	0.2	0.0	10.7	10.8	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	10.8	0.0	1.0	16.1	1.4	7.2	0.0	20.3	0.1	4.7	0.2	10.7	0.0	0.0	5.6	3.5	0.2	0.2	0.2	0.2	0.2	0.2	0.4	0.0	0.0	0.0	0.0	0.0	38.7	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.9	7.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	14.6	0.0	0.0
FCRL4	"CD307d, FCRH4, IGFP2, IRTA1"	ENSG00000163518	"Fc receptor like 4"	Q96PJ5	1	157573749-157598080	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	4	"intestine: 5.4;lymphoid tissue: 15.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	12	"memory B-cell: 1.1"	"Lineage enriched"	"Detected in single"	12	"B-cells: 1.1"	"Cell line enriched"	"Detected in single"	104	"U-266/70: 10.4"					"Not detected"	"Not detected"			HPA054030	Approved					NA	NA					"HPA054030: "	"unprognostic (6.06e-2)"	"unprognostic (3.41e-3)"	"unprognostic (2.57e-1)"	"unprognostic (5.08e-2)"		"unprognostic (4.69e-4)"		"unprognostic (2.06e-2)"			"unprognostic (6.38e-2)"			"unprognostic (1.99e-1)"	"unprognostic (2.14e-1)"	"unprognostic (3.37e-1)"	"unprognostic (6.77e-2)"	0.1	0.1	0.1	15.6	0.1	0.0	0.1	0.1	0.2	0.1	0.3	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	5.1	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.4	0.0	2.5	0.0	0.1	0.1	5.4	0.0	0.1	2.2	0.3	0.1	0.0	1.1	0.1	1.9	14.9	0.4	0.1	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCRL5	"BXMAS1, CD307e, FCRH5, IRTA2"	ENSG00000143297	"Fc receptor like 5"	Q96RD9	1	157513377-157552520	"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 13.3;lymphoid tissue: 39.1;salivary gland: 12.4"	"Group enriched"	"Detected in some"	7	"B-cells: 61.9;Early spermatids: 51.2;Melanocytes: 21.9"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	18	"memory B-cell: 11.4;naive B-cell: 13.3"	"Lineage enriched"	"Detected in single"	19	"B-cells: 13.3"	"Group enriched"	"Detected in some"	5	"U-266/70: 5.8;U-698: 12.3"														"Secreted to blood"	NA	NA	169000000	36000000				"unprognostic (1.30e-3)"	"unprognostic (3.51e-2)"	"unprognostic (7.59e-3)"	"unprognostic (1.57e-2)"	"unprognostic (9.41e-3)"	"unprognostic (4.32e-5)"	"unprognostic (2.61e-2)"	"unprognostic (6.93e-2)"	"unprognostic (7.40e-2)"	"unprognostic (7.66e-3)"	"unprognostic (4.01e-1)"	"unprognostic (1.39e-1)"	"unprognostic (9.51e-10)"	"unprognostic (1.20e-1)"	"unprognostic (4.40e-1)"	"unprognostic (8.99e-2)"	"unprognostic (2.78e-1)"	0.7	0.4	0.3	33.9	0.3	1.1	1.3	0.3	0.3	1.6	7.4	0.1	0.0	3.6	0.5	0.1	4.6	0.8	0.8	0.4	0.3	0.3	1.6	0.8	1.6	17.4	0.3	0.0	0.6	0.4	0.0	0.3	0.0	0.0	0.5	2.7	1.0	12.4	0.8	0.3	0.3	6.4	0.1	0.3	29.5	2.5	0.9	0.0	3.1	1.1	0.7	39.1	5.3	0.6	13.3	0.6	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	0.1	12.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.4	0.0	0.0	0.0	13.3	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.6	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.0	0.0	0.0	0.0	4.5	61.9	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	51.2	0.0	0.0	0.0	0.0	0.1	0.0	0.1	1.1	0.0	0.3	0.0	0.0	0.6	0.3	4.4	0.3	0.0	21.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	1.1	0.0	0.0	0.6	0.5	0.0	0.0
FGFR1	"BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM"	ENSG00000077782	"Fibroblast growth factor receptor 1"	P11362	8	38411138-38468834	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Transcription, Transcription regulation"	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Leydig cells: 177.8;Muller glia cells: 106.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 111.2;BJ hTERT+: 50.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB033614, HPA056402"	Approved					NA	NA		120000000			"CAB033614: AB_783377, HPA056402: AB_2683118"	"unprognostic (9.53e-2)"	"unprognostic (7.33e-2)"	"unprognostic (2.44e-1)"	"unprognostic (1.35e-2)"	"unprognostic (4.23e-3)"	"unprognostic (7.02e-2)"	"unprognostic (6.59e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.81e-1)"	"unprognostic (3.99e-2)"	"unprognostic (7.97e-3)"	"unprognostic (4.59e-2)"	"unprognostic (7.69e-2)"	"unprognostic (6.87e-3)"	"unprognostic (5.60e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.05e-3)"	41.1	8.6	12.5	14.5	12.2	7.2	39.5	45.0	10.5	36.0	31.5	10.1	11.6	5.5	29.3	20.6	22.9	29.4	32.4	31.7	12.8	10.1	11.8	5.4	18.6	9.7	11.4	14.3	42.0	51.2	11.5	22.3	28.4	20.0	28.2	10.8	35.8	14.0	31.6	12.0	12.9	14.4	52.4	15.6	4.5	16.4	16.4	8.5	11.3	12.6	13.0	9.8	39.6	41.2	1.6	0.7	1.8	1.1	0.8	5.7	0.7	2.4	9.4	41.1	111.2	25.5	18.2	27.1	25.3	50.7	17.6	18.4	6.1	1.4	0.3	7.0	24.2	22.6	0.0	19.4	1.2	20.4	6.6	4.3	0.0	1.6	6.0	14.4	5.9	0.1	16.5	0.1	14.3	2.9	9.5	16.9	1.4	2.3	0.1	8.3	2.9	17.4	2.0	28.9	0.3	3.9	16.0	4.3	0.0	8.5	0.0	1.6	3.6	4.5	0.2	1.0	21.5	2.3	1.1	10.6	11.5	6.4	31.8	6.0	0.4	0.8	0.0	13.6	0.3	6.0	1.4	1.1	0.4	5.7	0.3	3.9	0.7	2.7	3.7	0.1	1.6	1.5	4.1	1.8	0.8	0.5	0.7	2.2	0.7	12.5	12.2	45.0	10.5	12.8	10.1	11.4	14.3	20.0	8.5	3.0	12.0	0.0	68.4	27.9	1.3	48.2	17.8	1.4	9.1	8.7	3.9	6.5	0.0	23.4	14.2	57.3	0.0	0.0	56.3	69.1	85.6	80.3	8.1	0.9	19.7	20.6	24.0	47.3	3.2	9.3	177.8	7.5	32.1	2.8	0.0	106.2	29.8	0.0	93.7	8.0	2.4	12.9	68.0	1.4	11.3	17.2	8.7	6.4	0.4	8.4
FGFR2	"BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25"	ENSG00000066468	"Fibroblast growth factor receptor 2"	P21802	10	121478334-121598458	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Apoptosis	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 74.8"	"Cell type enhanced"	"Detected in many"	16	"Cholangiocytes: 191.1;Club cells: 52.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	15	"basophil: 10.8;eosinophil: 4.6"	"Lineage enriched"	"Detected in single"	35	"granulocytes: 10.8"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 58.9;BEWO: 19.8;CACO-2: 15.4;HaCaT: 17.8;HAP1: 19.1;NTERA-2: 18.9;T-47d: 15.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010886, HPA035305"	Uncertain		Supported	"Nucleoplasm,Vesicles,Cell Junctions"	"Secreted - unknown location"	NA	NA		500000	"Cell Junctions"	"Nucleoplasm, Vesicles"	"CAB010886: AB_259379, HPA035305: AB_10672862"	"unprognostic (5.53e-2)"	"prognostic favorable (8.79e-4)"	"unprognostic (1.08e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.73e-1)"	"prognostic favorable (9.32e-4)"	"unprognostic (1.53e-1)"	"unprognostic (4.96e-3)"	"unprognostic (1.74e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.74e-2)"	"unprognostic (1.01e-1)"	"unprognostic (6.11e-2)"	"unprognostic (2.54e-1)"	"unprognostic (6.93e-2)"	"unprognostic (2.25e-1)"	2.1	8.8	16.4	3.0	30.3	0.0	9.9	15.8	21.3	6.8	14.1	55.7	5.6	4.2	22.0	6.6	10.2	12.5	12.5	1.4	20.6	11.1	11.4	16.1	13.1	1.0	41.2	13.3	7.4	12.8	25.5	2.5	6.2	30.2	11.7	8.7	16.4	23.8	24.3	0.4	45.4	4.7	18.3	74.8	0.5	9.3	2.9	32.1	0.8	23.4	1.6	3.4	6.9	8.5	0.1	0.1	10.8	0.1	0.1	0.3	0.0	2.2	0.1	9.2	58.9	0.0	0.0	19.8	0.1	0.0	0.0	0.0	15.4	0.3	0.0	4.2	0.9	0.0	17.8	19.1	4.0	0.0	0.0	4.1	0.0	0.0	0.3	0.4	0.0	3.8	0.0	8.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	18.9	2.7	0.0	0.0	0.0	2.3	5.7	5.0	0.1	0.1	0.1	10.8	0.0	11.5	15.8	0.0	0.0	0.1	2.9	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.1	10.8	0.1	4.6	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.1	0.5	0.1	0.0	0.1	0.0	0.0	16.4	30.3	15.8	21.3	20.6	11.1	41.2	13.3	30.2	32.1	17.9	31.8	0.0	29.5	35.6	0.0	2.7	191.1	18.7	52.4	34.9	0.0	12.6	0.0	4.0	2.9	0.5	2.6	0.0	0.2	2.7	17.5	9.8	0.0	4.3	2.0	0.0	2.4	3.1	0.3	6.5	1.1	1.3	5.0	1.0	32.0	1.6	0.6	1.4	5.6	11.5	0.1	0.0	2.1	0.9	7.7	24.2	3.3	1.5	3.0	27.7
FGFR3	"ACH, CD333, CEK2, JTK4"	ENSG00000068078	"Fibroblast growth factor receptor 3"	P22607	4	1793293-1808872	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Apoptosis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"skin 1: 131.7"	"Cell type enhanced"	"Detected in many"	9	"Basal keratinocytes: 92.2;Cholangiocytes: 94.3;Suprabasal keratinocytes: 77.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"CACO-2: 19.3;HaCaT: 15.1;Hep G2: 32.5;NTERA-2: 15.8;RT4: 19.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004231, HPA067204"	Enhanced		Supported	"Endoplasmic reticulum"	"Intracellular and membrane"	NA	NA		670000	"Endoplasmic reticulum"		"CAB004231: AB_627596, HPA067204: AB_2685804"	"unprognostic (1.34e-1)"	"unprognostic (5.29e-3)"	"unprognostic (1.49e-1)"	"prognostic unfavorable (3.77e-4)"	"unprognostic (5.90e-2)"	"unprognostic (1.24e-3)"	"unprognostic (7.22e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.99e-1)"	"unprognostic (2.17e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.88e-2)"	"unprognostic (1.30e-1)"	"unprognostic (9.11e-3)"	"unprognostic (1.98e-1)"	"unprognostic (4.74e-2)"	"unprognostic (1.97e-1)"	1.5	1.5	24.7	1.7	30.3	1.6	4.2	10.2	22.0	4.1	4.9	15.8	3.4	9.9	1.8	2.7	26.9	2.0	5.0	2.0	21.6	11.7	9.6	7.4	4.5	1.3	17.6	21.5	1.1	23.0	1.2	3.0	5.6	15.1	3.7	3.8	1.7	3.8	9.0	1.7	131.7	7.4	1.3	9.0	2.1	4.9	8.1	10.6	0.1	1.3	8.5	7.3	8.5	10.1	0.1	0.6	0.1	0.1	0.2	0.3	0.0	0.0	1.5	9.2	2.6	0.0	0.1	9.4	1.1	0.1	0.4	0.2	19.3	0.4	0.0	7.7	0.3	0.4	15.1	2.6	0.1	0.1	0.1	9.7	6.0	1.5	32.5	0.0	0.0	0.2	0.0	5.1	0.1	0.0	0.0	0.0	0.9	6.5	0.0	0.0	9.6	0.4	0.2	15.8	8.8	0.0	0.5	0.5	0.1	1.3	19.3	2.7	0.7	0.8	1.6	0.0	11.1	9.0	1.1	0.4	0.0	0.9	0.2	0.6	0.0	0.0	0.0	0.1	0.7	0.5	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.2	0.0	0.6	0.1	0.0	24.7	30.3	10.2	22.0	21.6	11.7	17.6	21.5	15.1	10.6	0.0	23.8	2.4	3.6	92.2	0.0	2.0	94.3	0.0	21.6	14.0	0.0	0.4	0.0	4.8	5.4	0.9	20.6	0.0	0.6	9.2	7.0	3.3	0.0	27.0	0.5	0.0	4.1	14.7	1.2	0.4	0.6	1.2	11.8	1.0	20.7	0.2	0.4	17.3	0.4	7.5	0.6	0.0	2.8	0.4	17.9	77.5	0.7	0.0	13.0	11.8
FGFR4	"CD334, JTK2"	ENSG00000160867	"Fibroblast growth factor receptor 4"	P22455	5	177086886-177098144	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 33.6;kidney: 37.7;liver: 45.3"	"Cell type enhanced"	"Detected in many"	11	"Cholangiocytes: 50.9;Hepatocytes: 23.7;Proximal tubular cells: 19.5;Sertoli cells: 19.4;Undifferentiated cells: 33.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"neutrophil: 3.0"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"CACO-2: 43.0;Hep G2: 43.0;RH-30: 69.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB005196, HPA027273, HPA027369, HPA028251"	Approved				"Intracellular and membrane"	NA	NA		4300000			"CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221"	"unprognostic (1.96e-1)"	"unprognostic (2.10e-2)"	"unprognostic (1.12e-1)"	"unprognostic (9.06e-3)"	"unprognostic (2.87e-1)"	"unprognostic (1.95e-2)"	"unprognostic (7.85e-3)"	"unprognostic (9.19e-2)"	"unprognostic (4.25e-1)"	"unprognostic (4.46e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.48e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.71e-3)"	"unprognostic (2.41e-1)"	"unprognostic (5.75e-2)"	"unprognostic (4.68e-2)"	0.5	5.7	0.7	14.3	0.6	0.1	1.6	2.6	0.5	2.8	10.4	0.9	0.7	13.5	0.9	4.8	1.6	1.7	33.6	0.7	0.8	0.3	37.7	45.3	25.3	2.5	0.7	1.0	13.6	26.0	0.0	0.7	1.3	0.8	4.0	3.7	2.0	1.6	0.3	4.3	0.5	17.3	1.6	0.8	11.2	5.4	2.9	0.4	0.3	0.8	2.3	0.7	1.9	3.6	1.1	0.9	3.0	1.1	0.4	0.4	0.0	0.7	12.1	0.2	2.9	0.0	0.0	5.9	0.0	0.0	0.0	0.0	43.0	1.6	1.3	5.6	0.0	0.6	0.6	2.4	0.4	0.0	0.7	2.8	0.1	0.6	43.0	1.3	0.1	1.0	0.2	0.0	2.1	0.0	0.0	0.0	0.8	4.0	0.1	0.9	9.8	0.0	0.8	7.3	7.6	1.0	1.9	69.1	7.2	5.8	0.1	0.4	0.7	0.4	3.1	1.4	1.6	2.9	0.6	0.2	0.0	5.8	0.0	0.1	0.4	0.4	0.7	0.0	0.2	0.5	1.5	1.1	0.4	0.4	0.3	0.3	1.1	0.4	0.0	0.1	0.6	0.4	0.4	3.0	0.4	0.3	0.9	0.2	0.0	0.7	0.6	2.6	0.5	0.8	0.3	0.7	1.0	0.8	0.4	0.0	0.0	0.8	0.6	0.6	0.4	0.8	50.9	0.0	0.0	3.5	0.0	1.1	3.3	8.4	0.1	0.1	10.6	0.0	4.4	3.2	1.7	0.3	0.0	23.7	0.3	0.0	4.1	2.5	0.8	0.0	0.6	0.0	0.0	1.0	5.2	0.9	3.6	2.9	1.4	19.5	0.1	19.4	0.5	1.6	12.8	0.4	7.3	0.0	33.6	0.6
FLT3	"CD135, FLK2, STK1"	ENSG00000122025	"Fms related tyrosine kinase 3"	P36888	13	28003274-28100592	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Host-virus interaction"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 29.9;brain: 19.3;lymphoid tissue: 15.0"	"Cell type enhanced"	"Detected in some"	25	"Kupffer cells: 29.6;Macrophages: 12.4;monocytes: 55.9"	"Cancer enhanced"	"Detected in some"		"breast cancer: 1.8"	"Region enhanced"	"Detected in many"		"cerebellum: 19.3"	"Group enriched"	"Detected in some"	11	"myeloid DC: 29.9;plasmacytoid DC: 12.1"	"Lineage enriched"	"Detected in many"	16	"dendritic cells: 29.9"	"Group enriched"	"Detected in some"	11	"REH: 28.5;THP-1: 17.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA047539			Approved	"Endoplasmic reticulum"		NA	NA		180000	"Endoplasmic reticulum"		"HPA047539: AB_2680080"	"unprognostic (2.19e-3)"	"unprognostic (3.16e-3)"	"unprognostic (6.54e-3)"	"unprognostic (9.96e-2)"	"unprognostic (3.88e-1)"	"unprognostic (3.96e-7)"	"unprognostic (7.99e-3)"	"unprognostic (1.65e-2)"	"unprognostic (5.37e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.03e-1)"	"unprognostic (4.56e-2)"	"unprognostic (3.65e-1)"	"unprognostic (3.91e-2)"	"unprognostic (2.51e-1)"	"unprognostic (2.22e-1)"	0.9	0.6	0.6	7.2	1.1	7.5	2.6	19.3	3.5	0.9	1.2	0.1	0.1	0.4	0.8	0.8	1.0	1.2	4.6	0.5	0.9	1.7	2.8	0.7	2.7	15.0	1.8	1.1	0.5	5.7	0.0	0.4	0.0	7.4	0.6	1.4	0.1	2.3	0.6	0.4	1.2	3.0	1.3	4.4	8.8	0.9	1.2	0.0	8.2	0.6	0.0	5.8	2.4	0.7	0.1	29.9	1.4	1.8	0.8	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	2.1	0.5	0.0	0.0	28.5	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	17.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.8	1.4	0.0	0.3	0.0	0.1	0.0	0.0	29.9	0.0	0.0	0.0	0.0	0.8	0.0	12.1	0.0	1.2	0.6	1.1	19.3	3.5	0.9	1.7	1.8	1.1	7.4	0.0	0.0	0.0	0.8	0.0	0.2	0.0	0.3	2.5	0.0	0.0	0.0	0.0	0.0	0.0	2.2	3.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.5	0.0	0.0	1.3	29.6	1.6	0.0	12.4	1.7	55.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.5	0.5	0.0	0.0	0.0	0.0
FZD10	CD350	ENSG00000111432	"Frizzled class receptor 10"	Q9ULW2	12	130162459-130165740	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	"Wnt signaling pathway"	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 26.9;lymphoid tissue: 18.6"	"Cell type enhanced"	"Detected in some"	17	"Basal glandular cells: 3.9;Basal keratinocytes: 7.4;Smooth muscle cells: 14.4;Suprabasal keratinocytes: 7.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"AF22: 8.6;BEWO: 9.9;hTCEpi: 5.7;RPTEC TERT1: 3.0;RT4: 4.8"	"Region enhanced"	"Detected in some"		"thalamus: 7.6"	"Low region specificity"	"Detected in many"			"HPA014484, HPA014485"	Uncertain		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA014484: AB_1849132, HPA014485: AB_1849134"	"unprognostic (2.41e-3)"	"unprognostic (3.29e-1)"	"unprognostic (4.74e-2)"	"prognostic favorable (5.05e-7)"	"unprognostic (2.81e-2)"	"unprognostic (4.63e-2)"	"unprognostic (8.62e-3)"	"unprognostic (6.33e-2)"	"unprognostic (5.41e-2)"	"unprognostic (3.77e-2)"	"unprognostic (2.70e-1)"	"unprognostic (2.24e-3)"	"unprognostic (2.66e-9)"	"unprognostic (2.18e-1)"	"unprognostic (3.07e-1)"	"unprognostic (1.49e-2)"	"unprognostic (1.07e-1)"	1.1	0.4	1.0	0.5	1.9	0.2	1.5	5.4	2.1	11.6	0.6	2.1	1.6	0.4	5.1	3.4	26.9	2.2	7.1	0.5	1.0	1.0	0.4	0.2	2.0	0.9	1.6	1.2	3.4	1.1	0.2	1.4	9.2	1.9	3.7	0.6	3.0	5.4	3.1	1.2	10.2	0.7	0.9	1.2	0.3	1.0	0.7	2.0	0.6	1.7	9.0	18.6	5.1	7.2	0.0	0.0	0.4	0.2	0.0	0.1	0.0	0.0	0.0	8.6	0.0	0.0	0.0	9.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.7	1.5	0.7	0.0	0.0	0.3	0.0	1.1	0.0	0.0	0.1	0.0	0.0	5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.1	3.0	4.8	0.1	0.0	0.5	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	1.0	1.9	5.4	2.1	1.0	1.0	1.6	1.2	1.9	2.0	0.0	0.3	0.0	3.9	7.4	0.0	0.4	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.1	0.0	1.1	0.0	0.0	0.2	0.3	2.5	1.8	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	14.4	0.0	0.4	7.4	0.7	0.0	0.0	1.1
FZD4	"CD344, EVR1"	ENSG00000174804	"Frizzled class receptor 4"	Q9ULV1	11	86945679-86955391	"CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins"	"Wnt signaling pathway"	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 75.7"	"Cell type enhanced"	"Detected in many"	18	"Collecting duct cells: 34.9;Endothelial cells: 26.3;Ito cells: 108.6;Sertoli cells: 32.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"ASC diff: 25.9;Hep G2: 32.6;HSkMC: 18.8;HUVEC TERT2: 36.8;TIME: 18.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA042328, HPA074833"	Approved		Approved	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"HPA042328: AB_10962494, HPA074833: AB_2686716"	"unprognostic (6.49e-2)"	"unprognostic (1.49e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.03e-1)"	"unprognostic (5.87e-2)"	"unprognostic (5.51e-2)"	"unprognostic (1.82e-1)"	"unprognostic (6.97e-2)"	"unprognostic (3.33e-2)"	"unprognostic (3.79e-2)"	"unprognostic (1.36e-2)"	"unprognostic (2.22e-1)"	"prognostic favorable (8.60e-5)"	"unprognostic (1.05e-2)"	"unprognostic (9.96e-2)"	"unprognostic (9.22e-2)"	"unprognostic (1.97e-1)"	75.7	5.3	3.4	6.0	4.8	0.5	57.8	1.5	4.3	11.5	9.0	1.4	32.6	2.0	13.1	13.5	6.3	9.6	8.7	12.5	3.1	2.2	17.0	8.9	19.0	4.7	2.9	3.2	12.8	6.0	4.4	10.1	7.3	5.5	9.3	4.3	20.0	7.1	56.0	17.9	3.7	5.4	8.6	2.8	8.6	8.2	5.5	1.6	0.5	11.4	11.1	3.0	8.3	20.7	0.4	0.2	0.8	0.4	1.4	0.3	0.0	0.5	0.4	1.1	2.0	25.9	6.8	1.5	3.2	2.9	1.2	1.3	2.7	0.3	0.0	0.7	1.0	1.7	1.1	1.2	0.5	1.0	0.1	0.8	1.0	0.8	32.6	7.7	0.0	0.0	18.8	0.2	1.1	0.2	3.0	36.8	0.0	1.4	0.1	0.8	0.8	0.0	0.0	1.5	2.8	7.4	0.0	1.9	0.0	3.6	5.3	0.2	0.3	1.3	0.4	0.5	2.3	4.7	0.0	18.0	3.1	2.1	3.6	0.6	0.1	0.5	0.0	0.4	0.0	0.8	0.7	0.3	0.1	0.3	0.2	0.1	0.2	0.3	0.2	0.1	0.4	0.2	0.3	0.8	1.4	0.4	0.2	0.0	0.0	3.4	4.8	1.5	4.3	3.1	2.2	2.9	3.2	5.5	1.6	0.0	2.2	1.9	0.4	1.3	0.7	7.8	7.6	1.4	1.2	34.9	9.8	0.1	3.3	0.6	0.4	26.3	0.8	0.0	1.4	0.1	4.3	0.8	0.0	10.4	0.2	0.0	0.0	108.6	11.2	1.7	8.6	0.9	0.0	0.0	1.1	0.3	1.0	0.0	6.3	6.9	0.1	32.3	5.1	0.2	3.0	0.5	0.2	0.0	0.6	0.1
FZD9	"CD349, FZD3"	ENSG00000188763	"Frizzled class receptor 9"	O00144	7	73433783-73436120	"CD markers, G-protein coupled receptors, Predicted membrane proteins"	"Wnt signaling pathway"	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"skeletal muscle: 14.4"	"Group enriched"	"Detected in some"	5	"Early spermatids: 7.3;Late spermatids: 10.0;Muller glia cells: 4.8;Sertoli cells: 6.5"	"Cancer enhanced"	"Detected in many"		"melanoma: 6.8"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEK 293: 8.4;MCF7: 3.6;NTERA-2: 6.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (9.60e-2)"	"unprognostic (4.03e-2)"	"unprognostic (3.16e-2)"	"unprognostic (9.15e-3)"	"unprognostic (1.10e-1)"	"unprognostic (6.91e-2)"	"unprognostic (2.29e-2)"	"unprognostic (2.26e-1)"	"unprognostic (2.04e-1)"	"unprognostic (7.17e-3)"	"unprognostic (1.20e-1)"	"unprognostic (7.24e-2)"	"unprognostic (5.90e-5)"	"unprognostic (8.99e-2)"	"unprognostic (4.57e-2)"	"unprognostic (1.22e-1)"	"unprognostic (5.21e-2)"	4.4	1.2	6.8	0.7	4.7	2.4	1.1	3.3	7.0	1.1	1.3	4.5	0.0	1.9	0.9	0.9	1.3	0.9	0.7	0.8	7.1	6.3	0.9	0.8	0.9	0.9	7.0	4.5	0.9	3.8	1.6	4.3	1.9	5.0	3.0	0.8	1.4	4.4	1.4	14.4	1.7	2.9	0.9	3.6	1.0	1.0	5.4	6.7	0.3	0.9	1.7	0.8	0.7	0.3	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.6	2.7	2.8	3.1	0.0	0.1	0.0	1.9	0.0	0.4	0.1	0.7	0.0	0.0	0.9	0.1	1.2	0.2	1.4	0.0	0.0	0.0	8.4	0.0	0.6	0.9	1.2	0.0	0.3	0.3	0.0	0.1	0.0	0.1	0.2	0.0	2.8	0.0	0.2	3.6	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	2.7	2.4	1.7	1.8	0.4	1.7	0.9	0.1	0.0	0.7	0.0	0.0	0.4	0.0	0.0	0.0	0.6	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.0	6.8	4.7	3.3	7.0	7.1	6.3	7.0	4.5	5.0	6.7	0.0	0.0	0.0	0.7	0.6	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	7.3	0.6	0.0	0.0	0.3	0.2	0.3	1.4	0.0	0.0	0.8	0.0	0.0	0.0	0.0	10.0	0.0	0.0	0.0	1.0	0.0	4.8	0.2	0.0	0.4	0.0	0.7	6.5	0.5	0.4	0.3	1.0	0.0	0.0	0.0	0.3
GGT1	"CD224, D22S672, D22S732, GGT"	ENSG00000100031	"Gamma-glutamyltransferase 1"	P19440	22	24583750-24629005	"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Glutathione biosynthesis"	"Acyltransferase, Hydrolase, Protease, Transferase"	"Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 54.1;seminal vesicle: 41.7"	"Group enriched"	"Detected in many"	6	"Alveolar cells type 1: 74.5;Alveolar cells type 2: 21.4;Cholangiocytes: 40.8;Ductal cells: 54.8;Enterocytes: 80.7;Hepatocytes: 34.1;Pancreatic endocrine cells: 33.5;Paneth cells: 23.0;Proximal tubular cells: 32.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 35.6;Karpas-707: 52.5;OE19: 37.9;RPMI-8226: 51.6;RPTEC TERT1: 48.0"									"HPA045635, HPA047534, HPA065444"	Supported		Uncertain	Vesicles	"Intracellular and membrane"	NA	NA		4600000	Vesicles		"HPA045635: AB_2679400, HPA047534: AB_2680079, HPA065444: AB_2685491"	"unprognostic (8.13e-3)"	"unprognostic (4.76e-1)"	"unprognostic (8.29e-2)"	"unprognostic (1.28e-2)"	"unprognostic (3.70e-2)"	"unprognostic (1.43e-2)"	"unprognostic (5.60e-3)"	"unprognostic (1.68e-1)"	"unprognostic (2.21e-1)"	"prognostic favorable (7.44e-4)"	"unprognostic (4.55e-2)"	"unprognostic (2.55e-2)"	"prognostic favorable (4.83e-4)"	"unprognostic (1.44e-2)"	"unprognostic (5.37e-2)"	"unprognostic (1.74e-1)"	"unprognostic (6.10e-2)"	1.6	0.5	1.7	1.7	2.2	2.7	8.2	2.3	2.6	7.3	7.9	1.6	23.7	22.3	1.4	19.9	1.2	0.8	12.2	2.0	1.8	1.2	54.1	29.2	14.3	3.2	1.7	1.6	1.3	17.3	0.0	1.6	1.4	2.2	14.7	2.4	1.4	8.7	41.7	0.9	1.1	20.9	1.7	1.9	4.7	6.6	5.0	2.1	2.4	4.8	1.6	5.5	2.1	1.1	3.3	7.5	15.9	14.6	6.6	8.6	6.6	0.2	19.3	0.2	0.0	0.0	0.1	0.5	0.1	0.6	0.2	0.2	2.6	4.2	0.2	4.3	0.0	3.8	2.8	1.4	0.2	0.1	35.6	2.9	0.1	8.6	14.0	1.5	0.3	11.9	0.4	0.2	0.6	0.4	0.3	0.1	5.3	2.0	52.5	0.2	0.4	0.3	14.6	1.4	37.9	0.2	0.2	2.2	51.6	48.0	0.6	0.2	0.3	0.1	9.3	0.2	5.5	9.3	11.1	2.2	3.5	2.3	10.8	0.3	15.8	5.9	0.2	7.4	15.0	0.1	5.2	14.6	0.4	1.4	6.8	5.2	3.3	7.7	3.4	7.5	0.3	1.0	1.9	15.9	6.6	5.5	0.1	8.6	6.6	1.7	2.2	2.3	2.6	1.8	1.2	1.7	1.6	2.2	2.1	74.5	21.4	3.4	0.1	0.7	0.4	0.4	40.8	2.7	7.9	1.8	0.0	0.9	1.7	54.8	1.1	0.1	80.7	0.0	7.2	0.3	1.3	3.0	5.7	34.1	4.7	0.0	1.2	2.5	3.0	4.1	0.0	2.9	1.7	5.4	2.5	2.0	33.5	23.0	0.4	32.7	0.0	0.0	0.2	0.6	0.7	0.4	0.7	3.2	4.2	0.0
GP1BA	"CD42b, GP1B, GPIbalpha"	ENSG00000185245	"Glycoprotein Ib platelet alpha subunit"	P07359	17	4932297-4935030	"CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	"Blood coagulation, Cell adhesion, Hemostasis"		"Bernard Soulier syndrome, Disease mutation, von Willebrand disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 37.8"	"Cell type enhanced"	"Detected in some"	6	"Distal tubular cells: 3.3;Ito cells: 3.7;Rod photoreceptor cells: 3.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in some"	7	"basophil: 7.5"	"Lineage enriched"	"Detected in single"	25	"granulocytes: 7.5"	"Cell line enriched"	"Detected in some"	24	"HEL: 40.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB002496, HPA013316"	Supported					NA	NA		2000000000			"CAB002496: AB_563748, HPA013316: AB_1855459"	"unprognostic (4.87e-4)"	"unprognostic (8.21e-2)"	"unprognostic (2.81e-2)"	"unprognostic (6.11e-3)"	"unprognostic (1.50e-2)"	"unprognostic (1.59e-3)"	"unprognostic (7.30e-3)"	"unprognostic (5.58e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.64e-1)"	"unprognostic (6.54e-4)"	"unprognostic (1.27e-1)"	"unprognostic (4.85e-3)"	"unprognostic (4.58e-3)"	"unprognostic (2.56e-1)"	"unprognostic (3.53e-4)"	"unprognostic (8.35e-2)"	0.7	0.1	0.4	15.8	1.2	5.3	0.7	1.9	0.7	0.7	1.0	0.2	0.2	1.5	0.6	0.7	5.7	0.8	0.3	4.2	0.5	0.4	1.0	1.6	3.5	37.8	0.4	0.2	0.7	0.4	0.0	0.4	1.1	0.4	0.7	0.6	0.3	7.7	0.2	3.0	4.6	3.7	0.2	0.4	13.0	0.9	0.6	0.2	2.0	0.8	0.8	17.6	0.9	1.1	0.0	0.3	7.5	0.2	0.0	0.2	3.6	0.0	1.3	0.3	0.2	0.0	0.0	0.6	0.2	0.0	0.0	0.0	1.2	0.1	1.2	0.4	0.0	0.0	1.3	0.0	0.0	0.0	0.4	1.0	40.2	0.5	0.0	0.0	0.2	1.5	0.0	0.0	0.0	0.0	0.4	0.0	0.7	0.4	0.4	0.0	0.4	0.3	0.2	0.1	0.1	0.2	0.7	0.3	0.2	0.0	0.7	0.0	0.2	0.5	0.0	0.2	0.4	1.7	0.7	0.2	0.2	0.2	0.9	0.1	0.7	0.2	1.0	0.6	0.6	0.4	7.5	0.1	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.2	0.0	0.1	0.1	1.0	0.0	0.1	0.3	0.0	3.6	0.4	1.2	1.9	0.4	0.5	0.4	0.4	0.2	0.4	0.2	0.0	0.0	0.0	0.4	1.3	1.9	0.8	0.0	0.0	0.0	0.0	2.0	0.3	3.3	0.1	0.2	0.1	0.0	0.0	0.0	0.2	0.6	0.3	0.0	0.8	0.1	0.0	0.0	3.7	1.9	0.2	0.3	1.1	0.0	1.0	0.0	0.4	0.0	0.0	1.8	0.6	3.1	0.0	0.3	0.9	0.6	1.6	0.2	0.5	0.0	0.3
GP1BB	"CD42c, GPIbbeta"	ENSG00000203618	"Glycoprotein Ib platelet beta subunit"	P13224	22	19722945-19724771	"CD markers, Disease related genes, Predicted membrane proteins"	"Blood coagulation, Cell adhesion, Hemostasis"		"Bernard Soulier syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 61.7;brain: 19.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Group enriched"	"Detected in some"	5	"basophil: 6.3;neutrophil: 11.0"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 11.0"	"Cell line enhanced"	"Detected in some"		"HEK 293: 5.8;K-562: 10.3;NB-4: 8.6;REH: 10.5;SH-SY5Y: 5.0;U-2 OS: 10.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"									NA	NA		110000000																					0.9	0.5	16.7	1.2	19.6	0.5	0.5	7.3	9.0	0.5	1.7			1.2	0.7	0.5	1.8	0.5	0.7	2.9	15.0	4.1	0.5	0.9	0.6	0.6	2.7		0.5	0.5	0.5	2.5	0.6		1.3	0.7		1.9	0.5	1.2	10.4	0.5	1.0	0.2	1.8	1.9	0.5			0.7		0.7	0.5	0.2	0.1	1.7	11.0	1.2	0.1	0.3	61.7	0.0	0.9	0.0	0.0	0.0	0.0	0.1	1.6	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.5	0.0	0.0	0.0	1.7	5.8	2.3	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	10.3	0.1	0.1	0.4	0.4	8.6	0.4	0.0	3.2	10.5	0.0	0.1	0.0	0.0	3.8	5.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.4	0.1	0.0	0.7	0.0	0.0	0.0	0.2	0.0	6.3	1.2	1.1	0.2	0.3	0.1	0.0	0.1	0.0	0.4	0.1	0.1	0.1	11.0	0.1	0.0	1.7	0.3	61.7											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GP5	CD42d	ENSG00000178732	"Glycoprotein V platelet"	P40197	3	194394821-194398354	"CD markers, Plasma proteins, Predicted membrane proteins"	"Blood coagulation, Cell adhesion, Hemostasis"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 3.7"	"Not detected"	"Not detected"			"Cancer enriched"	"Detected in single"	5	"testis cancer: 0.5"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive CD4 T-cell: 2.0;naive CD8 T-cell: 2.2"	"Group enriched"	"Detected in many"	6	"dendritic cells: 1.1;T-cells: 2.2"	"Cell line enriched"	"Detected in some"	9	"HEL: 19.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			HPA072646			Approved	Cytosol		NA	NA		400000000	Cytosol		"HPA072646: "	"unprognostic (3.74e-2)"	"unprognostic (3.40e-1)"	"unprognostic (5.22e-2)"	"unprognostic (2.96e-2)"	"unprognostic (1.74e-2)"	"unprognostic (1.35e-3)"	"unprognostic (1.69e-3)"	"unprognostic (1.68e-1)"	"unprognostic (3.41e-1)"	"unprognostic (2.80e-2)"	"unprognostic (1.65e-1)"	"unprognostic (5.51e-2)"	"unprognostic (1.21e-2)"	"unprognostic (4.18e-2)"	"unprognostic (3.14e-1)"	"unprognostic (1.72e-2)"	"unprognostic (1.94e-1)"	0.3	0.0	0.4	2.1	0.5	1.6	0.3	0.3	0.3	0.6	0.3	0.3	0.3	0.0	0.3	0.3	0.3	2.5	0.3	0.3	0.4	0.6	0.3	0.6	0.9	3.7	0.3	0.3	0.8	0.3	0.0	0.4	0.3	0.3	0.3	0.1	0.3	0.3	0.3	0.3	0.1	0.9	0.3	0.3	1.7	0.2	0.3	0.3	0.3	1.0	0.3	1.9	0.3	0.5	0.1	1.1	0.2	0.0	0.0	2.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.3	0.0	0.5	0.4	0.1	0.1	2.0	2.2	0.1	0.0	0.0	1.1	0.0	0.4	0.4	0.5	0.3	0.3	0.4	0.6	0.3	0.3	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GP9	"CD42a, GPIX"	ENSG00000169704	"Glycoprotein IX platelet"	P14770	3	129060767-129062406	"CD markers, Disease related genes, Predicted membrane proteins"	"Blood coagulation, Cell adhesion, Hemostasis"		"Bernard Soulier syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"blood: 27.1;bone marrow: 10.0;lymphoid tissue: 24.5"	"Group enriched"	"Detected in some"	11	"Early spermatids: 14.0;Late spermatids: 13.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"basophil: 8.8;neutrophil: 7.5"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 8.8"	"Cell line enriched"	"Detected in some"	14	"HEL: 43.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA063182	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA		68000000	"Plasma membrane, Cytosol"	Nucleoplasm	"HPA063182: AB_2684956"			"unprognostic (1.70e-1)"	"unprognostic (3.97e-1)"	"unprognostic (1.10e-1)"			"unprognostic (3.80e-2)"		"unprognostic (2.50e-2)"		"unprognostic (3.24e-1)"	"unprognostic (2.53e-2)"	"unprognostic (8.47e-2)"		"unprognostic (8.70e-2)"		0.2	0.1	0.1	0.1	0.1	10.0	0.1	0.0	0.6	0.4	0.5	0.0	0.0	0.1	0.1	0.0	0.1	0.3	0.1	5.0	0.8	0.1	0.1	0.4	4.8	0.0	0.8	0.2	0.5	0.1	0.0	0.3	1.5	0.4	0.1	0.4	0.2	0.0	0.6	0.2	0.0	0.1	0.0	0.1	24.5	0.3	2.2	0.0	0.0	0.6	0.6	0.0	0.6	3.0	0.1	1.5	8.8	0.6	0.0	0.2	27.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	43.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.8	0.6	0.1	0.1	0.3	0.1	0.0	0.0	0.2	0.3	0.1	0.0	0.0	7.5	0.0	0.0	1.5	0.0	27.1	0.1	0.1	0.0	0.6	0.8	0.1	0.8	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.3	13.3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0
GYPA	"CD235a, GPA, MN, MNS"	ENSG00000170180	"Glycophorin A (MNS blood group)"	P02724	4	144109303-144140786	"Blood group antigen proteins, CD markers, Predicted membrane proteins"	"Host-virus interaction"	"Blood group antigen, Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	9	"bone marrow: 56.9"	"Cell type enriched"	"Detected in some"	311	"Erythroid cells: 1331.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"naive B-cell: 1.5"	"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	4	"HEL: 57.0"									"CAB002658, HPA014811"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Nucleoplasm, Plasma membrane, Cytosol"		"CAB002658: , HPA014811: AB_1849827"					"unprognostic (1.60e-1)"								"unprognostic (2.47e-2)"					0.1	0.0	0.2	0.1	0.4	56.9	0.1	0.1	0.5	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.3	1.7	1.3	3.2	0.1	0.3	0.1	0.1	0.1	0.0	0.3	4.8	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	6.2	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	1.5	0.3	0.4	0.2	0.2	0.6	0.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	57.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.0	0.4	0.0	0.2	0.9	0.1	0.2	0.2	1.5	0.2	0.6	0.2	0.2	0.2	0.3	0.0	0.8	0.2	0.4	0.1	0.5	0.2	0.3	0.3	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.3	1.7	0.0	0.3	0.0	0.0	1331.6	0.0	1.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0
GYPB	"CD235b, GPB, MNS, SS"	ENSG00000250361	"Glycophorin B (MNS blood group)"	P06028	4	143996104-144019345	"Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins"		"Blood group antigen"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	5	"bone marrow: 37.1"	"Cell type enriched"	"Detected in some"	591	"Erythroid cells: 981.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	4	"HEL: 61.4"														"Intracellular and membrane"	NA	NA																							0.2	0.0	0.2	0.1	0.1	37.1	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.6	0.8	0.6	0.1	0.1	0.1	0.1	0.1	0.0	0.2	3.3	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	6.8	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.4	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	61.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	3.2	0.2	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	981.2	0.0	0.4	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0
GYPC	"CD236, CD236R, Ge, GPC, GYPD"	ENSG00000136732	"Glycophorin C (Gerbich blood group)"	P04921	2	126655933-126696670	"Blood group antigen proteins, CD markers, Predicted membrane proteins"		"Blood group antigen"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	18	"Erythroid cells: 1448.3;Hofbauer cells: 391.9"	"Cancer enhanced"	"Detected in all"		"melanoma: 66.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HHSteC: 62.6;K-562: 46.5;SK-MEL-30: 91.9;U-266/70: 51.9"	"Low region specificity"	"Detected in all"							"HPA008965, CAB009445"	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB009445: AB_2116251, HPA008965: AB_1078455"	"unprognostic (1.63e-2)"	"unprognostic (7.14e-3)"	"unprognostic (8.39e-2)"	"unprognostic (3.31e-3)"	"unprognostic (4.19e-2)"	"unprognostic (1.69e-2)"	"unprognostic (8.82e-2)"	"unprognostic (3.52e-1)"	"unprognostic (1.19e-1)"	"unprognostic (2.21e-1)"	"unprognostic (1.25e-1)"	"unprognostic (1.11e-1)"	"unprognostic (2.05e-2)"	"unprognostic (2.73e-2)"	"unprognostic (1.51e-1)"	"unprognostic (2.29e-1)"	"unprognostic (8.00e-3)"	44.5	21.7	3.9	34.5	5.3	95.0	99.8	1.3	4.3	20.7	24.8	5.9	9.8	5.0	20.3	26.0	22.9	18.5	21.4	61.2	4.4	3.4	15.2	6.3	29.5	75.8	8.0	3.7	37.4	18.7	1.7	5.5	17.5	5.6	24.5	5.5	13.8	13.0	15.5	48.9	11.3	15.2	34.8	8.3	41.1	13.5	13.4	4.6	28.5	11.6	29.9	22.5	37.1	38.8	21.2	9.9	4.2	7.7	14.7	41.4	21.8	0.1	0.0	22.5	0.0	16.7	14.6	0.0	3.3	26.0	4.0	12.1	0.0	0.0	0.0	0.0	9.4	15.6	0.0	12.2	0.0	1.3	10.7	0.0	37.8	0.0	0.0	62.6	13.2	0.1	32.9	0.0	3.2	0.0	0.3	0.1	26.2	46.5	31.3	9.8	0.0	0.0	20.9	6.7	0.0	0.0	2.4	1.6	0.0	1.6	0.0	0.0	0.0	0.0	0.0	91.9	3.0	0.0	35.9	9.0	15.4	0.1	1.0	0.1	51.9	33.6	0.0	7.5	19.1	13.9	0.1	5.9	0.4	32.3	7.7	36.4	18.9	29.3	39.1	9.9	21.2	41.4	40.4	4.2	14.7	4.7	5.5	35.1	21.8	3.9	5.3	1.3	4.3	4.4	3.4	8.0	3.7	5.6	4.6	6.0	11.4	163.5	2.9	33.8	0.7	31.5	68.8	2.7	5.7	14.0	2.0	4.8	114.4	182.3	1.2	74.4	0.0	1448.3	4.2	6.4	148.3	3.8	23.0	3.4	391.9	0.0	0.0	252.3	99.7	1.5	80.8	80.7	290.1	117.2	0.0	4.9	8.0	0.0	65.0	3.9	2.3	58.2	117.4	0.3	0.8	23.2	7.6	235.7	0.0	0.9
HMMR	"CD168, RHAMM"	ENSG00000072571	"Hyaluronan mediated motility receptor"	O75330	5	163460203-163491945	"CD markers, FDA approved drug targets, Predicted intracellular proteins"			"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 54.5;testis: 16.7"	"Cell type enhanced"	"Detected in many"	21	"Early spermatids: 60.3;Erythroid cells: 256.9;Extravillous trophoblasts: 50.4;Spermatocytes: 80.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"T-reg: 4.8"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB002433, HPA040025, HPA043926, HPA061524"	Enhanced		Enhanced	Microtubules,Centrosome,Cytosol		Yes	Yes			Microtubules	"Centrosome, Cytosol"	"CAB002433: AB_564080, HPA040025: AB_2676805, HPA043926: , HPA061524: AB_2684551"	"unprognostic (3.53e-3)"	"unprognostic (1.01e-1)"	"unprognostic (3.38e-3)"	"unprognostic (8.88e-3)"	"unprognostic (2.12e-1)"	"prognostic unfavorable (5.52e-4)"	"prognostic unfavorable (1.93e-7)"	"prognostic unfavorable (1.09e-4)"	"unprognostic (5.68e-2)"	"unprognostic (2.50e-1)"	"prognostic unfavorable (3.71e-5)"	"unprognostic (1.02e-1)"	"unprognostic (0.00e+0)"	"unprognostic (1.65e-2)"	"unprognostic (4.98e-2)"	"unprognostic (2.39e-1)"	"unprognostic (1.77e-2)"	1.6	1.4	0.6	13.4	0.6	11.4	2.4	0.4	0.9	1.7	5.0	0.6	0.6	4.5	0.6	2.3	6.4	0.5	0.9	1.6	0.8	0.7	1.4	1.8	2.5	10.9	1.0	0.4	0.6	1.1	0.6	0.5	6.9	1.1	0.7	5.6	0.4	1.6	0.2	1.4	2.3	4.8	1.4	1.9	8.6	2.6	16.7	0.3	54.5	0.7	5.6	10.8	1.8	2.1	1.2	1.8	0.6	0.7	1.5	4.8	0.8	21.1	13.3	27.2	14.5	1.4	2.7	20.3	20.1	9.8	25.2	22.9	27.0	40.9	35.2	19.2	6.2	34.4	24.5	31.4	19.1	43.1	31.9	9.7	21.0	9.5	13.2	0.4	18.6	19.4	0.7	1.1	23.7	18.6	4.2	14.3	24.2	19.9	28.8	26.2	7.7	19.6	10.6	23.4	14.2	14.6	21.4	36.4	17.6	9.8	5.7	22.7	12.6	29.9	9.4	11.4	13.5	27.7	15.0	9.3	18.1	15.4	14.5	26.9	15.5	25.9	28.4	12.0	28.9	17.4	0.5	0.7	0.0	0.5	0.3	0.9	1.2	1.0	0.6	0.9	0.9	0.4	0.7	0.6	1.5	0.0	1.8	4.8	0.8	0.6	0.6	0.4	0.9	0.8	0.7	1.0	0.4	1.1	0.3	0.0	0.6	15.5	0.8	2.3	0.6	1.7	7.6	4.0	4.5	0.0	0.0	5.1	0.0	0.6	60.3	0.1	1.3	256.9	0.2	50.4	2.4	0.8	0.0	1.7	17.7	0.0	1.2	3.1	3.5	44.1	2.0	4.3	0.0	3.6	1.6	0.0	0.1	0.0	0.7	2.4	0.7	6.5	0.0	80.6	18.5	1.3	3.8	1.0	4.2	0.9
ICAM1	"BB2, CD54"	ENSG00000090339	"Intercellular adhesion molecule 1"	P05362	19	10270835-10286615	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 68.3;lung: 91.3"	"Cell type enhanced"	"Detected in many"	9	"Alveolar cells type 1: 568.7;Alveolar cells type 2: 522.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HHSteC: 31.6;Karpas-707: 90.1;RPMI-8226: 28.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA002126, CAB002142, HPA004877"	Enhanced		Approved	"Plasma membrane,Cytosol"		NA	NA	87900000	3100000000	"Plasma membrane, Cytosol"		"CAB002142: AB_563596, HPA002126: AB_1078470, HPA004877: AB_1846317"	"prognostic favorable (7.09e-4)"	"unprognostic (1.88e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.63e-2)"	"unprognostic (3.25e-3)"	"unprognostic (3.05e-1)"	"unprognostic (1.45e-2)"	"unprognostic (3.48e-1)"	"unprognostic (3.18e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.49e-2)"	"unprognostic (1.79e-1)"	"prognostic unfavorable (1.32e-6)"	"unprognostic (2.77e-1)"	"unprognostic (2.16e-2)"	"unprognostic (2.25e-1)"	"unprognostic (3.70e-3)"	26.1	8.6	4.0	41.0	4.1	36.5	15.0	1.0	4.5	5.6	10.0	2.7	1.6	6.1	8.5	7.7	7.9	10.7	19.8	16.3	2.6	2.1	10.9	68.3	91.3	32.8	5.4	1.7	12.4	7.2	2.5	4.0	9.3	6.8	10.4	6.6	10.6	7.2	3.6	13.9	6.9	7.9	8.0	7.8	42.2	7.3	6.5	3.6	8.3	11.6	13.7	13.4	14.8	17.1	2.2	13.3	22.2	14.2	7.9	5.6	8.9	8.4	0.1	1.5	0.0	0.4	0.9	2.1	1.7	18.8	4.2	12.7	2.8	9.5	7.7	26.2	0.7	19.3	1.7	0.3	0.0	8.9	23.1	0.0	0.7	0.2	11.5	31.6	0.2	4.5	11.1	0.7	2.6	4.1	0.4	2.1	0.9	2.9	90.1	0.3	0.6	0.1	6.5	0.5	0.1	4.8	0.2	0.0	28.6	7.2	0.0	0.0	0.2	11.6	0.6	18.4	0.7	1.4	0.5	6.5	4.3	0.4	2.4	0.1	27.5	28.3	4.8	7.0	4.9	6.3	2.2	13.9	2.6	3.0	14.2	5.6	2.2	2.4	3.6	13.3	0.9	1.0	2.2	22.2	7.9	7.9	7.5	3.4	8.9	4.0	4.1	1.0	4.5	2.6	2.1	5.4	1.7	6.8	3.6	568.7	522.3	12.0	22.9	75.8	0.0	0.8	20.4	80.3	159.3	3.5	0.0	1.0	0.0	152.6	1.9	139.3	0.5	0.0	84.4	2.5	171.6	19.1	133.1	12.9	75.0	0.0	2.4	56.4	41.3	1.1	4.4	160.6	72.6	168.7	0.3	2.3	107.4	0.0	1.4	9.4	0.3	6.5	95.4	0.5	1.7	60.6	1.0	12.7	0.5	10.0
ICAM2	CD102	ENSG00000108622	"Intercellular adhesion molecule 2"	P13598	17	64002594-64020634	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 74.5;lymphoid tissue: 63.9"	"Cell type enhanced"	"Detected in many"	13	"B-cells: 46.1;Endothelial cells: 80.1;Ito cells: 147.3;Kupffer cells: 54.5;T-cells: 52.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"HUVEC TERT2: 167.1;TIME: 42.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA071155			Approved	"Plasma membrane,Cytosol"		NA	NA		1200000000	"Plasma membrane"	Cytosol	"HPA071155: "	"unprognostic (9.43e-3)"	"unprognostic (3.31e-2)"	"unprognostic (5.15e-2)"	"unprognostic (1.15e-1)"	"unprognostic (8.97e-2)"	"unprognostic (1.64e-3)"	"unprognostic (1.34e-1)"	"unprognostic (3.74e-1)"	"unprognostic (8.28e-2)"	"unprognostic (2.15e-1)"	"unprognostic (4.18e-2)"	"unprognostic (1.55e-2)"	"unprognostic (9.07e-2)"	"unprognostic (1.48e-1)"	"unprognostic (3.93e-2)"	"unprognostic (6.04e-2)"	"unprognostic (2.29e-1)"	36.0	3.6	8.4	13.0	11.5	8.3	34.1	3.5	7.7	9.4	9.7	5.6	2.8	6.4	9.8	5.2	9.5	7.4	8.8	22.8	9.5	8.9	10.5	8.7	27.9	24.0	12.3	3.1	6.3	7.4	3.1	4.5	36.8	9.1	7.9	8.5	8.1	8.8	4.3	17.1	5.5	10.8	13.9	10.5	63.9	8.0	4.0	7.4	14.3	11.6	9.0	18.0	12.8	23.6	49.0	30.9	56.5	74.5	26.0	65.3	67.5	0.0	0.0	0.0	0.0	1.4	1.5	0.4	0.1	0.1	0.0	0.1	0.3	6.9	11.7	2.1	0.0	0.0	0.0	0.1	0.0	0.2	2.6	0.0	10.5	0.6	1.2	0.2	1.7	0.0	0.0	0.0	0.1	0.0	0.0	167.1	9.9	8.6	6.9	0.0	0.0	13.1	1.5	0.0	0.0	0.0	7.9	0.0	16.3	0.8	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	42.2	0.0	0.1	0.8	0.0	6.6	2.2	10.5	0.0	2.2	0.0	56.5	30.0	8.9	45.8	66.5	52.8	36.5	60.1	42.8	30.9	49.0	65.3	40.7	3.6	26.0	74.5	10.0	64.5	67.5	8.4	11.5	3.5	7.7	9.5	8.9	12.3	3.1	9.1	7.4	0.0	12.5	46.1	3.4	6.5	0.0	0.3	0.0	6.7	6.8	7.0	0.0	0.4	0.0	0.8	0.5	80.1	0.3	0.0	1.2	0.3	6.9	1.6	11.5	1.0	18.7	0.0	1.2	147.3	54.5	0.0	0.3	23.4	27.0	6.4	1.4	0.4	5.1	5.8	1.8	0.5	0.3	6.5	4.4	0.2	0.2	4.6	0.8	52.4	1.7	2.6
ICAM3	"CD50, CDW50, ICAM-R"	ENSG00000076662	"Intercellular adhesion molecule 3"	P32942	19	10333776-10339823	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Phagocytosis"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 172.3;bone marrow: 51.5;lymphoid tissue: 68.5"	"Cell type enhanced"	"Detected in many"	7	"B-cells: 138.5;Hepatocytes: 150.6;Kupffer cells: 110.3;T-cells: 189.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in all"		"neutrophil: 172.3"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 172.3"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 65.6;NB-4: 42.3;RPMI-8226: 49.2;U-266/84: 34.9;U-937: 34.5"									"CAB002498, HPA049820"	Enhanced		Approved	"Nucleoplasm,Nuclear membrane,Mitochondria"		NA	NA		370000000	Mitochondria	"Nucleoplasm, Nuclear membrane"	"CAB002498: AB_563593, HPA049820: AB_2680897"	"unprognostic (6.85e-4)"	"unprognostic (5.28e-3)"	"unprognostic (3.09e-3)"	"unprognostic (1.57e-2)"	"unprognostic (5.34e-3)"	"unprognostic (5.79e-6)"	"unprognostic (5.05e-3)"	"unprognostic (3.73e-2)"	"unprognostic (1.73e-3)"	"unprognostic (7.93e-2)"	"unprognostic (3.45e-2)"	"unprognostic (2.54e-1)"	"unprognostic (5.62e-4)"	"unprognostic (1.13e-1)"	"unprognostic (1.06e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.84e-1)"	6.8	2.8	1.7	23.5	1.9	51.5	5.5	0.6	1.5	3.0	6.8	1.1	1.2	4.3	1.7	3.0	4.0	2.9	7.2	6.4	1.1	0.9	5.1	28.7	13.2	68.5	1.8	1.4	1.7	6.8	0.2	0.4	4.8	1.5	2.8	3.3	2.4	10.3	1.3	5.0	1.6	11.9	1.8	1.0	39.4	5.4	1.4	1.0	47.6	3.0	5.7	38.4	4.5	4.9	25.5	28.4	172.3	33.5	31.0	41.0	43.1	2.7	1.3	1.0	3.0	1.6	1.3	1.7	1.7	1.1	1.4	1.2	1.1	1.8	0.0	5.8	1.5	0.0	1.1	0.0	1.2	0.4	20.3	0.8	5.2	1.2	5.1	0.8	18.7	21.1	1.1	1.0	1.6	0.6	1.5	0.6	10.9	2.8	65.6	1.6	5.5	2.4	42.3	0.7	6.9	9.2	1.5	0.6	49.2	1.4	2.4	0.3	1.3	1.4	4.6	3.7	0.5	4.0	5.3	1.1	6.5	0.5	7.1	1.6	3.2	34.9	7.8	4.6	34.5	5.0	15.3	33.1	72.0	33.8	24.4	41.0	25.5	32.7	31.2	28.4	23.9	29.3	27.4	172.3	31.0	33.5	4.8	36.9	43.1	1.7	1.9	0.6	1.5	1.1	0.9	1.8	1.4	1.5	1.0	3.0	43.3	138.5	7.1	7.2	0.1	0.0	25.5	9.4	4.5	5.2	0.0	10.4	53.0	13.7	4.2	18.0	53.5	0.0	30.7	20.6	13.1	14.3	30.0	150.6	21.1	1.6	5.2	26.4	110.3	7.2	5.8	19.9	52.3	12.6	29.1	1.5	17.7	45.3	3.9	54.2	1.2	0.0	13.3	0.5	0.9	7.3	3.9	189.2	31.2	8.4
ICAM4	"CD242, LW"	ENSG00000105371	"Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)"	Q14773	19	10286967-10288522	"Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Blood group antigen"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 53.1;bone marrow: 13.7;lung: 13.5"	"Cell type enhanced"	"Detected in many"	14	"Alveolar cells type 1: 62.5;Alveolar cells type 2: 75.3;Club cells: 34.2"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"cerebral cortex: 2.0;pons and medulla: 2.4"	"Cell type enriched"	"Detected in many"	5	"non-classical monocyte: 53.1"	"Lineage enriched"	"Detected in many"	6	"monocytes: 53.1"	"Cell line enhanced"	"Detected in some"		"HEL: 36.1;HMC-1: 9.1;K-562: 18.6;NB-4: 15.5;U-937: 8.7"														"Intracellular and membrane"	NA	NA																							1.9	0.4	0.4	1.6	0.4	13.7	0.6	0.2	2.0	1.0	2.9	0.2	0.0	1.1	1.1	2.9	2.3	1.1	1.1	1.1	0.5	0.3	1.6	1.7	13.5	3.3	0.4	0.0	1.2	0.4	0.1	0.4	1.9	2.4	2.4	0.5	0.9	2.5	2.7	1.7	0.8	1.4	0.2	0.9	2.8	1.6	0.6	0.3	1.5	0.9	0.0	4.5	3.3	0.7	0.5	8.4	4.5	53.1	0.1	0.6	2.4	0.1	0.1	0.1	0.2	0.0	0.0	3.1	0.3	0.1	0.0	0.0	4.0	0.2	0.4	0.4	0.0	0.2	0.3	0.1	0.0	0.0	0.3	0.2	36.1	0.2	5.4	1.0	0.6	9.1	0.2	0.0	0.1	0.1	0.0	0.0	5.8	18.6	1.6	0.0	0.1	1.0	15.5	0.1	0.0	0.1	2.6	1.5	6.8	0.1	0.1	0.0	0.1	0.3	0.1	0.1	0.4	0.1	1.0	0.3	0.1	0.0	0.3	0.0	0.5	1.0	0.1	0.3	8.7	0.2	4.5	2.6	2.6	0.2	9.7	0.5	0.5	0.3	0.2	8.4	0.4	0.3	0.1	0.7	0.1	53.1	2.7	0.6	2.4	0.4	0.4	0.2	2.0	0.5	0.3	0.4	0.0	2.4	0.3	62.5	75.3	0.8	0.9	0.9	0.0	0.0	0.0	4.0	34.2	0.0	0.0	0.3	0.0	0.5	0.0	6.7	0.0	0.0	1.8	0.7	11.2	1.4	20.9	0.0	5.2	0.0	0.0	1.8	3.5	0.0	0.0	8.1	5.0	19.8	0.0	0.3	1.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.1	1.1	0.7	0.0	0.0	1.6
ICOS	"AILIM, CD278"	ENSG00000163600	"Inducible T cell costimulator"	Q9Y6W8	2	203936748-203961577	"CD markers, Disease related genes, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 18.4;bone marrow: 13.8;lymphoid tissue: 51.8"	"Cell type enriched"	"Detected in some"	4	"T-cells: 23.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"T-reg: 18.4"	"Lineage enriched"	"Detected in single"	58	"T-cells: 18.4"	"Group enriched"	"Detected in some"	7	"HEL: 6.0;MOLT-4: 15.7"	"Low region specificity"	"Detected in single"							"CAB032575, HPA034865"	Approved		Approved	"Plasma membrane,Actin filaments"	"Intracellular and membrane"	NA	NA			"Plasma membrane"	"Actin filaments"	"CAB032575: AB_2122593, HPA034865: "	"unprognostic (2.66e-2)"	"unprognostic (2.13e-3)"	"unprognostic (4.19e-4)"	"unprognostic (2.35e-5)"	"unprognostic (1.07e-1)"	"prognostic favorable (1.80e-4)"	"unprognostic (9.38e-2)"	"unprognostic (2.89e-2)"	"unprognostic (1.49e-2)"	"unprognostic (3.51e-4)"	"unprognostic (7.50e-2)"	"unprognostic (2.12e-1)"	"unprognostic (2.86e-5)"	"unprognostic (7.05e-2)"	"unprognostic (2.48e-2)"	"unprognostic (1.93e-1)"	"unprognostic (8.82e-3)"	1.5	0.3	0.2	15.6	0.2	13.8	0.7	0.2	0.2	0.8	1.2	0.0	0.2	0.5	1.2	0.5	1.1	1.2	1.6	0.5	0.2	0.2	1.0	0.8	4.0	19.4	0.3	0.0	0.6	0.3	0.0	0.4	0.1	0.1	0.7	1.1	0.7	2.9	0.0	0.2	0.6	6.2	0.3	0.4	6.1	1.0	0.6	0.0	51.8	1.4	2.4	28.9	3.0	0.9	0.0	0.0	0.0	0.0	0.3	18.4	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	15.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	2.9	0.0	10.5	4.6	0.0	0.0	11.0	5.0	0.0	0.3	0.0	0.0	18.4	3.0	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.0	0.1	0.0	0.0	2.2	0.0	0.0	2.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	5.8	0.0	0.1	0.0	0.0	0.6	0.3	0.0	0.0	0.6	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2	1.6	0.1	23.5	0.0	0.0
ICOSLG	"B7-H2, B7H2, B7RP-1, B7RP1, CD275, GL50, ICOS-L, ICOSL, KIAA0653"	ENSG00000160223	"Inducible T cell costimulator ligand"	O75144	21	44217014-44240966	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, B-cell activation, Immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 14.1"	"Cell type enhanced"	"Detected in many"	9	"B-cells: 17.5;monocytes: 34.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"naive B-cell: 6.5"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"Daudi: 14.1"									"CAB026037, HPA029179"	Uncertain		Approved	"Plasma membrane,Cytoplasmic bodies"		NA	NA		150000000	"Plasma membrane, Cytoplasmic bodies"		"CAB026037: , HPA029179: AB_2732445"	"unprognostic (3.03e-2)"	"unprognostic (1.40e-4)"	"unprognostic (3.52e-2)"	"unprognostic (1.94e-2)"	"unprognostic (6.74e-2)"	"unprognostic (9.40e-2)"	"unprognostic (6.94e-2)"	"unprognostic (3.71e-1)"	"unprognostic (1.40e-1)"	"unprognostic (3.76e-2)"	"unprognostic (1.40e-1)"	"unprognostic (2.42e-1)"	"unprognostic (3.00e-2)"	"unprognostic (3.11e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.84e-1)"	2.3	3.0	5.3	3.9	7.1	14.1	2.3	2.3	5.9	2.9	2.3	2.3	2.3	1.8	2.3	2.3	4.0	2.7	3.5	3.7	8.8	3.7	5.3	2.7	2.3	6.5	6.5	2.3	2.3	2.3	0.0	2.3	2.3	2.3	2.3	1.2	2.3	2.3	2.3	2.3	5.5	2.9	2.3	8.4	3.2	4.2	2.3	2.3	2.3	2.3	2.3	4.5	2.4	2.6	6.5	1.6	1.0	0.8	0.5	1.1	0.4	0.3	3.3	0.1	2.8	0.8	1.1	7.7	0.7	0.7	0.4	0.2	5.6	0.4	14.1	2.1	0.3	1.3	4.3	2.0	1.3	0.2	1.4	1.4	0.4	2.7	1.6	0.7	6.1	10.4	1.1	1.9	0.9	0.9	0.2	0.8	0.5	2.3	1.3	0.2	3.7	0.3	8.0	2.0	9.5	3.5	12.0	0.9	8.2	0.6	7.5	1.4	0.0	9.4	13.3	0.3	1.1	3.9	8.7	0.8	0.4	3.3	0.3	0.2	12.1	8.3	11.8	4.4	5.7	1.9	0.6	0.8	0.4	0.3	0.8	0.3	3.7	0.8	0.5	0.5	6.5	0.8	1.1	1.0	0.5	0.5	1.6	0.4	0.4	5.3	7.1	2.3	2.3	8.8	3.7	6.5	2.3	2.3	2.3	0.0	1.0	17.5	5.3	6.6	0.4	0.3	0.0	0.0	1.2	8.7	0.0	0.3	0.0	1.3	0.7	3.1	4.2	0.0	0.6	0.9	4.8	11.7	0.0	1.9	3.4	0.0	5.1	1.3	6.7	2.7	2.8	10.5	8.5	34.3	4.4	1.3	0.7	1.4	10.3	3.6	0.8	0.0	8.1	0.0	0.2	5.6	0.5	0.0	3.9	5.9
IFITM1	"9-27, CD225, IFI17"	ENSG00000185885	"Interferon induced transmembrane protein 1"	P13164	11	313506-315272	"CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Antiviral defense, Immunity, Innate immunity, Osteogenesis"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Club cells: 187.7;Leydig cells: 278.5;Sertoli cells: 271.7;T-cells: 358.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	6	"eosinophil: 56.6;gdT-cell: 120.0;MAIT T-cell: 80.7;memory CD4 T-cell: 128.1;memory CD8 T-cell: 121.4;naive CD4 T-cell: 123.5;naive CD8 T-cell: 123.4;neutrophil: 106.8;NK-cell: 164.4;T-reg: 70.4"	"Group enriched"	"Detected in all"	7	"granulocytes: 106.8;NK-cells: 164.4;T-cells: 128.1"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+ SV40 Large T+: 122.7;BJ hTERT+ SV40 Large T+ RasG12V: 219.9;HMC-1: 67.9"									"HPA004810, CAB017615"	Enhanced		Uncertain	"Golgi apparatus,Cytosol"		NA	NA			"Golgi apparatus"	Cytosol	"CAB017615: AB_2264496, HPA004810: AB_1851419"	"unprognostic (1.03e-3)"	"unprognostic (6.79e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.98e-1)"	"unprognostic (2.57e-1)"	"unprognostic (9.06e-2)"	"unprognostic (7.58e-2)"	"unprognostic (3.03e-1)"	"unprognostic (6.21e-2)"	"unprognostic (5.53e-2)"	"unprognostic (6.64e-3)"	"unprognostic (1.48e-2)"	"prognostic unfavorable (5.77e-9)"	"unprognostic (7.29e-2)"	"unprognostic (6.29e-2)"	"unprognostic (3.15e-2)"	"unprognostic (3.82e-2)"	81.1	14.2	17.4	36.7	24.5	41.2	57.0	11.9	23.1	71.0	28.2	12.9	20.6	17.2	48.3	152.4	44.4	67.2	31.2	62.6	19.8	13.9	59.8	34.5	44.1	159.7	34.8	14.7	100.2	16.3	22.3	23.3	36.3	27.3	38.7	22.1	49.5	27.4	41.6	38.7	23.6	33.0	46.0	37.9	112.9	20.5	29.4	20.1	42.7	48.3	28.0	50.3	39.3	52.8	13.0	4.3	106.8	18.6	164.4	128.1	147.7	6.4	0.1	53.3	4.3	3.9	13.7	0.3	11.3	53.0	122.7	219.9	0.1	44.5	0.1	8.5	11.9	1.2	15.1	1.7	1.1	2.4	13.5	2.8	6.5	4.1	0.4	35.3	9.5	67.9	25.6	0.0	1.3	0.1	1.3	0.2	2.1	23.2	53.9	0.0	0.9	4.7	18.3	15.2	0.0	1.6	1.2	0.1	1.2	32.8	0.0	0.0	0.0	5.9	0.6	10.9	7.6	2.2	0.8	0.3	0.1	0.1	0.0	0.0	3.8	2.0	0.3	0.1	14.3	0.1	15.6	2.3	56.6	120.0	10.9	80.7	13.0	128.1	121.4	4.3	11.3	123.5	123.4	106.8	164.4	18.6	1.2	70.4	147.7	17.4	24.5	11.9	23.1	19.8	13.9	34.8	14.7	27.3	20.1	32.8	96.7	12.5	9.5	24.7	0.0	4.8	0.0	36.1	187.7	31.4	0.0	1.2	5.0	0.9	1.2	146.9	12.4	0.0	1.2	25.0	131.5	1.8	17.4	17.9	9.3	0.0	1.2	130.1	11.0	0.0	278.5	21.9	74.2	0.0	14.4	0.0	0.9	10.1	117.0	0.3	0.0	271.7	95.7	0.3	1.0	12.5	3.3	358.0	24.3	4.4
IFNGR1	"CD119, IFNGR"	ENSG00000027697	"Interferon gamma receptor 1"	P15260	6	137197484-137219449	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Kupffer cells: 258.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"hTCEpi: 57.1"					"Low region specificity"	"Detected in all"			"CAB025889, HPA029213, HPA063871"	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB025889: , HPA029213: AB_10601023, HPA063871: AB_2685138"	"unprognostic (1.73e-1)"	"unprognostic (8.86e-2)"	"unprognostic (9.85e-3)"	"unprognostic (1.71e-1)"	"unprognostic (6.55e-2)"	"unprognostic (1.25e-1)"	"unprognostic (4.05e-1)"	"unprognostic (6.97e-2)"	"unprognostic (9.86e-2)"	"unprognostic (1.57e-2)"	"unprognostic (4.09e-2)"	"unprognostic (2.85e-1)"	"prognostic unfavorable (5.48e-4)"	"unprognostic (1.58e-1)"	"unprognostic (2.87e-2)"	"unprognostic (1.81e-2)"	"unprognostic (5.38e-3)"	69.5	22.2	17.4	36.9	23.5	37.7	65.3	8.4	18.5	23.6	27.1	27.8	13.8	28.0	19.2	21.2	23.0	20.3	25.9	53.7	20.6	17.4	19.3	66.4	58.7	86.9	33.8	13.2	19.2	17.5	9.2	12.8	47.0	29.9	20.1	22.8	11.6	24.5	18.0	25.3	24.0	46.7	22.5	45.7	69.1	20.3	14.1	26.3	14.5	22.8	19.7	38.2	25.0	22.3	12.2	39.4	92.3	65.4	5.4	29.7	52.3	4.8	4.7	6.2	8.0	40.8	21.5	5.2	13.9	20.7	9.1	12.3	30.5	9.5	4.8	22.3	8.0	13.2	30.3	5.4	14.1	12.7	10.4	7.5	7.6	5.8	45.1	23.1	23.7	11.4	47.5	57.1	7.6	12.3	8.4	11.4	7.0	6.4	8.3	6.8	5.5	3.8	10.9	5.1	44.4	3.8	11.7	6.5	7.3	15.8	23.0	6.2	9.6	17.2	10.1	12.6	12.3	3.6	15.7	15.8	8.9	6.5	11.5	7.3	6.1	5.7	5.4	4.6	15.8	8.6	16.5	65.4	43.3	14.1	63.0	29.7	10.9	8.0	11.8	39.4	12.2	5.2	5.8	92.3	5.4	44.1	10.1	5.6	52.3	17.4	23.5	8.4	18.5	20.6	17.4	33.8	13.2	29.9	26.3	74.5	64.2	57.6	146.1	113.3	14.2	38.0	33.1	83.0	77.3	26.2	11.8	63.2	6.6	61.6	3.2	106.4	70.3	0.0	88.3	59.0	70.9	89.3	61.2	50.3	132.8	9.5	12.6	63.8	258.9	4.3	40.9	249.4	47.2	88.4	19.2	19.7	74.0	28.1	46.3	15.1	20.6	12.9	65.2	8.4	20.4	99.0	175.5	67.8	27.9	144.7
IGF1R	"CD221, IGFIR, IGFR, JTK13, MGC18216"	ENSG00000140443	"Insulin like growth factor 1 receptor"	P08069	15	98648971-98964530	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 7.7"	"Group enriched"	"Detected in many"	5	"granulocytes: 7.7;T-cells: 2.9"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"CAB010268, HPA045563"	Approved					NA	NA		36000			"CAB010268: AB_671792, HPA045563: AB_2679368"	"unprognostic (1.30e-3)"	"unprognostic (5.81e-3)"	"unprognostic (1.53e-1)"	"unprognostic (3.34e-2)"	"unprognostic (2.65e-1)"	"unprognostic (2.05e-2)"	"unprognostic (1.29e-2)"	"unprognostic (6.87e-2)"	"unprognostic (2.64e-2)"	"unprognostic (2.87e-2)"	"unprognostic (8.56e-2)"	"unprognostic (1.62e-1)"	"prognostic favorable (3.75e-7)"	"unprognostic (1.57e-1)"	"unprognostic (3.59e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.06e-1)"	8.4	12.7	11.5	5.9	13.5	16.3	18.5	23.0	15.7	15.3	13.4	10.4	22.7	4.2	15.3	16.3	9.2	18.9	7.7	11.6	11.7	7.3	17.0	2.0	11.0	4.9	8.0	11.8	23.2	22.5	4.7	13.8	17.5	9.5	21.7	7.2	16.7	12.5	23.2	9.1	13.0	7.5	18.1	8.0	7.3	10.7	12.0	11.5	10.7	16.1	7.0	5.6	12.8	21.6	1.0	0.4	7.7	0.6	1.0	2.9	0.7	3.2	16.3	11.4	0.2	5.7	4.2	7.6	3.6	7.3	1.2	1.0	7.0	8.6	0.8	10.6	7.1	8.0	15.5	5.1	14.8	1.0	0.0	5.1	12.3	18.2	14.0	5.0	6.5	1.3	6.5	7.0	2.1	10.0	4.3	4.0	1.3	0.6	2.9	5.6	23.0	2.5	4.4	10.6	5.4	0.9	4.0	8.9	2.9	3.4	20.0	3.8	17.1	26.2	1.5	14.1	25.7	8.0	3.0	11.1	1.1	14.7	2.9	5.7	1.0	4.4	2.7	2.2	4.8	2.7	4.0	0.6	1.8	0.9	0.6	0.6	0.4	0.8	0.3	0.4	1.0	2.9	1.0	7.7	1.0	0.5	0.3	0.0	0.7	11.5	13.5	23.0	15.7	11.7	7.3	8.0	11.8	9.5	11.5	26.8	11.2	0.0	25.0	29.1	51.6	25.7	10.2	38.8	31.8	21.0	86.4	26.8	1.7	13.8	23.0	23.2	5.1	0.0	9.4	16.8	24.2	51.2	0.0	0.4	5.8	71.5	33.7	38.1	7.0	38.8	16.7	5.0	20.3	2.8	21.9	47.2	25.3	10.5	12.7	18.6	32.3	0.0	17.6	3.3	13.6	28.0	23.0	3.2	20.4	39.1
IGF2R	"CD222, CI-M6PR, CI-MPR, CIMPR, M6P-R, MPR1, MPR300, MPRI"	ENSG00000197081	"Insulin like growth factor 2 receptor"	P11717	6	159969099-160113507	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 13.3"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009661, HPA011332"	Supported		Enhanced	"Golgi apparatus,Vesicles"		NA	NA		150000000	"Golgi apparatus, Vesicles"		"CAB009661: AB_2122795, HPA011332: AB_1846276"	"prognostic unfavorable (3.01e-4)"	"prognostic unfavorable (2.92e-5)"	"unprognostic (5.83e-2)"	"unprognostic (1.72e-1)"	"unprognostic (4.15e-1)"	"unprognostic (3.25e-1)"	"unprognostic (7.32e-3)"	"unprognostic (2.32e-1)"	"unprognostic (1.62e-1)"	"unprognostic (1.07e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.45e-1)"	"unprognostic (5.74e-3)"	"unprognostic (1.16e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.85e-1)"	"prognostic unfavorable (6.08e-4)"	28.0	22.2	6.8	13.5	8.1	16.7	39.4	6.4	8.2	14.9	17.3	9.5	13.0	9.4	19.6	16.0	16.7	13.1	17.9	27.9	6.7	6.2	20.6	26.6	32.6	44.7	12.3	3.6	18.0	19.6	23.5	13.6	15.5	10.0	14.1	13.3	13.9	18.2	13.5	62.0	15.9	15.4	16.5	7.6	30.2	14.4	13.8	9.0	37.9	18.5	17.3	14.1	16.3	26.9	0.4	2.9	13.3	2.0	1.0	3.6	0.9	7.7	7.0	12.4	17.4	45.2	25.0	16.8	12.2	26.3	10.1	17.4	10.6	12.2	3.2	13.7	13.4	40.7	10.4	9.3	59.5	17.0	16.8	6.6	1.4	12.2	19.1	26.7	7.4	12.1	19.8	19.1	21.0	60.6	24.4	6.5	13.9	13.8	17.4	15.8	5.7	3.4	7.4	5.5	7.1	7.5	8.0	8.5	16.3	14.2	7.8	4.1	9.1	16.5	14.8	16.5	17.8	6.2	21.0	9.8	9.8	10.3	21.0	22.3	10.3	14.4	3.3	18.9	10.1	15.1	0.1	2.0	1.1	3.6	0.8	1.4	0.3	1.2	1.7	0.3	0.4	1.0	2.4	13.3	1.0	1.4	2.9	0.7	0.9	6.8	8.1	6.4	8.2	6.7	6.2	12.3	3.6	10.0	9.0	44.7	38.9	12.8	8.9	19.7	14.1	33.2	33.1	6.7	19.4	15.7	19.6	6.2	0.0	29.2	5.3	22.4	21.3	0.0	16.6	11.0	16.7	15.0	3.5	54.4	22.3	14.3	21.5	30.7	48.2	3.6	44.0	26.4	11.8	8.2	20.6	13.6	37.4	14.4	36.0	21.7	13.9	64.7	17.0	6.5	9.6	17.2	7.8	21.8	20.1	15.6
IGLL1	"14.1, CD179B, IGL5, IGLL, IGVPB"	ENSG00000128322	"Immunoglobulin lambda like polypeptide 1"	P15814	22	23573125-23580308	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	35	"blood: 11.6;bone marrow: 37.7;lymphoid tissue: 29.4;testis: 20.8"	"Group enriched"	"Detected in some"	10	"Early spermatids: 60.5;Late spermatids: 104.2;Melanocytes: 113.1"	"Cancer enhanced"	"Detected in some"		"stomach cancer: 2.1"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"memory B-cell: 11.6;naive B-cell: 9.8"	"Lineage enriched"	"Detected in many"	8	"B-cells: 11.6"	"Cell line enriched"	"Detected in some"	34	"REH: 129.9"									"HPA051134, HPA071406"	Enhanced		Approved	"Endoplasmic reticulum"	"Secreted to blood"	NA	NA		100000000000	"Endoplasmic reticulum"		"HPA051134: AB_2681356, HPA071406: AB_2686393"	"unprognostic (6.21e-2)"	"unprognostic (5.12e-2)"	"unprognostic (7.31e-2)"	"unprognostic (4.75e-2)"	"unprognostic (1.56e-1)"	"unprognostic (5.91e-6)"		"unprognostic (1.08e-1)"	"unprognostic (5.27e-2)"	"unprognostic (6.17e-3)"	"unprognostic (5.89e-2)"	"unprognostic (9.07e-2)"	"unprognostic (1.99e-4)"	"unprognostic (2.35e-2)"	"unprognostic (5.16e-1)"	"unprognostic (2.28e-2)"	"unprognostic (1.21e-2)"	0.0	0.0	0.1	0.1	0.2	37.7	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.2	0.6	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	20.8	0.0	29.4	0.0	0.0	1.1	0.0	0.0	11.6	1.3	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.2	0.4	0.0	0.0	0.0	129.9	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.6	0.0	0.0	0.0	9.8	0.0	0.0	0.0	0.0	0.0	1.3	0.0	1.5	0.1	0.2	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	60.5	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.0	0.0	0.2	0.0	0.0	0.6	0.0	104.2	1.1	0.0	113.1	0.0	0.0	0.0	0.0	0.0	0.4	4.4	0.0	0.0	0.0	9.7	0.5	0.3	0.0	0.0	0.0	0.1
IGSF8	"CD316, CD81P3, EWI2, PGRL"	ENSG00000162729	"Immunoglobulin superfamily member 8"	Q969P0	1	160091340-160098943	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 54.2"	"Cell type enhanced"	"Detected in many"	7	"Extravillous trophoblasts: 187.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-MEL-30: 58.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011917, HPA075970"	Approved		Supported	Vesicles		NA	NA		190000	Vesicles		"HPA011917: AB_1851536, HPA075970: "	"unprognostic (4.08e-1)"	"prognostic unfavorable (7.32e-4)"	"unprognostic (1.30e-2)"	"unprognostic (9.31e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.20e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.01e-3)"	"unprognostic (1.63e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.63e-1)"	"unprognostic (2.31e-1)"	"unprognostic (2.60e-2)"	"unprognostic (2.35e-1)"	"unprognostic (3.74e-3)"	"unprognostic (1.75e-3)"	9.9	10.4	25.2	9.0	30.3	2.4	11.1	40.9	54.2	9.6	11.8	53.5	6.4	18.2	8.6	16.6	7.0	13.9	8.5	11.6	32.4	24.1	10.4	19.3	10.1	10.3	32.2	29.9	15.1	19.1	9.0	8.7	7.8	25.9	13.8	7.4	11.2	21.0	14.0	6.0	34.0	14.4	5.1	42.6	10.6	9.8	11.5	25.3	6.2	10.0	5.9	6.2	6.0	6.9	14.3	5.6	1.2	4.0	4.7	15.6	6.4	8.9	5.4	7.0	17.9	4.1	2.6	14.8	4.4	5.8	9.5	8.9	6.1	6.2	13.2	16.6	6.4	8.2	17.3	2.8	6.5	1.3	15.7	5.1	1.7	6.0	10.4	6.9	4.5	14.7	3.2	13.2	6.1	2.0	6.7	1.9	14.6	2.3	7.6	2.2	8.5	11.2	10.5	14.8	18.8	8.6	6.4	3.6	9.5	8.6	9.3	2.9	12.8	5.0	16.5	58.9	6.4	11.7	5.8	1.9	4.2	9.1	7.5	3.5	21.0	23.2	5.9	14.8	1.8	10.9	0.0	2.9	1.2	13.3	4.0	11.7	12.2	11.0	15.4	3.3	14.3	14.8	15.6	0.8	4.7	2.4	5.6	14.9	6.4	25.2	30.3	40.9	54.2	32.4	24.1	32.2	29.9	25.9	25.3	8.9	3.5	22.5	26.4	38.8	54.6	3.2	12.7	0.0	1.2	36.6	9.8	28.1	5.0	30.1	3.1	7.9	34.9	0.0	10.8	187.6	24.7	18.9	10.3	26.8	13.7	62.0	19.1	9.8	3.2	0.5	15.5	8.0	40.5	85.6	23.2	90.2	17.8	37.4	14.9	13.3	11.7	6.5	16.3	1.7	5.8	54.5	58.0	14.4	27.4	24.0
IL10RA	"CD210, CD210a, CDW210A, HIL-10R, IL10R"	ENSG00000110324	"Interleukin 10 receptor subunit alpha"	Q13651	11	117986348-118003037	"CD markers, Disease related genes, Predicted membrane proteins"		Receptor	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 56.2"	"Cell type enhanced"	"Detected in many"	11	"Extravillous trophoblasts: 88.9;Kupffer cells: 162.4;Macrophages: 88.5;monocytes: 146.1;T-cells: 102.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 14.9;HDLM-2: 37.1;Karpas-707: 13.9;RPMI-8226: 16.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA065647, HPA069086"			Supported	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	Cytosol	"HPA065647: , HPA069086: "	"unprognostic (1.01e-2)"	"unprognostic (2.07e-3)"	"unprognostic (1.58e-2)"	"unprognostic (7.08e-2)"	"unprognostic (8.27e-2)"	"prognostic favorable (4.47e-4)"	"unprognostic (5.27e-2)"	"unprognostic (4.84e-2)"	"unprognostic (7.70e-3)"	"unprognostic (5.94e-2)"	"unprognostic (2.14e-2)"	"unprognostic (3.83e-1)"	"prognostic unfavorable (1.45e-5)"	"unprognostic (1.82e-1)"	"unprognostic (8.43e-3)"	"unprognostic (2.19e-1)"	"unprognostic (1.27e-1)"	11.3	6.5	2.9	29.6	3.5	27.2	7.2	1.1	3.0	3.4	7.9	4.7	0.5	3.8	5.5	11.0	4.3	4.9	9.7	7.6	3.0	3.6	5.0	6.4	13.6	49.8	4.7	1.4	3.4	3.6	1.3	3.4	6.9	4.5	5.8	7.5	6.4	7.9	1.9	2.6	3.0	17.6	5.0	8.0	56.2	4.9	3.1	3.5	9.6	3.6	3.9	32.2	9.5	3.4	4.6	15.4	1.2	23.9	23.7	30.7	22.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.9	0.1	0.0	0.3	0.0	0.2	0.0	0.0	37.1	0.0	0.1	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	2.7	13.9	0.0	0.0	0.2	2.9	0.0	0.0	0.0	0.0	0.0	16.9	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	1.0	0.0	0.0	0.0	0.0	0.0	2.9	0.4	3.9	0.0	5.6	0.0	1.1	15.8	0.8	19.7	23.9	14.2	4.6	19.0	22.7	15.4	2.3	6.9	12.3	1.2	23.7	18.8	6.0	30.7	22.8	2.9	3.5	1.1	3.0	3.0	3.6	4.7	1.4	4.5	3.5	6.0	26.0	27.4	0.5	5.0	0.0	2.0	0.0	2.7	2.3	0.0	0.0	1.2	0.0	0.1	0.0	1.2	0.0	0.0	0.7	88.9	2.8	0.0	11.6	0.5	54.1	0.0	0.0	4.3	162.4	0.0	0.3	88.5	16.9	146.1	0.0	0.5	0.1	0.0	0.0	0.6	0.0	0.0	1.0	0.1	0.2	3.6	2.7	102.0	0.0	0.4
IL10RB	"CDW210B, CRF2-4, CRFB4, D21S58, D21S66, IL-10R2"	ENSG00000243646	"Interleukin 10 receptor subunit beta"	Q08334	21	33266358-33310187	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Antiviral defense"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Cytotrophoblasts: 170.3;Syncytiotrophoblasts: 264.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"CAB020670, HPA047550"	Approved		Approved	Cytosol		NA	NA		1300000	Cytosol		"CAB020670: , HPA047550: AB_2680086"	"unprognostic (8.43e-2)"	"unprognostic (6.50e-2)"	"unprognostic (5.88e-2)"	"unprognostic (1.77e-1)"	"unprognostic (1.48e-2)"	"unprognostic (7.78e-2)"	"unprognostic (1.97e-3)"	"unprognostic (1.26e-1)"	"unprognostic (5.69e-3)"	"unprognostic (1.31e-1)"	"unprognostic (1.19e-1)"	"unprognostic (6.93e-2)"	"prognostic unfavorable (5.62e-9)"	"unprognostic (3.09e-1)"	"unprognostic (2.76e-1)"	"unprognostic (1.29e-2)"	"unprognostic (1.05e-1)"	17.6	11.0	5.4	19.6	7.3	8.9	21.5	3.6	4.4	15.2	29.2	10.3	10.6	19.6	17.5	9.6	22.7	13.2	14.8	12.3	5.6	5.4	11.6	27.5	19.3	36.1	6.6	3.1	18.2	23.2	5.5	9.7	47.4	9.3	17.7	20.8	11.7	26.0	9.7	12.4	13.8	53.6	12.2	8.0	31.7	17.6	8.4	7.3	34.0	14.3	15.3	26.2	15.1	22.6	13.8	19.4	57.9	34.7	14.0	19.5	20.4	10.3	8.0	1.5	6.4	32.4	23.8	11.4	7.9	22.5	8.8	12.6	7.5	12.8	2.9	9.1	13.8	17.9	12.9	4.3	5.4	5.8	9.6	5.9	8.0	6.0	5.7	22.6	10.2	19.5	23.9	10.2	15.3	9.0	13.8	11.6	8.6	7.2	24.2	12.1	10.7	6.8	9.9	1.1	21.0	4.3	6.4	3.6	12.2	7.9	6.1	2.1	2.9	16.3	12.1	13.8	3.6	8.0	38.7	10.5	8.8	8.6	14.9	4.3	12.8	14.3	1.7	15.5	14.7	5.6	22.3	30.1	24.8	8.8	34.4	9.6	13.6	11.1	10.6	17.8	13.8	10.5	10.4	57.9	14.0	34.7	19.4	19.5	20.4	5.4	7.3	3.6	4.4	5.6	5.4	6.6	3.1	9.3	7.3	32.8	21.5	27.9	30.6	12.9	6.2	10.4	22.9	5.3	6.8	3.5	13.7	170.3	0.0	16.0	0.7	24.6	75.7	46.7	26.6	126.8	31.9	37.4	35.7	19.5	105.9	7.9	9.8	35.6	102.1	0.7	29.4	27.9	13.5	55.1	53.6	5.6	21.9	73.7	22.3	0.8	5.5	19.4	14.2	2.2	4.7	12.8	264.0	21.8	41.1	53.1
IL12RB1	"CD212, IL12RB"	ENSG00000096996	"Interleukin 12 receptor subunit beta 1"	P42701	19	18058995-18098944	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 28.6;lymphoid tissue: 21.4"	"Cell type enhanced"	"Detected in some"	20	"B-cells: 9.0;Kupffer cells: 10.0;T-cells: 35.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 10.7;HDLM-2: 18.0;Karpas-707: 30.8;U-698: 9.0"					"Low region specificity"	"Detected in all"			HPA074414			Approved	"Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"		"HPA074414: AB_2686687"	"unprognostic (7.70e-3)"	"prognostic favorable (3.41e-4)"	"unprognostic (9.08e-3)"	"unprognostic (1.18e-4)"	"unprognostic (2.91e-1)"	"unprognostic (1.33e-3)"	"unprognostic (2.27e-1)"	"unprognostic (8.99e-2)"	"unprognostic (1.65e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.94e-1)"	"prognostic unfavorable (5.90e-5)"	"unprognostic (1.49e-1)"	"unprognostic (2.21e-2)"	"unprognostic (4.34e-2)"	"unprognostic (2.93e-2)"	1.9	1.5	1.3	17.5	2.1	5.6	1.2	0.5	1.0	0.9	3.4	2.4	1.1	2.9	1.0	2.4	1.3	1.5	2.5	1.4	1.3	1.2	1.8	1.8	5.0	16.0	2.0	0.2	1.1	1.3	1.2	1.1	2.4	1.4	1.7	2.0	1.1	6.6	0.2	0.9	1.0	8.0	1.0	2.4	21.4	2.3	0.7	2.2	10.1	1.3	0.7	16.9	3.8	1.0	4.9	5.9	6.2	14.0	16.2	28.6	9.0	0.2	0.1	0.1	0.2	0.0	0.1	0.5	0.1	0.1	0.2	0.6	0.2	1.0	10.7	0.1	0.1	0.3	0.2	0.1	0.0	0.0	18.0	0.2	1.2	0.3	0.2	0.4	0.7	1.7	0.0	0.0	0.3	0.1	0.1	0.0	2.4	0.2	30.8	0.0	0.1	5.1	0.2	0.1	0.0	0.1	3.6	0.1	0.5	0.0	0.0	0.3	0.1	0.2	0.2	0.2	0.1	0.2	5.8	0.2	0.3	0.3	0.1	0.1	3.7	5.5	9.0	0.4	6.2	0.7	3.3	5.1	3.6	22.8	14.0	28.6	4.9	15.5	18.3	5.9	3.7	8.7	15.2	6.2	16.2	13.2	3.5	20.5	9.0	1.3	2.1	0.5	1.0	1.3	1.2	2.0	0.2	1.4	2.2	0.0	4.8	9.0	0.6	0.2	0.0	0.8	2.5	0.0	1.2	0.0	0.0	0.1	0.0	0.0	0.4	0.3	0.0	0.0	0.0	0.4	0.4	0.4	4.6	0.0	5.9	0.0	0.0	0.6	10.0	0.0	0.0	5.8	0.0	6.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.1	0.6	0.1	35.2	0.0	1.0
IL13RA1	"CD213a1, IL-13Ra, NR4"	ENSG00000131724	"Interleukin 13 receptor subunit alpha 1"	P78552	X	118727572-118794539	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"monocytes: 235.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"classical monocyte: 6.9;eosinophil: 7.1;myeloid DC: 10.9;neutrophil: 19.0"	"Group enriched"	"Detected in many"	6	"dendritic cells: 10.9;granulocytes: 19.0;monocytes: 6.9"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 45.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001587			Approved	Nucleoplasm,Vesicles	"Intracellular and membrane"	NA	NA		4500000	Vesicles	Nucleoplasm	"HPA001587: AB_1079133"	"unprognostic (5.14e-3)"	"unprognostic (4.72e-2)"	"unprognostic (7.12e-2)"	"unprognostic (7.75e-2)"	"unprognostic (8.81e-3)"	"unprognostic (3.82e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.44e-1)"	"unprognostic (1.90e-1)"	"unprognostic (8.21e-2)"	"prognostic unfavorable (1.19e-8)"	"unprognostic (1.88e-2)"	"unprognostic (2.37e-2)"	"unprognostic (2.82e-2)"	"unprognostic (5.08e-2)"	31.5	17.5	9.3	15.3	13.3	2.1	19.8	3.6	10.2	16.6	23.8	12.6	7.2	18.9	16.6	18.0	33.0	15.4	17.7	17.5	11.4	9.4	22.7	73.3	27.7	33.9	15.2	6.0	25.2	12.9	9.5	16.1	15.2	13.4	15.3	25.2	14.5	21.8	13.0	22.3	10.2	37.7	16.3	24.5	17.4	18.5	9.9	11.9	4.8	24.0	20.1	20.0	16.5	15.4	1.9	10.9	19.0	6.9	0.0	0.1	1.7	8.2	10.3	4.9	13.5	11.2	33.2	8.9	17.4	24.2	8.3	10.8	6.0	15.4	0.0	30.6	23.9	24.1	7.9	5.3	7.4	9.2	45.2	4.1	1.4	9.3	15.1	6.8	0.1	3.6	30.1	6.7	11.3	14.0	25.1	17.3	0.0	4.4	0.9	11.7	12.1	0.0	2.2	4.5	15.8	9.9	0.0	12.1	0.0	12.4	9.1	1.8	1.7	27.3	10.0	6.8	6.7	6.4	7.9	22.0	16.2	7.7	27.3	13.6	0.2	4.1	0.0	35.8	4.3	6.8	0.0	6.9	7.1	0.0	1.7	0.0	1.9	0.0	0.0	10.9	1.8	0.0	0.0	19.0	0.0	0.6	1.9	0.1	1.7	9.3	13.3	3.6	10.2	11.4	9.4	15.2	6.0	13.4	11.9	65.5	43.2	10.0	29.8	15.2	2.0	9.2	53.5	40.2	51.2	27.9	15.7	7.4	8.3	30.4	30.3	46.6	51.4	0.0	85.9	27.9	14.8	39.1	0.0	133.7	39.4	0.0	89.3	79.8	108.2	5.6	22.5	97.3	20.3	235.4	131.1	39.2	63.8	20.1	17.7	20.5	10.7	32.3	30.6	3.6	26.6	10.7	7.9	3.8	25.1	29.4
IL13RA2	"CD213a2, CT19, IL-13R, IL13BP"	ENSG00000123496	"Interleukin 13 receptor subunit alpha 2"	Q14627	X	115003975-115019977	"Cancer-related genes, CD markers, Predicted membrane proteins"		Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pituitary gland: 16.1;testis: 31.5"	"Cell type enhanced"	"Detected in some"	28	"Early spermatids: 253.7;Ito cells: 63.3;Late spermatids: 36.6;Spermatocytes: 64.6"	"Cancer enhanced"	"Detected in many"		"glioma: 17.2"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"PC-3: 27.0;U-2197: 86.8;U-251 MG: 58.3;U-87 MG: 34.6"	"Region enhanced"	"Detected in some"		"olfactory region: 8.7"	"Low region specificity"	"Detected in many"			"HPA045831, HPA067363"			Approved	"Nucleoplasm,Vesicles,Plasma membrane,Cell Junctions"		NA	NA			"Plasma membrane, Cell Junctions"	"Nucleoplasm, Vesicles"	"HPA045831: , HPA067363: "	"unprognostic (1.97e-1)"	"unprognostic (2.83e-1)"	"unprognostic (6.62e-4)"	"unprognostic (7.39e-2)"	"unprognostic (8.45e-2)"	"unprognostic (1.80e-1)"	"prognostic favorable (3.55e-4)"	"unprognostic (3.54e-1)"	"unprognostic (2.85e-1)"	"unprognostic (1.92e-2)"	"unprognostic (2.20e-3)"	"unprognostic (2.19e-2)"	"unprognostic (1.53e-5)"	"unprognostic (1.58e-1)"	"unprognostic (1.63e-1)"	"unprognostic (9.70e-3)"	"unprognostic (1.20e-1)"	0.5	4.8	3.7	3.9	11.3	0.0	0.8	0.3	3.1	1.2	0.4	2.1	5.7	0.3	0.9	4.4	0.5	0.1	0.8	0.6	5.1	11.2	3.5	9.6	1.0	0.1	1.2	2.6	0.1	0.1	0.5	16.1	2.1	3.9	4.3	0.7	1.6	0.8	3.7	0.0	0.1	0.3	0.4	0.6	0.2	0.1	31.5	1.4	0.0	1.3	0.2	0.2	1.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.1	0.7	0.0	5.9	5.7	0.0	0.0	0.0	0.0	0.0	0.1	2.9	9.6	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	1.0	0.1	0.9	5.5	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	27.0	0.0	0.0	0.0	0.5	0.0	0.0	1.4	0.4	0.0	0.1	0.0	0.0	0.0	0.0	3.1	0.0	86.8	58.3	0.0	0.0	0.0	34.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	11.3	0.3	3.1	5.1	11.2	1.2	2.6	3.9	1.4	0.0	0.0	0.0	2.6	0.1	0.0	0.2	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	253.7	1.0	0.0	0.0	0.0	0.0	0.4	2.3	0.0	0.4	0.0	0.0	4.1	63.3	4.8	36.6	2.6	0.0	0.0	1.0	0.0	0.0	5.5	0.0	4.6	0.0	0.0	0.0	0.2	64.6	2.1	0.0	0.0	0.0	0.0	2.5
IL15RA	"CD215, IL-15RA"	ENSG00000134470	"Interleukin 15 receptor subunit alpha"	Q13261	10	5943639-5978187	"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	10	"Exocrine glandular cells: 48.0;monocytes: 89.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 30.0;EFO-21: 18.2;HDLM-2: 32.7;HHSteC: 18.7"									CAB026215	Approved				"Secreted to blood"	NA	NA					"CAB026215: "	"unprognostic (2.86e-2)"	"unprognostic (8.41e-2)"	"unprognostic (6.13e-2)"	"unprognostic (4.45e-2)"	"unprognostic (7.87e-2)"	"unprognostic (5.49e-2)"	"prognostic unfavorable (2.67e-6)"	"unprognostic (5.09e-3)"	"unprognostic (1.82e-2)"	"unprognostic (1.69e-1)"	"prognostic unfavorable (5.35e-4)"	"unprognostic (6.18e-3)"	"prognostic unfavorable (1.27e-12)"	"unprognostic (4.43e-2)"	"unprognostic (4.69e-2)"	"unprognostic (4.08e-2)"	"unprognostic (5.75e-2)"	20.5	5.6	2.2	13.0	4.1	6.4	33.9	1.4	2.6	12.7	15.6	1.6	7.7	10.1	10.9	9.4	14.3	10.6	18.7	19.2	2.6	1.9	7.8	17.5	35.7	15.2	4.0	2.0	8.7	9.6	0.9	3.9	15.5	3.6	13.2	7.4	6.4	8.9	9.4	9.2	7.6	18.8	10.8	2.7	18.8	10.3	5.0	2.7	3.5	13.9	7.5	9.8	12.9	17.3	7.0	4.2	6.3	19.5	6.8	18.7	6.7	7.0	1.0	0.0	0.3	9.3	2.2	1.9	3.6	7.8	4.8	5.0	0.1	30.0	0.8	18.2	6.8	2.6	6.7	0.8	5.3	1.0	32.7	1.4	0.8	1.8	0.5	18.7	0.4	0.2	1.9	1.8	2.5	0.1	1.8	11.7	0.6	8.7	10.0	0.1	3.7	1.4	3.4	0.2	2.5	3.3	4.2	0.0	5.7	1.1	0.5	0.0	0.0	5.5	0.5	0.2	0.0	2.6	3.2	4.5	0.1	0.5	13.0	4.8	9.0	2.4	0.1	2.2	5.3	0.3	6.3	16.0	3.9	12.3	19.5	18.7	7.0	9.5	12.5	4.2	3.3	4.1	7.1	4.7	6.8	11.7	0.0	10.2	6.7	2.2	4.1	1.4	2.6	2.6	1.9	4.0	2.0	3.6	2.7	6.0	5.3	7.5	4.2	5.0	0.0	5.3	25.5	2.7	0.0	0.0	0.0	0.6	0.0	30.4	1.5	20.4	6.9	23.3	48.0	1.6	12.7	6.8	3.5	6.4	6.3	0.0	5.2	34.4	12.7	1.5	4.6	6.2	3.3	89.2	7.1	0.0	29.3	13.5	0.7	0.0	0.0	0.0	5.1	0.2	0.2	5.6	0.1	5.7	7.5	6.5
IL17RA	"CD217, CDw217, hIL-17R, IL-17RA, IL17R"	ENSG00000177663	"Interleukin 17 receptor A"	Q96F46	22	17084954-17115694	"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 50.0"	"Cell type enhanced"	"Detected in many"	8	"Kupffer cells: 84.8;Macrophages: 43.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 15.6"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HL-60: 27.6;NB-4: 24.3;THP-1: 35.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB024996	Enhanced		Approved	Nucleoplasm,Cytosol	"Secreted - unknown location"	NA	NA		20000	"Nucleoplasm, Cytosol"		"CAB024996: "	"unprognostic (1.92e-1)"	"unprognostic (3.15e-1)"	"unprognostic (1.65e-2)"	"unprognostic (9.83e-2)"	"unprognostic (7.66e-2)"	"unprognostic (5.15e-2)"	"unprognostic (3.56e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.41e-2)"	"unprognostic (8.52e-2)"	"unprognostic (1.91e-1)"	"unprognostic (3.04e-1)"	"unprognostic (1.96e-2)"	"prognostic favorable (8.35e-4)"	"unprognostic (2.16e-2)"	"unprognostic (1.27e-1)"	"unprognostic (6.51e-3)"	17.7	7.6	6.5	13.6	13.8	40.5	24.7	4.0	6.7	8.6	8.1	7.7	4.6	6.2	7.4	9.4	6.8	7.8	7.4	8.8	6.1	4.9	8.3	11.6	16.8	39.2	10.3	2.0	7.7	7.7	6.9	5.4	6.2	8.3	6.9	5.7	5.3	7.0	5.3	5.3	8.6	9.1	8.3	11.2	23.4	7.3	5.3	9.7	50.0	7.9	3.2	11.0	6.3	12.8	0.5	3.6	15.6	6.9	1.4	2.4	2.0	3.6	2.1	1.9	2.5	3.9	2.3	2.5	5.5	3.6	2.6	3.3	2.0	2.4	3.3	2.3	5.5	3.4	6.0	2.7	2.6	1.8	5.4	3.2	0.0	1.2	1.3	4.5	27.6	8.6	3.4	3.8	2.3	1.8	2.5	2.7	2.7	1.4	3.5	2.6	3.1	3.3	24.3	1.1	4.7	2.1	0.7	0.4	0.6	2.4	2.7	1.3	0.0	3.8	3.3	2.7	2.3	2.5	35.0	7.5	2.0	2.9	3.0	2.0	2.8	1.5	1.6	2.9	13.4	2.1	6.7	6.9	6.1	1.1	3.2	0.9	0.4	1.5	1.1	3.6	0.5	2.4	1.8	15.6	1.4	2.9	1.7	0.9	2.0	6.5	13.8	4.0	6.7	6.1	4.9	10.3	2.0	8.3	9.7	11.9	13.1	6.7	5.5	7.8	2.0	4.5	15.3	5.3	3.4	5.2	7.9	5.4	0.0	8.0	2.5	9.3	15.1	0.0	10.8	10.6	8.2	8.5	7.0	9.6	29.2	3.2	12.7	20.9	84.8	1.4	8.3	43.1	8.5	3.6	13.1	3.8	10.5	11.8	4.2	3.1	3.2	12.9	9.0	1.4	14.7	5.9	5.4	20.0	10.6	9.3
IL18R1	"CD218a, IL-1Rrp, IL1RRP"	ENSG00000115604	"Interleukin 18 receptor 1"	Q13478	2	102311529-102398775	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Inflammatory response"	"Hydrolase, Receptor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 39.3"	"Cell type enriched"	"Detected in many"	5	"granulocytes: 104.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"NK-cell: 26.8"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 13.8;HHSteC: 29.8;HMC-1: 20.0;U-937: 32.0"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			HPA007615	Approved		Approved	Mitochondria	"Intracellular and membrane"	Yes	No			Mitochondria		"HPA007615: AB_1851675"	"unprognostic (3.60e-3)"	"unprognostic (9.75e-3)"	"unprognostic (1.12e-3)"	"unprognostic (3.01e-2)"	"unprognostic (2.34e-3)"	"unprognostic (7.11e-2)"	"unprognostic (2.95e-2)"	"unprognostic (1.74e-2)"	"unprognostic (3.59e-1)"	"unprognostic (7.86e-2)"	"unprognostic (3.40e-2)"	"unprognostic (1.70e-1)"	"prognostic unfavorable (4.52e-4)"	"unprognostic (2.62e-1)"	"unprognostic (1.62e-2)"	"unprognostic (5.71e-2)"	"unprognostic (2.48e-2)"	17.8	2.6	1.4	8.3	1.7	12.5	11.2	0.8	1.3	8.2	8.1	0.7	6.6	5.1	4.2	5.7	4.5	4.5	14.1	10.5	1.7	1.9	7.4	8.8	39.3	29.6	2.0	0.1	3.3	2.6	0.8	4.6	10.7	1.6	6.3	3.4	5.0	3.0	28.4	2.8	3.2	10.7	7.9	1.9	19.5	4.6	2.4	0.4	2.5	3.2	3.2	6.6	8.2	12.9	0.1	6.8	5.5	0.1	26.8	10.6	1.1	0.9	0.3	0.0	0.0	0.7	0.7	1.6	0.0	0.5	0.0	0.3	0.0	0.4	0.0	0.0	0.0	1.8	0.5	0.0	1.9	0.0	13.8	0.8	2.5	0.6	0.1	29.8	5.2	20.0	6.8	1.1	2.2	3.6	0.0	5.0	0.1	0.0	0.0	0.0	0.0	0.0	0.9	0.3	0.7	0.5	0.0	0.0	0.0	0.2	0.5	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.1	0.4	0.6	0.4	2.4	0.4	0.0	0.0	0.0	0.1	32.0	2.3	5.5	0.0	2.4	4.2	0.1	10.6	0.1	2.4	3.0	2.0	0.1	0.4	0.8	4.1	26.8	0.0	6.8	2.4	1.1	1.4	1.7	0.8	1.3	1.7	1.9	2.0	0.1	1.6	0.4	0.0	13.3	0.0	1.0	0.7	0.0	1.5	0.0	5.3	3.4	1.8	0.0	0.0	1.7	0.8	0.0	7.1	0.0	0.0	0.5	0.7	2.2	0.8	104.4	6.2	0.1	0.0	0.0	13.5	3.1	0.0	0.3	19.4	3.3	0.0	0.0	0.3	0.7	0.0	0.0	0.8	0.0	6.5	0.9	0.2	0.4	0.9	0.0	22.4	0.0	0.7
IL18RAP	"AcPL, CD218b"	ENSG00000115607	"Interleukin 18 receptor accessory protein"	O95256	2	102418689-102452565	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Inflammatory response"	"Hydrolase, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"blood: 34.6;bone marrow: 50.2;lymphoid tissue: 29.8"	"Cell type enriched"	"Detected in some"	8	"T-cells: 24.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"NK-cell: 34.6"	"Group enriched"	"Detected in many"	108	"granulocytes: 22.5;NK-cells: 34.6;T-cells: 22.1"	"Cell line enriched"	"Detected in some"	10	"U-937: 34.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB025270	Enhanced					NA	NA					"CAB025270: "	"unprognostic (1.73e-3)"	"unprognostic (6.27e-3)"	"unprognostic (5.07e-3)"	"unprognostic (4.64e-6)"	"unprognostic (2.90e-1)"	"unprognostic (1.18e-2)"	"unprognostic (5.86e-5)"	"unprognostic (5.09e-3)"	"unprognostic (4.02e-2)"	"unprognostic (1.57e-3)"	"unprognostic (4.78e-2)"	"unprognostic (5.31e-2)"	"unprognostic (1.51e-2)"	"unprognostic (2.71e-1)"	"unprognostic (6.35e-2)"	"unprognostic (8.56e-2)"	"unprognostic (2.73e-2)"	3.6	0.3	0.2	6.1	0.5	50.2	0.9	0.3	0.4	1.2	4.8	0.5	0.0	1.2	1.2	2.1	0.8	3.8	3.0	2.1	0.2	0.2	0.9	2.6	9.6	16.4	0.9	0.0	1.1	0.4	0.0	0.9	0.8	0.2	0.6	0.9	1.5	0.8	0.3	0.6	0.2	8.1	1.0	1.0	29.8	1.5	1.3	0.0	1.3	0.8	0.9	3.5	2.5	1.3	0.0	0.2	22.5	0.0	34.6	22.1	2.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.0	0.0	1.4	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	34.8	0.2	0.0	0.0	6.1	15.7	0.0	22.1	0.0	2.0	4.2	0.1	0.0	0.0	0.5	22.5	34.6	0.0	0.2	0.1	2.0	0.2	0.5	0.3	0.4	0.2	0.2	0.9	0.0	0.2	0.0	3.0	0.6	0.5	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.9	0.0	0.0
IL1R1	"CD121A, D2S1473, IL1R, IL1RA"	ENSG00000115594	"Interleukin 1 receptor type 1"	P14778	2	102064544-102179874	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters"	"Inflammatory response"	"Hydrolase, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Club cells: 93.3;Ito cells: 139.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 4.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 95.6;ASC TERT1: 42.7;HHSteC: 30.0;HSkMC: 117.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA001237, HPA005823, CAB007779, HPA029560"	Approved		Approved	"Nucleoplasm,Vesicles,Plasma membrane,Cytosol"	"Secreted to blood"	NA	NA		1000000	"Nucleoplasm, Vesicles"	"Plasma membrane, Cytosol"	"CAB007779: AB_562073, HPA001237: , HPA005823: AB_2667445, HPA029560: AB_2673094"	"unprognostic (6.16e-3)"	"unprognostic (3.55e-2)"	"unprognostic (3.33e-1)"	"unprognostic (1.22e-1)"	"unprognostic (4.26e-2)"	"unprognostic (7.10e-2)"	"unprognostic (2.01e-1)"	"unprognostic (3.36e-2)"	"unprognostic (1.44e-1)"	"unprognostic (3.16e-1)"	"unprognostic (4.26e-2)"	"unprognostic (7.77e-2)"	"prognostic unfavorable (6.92e-6)"	"unprognostic (2.48e-2)"	"unprognostic (6.95e-2)"	"unprognostic (4.83e-2)"	"unprognostic (7.73e-2)"	48.6	25.2	2.6	18.2	5.2	4.0	92.4	2.4	3.9	47.8	21.0	2.5	34.3	5.2	15.2	30.2	18.2	17.1	25.8	27.0	4.2	2.5	23.7	74.8	40.5	28.0	5.6	1.1	25.1	17.1	16.9	7.3	66.2	10.9	26.0	8.4	8.6	12.7	36.4	15.5	13.5	13.0	15.1	10.0	19.2	15.6	13.4	2.8	3.5	33.6	9.0	9.6	32.0	36.4	0.1	0.1	4.0	0.5	0.8	1.8	0.2	0.2	1.8	0.0	1.5	95.6	42.7	0.6	4.0	18.2	2.8	4.3	0.8	0.5	0.0	2.9	8.0	5.0	0.8	0.0	0.3	2.4	7.9	0.0	0.1	0.4	4.4	30.0	0.0	0.0	117.7	0.3	3.2	0.7	1.2	1.2	0.0	0.5	0.1	4.1	0.8	0.0	0.1	0.1	0.8	0.1	0.0	0.3	0.0	2.7	1.9	0.0	0.0	1.8	1.1	0.0	0.5	1.6	0.1	0.0	8.2	0.5	13.7	0.3	0.0	0.0	0.0	3.2	0.0	0.5	0.6	0.5	0.1	0.0	0.0	0.7	0.1	1.1	0.0	0.1	0.1	0.0	0.1	4.0	0.8	0.0	0.1	1.8	0.2	2.6	5.2	2.4	3.9	4.2	2.5	5.6	1.1	10.9	2.8	23.8	55.6	3.7	27.6	27.6	0.0	3.9	28.1	40.2	93.3	5.2	0.0	5.3	3.3	21.6	6.4	58.3	0.0	0.0	18.7	76.6	77.2	84.5	1.1	43.2	5.1	0.0	1.2	139.3	12.4	9.4	25.9	21.6	18.6	9.0	0.7	7.3	15.4	0.0	1.4	6.2	1.0	6.5	23.1	0.7	0.9	33.8	20.0	2.6	0.9	19.6
IL1R2	"CD121b, IL1RB"	ENSG00000115590	"Interleukin 1 receptor type 2"	P27930	2	101991844-102028544	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 73.2;lymphoid tissue: 74.1"	"Group enriched"	"Detected in many"	5	"Basal keratinocytes: 131.3;Kupffer cells: 197.6;Macrophages: 236.7;Mucus-secreting cells: 105.1;Pancreatic endocrine cells: 123.7;Suprabasal keratinocytes: 73.4"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	4	"midbrain: 9.2"	"Cell type enriched"	"Detected in some"	25	"neutrophil: 73.2"	"Lineage enriched"	"Detected in many"	25	"granulocytes: 73.2"	"Cell line enriched"	"Detected in some"	8	"HDLM-2: 102.2"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA027597, HPA027598"	Uncertain				"Secreted to blood"	NA	NA	7130000	21000000			"HPA027597: AB_10600768, HPA027598: AB_10601229"	"unprognostic (3.54e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.21e-1)"	"unprognostic (3.83e-2)"	"unprognostic (6.59e-2)"	"unprognostic (1.42e-1)"	"unprognostic (6.36e-2)"	"unprognostic (4.82e-3)"	"unprognostic (1.62e-2)"	"unprognostic (7.15e-2)"	"unprognostic (8.20e-3)"	"unprognostic (1.07e-1)"	"prognostic unfavorable (5.58e-12)"	"unprognostic (1.92e-1)"	"unprognostic (7.51e-2)"	"unprognostic (1.77e-1)"	"unprognostic (6.62e-2)"	9.1	3.2	1.2	16.4	1.9	22.3	1.6	1.2	1.9	6.4	13.4	0.4	0.1	0.1	1.3	1.3	20.4	9.7	3.4	15.1	1.2	0.5	5.8	8.2	25.5	74.1	9.2	0.2	2.5	1.4	0.0	2.4	24.9	2.2	1.1	20.0	1.8	4.3	0.8	2.8	14.1	2.2	1.3	4.4	47.5	14.6	1.6	1.1	1.6	1.8	8.5	25.1	3.2	9.1	0.0	2.8	73.2	0.8	0.0	1.1	0.2	1.5	0.2	0.0	0.0	0.2	0.2	0.1	0.0	0.0	0.0	0.0	1.6	0.0	0.0	3.3	0.0	0.0	0.6	0.0	0.1	0.0	102.2	0.1	0.0	0.0	0.8	0.5	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.2	0.0	0.0	0.0	0.0	5.3	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	1.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.8	0.0	0.0	0.4	0.0	0.0	0.1	0.0	2.8	0.0	0.0	0.0	73.2	0.0	0.0	0.0	1.1	0.2	1.2	1.9	1.2	1.9	1.2	0.5	9.2	0.2	2.2	1.1	6.0	0.6	5.4	8.6	131.3	0.0	0.4	17.8	4.0	0.0	1.8	0.0	0.4	5.0	8.0	2.6	1.9	8.6	0.0	7.3	28.9	9.3	2.5	2.3	14.4	5.9	0.0	6.4	4.3	197.6	1.5	0.3	236.7	30.4	1.0	105.1	0.0	123.7	31.7	0.0	0.4	0.0	6.5	8.9	0.0	1.4	73.4	23.2	1.0	20.4	7.1
IL21R	CD360	ENSG00000103522	"Interleukin 21 receptor"	Q9HBE5	16	27402162-27452042	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 17.9;lymphoid tissue: 47.8"	"Cell type enhanced"	"Detected in some"	10	"B-cells: 11.8;Early spermatids: 5.2;Hofbauer cells: 7.0;T-cells: 8.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Daudi: 10.3;HDLM-2: 43.9;Karpas-707: 20.4;RH-30: 15.4;RPMI-8226: 24.5;U-266/70: 10.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA042296	Uncertain		Uncertain	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA042296: AB_10806236"	"unprognostic (2.91e-2)"	"unprognostic (2.65e-3)"	"unprognostic (6.64e-4)"	"unprognostic (1.58e-3)"	"unprognostic (2.14e-1)"	"prognostic favorable (7.29e-4)"	"unprognostic (8.33e-2)"	"unprognostic (2.06e-1)"	"unprognostic (8.50e-6)"	"unprognostic (2.26e-2)"	"unprognostic (1.13e-2)"	"unprognostic (8.71e-2)"	"unprognostic (2.34e-10)"	"unprognostic (8.79e-2)"	"unprognostic (4.42e-2)"	"unprognostic (1.50e-1)"	"unprognostic (9.58e-2)"	0.8	0.6	0.6	33.6	3.7	5.7	0.6	0.5	1.6	0.5	0.9	0.3	0.0	0.5	0.5	1.3	1.0	0.8	1.1	1.8	0.6	2.3	1.6	1.3	5.6	20.9	1.3	0.0	0.5	0.5	0.0	0.9	0.9	1.9	0.9	0.9	1.8	3.7	0.3	0.7	0.7	4.0	0.6	1.7	11.2	1.3	1.0	1.4	47.8	1.3	0.8	31.7	2.7	0.8	11.5	1.6	0.7	17.9	6.3	10.3	4.2	0.0	0.0	0.1	0.1	0.0	0.5	0.3	0.3	0.0	0.0	0.9	0.0	0.0	10.3	0.1	0.8	0.5	0.0	0.0	0.0	0.0	43.9	0.0	2.1	0.0	0.3	1.4	0.0	0.6	1.6	0.0	2.8	0.0	0.3	0.0	0.2	0.1	20.4	1.5	0.0	0.0	0.2	0.3	0.0	0.0	0.1	15.4	24.5	0.0	0.0	0.1	0.0	0.0	0.0	1.1	0.1	0.0	0.5	1.1	0.8	0.3	0.2	0.0	10.3	3.6	2.3	2.1	0.5	0.0	0.2	0.3	0.0	9.8	5.8	3.6	1.0	6.3	10.3	1.6	11.5	6.9	6.7	0.7	6.3	17.9	0.7	7.6	4.2	0.6	3.7	0.5	1.6	0.6	2.3	1.3	0.0	1.9	1.4	0.0	2.2	11.8	0.1	0.3	1.5	2.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	5.2	0.6	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	7.0	0.0	0.0	1.3	4.5	4.0	0.0	2.2	1.7	1.0	0.0	0.4	0.0	0.0	0.0	0.0	0.5	0.0	0.9	0.1	0.0	0.6	0.1	8.2	0.0	0.0
IL2RA	"CD25, IDDM10, IL2R"	ENSG00000134460	"Interleukin 2 receptor subunit alpha"	P01589	10	6010689-6062370	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor	"Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"adipose tissue: 16.5;blood: 55.4;lymphoid tissue: 56.7"	"Cell type enriched"	"Detected in some"	4	"monocytes: 309.2"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in single"		"pons and medulla: 2.4"	"Group enriched"	"Detected in many"	6	"basophil: 30.3;T-reg: 55.4"	"Group enriched"	"Detected in many"	12	"granulocytes: 30.3;T-cells: 55.4"	"Cell line enriched"	"Detected in some"	59	"HDLM-2: 157.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"CAB002419, HPA054622"	Enhanced					NA	NA		110000			"CAB002419: AB_563538, HPA054622: AB_2682546"	"unprognostic (2.82e-1)"	"unprognostic (8.10e-3)"	"unprognostic (1.75e-2)"	"unprognostic (5.86e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.45e-3)"	"unprognostic (2.78e-2)"	"unprognostic (2.73e-1)"	"unprognostic (5.03e-2)"	"unprognostic (6.32e-2)"	"unprognostic (7.21e-2)"	"unprognostic (2.07e-1)"	"prognostic unfavorable (2.08e-9)"	"unprognostic (2.10e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.22e-1)"	"unprognostic (5.10e-2)"	16.5	2.5	0.3	10.9	0.6	0.1	1.4	0.3	0.3	0.6	3.1	0.1	0.0	1.3	0.8	4.9	1.9	0.8	2.2	1.9	0.4	0.5	2.6	1.3	4.0	50.4	0.5	0.0	0.6	1.0	0.0	1.8	1.8	2.4	1.1	1.6	3.4	2.2	0.5	0.8	0.6	10.3	3.5	2.2	56.7	1.4	0.4	0.0	4.5	4.2	2.0	16.8	5.0	0.6	3.6	0.0	30.3	0.0	2.9	55.4	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	157.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.6	0.0	0.0	0.0	30.3	0.0	4.5	0.1	0.0	0.5	3.6	6.8	0.7	0.0	1.5	0.5	0.0	0.2	2.9	0.0	0.0	55.4	0.7	0.3	0.6	0.3	0.3	0.4	0.5	0.5	0.0	2.4	0.0	0.0	2.6	7.5	0.1	0.8	0.0	0.4	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.3	0.2	74.4	0.0	0.3	0.0	0.0	0.6	5.6	0.0	0.0	3.7	3.3	309.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.5	0.0	7.7	0.0	0.1
IL2RB	"CD122, IL15RB"	ENSG00000100385	"Interleukin 2 receptor subunit beta"	P14784	22	37125838-37175054	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Host-virus interaction"	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 51.6;lymphoid tissue: 35.0;placenta: 58.5"	"Group enriched"	"Detected in many"	8	"Extravillous trophoblasts: 80.1;T-cells: 97.0"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	4	"gdT-cell: 14.7;NK-cell: 51.6"	"Group enriched"	"Detected in many"	32	"NK-cells: 51.6;T-cells: 14.7"	"Cell line enriched"	"Detected in some"	8	"HDLM-2: 106.6"	"Region enriched"	"Detected in single"	7	"basal ganglia: 1.6"	"Low region specificity"	"Detected in single"			HPA062657	Enhanced					NA	NA					"HPA062657: AB_2684822"	"unprognostic (3.38e-3)"	"unprognostic (1.21e-2)"	"prognostic favorable (6.76e-4)"	"prognostic favorable (3.18e-5)"	"unprognostic (2.44e-2)"	"unprognostic (9.69e-3)"	"unprognostic (2.60e-1)"	"unprognostic (5.22e-2)"	"unprognostic (1.03e-3)"	"unprognostic (5.37e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.74e-1)"	"prognostic unfavorable (3.50e-7)"	"unprognostic (4.63e-2)"	"unprognostic (7.96e-2)"	"unprognostic (3.94e-3)"	"unprognostic (2.46e-2)"	2.2	1.0	0.8	20.5	0.8	12.3	1.6	0.6	0.7	1.3	5.5	0.6	1.4	1.8	4.3	2.8	2.6	1.8	5.8	3.7	0.7	0.8	1.9	6.0	7.4	20.8	0.8	0.2	1.5	1.0	0.0	1.1	58.5	0.7	3.5	1.8	2.9	3.7	2.1	0.9	4.0	7.3	0.6	1.1	35.0	2.3	1.1	0.2	21.0	2.1	1.8	28.7	4.0	1.5	0.3	0.0	1.0	0.1	51.6	14.7	7.9	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	106.6	0.1	0.2	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.8	0.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.2	0.0	0.0	2.8	0.0	0.1	7.7	13.2	0.0	0.1	0.0	0.1	1.0	0.0	0.1	14.7	0.1	8.1	0.1	3.3	8.2	0.0	0.3	1.1	4.3	0.3	51.6	0.1	0.0	6.8	7.9	0.8	0.8	0.6	0.7	0.7	0.8	0.8	0.2	0.7	0.2	3.0	11.6	1.5	0.8	2.9	0.0	1.1	0.0	1.4	1.2	1.8	0.0	0.4	0.0	0.0	1.7	0.0	0.0	0.0	0.2	80.1	1.1	0.1	9.3	1.0	2.1	0.0	0.0	8.6	1.6	0.9	0.3	0.5	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.4	1.0	97.0	0.0	0.0
IL2RG	"CD132, CIDX, IMD4, SCIDX1"	ENSG00000147168	"Interleukin 2 receptor subunit gamma"	P31785	X	71107404-71112108	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Host-virus interaction"	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 115.3;lymphoid tissue: 169.3"	"Cell type enhanced"	"Detected in many"	12	"B-cells: 121.6;Enterocytes: 82.5;monocytes: 130.8;T-cells: 235.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in some"	6	"Karpas-707: 225.6"									"HPA046641, HPA049691"	Enhanced		Approved	Vesicles		NA	NA			Vesicles		"HPA046641: AB_2679733, HPA049691: AB_2680851"	"unprognostic (2.97e-3)"	"unprognostic (4.24e-2)"	"unprognostic (1.23e-1)"	"prognostic favorable (1.73e-4)"	"unprognostic (8.25e-2)"	"unprognostic (1.93e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.91e-3)"	"unprognostic (1.23e-2)"	"unprognostic (4.36e-1)"	"unprognostic (1.45e-1)"	"prognostic unfavorable (2.28e-7)"	"unprognostic (1.73e-1)"	"unprognostic (4.69e-2)"	"unprognostic (4.89e-2)"	"unprognostic (9.54e-2)"	5.8	1.3	1.4	39.5	1.4	12.8	3.6	0.8	0.9	2.9	16.6	0.9	0.9	8.2	3.0	2.1	5.3	3.1	5.3	2.6	1.4	1.5	3.7	4.7	13.6	70.4	1.8	0.6	2.9	1.5	0.0	1.2	5.3	1.5	3.2	20.8	2.9	10.4	1.8	1.6	2.7	28.6	1.5	2.9	58.7	6.0	2.0	0.9	169.3	3.3	4.2	61.4	7.6	3.1	51.9	30.6	65.6	19.7	94.6	115.3	99.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	17.6	1.3	0.0	0.0	0.1	0.0	0.0	0.0	14.8	0.0	2.3	0.0	0.0	0.0	9.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	21.0	3.9	225.6	0.0	0.0	32.6	17.8	0.0	0.0	0.0	7.5	0.0	1.8	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	12.9	22.7	11.3	0.2	37.8	0.0	35.2	8.5	13.4	107.2	19.7	105.6	51.9	97.7	110.4	20.3	51.6	68.0	84.9	65.6	94.6	13.5	30.6	115.3	99.0	1.4	1.4	0.8	0.9	1.4	1.5	1.8	0.6	1.5	0.9	3.0	15.7	121.6	6.6	7.2	0.0	0.3	0.0	0.0	1.2	0.0	0.0	0.3	0.0	1.0	0.0	4.5	82.5	0.0	2.0	0.2	3.3	3.6	38.1	1.5	32.3	0.0	74.7	6.7	21.7	0.0	0.0	41.4	40.5	130.8	19.5	0.0	16.5	58.8	0.4	1.1	0.2	0.0	4.1	0.0	0.0	5.9	0.2	235.1	18.0	6.8
IL3RA	CD123	ENSG00000185291	"Interleukin 3 receptor subunit alpha"	P26951	X	1336616-1382689	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 163.1;breast: 50.7;vagina: 65.4"	"Group enriched"	"Detected in many"	5	"Endothelial cells: 40.7;Macrophages: 35.6;monocytes: 120.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	16	"basophil: 163.1;plasmacytoid DC: 49.1"	"Group enriched"	"Detected in many"	33	"dendritic cells: 49.1;granulocytes: 163.1"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 49.0;NB-4: 9.4;RPMI-8226: 20.0"									"HPA003539, CAB018374"	Uncertain					NA	NA					"CAB018374: AB_2233620, HPA003539: AB_1078438"	"prognostic favorable (9.78e-4)"	"prognostic favorable (4.27e-4)"	"unprognostic (8.13e-2)"	"unprognostic (9.32e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.29e-3)"	"unprognostic (1.32e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.38e-1)"	"unprognostic (3.73e-2)"	"unprognostic (5.77e-3)"	"unprognostic (1.43e-1)"	"unprognostic (1.50e-3)"	"unprognostic (9.41e-2)"	"unprognostic (2.85e-3)"	"unprognostic (2.49e-1)"	"unprognostic (1.46e-1)"	14.9	1.2	7.8	7.7	7.8	12.1	50.7	5.0	10.1	9.7	4.6	1.5	1.5	2.4	13.8	1.5	2.8	4.2	5.6	9.2	11.1	2.4	5.4	1.5	15.9	12.3	8.5	3.9	7.6	2.6	0.6	3.7	9.3	10.9	4.4	3.1	1.5	5.6	1.5	5.7	6.8	5.4	6.1	7.6	5.3	4.2	1.5	7.9	1.5	7.0	1.5	6.4	6.8	65.4	0.7	49.1	163.1	3.2	1.1	0.0	0.7	0.1	4.0	1.5	0.5	0.0	0.0	0.5	0.5	0.1	0.0	0.0	0.4	0.6	0.5	2.8	0.0	0.2	3.9	0.0	0.0	0.0	49.0	1.6	0.2	0.7	0.1	0.0	0.3	6.7	0.0	0.0	0.0	0.0	1.7	3.2	0.4	0.1	2.5	0.0	0.6	0.2	9.4	1.2	0.3	0.2	0.6	1.8	20.0	0.0	0.5	0.2	0.2	0.2	0.1	1.1	0.7	0.5	7.5	0.1	0.2	0.6	0.2	0.1	5.3	1.5	0.4	4.4	1.1	0.0	163.1	0.4	6.7	0.0	2.4	0.0	0.2	0.0	0.0	1.1	0.7	0.0	0.0	0.3	1.1	3.2	49.1	0.0	0.7	7.8	7.8	5.0	10.1	11.1	2.4	8.5	3.9	10.9	7.9	3.0	2.6	7.7	0.5	5.3	2.7	2.4	2.5	0.0	1.2	0.0	9.8	0.0	0.0	0.3	0.0	40.7	0.4	0.0	0.2	0.1	2.8	0.4	11.5	0.0	4.4	0.0	0.0	14.1	3.5	0.0	0.3	35.6	8.5	120.0	1.3	0.8	0.1	3.4	0.7	0.0	2.2	0.0	4.1	0.0	0.2	4.8	0.2	0.0	0.2	1.8
IL4R	CD124	ENSG00000077238	"Interleukin 4 receptor"	P24394	16	27313668-27364778	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"granulocytes: 107.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 34.4"	"Group enriched"	"Detected in all"	6	"B-cells: 34.4;granulocytes: 11.9"	"Cell line enhanced"	"Detected in many"		"Daudi: 36.5;HBEC3-KT: 35.1;U-698: 34.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB004451, HPA050124, HPA070380"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Centriolar satellite"	"Secreted to blood"	NA	NA		49000	"Nucleoplasm, Plasma membrane"	"Centriolar satellite"	"CAB004451: AB_626889, HPA050124: AB_2681026, HPA070380: "	"unprognostic (6.80e-2)"	"unprognostic (6.35e-2)"	"unprognostic (2.84e-1)"	"prognostic favorable (6.43e-4)"	"unprognostic (1.12e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.33e-2)"	"unprognostic (1.95e-3)"	"unprognostic (1.34e-1)"	"unprognostic (1.54e-1)"	"unprognostic (2.41e-1)"	"unprognostic (1.97e-1)"	"prognostic unfavorable (1.23e-5)"	"unprognostic (1.49e-2)"	"unprognostic (1.73e-1)"	"unprognostic (1.36e-1)"	"unprognostic (9.58e-2)"	20.7	14.8	8.7	31.6	10.6	36.9	12.0	4.4	7.7	20.8	30.3	5.9	11.5	10.9	18.0	12.8	24.7	13.6	25.1	12.3	6.7	4.4	13.3	39.1	40.9	44.8	10.8	1.7	14.7	11.3	3.8	5.5	16.1	10.1	18.8	15.1	12.3	7.7	11.5	7.2	9.9	18.6	39.6	13.6	31.8	21.1	10.4	9.8	9.1	8.6	13.7	38.4	31.6	15.4	34.4	1.6	11.9	2.6	3.3	4.0	1.8	11.5	3.0	2.0	3.9	1.0	4.6	4.2	7.3	8.5	2.9	2.4	6.2	32.0	36.5	9.1	11.5	5.7	12.3	2.1	35.1	2.5	31.6	1.0	6.8	1.8	9.5	13.2	1.8	19.4	7.0	14.2	13.5	8.0	15.5	15.7	2.1	2.9	3.1	4.7	5.1	0.1	5.5	2.4	10.4	2.7	0.1	15.2	2.9	13.6	13.2	0.6	0.3	1.0	7.0	1.6	5.3	2.7	7.0	23.5	6.7	3.0	5.9	5.1	1.8	0.5	34.0	0.7	6.1	0.0	0.5	2.6	4.7	1.7	1.1	1.3	7.7	2.6	1.7	1.6	34.4	4.0	1.9	11.9	3.3	0.6	1.6	1.8	1.8	8.7	10.6	4.4	7.7	6.7	4.4	10.8	1.7	10.1	9.8	26.8	51.7	49.6	35.5	11.7	0.0	2.2	20.4	17.4	30.7	1.8	0.0	15.0	0.0	31.7	0.1	31.5	27.6	0.0	28.2	3.5	13.9	27.2	107.5	47.4	22.9	0.0	22.4	54.6	31.1	0.2	0.3	21.3	13.5	40.5	32.8	0.0	35.6	22.1	0.0	1.1	0.0	38.8	27.4	0.5	1.9	13.0	20.8	20.3	15.0	38.2
IL5RA	"CD125, CDw125, IL5R"	ENSG00000091181	"Interleukin 5 receptor subunit alpha"	Q01344	3	3066326-3126613	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 70.1;fallopian tube: 18.6"	"Cell type enhanced"	"Detected in some"	18	"Ciliated cells: 21.4;granulocytes: 18.5;Melanocytes: 5.0"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.4"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	196	"basophil: 31.4;eosinophil: 70.1"	"Lineage enriched"	"Detected in single"	308	"granulocytes: 70.1"	"Cell line enriched"	"Detected in some"	30	"HMC-1: 42.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"								"Intracellular and membrane"	NA	NA		92000				"unprognostic (1.38e-3)"	"unprognostic (2.26e-2)"	"unprognostic (2.66e-1)"	"unprognostic (6.13e-3)"	"unprognostic (2.66e-1)"	"unprognostic (1.54e-3)"	"unprognostic (7.79e-3)"	"unprognostic (8.42e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.67e-1)"	"unprognostic (9.84e-4)"	"unprognostic (4.32e-3)"	"unprognostic (3.08e-2)"	"unprognostic (6.95e-2)"	"unprognostic (2.20e-1)"	"unprognostic (7.49e-2)"	"unprognostic (4.93e-2)"	0.5	0.2	6.7	0.6	6.2	0.7	1.3	0.2	0.3	1.8	0.9	1.8	0.0	2.2	0.6	8.2	0.6	18.6	2.0	2.4	2.3	2.1	0.6	1.3	7.9	1.2	0.1	0.0	3.8	0.5	0.1	7.5	0.1	11.8	2.6	1.4	0.5	2.2	0.1	0.3	0.4	2.1	0.6	0.6	4.6	1.3	1.6	0.7	1.1	0.4	1.1	1.9	4.2	0.4	0.1	0.0	70.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.4	42.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.1	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	31.4	0.0	70.1	0.2	0.0	0.0	0.1	0.2	0.1	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.1	6.7	6.2	0.2	0.3	2.3	2.1	0.1	0.0	11.8	0.7	0.0	4.5	0.0	0.0	0.1	0.0	2.4	0.0	21.4	2.3	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.9	18.5	0.0	0.1	0.0	0.0	0.0	0.0	4.7	0.0	0.0	5.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0
IL6R	CD126	ENSG00000160712	"Interleukin 6 receptor"	P08887	1	154405193-154469450	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 59.6"	"Cell type enhanced"	"Detected in many"	5	"Alveolar cells type 1: 107.2;Hepatocytes: 81.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 35.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"THP-1: 55.9;U-266/84: 65.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"								"Intracellular and membrane"	NA	NA	24800000	22000000				"unprognostic (1.19e-1)"	"unprognostic (3.97e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.95e-1)"	"unprognostic (4.47e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.05e-2)"	"unprognostic (3.27e-1)"	"unprognostic (6.42e-2)"	"prognostic favorable (1.65e-4)"	"unprognostic (7.94e-2)"	"unprognostic (1.05e-1)"	"unprognostic (7.75e-2)"	"unprognostic (1.51e-1)"	"unprognostic (3.35e-1)"	"unprognostic (1.07e-1)"	8.4	4.0	4.7	14.8	5.1	9.0	6.5	1.4	6.3	6.1	16.9	4.8	1.2	9.6	6.3	4.7	5.2	7.9	6.9	5.0	5.2	2.9	8.9	38.1	20.8	15.4	7.2	2.2	5.7	5.3	0.0	7.7	3.7	7.8	4.5	6.0	3.6	5.4	1.7	59.6	4.7	12.6	5.3	5.0	11.3	6.6	3.7	5.0	4.2	2.5	6.1	13.3	6.3	4.8	0.6	14.3	35.0	11.7	0.5	8.0	5.5	0.8	1.5	0.1	0.1	0.9	1.3	0.1	0.8	0.6	0.5	0.2	0.1	1.0	0.0	1.9	1.0	3.1	0.4	0.3	4.5	0.4	15.1	0.5	0.2	0.6	3.4	0.1	2.4	1.3	0.8	2.7	0.4	6.8	0.1	0.6	0.0	0.1	6.2	0.1	0.3	0.0	3.9	0.4	0.2	3.4	0.0	0.0	13.0	2.8	1.1	0.1	0.0	0.2	9.2	15.1	1.2	0.8	55.9	0.6	0.9	0.9	0.8	0.5	10.7	65.8	0.1	1.1	15.2	1.4	2.8	11.7	10.4	0.2	7.1	0.6	0.6	6.4	0.7	14.3	0.2	6.4	2.2	35.0	0.5	3.0	5.1	8.0	5.5	4.7	5.1	1.4	6.3	5.2	2.9	7.2	2.2	7.8	5.0	107.2	76.2	9.0	41.2	33.7	0.0	8.5	25.5	37.5	59.1	1.8	0.0	0.4	0.0	3.5	35.4	7.1	43.2	0.0	1.0	0.9	20.1	71.1	57.9	81.0	36.1	0.0	7.5	3.1	36.2	9.6	0.3	29.9	23.6	39.7	5.7	5.6	4.9	5.3	0.4	12.6	0.2	0.0	27.0	0.2	0.9	26.0	0.8	4.4	11.5	12.5
IL6ST	"CD130, GP130"	ENSG00000134352	"Interleukin 6 signal transducer"	P40189	5	55935095-55994993	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Host-virus interaction"	Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	10	"Ito cells: 851.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 21.0"	"Lineage enriched"	"Detected in many"	5	"T-cells: 21.0"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 57.7;BJ hTERT+: 58.7;HHSteC: 65.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010558, CAB025784"	Approved		Supported	"Golgi apparatus,Plasma membrane"	"Secreted to blood"	NA	NA		100000000	"Plasma membrane"	"Golgi apparatus"	"CAB025784: , HPA010558: AB_1078439"	"unprognostic (1.81e-2)"	"unprognostic (1.25e-1)"	"unprognostic (7.61e-2)"	"unprognostic (3.95e-2)"	"unprognostic (8.93e-2)"	"unprognostic (3.99e-2)"	"unprognostic (5.18e-2)"	"unprognostic (9.53e-3)"	"unprognostic (1.89e-2)"	"unprognostic (2.29e-1)"	"unprognostic (4.78e-2)"	"unprognostic (1.59e-1)"	"prognostic unfavorable (5.05e-4)"	"unprognostic (3.69e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.25e-1)"	44.8	34.2	24.7	25.5	23.4	8.8	76.9	15.9	22.9	38.1	23.9	15.0	29.0	8.7	26.1	24.9	22.7	23.1	31.1	31.9	21.9	19.7	37.2	71.2	36.3	70.0	25.8	14.7	42.1	16.4	35.8	36.2	97.0	22.5	31.9	17.1	20.0	26.3	33.0	27.1	12.5	20.6	36.6	33.8	35.5	19.7	13.7	20.3	19.4	37.6	12.5	18.7	33.7	51.1	0.7	2.1	0.9	3.8	0.8	21.0	4.0	9.5	11.9	3.9	9.2	27.6	57.7	15.9	28.5	58.7	15.4	22.9	16.7	9.2	0.3	21.4	17.6	35.0	4.1	3.0	8.5	31.6	0.8	3.1	2.2	9.8	13.7	65.6	0.2	4.6	50.5	4.6	33.4	16.3	22.9	35.1	0.8	1.6	40.2	17.7	1.6	0.4	0.4	0.6	1.2	3.9	0.5	10.8	5.5	8.4	5.6	2.1	3.4	11.5	3.8	11.7	10.7	19.2	1.5	56.4	5.9	6.7	24.1	15.0	9.9	4.2	0.3	15.9	0.4	15.5	0.2	3.8	0.1	0.8	3.5	0.4	0.7	4.9	0.8	2.1	0.6	21.0	5.9	0.9	0.8	0.6	1.8	3.4	4.0	24.7	23.4	15.9	22.9	21.9	19.7	25.8	14.7	22.5	20.3	125.0	112.6	23.8	82.7	92.3	54.8	67.9	140.1	99.0	149.0	64.6	33.4	63.8	6.6	64.2	9.5	210.0	31.1	23.3	53.6	60.1	240.2	110.2	31.3	186.2	46.3	15.9	19.0	851.3	103.7	11.5	98.1	51.0	75.9	21.6	29.0	179.7	66.2	30.6	122.7	46.2	33.9	97.0	142.0	37.1	34.3	73.0	85.1	35.0	13.3	89.2
IL7R	CD127	ENSG00000168685	"Interleukin 7 receptor"	P16871	5	35852695-35879603	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 70.3;intestine: 34.0;lung: 52.6;lymphoid tissue: 133.1"	"Group enriched"	"Detected in many"	5	"monocytes: 441.0;T-cells: 326.6"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"gdT-cell: 19.2;MAIT T-cell: 70.3;memory CD4 T-cell: 39.9;memory CD8 T-cell: 28.0;naive CD4 T-cell: 34.5;naive CD8 T-cell: 22.5;NK-cell: 19.1"	"Group enriched"	"Detected in many"	33	"NK-cells: 19.1;T-cells: 70.3"	"Cell line enhanced"	"Detected in many"		"BJ: 22.2;BJ hTERT+ SV40 Large T+: 20.1;fHDF/TERT166: 41.6;HBF TERT88: 38.3;REH: 86.5"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"CAB010215, HPA067550"			Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA		180000	"Plasma membrane"		"CAB010215: AB_673727, HPA067550: "	"unprognostic (2.93e-3)"	"unprognostic (3.38e-2)"	"unprognostic (3.82e-3)"	"unprognostic (5.58e-3)"	"unprognostic (3.06e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.51e-3)"	"unprognostic (5.53e-2)"	"unprognostic (1.12e-1)"	"unprognostic (9.29e-3)"	"unprognostic (1.43e-1)"	"unprognostic (2.69e-1)"	"unprognostic (1.76e-2)"	"unprognostic (5.64e-2)"	"unprognostic (3.27e-3)"	"unprognostic (2.22e-1)"	"unprognostic (1.78e-1)"	6.7	3.6	0.7	34.0	0.7	3.1	4.8	0.5	0.6	4.8	20.6	0.3	0.9	3.5	1.8	2.9	6.6	3.7	8.5	1.9	0.7	0.7	7.0	2.7	52.6	133.1	0.8	0.1	2.5	1.7	0.0	1.5	1.2	0.8	3.3	5.4	1.7	13.2	1.8	0.9	1.8	34.0	1.2	1.5	32.3	7.8	3.0	0.4	130.9	5.1	5.3	42.9	12.6	4.6	0.4	0.3	1.3	0.2	19.1	70.3	12.7	0.1	0.0	0.1	0.1	0.1	0.1	0.2	22.2	11.2	20.1	11.9	0.1	0.1	2.1	0.0	41.6	3.7	3.5	0.0	1.3	38.3	1.8	0.2	0.6	2.4	0.0	0.3	0.2	1.6	0.3	0.0	4.3	0.9	0.5	0.5	0.1	0.1	0.3	15.7	0.0	0.5	0.2	0.1	0.0	1.0	86.5	1.2	0.1	0.0	1.2	0.0	0.0	3.7	0.3	0.0	0.1	0.1	0.0	1.5	7.9	13.4	3.4	2.9	0.2	0.0	2.5	4.0	2.1	6.1	0.5	0.2	0.1	19.2	0.2	70.3	0.2	39.9	28.0	0.1	0.4	34.5	22.5	1.3	19.1	0.2	0.3	6.7	12.7	0.7	0.7	0.5	0.6	0.7	0.7	0.8	0.1	0.8	0.4	14.9	19.4	10.9	1.9	10.3	0.0	3.2	0.0	10.7	4.5	0.0	0.0	0.1	0.0	0.9	0.1	3.6	0.0	23.3	1.6	0.1	7.1	1.1	18.5	4.5	10.4	0.0	0.0	17.8	12.7	0.0	0.0	79.7	20.3	441.0	0.0	0.0	0.2	0.9	0.0	0.6	0.0	0.0	9.0	0.0	0.0	9.2	0.2	326.6	0.0	3.8
IL9R	CD129	ENSG00000124334	"Interleukin 9 receptor"	Q01113	X	155997581-156010817	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"blood: 6.3;urinary bladder: 10.9"	"Cell type enriched"	"Detected in some"	4	"granulocytes: 4.6"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 1.4"	"Group enriched"	"Detected in some"	6	"basal ganglia: 1.7;pons and medulla: 4.7;thalamus: 1.5"	"Cell type enhanced"	"Detected in many"		"eosinophil: 6.3"	"Group enriched"	"Detected in many"	25	"B-cells: 4.1;granulocytes: 6.3;T-cells: 2.4"	"Cell line enriched"	"Detected in some"	11	"HMC-1: 76.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA063240, HPA064557"	Approved				"Intracellular and membrane"	NA	NA					"HPA063240: AB_2732700, HPA064557: AB_2732716"	"unprognostic (1.07e-2)"	"unprognostic (3.27e-3)"	"unprognostic (9.52e-3)"	"unprognostic (4.13e-2)"	"unprognostic (7.35e-2)"	"unprognostic (3.26e-4)"	"unprognostic (8.94e-2)"	"unprognostic (3.56e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.82e-1)"	"unprognostic (2.90e-2)"	"unprognostic (2.04e-1)"	"unprognostic (3.98e-8)"	"unprognostic (2.06e-1)"	"unprognostic (2.38e-1)"	"unprognostic (4.07e-1)"	"prognostic favorable (1.90e-7)"	0.3	0.1	0.3	1.1	1.7	0.4	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.7	3.0	0.3	0.5	0.4	0.9	0.3	0.3	0.2	0.3	0.5	1.3	3.2	0.3	0.3	0.3	0.3	0.0	0.3	0.3	4.7	0.4	1.2	0.3	0.4	0.3	0.3	0.4	2.4	0.3	0.3	3.5	0.8	0.3	1.5	0.3	0.4	0.3	2.9	10.9	0.3	4.1	0.0	6.3	0.0	0.1	2.4	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	7.0	0.0	0.0	0.0	0.1	76.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.0	0.2	0.0	0.3	2.7	1.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.3	0.1	0.2	0.0	0.1	0.0	0.0	0.0	6.3	0.0	0.0	0.0	1.8	0.8	1.3	0.0	4.1	0.0	0.0	1.8	0.1	0.0	0.0	2.4	0.3	0.3	1.7	0.4	0.3	0.3	0.2	0.3	0.3	4.7	1.5	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0
INSR	CD220	ENSG00000171105	"Insulin receptor"	P06213	19	7112255-7294034	"CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Carbohydrate metabolism"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Diabetes mellitus, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pancreas: 64.5"	"Cell type enhanced"	"Detected in many"	4	"Peritubular cells: 230.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	7	"dendritic cells: 8.8;granulocytes: 5.1;monocytes: 10.5"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 31.3;U-266/70: 23.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036302, HPA036303"	Uncertain		Approved	"Vesicles,Plasma membrane"		NA	NA		72000	Vesicles	"Plasma membrane"	"HPA036302: AB_2675048, HPA036303: "	"unprognostic (4.64e-2)"	"unprognostic (2.42e-1)"	"unprognostic (9.65e-3)"	"unprognostic (9.70e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.15e-2)"	"unprognostic (2.58e-1)"	"unprognostic (5.09e-2)"	"unprognostic (1.97e-1)"	"unprognostic (3.05e-1)"	"unprognostic (9.29e-2)"	"unprognostic (1.86e-1)"	"unprognostic (6.33e-2)"	"unprognostic (3.45e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.75e-1)"	"unprognostic (8.82e-2)"	13.9	14.7	7.1	3.5	8.2	4.5	12.0	12.0	8.2	10.3	15.2	11.7	10.6	8.4	15.5	6.1	4.7	13.1	7.7	17.7	6.4	5.8	18.7	32.5	5.3	2.2	10.1	4.9	28.3	64.5	11.6	11.6	26.2	8.0	10.5	8.9	11.0	12.0	10.6	15.1	7.3	16.0	10.6	6.8	47.3	8.7	6.9	9.7	2.2	17.1	5.0	3.2	11.3	16.0	1.1	8.8	5.1	10.5	0.8	0.7	1.3	3.8	2.1	2.0	3.0	10.9	3.8	6.5	2.2	2.0	1.2	1.2	5.4	4.4	4.8	5.4	3.9	2.6	1.0	4.7	1.0	0.7	0.0	3.8	0.0	1.5	11.8	4.7	2.2	3.9	5.9	2.4	0.1	2.8	2.4	2.2	2.7	5.9	31.3	0.9	1.7	1.7	3.9	1.8	2.0	3.4	16.7	1.1	4.2	0.1	15.8	3.7	2.9	3.9	2.1	2.1	3.7	1.0	11.0	2.0	2.3	1.4	4.9	2.8	23.1	12.6	11.2	2.6	3.9	0.0	2.0	8.2	5.1	0.2	7.8	0.3	0.8	0.3	0.1	8.8	1.1	0.7	0.1	1.7	0.8	10.5	7.4	0.0	1.3	7.1	8.2	12.0	8.2	6.4	5.8	10.1	4.9	8.0	9.7	44.7	26.7	8.2	54.6	57.7	38.7	85.3	107.0	41.5	50.0	59.3	74.6	15.8	13.3	41.1	2.9	52.3	87.1	0.0	68.2	39.2	29.8	84.0	3.5	214.7	8.6	36.5	157.1	201.3	47.7	3.6	89.2	26.7	49.0	8.2	103.9	26.9	67.8	56.1	230.5	116.2	22.2	58.2	42.3	6.2	1.2	60.1	32.0	6.4	56.3	113.2
ITGA1	"CD49a, VLA1"	ENSG00000213949	"Integrin subunit alpha 1"	P56199	5	52787896-52959210	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"Alveolar cells type 1: 50.6;Alveolar cells type 2: 39.3;Endothelial cells: 75.2;Fibroblasts: 29.3;Hepatocytes: 101.1;Ito cells: 98.2;Sertoli cells: 97.0;Smooth muscle cells: 74.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory CD8 T-cell: 1.8"	"Group enriched"	"Detected in many"	5	"granulocytes: 1.2;T-cells: 1.8"	"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 21.4;HHSteC: 26.3;WM-115: 19.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA042555	Uncertain					NA	NA		2300000			"HPA042555: AB_10794281"	"unprognostic (1.48e-1)"	"unprognostic (1.07e-2)"	"unprognostic (2.44e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.38e-1)"	"unprognostic (9.89e-3)"	"unprognostic (2.74e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.79e-3)"	"unprognostic (1.50e-2)"	"unprognostic (2.62e-1)"	"unprognostic (9.86e-2)"	"prognostic unfavorable (2.24e-4)"	"unprognostic (3.13e-3)"	"unprognostic (2.06e-2)"	"unprognostic (1.07e-2)"	"unprognostic (1.62e-2)"	22.6	20.2	2.3	12.7	2.7	0.0	12.4	1.2	2.9	10.9	28.2	1.5	13.6	5.3	15.9	12.5	22.3	9.2	13.9	11.1	2.5	2.2	17.9	40.4	28.8	10.2	3.1	1.4	9.6	3.3	11.5	3.0	24.8	3.3	26.1	8.2	5.9	2.9	18.2	9.7	2.4	13.5	52.8	2.7	66.0	16.8	4.1	1.6	0.6	10.7	3.5	2.2	42.7	17.8	0.0	0.1	1.2	0.3	0.0	1.8	0.1	0.0	0.0	2.0	0.0	5.9	1.7	1.2	2.8	7.3	1.6	4.9	3.8	0.3	0.0	0.9	21.4	4.8	1.4	0.4	2.4	1.5	0.0	1.5	0.0	3.5	2.7	26.3	0.0	0.0	4.0	0.2	2.0	0.7	4.5	0.3	0.1	0.0	0.0	2.5	0.0	0.8	0.0	1.2	0.1	0.7	0.0	2.0	0.0	3.1	0.0	0.1	9.2	2.8	0.7	0.6	6.0	0.0	0.0	2.2	4.5	0.4	0.1	1.4	0.0	0.0	0.0	2.9	0.0	19.5	0.0	0.3	1.1	0.1	0.0	0.0	0.0	0.6	1.8	0.1	0.0	0.2	0.0	1.2	0.0	0.0	0.0	0.1	0.1	2.3	2.7	1.2	2.9	2.5	2.2	3.1	1.4	3.3	1.6	50.6	39.3	2.2	3.3	2.9	1.7	10.4	2.5	10.7	14.8	5.2	2.0	1.2	1.7	2.6	16.7	75.2	5.2	0.0	4.8	12.0	29.3	1.3	9.3	101.1	2.0	0.0	15.7	98.2	9.7	4.1	8.6	3.9	6.8	14.4	11.8	0.2	12.6	7.0	7.8	15.3	1.6	97.0	74.8	0.9	0.7	2.8	2.9	15.2	9.9	1.7
ITGA2	CD49b	ENSG00000164171	"Integrin subunit alpha 2"	P17301	5	52989326-53094779	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Basal glandular cells: 300.3;Glandular cells: 266.4;Pancreatic endocrine cells: 350.7;Urothelial cells: 321.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 29.9;HaCaT: 30.2;hTERT-RPE1: 28.1;HUVEC TERT2: 27.8;TIME: 23.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB017690, HPA060991, HPA063556"	Enhanced		Approved	Nucleoplasm,Cytosol		Yes	No		46000000	Nucleoplasm	Cytosol	"CAB017690: AB_1124939, HPA060991: AB_2684405, HPA063556: AB_2685040"	"unprognostic (8.35e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.85e-3)"	"unprognostic (1.07e-1)"	"unprognostic (1.22e-1)"	"unprognostic (3.70e-2)"	"unprognostic (2.67e-3)"	"unprognostic (2.38e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.69e-2)"	"prognostic unfavorable (1.02e-5)"	"unprognostic (4.27e-1)"	"unprognostic (3.88e-2)"	"unprognostic (2.87e-2)"	"unprognostic (1.84e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.11e-1)"	1.9	14.0	2.9	4.7	13.4	0.4	7.9	1.8	6.8	7.1	6.5	22.5	12.1	7.6	5.1	10.4	16.7	2.8	9.3	2.5	5.4	3.6	15.1	1.8	17.2	1.4	18.3	4.5	1.8	2.7	16.1	2.5	4.8	10.7	8.5	6.0	0.8	15.8	16.8	1.2	16.9	17.0	2.5	8.4	9.1	7.4	1.3	13.0	1.5	2.5	7.4	10.0	7.5	11.1	0.5	1.5	1.7	0.6	0.2	0.6	0.3	19.4	5.0	0.4	0.2	1.3	2.4	1.5	19.6	29.9	0.7	1.2	9.3	13.7	0.0	3.4	8.3	11.5	30.2	1.6	22.1	2.8	0.0	1.5	1.4	1.2	5.5	4.5	0.2	0.4	0.9	3.8	19.7	3.5	28.1	27.8	1.0	0.0	0.0	0.5	3.6	0.2	0.0	1.2	5.0	10.0	0.0	0.1	0.0	6.3	10.3	0.2	1.1	1.0	1.3	2.0	0.8	3.2	0.0	23.8	3.6	2.1	0.5	3.9	0.0	0.0	0.0	21.6	0.0	15.8	1.7	0.6	0.2	0.6	0.2	0.4	0.4	0.5	0.5	0.1	0.5	0.5	0.6	0.8	0.2	0.1	1.5	0.4	0.3	2.9	13.4	1.8	6.8	5.4	3.6	18.3	4.5	10.7	13.0	53.6	13.6	0.0	300.3	134.2	2.3	1.2	20.4	88.3	161.5	50.6	3.9	0.2	8.3	157.1	0.0	15.8	20.6	0.0	144.3	1.6	1.9	266.4	1.1	0.0	0.3	0.0	13.3	5.5	0.0	0.0	1.1	3.8	11.8	1.8	32.4	18.0	350.7	15.2	0.0	2.9	5.0	0.0	4.2	0.0	0.9	32.5	0.3	1.9	28.1	321.7
ITGA2B	"CD41, CD41B, GP2B, PPP1R93"	ENSG00000005961	"Integrin subunit alpha 2b"	P08514	17	44372180-44389505	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 28.5;epididymis: 25.2;lymphoid tissue: 22.8"	"Cell type enhanced"	"Detected in some"	11	"Cone photoreceptor cells: 7.9;Early spermatids: 14.4;granulocytes: 18.4;Late spermatids: 20.0"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	10	"basophil: 28.5"	"Lineage enriched"	"Detected in single"	54	"granulocytes: 28.5"	"Group enriched"	"Detected in some"	13	"HEL: 71.0;HMC-1: 121.4"	"Low region specificity"	"Detected in single"							"CAB018611, HPA031168, HPA031169, HPA031170, HPA031171"	Enhanced		Approved	"Plasma membrane"		NA	NA		1100000000	"Plasma membrane"		"CAB018611: AB_2265153, HPA031168: AB_10664706, HPA031169: AB_10669671, HPA031170: AB_10696214, HPA031171: AB_10669773"	"unprognostic (6.11e-2)"	"unprognostic (3.23e-2)"	"unprognostic (1.23e-1)"	"unprognostic (4.85e-2)"	"unprognostic (1.59e-2)"	"unprognostic (3.98e-3)"	"unprognostic (4.23e-5)"	"unprognostic (1.25e-1)"	"unprognostic (1.33e-2)"	"unprognostic (7.22e-2)"	"unprognostic (2.97e-3)"	"unprognostic (1.30e-1)"	"unprognostic (8.83e-9)"	"unprognostic (7.82e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.95e-1)"	"unprognostic (2.25e-1)"	0.7	0.2	1.4	0.4	1.0	15.2	0.6	3.8	2.4	1.2	0.9	0.4	0.4	0.1	1.1	25.2	0.7	1.9	1.4	10.6	0.9	1.6	1.0	0.4	6.5	0.5	0.7	0.8	2.1	2.5	0.1	2.5	1.9	1.1	0.6	0.3	0.6	0.4	1.6	0.8	0.1	0.6	0.4	0.8	22.8	0.2	3.0	0.4	0.4	5.2	1.0	0.6	0.7	1.9	0.0	0.5	28.5	0.2	0.0	0.2	11.1	0.0	0.1	0.7	0.0	0.0	0.0	2.9	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.4	71.0	0.1	0.7	0.0	0.0	121.4	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.3	0.0	7.3	0.1	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.7	0.6	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	28.5	0.2	2.1	0.1	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	2.8	0.0	0.0	0.5	0.0	11.1	1.4	1.0	3.8	2.4	0.9	1.6	0.7	0.8	1.1	0.4	0.0	1.0	0.0	0.5	0.2	4.5	1.2	0.0	0.0	2.3	5.2	7.9	0.5	0.0	0.0	14.4	0.6	0.0	0.0	0.0	1.1	0.8	0.3	18.4	0.0	0.2	3.2	0.0	0.6	0.3	20.0	1.7	0.0	0.0	0.0	0.0	1.9	0.1	0.0	1.8	0.0	3.1	0.0	0.0	0.7	3.4	0.0	0.6	0.0	0.0	0.1
ITGA3	"CD49c, GAP-B3, MSK18, VCA-2, VLA3a"	ENSG00000005884	"Integrin subunit alpha 3"	P26006	17	50055968-50090481	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, Disease mutation, Epidermolysis bullosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	7	"Ductal cells: 96.5;Exocrine glandular cells: 90.7;Pancreatic endocrine cells: 158.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"T-reg: 1.1"	"Lineage enriched"	"Detected in single"	4	"T-cells: 1.1"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 74.4;hTERT-RPE1: 68.2;RPTEC TERT1: 65.6;U-87 MG: 111.7;WM-115: 67.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008572, CAB018594"	Enhanced		Supported	"Plasma membrane"		NA	NA		180000	"Plasma membrane"		"CAB018594: AB_668044, HPA008572: AB_2668094"	"unprognostic (3.24e-3)"	"prognostic unfavorable (6.75e-4)"	"unprognostic (9.51e-2)"	"unprognostic (3.46e-3)"	"unprognostic (3.45e-3)"	"prognostic unfavorable (1.36e-4)"	"unprognostic (8.28e-3)"	"unprognostic (2.76e-3)"	"unprognostic (1.26e-3)"	"unprognostic (1.82e-2)"	"prognostic unfavorable (5.95e-5)"	"unprognostic (7.05e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.93e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.28e-2)"	"unprognostic (2.35e-2)"	15.7	15.8	4.1	8.6	5.1	0.1	8.7	7.7	6.5	10.9	20.9	2.3	8.9	17.1	11.6	11.6	12.8	14.5	32.6	8.4	4.2	5.4	36.0	1.7	37.6	3.2	3.2	6.7	10.7	8.0	13.0	11.2	26.4	4.3	12.0	8.9	11.6	10.0	9.7	6.6	17.3	37.3	11.6	3.3	6.5	13.7	3.9	1.5	3.3	36.1	13.3	8.3	19.0	8.1	0.2	0.0	0.0	0.0	0.0	1.1	0.2	20.4	27.1	0.1	0.8	0.5	2.1	4.4	9.6	20.7	14.5	11.1	0.6	31.9	0.0	60.6	6.9	48.4	14.6	0.2	74.4	8.9	2.5	0.4	0.0	6.8	0.1	12.8	0.0	0.6	2.6	36.7	14.5	64.6	68.2	10.6	1.0	0.0	0.3	27.3	5.9	0.0	0.0	0.6	9.2	16.4	0.0	1.4	1.5	65.6	35.7	1.1	0.4	10.4	1.4	24.0	6.9	2.4	0.2	23.0	64.8	20.4	0.6	37.3	0.9	1.5	0.6	111.7	0.2	67.3	0.0	0.0	0.0	0.8	0.0	1.0	0.2	0.1	0.1	0.0	0.2	0.2	0.6	0.0	0.0	0.0	0.0	1.1	0.2	4.1	5.1	7.7	6.5	4.2	5.4	3.2	6.7	4.3	1.5	50.6	29.6	5.7	51.4	50.9	14.4	4.4	33.1	4.0	27.3	73.3	23.6	1.8	0.0	96.5	0.4	11.2	77.3	0.0	90.7	2.6	4.5	26.1	3.5	0.0	1.1	3.2	13.9	4.9	1.5	0.0	1.7	3.8	16.9	7.2	21.8	2.3	158.1	31.7	3.9	2.2	13.1	12.9	18.6	0.2	1.6	20.3	1.5	1.3	29.6	70.4
ITGA4	CD49d	ENSG00000115232	"Integrin subunit alpha 4"	P13612	2	181457202-181536187	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 38.4;lymphoid tissue: 101.6"	"Cell type enhanced"	"Detected in many"	11	"B-cells: 42.0;Erythroid cells: 70.0;monocytes: 36.1;T-cells: 59.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 39.1;HEL: 62.0;JURKAT: 32.6;MOLT-4: 72.3"	"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in many"	7	"cerebellum: 26.0"	HPA074961			Approved	"Plasma membrane"	"Intracellular and membrane"	NA	NA		100000	"Plasma membrane"		"HPA074961: AB_2732273"	"unprognostic (5.31e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.99e-2)"	"unprognostic (3.94e-2)"	"unprognostic (3.76e-1)"	"prognostic favorable (8.29e-4)"	"unprognostic (1.27e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.76e-1)"	"unprognostic (2.67e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.94e-1)"	"prognostic unfavorable (3.08e-5)"	"unprognostic (2.26e-2)"	"unprognostic (8.64e-3)"	"unprognostic (2.49e-1)"	"unprognostic (2.57e-2)"	3.8	1.7	1.3	39.7	1.1	19.2	3.2	2.4	1.9	6.7	4.8	0.5	1.1	3.8	3.0	3.1	2.9	2.1	6.9	1.7	2.9	1.3	3.0	2.5	13.6	33.7	1.2	0.5	1.8	1.6	0.0	1.3	7.1	0.9	3.8	4.9	2.9	7.5	2.0	1.0	1.5	11.6	2.4	1.6	36.0	4.4	1.2	0.2	101.6	2.6	1.5	14.3	6.0	4.1	11.0	19.1	38.4	38.3	8.8	15.9	16.2	0.0	0.2	1.0	0.0	9.2	13.9	0.0	9.0	11.3	4.8	10.2	0.0	0.0	7.2	0.0	39.1	4.2	5.3	3.2	0.1	5.8	0.0	0.7	62.0	0.2	0.0	0.9	27.4	1.5	9.9	0.0	0.3	0.0	4.7	0.5	32.6	0.0	10.5	3.0	0.0	72.3	19.2	0.8	0.0	0.0	15.9	4.5	1.0	0.0	0.0	1.6	0.6	0.0	0.0	0.3	0.4	0.0	18.1	4.9	1.5	0.9	0.1	1.8	20.5	15.2	4.1	0.8	13.6	20.8	6.7	16.2	38.4	12.9	38.3	9.7	11.0	14.6	15.9	19.1	10.0	8.5	10.4	2.1	8.8	37.5	5.0	3.7	16.2	1.3	1.1	2.4	1.9	2.9	1.3	1.2	0.5	0.9	0.2	0.0	7.9	42.0	0.2	0.2	2.4	0.8	5.1	1.4	3.4	0.0	5.9	0.1	0.0	0.0	0.0	0.0	0.0	70.0	0.0	0.2	2.9	0.3	17.4	0.0	5.8	0.0	0.0	1.8	21.0	0.0	0.6	22.7	0.0	36.1	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	1.6	0.4	0.9	0.5	0.3	59.7	0.0	0.2
ITGA5	"CD49e, FNRA"	ENSG00000161638	"Integrin subunit alpha 5"	P08648	12	54395261-54419460	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"smooth muscle: 137.7"	"Cell type enriched"	"Detected in many"	4	"Extravillous trophoblasts: 377.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 31.5"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 67.2;HUVEC TERT2: 141.7;TIME: 134.9;U-87 MG: 67.3"	"Region enriched"	"Detected in single"	7	"basal ganglia: 9.3"	"Not detected"	"Not detected"			"HPA002642, CAB009008"	Enhanced					NA	NA		23000000			"CAB009008: AB_647474, HPA002642: AB_1078469"	"unprognostic (7.51e-3)"	"prognostic unfavorable (4.07e-6)"	"prognostic unfavorable (8.43e-4)"	"unprognostic (1.58e-1)"	"unprognostic (8.51e-3)"	"prognostic unfavorable (2.91e-4)"	"prognostic unfavorable (2.23e-5)"	"prognostic unfavorable (2.44e-4)"	"unprognostic (2.76e-2)"	"unprognostic (6.19e-2)"	"unprognostic (8.99e-2)"	"unprognostic (8.28e-2)"	"prognostic unfavorable (1.32e-8)"	"unprognostic (2.11e-3)"	"unprognostic (3.35e-2)"	"prognostic unfavorable (8.89e-4)"	"unprognostic (2.18e-3)"	23.3	7.9	2.1	32.2	2.8	9.2	30.5	1.2	2.2	16.0	66.9	2.2	19.0	3.4	19.3	13.8	18.2	12.0	12.4	20.3	2.9	0.8	4.6	15.2	20.4	9.2	3.2	1.2	13.6	5.3	3.7	1.8	57.7	3.3	26.6	10.2	4.9	4.4	28.9	10.0	8.8	14.9	137.7	3.5	3.1	19.7	6.6	2.5	3.0	7.3	5.8	4.5	82.1	20.6	0.1	22.2	31.5	22.9	9.1	5.6	12.4	6.6	2.4	4.6	0.0	14.4	30.6	12.1	30.2	31.4	31.1	23.0	1.7	1.5	0.0	22.0	31.5	15.7	1.0	1.2	8.4	21.6	0.0	1.2	2.9	3.4	0.1	19.9	9.0	4.6	22.1	4.2	36.5	28.0	67.2	141.7	1.5	2.4	0.0	17.6	0.6	1.4	10.1	1.9	0.4	2.0	1.4	3.1	0.6	4.9	0.1	0.0	0.0	6.0	0.4	0.2	10.6	0.7	8.2	134.9	37.9	6.7	9.2	12.5	0.0	0.3	0.0	67.3	8.6	12.3	5.6	22.9	0.1	5.6	10.0	4.4	0.0	4.2	4.2	22.2	0.1	3.1	2.6	31.5	9.1	7.6	1.2	1.7	12.4	2.1	2.8	1.2	2.2	2.9	0.8	3.2	1.2	3.3	2.5	3.0	4.1	1.4	2.7	12.7	0.8	13.2	5.1	1.4	4.5	0.0	0.0	2.7	0.0	32.2	0.1	93.4	0.0	0.0	3.0	377.0	54.1	3.6	19.6	20.7	27.5	0.0	0.0	77.3	18.7	0.4	6.1	35.5	10.1	9.0	0.0	0.0	7.2	0.0	4.2	0.0	1.3	12.9	33.1	0.0	0.7	9.4	28.9	8.2	0.0	1.7
ITGA6	CD49f	ENSG00000091409	"Integrin subunit alpha 6"	P23229	2	172427354-172506282	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, Epidermolysis bullosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Basal glandular cells: 170.5;Basal keratinocytes: 217.4;Urothelial cells: 209.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 16.2"	"Group enriched"	"Detected in many"	34	"granulocytes: 16.2;NK-cells: 5.5;T-cells: 10.0"	"Cell line enhanced"	"Detected in many"		"BJ: 51.0;HaCaT: 56.1;HBEC3-KT: 110.4;hTCEpi: 48.1;hTERT-HME1: 48.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009009, HPA012696, HPA027582"	Enhanced					NA	NA		45000000			"CAB009009: AB_2128038, HPA012696: AB_1851822, HPA027582: AB_10602606"	"unprognostic (1.02e-1)"	"unprognostic (3.33e-1)"	"unprognostic (2.59e-2)"	"unprognostic (5.96e-2)"	"unprognostic (4.93e-2)"	"prognostic unfavorable (1.03e-4)"	"unprognostic (1.19e-1)"	"unprognostic (1.61e-3)"	"unprognostic (9.34e-2)"	"unprognostic (6.01e-2)"	"unprognostic (1.85e-3)"	"unprognostic (1.84e-1)"	"prognostic favorable (2.35e-11)"	"unprognostic (3.35e-2)"	"unprognostic (3.32e-1)"	"unprognostic (2.98e-2)"	"unprognostic (1.21e-3)"	28.0	3.1	9.8	19.1	10.5	1.6	30.1	3.0	8.4	27.0	34.9	9.4	42.3	28.5	28.2	11.3	17.0	11.1	23.8	21.7	9.7	8.2	22.0	4.9	29.0	14.9	9.8	5.1	7.6	31.3	7.4	4.9	38.7	12.6	14.3	25.2	17.6	37.1	32.4	13.5	17.5	44.2	15.2	9.6	14.9	25.0	12.4	6.9	15.1	11.5	35.2	13.2	24.1	17.3	0.3	0.1	16.2	0.2	5.5	10.0	3.3	11.6	10.0	4.4	7.8	0.2	0.1	24.0	51.0	5.5	5.2	3.2	5.6	22.3	0.1	14.4	13.5	11.9	56.1	2.9	110.4	9.5	0.1	2.6	0.2	10.7	9.3	0.7	3.2	0.3	1.0	48.1	0.3	48.9	5.3	33.4	6.3	0.0	0.8	6.6	0.5	0.9	2.8	7.9	33.2	8.6	0.1	13.1	0.2	7.9	16.4	0.1	0.5	9.4	0.0	10.9	4.8	2.1	0.2	15.0	7.3	6.6	13.5	8.8	0.7	0.5	0.3	0.2	1.1	29.4	2.6	0.2	16.2	4.2	0.0	8.5	0.2	5.4	5.0	0.1	0.3	10.0	4.6	0.5	5.5	0.0	0.0	5.7	3.3	9.8	10.5	3.0	8.4	9.7	8.2	9.8	5.1	12.6	6.9	8.9	15.0	7.5	170.5	217.4	1.2	28.0	28.1	4.0	5.7	26.2	53.0	80.2	5.0	26.3	28.6	129.7	78.8	0.0	53.3	26.5	14.5	163.8	8.1	17.0	24.0	1.6	55.0	14.1	1.6	33.8	3.7	9.2	49.0	0.0	103.3	1.5	85.9	64.5	2.5	49.4	12.5	0.0	12.7	3.3	25.5	73.4	18.7	14.9	95.0	209.9
ITGAD	"ADB2, CD11d"	ENSG00000156886	"Integrin subunit alpha D"	Q13349	16	31393312-31426505	"CD markers, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	9	"lymphoid tissue: 25.4"	"Cell type enhanced"	"Detected in single"	21	"Kupffer cells: 2.2"	"Low cancer specificity"	"Detected in single"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 1.1;NK-cell: 2.6"	"Group enriched"	"Detected in many"	19	"NK-cells: 2.6;T-cells: 1.1"	"Cell line enhanced"	"Detected in single"		"NB-4: 1.7"	"Low region specificity"	"Detected in many"							HPA026786	Uncertain					NA	NA					"HPA026786: AB_10603773"	"unprognostic (2.79e-2)"	"unprognostic (2.39e-4)"	"unprognostic (2.88e-2)"	"unprognostic (3.24e-2)"	"unprognostic (6.17e-2)"	"unprognostic (1.79e-2)"	"unprognostic (7.44e-4)"	"unprognostic (6.99e-3)"	"unprognostic (6.89e-3)"	"unprognostic (5.02e-4)"	"unprognostic (5.50e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.74e-1)"	"unprognostic (3.80e-2)"	"unprognostic (3.17e-1)"	"unprognostic (8.10e-2)"	"unprognostic (5.51e-2)"	0.3	0.1	0.1	1.0	0.1	2.5	0.2	0.1	0.1	0.2	0.1	0.0	0.0	0.0	1.2	0.0	0.4	0.2	0.2	0.2	0.1	0.1	0.1	1.2	0.7	4.0	0.1	0.0	1.6	0.1	0.0	0.1	1.2	0.0	0.1	0.0	0.2	1.5	0.0	1.3	0.1	0.3	0.0	0.2	25.4	0.1	0.2	0.0	0.4	0.1	0.0	1.4	0.2	0.1	0.0	0.0	0.0	0.0	2.6	1.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.9	0.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.2	1.7	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	2.6	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.6	2.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0
ITGAE	"CD103, HUMINAE"	ENSG00000083457	"Integrin subunit alpha E"	P38570	17	3714628-3801243	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 20.2;lung: 25.9;lymphoid tissue: 13.0"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"MAIT T-cell: 3.1;memory CD8 T-cell: 7.4;T-reg: 1.9"	"Lineage enriched"	"Detected in many"	7	"T-cells: 7.4"	"Cell line enriched"	"Detected in single"	21	"MOLT-4: 16.3"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA036313, HPA052147"	Enhanced					NA	NA		13000			"HPA036313: AB_10795355, HPA052147: "	"unprognostic (9.81e-2)"	"unprognostic (1.78e-3)"	"unprognostic (7.86e-2)"	"prognostic favorable (1.04e-4)"	"unprognostic (2.17e-1)"	"unprognostic (1.45e-2)"	"unprognostic (2.91e-1)"	"unprognostic (8.02e-2)"	"unprognostic (2.92e-2)"	"unprognostic (1.10e-1)"	"prognostic favorable (5.78e-4)"	"unprognostic (3.34e-2)"	"prognostic unfavorable (1.13e-8)"	"unprognostic (8.40e-3)"	"unprognostic (1.15e-1)"	"unprognostic (1.82e-2)"	"prognostic favorable (3.56e-4)"	3.6	0.2	0.3	13.0	0.6	8.0	0.9	0.2	0.2	0.6	9.6	0.2	0.0	4.9	0.4	0.4	2.0	1.5	2.7	0.2	0.5	0.4	0.3	0.3	25.9	8.1	0.3	0.0	0.9	1.2	0.5	0.4	0.1	0.2	1.2	2.0	0.2	1.8	3.9	0.3	0.6	20.2	2.0	0.7	1.4	3.6	1.6	0.1	3.1	1.0	1.5	5.3	1.9	2.5	0.2	0.1	0.0	1.0	0.0	7.4	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.2	0.0	0.7	16.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.2	1.0	3.1	0.2	1.0	7.4	0.1	0.0	0.0	0.2	0.0	0.0	0.6	0.0	1.9	0.9	0.3	0.6	0.2	0.2	0.5	0.4	0.3	0.0	0.2	0.1	6.0	25.5	50.2	35.5	26.7	15.9	58.6	43.3	28.1	21.6	14.0	7.9	24.2	77.9	33.2	38.9	29.2	23.6	0.0	57.0	49.7	37.3	38.0	67.9	39.4	49.2	6.4	27.1	40.5	43.7	30.3	24.7	54.5	55.6	41.5	24.9	35.9	42.9	21.0	28.0	67.5	13.0	25.8	38.1	61.9	29.7	36.1	11.0	55.3	34.6	29.8
ITGAL	"CD11A, LFA-1"	ENSG00000005844	"Integrin subunit alpha L"	P20701	16	30472658-30523185	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction, Phagocytosis"	"Integrin, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 36.7;lymphoid tissue: 74.6"	"Cell type enhanced"	"Detected in some"	19	"Alveolar cells type 2: 14.6;Hofbauer cells: 17.3;Kupffer cells: 16.8;T-cells: 66.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in some"	4	"HMC-1: 121.9"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			CAB025011	Enhanced				"Intracellular and membrane"	NA	NA		1100000			"CAB025011: "	"unprognostic (1.10e-2)"	"unprognostic (4.26e-3)"	"unprognostic (3.72e-3)"	"prognostic favorable (5.63e-5)"	"unprognostic (2.88e-1)"	"prognostic favorable (3.34e-4)"	"unprognostic (1.63e-1)"	"unprognostic (5.69e-3)"	"prognostic favorable (5.57e-4)"	"unprognostic (3.37e-2)"	"unprognostic (4.98e-2)"	"unprognostic (1.84e-1)"	"prognostic unfavorable (2.69e-5)"	"unprognostic (2.89e-1)"	"unprognostic (3.05e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.71e-2)"	2.8	1.1	1.8	29.8	2.0	15.1	1.8	0.6	1.5	1.3	3.0	2.7	0.5	2.4	1.7	1.4	2.2	2.6	4.9	1.4	1.3	1.3	2.6	6.7	16.2	29.0	3.1	1.4	1.4	1.2	0.0	1.4	1.7	1.7	2.0	3.4	1.9	6.6	0.7	0.8	1.0	12.7	1.4	4.7	44.1	3.5	0.8	2.7	74.6	2.8	2.0	41.8	4.4	1.9	2.1	7.5	7.2	36.7	9.5	22.5	11.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.2	121.9	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	27.3	0.0	0.0	8.1	0.7	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.4	4.3	0.0	0.0	0.0	0.0	0.0	7.7	2.6	0.0	0.1	0.8	0.0	3.1	8.4	6.5	22.5	16.9	11.2	2.1	8.8	16.2	7.5	1.3	4.9	11.4	7.2	9.5	36.7	3.0	6.3	11.5	1.8	2.0	0.6	1.5	1.3	1.3	3.1	1.4	1.7	2.7	6.0	14.6	8.2	0.2	0.7	0.0	1.1	0.0	12.0	3.4	1.8	0.0	0.2	0.0	0.0	0.2	0.7	0.4	0.0	0.0	0.4	0.8	0.1	4.7	3.2	17.3	0.0	0.0	4.3	16.8	0.4	0.0	5.4	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.0	0.4	0.1	0.2	0.3	0.6	66.0	0.0	0.1
ITGAM	"CD11b, CR3A, MAC-1"	ENSG00000169896	"Integrin subunit alpha M"	P11215	16	31259990-31332892	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Immunity, Innate immunity"	"Integrin, Receptor"	"Cancer-related genes, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 93.7"	"Cell type enhanced"	"Detected in many"	22	"granulocytes: 34.6;Hofbauer cells: 42.4;Kupffer cells: 152.2;Macrophages: 53.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"basophil: 29.4;classical monocyte: 19.1;eosinophil: 23.8;gdT-cell: 12.2;intermediate monocyte: 7.6;neutrophil: 21.0;NK-cell: 18.8"	"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"HMC-1: 33.5;NB-4: 11.8;U-937: 14.3"									"HPA002274, CAB025091, CAB072870"	Enhanced					NA	NA		900000			"CAB025091: , CAB072870: AB_2665722, HPA002274: AB_1078435"	"unprognostic (1.82e-2)"	"unprognostic (1.70e-2)"	"unprognostic (8.78e-2)"	"unprognostic (2.54e-2)"	"unprognostic (2.40e-2)"	"unprognostic (4.20e-2)"	"prognostic unfavorable (3.43e-4)"	"unprognostic (1.86e-1)"	"unprognostic (1.73e-1)"	"unprognostic (3.29e-3)"	"unprognostic (1.27e-1)"	"unprognostic (1.80e-1)"	"prognostic unfavorable (6.93e-5)"	"unprognostic (9.89e-2)"	"prognostic unfavorable (6.93e-4)"	"unprognostic (3.99e-2)"	"unprognostic (5.03e-2)"	19.7	5.0	6.0	14.0	7.2	93.7	6.0	2.0	4.5	2.9	3.2	9.4	0.5	1.8	2.5	3.5	2.2	4.8	4.0	6.5	4.3	3.9	3.0	3.3	14.6	22.8	10.5	1.6	2.5	2.9	1.6	1.8	4.9	5.3	3.6	2.7	3.3	3.2	2.0	1.6	1.5	4.4	6.9	8.6	29.9	2.8	1.5	7.4	2.3	2.1	1.7	6.6	4.9	4.5	1.9	3.4	29.4	19.1	18.8	12.2	8.0	0.5	1.1	0.0	0.0	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.3	0.5	0.9	0.6	0.0	0.2	0.1	0.0	0.2	0.0	4.8	0.0	0.6	0.0	0.0	0.0	1.2	33.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.1	0.1	0.0	0.0	0.0	11.8	0.0	0.0	0.0	0.2	0.0	0.6	0.0	1.3	0.0	0.0	0.0	0.3	0.2	0.0	0.1	2.7	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	14.3	0.0	29.4	19.1	23.8	12.2	7.6	0.7	1.9	1.3	3.6	3.4	0.3	0.3	3.0	21.0	18.8	1.1	0.2	0.5	8.0	6.0	7.2	2.0	4.5	4.3	3.9	10.5	1.6	5.3	7.4	3.0	15.6	5.1	0.1	1.0	0.0	1.5	2.5	0.0	2.3	0.0	0.0	0.3	0.0	1.1	0.3	0.6	0.0	0.0	0.0	0.4	1.0	0.5	34.6	0.8	42.4	0.0	3.5	1.8	152.2	1.5	0.3	53.9	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	12.9	0.0	0.4	0.7	0.9	0.7	5.4	0.0	0.1
ITGAV	"CD51, MSK8, VNRA, VTNR"	ENSG00000138448	"Integrin subunit alpha V"	P06756	2	186590065-186680901	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 7.7"	"Group enriched"	"Detected in many"	4	"granulocytes: 7.7;monocytes: 2.3"	"Cell line enhanced"	"Detected in many"		"RT4: 71.7;SuSa: 62.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002499, HPA004856"	Supported		Approved	"Focal adhesion sites,Cytosol"		NA	NA		750000	"Focal adhesion sites, Cytosol"		"CAB002499: AB_563594, HPA004856: AB_1846316"	"unprognostic (4.03e-2)"	"unprognostic (5.17e-3)"	"unprognostic (1.22e-2)"	"unprognostic (5.22e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.18e-1)"	"prognostic unfavorable (2.08e-4)"	"unprognostic (1.48e-2)"	"unprognostic (6.95e-2)"	"unprognostic (2.89e-1)"	"prognostic unfavorable (5.07e-4)"	"unprognostic (5.84e-2)"	"unprognostic (2.67e-2)"	"prognostic unfavorable (1.05e-6)"	"unprognostic (2.61e-1)"	"unprognostic (9.11e-2)"	"unprognostic (8.07e-2)"	23.2	22.1	17.9	18.3	21.8	3.1	25.8	16.7	23.1	22.9	13.6	23.4	11.6	8.4	26.0	11.4	14.2	14.5	25.2	40.7	16.8	12.3	51.5	9.5	20.6	7.6	24.2	11.6	35.4	18.7	65.0	11.0	29.6	22.1	16.5	11.9	83.4	17.9	15.9	13.1	21.5	10.1	29.6	33.0	12.1	17.3	11.2	17.0	7.8	33.1	10.9	11.1	17.6	17.9	0.3	0.9	7.7	2.3	0.4	1.1	0.5	9.3	11.1	7.4	23.7	27.3	18.5	28.3	18.3	14.8	6.5	6.5	9.7	32.2	0.0	36.1	20.6	22.7	11.7	3.8	17.2	9.4	1.8	3.4	2.2	14.6	13.3	10.8	1.5	1.4	13.4	8.2	14.4	12.3	39.0	15.4	1.1	2.1	4.7	17.2	3.7	0.9	1.3	5.6	5.6	5.6	0.0	15.2	1.2	16.8	71.7	1.5	4.6	21.1	6.5	7.7	62.1	5.1	4.3	46.8	40.2	12.6	8.2	15.4	1.1	1.9	1.0	16.2	0.6	19.8	7.7	1.1	1.6	1.0	2.3	0.7	0.3	0.5	0.8	0.9	0.1	0.5	0.5	0.5	0.4	1.2	0.4	1.1	0.5	17.9	21.8	16.7	17.3	16.8	12.3	24.2	11.6	22.1	17.0	26.8	18.5	2.4	54.8	114.0	118.2	124.7	73.9	12.0	20.5	73.3	72.6	46.9	1.7	78.4	0.5	50.4	13.2	0.0	89.0	21.8	61.3	83.9	49.5	15.8	26.1	14.3	7.0	34.4	33.9	1.6	17.8	18.2	43.9	20.8	18.9	82.5	120.4	18.2	24.4	16.5	54.8	32.3	47.2	0.7	1.4	90.7	33.2	6.9	11.4	48.6
ITGAX	CD11c	ENSG00000140678	"Integrin subunit alpha X"	P20702	16	31355134-31382997	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 47.9;blood: 31.7;lung: 33.2;lymphoid tissue: 46.3"	"Cell type enhanced"	"Detected in many"	12	"Alveolar cells type 2: 80.7;granulocytes: 70.6;Hofbauer cells: 46.3;Kupffer cells: 28.3;Macrophages: 71.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 10.1;eosinophil: 9.2;intermediate monocyte: 18.1;myeloid DC: 12.4;neutrophil: 31.7;NK-cell: 14.9;non-classical monocyte: 20.3"	"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	6	"HMC-1: 49.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB004458, HPA004723, CAB072871"	Enhanced					NA	NA					"CAB004458: AB_626859, CAB072871: AB_2665723, HPA004723: AB_1846231"	"unprognostic (9.75e-3)"	"unprognostic (2.49e-2)"	"unprognostic (1.75e-1)"	"unprognostic (1.99e-2)"	"unprognostic (1.89e-1)"	"unprognostic (2.29e-2)"	"unprognostic (1.27e-1)"	"unprognostic (9.59e-2)"	"unprognostic (8.06e-3)"	"unprognostic (3.20e-1)"	"unprognostic (7.75e-2)"	"unprognostic (3.34e-1)"	"prognostic unfavorable (1.37e-4)"	"unprognostic (3.92e-2)"	"unprognostic (3.04e-2)"	"unprognostic (2.82e-1)"	"unprognostic (2.95e-2)"	47.9	1.9	4.4	28.1	5.7	28.6	2.9	1.4	4.4	1.8	2.1	17.1	0.6	1.7	2.1	2.5	1.9	4.3	7.7	2.5	5.3	4.6	2.3	4.6	33.2	24.4	13.6	3.8	3.0	2.1	0.8	2.4	3.3	8.1	2.5	3.2	2.5	4.3	1.3	1.1	1.6	3.8	3.3	15.6	46.3	3.3	0.9	7.5	3.8	2.2	0.9	9.7	5.1	1.9	0.8	12.4	31.7	20.3	14.9	1.8	3.2	0.0	0.3	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	4.2	0.0	0.1	0.0	0.0	0.1	0.0	8.3	0.0	0.0	0.1	0.1	0.0	0.5	49.2	0.0	0.0	0.8	0.1	0.3	0.4	0.0	0.0	0.1	0.0	0.0	0.0	3.9	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	1.5	0.3	0.0	0.7	0.0	0.0	0.0	0.0	0.0	2.3	0.8	0.1	3.9	10.1	9.2	1.8	18.1	0.1	0.8	0.0	0.3	12.4	0.4	0.0	0.2	31.7	14.9	20.3	0.2	0.0	3.2	4.4	5.7	1.4	4.4	5.3	4.6	13.6	3.8	8.1	7.5	11.9	80.7	2.9	0.2	2.5	0.0	1.4	0.0	2.7	19.4	0.0	0.0	0.3	0.0	0.2	0.0	1.6	0.0	0.0	0.0	0.2	2.1	0.2	70.6	0.0	46.3	0.0	0.0	0.0	28.3	0.0	0.0	71.4	1.7	2.8	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	2.0	0.0	0.1	1.0	0.3	5.0	0.0	0.0
ITGB1	"CD29, FNRB, GPIIA, MDF2, MSK12"	ENSG00000150093	"Integrin subunit beta 1"	P05556	10	32900319-33005792	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Ductal cells: 1163.1;Pancreatic endocrine cells: 917.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"hTERT-RPE1: 196.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003434, HPA059297, HPA069003"	Enhanced		Supported	"Endoplasmic reticulum,Plasma membrane,Focal adhesion sites"		NA	NA		540000000	"Plasma membrane, Focal adhesion sites"	"Endoplasmic reticulum"	"CAB003434: AB_303570, HPA059297: AB_2732634, HPA069003: AB_2732125"	"unprognostic (3.07e-2)"	"prognostic unfavorable (5.01e-4)"	"unprognostic (8.67e-2)"	"unprognostic (4.36e-1)"	"unprognostic (1.20e-2)"	"unprognostic (3.87e-2)"	"unprognostic (1.60e-2)"	"prognostic unfavorable (3.36e-6)"	"unprognostic (3.22e-1)"	"unprognostic (2.36e-3)"	"unprognostic (3.68e-3)"	"unprognostic (2.42e-1)"	"unprognostic (1.02e-3)"	"unprognostic (1.25e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.48e-1)"	"unprognostic (3.08e-2)"	95.2	30.6	13.7	32.1	19.7	9.7	107.7	6.5	14.8	55.1	61.3	17.0	80.2	20.2	84.2	56.2	59.9	45.0	49.8	68.7	15.0	14.4	47.3	85.8	55.4	34.5	23.0	11.1	47.4	37.4	17.6	35.2	83.3	19.5	53.1	32.2	18.6	30.3	76.2	58.0	19.5	42.3	109.3	30.1	59.8	45.4	26.9	18.8	12.7	36.8	27.6	19.4	92.7	47.4	31.3	9.1	4.3	27.1	21.9	68.4	26.2	45.6	67.0	36.2	40.1	87.3	75.2	31.6	153.5	89.0	73.1	66.9	15.0	106.9	12.3	27.8	128.7	48.0	31.9	10.9	87.3	81.6	12.1	8.8	14.8	31.9	17.5	61.5	3.3	14.7	76.2	47.8	76.9	31.3	196.1	89.8	6.1	10.2	5.4	120.5	7.5	5.7	3.3	8.0	13.9	34.0	3.7	26.8	2.2	104.2	13.2	8.6	21.4	47.8	8.1	34.4	61.5	10.9	11.9	100.4	94.2	54.7	66.9	51.1	5.0	1.1	6.9	69.4	14.1	36.9	1.6	9.8	4.3	25.5	17.8	6.0	31.3	54.6	37.5	9.1	8.6	7.1	19.1	2.3	21.9	27.1	3.7	68.4	26.2	13.7	19.7	6.5	14.8	15.0	14.4	23.0	11.1	19.5	18.8	318.6	128.6	76.4	295.7	485.6	32.6	175.3	242.0	164.6	252.5	214.6	29.5	156.7	11.6	1163.1	4.3	314.7	83.6	70.0	355.7	460.3	265.1	177.2	86.6	221.3	161.3	36.5	185.6	387.9	152.7	9.7	235.6	174.3	325.6	83.0	81.4	76.8	917.0	113.2	565.7	64.3	45.2	627.3	497.4	10.0	63.7	149.1	183.8	106.6	98.8	257.2
ITGB2	"CD18, LFA-1, MAC-1, MFI7"	ENSG00000160255	"Integrin subunit beta 2"	P05107	21	44885953-44931989	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Phagocytosis"	"Integrin, Receptor"	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 159.7;bone marrow: 91.4;lymphoid tissue: 75.6"	"Group enriched"	"Detected in many"	4	"Hofbauer cells: 620.8;Kupffer cells: 458.1;Macrophages: 428.6;T-cells: 303.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"THP-1: 117.5;U-937: 87.3"					"Low region specificity"	"Detected in all"			"HPA008877, HPA016894"	Enhanced		Supported	"Plasma membrane,Rods & Rings"		NA	NA		2500000	"Plasma membrane"	"Rods & Rings"	"HPA008877: AB_1846256, HPA016894: AB_1846257"	"unprognostic (1.94e-2)"	"unprognostic (7.66e-3)"	"unprognostic (1.23e-1)"	"unprognostic (6.21e-3)"	"unprognostic (2.95e-2)"	"unprognostic (9.73e-3)"	"unprognostic (2.53e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.18e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.20e-1)"	"unprognostic (6.34e-2)"	"unprognostic (1.87e-3)"	"unprognostic (1.42e-1)"	"unprognostic (4.42e-2)"	"unprognostic (2.65e-2)"	"unprognostic (4.83e-2)"	59.1	9.8	9.0	47.5	16.8	91.4	8.4	1.7	8.0	5.6	7.4	12.2	1.2	6.3	4.9	9.0	4.8	10.7	10.3	9.7	7.2	6.4	8.1	7.0	32.9	73.8	14.3	2.9	6.6	5.1	1.1	3.3	12.7	12.1	6.9	4.2	5.2	8.8	2.7	3.0	4.1	13.2	12.3	18.3	75.6	7.6	4.2	12.2	53.5	4.5	2.2	29.0	15.7	4.2	9.5	76.0	104.6	122.9	41.0	57.4	159.7	0.2	0.7	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.0	0.0	0.0	2.5	20.3	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.2	2.4	0.0	0.4	0.0	15.3	4.0	0.2	0.0	0.0	0.0	0.0	0.0	8.1	0.1	0.2	1.0	0.5	17.4	18.5	0.0	0.0	0.3	0.2	3.6	9.5	0.7	0.0	0.1	0.2	0.5	0.3	0.3	0.0	0.0	117.5	0.3	0.0	1.0	0.0	0.5	0.1	0.8	0.4	0.0	87.3	0.1	10.5	122.9	85.7	57.4	84.1	25.8	6.7	28.4	39.5	76.0	9.5	19.1	32.0	104.6	41.0	81.0	11.6	20.7	159.7	9.0	16.8	1.7	8.0	7.2	6.4	14.3	2.9	12.1	12.2	14.9	42.5	86.5	0.5	4.8	0.0	3.5	15.3	5.3	19.4	5.2	0.0	3.4	0.0	2.7	0.5	5.2	0.0	0.0	0.3	3.3	5.7	0.5	23.1	4.3	620.8	0.0	0.0	11.6	458.1	2.1	0.6	428.6	5.0	109.2	0.1	0.3	0.4	0.0	1.4	3.4	0.6	6.5	3.1	0.2	1.1	4.4	4.7	303.6	0.2	0.6
ITGB3	"CD61, GP3A, GPIIIa"	ENSG00000259207	"Integrin subunit beta 3"	P05106	17	47253846-47311816	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"thyroid gland: 36.6"	"Cell type enhanced"	"Detected in some"	10	"Late spermatids: 4.1;Proximal tubular cells: 3.5;Sertoli cells: 6.5"	"Group enriched"	"Detected in many"	6	"melanoma: 7.5;renal cancer: 3.6;thyroid cancer: 11.5"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	19	"basophil: 2.8;neutrophil: 2.8"	"Lineage enriched"	"Detected in single"	19	"granulocytes: 2.8"	"Cell line enhanced"	"Detected in many"		"EFO-21: 46.6;HEL: 41.2;RPTEC TERT1: 26.8;U-87 MG: 21.1;WM-115: 67.2"									HPA027852	Approved		Supported	"Nucleoplasm,Plasma membrane"	"Intracellular and membrane"	NA	NA		710000000	"Plasma membrane"	Nucleoplasm	"HPA027852: AB_10601760"	"unprognostic (1.13e-2)"	"unprognostic (1.97e-3)"	"unprognostic (2.47e-1)"	"unprognostic (3.00e-2)"	"unprognostic (1.91e-2)"	"unprognostic (6.04e-3)"	"unprognostic (3.70e-1)"	"unprognostic (3.00e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.85e-1)"	"unprognostic (6.35e-2)"	"unprognostic (7.22e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.03e-2)"	"unprognostic (2.72e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.17e-3)"	10.0	0.6	1.0	6.2	2.5	2.7	7.0	0.4	1.6	4.6	13.6	0.9	2.4	2.2	9.7	5.7	6.4	6.4	2.8	8.5	0.7	0.6	16.0	3.7	5.2	1.2	2.3	0.1	4.6	0.6	0.7	1.6	23.5	1.6	6.4	4.8	1.8	2.5	11.5	4.9	2.4	5.0	17.0	1.8	9.5	3.6	2.6	0.6	0.2	36.6	1.9	0.9	11.0	7.8	0.1	0.0	2.8	0.1	0.0	0.0	9.5	0.0	0.4	0.1	0.0	2.4	1.0	0.0	1.2	6.1	2.6	2.4	0.0	0.0	0.1	46.6	0.3	3.6	0.0	0.0	0.0	3.4	0.9	0.0	41.2	0.1	0.0	2.0	0.0	0.0	1.0	0.0	15.6	0.4	1.8	11.6	0.6	0.1	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.1	0.0	1.1	0.0	26.8	0.0	0.0	0.1	1.5	0.0	8.4	2.4	0.0	0.0	12.6	0.5	0.7	0.3	2.8	0.0	0.0	0.3	21.1	0.0	67.2	2.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.8	0.0	0.0	0.0	0.0	9.5	1.0	2.5	0.4	1.6	0.7	0.6	2.3	0.1	1.6	0.6	0.0	0.0	0.0	0.1	0.1	0.0	0.8	0.0	0.0	1.2	0.0	0.0	0.0	0.0	1.1	2.7	1.4	0.0	0.0	0.4	0.0	0.8	0.1	0.0	0.8	0.8	0.0	0.0	1.8	0.0	4.1	0.3	0.3	0.0	0.0	0.0	0.0	1.0	0.0	1.1	3.5	0.0	6.5	1.9	0.0	2.3	0.4	1.0	0.0	0.0	0.1
ITGB4	CD104	ENSG00000132470	"Integrin subunit beta 4"	P16144	17	75721328-75757818	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, Disease mutation, Epidermolysis bullosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Enterocytes: 84.6;Pancreatic endocrine cells: 175.0;Syncytiotrophoblasts: 92.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 8.2"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 120.2;HaCaT: 46.0;HBEC3-KT: 102.5;hTCEpi: 35.1;RT4: 33.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB002422, CAB005258, HPA036348, HPA036349"	Enhanced		Supported	"Plasma membrane,Cell Junctions"		NA	NA		79000	"Plasma membrane, Cell Junctions"		"CAB002422: AB_563480, CAB005258: AB_2129021, HPA036348: AB_2675077, HPA036349: AB_2675078"	"unprognostic (3.17e-3)"	"unprognostic (3.52e-1)"	"unprognostic (4.19e-1)"	"unprognostic (2.27e-1)"	"unprognostic (5.75e-2)"	"unprognostic (6.11e-3)"	"unprognostic (1.28e-1)"	"prognostic unfavorable (7.18e-4)"	"unprognostic (1.05e-1)"	"unprognostic (4.14e-2)"	"prognostic unfavorable (6.39e-4)"	"unprognostic (1.02e-1)"	"unprognostic (2.23e-2)"	"unprognostic (1.65e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.43e-1)"	6.3	3.4	9.7	10.9	9.7	1.4	13.7	4.7	7.7	14.3	32.1	15.6	10.0	35.3	9.7	8.8	24.0	13.7	47.8	4.3	9.4	7.9	4.8	1.5	7.4	3.7	10.1	9.1	4.7	6.7	3.1	5.7	50.0	17.2	19.7	10.4	9.8	52.3	13.2	2.4	47.0	58.5	7.4	10.7	17.0	41.0	3.9	9.8	1.8	3.2	22.1	15.9	17.2	20.5	2.4	8.2	1.3	0.7	0.0	2.2	0.8	22.3	19.7	0.0	0.2	0.0	0.1	27.2	0.1	0.0	0.0	0.1	2.1	120.2	0.0	4.3	0.0	0.1	46.0	0.1	102.5	0.0	0.1	0.0	0.1	5.0	2.2	0.1	0.0	0.2	0.1	35.1	0.0	21.9	2.4	0.7	0.0	0.0	2.1	0.0	12.5	0.2	0.2	0.1	12.1	17.2	0.3	0.6	0.2	27.5	33.8	0.0	0.2	0.6	2.0	0.3	0.7	8.6	0.2	2.2	0.6	1.1	0.0	0.2	0.7	0.2	0.0	0.2	0.1	0.3	0.0	0.4	0.0	0.7	0.7	2.2	1.4	0.3	1.0	0.1	2.4	0.9	0.6	1.3	0.0	0.0	8.2	1.4	0.8	9.7	9.7	4.7	7.7	9.4	7.9	10.1	9.1	17.2	9.8	11.9	2.1	0.5	35.9	44.0	0.2	5.9	20.4	12.0	14.8	22.7	2.0	70.7	1.7	26.1	0.3	15.7	84.6	0.0	25.5	15.4	4.9	5.9	2.3	0.0	8.2	0.0	9.2	9.8	0.0	0.0	3.4	2.5	11.8	0.0	49.0	40.4	175.0	66.4	1.4	2.0	0.4	0.0	2.5	0.1	5.9	11.4	92.9	2.2	50.4	34.6
JAG1	"AGS, AHD, AWS, CD339, HJ1, JAGL1"	ENSG00000101384	"Jagged 1"	P78504	20	10637684-10673999	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Notch signaling pathway"	"Developmental protein"	"Deafness, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Smooth muscle cells: 154.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"eosinophil: 2.4"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 56.7;hTERT-HME1: 35.0;U-251 MG: 47.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB010343, HPA021555"	Supported		Approved	"Golgi apparatus,Plasma membrane"		NA	NA		14000000	"Golgi apparatus, Plasma membrane"		"CAB010343: AB_649685, HPA021555: AB_1851969"	"unprognostic (2.23e-1)"	"unprognostic (2.04e-2)"	"unprognostic (1.78e-1)"	"unprognostic (4.15e-2)"	"unprognostic (1.21e-1)"	"unprognostic (6.42e-2)"	"unprognostic (4.21e-2)"	"unprognostic (8.94e-3)"	"unprognostic (6.07e-2)"	"unprognostic (5.20e-2)"	"prognostic unfavorable (4.10e-6)"	"unprognostic (5.48e-2)"	"unprognostic (1.71e-3)"	"unprognostic (2.22e-1)"	"unprognostic (1.66e-1)"	"unprognostic (3.10e-1)"	"unprognostic (1.41e-3)"	27.7	5.6	6.8	14.5	5.4	9.7	56.5	2.9	6.7	34.2	20.1	4.3	17.4	7.2	26.1	22.8	33.9	16.7	23.1	18.8	5.4	5.1	12.9	3.8	22.0	12.4	5.4	4.0	14.7	22.2	21.7	6.0	36.3	6.0	19.2	12.7	21.4	11.2	23.4	16.8	34.8	11.7	21.4	13.0	14.2	13.4	9.1	3.8	1.5	14.5	24.6	16.1	18.7	31.4	0.0	0.9	2.4	2.0	0.4	0.1	0.4	1.0	5.3	16.6	20.4	3.2	3.1	0.6	0.6	3.1	0.9	0.4	4.7	2.9	0.1	15.7	0.6	4.7	22.2	2.4	56.7	0.7	0.0	1.1	1.7	0.5	22.2	1.5	7.1	0.1	1.2	16.8	2.8	35.0	3.3	5.5	0.0	0.0	2.3	1.5	0.0	0.0	5.1	4.8	17.5	5.3	1.3	1.0	3.3	8.0	6.5	0.7	0.5	1.6	1.1	6.7	13.8	0.1	0.8	20.7	3.8	2.6	3.1	47.7	0.9	0.1	0.2	2.4	2.6	2.9	0.0	2.0	2.4	0.0	0.2	0.0	0.0	0.0	0.0	0.7	0.0	0.1	0.0	1.6	0.4	0.3	0.9	0.0	0.4	6.8	5.4	2.9	6.7	5.4	5.1	5.4	4.0	6.0	3.8	38.7	12.5	0.0	46.4	93.0	10.0	12.5	35.7	20.1	22.7	15.7	41.2	12.0	1.7	26.8	3.9	70.8	26.0	0.0	27.0	0.9	33.7	18.4	6.9	1.5	3.7	20.6	5.1	38.1	3.7	6.3	19.8	7.7	13.5	1.8	10.2	9.3	60.7	22.4	31.8	2.1	72.6	84.1	154.6	0.7	2.8	93.3	1.8	0.0	22.9	32.5
JAM2	"C21orf43, CD322, JAM-B, JAMB, VE-JAM"	ENSG00000154721	"Junctional adhesion molecule 2"	P57087	21	25639272-25717562	"CD markers, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 66.7"	"Cell type enhanced"	"Detected in many"	20	"Cardiomyocytes: 31.9;Endothelial cells: 151.0;Ito cells: 49.7"	"Cancer enriched"	"Detected in all"	9	"glioma: 27.2"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"AF22: 18.2;BJ hTERT+: 11.6;HDLM-2: 11.3;hTERT-RPE1: 16.2;U-138 MG: 13.1;U-87 MG: 9.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA028789, HPA077346"			Supported	"Nucleoplasm,Plasma membrane"		NA	NA		17000	"Plasma membrane"	Nucleoplasm	"HPA028789: AB_2732443, HPA077346: AB_2732341"	"unprognostic (1.42e-1)"	"unprognostic (6.39e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.02e-2)"	"unprognostic (1.53e-2)"	"unprognostic (7.51e-4)"	"unprognostic (2.61e-2)"	"unprognostic (4.55e-1)"	"unprognostic (1.02e-1)"	"unprognostic (3.46e-2)"	"unprognostic (3.81e-1)"	"unprognostic (8.86e-2)"	"unprognostic (5.71e-3)"	"unprognostic (2.18e-1)"	"unprognostic (2.20e-1)"	"unprognostic (4.85e-3)"	16.6	17.2	13.8	8.4	18.9	1.5	14.6	9.9	23.4	18.1	14.7	14.5	8.0	7.5	20.5	13.5	13.3	12.0	14.4	21.9	13.5	12.5	6.5	3.5	17.1	4.6	17.6	13.5	18.9	3.9	5.8	7.7	66.7	18.5	12.0	9.7	11.1	5.5	18.0	8.4	6.9	9.2	21.8	23.0	2.8	9.7	25.8	12.2	0.6	9.5	10.1	6.3	13.5	15.1	3.1	1.9	1.9	0.7	2.8	1.1	0.4	0.0	0.0	18.2	0.1	0.7	0.2	0.4	0.5	11.6	1.5	5.5	0.0	0.0	0.1	0.0	0.2	7.0	0.0	1.6	0.0	3.4	11.3	0.5	0.1	0.0	0.0	0.0	0.0	0.1	1.0	0.0	1.3	0.0	16.2	0.0	0.4	0.0	0.2	5.6	0.1	0.3	0.1	5.7	0.1	0.0	2.1	3.7	0.0	0.0	0.0	0.3	2.7	0.1	0.2	0.0	0.2	0.6	0.1	0.0	13.1	1.2	0.1	1.8	1.5	0.0	0.0	9.6	0.1	0.5	1.4	0.7	0.3	0.4	0.5	0.6	0.3	0.4	0.9	0.4	3.1	0.7	1.1	1.9	2.8	0.6	1.9	0.2	0.4	13.8	18.9	9.9	20.5	13.5	12.5	17.6	13.5	18.5	12.2	0.0	2.9	1.4	1.4	6.6	1.5	31.9	0.0	1.4	0.0	3.5	13.7	0.3	0.0	0.3	12.9	151.0	0.0	0.0	0.2	2.2	18.5	1.2	0.0	0.0	1.0	0.0	0.0	49.7	2.2	13.2	9.2	1.4	15.1	0.0	0.0	0.9	0.1	0.0	23.0	0.0	3.6	0.0	7.6	4.8	3.9	5.8	0.7	0.0	0.0	0.7
KDR	"CD309, FLK1, VEGFR, VEGFR2"	ENSG00000128052	"Kinase insert domain receptor"	P35968	4	55078259-55125595	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation, Host-virus interaction"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"Endothelial cells: 100.3;Ito cells: 200.7;Muller glia cells: 229.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"HUVEC TERT2: 32.5;TIME: 36.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB004028	Enhanced		Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA		7400000	"Plasma membrane"		"CAB004028: AB_2212507"	"unprognostic (1.61e-1)"	"unprognostic (2.03e-1)"	"unprognostic (9.65e-2)"	"unprognostic (1.97e-1)"	"unprognostic (9.63e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.78e-3)"	"unprognostic (2.59e-2)"	"unprognostic (1.19e-2)"	"unprognostic (1.10e-1)"	"unprognostic (8.79e-3)"	"unprognostic (1.34e-1)"	"prognostic unfavorable (7.26e-4)"	"unprognostic (4.00e-2)"	"unprognostic (2.30e-1)"	"unprognostic (3.22e-1)"	"unprognostic (1.86e-1)"	19.7	6.2	1.8	4.4	3.1	0.4	20.5	1.1	2.2	11.4	6.0	1.8	11.5	2.3	28.8	10.2	5.2	9.5	6.2	12.1	2.3	1.7	7.8	10.4	13.2	14.1	3.1	2.9	6.0	8.1	8.0	6.8	34.5	3.9	9.5	1.4	27.6	7.1	10.3	5.3	3.0	3.8	7.7	2.6	4.4	4.2	5.3	1.2	0.5	20.0	5.3	3.0	4.4	12.0	0.1	0.1	0.7	0.0	0.2	0.2	0.1	0.0	0.0	1.7	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	3.8	0.0	0.0	0.3	0.0	0.0	0.2	0.2	32.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.8	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.7	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.4	0.0	0.1	0.1	0.0	0.7	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.1	1.8	3.1	1.1	2.2	2.3	1.7	3.1	2.9	3.9	1.2	0.0	8.2	7.5	0.4	2.3	7.4	4.8	0.0	6.7	30.7	0.0	0.0	0.1	0.0	0.5	0.8	100.3	0.0	0.0	0.0	0.1	1.9	0.4	2.3	1.3	0.4	0.0	0.0	200.7	14.5	0.6	0.0	1.0	6.8	0.0	0.0	229.2	0.3	0.0	0.4	0.0	6.0	0.0	1.4	0.2	0.2	2.4	0.1	0.0	0.0	0.4
KEL	"CD238, ECE3"	ENSG00000197993	"Kell blood group, metallo-endopeptidase"	P23276	7	142941114-142962681	"Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Blood group antigen, Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"bone marrow: 21.1;testis: 36.4"	"Cell type enriched"	"Detected in some"	14	"Erythroid cells: 46.7"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	7	"intermediate monocyte: 1.4"	"Lineage enriched"	"Detected in single"	14	"monocytes: 1.4"	"Group enriched"	"Detected in some"	12	"HEL: 15.3;K-562: 12.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA064442			Supported	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"HPA064442: "	"unprognostic (5.78e-3)"	"unprognostic (1.08e-5)"	"unprognostic (5.29e-3)"	"unprognostic (4.85e-3)"	"unprognostic (9.68e-2)"	"unprognostic (1.96e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.54e-2)"	"unprognostic (5.18e-2)"	"unprognostic (1.08e-2)"	"unprognostic (3.71e-2)"	"unprognostic (3.57e-2)"	"unprognostic (2.29e-3)"	"unprognostic (9.24e-2)"	"unprognostic (7.05e-2)"	"unprognostic (3.32e-2)"	"unprognostic (3.25e-3)"	0.2	0.0	0.9	2.5	1.1	21.1	0.2	0.2	0.4	0.4	0.2	0.3	0.2	0.0	0.2	0.2	0.6	0.1	0.2	0.2	1.4	0.7	0.4	0.2	1.4	5.0	2.0	0.2	0.2	0.2	0.0	0.2	1.1	0.3	0.2	0.0	0.3	2.5	0.2	0.2	0.0	0.5	0.2	4.4	3.8	0.0	36.4	0.3	0.4	0.2	0.2	3.7	0.2	0.2	0.0	0.0	0.0	1.4	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	12.4	0.1	0.0	0.0	0.5	0.3	0.3	0.0	0.0	0.1	0.0	0.1	0.0	1.2	0.0	0.1	0.2	0.0	0.5	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.9	1.1	0.2	0.4	1.4	0.7	2.0	0.2	0.3	0.3	0.0	0.0	0.0	0.8	0.0	0.0	0.3	0.0	0.0	2.3	3.5	0.0	0.0	1.7	0.2	1.9	0.0	0.0	46.7	0.0	0.2	0.0	0.2	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.4	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.1	0.0	0.0	1.0
KIR2DL1	"47.11, CD158A, cl-42, nkat1, p58.1"	ENSG00000125498	"Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1"	P43626	19	54769811-54784322	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"endometrium 1: 2.8;lung: 4.0;lymphoid tissue: 4.5"	"Cell type enhanced"	"Detected in some"	30	"Alveolar cells type 2: 4.5;granulocytes: 2.3;T-cells: 9.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"gdT-cell: 1.4"	"Lineage enhanced"	"Detected in single"		"T-cells: 1.4"	"Cell line enriched"	"Detected in single"	26	"U-266/84: 2.5"															NA	NA						"unprognostic (2.14e-1)"	"unprognostic (9.82e-2)"		"unprognostic (8.18e-2)"		"unprognostic (2.19e-2)"	"unprognostic (3.93e-1)"	"unprognostic (1.55e-2)"	"unprognostic (3.19e-4)"	"unprognostic (4.11e-2)"	"unprognostic (6.87e-2)"		"unprognostic (1.14e-2)"	"unprognostic (1.13e-1)"	"unprognostic (6.84e-2)"	"unprognostic (3.61e-2)"		0.2	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.6	0.1	0.1	0.0	0.0	0.1	2.8	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.4	2.2	4.0	0.1	0.0	0.0	0.1	0.1	0.1	0.0	1.8	0.0	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.8	4.5	0.4	1.4	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.4	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.6	0.0	0.0
KIR2DL3	"CD158B2, cl-6, nkat2, nkat2a, nkat2b, p58"	ENSG00000243772	"Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3"	P43628	19	54738515-54753052	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"lung: 3.0;lymphoid tissue: 5.6"	"Group enriched"	"Detected in some"	42	"Alveolar cells type 2: 2.2;T-cells: 7.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																	NA	NA						"unprognostic (7.37e-2)"	"unprognostic (2.35e-2)"		"unprognostic (2.23e-1)"		"unprognostic (6.88e-2)"	"unprognostic (2.92e-1)"	"unprognostic (7.76e-3)"	"unprognostic (1.55e-2)"	"unprognostic (1.99e-1)"	"unprognostic (1.41e-2)"		"unprognostic (2.41e-4)"	"unprognostic (1.19e-1)"	"unprognostic (1.91e-1)"	"unprognostic (1.62e-2)"	"unprognostic (1.59e-2)"	0.5	0.1	0.0	0.1	0.0	0.1	0.2	0.0	0.5	0.1	0.1	0.0	0.0	0.1	2.1	0.1	0.1	0.2	0.1	2.2	0.0	0.0	0.1	0.4	3.0	2.4	0.0	0.0	1.0	0.1	0.1	0.0	0.8	0.1	1.3	0.1	1.1	1.9	0.1	0.1	0.1	0.1	0.1	0.0	5.6	0.1	0.1	0.8	0.6	0.1	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.8	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	7.5	0.0	0.0
KIR2DL4	"103AS, 15.212, CD158D"	ENSG00000189013	"Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4"	Q99706	19	54803535-54814517	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"blood: 5.6;intestine: 7.3;lymphoid tissue: 13.9"	"Cell type enhanced"	"Detected in some"	26	"Alveolar cells type 2: 3.4;Collecting duct cells: 1.8;granulocytes: 2.3;T-cells: 10.1"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	56	"NK-cell: 5.6"	"Lineage enriched"	"Detected in single"	56	"NK-cells: 5.6"	"Not detected"	"Not detected"																"Intracellular and membrane"	NA	NA						"unprognostic (1.98e-2)"	"unprognostic (4.16e-2)"	"unprognostic (1.84e-2)"	"unprognostic (3.70e-4)"	"unprognostic (2.23e-1)"	"unprognostic (5.95e-4)"	"unprognostic (1.34e-1)"	"unprognostic (1.49e-1)"	"unprognostic (2.92e-5)"	"unprognostic (5.15e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.32e-1)"	"unprognostic (4.53e-8)"	"unprognostic (6.47e-2)"	"unprognostic (2.66e-1)"	"unprognostic (6.10e-4)"	"unprognostic (3.59e-3)"	0.2	0.3	0.0	2.8	0.0	0.3	0.1	0.0	0.2	0.1	3.8	0.0	0.0	0.1	1.4	0.2	0.2	0.2	0.3	0.9	0.1	0.0	0.2	0.3	1.2	0.3	0.0	0.0	1.1	0.1	0.1	0.1	1.7	0.0	0.2	0.3	0.0	0.1	0.8	0.1	0.1	7.3	0.1	0.0	13.9	0.3	0.3	0.0	0.4	0.5	0.0	1.5	0.8	0.1	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.1	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.1	0.0	0.0
KIR3DL1	"AMB11, CD158E1, CD158e1/2, CD158e2, cl-11, cl-2, KIR, nkat3, NKB1, NKB1B"	ENSG00000167633	"Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1"	P43629	19	54816468-54830778	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"blood: 5.4;bone marrow: 2.0;lymphoid tissue: 3.0"	"Group enriched"	"Detected in some"	9	"Alveolar cells type 2: 3.4;granulocytes: 1.1;T-cells: 4.4"	"Not detected"	"Not detected"							"Cell type enriched"	"Detected in some"	4	"gdT-cell: 5.4"	"Lineage enriched"	"Detected in many"	4	"T-cells: 5.4"	"Not detected"	"Not detected"																	NA	NA						"unprognostic (3.18e-1)"	"unprognostic (8.01e-2)"		"unprognostic (3.53e-2)"	"unprognostic (4.85e-1)"	"unprognostic (5.18e-3)"	"unprognostic (6.19e-2)"	"unprognostic (4.37e-2)"	"unprognostic (9.97e-2)"	"unprognostic (1.89e-2)"	"unprognostic (3.28e-1)"	"unprognostic (7.34e-2)"	"unprognostic (2.07e-3)"	"unprognostic (3.22e-2)"	"unprognostic (2.07e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.19e-2)"	0.1	0.0	0.0	0.0	0.0	2.0	0.1	0.0	0.0	0.0	0.0			0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	1.1	0.1	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.2	0.0	0.0	3.0	0.0	0.0			0.1		0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	5.4	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.2	0.0	1.2	0.0	0.0	0.0	0.5											0.0	3.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0
KIR3DL2	"CD158K, cl-5, nkat4, nkat4a, nkat4b"	ENSG00000240403	"Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2"	P43630	19	54850443-54867207	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"heart muscle: 2.0;lymphoid tissue: 5.3;salivary gland: 2.0"	"Cell type enriched"	"Detected in some"	4	"T-cells: 5.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"naive CD8 T-cell: 1.2"	"Lineage enhanced"	"Detected in single"		"T-cells: 1.2"	"Not detected"	"Not detected"																	NA	NA						"unprognostic (6.99e-2)"	"unprognostic (1.83e-1)"		"unprognostic (3.64e-1)"		"unprognostic (4.56e-4)"	"unprognostic (1.40e-1)"	"unprognostic (2.99e-2)"	"unprognostic (8.39e-3)"	"unprognostic (5.96e-2)"	"unprognostic (2.73e-1)"	"unprognostic (2.12e-1)"	"unprognostic (4.04e-3)"	"unprognostic (1.22e-1)"	"unprognostic (2.58e-1)"	"unprognostic (1.65e-3)"	"unprognostic (3.62e-2)"	0.2	0.0	0.0	0.1	0.0	1.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.3	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	2.0	0.0	0.0	0.0	0.8	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	1.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.1	0.0	0.0	0.0	0.0	1.2	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0
KIT	"C-Kit, CD117, PBT, SCFR"	ENSG00000157404	"KIT proto-oncogene receptor tyrosine kinase"	P10721	4	54657918-54740715	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"breast: 65.5"	"Group enriched"	"Detected in many"	10	"granulocytes: 496.5;Melanocytes: 200.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7"	"Group enriched"	"Detected in many"	6	"granulocytes: 12.7;NK-cells: 9.7"	"Group enriched"	"Detected in some"	13	"HEL: 48.8;HMC-1: 102.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003288, HPA004471, CAB068253, CAB072867, HPA073252"	Enhanced	Supported	Supported	"Plasma membrane"		NA	NA		48000000	"Plasma membrane"		"CAB003288: AB_2335702, CAB068253: AB_2665717, CAB072867: AB_2665718, HPA004471: AB_1078431, HPA073252: AB_2686589"	"unprognostic (1.55e-2)"	"unprognostic (1.91e-1)"	"unprognostic (4.04e-2)"	"unprognostic (8.19e-2)"	"unprognostic (3.96e-2)"	"unprognostic (2.18e-2)"	"unprognostic (2.33e-2)"	"unprognostic (1.97e-2)"	"unprognostic (3.60e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.92e-2)"	"prognostic favorable (5.63e-4)"	"unprognostic (1.34e-3)"	"unprognostic (1.87e-1)"	"unprognostic (1.29e-2)"	"unprognostic (2.30e-1)"	8.1	1.6	9.5	6.6	11.8	3.7	65.5	18.3	12.0	12.1	10.3	6.5	10.2	5.8	8.9	4.2	9.9	2.5	15.5	2.4	36.0	4.4	9.4	1.1	13.8	3.8	3.6	6.0	28.5	2.1	1.3	2.3	6.2	5.7	9.6	10.4	20.7	12.9	6.9	1.3	14.6	8.9	10.2	3.9	3.2	12.8	4.0	4.5	0.4	28.9	4.3	4.9	9.8	12.5	0.0	1.8	12.7	0.9	9.7	1.9	0.1	0.0	0.0	0.8	0.0	0.1	0.0	0.0	0.6	0.9	2.6	3.2	0.0	0.0	0.0	0.0	1.4	0.1	0.0	0.5	0.0	2.2	0.0	1.2	48.8	0.0	0.0	0.0	0.0	102.6	0.0	0.0	0.0	0.0	0.0	5.7	0.8	0.6	0.1	0.0	0.0	0.2	0.4	1.4	0.0	0.0	0.1	0.0	0.0	0.0	4.8	1.2	0.4	0.0	0.0	0.0	3.0	0.0	0.5	0.0	0.1	0.0	1.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	12.7	0.0	10.0	0.1	0.0	1.9	0.0	0.3	0.7	1.8	0.0	0.0	0.0	0.8	9.7	0.9	0.0	0.0	0.1	9.5	11.8	18.3	12.0	36.0	4.4	3.6	6.0	5.7	4.5	6.0	34.8	1.4	1.1	12.7	0.0	0.4	5.1	0.0	5.7	3.5	0.0	0.0	3.3	0.8	0.0	2.4	0.0	0.0	0.0	0.1	1.3	0.5	496.5	0.0	0.3	0.0	5.2	1.8	0.3	0.0	1.1	3.1	200.8	0.0	0.3	2.4	0.0	0.0	0.0	0.6	0.3	0.0	0.5	0.0	8.2	3.3	0.2	2.2	0.3	0.3
KLRB1	"CD161, CLEC5B, hNKR-P1A, NKR, NKR-P1, NKR-P1A"	ENSG00000111796	"Killer cell lectin like receptor B1"	Q12918	12	9594551-9607886	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"blood: 178.9"	"Cell type enriched"	"Detected in many"	21	"T-cells: 765.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 178.9"	"Group enriched"	"Detected in many"	133	"NK-cells: 53.0;T-cells: 178.9"	"Cell line enhanced"	"Detected in some"		"HEL: 3.0;Karpas-707: 2.2"					"Low region specificity"	"Detected in all"			HPA039113	Approved		Uncertain	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA039113: AB_10674979"	"prognostic favorable (3.51e-5)"	"unprognostic (1.23e-3)"	"unprognostic (7.03e-3)"	"prognostic favorable (1.42e-5)"	"unprognostic (1.69e-1)"	"prognostic favorable (6.99e-5)"	"unprognostic (1.54e-3)"	"unprognostic (7.15e-3)"	"unprognostic (4.12e-1)"	"unprognostic (8.23e-3)"	"unprognostic (3.57e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.17e-2)"	"unprognostic (2.45e-1)"	"unprognostic (1.34e-1)"	"prognostic favorable (5.61e-4)"	"unprognostic (1.17e-2)"	3.8	0.8	0.8	22.8	0.8	18.6	2.1	0.5	0.6	2.9	9.1	0.0	1.3	5.0	1.8	3.7	2.6	1.8	7.3	1.3	0.7	0.8	3.8	4.9	11.8	23.7	1.1	0.2	2.0	1.0	0.0	0.9	2.1	0.8	1.8	3.9	0.9	4.8	1.4	0.9	0.8	20.4	0.6	1.8	25.2	4.4	1.3	0.2	6.2	1.9	2.9	17.7	5.5	2.0	0.1	0.3	0.8	0.2	53.0	178.9	18.5	0.1	0.0	1.5	0.1	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.4	1.3	0.1	0.0	0.9	0.2	1.9	0.0	0.0	0.2	0.0	3.0	0.0	0.4	0.0	0.7	0.6	0.0	0.0	0.0	0.0	0.5	0.0	1.1	0.2	2.2	0.0	0.8	0.8	0.6	0.5	0.5	0.0	1.1	0.3	0.9	0.0	0.5	0.4	0.6	0.6	0.7	0.1	1.7	0.3	0.2	0.0	1.6	0.0	0.4	0.7	0.6	0.4	1.5	0.0	1.8	1.0	0.5	0.1	0.0	43.1	0.1	178.9	0.1	25.6	28.1	0.1	0.1	1.5	8.7	0.8	53.0	0.2	0.3	5.7	18.5	0.8	0.8	0.5	0.6	0.7	0.8	1.1	0.2	0.8	0.2	0.0	12.8	14.5	0.6	8.7	0.0	0.8	0.0	0.0	2.3	0.0	0.0	0.1	0.0	0.0	0.0	1.4	0.4	0.0	0.0	0.0	5.1	1.3	0.0	5.5	0.9	0.0	0.0	35.6	22.5	0.0	0.0	3.0	23.6	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	2.5	0.0	0.0	7.8	0.8	765.3	0.3	1.3
KLRC1	"CD159a, NKG2, NKG2-A, NKG2-B"	ENSG00000134545	"Killer cell lectin like receptor C1"	P26715	12	10442264-10454685	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"blood: 64.3;lymphoid tissue: 22.1"	"Cell type enriched"	"Detected in some"	22	"T-cells: 112.3"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	7	"gdT-cell: 45.7;NK-cell: 64.3"	"Group enriched"	"Detected in many"	42	"NK-cells: 64.3;T-cells: 45.7"	"Cell line enhanced"	"Detected in some"		"HeLa: 9.3;Karpas-707: 3.8;SuSa: 3.7"									HPA058052			Approved	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA058052: AB_2683589"	"unprognostic (8.17e-3)"	"unprognostic (2.13e-2)"	"unprognostic (1.48e-2)"	"unprognostic (4.58e-7)"	"unprognostic (3.57e-1)"	"unprognostic (1.17e-2)"	"unprognostic (1.05e-1)"	"unprognostic (3.68e-2)"	"unprognostic (3.73e-4)"	"unprognostic (4.13e-2)"	"unprognostic (6.49e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.18e-4)"	"unprognostic (1.88e-1)"	"unprognostic (3.23e-1)"	"unprognostic (2.45e-1)"	"unprognostic (1.92e-3)"	2.4	0.5	1.2	5.8	1.4	5.6	2.3	1.0	2.7	1.7	3.3	0.7	1.2	1.5	5.5	3.9	1.7	2.5	2.4	2.6	1.6	1.3	1.9	2.0	5.9	10.3	2.3	0.6	1.2	1.4	0.3	1.3	3.6	1.5	1.9	2.5	2.0	3.1	0.3	0.5	1.0	5.0	2.1	2.6	22.1	5.2	1.4	0.5	3.5	1.9	3.0	2.9	2.9	1.8	0.1	0.0	1.2	0.1	64.3	45.7	5.1	0.4	1.6	0.1	0.1	0.5	0.4	0.8	0.0	0.0	0.8	1.7	0.0	1.3	0.2	0.1	0.4	3.3	0.3	0.6	2.8	1.1	0.9	0.4	2.1	9.3	0.0	0.1	0.6	0.4	1.0	0.0	0.3	0.0	0.0	0.8	0.7	1.3	3.8	0.8	0.0	0.2	2.8	0.0	0.1	0.0	0.9	0.2	0.3	0.2	0.0	0.5	0.1	0.8	0.0	0.3	3.7	0.3	0.0	2.6	0.4	0.0	0.0	0.3	0.0	0.0	0.7	2.1	0.8	0.0	0.2	0.0	0.0	45.7	0.0	5.8	0.1	0.0	7.9	0.0	0.0	0.0	6.9	1.2	64.3	0.1	0.0	0.0	5.1	1.2	1.4	1.0	0.9	1.6	1.3	2.3	0.6	1.5	0.5	0.0	1.1	0.0	0.2	0.1	0.0	0.4	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.8	0.1	1.6	1.7	1.3	3.2	0.0	0.6	0.0	5.0	0.0	1.9	0.0	0.0	0.3	1.1	0.6	1.5	0.0	0.3	0.5	0.2	0.1	0.1	112.3	0.0	0.4
KLRC2	"CD159c, NKG2-C"	ENSG00000205809	"Killer cell lectin like receptor C2"	P26717	12	10426854-10442300	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"blood: 32.8;brain: 16.2"	"Group enriched"	"Detected in some"	20	"Intestinal endocrine cells: 9.2;T-cells: 36.2"	"Cancer enriched"	"Detected in single"	8	"glioma: 3.6"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"gdT-cell: 10.7;NK-cell: 32.8"	"Group enriched"	"Detected in many"	92	"NK-cells: 32.8;T-cells: 10.7"	"Cell line enhanced"	"Detected in some"		"GAMG: 17.9;HEL: 5.3;HeLa: 16.4;HSkMC: 4.0"									HPA058052			Approved	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA058052: AB_2683589"	"unprognostic (9.05e-4)"	"unprognostic (2.54e-2)"	"unprognostic (3.77e-2)"	"unprognostic (2.51e-3)"	"unprognostic (2.83e-1)"	"unprognostic (9.49e-4)"	"unprognostic (1.27e-1)"	"unprognostic (8.74e-2)"	"unprognostic (2.88e-1)"	"unprognostic (4.00e-3)"	"unprognostic (2.88e-2)"	"unprognostic (9.16e-3)"	"unprognostic (1.55e-9)"	"unprognostic (8.10e-2)"	"unprognostic (2.34e-1)"	"unprognostic (8.93e-2)"	"unprognostic (5.31e-3)"	0.5	0.2	8.2	0.6	4.6	2.8	1.1	1.2	16.2	0.4	1.9	2.3	0.1	1.0	1.4	1.0	0.8	0.6	1.7	0.2	6.1	5.4	0.1	1.1	1.4	1.5	6.2	2.6	1.5	0.1	0.0	0.1	0.6	3.7	0.3	1.3	0.1	0.5	0.3	0.1	0.2	1.8	0.1	4.1	8.1	3.2	0.5	1.7	2.2	0.2	0.1	2.0	1.2	0.1	0.0	0.0	0.2	0.0	32.8	10.7	1.7	0.0	0.8	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	17.9	0.0	0.0	2.0	0.0	0.0	0.0	5.3	16.4	0.3	0.0	0.5	0.0	4.0	0.1	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	2.5	0.0	0.1	1.1	0.1	0.4	0.0	0.0	0.0	0.0	0.5	2.7	0.1	0.1	0.0	0.0	0.0	10.7	0.0	0.2	0.0	0.0	4.7	0.0	0.0	0.0	3.7	0.2	32.8	0.0	0.0	0.0	1.7	8.2	4.6	1.2	3.6	6.1	5.4	6.2	2.6	3.7	1.7	0.0	0.0	0.0	0.2	0.0	0.0	0.8	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	9.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.2	0.0	0.0
KLRD1	CD94	ENSG00000134539	"Killer cell lectin like receptor D1"	Q13241	12	10226058-10329600	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 85.5;lymphoid tissue: 31.0;pituitary gland: 44.6"	"Cell type enriched"	"Detected in many"	26	"T-cells: 450.1"	"Low cancer specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	7	"gdT-cell: 67.2;memory CD8 T-cell: 28.0;naive CD8 T-cell: 30.3;NK-cell: 85.5"	"Group enriched"	"Detected in many"	63	"NK-cells: 85.5;T-cells: 67.2"	"Low cell line specificity"	"Detected in many"			"Not detected"	"Not detected"							HPA069688	Uncertain					NA	NA					"HPA069688: AB_2686170"	"unprognostic (3.75e-2)"	"unprognostic (2.15e-3)"	"unprognostic (4.95e-2)"	"unprognostic (2.48e-3)"	"unprognostic (2.13e-2)"	"unprognostic (2.60e-3)"	"unprognostic (2.26e-2)"	"unprognostic (1.13e-1)"	"unprognostic (8.94e-3)"	"unprognostic (4.53e-3)"	"unprognostic (8.78e-2)"	"unprognostic (2.97e-2)"	"unprognostic (1.47e-3)"	"unprognostic (1.78e-1)"	"unprognostic (3.07e-1)"	"unprognostic (3.06e-1)"	"unprognostic (1.37e-2)"	5.2	1.3	0.9	6.4	1.1	6.9	1.7	0.8	0.9	1.4	2.7	0.6	0.2	1.5	3.3	1.9	2.0	1.1	1.5	1.7	1.0	1.0	1.5	3.7	12.3	10.2	3.8	0.7	0.9	1.9	0.0	44.6	2.3	0.8	2.0	0.9	2.1	1.2	0.5	1.1	0.8	10.6	0.5	2.6	31.0	1.8	1.4	0.4	2.2	1.3	0.3	3.6	6.3	1.3	0.1	0.2	1.2	0.2	85.5	67.2	16.2	0.9	0.7	1.1	1.5	1.5	0.6	0.9	2.3	0.1	0.2	0.7	1.4	1.0	1.3	1.1	1.9	0.8	1.1	0.5	1.3	0.2	2.2	2.8	1.7	2.6	0.6	2.7	1.1	2.2	0.7	1.7	0.4	1.2	1.3	0.3	1.2	1.0	4.9	0.3	1.9	1.0	1.3	1.8	0.8	1.4	0.6	1.6	1.2	0.7	2.1	2.4	1.2	1.1	2.2	0.5	3.1	0.8	2.1	1.7	1.8	3.1	1.5	0.7	2.0	1.8	1.1	2.6	1.6	1.6	0.1	0.1	0.1	67.2	0.2	7.6	0.1	0.4	28.0	0.2	0.1	0.1	30.3	1.2	85.5	0.1	0.2	0.1	16.2	0.9	1.1	0.8	0.9	1.0	1.0	3.8	0.7	0.8	0.4	0.0	14.6	0.8	1.0	0.5	0.7	2.0	5.1	2.7	3.4	0.0	5.9	1.2	0.0	0.2	5.9	3.4	0.0	0.0	0.0	0.8	1.9	1.2	2.3	2.1	0.7	1.6	0.0	13.5	17.1	9.8	0.3	1.7	5.0	0.0	0.0	0.6	0.0	0.0	0.7	1.0	0.9	0.0	0.9	1.2	3.4	0.5	0.7	450.1	0.0	1.0
KLRK1	"CD314, D12S2489E, KLR, NKG2-D, NKG2D"	ENSG00000213809	"Killer cell lectin like receptor K1"	P26718	12	10372353-10391874	"Cancer-related genes, CD markers, Predicted membrane proteins, Transporters"	"Adaptive immunity, Differentiation, Immunity, Innate immunity"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 50.8;lymphoid tissue: 30.7"	"Cell type enriched"	"Detected in some"	9	"T-cells: 20.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	39	"gdT-cell: 49.4;MAIT T-cell: 18.5;memory CD8 T-cell: 44.0;naive CD8 T-cell: 44.3;NK-cell: 50.8"	"Group enriched"	"Detected in many"	47	"NK-cells: 50.8;T-cells: 49.4"	"Cell line enriched"	"Detected in some"	8	"U-698: 36.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB021896, HPA068877"	Enhanced		Supported	"Plasma membrane"		NA	NA		33000	"Plasma membrane"		"CAB021896: , HPA068877: AB_2686052"	"unprognostic (3.34e-4)"	"unprognostic (2.65e-4)"	"unprognostic (3.25e-1)"	"unprognostic (2.59e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.01e-5)"	"unprognostic (5.61e-4)"	"unprognostic (1.00e-3)"	"unprognostic (1.33e-1)"	"unprognostic (9.22e-2)"	"unprognostic (1.28e-2)"	"unprognostic (2.10e-2)"	"unprognostic (6.56e-10)"	"unprognostic (1.24e-2)"	"unprognostic (6.32e-2)"	"unprognostic (7.59e-2)"	"unprognostic (7.08e-10)"	4.1	0.9	1.3	18.3	1.1	10.6	2.1	0.4	0.8	2.8	4.5	1.2	0.6	2.0	2.4	2.7	3.1	2.0	7.7	1.3	1.3	1.1	2.4	3.6	13.6	22.2	2.1	0.1	1.5	3.3	0.0	1.2	1.6	1.2	2.2	2.1	2.4	7.0	0.6	0.5	1.1	13.1	1.3	2.1	30.7	3.3	1.9	0.6	6.0	2.9	2.8	11.4	11.3	2.5	1.0	0.2	0.8	0.1	50.8	49.4	16.7	0.2	0.0	0.4	1.9	0.1	4.7	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.1	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.2	1.6	0.0	0.0	0.1	0.1	0.0	0.4	0.7	0.0	0.2	0.0	0.2	0.1	0.4	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.2	0.0	0.0	0.0	1.2	0.1	0.1	0.0	0.1	0.5	0.0	0.0	0.0	0.0	36.9	0.1	0.0	0.2	0.0	0.0	0.0	49.4	0.1	18.5	0.8	0.3	44.0	0.1	1.0	0.4	44.3	0.8	50.8	0.1	0.2	0.1	16.7	1.3	1.1	0.4	0.8	1.3	1.1	2.1	0.1	1.2	0.6	0.0	2.2	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	20.3	0.0	0.0
L1CAM	"CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1"	ENSG00000198910	"L1 cell adhesion molecule"	P32004	X	153861514-153886174	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Differentiation, Neurogenesis"	"Developmental protein"	"Disease mutation, Hereditary spastic paraplegia, Hirschsprung disease, Mental retardation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 29.6;brain: 54.5"	"Group enriched"	"Detected in some"	6	"Collecting duct cells: 80.3;Horizontal cells: 31.8;Melanocytes: 42.2"	"Cancer enhanced"	"Detected in many"		"melanoma: 34.1"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"memory B-cell: 1.0;naive B-cell: 2.2"	"Lineage enriched"	"Detected in single"	7	"B-cells: 2.2"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 73.5;BJ hTERT+ SV40 Large T+ RasG12V: 40.4;HeLa: 53.0;RH-30: 32.2;RPTEC TERT1: 43.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB010896	Enhanced		Approved	"Nucleoplasm,Plasma membrane"		NA	NA		59000000	"Nucleoplasm, Plasma membrane"		"CAB010896: AB_609903"	"unprognostic (1.33e-3)"	"unprognostic (3.43e-2)"	"unprognostic (2.75e-1)"	"prognostic unfavorable (8.51e-10)"	"unprognostic (2.04e-2)"	"prognostic unfavorable (3.81e-4)"	"unprognostic (9.44e-2)"	"prognostic unfavorable (2.36e-6)"	"unprognostic (1.13e-1)"	"unprognostic (9.12e-2)"	"unprognostic (8.52e-3)"	"unprognostic (8.02e-2)"	"prognostic unfavorable (1.17e-4)"	"unprognostic (3.07e-1)"	"unprognostic (6.31e-2)"	"unprognostic (1.69e-1)"	"unprognostic (7.47e-3)"	4.4	29.6	19.9	8.0	21.9	1.2	1.7	54.5	43.6	2.8	16.3	1.5	2.0	4.9	1.7	3.0	5.3	2.6	3.2	5.2	11.2	20.6	12.3	1.3	1.3	3.7	7.3	22.4	1.4	3.0	1.0	6.1	1.4	19.3	3.5	5.7	6.2	5.9	10.8	1.6	9.9	7.6	6.1	3.5	1.7	4.8	1.5	3.4	0.0	1.2	1.3	2.6	2.3	3.9	2.2	0.0	0.0	0.0	0.0	0.3	0.2	17.9	1.4	5.4	0.0	0.0	0.0	2.3	25.5	73.5	24.6	40.4	7.3	0.1	0.0	24.3	0.1	20.6	0.7	0.6	0.4	12.9	0.0	0.1	0.0	53.0	1.1	0.0	0.0	4.0	0.1	0.3	3.7	2.5	0.0	0.0	0.0	0.0	0.0	0.1	24.4	0.0	0.5	1.2	0.0	0.9	0.0	32.2	0.1	43.2	0.3	16.2	10.6	14.3	12.7	10.3	12.7	1.3	0.3	0.0	0.0	10.8	1.1	12.1	0.2	0.3	0.1	0.1	0.2	20.6	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.3	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	19.9	21.9	54.5	30.2	11.2	20.6	7.3	22.4	19.3	3.4	0.0	0.0	0.8	0.0	1.0	8.5	0.8	0.0	0.0	0.0	80.3	3.9	0.0	0.0	0.3	0.0	0.5	0.0	0.0	0.0	0.2	0.5	0.0	0.0	0.0	0.1	31.8	0.0	1.8	0.0	0.0	0.9	0.0	42.2	0.0	0.0	0.8	0.0	0.0	0.0	0.2	8.6	0.0	0.4	0.0	0.1	1.1	0.1	0.0	0.0	0.1
LAG3	CD223	ENSG00000089692	"Lymphocyte activating 3"	P18627	12	6772512-6778455	"CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 58.1;ovary: 28.4"	"Cell type enhanced"	"Detected in many"	13	"Intestinal endocrine cells: 20.8;Leydig cells: 36.2;Peritubular cells: 65.0;T-cells: 29.6"	"Low cancer specificity"	"Detected in all"			"Region enhanced"	"Detected in single"		"pons and medulla: 2.7"	"Cell type enhanced"	"Detected in many"		"gdT-cell: 11.3;MAIT T-cell: 9.2;memory CD8 T-cell: 10.0"	"Lineage enriched"	"Detected in single"	56	"T-cells: 11.3"	"Cell line enriched"	"Detected in single"	144	"HDLM-2: 57.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB002301, HPA013967"	Enhanced				"Secreted - unknown location"	NA	NA					"CAB002301: AB_564101, HPA013967: AB_1846277"	"unprognostic (9.39e-2)"	"prognostic favorable (3.89e-4)"	"unprognostic (8.88e-2)"	"unprognostic (7.00e-3)"	"unprognostic (1.08e-1)"	"unprognostic (6.74e-3)"	"unprognostic (8.85e-2)"	"unprognostic (4.63e-3)"	"unprognostic (1.94e-2)"	"unprognostic (1.97e-3)"	"unprognostic (8.71e-2)"	"unprognostic (9.93e-2)"	"prognostic unfavorable (4.62e-11)"	"unprognostic (3.07e-2)"	"unprognostic (2.70e-1)"	"unprognostic (6.13e-2)"	"unprognostic (8.19e-3)"	1.7	0.4	0.3	33.2	0.3	1.0	1.0	0.8	0.7	7.7	4.4	0.5	2.7	2.9	6.4	3.3	2.4	3.8	3.0	2.2	0.3	0.4	1.2	5.9	3.8	12.4	0.4	0.0	28.4	0.4	0.1	1.0	1.3	2.7	2.8	1.8	1.1	2.0	6.8	0.8	0.6	9.6	1.7	0.9	58.1	2.0	6.1	0.1	4.1	1.0	1.3	23.5	2.6	3.6	0.0	0.2	0.0	0.0	0.0	11.3	0.8	0.0	0.2	0.3	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	57.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.3	0.0	9.2	0.0	2.2	10.0	0.0	0.0	0.6	4.0	0.0	0.0	0.0	0.2	1.7	0.8	0.3	0.3	0.8	0.7	0.3	0.4	0.4	0.0	2.7	0.1	0.0	3.5	0.9	0.8	4.5	4.0	1.2	0.0	0.0	5.7	0.0	9.8	0.2	0.0	0.1	0.3	1.9	1.1	0.0	0.0	0.2	2.1	1.9	0.0	2.5	8.7	0.0	20.8	5.5	3.5	1.1	36.2	0.3	1.7	4.6	4.5	1.3	0.3	0.0	65.0	0.2	6.2	6.5	2.5	0.3	2.0	2.6	0.1	29.6	2.5	0.3
LAIR1	CD305	ENSG00000167613	"Leukocyte associated immunoglobulin like receptor 1"	Q6GTX8	19	54351384-54370558	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 39.0"	"Cell type enhanced"	"Detected in many"	12	"granulocytes: 103.2;Hofbauer cells: 178.5;Kupffer cells: 84.4;Macrophages: 142.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"HMC-1: 6.6;Karpas-707: 17.1;THP-1: 19.4"									HPA011155	Enhanced		Supported	"Plasma membrane"		NA	NA		130000	"Plasma membrane"		"HPA011155: AB_1852685"	"unprognostic (1.91e-1)"	"unprognostic (1.12e-2)"	"unprognostic (2.81e-2)"	"unprognostic (1.25e-2)"	"unprognostic (2.03e-2)"	"unprognostic (4.38e-2)"	"unprognostic (2.16e-2)"	"unprognostic (1.74e-1)"	"unprognostic (5.00e-2)"	"unprognostic (2.24e-1)"	"unprognostic (2.21e-1)"	"unprognostic (7.11e-2)"	"prognostic unfavorable (5.01e-5)"	"unprognostic (1.72e-1)"	"unprognostic (2.72e-3)"	"unprognostic (3.52e-2)"	"unprognostic (5.22e-2)"	12.7	7.0	4.5	10.9	9.9	13.5	6.9	0.5	4.5	2.7	5.1	6.7	0.2	2.7	2.2	6.8	2.5	3.6	4.4	3.9	5.2	4.2	3.8	2.9	16.5	33.1	10.2	1.9	2.0	2.4	1.4	2.8	7.0	7.0	3.0	2.0	3.1	3.9	2.2	2.3	2.3	7.6	7.8	11.9	28.6	2.9	3.1	7.4	39.0	2.0	0.5	6.1	3.7	1.7	6.0	10.3	12.4	8.8	5.8	8.0	5.7	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.2	0.0	0.0	0.0	2.8	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	17.1	0.0	0.0	2.2	1.5	0.0	0.0	0.0	2.2	0.1	2.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	19.4	0.1	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.2	2.7	0.2	12.4	4.2	10.0	8.0	8.3	4.6	2.3	2.4	4.3	0.1	6.0	3.8	4.9	0.6	5.8	8.8	10.3	1.6	5.7	4.5	9.9	0.5	4.5	5.2	4.2	10.2	1.9	7.0	7.4	14.9	34.1	29.8	0.5	0.6	5.5	1.3	0.0	20.1	20.5	0.0	35.3	4.4	0.0	0.0	15.9	0.7	0.0	0.0	0.0	4.1	1.9	0.5	103.2	0.8	178.5	1.6	0.0	4.3	84.4	20.4	0.3	142.0	0.0	1.0	0.0	1.1	0.1	0.0	0.0	0.1	14.8	0.0	0.9	1.4	1.0	1.0	8.4	33.0	0.0	0.8
LAIR2	CD306	ENSG00000167618	"Leukocyte associated immunoglobulin like receptor 2"	Q6ISS4	19	54497879-54510687	"CD markers, Predicted intracellular proteins, Predicted secreted proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"blood: 12.8;lymphoid tissue: 19.6;pituitary gland: 7.1;placenta: 15.5"	"Cell type enriched"	"Detected in some"	9	"Extravillous trophoblasts: 233.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	4	"T-reg: 12.8"	"Lineage enriched"	"Detected in single"	21	"T-cells: 12.8"	"Group enriched"	"Detected in some"	5	"BEWO: 6.9;Hep G2: 3.3"														"Secreted - unknown location"	NA	NA						"unprognostic (1.99e-3)"	"unprognostic (7.49e-2)"	"unprognostic (4.19e-2)"	"unprognostic (1.02e-2)"	"unprognostic (1.42e-1)"	"unprognostic (4.86e-4)"	"unprognostic (1.06e-2)"	"unprognostic (8.37e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.93e-1)"	"unprognostic (2.21e-1)"	"unprognostic (9.52e-2)"	"unprognostic (3.68e-9)"	"unprognostic (1.21e-2)"	"unprognostic (3.15e-3)"	"unprognostic (3.40e-5)"	"unprognostic (6.71e-2)"	0.9	0.5	0.6	5.9	1.7	1.6	0.5	0.2	1.3	0.4	0.6	1.3	0.0	0.4	0.5	1.3	0.7	0.5	1.3	0.4	1.4	3.0	0.6	0.8	3.2	12.3	0.6	0.5	0.2	0.9	0.1	7.1	15.5	1.3	0.8	1.3	0.4	0.5	0.4	0.6	0.5	1.2	0.5	1.5	6.6	1.0	1.2	0.4	19.6	0.5	0.0	2.0	0.3	0.3	0.0	0.0	0.1	0.1	0.6	12.8	1.8	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	3.3	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.5	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.7	0.3	0.1	0.0	1.1	0.0	0.0	0.1	0.0	0.2	0.0	0.4	0.0	3.0	2.0	0.0	0.0	0.8	2.7	0.1	0.6	0.1	0.0	12.8	1.8	0.6	1.7	0.2	1.3	1.4	3.0	0.6	0.5	1.3	0.4	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	233.4	0.5	0.0	0.0	0.0	21.7	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	26.9	24.5	0.0	0.0
LAMP1	CD107a	ENSG00000185896	"Lysosomal associated membrane protein 1"	P11279	13	113297241-113323672	"CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Host-virus interaction"	"Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Late spermatids: 526.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004260, HPA014750"	Supported					NA	NA		460000000			"CAB004260: AB_626851, HPA014750: AB_1846219"	"unprognostic (3.98e-1)"	"unprognostic (1.18e-1)"	"unprognostic (7.55e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.04e-1)"	"unprognostic (7.04e-3)"	"unprognostic (9.26e-2)"	"unprognostic (1.07e-1)"	"unprognostic (5.80e-2)"	"unprognostic (1.44e-2)"	"unprognostic (2.91e-3)"	"unprognostic (2.04e-1)"	"prognostic favorable (4.15e-5)"	"unprognostic (2.06e-2)"	"unprognostic (2.22e-1)"	"unprognostic (2.59e-1)"	"unprognostic (1.54e-1)"	61.3	41.9	34.6	36.7	44.7	28.5	70.7	17.6	50.6	50.4	39.0	77.9	46.7	49.9	55.7	73.4	50.6	38.1	60.8	45.0	38.0	30.7	61.2	83.3	74.6	78.1	64.3	42.3	44.4	79.5	38.2	43.7	68.6	42.1	47.0	31.3	30.1	60.6	47.8	26.6	72.0	46.7	43.3	67.6	46.2	43.6	41.6	57.3	34.9	59.5	43.1	37.0	47.6	48.1	3.1	7.6	12.2	7.0	5.4	6.5	2.7	43.5	15.1	15.8	43.1	88.8	33.5	29.8	51.5	54.3	32.1	43.0	29.6	81.5	10.3	23.6	52.2	55.1	56.0	15.4	32.7	22.0	21.5	25.5	17.0	30.1	27.8	46.0	51.9	39.9	40.8	44.7	29.7	19.5	52.4	38.7	10.1	14.1	15.2	39.4	17.5	10.4	25.4	11.9	42.0	16.6	15.5	13.7	15.5	29.1	32.9	14.5	15.2	30.2	45.0	29.7	15.9	43.4	37.0	58.4	33.0	35.8	43.5	22.9	28.6	28.2	11.0	55.1	51.9	38.1	3.8	7.0	12.2	5.9	5.3	5.0	3.1	4.6	6.5	3.5	3.0	5.2	4.3	9.2	5.4	5.8	7.6	4.6	2.7	34.6	44.7	17.6	50.6	38.0	30.7	64.3	42.3	42.1	57.3	80.4	59.2	63.9	130.8	125.1	41.6	48.2	104.4	22.7	31.8	174.5	72.6	154.6	34.9	98.2	251.4	94.3	194.6	46.7	53.5	180.7	117.2	107.4	70.3	264.0	253.3	28.6	114.5	160.2	161.9	526.2	151.6	139.9	94.5	36.1	89.0	55.4	78.3	154.3	160.1	159.6	73.1	116.4	98.8	100.7	113.1	172.6	261.2	98.0	112.3	103.9
LAMP2	CD107b	ENSG00000005893	"Lysosomal associated membrane protein 2"	P13473	X	120427827-120469365	"CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	Autophagy		"Disease mutation, Glycogen storage disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Syncytiotrophoblasts: 336.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 112.9"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 112.9"	"Cell line enhanced"	"Detected in all"		"ASC diff: 112.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005272, HPA029100, HPA029101"	Supported		Supported	"Vesicles,Plasma membrane"		NA	NA		820000000	"Vesicles, Plasma membrane"		"CAB005272: AB_647855, HPA029100: AB_10795022, HPA029101: "	"unprognostic (2.99e-3)"	"unprognostic (5.26e-2)"	"unprognostic (2.66e-3)"	"unprognostic (1.74e-1)"	"unprognostic (3.10e-1)"	"unprognostic (2.50e-2)"	"unprognostic (4.84e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.55e-1)"	"unprognostic (9.73e-2)"	"unprognostic (1.11e-2)"	"unprognostic (2.50e-2)"	"unprognostic (2.85e-1)"	"unprognostic (6.78e-2)"	"unprognostic (2.66e-1)"	"unprognostic (5.53e-3)"	21.8	33.6	39.9	16.1	87.9	22.6	27.1	16.2	55.5	33.0	18.3	88.7	27.9	25.1	20.8	37.5	34.6	22.4	43.3	20.9	52.5	30.3	55.0	83.7	25.3	14.3	131.0	36.9	22.7	27.4	28.8	20.2	35.4	58.6	37.3	19.7	17.2	47.8	32.9	32.4	26.9	20.5	21.1	84.3	17.9	23.6	11.9	116.9	21.2	33.7	14.3	15.4	21.1	27.0	3.7	11.6	112.9	21.7	5.4	5.8	10.5	11.7	11.6	8.6	10.9	112.3	38.3	23.6	20.3	35.4	19.7	37.0	9.6	21.0	8.3	17.9	35.2	63.0	19.7	12.4	15.3	32.2	9.3	8.8	6.5	12.9	12.9	37.4	28.7	18.2	41.5	30.9	26.3	17.4	52.1	26.9	5.9	7.5	29.7	31.9	21.6	8.0	14.7	6.6	16.8	10.2	6.2	14.5	14.8	28.9	8.7	2.9	4.5	21.7	22.1	43.3	15.8	13.1	32.1	27.8	28.4	13.8	36.5	54.7	14.9	14.2	5.4	27.1	34.7	67.9	4.9	21.7	41.3	5.0	18.7	4.0	3.1	4.8	4.7	11.6	3.7	4.3	4.1	112.9	5.4	17.3	6.3	5.8	10.5	39.9	87.9	16.2	55.5	52.5	30.3	131.0	36.9	58.6	116.9	68.5	48.0	23.8	73.6	89.6	15.0	29.0	186.0	44.2	52.4	62.8	13.7	140.2	33.2	170.8	2.3	65.2	53.1	0.0	62.0	111.7	86.5	124.2	16.3	167.8	191.1	17.5	35.2	100.7	120.2	4.2	105.3	97.6	124.9	124.4	31.2	128.8	66.8	43.5	103.3	128.2	9.3	38.8	61.8	5.6	13.2	119.1	336.5	30.5	31.0	76.1
LAMP3	"CD208, DC-LAMP, DCLAMP, LAMP, TSC403"	ENSG00000078081	"Lysosomal associated membrane protein 3"	Q9UQV4	3	183122213-183163839	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"lung: 123.9"	"Group enriched"	"Detected in many"	7	"Alveolar cells type 2: 374.8;monocytes: 592.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"eosinophil: 7.6"	"Group enriched"	"Detected in many"	8	"granulocytes: 7.6;T-cells: 6.6"	"Cell line enhanced"	"Detected in some"		"EFO-21: 57.7;HDLM-2: 14.6;HHSteC: 21.4;hTCEpi: 19.5;JURKAT: 17.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB025133, HPA051467"	Enhanced		Enhanced	Vesicles		NA	NA		47000	Vesicles		"CAB025133: , HPA051467: AB_2681495"	"unprognostic (1.43e-3)"	"unprognostic (2.06e-2)"	"unprognostic (1.70e-1)"	"unprognostic (2.99e-3)"	"unprognostic (1.30e-2)"	"unprognostic (2.15e-1)"	"unprognostic (7.67e-2)"	"unprognostic (8.64e-2)"	"unprognostic (4.95e-2)"	"prognostic favorable (9.90e-4)"	"unprognostic (1.80e-3)"	"unprognostic (5.80e-2)"	"prognostic unfavorable (1.89e-7)"	"unprognostic (3.12e-1)"	"unprognostic (4.13e-2)"	"unprognostic (8.35e-2)"	"unprognostic (1.29e-1)"	0.5	0.7	0.4	14.1	0.4	0.0	0.5	0.3	0.4	1.0	0.6	0.1	0.6	0.4	0.4	1.0	2.5	0.5	0.8	0.4	0.4	0.4	0.8	0.6	123.9	11.2	0.4	0.1	0.4	8.3	0.0	0.6	1.0	0.6	1.0	1.7	0.2	6.8	1.9	0.4	1.9	1.4	0.8	0.5	2.0	0.8	8.4	0.0	21.3	8.3	3.1	11.3	3.3	0.9	0.4	0.0	7.6	0.1	0.8	6.6	1.1	3.5	0.1	0.0	0.5	0.0	0.0	2.8	0.0	0.9	0.6	0.1	0.8	1.8	0.0	57.7	0.3	6.5	0.5	1.2	2.2	0.1	14.6	1.7	0.0	0.1	0.1	21.4	0.0	0.5	0.3	19.5	0.0	2.6	0.0	2.6	17.7	0.1	3.4	0.1	0.0	0.8	0.1	0.1	0.3	0.8	0.0	0.0	0.2	0.0	1.1	0.2	0.1	0.2	0.1	1.5	0.7	1.1	0.1	2.7	0.0	1.0	0.1	0.0	1.2	4.3	0.1	0.0	0.0	0.0	0.4	0.1	7.6	0.4	0.0	3.2	0.1	2.7	1.7	0.0	0.4	3.5	2.0	1.9	0.8	0.1	0.0	6.6	1.1	0.4	0.4	0.3	0.4	0.4	0.4	0.4	0.1	0.6	0.0	59.6	374.8	0.5	3.2	5.4	0.0	1.2	2.5	9.4	15.9	1.8	0.0	1.9	0.0	0.6	26.0	0.5	0.0	0.0	5.3	0.2	0.2	1.2	17.4	0.0	1.3	0.0	0.0	0.0	0.0	69.6	0.6	3.1	1.7	592.5	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.4	0.7	0.5	5.0	1.0	0.5	0.3	2.0
LEPR	"CD295, OBR"	ENSG00000116678	"Leptin receptor"	P48357	1	65420652-65641559	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 82.8"	"Cell type enhanced"	"Detected in many"	18	"Endothelial cells: 59.1;Hepatocytes: 196.4"	"Cancer enriched"	"Detected in many"	7	"liver cancer: 13.1"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 6.9"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 15.7;K-562: 46.5;RPTEC TERT1: 22.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA030899	Approved	Supported			"Secreted to blood"	NA	NA	8240000	8300000			"HPA030899: AB_10610003"	"unprognostic (1.59e-2)"	"unprognostic (1.09e-3)"	"unprognostic (3.09e-1)"	"unprognostic (8.95e-2)"	"unprognostic (2.32e-1)"	"unprognostic (2.64e-1)"	"unprognostic (2.58e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.78e-1)"	"unprognostic (6.59e-3)"	"unprognostic (1.79e-1)"	"unprognostic (2.41e-1)"	"unprognostic (7.53e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.27e-1)"	"unprognostic (3.49e-2)"	"unprognostic (1.73e-1)"	15.9	5.5	3.8	3.7	4.3	3.3	23.5	2.5	3.9	15.0	9.2	5.6	5.4	3.2	20.6	7.3	10.9	11.7	10.1	9.2	4.3	4.9	14.6	82.8	20.3	9.0	4.9	3.3	18.4	16.7	3.9	13.1	12.8	8.2	10.8	4.1	18.1	12.0	5.7	5.6	10.2	7.3	12.9	7.0	6.4	11.9	6.6	3.1	1.9	13.1	11.2	6.9	13.6	8.6	0.6	1.8	6.9	1.9	1.1	2.3	1.8	1.3	0.8	1.1	1.2	5.0	4.7	3.9	5.9	3.4	2.0	1.9	0.6	3.2	0.5	4.4	7.5	0.5	1.1	0.9	5.2	5.5	7.0	1.5	7.7	3.6	0.1	3.0	0.5	0.6	13.2	3.0	1.2	4.7	15.7	5.9	0.6	46.5	0.9	9.5	0.3	0.6	0.1	1.8	0.8	0.1	0.1	0.9	0.3	22.5	0.6	0.7	11.4	1.4	0.6	1.6	6.7	2.1	2.1	2.2	2.1	4.4	0.4	3.2	1.3	0.9	0.2	4.5	2.2	2.0	6.9	1.9	2.8	1.3	1.5	1.3	0.6	1.1	1.1	1.8	0.3	0.9	1.5	1.1	1.1	1.7	1.2	2.3	1.8	3.8	4.3	2.5	3.9	4.3	4.9	4.9	3.3	8.2	3.1	0.0	16.5	3.0	1.9	31.4	4.9	3.5	10.2	2.7	4.5	8.7	0.0	1.2	3.3	1.5	1.0	59.1	0.4	0.0	0.9	2.3	20.2	3.3	1.1	196.4	1.9	1.6	0.0	27.6	6.5	1.5	31.9	5.8	33.7	2.8	0.9	0.0	1.6	1.7	7.1	6.8	0.9	0.0	17.7	1.1	0.6	25.7	2.2	0.5	0.8	1.4
LIFR	CD118	ENSG00000113594	"LIF receptor alpha"	P42702	5	38474963-38608354	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	6	"Ito cells: 765.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AF22: 40.6;HHSteC: 17.3;SCLC-21H: 26.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Intracellular and membrane"	NA	NA		74000				"unprognostic (6.00e-3)"	"unprognostic (2.53e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.81e-3)"	"unprognostic (8.80e-2)"	"unprognostic (7.13e-2)"	"unprognostic (1.11e-1)"	"prognostic favorable (1.92e-4)"	"unprognostic (1.78e-1)"	"unprognostic (9.80e-2)"	"unprognostic (2.73e-3)"	"unprognostic (1.06e-1)"	"prognostic favorable (1.40e-7)"	"unprognostic (3.69e-2)"	"unprognostic (1.15e-1)"	"unprognostic (2.03e-2)"	"unprognostic (1.65e-1)"	35.3	14.7	15.8	8.2	19.2	0.5	33.9	10.1	21.3	27.7	10.4	25.3	22.8	4.9	34.8	14.8	10.4	26.0	10.2	16.3	19.1	11.0	20.3	23.9	21.7	20.2	24.3	11.8	17.9	17.8	13.5	12.5	41.5	23.4	23.6	7.5	17.1	24.9	24.7	24.0	10.5	11.7	26.9	21.4	22.5	18.8	9.3	25.3	4.7	31.4	7.3	8.1	13.6	15.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	2.3	40.6	3.0	11.4	12.7	0.3	3.4	1.9	2.7	1.7	0.4	2.2	0.0	0.5	4.8	6.9	0.3	2.6	0.9	4.7	0.0	3.7	0.0	4.3	1.6	17.3	0.0	0.2	10.6	0.7	6.6	0.7	2.6	3.8	0.4	1.1	6.5	3.4	0.5	0.0	0.1	1.0	0.0	7.2	0.0	8.6	0.0	2.6	1.0	26.6	3.3	14.0	0.7	0.0	5.3	0.9	0.0	0.8	4.4	8.7	10.3	2.0	0.0	0.0	0.0	7.2	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.8	19.2	10.1	21.3	19.1	11.0	24.3	11.8	23.4	25.3	11.9	34.9	9.3	5.9	20.6	5.8	24.6	10.2	10.7	10.3	14.0	7.9	7.7	5.0	1.9	12.6	122.5	0.0	0.0	7.8	22.5	46.1	21.1	1.1	6.8	3.2	1.6	0.0	765.5	62.0	21.6	105.3	2.6	16.9	0.0	0.0	5.1	6.9	0.0	18.7	13.5	35.3	38.8	42.2	8.9	6.1	15.8	23.9	7.5	0.0	4.7
LILRA1	"CD85i, LIR-6, LIR6"	ENSG00000104974	"Leukocyte immunoglobulin like receptor A1"	O75019	19	54593582-54602090	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	9	"blood: 22.2;lymphoid tissue: 21.0"	"Cell type enriched"	"Detected in some"	4	"Kupffer cells: 35.6"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 17.9;non-classical monocyte: 22.2"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"REH: 1.3;THP-1: 2.4"															NA	NA						"unprognostic (4.52e-2)"	"unprognostic (1.12e-1)"	"unprognostic (6.30e-2)"	"unprognostic (1.59e-1)"	"unprognostic (2.34e-1)"	"unprognostic (9.46e-3)"	"unprognostic (1.17e-1)"	"unprognostic (4.07e-2)"	"unprognostic (1.12e-1)"	"unprognostic (4.90e-2)"	"unprognostic (8.72e-2)"	"unprognostic (1.13e-1)"	"unprognostic (8.28e-3)"	"unprognostic (8.82e-2)"	"unprognostic (3.79e-4)"	"unprognostic (2.53e-1)"	"unprognostic (9.83e-2)"	0.7	0.9	1.0	3.7	1.7	1.0	0.6	0.2	1.3	0.5	0.3	1.1	0.0	0.4	0.2	1.7	0.6	0.5	1.0	0.6	0.9	0.8	0.5	2.1	2.4	18.8	1.5	0.5	0.4	0.4	0.6	0.3	0.8	1.6	0.4	0.7	0.8	1.0	0.3	0.5	0.3	1.0	0.5	2.2	21.0	0.5	0.3	1.1	0.1	0.4	0.4	0.9	0.9	0.2	0.0	5.4	6.1	22.2	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	7.4	6.1	0.0	17.9	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	5.3	0.0	22.2	0.7	0.0	4.2	1.0	1.7	0.2	1.3	0.9	0.8	1.5	0.5	1.6	1.1	0.0	3.4	0.5	0.0	0.0	0.0	0.0	0.0	1.4	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	0.0	0.6	35.6	0.0	0.0	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
LILRA2	"CD85h, ILT1, LIR-7, LIR7"	ENSG00000239998	"Leukocyte immunoglobulin like receptor A2"	Q8N149	19	54572920-54590287	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Immunity, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 21.6;bone marrow: 21.7;lymphoid tissue: 39.9"	"Group enriched"	"Detected in some"	8	"Hofbauer cells: 21.6;Kupffer cells: 82.8;Macrophages: 28.1"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 21.6"	"Group enriched"	"Detected in many"	7	"granulocytes: 21.6;monocytes: 7.1"	"Cell line enhanced"	"Detected in some"		"NB-4: 2.5;REH: 3.0;THP-1: 6.1;U-937: 13.6"														"Secreted to blood"	NA	NA		130000000				"unprognostic (2.04e-1)"	"unprognostic (7.72e-2)"	"unprognostic (6.94e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.54e-2)"	"unprognostic (2.65e-2)"	"unprognostic (8.45e-2)"	"unprognostic (3.56e-2)"	"unprognostic (1.22e-1)"	"unprognostic (3.53e-5)"	"unprognostic (2.67e-1)"	"unprognostic (1.12e-1)"	"unprognostic (5.43e-2)"	"unprognostic (5.58e-2)"	"unprognostic (3.30e-4)"	"unprognostic (4.21e-2)"	"unprognostic (6.59e-2)"	2.8	1.5	1.4	4.7	1.1	21.7	0.9	0.1	2.0	0.6	0.8	3.0	0.0	0.6	0.5	1.0	0.5	2.3	1.0	3.7	1.1	1.1	1.2	3.8	6.8	14.6	2.9	0.4	1.1	0.6	0.5	0.4	1.7	1.4	0.6	0.6	1.1	0.8	0.5	0.6	0.7	0.7	1.0	3.7	39.9	0.7	0.7	2.3	0.7	0.6	0.0	0.8	0.9	1.8	0.2	2.1	21.6	7.1	0.3	0.1	3.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.4	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.3	0.0	0.0	0.1	2.5	0.0	0.1	0.0	3.0	0.1	1.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.1	6.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.1	13.6	0.1	2.4	4.9	1.8	0.1	7.1	0.0	0.1	0.1	0.1	2.1	0.2	0.1	0.1	21.6	0.3	6.8	0.4	0.0	3.0	1.4	1.1	0.1	2.0	1.1	1.1	2.9	0.4	1.4	2.3	3.0	4.8	0.0	0.7	0.2	0.4	0.4	2.5	2.7	3.4	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.1	0.3	0.9	5.8	0.0	21.6	0.0	0.0	0.6	82.8	0.0	0.0	28.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.2	0.4	0.1	0.3	0.0	0.0	0.4
LILRA4	"CD85g, ILT7"	ENSG00000239961	"Leukocyte immunoglobulin like receptor A4"	P59901	19	54333185-54339150	"CD markers, Predicted membrane proteins"	"Immunity, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	13	"blood: 49.7;brain: 12.5;lymphoid tissue: 16.8"	"Cell type enhanced"	"Detected in some"	23	"B-cells: 8.5;Hofbauer cells: 3.1;Kupffer cells: 3.2;Macrophages: 2.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	21	"plasmacytoid DC: 49.7"	"Lineage enriched"	"Detected in many"	21	"dendritic cells: 49.7"	"Cell line enriched"	"Detected in single"	31	"RPMI-8226: 3.0"									HPA049418	Approved					NA	NA					"HPA049418: AB_2680756"	"unprognostic (5.11e-2)"	"unprognostic (1.21e-4)"	"unprognostic (2.65e-2)"	"unprognostic (5.94e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.19e-3)"	"unprognostic (7.62e-2)"	"unprognostic (1.36e-3)"	"unprognostic (1.08e-1)"	"unprognostic (9.46e-2)"	"unprognostic (4.90e-2)"	"unprognostic (9.30e-2)"	"unprognostic (8.28e-7)"	"unprognostic (2.12e-2)"	"unprognostic (1.17e-3)"	"unprognostic (4.53e-1)"	"unprognostic (5.86e-2)"	0.7	0.4	2.1	2.3	2.5	0.6	0.7	1.1	4.3	0.4	0.9	12.5	0.0	0.7	0.4	0.4	0.6	0.4	0.8	0.4	3.5	1.4	0.4	0.7	1.4	5.3	12.2	1.2	0.4	0.4	0.4	0.3	0.4	7.6	0.5	0.5	0.0	0.7	0.5	0.4	0.6	2.0	0.6	7.4	16.8	0.5	0.5	6.7	2.3	0.4	0.0	10.1	0.7	0.2	2.4	49.7	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.2	1.2	0.0	0.0	0.0	0.1	0.0	49.7	0.0	0.1	2.1	2.5	1.1	4.3	3.5	1.4	12.2	1.2	7.6	6.7	0.0	1.1	8.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	3.2	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
LILRA5	"CD85, CD85f, ILT11, LILRB7, LIR9"	ENSG00000187116	"Leukocyte immunoglobulin like receptor A5"	A6NI73	19	54307070-54313139	"CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Immunity, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 30.2;lymphoid tissue: 67.3"	"Group enriched"	"Detected in some"	4	"Kupffer cells: 84.9;Macrophages: 23.1"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	8	"classical monocyte: 10.6;intermediate monocyte: 27.0;neutrophil: 14.5;non-classical monocyte: 30.2"	"Group enriched"	"Detected in many"	8	"granulocytes: 14.5;monocytes: 30.2"	"Cell line enriched"	"Detected in single"	11	"RPMI-8226: 4.1"														"Secreted to blood"	NA	NA		370000				"unprognostic (8.52e-2)"	"unprognostic (3.61e-1)"	"unprognostic (2.23e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.57e-2)"	"unprognostic (6.56e-2)"	"unprognostic (2.90e-1)"	"unprognostic (1.86e-1)"	"unprognostic (3.11e-1)"	"unprognostic (6.61e-3)"	"unprognostic (2.01e-1)"	"unprognostic (1.50e-1)"	"prognostic unfavorable (7.78e-4)"	"unprognostic (3.61e-2)"	"unprognostic (6.51e-3)"	"unprognostic (4.68e-2)"	"unprognostic (6.21e-2)"	3.4	0.6	0.3	9.9	0.3	19.1	0.7	0.1	0.3	0.4	0.6	0.1	0.0	0.8	0.4	2.0	0.6	2.0	0.9	7.0	0.2	0.2	1.7	10.8	14.4	24.2	0.5	0.0	1.5	0.4	0.1	0.4	1.3	0.6	0.6	0.7	0.6	0.5	0.3	0.9	0.1	1.8	1.3	0.7	67.3	1.0	0.6	0.0	0.1	1.4	0.4	0.4	2.7	2.8	0.0	2.6	14.5	30.2	0.0	0.0	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	10.6	0.0	0.0	27.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	14.5	0.0	30.2	2.1	0.0	5.1	0.3	0.3	0.1	0.3	0.2	0.2	0.5	0.0	0.6	0.0	0.0	13.3	1.4	0.1	0.1	0.0	0.0	0.0	4.0	5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	10.5	0.2	6.5	0.0	0.0	0.6	84.9	0.0	0.0	23.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
LILRB2	"CD85d, ILT4, LIR-2, LIR2, MIR-10, MIR10"	ENSG00000131042	"Leukocyte immunoglobulin like receptor B2"	Q8N423	19	54273821-54281184	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 37.9;bone marrow: 30.3;lymphoid tissue: 31.9"	"Cell type enhanced"	"Detected in some"	24	"Hofbauer cells: 26.7;Kupffer cells: 133.7;Macrophages: 59.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"classical monocyte: 15.9;intermediate monocyte: 33.8;neutrophil: 16.7;non-classical monocyte: 37.9"	"Group enriched"	"Detected in many"	5	"granulocytes: 16.7;monocytes: 37.9"	"Cell line enhanced"	"Detected in single"		"THP-1: 1.2"															NA	NA		52000000				"unprognostic (1.23e-1)"	"unprognostic (1.12e-2)"	"unprognostic (3.21e-2)"	"unprognostic (3.51e-2)"	"unprognostic (6.21e-3)"	"unprognostic (1.70e-2)"	"unprognostic (1.44e-2)"	"unprognostic (2.94e-1)"	"unprognostic (1.08e-2)"	"unprognostic (2.98e-2)"	"unprognostic (2.64e-1)"	"unprognostic (2.15e-1)"	"prognostic unfavorable (5.45e-7)"	"unprognostic (1.90e-2)"	"unprognostic (4.68e-3)"	"unprognostic (3.72e-1)"	"unprognostic (9.73e-2)"	3.2	1.4	0.4	6.8	0.6	30.3	1.0	0.3	1.9	0.5	1.1	0.6	0.4	3.3	0.6	0.9	0.5	2.3	6.6	1.5	1.6	0.4	1.5	3.6	18.4	4.9	2.6	0.0	0.4	0.7	0.2	0.7	0.7	1.8	0.9	1.0	1.1	7.4	2.6	0.5	0.4	1.5	0.6	3.4	31.9	1.0	0.3	0.8	0.8	0.6	5.0	0.7	0.6	1.9	0.0	5.3	16.7	37.9	0.0	0.1	8.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	15.9	4.2	0.0	33.8	0.1	0.0	0.0	0.0	5.3	0.0	0.0	0.0	16.7	0.0	37.9	2.2	0.1	8.1	0.4	0.6	0.3	1.9	1.6	0.4	2.6	0.0	1.8	0.8	3.0	17.0	3.4	0.0	1.3	0.0	0.6	2.5	4.0	5.7	0.0	0.0	0.1	0.0	0.0	0.1	0.5	0.0	0.0	0.0	0.2	0.8	0.0	4.7	0.8	26.7	0.0	0.0	3.1	133.7	0.0	0.0	59.3	3.3	5.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	6.5	0.2	0.0	0.0	0.5	0.1	0.0	0.0	0.0
LILRB3	"CD85a, HL9, ILT5, LIR-3, LIR3, PIR-B, PIRB"	ENSG00000204577	"Leukocyte immunoglobulin like receptor B3"	O75022	19	54216278-54223506	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 24.4;bone marrow: 15.3;lymphoid tissue: 23.4"	"Cell type enhanced"	"Detected in many"	14	"Hofbauer cells: 57.4;Kupffer cells: 90.9;Macrophages: 66.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"neutrophil: 24.4"	"Group enriched"	"Detected in many"	4	"granulocytes: 24.4;monocytes: 9.4"	"Cell line enhanced"	"Detected in some"		"BJ: 1.7;HaCaT: 1.9;HEK 293: 2.6"															NA	NA						"unprognostic (7.51e-2)"	"unprognostic (3.52e-2)"	"unprognostic (9.59e-2)"	"unprognostic (4.53e-1)"	"unprognostic (1.83e-3)"	"unprognostic (5.28e-3)"	"unprognostic (2.91e-2)"	"unprognostic (2.55e-1)"	"unprognostic (5.58e-2)"	"unprognostic (2.35e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.92e-8)"	"unprognostic (2.18e-1)"	"unprognostic (2.19e-3)"	"unprognostic (1.84e-1)"	"unprognostic (1.75e-1)"	5.1	0.8	0.4	8.9	1.0	15.3	0.8	0.4	0.5	0.7	1.6	0.0	0.2	0.2	0.6	2.5	0.7	1.3	1.1	7.8	1.5	0.6	0.7	1.5	10.9	19.7	0.5	0.0	3.0	1.7	0.0	0.5	2.0	0.6	0.9	0.0	1.0	0.8	0.0	1.7	0.6	0.9	0.9	2.2	23.4	0.8	0.7	0.0	0.3	1.5	0.0	0.1	6.4	1.1	0.1	4.0	24.4	9.4	0.0	0.1	4.5	1.5	0.6	0.4	0.8	0.0	0.0	0.5	1.7	0.0	0.0	0.0	1.0	0.0	0.0	0.4	0.0	0.4	1.9	0.0	0.0	0.0	0.4	2.6	1.0	0.6	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.2	0.0	0.0	0.0	1.4	0.0	1.1	0.2	0.5	0.6	0.2	0.0	0.0	1.0	1.7	0.0	0.0	0.6	0.1	0.0	1.6	0.0	0.0	0.7	0.8	0.0	0.0	0.5	0.3	0.0	0.3	1.0	0.0	0.4	9.4	0.3	0.0	7.5	0.1	0.1	0.1	0.0	4.0	0.1	0.0	0.0	24.4	0.0	3.3	0.4	0.0	4.5	0.4	1.0	0.4	0.5	1.5	0.6	0.5	0.0	0.6	0.0	8.9	18.3	3.0	1.2	2.2	0.7	0.4	5.1	8.1	11.4	1.8	0.0	1.4	0.0	0.3	0.9	0.6	0.0	0.0	0.5	2.6	1.3	0.8	7.0	2.1	57.4	0.0	0.0	2.5	90.9	2.6	0.3	66.5	1.7	2.8	0.7	0.9	0.2	0.6	0.7	0.3	3.0	6.5	1.2	0.5	1.6	2.6	1.0	1.8	1.2	0.3
LILRB4	"CD85k, HM18, ILT3, LIR-5, LIR5"	ENSG00000186818	"Leukocyte immunoglobulin like receptor B4"	Q8NHJ6	19	54643889-54670359	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 22.8;lymphoid tissue: 33.1"	"Group enriched"	"Detected in some"	6	"Hofbauer cells: 134.1;Kupffer cells: 95.5;Macrophages: 56.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 22.8"	"Group enriched"	"Detected in many"	69	"dendritic cells: 22.8;monocytes: 6.2"	"Cell line enriched"	"Detected in some"	35	"Karpas-707: 97.2"									HPA052807	Approved					NA	NA		9900			"HPA052807: AB_2681958"	"unprognostic (4.09e-2)"	"unprognostic (5.75e-3)"	"unprognostic (6.06e-2)"	"unprognostic (1.91e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.55e-1)"	"unprognostic (5.03e-2)"	"unprognostic (3.53e-1)"	"unprognostic (4.13e-2)"	"unprognostic (1.52e-1)"	"unprognostic (5.43e-1)"	"unprognostic (2.79e-1)"	"unprognostic (1.91e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.42e-2)"	"unprognostic (4.51e-2)"	"unprognostic (4.52e-2)"	15.4	4.3	5.1	20.1	7.4	4.5	3.1	0.8	5.9	1.6	3.6	12.8	0.0	4.0	1.0	4.7	2.1	4.2	4.4	3.9	5.3	5.3	3.1	3.9	12.3	33.1	10.8	1.9	1.7	1.6	1.5	2.4	4.2	6.6	1.7	5.5	2.9	3.8	1.4	0.8	0.9	5.4	2.1	15.1	18.0	2.8	1.3	6.9	3.1	2.3	0.7	6.1	13.8	0.8	0.2	22.8	0.1	6.2	0.1	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	97.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.3	2.8	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	6.2	0.0	0.1	0.0	0.0	7.0	0.2	0.0	0.0	0.1	0.1	4.8	22.8	0.0	1.8	5.1	7.4	0.8	4.5	5.3	5.3	10.8	1.9	6.6	6.9	0.0	5.5	16.7	0.0	0.3	0.0	0.6	0.0	0.0	2.3	0.0	0.0	0.3	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.6	0.5	0.0	1.1	0.2	134.1	0.0	0.0	2.5	95.5	0.0	0.0	56.7	1.7	12.6	0.0	0.0	0.1	0.0	0.0	0.0	0.1	6.5	0.3	0.0	0.4	0.1	0.7	0.0	0.0	0.0
LILRB5	"CD85c, LIR-8, LIR8"	ENSG00000105609	"Leukocyte immunoglobulin like receptor B5"	O75023	19	54249431-54257301	"CD markers, Plasma proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 31.0;lymphoid tissue: 35.1"	"Group enriched"	"Detected in some"	5	"Hofbauer cells: 46.1;Kupffer cells: 83.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"SiHa: 2.3"									HPA012069	Approved					NA	NA		36000000			"HPA012069: AB_1852873"	"unprognostic (3.55e-3)"	"unprognostic (5.38e-2)"	"unprognostic (2.20e-2)"	"unprognostic (7.03e-2)"	"unprognostic (8.86e-2)"	"unprognostic (5.44e-2)"	"unprognostic (3.02e-5)"	"unprognostic (6.80e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.33e-1)"	"unprognostic (9.95e-2)"	"unprognostic (8.68e-2)"	"unprognostic (3.31e-1)"	"unprognostic (2.07e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.42e-2)"	"unprognostic (1.73e-1)"	23.6	8.3	0.7	5.4	0.8	0.8	31.0	0.6	0.6	2.1	11.9	0.5	1.6	5.2	1.2	16.2	5.8	4.9	6.2	10.0	0.7	0.8	2.1	22.8	8.6	13.3	0.8	0.0	4.1	2.7	0.7	1.0	5.6	0.7	4.0	5.5	3.6	2.9	1.1	6.1	2.0	9.0	5.9	0.9	35.1	2.4	3.9	0.0	1.2	2.6	4.9	1.3	10.6	1.8	0.9	0.7	3.1	0.9	0.9	0.5	0.3	0.4	0.0	0.8	0.5	0.2	0.1	1.0	1.1	0.3	0.4	0.0	0.3	0.6	0.2	0.4	0.1	0.5	1.4	0.3	0.6	0.0	0.5	0.9	1.1	1.8	0.4	0.5	0.6	0.7	0.5	0.3	0.1	0.3	0.1	0.5	0.7	0.6	1.0	0.2	0.0	0.3	0.3	0.7	0.2	0.0	0.6	0.7	0.6	0.2	0.8	0.5	0.9	2.3	0.8	0.7	0.8	0.8	0.1	0.3	0.8	0.7	0.5	0.6	0.4	1.1	0.1	0.4	0.3	0.2	3.1	0.9	0.4	0.4	0.6	0.3	0.4	0.5	0.3	0.3	0.9	0.4	0.4	2.3	0.9	0.8	0.7	0.3	0.3	0.7	0.8	0.6	0.6	0.7	0.8	0.8	0.0	0.7	0.0	0.0	0.6	0.8	0.0	0.9	0.0	1.2	2.5	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.0	1.0	46.1	0.0	0.0	12.9	83.3	1.6	0.0	7.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.7	0.0	0.0	0.0
LRP1	"A2MR, APOER, APR, CD91, IGFBP-3R, IGFBP3R1, LRP, LRP1A"	ENSG00000123384	"LDL receptor related protein 1"	Q07954	12	57128493-57213351	"Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis	"Developmental protein, Receptor"	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Hepatocytes: 153.3;Leydig cells: 216.0;Peritubular cells: 173.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	18	"classical monocyte: 7.6;intermediate monocyte: 4.0;myeloid DC: 2.8;non-classical monocyte: 3.7"	"Group enriched"	"Detected in many"	20	"dendritic cells: 2.8;monocytes: 7.6"	"Cell line enhanced"	"Detected in many"		"ASC diff: 83.1;ASC TERT1: 84.4;fHDF/TERT166: 36.2;HSkMC: 54.7;hTERT-RPE1: 42.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004182, CAB018621, HPA022903"	Supported		Approved	Nucleoplasm,Vesicles	"Intracellular and membrane"	NA	NA		88000000	Vesicles	Nucleoplasm	"CAB018621: AB_627893, HPA004182: AB_2667163, HPA022903: AB_10602426"	"unprognostic (1.65e-1)"	"unprognostic (1.61e-1)"	"unprognostic (1.76e-1)"	"unprognostic (2.71e-1)"	"unprognostic (5.00e-2)"	"unprognostic (4.33e-2)"	"unprognostic (3.98e-1)"	"unprognostic (8.68e-2)"	"unprognostic (1.70e-1)"	"unprognostic (3.37e-3)"	"unprognostic (1.48e-1)"	"unprognostic (1.25e-1)"	"prognostic unfavorable (1.52e-5)"	"unprognostic (2.81e-3)"	"unprognostic (6.13e-2)"	"unprognostic (2.80e-2)"	"prognostic unfavorable (1.29e-5)"	77.8	12.0	19.8	21.5	21.3	6.1	27.7	28.1	25.3	31.4	19.7	11.9	9.0	17.8	26.9	18.2	19.2	21.0	24.1	26.0	18.6	10.4	6.3	31.4	24.7	5.5	13.9	15.6	56.9	8.8	8.5	8.0	29.4	17.1	21.4	9.5	20.0	14.8	17.0	11.3	15.7	14.2	22.4	14.3	11.3	11.8	11.1	15.4	0.3	13.2	9.3	3.1	22.9	39.4	0.0	2.8	0.1	7.6	0.0	0.2	1.9	1.2	2.3	5.1	4.0	83.1	84.4	15.3	14.0	18.1	4.6	4.5	4.3	2.0	0.0	1.7	36.2	1.0	5.5	0.8	1.4	1.6	0.1	0.2	0.0	2.7	9.0	11.4	0.0	2.4	54.7	0.5	10.3	1.2	42.1	0.2	0.1	0.0	0.2	14.4	0.2	0.0	0.0	5.8	1.7	1.4	0.5	28.8	0.2	0.3	0.3	0.2	2.8	3.1	0.1	2.2	7.4	0.4	0.2	0.2	16.2	6.0	9.0	0.8	0.1	0.0	0.0	28.4	0.0	3.1	0.0	7.6	0.0	0.0	4.0	0.0	0.0	0.1	0.0	2.8	0.0	0.0	0.2	0.1	0.0	3.7	0.0	0.0	1.9	19.8	21.3	28.1	19.7	18.6	10.4	13.9	15.6	17.1	15.4	11.9	9.6	3.7	11.4	21.3	25.5	12.1	20.4	5.3	11.4	1.8	0.0	65.3	0.0	7.8	1.6	5.8	72.1	0.0	1.6	42.2	117.6	4.4	5.8	153.3	72.0	7.9	4.1	16.0	118.9	3.6	216.0	50.7	27.0	3.6	14.3	130.1	9.9	18.6	173.2	2.2	3.8	38.8	44.2	1.4	2.2	14.1	105.3	0.9	20.9	10.2
LY75	"CD205, CLEC13B, DEC-205"	ENSG00000054219	"Lymphocyte antigen 75"	O60449	2	159803355-159904749	"CD markers, Predicted membrane proteins"	Endocytosis	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"intestine: 28.8;lymphoid tissue: 61.9"	"Cell type enriched"	"Detected in many"	7	"monocytes: 150.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"CAPAN-2: 10.5;HDLM-2: 9.9;Karpas-707: 42.2;RT4: 14.3;THP-1: 10.6"									"CAB001450, HPA049108, HPA054073"	Enhanced		Approved	"Golgi apparatus"		NA	NA		960000	"Golgi apparatus"		"CAB001450: AB_563525, HPA049108: AB_2680635, HPA054073: AB_2682370"	"unprognostic (7.29e-3)"	"unprognostic (1.92e-3)"	"unprognostic (3.15e-1)"	"unprognostic (1.52e-2)"	"unprognostic (4.60e-3)"	"unprognostic (3.65e-2)"	"unprognostic (8.87e-2)"	"unprognostic (6.24e-2)"	"unprognostic (2.80e-1)"	"unprognostic (2.36e-1)"	"unprognostic (8.74e-3)"	"unprognostic (3.92e-1)"	"prognostic unfavorable (2.39e-5)"	"unprognostic (2.66e-1)"	"unprognostic (4.89e-2)"	"unprognostic (1.94e-2)"	"prognostic favorable (3.86e-4)"	3.5	1.8	1.9	21.4	2.6	4.9	6.1	1.2	1.8	4.5	9.3	2.0	1.0	10.8	2.1	1.9	4.5	5.0	10.7	2.8	1.8	1.7	2.8	1.2	10.3	33.9	2.5	1.1	1.6	2.3	0.2	1.9	0.8	2.4	2.0	7.2	1.3	7.2	1.3	0.8	6.5	28.8	1.3	3.4	17.2	3.8	1.1	3.0	61.9	10.7	3.6	17.1	6.9	3.8	5.8	4.3	5.9	2.6	7.5	8.0	2.3	1.6	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	4.2	10.5	7.3	0.3	0.0	0.0	0.2	0.0	0.0	0.0	9.9	0.0	2.1	0.0	0.0	0.2	1.6	0.0	0.2	0.0	0.2	0.1	0.0	5.4	0.0	0.0	42.2	0.0	0.0	0.0	2.7	0.2	0.2	0.0	2.7	0.0	1.8	3.2	14.3	0.0	0.0	3.4	2.4	0.0	0.1	0.0	10.6	8.1	0.0	0.0	0.0	0.0	6.5	1.1	1.4	0.0	3.6	0.0	3.4	2.0	3.5	6.5	2.6	7.1	5.8	5.9	7.5	4.3	4.5	6.7	8.0	5.9	7.5	1.0	1.5	4.3	2.3	1.9	2.6	1.2	1.8	1.8	1.7	2.5	1.1	2.4	3.0	0.0	4.3	8.8	1.9	6.6	0.0	0.4	5.1	6.7	4.5	22.7	2.0	0.1	0.0	0.9	0.3	2.2	20.2	0.0	4.9	0.1	1.5	1.1	11.5	0.0	4.2	0.0	1.7	3.1	7.9	0.0	2.3	11.0	5.0	150.5	11.0	0.5	3.2	10.5	0.4	1.2	0.2	0.0	0.7	0.0	0.7	5.8	0.2	8.7	12.4	4.3
LY9	"CD229, hly9, mLY9, SLAMF3"	ENSG00000122224	"Lymphocyte antigen 9"	Q9HBG7	1	160796074-160828261	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Cell adhesion, Immunity, Innate immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 30.8;intestine: 11.3;lymphoid tissue: 43.7;urinary bladder: 28.6"	"Group enriched"	"Detected in some"	19	"B-cells: 55.0;Erythroid cells: 23.3;Melanocytes: 67.4;T-cells: 45.3"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"gdT-cell: 30.6;MAIT T-cell: 30.7;memory B-cell: 15.2;memory CD4 T-cell: 26.8;memory CD8 T-cell: 29.6;naive B-cell: 13.9;naive CD4 T-cell: 30.5;naive CD8 T-cell: 30.8;plasmacytoid DC: 18.6;T-reg: 19.7"	"Group enriched"	"Detected in many"	4	"B-cells: 15.2;dendritic cells: 18.6;T-cells: 30.8"	"Cell line enhanced"	"Detected in some"		"Daudi: 7.3;JURKAT: 7.4;Karpas-707: 14.9;U-266/70: 37.8;U-266/84: 14.6"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA050917	Approved					NA	NA		23000			"HPA050917: AB_2681272"	"unprognostic (8.04e-4)"	"unprognostic (2.31e-5)"	"unprognostic (8.08e-3)"	"unprognostic (1.20e-3)"	"unprognostic (9.83e-3)"	"unprognostic (1.87e-5)"	"unprognostic (1.16e-2)"	"unprognostic (3.84e-3)"	"unprognostic (1.23e-2)"	"unprognostic (2.89e-3)"	"unprognostic (1.64e-1)"	"unprognostic (2.30e-1)"	"unprognostic (2.70e-3)"	"unprognostic (8.69e-2)"	"unprognostic (9.47e-2)"	"unprognostic (3.49e-2)"	"unprognostic (6.88e-2)"	2.8	0.5	0.4	20.9	0.4	6.9	2.7	0.4	0.4	1.4	3.7	0.2	0.4	2.4	0.9	0.8	3.5	1.0	2.0	0.9	0.4	0.4	1.7	1.3	6.1	35.3	0.4	0.0	1.1	0.5	0.0	0.5	0.2	0.1	1.0	2.3	1.0	6.5	0.4	0.4	0.8	11.3	0.1	0.7	25.3	3.4	1.1	0.0	35.7	1.6	1.8	43.7	28.6	1.2	15.2	18.6	0.6	0.2	5.2	30.8	12.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	7.4	0.0	14.9	0.0	0.0	1.1	0.2	0.0	0.4	0.0	0.8	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	37.8	14.6	0.1	0.0	2.1	0.0	0.2	0.2	0.1	30.6	0.2	30.7	15.2	26.8	29.6	1.3	13.9	30.5	30.8	0.6	5.2	0.2	18.6	19.7	12.9	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.0	0.1	0.0	0.0	2.6	55.0	0.5	0.9	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	23.3	0.2	0.0	0.5	0.2	0.0	0.4	2.0	0.0	1.2	2.5	2.4	0.0	0.0	2.2	67.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.9	0.1	45.3	0.0	0.4
MCAM	"CD146, MUC18"	ENSG00000076706	"Melanoma cell adhesion molecule"	P43121	11	119308529-119321521	"CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	16	"Endothelial cells: 83.4;Muller glia cells: 87.4;Sertoli cells: 316.9;Smooth muscle cells: 214.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 2.2"	"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in many"	4	"HUVEC TERT2: 128.2;TIME: 125.2;WM-115: 99.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002147, HPA008848"	Enhanced		Approved	"Plasma membrane"		NA	NA		2600000000	"Plasma membrane"		"CAB002147: AB_563499, HPA008848: AB_1078445"	"unprognostic (6.45e-2)"	"prognostic unfavorable (7.61e-4)"	"unprognostic (7.03e-2)"	"unprognostic (1.22e-2)"	"unprognostic (6.67e-2)"	"unprognostic (2.34e-1)"	"unprognostic (2.23e-2)"	"unprognostic (8.42e-2)"	"unprognostic (2.09e-2)"	"unprognostic (1.45e-1)"	"unprognostic (1.58e-1)"	"unprognostic (9.39e-2)"	"prognostic unfavorable (5.14e-4)"	"unprognostic (8.75e-3)"	"unprognostic (7.84e-2)"	"unprognostic (2.31e-1)"	"unprognostic (2.79e-3)"	88.2	8.9	6.4	18.5	10.3	0.4	86.1	17.7	13.4	22.3	33.2	13.3	11.7	8.3	40.1	32.5	27.6	29.3	50.9	32.0	7.1	8.2	7.5	3.8	23.8	13.0	7.4	8.1	23.6	6.2	54.5	3.9	47.4	11.1	22.9	9.7	25.0	9.4	44.9	21.1	10.5	15.6	67.1	6.5	9.6	25.0	18.4	5.4	2.2	13.1	15.7	4.8	55.0	24.3	0.8	0.0	0.3	0.0	0.0	2.2	0.0	0.0	0.5	0.5	0.0	2.5	0.0	2.6	0.3	0.0	3.4	1.5	1.9	0.1	0.1	10.9	1.2	5.2	0.3	4.4	0.9	1.7	6.2	1.5	0.1	12.3	2.2	6.0	0.0	0.0	1.8	0.0	4.7	2.2	0.1	128.2	0.8	4.1	0.1	0.7	0.0	0.1	1.0	2.2	0.0	0.5	0.1	17.1	3.6	3.1	0.0	1.4	0.4	9.8	0.2	28.2	5.6	0.5	0.1	125.2	0.3	18.4	0.0	9.9	0.2	0.2	0.0	5.0	0.0	99.5	0.0	0.0	0.0	0.0	0.0	2.2	0.8	0.6	1.1	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	1.3	0.0	6.4	10.3	17.7	13.4	7.1	8.2	7.4	8.1	11.1	5.4	0.0	2.9	0.8	0.5	4.1	1.3	57.3	12.7	1.4	1.2	0.0	21.6	0.3	0.0	14.3	1.6	83.4	0.0	0.0	0.3	34.2	4.4	1.1	0.0	0.0	0.7	0.0	0.0	74.9	1.6	0.6	0.9	2.7	20.3	1.0	0.0	87.4	2.5	0.0	23.7	0.0	2.1	316.9	214.2	2.2	1.2	2.9	0.3	0.7	0.0	0.7
MELTF	"CD228, FLJ38863, MAP97, MFI2, MGC4856, MTf, MTF1"	ENSG00000163975	Melanotransferrin	P08582	3	196988621-197029816	"CD markers, Plasma proteins, Predicted intracellular proteins"	"Ion transport, Iron transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	4	"salivary gland: 65.7"	"Group enriched"	"Detected in some"	5	"Collecting duct cells: 14.0;Ductal cells: 23.5;Hofbauer cells: 16.2;Pancreatic endocrine cells: 42.2"	"Cancer enhanced"	"Detected in all"		"melanoma: 32.7"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 3.3"	"Group enriched"	"Detected in many"	5	"dendritic cells: 1.9;monocytes: 2.1;T-cells: 3.3"	"Cell line enhanced"	"Detected in many"		"A-431: 47.1;SK-MEL-30: 58.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA004880	Approved				"Intracellular and membrane"	NA	NA		230000000			"HPA004880: AB_1853844"	"unprognostic (8.68e-3)"	"unprognostic (3.68e-2)"	"unprognostic (1.75e-2)"	"unprognostic (7.68e-3)"	"unprognostic (1.06e-2)"	"unprognostic (1.08e-2)"	"unprognostic (5.53e-2)"	"unprognostic (1.64e-3)"	"unprognostic (1.20e-2)"	"unprognostic (1.23e-1)"	"unprognostic (3.68e-3)"	"unprognostic (8.14e-2)"	"prognostic unfavorable (6.99e-11)"	"unprognostic (2.29e-1)"	"unprognostic (2.11e-1)"	"unprognostic (5.75e-2)"	"unprognostic (2.09e-2)"	6.0	1.6	1.9	3.5	2.0	1.8	7.5	2.7	2.8	4.4	5.1	3.3	3.5	2.1	4.9	4.8	2.4	6.4	2.5	3.3	1.8	1.1	5.1	1.4	1.6	1.7	1.0	1.0	1.3	4.3	15.9	1.8	4.4	2.9	3.7	1.9	2.9	65.7	4.7	1.4	10.5	8.7	3.1	1.1	1.0	1.1	2.6	0.9	3.6	2.0	1.3	2.4	2.0	5.4	0.2	1.9	0.2	2.1	0.5	3.3	0.6	47.1	10.3	0.1	0.3	1.5	1.9	1.2	0.8	0.4	1.6	1.9	2.9	7.1	1.3	10.2	1.6	1.4	14.8	0.5	0.0	0.7	2.1	3.3	1.6	2.2	1.2	9.6	0.2	9.4	10.3	1.3	1.3	0.1	0.0	0.2	2.7	1.2	9.3	0.9	2.8	2.7	0.0	1.1	2.0	6.8	3.9	1.6	0.5	0.2	0.4	0.9	3.5	9.8	0.8	58.2	1.2	2.9	1.4	0.3	0.3	8.3	1.7	5.8	1.6	13.1	1.3	1.2	2.8	0.0	0.1	0.3	0.0	1.2	1.0	3.3	0.2	1.0	1.0	1.9	0.2	0.3	0.1	0.2	0.5	2.1	0.0	0.1	0.6	1.9	2.0	2.7	2.8	1.8	1.1	1.0	1.0	2.9	0.9	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	2.7	3.4	14.0	0.0	0.2	0.0	23.5	0.0	0.0	0.0	0.0	4.9	0.2	0.0	0.0	0.0	0.0	16.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	4.6	0.0	0.0	42.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0
MME	"CALLA, CD10, NEP"	ENSG00000196549	"Membrane metalloendopeptidase"	P08473	3	155024124-155183729	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 61.1;intestine: 136.0;kidney: 64.9"	"Cell type enhanced"	"Detected in many"	8	"Basal glandular cells: 62.4;Cytotrophoblasts: 71.6;Proximal tubular cells: 101.6;Syncytiotrophoblasts: 105.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	129	"neutrophil: 61.1"	"Lineage enriched"	"Detected in single"	129	"granulocytes: 61.1"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 97.1;BJ hTERT+: 146.1;HSkMC: 94.2"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"basal ganglia: 26.8"	"CAB000013, HPA052583, HPA056072"	Enhanced					NA	NA		99000			"CAB000013: AB_563478, HPA052583: AB_2681872, HPA056072: AB_2683027"	"unprognostic (1.36e-1)"	"unprognostic (1.02e-3)"	"unprognostic (8.52e-2)"	"unprognostic (2.95e-1)"	"unprognostic (2.78e-2)"	"unprognostic (6.52e-3)"	"unprognostic (1.20e-1)"	"unprognostic (1.67e-2)"	"unprognostic (8.67e-2)"	"unprognostic (1.96e-1)"	"unprognostic (7.30e-3)"	"unprognostic (1.31e-1)"	"unprognostic (2.71e-3)"	"unprognostic (1.50e-1)"	"unprognostic (7.29e-2)"	"unprognostic (1.06e-2)"	"unprognostic (1.37e-2)"	26.5	0.4	0.4	3.4	7.4	1.9	14.7	0.4	0.7	4.8	65.6	0.1	18.4	74.0	2.8	8.1	0.7	0.9	8.5	1.8	0.3	0.4	64.9	11.5	13.7	3.0	2.1	0.2	0.9	0.6	0.0	0.6	35.0	8.6	18.3	0.4	1.3	3.7	11.3	11.7	1.4	136.0	0.6	0.9	2.7	0.7	1.0	1.2	13.2	1.0	5.3	2.3	3.4	4.9	0.1	0.4	61.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	39.4	97.1	0.2	21.7	146.1	11.1	28.7	0.0	0.0	23.9	0.0	19.2	15.1	0.0	0.7	0.8	26.7	0.0	0.1	0.0	0.0	0.0	31.6	0.0	0.0	94.2	0.1	5.9	42.5	12.3	8.4	0.0	0.0	0.0	17.7	0.1	0.0	0.1	0.9	0.0	0.1	39.7	18.7	0.1	0.6	0.2	0.0	0.2	0.0	0.0	4.2	8.9	0.0	0.0	23.8	47.7	0.1	16.3	3.7	0.0	0.0	31.5	5.7	0.0	1.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	61.1	0.0	0.0	0.4	0.0	0.0	0.4	7.4	0.4	0.7	0.3	0.4	2.1	0.2	8.6	1.2	8.9	18.3	0.9	62.4	0.7	0.0	1.1	17.8	2.7	19.4	21.0	0.0	71.6	8.3	0.1	0.3	0.6	0.0	0.0	0.0	48.9	19.2	29.2	2.3	48.9	8.1	0.0	0.0	3.1	1.8	0.2	3.7	2.7	0.0	0.0	0.2	0.0	0.3	0.0	1.1	101.6	0.0	0.0	3.1	0.2	0.4	0.3	105.4	0.0	0.0	29.2
MPL	"CD110, TPOR"	ENSG00000117400	"MPL proto-oncogene, thrombopoietin receptor"	P40238	1	43337849-43352772	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 8.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	5	"neutrophil: 1.6"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.6"	"Cell line enriched"	"Detected in single"	78	"HEL: 41.7"	"Region enhanced"	"Detected in single"		"cerebral cortex: 1.4"	"Low region specificity"	"Detected in all"			HPA007619			Supported	"Nuclear membrane,Plasma membrane"		NA	NA			"Plasma membrane"	"Nuclear membrane"	"HPA007619: AB_1854080"	"unprognostic (2.74e-1)"	"unprognostic (6.56e-2)"	"unprognostic (2.95e-1)"	"unprognostic (8.71e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.06e-3)"	"unprognostic (1.19e-1)"	"unprognostic (1.22e-2)"	"unprognostic (5.83e-2)"	"unprognostic (1.03e-1)"	"unprognostic (5.94e-4)"	"unprognostic (1.51e-1)"	"unprognostic (1.19e-4)"	"unprognostic (2.39e-1)"	"unprognostic (3.26e-1)"	"unprognostic (1.03e-4)"	"unprognostic (1.42e-1)"	1.1	0.3	0.9	0.5	0.8	2.0	0.9	0.5	2.2	0.6	0.6	0.5	0.5	0.3	0.9	1.7	0.9	2.1	0.5	3.9	0.8	0.6	0.5	0.5	2.0	0.5	0.9	0.5	6.6	1.1	0.6	0.6	2.2	0.5	1.5	0.7	0.5	0.5	0.7	0.6	0.4	1.2	2.1	2.5	8.6	0.5	2.1	0.5	0.5	2.2	2.4	0.5	0.9	0.5	0.0	0.0	1.6	0.3	0.0	0.0	4.0	0.1	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	41.7	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.1	0.4	0.2	0.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	4.0	0.9	0.8	0.5	2.2	0.8	0.6	0.9	0.5	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MRC1	"bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1"	ENSG00000260314	"Mannose receptor C-type 1"	P22897	10	17809344-17911170	"CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins"	"Endocytosis, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 44.8;lymphoid tissue: 37.8"	"Group enriched"	"Detected in many"	6	"Hofbauer cells: 135.5;Ito cells: 511.3;Kupffer cells: 324.4;Macrophages: 182.8"	"Low cancer specificity"	"Detected in all"							"Cell type enriched"	"Detected in single"	15	"myeloid DC: 8.2"	"Lineage enriched"	"Detected in single"	15	"dendritic cells: 8.2"	"Group enriched"	"Detected in some"	19	"MOLT-4: 17.7;TIME: 16.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA004114, HPA045134, CAB068203"	Enhanced					NA	NA		130000000			"CAB068203: AB_2665652, HPA004114: AB_1846270, HPA045134: AB_2679228"	"unprognostic (2.20e-1)"	"unprognostic (2.07e-1)"	"unprognostic (1.03e-2)"	"unprognostic (2.58e-1)"	"unprognostic (5.62e-2)"	"unprognostic (4.30e-1)"	"unprognostic (6.36e-3)"	"unprognostic (1.35e-1)"	"unprognostic (1.05e-2)"	"unprognostic (6.05e-2)"	"unprognostic (5.61e-2)"	"unprognostic (4.12e-1)"	"unprognostic (2.94e-2)"	"unprognostic (4.97e-2)"	"unprognostic (3.05e-2)"	"unprognostic (1.74e-2)"	"unprognostic (7.02e-2)"	34.8	8.3	0.3	6.2	1.2	0.0	19.8	0.7	0.6	5.2	11.2	0.6	0.9	2.2	4.5	10.4	4.2	1.3	7.9	13.4	0.9		12.4	16.4	44.8	37.8	1.0	0.0	3.6	5.1	1.8	2.4	15.4	3.1	5.5	5.1	7.0	0.7	1.9	5.1	0.0	6.5	8.2	1.4	30.6	2.2	7.1	0.8	0.8	6.5	3.5	0.7	7.5	5.1	0.0	8.2	0.1	0.5	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	17.7	0.0	0.2	0.0	0.0	0.1	0.3	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	16.4	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.1	0.0	8.2	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.4	0.2											29.8	47.4	11.5	0.0	0.3	0.0	3.6	5.1	10.7	13.6	0.0	0.0	0.8	0.0	0.0	26.7	4.8	1.3	0.0	0.3	1.1	1.0	0.0	12.8	2.5	135.5	0.0	0.0	511.3	324.4	7.9	1.4	182.8	0.0	0.0	0.4	0.0	0.1	1.1	0.0	0.0	0.0	32.3	0.0	0.3	1.2	0.4	1.7	4.9	0.8	0.0
MRC2	"CD280, CLEC13E, ENDO180, KIAA0709"	ENSG00000011028	"Mannose receptor C type 2"	Q9UBG0	17	62627401-62693597	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	7	"Alveolar cells type 2: 33.9;Early spermatids: 89.0;Fibroblasts: 61.1;Late spermatids: 54.5;Leydig cells: 66.4;Peritubular cells: 96.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"naive CD4 T-cell: 1.0"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"BJ: 46.5;fHDF/TERT166: 31.6;U-138 MG: 47.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA041991	Enhanced					NA	NA		28000000			"HPA041991: AB_10794166"	"unprognostic (3.22e-1)"	"unprognostic (2.19e-1)"	"unprognostic (4.45e-2)"	"unprognostic (2.59e-2)"	"unprognostic (4.29e-2)"	"unprognostic (2.67e-2)"	"unprognostic (6.21e-2)"	"unprognostic (1.80e-1)"	"unprognostic (7.39e-2)"	"prognostic unfavorable (1.68e-4)"	"unprognostic (7.70e-2)"	"unprognostic (7.75e-2)"	"prognostic unfavorable (4.94e-7)"	"unprognostic (5.25e-2)"	"unprognostic (6.13e-2)"	"unprognostic (3.00e-2)"	"unprognostic (1.93e-2)"	14.7	5.7	2.4	14.7	5.2	3.2	27.3	1.4	3.4	30.4	7.0	6.5	18.7	4.4	31.7	46.3	15.7	15.7	37.2	44.1	2.5	2.6	8.7	2.2	46.8	2.5	3.4	4.0	33.6	4.7	0.9	11.3	5.4	6.8	25.7	1.9	35.1	10.9	17.1	7.3	19.0	7.1	28.7	8.2	9.7	5.8	13.3	2.5	4.8	4.6	21.2	5.3	18.1	18.1	0.0	0.6	0.2	0.0	0.0	1.0	0.0	0.0	8.5	4.6	6.1	12.8	23.1	0.7	46.5	27.2	6.8	8.2	0.5	0.1	0.0	3.3	31.6	3.0	3.9	0.8	3.9	1.9	5.8	1.3	3.9	6.2	0.0	19.1	4.8	0.0	30.0	2.0	6.0	0.6	29.4	3.1	2.3	2.2	0.0	9.4	1.4	1.2	16.6	1.1	0.0	0.5	4.7	3.3	0.0	0.7	0.1	0.7	12.2	3.1	0.1	0.0	3.1	0.1	19.4	15.5	47.9	19.6	8.3	8.2	0.0	0.0	0.0	15.0	4.9	7.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.6	0.0	1.0	0.9	0.2	0.0	0.0	0.0	0.9	0.0	2.4	5.2	1.4	3.4	2.5	2.6	3.4	4.0	6.8	2.5	3.0	33.9	0.0	6.4	10.1	1.6	3.2	0.0	1.4	2.3	1.8	0.0	0.7	0.0	0.3	89.0	2.2	0.0	0.0	0.2	2.1	61.1	1.1	2.3	0.0	6.8	0.0	0.0	5.5	6.7	54.5	66.4	6.4	5.0	1.0	0.0	0.8	0.4	0.0	96.2	0.0	0.5	0.0	6.6	5.2	3.2	6.8	1.6	0.5	0.0	0.9
MS4A1	"B1, Bp35, CD20, MS4A2"	ENSG00000156738	"Membrane spanning 4-domains A1"	P11836	11	60455752-60470760	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"B-cell activation"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 77.7;intestine: 46.1;lymphoid tissue: 134.1"	"Cell type enriched"	"Detected in some"	61	"B-cells: 527.8"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	105	"memory B-cell: 77.7;naive B-cell: 77.7"	"Lineage enriched"	"Detected in single"	105	"B-cells: 77.7"	"Group enriched"	"Detected in some"	25	"Daudi: 122.9;U-698: 61.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB000015, HPA014341, HPA014391"	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB000015: AB_2282030, HPA014341: AB_1846265, HPA014391: AB_1846264"	"prognostic favorable (4.34e-5)"	"unprognostic (4.45e-4)"	"unprognostic (1.19e-4)"	"unprognostic (2.04e-3)"	"unprognostic (1.06e-1)"	"unprognostic (5.53e-7)"	"unprognostic (2.46e-3)"	"unprognostic (1.85e-3)"	"unprognostic (3.06e-2)"	"unprognostic (2.89e-4)"	"unprognostic (6.96e-2)"	"unprognostic (2.84e-2)"	"unprognostic (3.96e-5)"	"unprognostic (2.23e-1)"	"unprognostic (8.04e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.30e-1)"	1.6	0.3	0.3	79.0	0.3	3.6	0.6	0.3	0.3	0.5	2.0	0.0	0.0	0.2	0.4	0.5	7.0	0.4	1.3	0.7	0.3	0.3	2.0	0.9	2.7	81.2	0.3	0.1	0.3	0.4	0.0	0.4	0.4	0.1	1.1	1.7	0.6	14.5	0.2	0.3	0.3	46.1	0.1	0.4	90.7	2.6	0.6	0.0	15.7	2.5	2.7	134.1	6.4	0.8	77.7	0.0	0.2	0.0	0.7	0.6	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	122.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	61.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	77.7	0.3	0.6	0.0	77.7	0.0	0.2	0.2	0.7	0.0	0.0	0.0	3.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.1	0.1	0.0	0.0	6.7	527.8	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.3	0.0	0.1	0.0	0.0	0.0	0.6	1.8	0.0	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	8.7	0.0	0.0
MSR1	"CD204, SCARA1, SR-A, SR-AI, SR-AII, SR-AIII"	ENSG00000038945	"Macrophage scavenger receptor 1"	P21757	8	16107878-16567490	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	5	"adipose tissue: 88.1;lung: 70.4"	"Group enriched"	"Detected in many"	4	"Hofbauer cells: 144.7;Kupffer cells: 246.5;Macrophages: 103.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 16.0"	"Lineage enriched"	"Detected in many"	5	"monocytes: 16.0"	"Group enriched"	"Detected in many"	7	"BJ hTERT+: 48.2;REH: 18.3"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"HPA000272, CAB032491"	Enhanced					NA	NA		25000			"CAB032491: AB_672722, HPA000272: AB_1846269"	"unprognostic (8.19e-3)"	"unprognostic (4.87e-2)"	"unprognostic (1.93e-2)"	"unprognostic (2.10e-1)"	"unprognostic (9.24e-2)"	"unprognostic (1.32e-2)"	"unprognostic (5.85e-3)"	"unprognostic (2.89e-1)"	"unprognostic (9.70e-2)"	"unprognostic (1.62e-2)"	"unprognostic (7.19e-2)"	"unprognostic (8.82e-2)"	"unprognostic (2.76e-2)"	"unprognostic (9.16e-2)"	"unprognostic (7.39e-2)"	"unprognostic (6.85e-2)"	"unprognostic (4.69e-2)"	88.1	9.0	2.2	6.1	4.5	3.7	6.9	10.4	3.3	4.5	3.1	1.8	1.0	2.1	3.1	6.2	2.4	4.5	11.4	8.0	3.8	3.1	9.5	13.6	70.4	6.9	4.3	0.8	6.7	3.8	1.2	2.6	10.4	7.7	3.2	3.9	4.5	6.2	2.3	3.2	1.6	4.0	6.5	11.9	10.9	2.5	4.9	3.1	1.5	2.2	1.7	0.7	10.8	1.8	1.5	1.0	3.0	16.0	0.3	1.3	0.5	0.6	0.9	1.3	0.6	0.6	0.6	0.6	0.3	48.2	0.1	0.2	1.6	0.1	1.5	2.4	0.4	0.3	0.3	0.3	0.4	0.9	0.2	2.0	2.0	1.8	1.9	0.4	1.0	1.1	0.3	0.4	0.4	0.7	0.8	0.0	0.8	0.7	1.4	0.9	1.9	0.6	0.6	0.2	0.7	0.6	18.3	1.0	0.4	0.9	2.8	1.0	0.5	0.4	1.3	0.1	2.4	0.2	0.5	1.1	1.3	0.5	5.0	1.3	4.9	3.8	3.3	0.5	0.7	1.0	1.1	3.1	0.5	0.9	16.0	0.4	0.9	0.7	0.7	1.0	1.5	1.3	0.9	3.0	0.3	7.8	0.5	0.6	0.5	2.2	4.5	10.4	2.7	3.8	3.1	4.3	0.8	7.7	3.1	20.8	40.5	8.2	0.0	2.4	0.0	1.7	5.1	12.0	14.8	3.5	23.6	0.5	1.7	0.0	2.2	1.3	0.0	0.0	0.0	0.4	0.9	0.0	16.3	0.9	144.7	0.0	0.0	7.4	246.5	2.1	1.7	103.5	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.7	19.4	0.9	3.3	1.4	1.8	0.7	1.3	0.0	0.1
MST1R	"CD136, CDw136, PTK8, RON"	ENSG00000164078	"Macrophage stimulating 1 receptor"	Q04912	3	49887002-49903873	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Innate immunity"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 27.7;intestine: 34.3;skin 1: 28.7"	"Cell type enhanced"	"Detected in many"	7	"Alveolar cells type 1: 23.8;Enterocytes: 29.1;Mucus-secreting cells: 21.5;Pancreatic endocrine cells: 19.7;Paneth cells: 20.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"MAIT T-cell: 2.1"	"Lineage enhanced"	"Detected in single"		"T-cells: 2.1"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 35.9;HaCaT: 19.8;HBEC3-KT: 21.6;hTCEpi: 30.3;RT4: 23.1"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"HPA007657, HPA008180, CAB008972"	Enhanced		Approved	Cytosol		NA	NA			Cytosol		"CAB008972: , HPA007657: AB_1079292, HPA008180: AB_1079291"	"unprognostic (3.84e-3)"	"unprognostic (3.86e-1)"	"unprognostic (1.92e-1)"	"unprognostic (7.33e-3)"	"unprognostic (3.82e-2)"	"unprognostic (2.32e-1)"	"unprognostic (8.07e-3)"	"unprognostic (1.54e-2)"	"unprognostic (4.12e-2)"	"unprognostic (2.15e-1)"	"unprognostic (1.24e-3)"	"unprognostic (2.28e-1)"	"unprognostic (8.08e-3)"	"unprognostic (2.38e-1)"	"unprognostic (2.18e-1)"	"unprognostic (8.00e-3)"	"prognostic favorable (2.33e-5)"	1.7	0.1	0.4	7.5	0.6	0.0	2.4	0.5	0.7	1.8	20.5	0.7	2.0	11.2	1.2	1.3	6.1	0.6	27.7	0.9	0.5	0.1	1.4	0.4	5.0	1.1	0.4	0.6	0.5	4.1	0.0	1.3	0.8	0.9	1.7	9.7	2.5	2.1	0.4	0.5	28.7	34.3	0.7	0.4	0.6	19.1	1.9	0.4	7.7	1.3	6.0	4.5	4.3	3.5	0.2	0.0	0.0	0.0	0.6	2.1	0.0	12.9	5.0	0.0	0.2	0.0	0.0	0.8	0.1	0.0	0.0	0.0	1.2	35.9	0.5	3.1	0.2	0.0	19.8	0.0	21.6	0.0	0.3	0.3	0.0	8.5	0.3	0.3	0.0	0.4	0.1	30.3	0.1	4.3	0.1	0.0	0.0	0.2	0.1	0.0	1.8	0.0	0.0	0.1	11.6	10.5	0.9	0.0	0.3	13.3	23.1	0.3	0.0	3.6	8.4	0.0	0.0	6.6	0.3	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.0	0.9	0.0	0.4	0.6	0.5	0.7	0.5	0.1	0.4	0.6	0.9	0.4	23.8	10.1	0.0	2.2	7.8	0.0	1.2	0.0	2.7	9.1	0.0	0.0	0.1	0.0	5.2	13.7	0.0	29.1	0.0	8.7	0.4	0.4	1.7	0.0	0.0	0.1	0.0	4.1	0.0	0.0	7.9	0.3	0.0	0.0	1.0	21.5	0.0	19.7	20.4	0.0	0.0	0.0	0.0	0.4	1.6	0.8	4.1	0.0	0.0	12.4	4.6
MUC1	"ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM"	ENSG00000185499	"Mucin 1, cell surface associated"	P15941	1	155185824-155192916	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"			"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 168.1;kidney: 158.5;lung: 143.5"	"Cell type enhanced"	"Detected in many"	11	"Alveolar cells type 2: 1308.2;Collecting duct cells: 465.9;Exocrine glandular cells: 994.6;Pancreatic endocrine cells: 807.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"T-reg: 4.0"	"Group enriched"	"Detected in many"	10	"granulocytes: 1.3;T-cells: 4.0"	"Group enriched"	"Detected in many"	6	"CAPAN-2: 139.4;OE19: 65.3;RPTEC TERT1: 107.0;T-47d: 47.0"									"CAB000036, CAB001986, HPA004179, HPA007235, HPA008855"	Enhanced		Supported	"Plasma membrane"	"Secreted in other tissues"	NA	NA		4900000	"Plasma membrane"		"CAB000036: AB_2148557, CAB001986: , HPA004179: AB_1846282, HPA007235: AB_1846281, HPA008855: AB_1846283"	"unprognostic (4.74e-2)"	"unprognostic (2.84e-2)"	"unprognostic (2.19e-1)"	"unprognostic (8.01e-2)"	"unprognostic (1.32e-2)"	"unprognostic (1.70e-1)"	"unprognostic (2.61e-3)"	"unprognostic (6.34e-2)"	"unprognostic (1.43e-1)"	"unprognostic (3.23e-1)"	"prognostic unfavorable (4.60e-4)"	"unprognostic (4.75e-1)"	"unprognostic (2.05e-2)"	"unprognostic (1.13e-1)"	"unprognostic (8.12e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.21e-1)"	1.5	0.7	0.8	12.6	1.2	0.9	12.6	0.4	0.7	31.6	15.9	1.2	2.4	2.9	10.5	9.8	51.8	18.7	168.1	0.8	0.5	0.3	158.5	2.0	143.5	0.3	0.5	0.3	14.9	74.2	0.0	4.7	15.5	2.1	6.1	16.1	0.8	17.0	5.9	0.8	1.8	3.6	2.8	0.7	0.6	105.0	4.3	0.5	0.7	15.7	10.5	47.8	12.3	5.2	0.0	0.2	1.3	0.1	0.0	4.0	0.2	1.8	0.9	0.6	0.5	0.4	0.5	0.2	0.6	1.4	0.7	1.9	0.0	139.4	0.0	10.1	1.1	0.3	2.8	0.1	0.0	0.2	1.2	0.1	0.2	11.8	0.0	0.3	0.0	4.4	1.2	0.2	0.3	0.2	1.5	0.2	0.2	1.0	1.9	0.5	14.2	0.1	0.1	0.4	65.3	0.2	0.2	0.0	3.4	107.0	0.1	0.6	0.2	3.3	5.9	0.1	0.5	47.0	0.6	0.2	0.4	0.8	1.3	0.1	2.1	1.1	0.0	0.7	0.1	0.1	1.3	0.1	0.0	0.0	0.0	0.8	0.0	2.3	0.4	0.2	0.0	0.3	0.7	0.0	0.0	0.0	0.0	4.0	0.2	0.8	1.2	0.4	0.7	0.5	0.3	0.5	0.3	2.1	0.5	402.0	1308.2	0.9	16.1	0.6	1.0	0.4	384.7	92.3	252.5	465.9	3.9	0.1	29.9	144.7	27.3	3.5	49.2	0.0	994.6	1.2	3.1	11.6	45.2	0.5	0.2	1.6	29.4	1.3	3.4	68.9	2.3	2.6	5.0	42.3	249.7	1.1	807.2	66.2	1.4	0.9	0.2	0.0	1.9	6.2	0.8	1.0	0.2	0.0	132.5	164.3
NCAM1	"CD56, NCAM"	ENSG00000149294	"Neural cell adhesion molecule 1"	P13591	11	112961247-113278436	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 110.6;heart muscle: 67.7"	"Group enriched"	"Detected in many"	4	"Bipolar cells: 108.7;Cardiomyocytes: 109.4;Horizontal cells: 165.3;Muller glia cells: 263.9;Rod photoreceptor cells: 95.4"	"Cancer enriched"	"Detected in many"	8	"glioma: 31.0"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	14	"NK-cell: 27.2"	"Lineage enriched"	"Detected in many"	14	"NK-cells: 27.2"	"Cell line enhanced"	"Detected in some"		"HEL: 19.5;RH-30: 44.0;SCLC-21H: 35.8;SH-SY5Y: 17.6;U-138 MG: 24.5;WM-115: 25.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000142, CAB018071, HPA039835"	Enhanced		Enhanced	"Plasma membrane,Cytosol"	"Intracellular and membrane"	NA	NA	1200000	2800000000	"Plasma membrane"	Cytosol	"CAB000142: , CAB018071: AB_627129, HPA039835: AB_2676705"	"unprognostic (7.04e-2)"	"unprognostic (1.16e-1)"	"unprognostic (2.77e-2)"	"unprognostic (2.18e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.74e-3)"	"unprognostic (2.82e-1)"	"unprognostic (4.42e-3)"	"unprognostic (2.13e-1)"	"unprognostic (1.63e-2)"	"prognostic favorable (9.11e-6)"	"unprognostic (8.13e-2)"	"prognostic unfavorable (8.20e-4)"	"unprognostic (2.97e-2)"	"unprognostic (2.24e-1)"	"unprognostic (3.75e-2)"	"unprognostic (5.82e-5)"	3.5	36.4	22.7	3.0	35.7	1.8	2.1	20.2	110.6	13.3	9.0	55.8	0.3	3.4	24.7	3.0	4.8	8.3	3.6	67.7	22.5	19.2	2.3	2.6	2.0	1.7	45.0	27.1	21.9	2.3	1.1	9.1	1.4	38.8	8.4	4.6	5.5	2.5	10.9	14.6	1.8	5.3	25.6	27.6	3.4	6.7	2.9	39.2	0.0	16.9	0.7	1.7	7.0	6.5	0.0	0.0	0.4	0.1	27.2	2.0	0.9	0.0	0.0	6.9	0.1	0.0	0.1	0.1	0.3	0.0	0.2	0.4	0.1	0.1	1.0	6.1	6.5	0.2	0.1	0.0	0.0	0.0	0.1	3.9	19.5	0.0	0.0	0.7	0.0	3.1	4.2	0.0	0.0	6.2	0.0	0.0	0.0	0.0	0.3	6.8	0.0	0.0	1.6	0.6	0.0	0.1	0.0	44.0	3.1	0.0	0.0	35.8	17.6	0.0	0.1	0.0	0.7	0.0	0.2	0.0	24.5	11.4	0.1	10.2	0.0	0.1	0.0	2.7	9.2	25.9	0.0	0.1	0.0	2.0	0.0	0.6	0.0	0.1	0.2	0.0	0.0	0.0	0.8	0.4	27.2	0.0	0.0	0.1	0.9	22.7	35.7	20.2	41.6	22.5	19.2	45.0	27.1	38.8	39.2	0.0	0.0	0.0	0.4	1.4	108.7	109.4	0.0	1.4	0.0	0.0	35.3	0.5	1.7	14.4	4.5	0.3	0.0	0.0	0.0	0.2	7.6	0.3	1.1	0.5	0.4	165.3	5.2	6.7	5.1	3.9	14.1	1.7	0.0	0.0	0.0	263.9	1.7	0.0	9.6	0.0	95.4	0.0	3.8	0.5	2.3	1.5	0.1	11.4	0.0	0.1
NCR1	"CD335, LY94, NK-p46, NKP46"	ENSG00000189430	"Natural cytotoxicity triggering receptor 1"	O76036	19	54906150-54916140	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 5.5;lymphoid tissue: 13.9"	"Cell type enriched"	"Detected in some"	9	"T-cells: 10.9"	"Cancer enhanced"	"Detected in single"		"testis cancer: 1.2"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"basophil: 1.0"	"Low lineage specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA049311			Approved	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA049311: AB_2680707"	"unprognostic (3.92e-2)"	"unprognostic (2.21e-3)"	"unprognostic (1.67e-1)"	"unprognostic (2.87e-4)"	"unprognostic (2.89e-1)"	"unprognostic (6.32e-4)"	"unprognostic (2.22e-2)"	"unprognostic (3.29e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.89e-2)"	"unprognostic (1.45e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.15e-5)"	"unprognostic (1.82e-2)"	"unprognostic (5.92e-2)"	"unprognostic (3.81e-3)"	"unprognostic (6.05e-3)"	1.4	0.2	0.1	3.7	0.4	2.1	0.3	0.1	0.3	0.3	2.1	0.0	0.5	0.1	1.2	1.3	0.3	0.2	2.1	1.9	0.2	0.2	0.3	2.5	5.5	3.8	0.2	0.0	0.2	0.1	0.1	0.2	0.4	0.0	0.6	0.2	1.0	0.4	0.1	0.3	0.5	3.4	1.2	0.2	13.9	0.3	0.4	0.0	2.0	0.3	0.1	2.6	0.7	0.3	0.2	0.2	1.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.1	0.0	0.3	0.1	0.0	0.0	0.4	0.0	0.0	0.1	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.3	0.3	0.0	0.0	0.1	0.4	0.0	0.0	0.1	0.0	0.2	0.0	0.4	0.1	0.2	0.0	0.0	0.3	0.2	0.0	0.3	0.0	0.3	0.1	0.0	0.0	0.2	0.2	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.7	0.0	0.2	0.0	0.0	0.1	0.4	0.1	0.3	0.2	0.2	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	1.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.9	0.0	0.1
NCR2	"CD336, LY95, NK-p44"	ENSG00000096264	"Natural cytotoxicity triggering receptor 2"	O95944	6	41335655-41350887	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 8.5;intestine: 3.3;lymphoid tissue: 3.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	13	"NK-cell: 2.5;plasmacytoid DC: 8.5"	"Group enriched"	"Detected in many"	13	"dendritic cells: 8.5;NK-cells: 2.5"	"Cell line enhanced"	"Detected in some"		"HMC-1: 1.6;JURKAT: 1.7;MOLT-4: 1.9"									HPA067249	Uncertain					NA	NA					"HPA067249: AB_2685811"		"unprognostic (5.81e-2)"				"unprognostic (3.39e-1)"		"unprognostic (1.95e-1)"		"unprognostic (2.12e-2)"				"unprognostic (1.65e-1)"				0.1	0.1	0.1	1.9	0.1	0.0	0.1	0.0	0.0	0.0	3.3	0.0	0.0	2.8	0.1	0.0	0.2	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	1.6	0.0	0.1	0.2	0.0	0.1	2.5	0.1	0.0	0.6	0.1	0.3	0.0	1.2	0.1	1.7	3.7	0.0	0.1	0.0	8.5	0.0	0.0	2.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.6	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.8	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	8.5	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
NCR3	"1C7, CD337, LY117, NKp30"	ENSG00000204475	"Natural cytotoxicity triggering receptor 3"	O14931	6	31588895-31592985	"CD markers, Predicted membrane proteins"	Immunity	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 28.5;lymphoid tissue: 18.5"	"Group enriched"	"Detected in some"	5	"B-cells: 22.0;T-cells: 69.1"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 28.5"	"Lineage enriched"	"Detected in many"	4	"T-cells: 28.5"	"Cell line enriched"	"Detected in some"	4	"NB-4: 9.5"															NA	NA						"unprognostic (3.99e-3)"	"unprognostic (9.23e-4)"	"unprognostic (1.23e-3)"	"unprognostic (2.49e-4)"	"unprognostic (2.15e-1)"	"unprognostic (2.57e-4)"	"unprognostic (5.99e-2)"	"unprognostic (1.15e-2)"	"unprognostic (1.40e-2)"	"unprognostic (3.62e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.81e-1)"	"unprognostic (2.21e-4)"	"unprognostic (1.72e-1)"	"unprognostic (1.83e-1)"	"unprognostic (8.17e-2)"	"unprognostic (1.43e-1)"	1.8	0.1	0.2	10.5	0.2	4.3	0.3	0.1	0.1	0.1	0.4	0.0	0.0	0.2	0.3	0.5	0.9	0.2	0.3	1.2	0.6	0.1	0.5	1.3	3.9	11.4	0.2	0.0	0.5	1.1	0.0	0.1	0.8	0.1	0.3	0.3	0.1	8.4	0.4	0.1	0.3	5.8	0.2	0.2	18.5	0.4	0.8	0.0	3.6	0.4	0.1	12.8	1.0	0.3	6.1	0.0	0.1	0.2	6.4	28.5	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.4	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	9.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.3	0.0	0.0	0.0	0.0	10.5	0.0	28.5	6.1	1.2	5.2	0.0	4.4	0.5	3.3	0.1	6.4	0.2	0.0	1.7	2.5	0.2	0.2	0.1	0.1	0.6	0.1	0.2	0.0	0.1	0.0	0.0	3.4	22.0	0.0	3.1	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.2	0.0	9.2	0.2	0.3	0.0	0.0	1.8	1.2	0.0	0.3	0.4	3.3	1.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.5	0.6	1.5	0.1	69.1	0.0	0.0
NECTIN1	"CD111, CLPED1, ED4, HIgR, HVEC, OFC7, PRR, PRR1, PVRL1, PVRR1, SK-12"	ENSG00000110400	"Nectin cell adhesion molecule 1"	Q15223	11	119623408-119729084	"CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"esophagus: 55.3;skin 1: 73.5"	"Cell type enhanced"	"Detected in some"	10	"Club cells: 7.9;Ductal cells: 6.5;Exocrine glandular cells: 10.7;Pancreatic endocrine cells: 12.5;Syncytiotrophoblasts: 7.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 4.8"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HaCaT: 59.2;hTCEpi: 36.9;RT4: 40.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016135, HPA026846"	Approved				"Secreted in other tissues"	NA	NA		97000000			"CAB016135: AB_626865, HPA026846: AB_1846226"	"unprognostic (1.62e-1)"	"unprognostic (1.16e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.87e-2)"	"unprognostic (1.26e-1)"	"unprognostic (3.20e-2)"	"unprognostic (2.25e-3)"	"unprognostic (2.03e-1)"	"unprognostic (3.76e-2)"	"unprognostic (3.42e-1)"	"unprognostic (3.58e-2)"	"unprognostic (3.28e-1)"	"unprognostic (3.59e-3)"	"unprognostic (2.13e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.46e-1)"	"unprognostic (9.62e-2)"	3.1	3.0	7.7	3.0	11.1	11.9	5.3	8.4	20.8	6.6	7.3	27.3	2.4	9.6	2.3	2.0	55.3	2.9	2.5	3.0	16.1	8.2	3.0	2.4	2.5	1.7	12.7	10.6	1.8	10.8	2.4	4.1	8.2	10.1	5.9	7.8	6.3	8.7	4.4	1.6	73.5	6.9	3.1	14.3	2.2	3.2	1.3	12.4	2.5	1.8	25.3	20.8	17.3	14.8	0.1	4.8	1.0	1.5	0.1	0.1	0.2	4.1	3.4	3.3	4.7	1.7	0.5	23.2	1.6	1.5	1.4	1.0	7.3	14.2	5.5	6.9	1.9	2.8	59.2	8.4	30.2	0.6	12.9	1.3	0.7	1.1	3.3	0.7	3.7	9.3	0.5	36.9	4.4	16.5	0.5	4.2	1.6	0.1	29.4	1.8	10.8	0.0	2.2	10.8	14.0	4.8	0.3	19.8	6.6	1.3	40.1	8.0	18.0	5.6	14.9	0.5	5.2	13.5	0.5	2.3	1.2	4.7	10.2	1.5	5.4	6.8	0.0	0.4	3.0	2.8	0.0	0.3	0.2	0.1	0.5	0.0	0.0	0.1	0.0	0.2	0.1	0.0	0.0	1.0	0.1	1.5	4.8	0.0	0.2	7.7	11.1	8.4	20.8	16.1	8.2	12.7	10.6	10.1	12.4	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	2.7	7.9	1.8	0.0	3.5	0.0	6.5	0.0	0.0	0.0	0.0	10.7	0.9	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.0	0.0	0.0	12.5	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0
NECTIN2	"CD112, HVEB, PRR2, PVRL2, PVRR2"	ENSG00000130202	"Nectin cell adhesion molecule 2"	Q92692	19	44846175-44889228	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Ductal cells: 182.4;Exocrine glandular cells: 136.8;monocytes: 139.7;Pancreatic endocrine cells: 178.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"eosinophil: 11.5"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA012759, CAB026138, HPA073459"	Enhanced		Approved	"Nucleoli fibrillar center,Cell Junctions"		NA	NA		3400000	"Nucleoli fibrillar center, Cell Junctions"		"CAB026138: , HPA012759: AB_1846227, HPA073459: "	"unprognostic (3.30e-2)"	"unprognostic (2.84e-1)"	"unprognostic (1.07e-1)"	"unprognostic (5.61e-3)"	"unprognostic (7.45e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.66e-2)"	"unprognostic (6.63e-2)"	"unprognostic (2.85e-1)"	"unprognostic (2.97e-1)"	"unprognostic (6.93e-2)"	"unprognostic (3.19e-1)"	"unprognostic (1.60e-1)"	"unprognostic (2.15e-1)"	"unprognostic (1.61e-1)"	"unprognostic (8.19e-2)"	"unprognostic (2.05e-1)"	29.5	28.2	7.9	15.6	7.7	5.6	38.0	4.5	9.0	24.2	34.0	9.3	22.3	24.2	23.2	27.4	33.6	16.7	54.1	21.9	10.5	8.1	29.0	53.7	39.6	23.0	8.2	6.8	25.5	20.6	22.5	15.9	45.8	11.2	25.8	14.8	22.9	24.4	28.9	14.6	18.3	42.9	13.8	8.4	31.4	26.2	38.7	5.8	3.8	32.2	19.2	24.1	21.6	31.4	0.0	3.3	11.5	2.6	0.0	0.3	0.7	16.9	20.3	26.2	31.0	13.3	8.1	30.5	14.5	18.0	25.7	29.7	41.9	37.3	0.1	19.6	16.7	13.5	23.2	23.2	12.0	20.5	0.7	12.1	10.3	7.0	27.0	31.9	0.1	27.5	14.1	4.8	12.2	10.0	27.4	33.2	0.6	16.7	0.1	12.8	30.8	0.1	1.2	21.8	53.0	6.1	0.9	8.9	0.6	30.4	20.9	1.2	3.5	18.0	27.4	6.2	49.0	21.4	10.0	33.1	7.1	24.9	5.2	10.7	2.1	6.0	0.1	12.9	2.2	18.3	1.5	2.6	11.5	0.0	0.9	0.3	0.0	0.1	0.0	3.3	0.0	0.0	0.0	2.4	0.0	0.5	0.3	0.0	0.7	7.9	7.7	4.5	9.0	10.5	8.1	8.2	6.8	11.2	5.8	32.8	33.2	0.0	0.0	0.0	0.0	0.0	0.0	6.7	12.5	55.8	0.0	82.4	3.3	182.4	0.0	0.0	0.0	0.0	136.8	82.2	0.0	0.0	3.5	0.0	47.7	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	139.7	0.0	0.0	178.3	0.0	0.0	25.8	0.0	0.0	0.0	0.0	0.0	0.0	85.1	0.0	0.0	0.0
NECTIN3	"CD113, CDw113, DKFZP566B0846, nectin-3, PPR3, PVRL3, PVRR3"	ENSG00000177707	"Nectin cell adhesion molecule 3"	Q9NQS3	3	111070071-111275563	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 94.2"	"Cell type enriched"	"Detected in some"	4	"Syncytiotrophoblasts: 98.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 1.7"	"Lineage enriched"	"Detected in single"	4	"T-cells: 1.7"	"Cell line enhanced"	"Detected in many"		"AF22: 33.5;TIME: 47.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009869, HPA011038"	Approved		Approved	"Cell Junctions,Cytosol"		NA	NA		20000000	Cytosol	"Cell Junctions"	"CAB009869: AB_2284699, HPA011038: AB_1079719"	"unprognostic (3.76e-2)"	"unprognostic (3.81e-3)"	"unprognostic (1.74e-1)"	"unprognostic (1.97e-2)"	"unprognostic (1.02e-1)"	"unprognostic (9.77e-2)"	"unprognostic (3.26e-3)"	"unprognostic (3.77e-1)"	"unprognostic (7.58e-2)"	"unprognostic (3.94e-2)"	"unprognostic (5.33e-2)"	"unprognostic (7.04e-2)"	"prognostic favorable (9.82e-7)"	"unprognostic (2.01e-1)"	"unprognostic (1.97e-1)"	"unprognostic (2.67e-1)"	"unprognostic (1.05e-1)"	5.6	4.0	5.4	4.4	6.0	0.0	4.5	1.3	8.9	4.6	12.6	6.5	2.8	17.8	5.0	2.2	3.5	5.4	4.4	4.8	6.3	5.0	6.9	16.4	5.6	1.9	6.0	4.1	9.2	4.7	1.9	1.9	94.2	5.5	6.9	12.6	10.7	3.4	4.8	2.3	1.8	18.9	7.2	8.9	1.8	13.2	27.6	4.5	0.4	24.1	2.0	1.4	5.4	7.7	0.1	0.0	0.3	0.0	0.2	1.7	0.7	0.0	10.1	33.5	2.2	13.6	25.2	2.0	22.0	23.3	13.7	11.7	9.3	4.7	0.0	7.3	31.3	7.6	0.1	9.3	3.2	25.2	0.2	2.5	0.0	3.6	0.7	23.0	1.6	0.3	12.7	1.4	9.0	8.7	12.3	11.5	0.4	0.0	8.8	29.5	0.0	2.2	0.0	9.4	3.1	3.6	0.0	16.6	0.0	8.5	5.3	0.8	6.1	0.4	0.0	4.6	11.7	0.3	0.1	47.5	17.4	7.2	3.1	13.1	4.9	0.0	0.0	11.0	0.0	16.0	0.0	0.0	0.3	0.1	0.0	1.2	0.0	1.7	1.0	0.0	0.1	0.3	0.4	0.0	0.2	0.0	0.0	0.1	0.7	5.4	6.0	1.3	8.9	6.3	5.0	6.0	4.1	5.5	4.5	23.8	7.3	0.0	0.0	0.0	0.0	0.0	0.0	1.4	5.7	12.2	0.0	3.3	0.0	3.9	0.0	0.0	0.0	0.0	16.4	7.6	0.0	0.0	1.1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	13.3	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.0	0.0	98.1	0.0	0.0	0.0
NGFR	"CD271, p75NTR, TNFRSF16"	ENSG00000064300	"Nerve growth factor receptor"	P08138	17	49495293-49515017	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Apoptosis, Biological rhythms, Differentiation, Neurogenesis"	"Developmental protein, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	17	"Basal glandular cells: 33.8;Leydig cells: 88.9;Muller glia cells: 122.0;Sertoli cells: 32.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	7	"plasmacytoid DC: 4.2"	"Lineage enriched"	"Detected in single"	7	"dendritic cells: 4.2"	"Group enriched"	"Detected in some"	7	"RH-30: 56.0;WM-115: 62.2"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"basal ganglia: 13.1;hypothalamus: 8.2;pons and medulla: 3.7"	"CAB000143, CAB001995, HPA004765"	Enhanced		Approved	"Nucleoplasm,Plasma membrane"		NA	NA		100000	"Nucleoplasm, Plasma membrane"		"CAB000143: , CAB001995: , HPA004765: AB_1079233"	"unprognostic (6.25e-3)"	"unprognostic (1.06e-3)"	"unprognostic (3.39e-3)"	"unprognostic (6.67e-2)"	"unprognostic (1.46e-2)"	"unprognostic (2.26e-1)"	"unprognostic (8.22e-2)"	"unprognostic (4.94e-2)"	"unprognostic (1.08e-2)"	"unprognostic (4.10e-3)"	"unprognostic (1.85e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.37e-2)"	"unprognostic (4.01e-2)"	"unprognostic (3.06e-2)"	"unprognostic (2.77e-3)"	"prognostic unfavorable (3.40e-4)"	30.9	24.0	1.2	9.2	7.4	1.0	11.7	6.1	4.5	7.6	9.4	10.4	7.9	3.2	6.8	15.0	11.3	12.6	10.8	22.2	2.4	2.9	4.8	29.1	1.4	11.6	13.8	1.3	7.6	6.2	2.8	6.7	16.7	15.9	17.7	3.4	20.2	17.2	9.7	4.8	8.4	5.0	10.7	22.4	18.9	4.9	12.2	4.4	0.4	25.8	7.4	7.0	13.1	6.8	0.0	4.2	0.0	0.4	0.0	0.5	0.2	0.0	0.0	1.7	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.9	1.3	0.4	1.2	0.0	0.1	0.2	0.1	0.0	1.0	0.1	0.0	0.1	6.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	8.1	0.1	0.0	0.0	1.0	0.0	0.0	1.0	56.0	0.0	0.0	0.0	0.5	0.3	0.0	0.0	3.7	2.2	0.1	0.0	0.0	0.0	1.0	0.1	2.7	0.0	0.0	0.0	0.0	0.5	62.2	0.0	0.0	0.0	0.5	0.2	0.1	0.0	0.3	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.4	4.2	0.0	0.2	1.2	7.4	6.1	4.0	2.4	2.9	13.8	1.3	15.9	4.4	0.0	0.0	0.5	33.8	3.2	6.1	0.5	0.0	1.4	2.3	0.0	3.9	0.2	0.0	0.0	0.6	1.3	0.0	0.0	0.0	0.4	3.3	2.4	0.0	0.0	0.1	0.0	0.0	3.1	0.0	0.9	88.9	1.8	15.1	0.0	0.0	122.0	0.0	0.0	26.2	0.0	5.7	32.3	9.5	0.5	0.9	1.5	0.1	1.0	0.0	2.0
NRP1	"CD304, NRP, VEGF165R"	ENSG00000099250	"Neuropilin 1"	O14786	10	33177492-33336262	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Angiogenesis, Differentiation, Neurogenesis"	"Developmental protein, Heparin-binding, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	10	"Ito cells: 238.8;Sertoli cells: 278.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	14	"plasmacytoid DC: 24.0"	"Lineage enriched"	"Detected in many"	14	"dendritic cells: 24.0"	"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 69.4;hTERT-RPE1: 59.9;TIME: 57.7;U-87 MG: 69.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB004511, HPA030278"	Approved				"Secreted in other tissues"	NA	NA		720000000			"CAB004511: AB_2282634, HPA030278: AB_10601976"	"unprognostic (3.19e-1)"	"prognostic unfavorable (7.10e-5)"	"unprognostic (1.50e-2)"	"unprognostic (3.80e-2)"	"prognostic unfavorable (5.79e-4)"	"unprognostic (6.17e-2)"	"unprognostic (1.46e-2)"	"unprognostic (1.08e-1)"	"unprognostic (6.66e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.82e-1)"	"unprognostic (4.78e-2)"	"prognostic unfavorable (3.87e-4)"	"prognostic unfavorable (1.22e-5)"	"unprognostic (3.83e-2)"	"unprognostic (5.48e-2)"	"unprognostic (7.79e-2)"	69.9	15.0	4.9	13.6	4.9	0.7	53.8	1.3	5.6	25.1	17.6	2.4	16.4	6.7	29.8	21.9	14.7	17.0	23.3	50.5	17.2	5.9	47.1	27.4	47.1	30.1	3.5	3.2	27.1	14.1	11.7	6.4	44.3	3.6	25.2	7.8	24.3	11.8	31.6	22.3	9.1	14.6	19.1	5.5	38.7	9.8	15.6	2.8	5.9	30.4	24.6	7.9	22.3	23.8	0.4	24.0	0.3	1.7	0.6	0.4	0.4	8.6	33.8	1.7	0.1	33.0	37.0	0.2	35.0	34.1	17.6	19.0	4.2	20.8	0.1	4.2	69.4	18.7	2.4	2.1	10.2	14.4	0.1	1.7	0.0	3.9	7.2	11.7	3.1	0.2	44.2	1.7	41.9	19.0	59.9	47.9	0.2	0.1	0.2	34.4	14.6	0.2	0.5	0.8	1.8	32.1	1.4	3.8	0.1	16.6	0.1	0.7	0.4	3.5	2.7	0.1	1.5	0.1	0.4	57.7	25.2	5.9	30.3	23.5	0.1	0.1	0.1	69.1	4.0	22.7	0.2	1.7	0.3	0.3	0.3	0.4	0.4	0.3	0.3	1.4	0.3	0.4	0.3	0.3	0.6	0.1	24.0	0.3	0.4	4.9	4.9	1.3	5.6	17.2	5.9	3.5	3.2	3.6	2.8	0.0	22.7	8.1	9.5	14.0	8.7	57.4	35.7	8.1	13.6	17.4	3.9	48.5	1.7	46.0	0.7	84.2	1.0	0.0	16.8	10.8	38.6	3.8	7.0	11.4	109.4	0.0	4.1	238.8	53.2	2.6	39.1	27.1	11.8	9.0	0.3	3.5	10.9	0.0	19.8	29.4	0.6	278.1	64.5	0.2	0.7	9.3	56.2	2.5	0.1	2.8
NT5E	"CALJA, CD73, eN, eNT, NT5"	ENSG00000135318	"5'-nucleotidase ecto"	P21589	6	85449584-85495791	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Hydrolase	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	7	"Ito cells: 45.4;Pancreatic endocrine cells: 72.9;Rod photoreceptor cells: 77.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"memory B-cell: 13.4;memory CD8 T-cell: 6.6;naive B-cell: 19.9;naive CD8 T-cell: 17.3"	"Group enriched"	"Detected in many"	47	"B-cells: 19.9;T-cells: 17.3"	"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 93.4;LHCN-M2: 105.7;TIME: 61.2;U-87 MG: 95.4"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			HPA017357	Approved		Supported	"Nucleoplasm,Plasma membrane,Cytosol"	"Intracellular and membrane"	NA	NA		1600000	"Plasma membrane"	"Nucleoplasm, Cytosol"	"HPA017357: AB_1846330"	"unprognostic (1.92e-2)"	"unprognostic (4.44e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.57e-3)"	"unprognostic (9.33e-2)"	"unprognostic (1.82e-3)"	"unprognostic (1.20e-2)"	"prognostic unfavorable (6.66e-4)"	"unprognostic (5.45e-2)"	"unprognostic (1.80e-1)"	"prognostic unfavorable (1.32e-5)"	"unprognostic (1.39e-1)"	"unprognostic (3.11e-2)"	"prognostic unfavorable (1.02e-4)"	"unprognostic (3.49e-2)"	"unprognostic (2.26e-1)"	"unprognostic (2.78e-1)"	12.2	3.2	9.3	7.7	11.6	0.5	16.6	1.1	6.9	58.8	13.9	3.6	8.1	18.6	33.3	14.8	7.6	12.2	15.4	6.1	5.7	5.5	8.8	26.0	3.4	6.8	6.3	6.6	25.4	1.4	1.6	9.3	42.2	5.3	16.4	15.6	15.3	4.6	17.8	5.7	4.5	14.9	35.3	6.3	7.0	6.0	12.4	4.2	1.6	26.5	7.3	7.1	16.6	20.2	19.9	0.0	0.2	0.0	0.4	17.3	3.9	5.3	2.8	4.9	0.1	11.2	35.7	0.0	34.5	37.8	17.0	32.0	0.0	53.0	0.0	12.4	30.1	43.8	2.7	0.0	34.7	40.6	0.0	0.0	0.0	0.8	0.6	5.6	0.0	0.0	9.1	0.4	34.7	22.1	93.4	14.1	0.0	0.0	0.1	105.7	0.9	0.0	0.0	0.1	0.9	3.8	0.1	1.1	0.1	36.8	2.4	0.0	0.6	0.4	2.1	11.7	0.2	0.0	0.9	61.2	13.9	0.1	17.5	56.1	2.6	1.6	0.0	95.4	0.0	43.5	0.0	0.0	0.2	2.0	0.0	3.5	13.4	2.3	6.6	0.0	19.9	2.4	17.3	0.2	0.4	0.0	0.0	0.8	3.9	9.3	11.6	1.1	6.9	5.7	5.5	6.3	6.6	5.3	4.2	0.0	4.3	15.6	1.0	4.6	4.6	0.8	20.4	6.7	6.8	1.8	9.8	0.4	3.3	3.7	0.5	13.5	10.3	0.0	3.7	1.5	16.9	0.9	0.0	29.0	1.3	0.0	0.0	45.4	5.3	0.9	12.0	2.5	6.8	0.0	33.2	5.6	72.9	31.7	24.1	20.6	77.4	0.0	8.0	0.0	0.2	4.3	12.7	2.2	13.8	5.9
PDCD1	"CD279, hSLE1, PD-1, PD1, SLEB2"	ENSG00000188389	"Programmed cell death 1"	Q15116	2	241849881-241858908	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Apoptosis, Immunity"		"FDA approved drug targets, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 11.6;lymphoid tissue: 21.5"	"Cell type enriched"	"Detected in some"	9	"T-cells: 15.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"gdT-cell: 4.1;MAIT T-cell: 3.9;memory CD4 T-cell: 6.8;memory CD8 T-cell: 11.6;T-reg: 3.5"	"Lineage enriched"	"Detected in single"	93	"T-cells: 11.6"	"Group enriched"	"Detected in some"	7	"MOLT-4: 9.5;RPMI-8226: 9.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA035981, CAB038418, CAB076386"	Enhanced					NA	NA					"CAB038418: AB_1160824, CAB076386: AB_881954, HPA035981: AB_10669664"	"unprognostic (2.90e-3)"	"unprognostic (4.50e-3)"	"unprognostic (7.78e-2)"	"prognostic favorable (9.44e-5)"	"unprognostic (7.18e-3)"	"unprognostic (1.31e-3)"	"unprognostic (3.83e-2)"	"unprognostic (7.33e-2)"	"unprognostic (5.82e-3)"	"unprognostic (3.75e-2)"	"unprognostic (6.57e-2)"	"unprognostic (3.94e-1)"	"prognostic unfavorable (3.48e-7)"	"unprognostic (1.20e-2)"	"unprognostic (3.10e-1)"	"unprognostic (5.35e-2)"	"unprognostic (5.06e-3)"	1.4	0.4	0.0	21.5	0.7	3.0	0.5	0.1	0.3	1.2	1.9	0.0	0.0	0.4	0.5	1.6	2.0	0.8	1.7	9.2	0.2	0.5	1.3	0.5	5.6	16.6	0.1	0.3	0.7	1.0	0.2	1.9	0.3	0.4	1.3	0.2	1.2	3.0	0.5	0.2	0.2	4.9	0.4	0.3	9.5	1.9	0.4	0.2	16.6	1.9	3.0	20.1	1.3	0.8	0.1	0.0	0.0	0.0	0.0	11.6	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.2	0.0	0.0	0.5	9.5	0.0	0.0	0.0	0.0	0.0	0.1	9.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	3.9	0.1	6.8	11.6	0.0	0.0	0.5	1.2	0.0	0.0	0.0	0.0	3.5	1.5	0.0	0.7	0.1	0.1	0.2	0.5	0.1	0.3	0.4	0.2	0.0	1.1	0.0	0.2	0.3	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	15.9	0.0	0.0
PDCD1LG2	"B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2"	ENSG00000197646	"Programmed cell death 1 ligand 2"	Q9BQ51	9	5510570-5571254	"Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"Extravillous trophoblasts: 15.1;monocytes: 45.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ: 25.9;BJ hTERT+: 40.8;HDLM-2: 31.1;TIME: 18.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA013411	Approved		Uncertain	Cytosol	"Secreted - unknown location"	NA	NA		34000000	Cytosol		"HPA013411: AB_1855102"	"unprognostic (3.93e-2)"	"unprognostic (1.90e-1)"	"unprognostic (3.51e-3)"	"unprognostic (6.68e-3)"	"unprognostic (7.66e-2)"	"unprognostic (6.77e-2)"	"unprognostic (5.72e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.68e-1)"	"unprognostic (4.37e-3)"	"unprognostic (5.79e-2)"	"unprognostic (5.29e-2)"	"prognostic unfavorable (1.15e-4)"	"unprognostic (5.00e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.01e-1)"	"unprognostic (7.51e-3)"	15.2	1.8	1.2	7.7	1.4	0.2	9.5	0.7	1.2	7.0	1.9	2.3	0.0	0.8	2.9	7.2	3.9	3.8	4.0	5.8	1.2	1.3	2.5	6.4	13.3	10.8	1.6	0.5	4.1	1.8	0.5	1.1	12.9	1.9	5.0	2.5	2.4	2.9	1.7	5.5	3.6	2.5	4.6	3.7	19.5	1.9	4.2	1.2	8.1	3.5	3.5	8.1	6.0	5.4	0.5	0.9	4.1	3.6	0.0	3.0	0.7	2.1	0.0	0.0	0.0	1.8	2.1	0.0	25.9	40.8	12.5	15.2	0.0	0.1	0.0	0.1	10.5	1.8	0.2	0.0	3.5	12.5	31.1	0.0	0.0	0.0	0.0	10.1	0.0	0.0	1.9	0.0	5.8	6.9	3.6	8.2	0.0	0.0	3.1	15.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.5	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	18.0	9.0	0.5	4.3	7.1	0.4	0.0	0.0	5.1	0.0	1.1	4.1	0.9	0.0	1.4	3.6	1.9	0.5	2.2	0.9	0.9	0.3	0.0	1.0	2.0	0.0	0.5	0.0	3.0	0.7	1.2	1.4	0.7	1.2	1.2	1.3	1.6	0.5	1.9	1.2	6.0	0.3	0.8	0.0	0.9	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.1	0.0	0.1	0.0	1.9	0.0	0.0	0.2	15.1	2.1	0.1	3.5	0.0	2.8	0.0	0.0	6.7	4.3	0.0	5.5	2.2	1.7	45.9	0.0	0.0	2.1	0.0	2.1	0.0	0.0	0.0	1.4	0.0	0.0	0.9	0.7	0.0	0.0	0.0
PDGFRA	"CD140a, GAS9, PDGFR2"	ENSG00000134853	"Platelet derived growth factor receptor alpha"	P16234	4	54229097-54298247	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Chemotaxis, Host-virus interaction"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ovary: 81.5"	"Group enriched"	"Detected in many"	9	"Fibroblasts: 171.4;Leydig cells: 416.6;Peritubular cells: 384.4"	"Cancer enhanced"	"Detected in all"		"glioma: 30.8"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"ASC diff: 82.8;ASC TERT1: 38.8;BJ hTERT+: 48.0;fHDF/TERT166: 33.4;HHSteC: 28.0;HSkMC: 70.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004947, CAB018143"	Supported		Approved	"Nucleoplasm,Plasma membrane,Cell Junctions"	"Intracellular and membrane"	NA	NA		150000	"Nucleoplasm, Plasma membrane, Cell Junctions"		"CAB018143: AB_2162351, HPA004947: AB_2732399"	"unprognostic (1.67e-1)"	"unprognostic (9.35e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.60e-1)"	"unprognostic (8.92e-2)"	"prognostic favorable (9.33e-4)"	"unprognostic (1.24e-1)"	"unprognostic (2.00e-2)"	"unprognostic (1.46e-1)"	"unprognostic (2.18e-2)"	"unprognostic (2.18e-1)"	"unprognostic (7.01e-2)"	"prognostic unfavorable (9.79e-6)"	"unprognostic (9.58e-3)"	"unprognostic (9.87e-2)"	"unprognostic (2.16e-2)"	"unprognostic (1.72e-3)"	35.0	12.4	12.6	16.1	7.6	0.9	17.2	2.4	20.1	33.2	19.1	9.2	6.4	9.6	27.6	14.6	21.9	22.5	16.2	15.3	8.9	7.4	22.8	8.4	24.1	26.9	9.2	4.0	81.5	6.8	1.6	2.1	25.1	7.2	18.6	15.2	19.2	8.5	8.3	11.9	7.0	17.4	19.7	8.8	51.6	13.6	19.0	9.3	0.5	11.3	12.8	4.3	35.9	24.6	0.9	0.4	2.5	0.4	0.3	0.8	0.3	0.0	0.0	0.2	0.1	82.8	38.8	0.1	4.3	48.0	0.0	0.1	11.5	0.0	0.1	0.1	33.4	0.1	0.1	3.3	0.0	0.0	0.4	0.1	0.1	0.1	0.2	28.0	0.0	0.0	70.4	0.0	5.5	0.0	0.9	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.2	0.6	0.0	0.1	0.1	0.0	0.0	0.0	0.3	0.1	6.7	0.0	0.1	0.0	0.3	0.1	0.0	0.1	15.2	0.5	16.6	0.0	0.0	0.0	0.1	0.4	0.0	0.3	2.5	0.4	0.2	0.5	0.2	0.2	0.6	0.8	0.4	0.0	0.9	0.7	0.4	2.3	0.3	0.3	0.4	0.2	0.3	12.6	7.6	2.4	7.3	8.9	7.4	9.2	4.0	7.2	9.3	0.0	0.3	0.9	0.3	15.1	0.7	4.0	0.0	0.0	0.0	0.0	0.0	1.3	1.7	2.9	1.6	3.3	0.0	0.0	5.8	1.2	171.4	0.4	0.0	0.8	2.8	0.0	0.0	38.1	0.6	3.7	416.6	1.6	21.9	8.2	0.0	18.3	12.2	0.0	384.4	0.0	0.4	0.0	13.2	1.1	3.5	13.8	1.1	0.0	0.0	0.8
PDGFRB	"CD140b, JTK12, PDGFR, PDGFR1"	ENSG00000113721	"Platelet derived growth factor receptor beta"	P09619	5	150113837-150155872	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Chemotaxis	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	5	"Sertoli cells: 1267.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.9;non-classical monocyte: 4.1"	"Group enriched"	"Detected in many"	8	"monocytes: 4.1;T-cells: 2.9"	"Group enriched"	"Detected in some"	4	"ASC diff: 173.0;ASC TERT1: 59.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003842, CAB018144, HPA028499"	Enhanced		Supported	"Golgi apparatus,Vesicles"		NA	NA		35000000	Vesicles	"Golgi apparatus"	"CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018"	"unprognostic (4.75e-2)"	"unprognostic (2.48e-1)"	"unprognostic (5.21e-2)"	"unprognostic (3.60e-2)"	"unprognostic (3.27e-1)"	"unprognostic (5.61e-2)"	"unprognostic (1.02e-1)"	"unprognostic (3.36e-2)"	"unprognostic (2.12e-2)"	"unprognostic (2.57e-3)"	"unprognostic (6.72e-2)"	"unprognostic (1.25e-1)"	"prognostic unfavorable (5.87e-8)"	"unprognostic (3.13e-3)"	"unprognostic (1.25e-2)"	"unprognostic (5.47e-2)"	"prognostic unfavorable (8.11e-4)"	61.8	10.4	8.3	11.0	9.1	0.5	66.1	4.6	10.4	73.1	15.7	6.7	6.9	5.1	44.3	17.3	21.7	26.1	51.7	24.2	8.2	3.9	17.0	4.6	28.9	21.5	7.9	8.1	46.5	7.5	10.4	7.7	46.4	7.7	24.2	6.3	22.9	11.2	19.3	29.8	20.3	11.2	29.8	5.0	19.6	9.2	21.5	6.7	1.4	21.4	16.0	7.3	23.6	35.1	0.4	0.1	0.0	4.1	0.0	2.9	0.6	0.0	0.0	1.0	0.0	173.0	59.9	0.4	6.0	25.1	4.2	7.1	0.6	0.0	0.0	0.8	17.3	2.4	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.4	0.4	24.5	0.0	0.0	27.0	0.0	5.8	0.0	13.5	0.0	0.0	0.0	0.6	0.6	0.0	0.0	0.0	1.1	0.0	0.0	0.4	0.3	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	5.0	0.0	0.0	0.0	6.8	2.2	2.9	0.3	0.0	0.0	0.0	4.2	0.0	0.1	0.0	0.0	0.0	2.9	0.6	0.0	0.4	0.1	0.8	0.1	0.1	0.0	1.3	0.0	0.0	4.1	0.0	0.0	0.6	8.3	9.1	4.6	10.4	8.2	3.9	7.9	8.1	7.7	6.7	0.0	0.6	0.0	0.5	21.3	5.0	13.4	0.0	1.4	0.0	1.8	3.9	0.6	0.0	0.0	0.8	16.2	0.0	0.0	0.0	1.0	68.8	0.6	0.0	1.5	1.4	0.0	0.0	6.7	0.0	4.7	153.1	2.2	23.6	1.0	0.0	74.9	0.1	0.0	191.6	0.0	1.1	1267.6	273.4	1.1	1.5	13.4	0.7	1.0	0.4	0.9
PLAUR	"CD87, UPAR, URKR"	ENSG00000011422	"Plasminogen activator, urokinase receptor"	Q03405	19	43646095-43670547	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 118.0;bone marrow: 165.0"	"Cell type enhanced"	"Detected in many"	17	"Basal glandular cells: 664.4;Macrophages: 801.6;Urothelial cells: 2343.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 118.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"hTEC/SVTERT24-B: 50.2;U-251 MG: 71.3;U-87 MG: 62.2;WM-115: 60.6"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA050843, CAB073533"	Uncertain		Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA		760000	"Plasma membrane"		"CAB073533: , HPA050843: AB_2681255"	"unprognostic (9.28e-2)"	"unprognostic (9.65e-3)"	"unprognostic (1.39e-1)"	"unprognostic (1.29e-3)"	"unprognostic (3.59e-3)"	"unprognostic (1.50e-2)"	"unprognostic (2.18e-3)"	"prognostic unfavorable (2.33e-5)"	"unprognostic (8.08e-3)"	"unprognostic (4.30e-2)"	"unprognostic (2.29e-3)"	"unprognostic (5.30e-2)"	"prognostic unfavorable (7.83e-9)"	"unprognostic (4.99e-2)"	"unprognostic (1.66e-1)"	"unprognostic (5.45e-2)"	"unprognostic (9.33e-2)"	25.2	3.6	3.0	23.6	4.8	165.0	6.3	2.2	6.1	10.7	7.5	4.4	1.8	3.3	9.5	6.0	8.6	10.6	23.0	11.5	4.5	3.2	5.1	6.1	39.4	8.1	6.0	1.1	11.9	4.3	2.5	4.4	12.2	6.9	6.1	6.0	4.6	11.0	3.7	7.9	3.5	7.3	7.2	7.1	12.6	12.0	6.3	6.3	2.5	4.4	7.7	7.0	22.7	14.9	0.2	21.3	118.0	50.5	0.6	0.9	21.0	14.3	5.0	4.5	0.3	4.1	14.6	2.8	30.0	30.5	19.0	23.8	0.4	16.9	0.5	7.6	18.5	11.0	6.1	1.2	7.4	21.2	0.9	0.9	2.7	7.5	0.6	5.2	3.2	34.9	15.0	1.5	50.2	7.5	27.8	20.9	3.3	2.7	0.6	18.2	1.0	3.4	8.6	1.5	25.7	10.8	4.0	3.0	1.0	5.9	0.7	0.2	3.9	13.4	3.1	3.9	2.3	0.6	10.0	21.4	41.9	21.5	19.1	71.3	0.6	1.4	0.1	62.2	5.8	60.6	7.2	48.9	72.4	0.7	41.5	0.8	0.2	0.9	0.6	21.3	0.1	0.3	0.4	118.0	0.6	50.5	6.8	0.3	21.0	3.0	4.8	2.2	6.1	4.5	3.2	6.0	1.1	6.9	6.3	68.5	114.1	4.7	664.4	93.4	0.4	3.5	15.3	20.1	44.3	19.2	0.0	4.1	1.7	219.5	0.8	49.2	68.8	0.0	94.2	28.2	110.9	445.0	294.8	1.3	440.8	9.5	14.3	18.4	142.0	0.9	6.4	801.6	69.2	13.6	15.1	1.2	350.1	4.9	3.9	2.4	0.6	6.5	151.4	0.9	3.2	55.2	11.0	9.6	5.0	2343.3
PLXNC1	"CD232, VESPR"	ENSG00000136040	"Plexin C1"	O60486	12	94148723-94307675	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 43.5;retina: 40.6"	"Cell type enhanced"	"Detected in many"	14	"Kupffer cells: 41.4;Macrophages: 32.1;Melanocytes: 91.1"	"Cancer enhanced"	"Detected in all"		"melanoma: 24.8"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 14.2"	"Group enriched"	"Detected in many"	4	"granulocytes: 14.2;monocytes: 6.7"	"Cell line enhanced"	"Detected in many"		"HAP1: 15.3;Karpas-707: 11.9;SK-MEL-30: 19.0;U-266/70: 30.1;U-266/84: 31.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA066899			Approved	Mitochondria		NA	NA		82000	Mitochondria		"HPA066899: AB_2685743"	"unprognostic (1.49e-1)"	"unprognostic (4.01e-2)"	"unprognostic (5.60e-2)"	"unprognostic (1.99e-1)"	"unprognostic (2.33e-1)"	"unprognostic (3.24e-2)"	"unprognostic (4.67e-3)"	"unprognostic (2.80e-2)"	"unprognostic (3.49e-1)"	"unprognostic (4.64e-2)"	"unprognostic (1.78e-2)"	"unprognostic (2.38e-1)"	"unprognostic (4.02e-2)"	"unprognostic (5.33e-3)"	"unprognostic (3.19e-2)"	"unprognostic (6.85e-3)"	"unprognostic (5.48e-2)"	6.6	7.5	7.1	16.1	6.9	12.6	3.9	16.8	8.6	8.0	5.1	3.1	0.8	3.1	7.3	2.2	4.9	4.3	8.3	4.1	6.3	15.2	3.2	2.0	15.2	43.5	4.5	7.7	13.0	2.3	0.5	6.3	7.5	5.2	4.3	5.4	40.6	3.7	3.7	2.9	6.6	5.0	5.7	4.9	28.6	3.4	12.1	3.3	8.6	3.3	2.7	10.2	9.6	6.5	2.4	2.5	14.2	6.7	0.9	1.7	1.5	0.4	0.2	1.2	0.2	0.7	0.5	0.1	0.6	0.8	0.8	2.4	4.1	0.0	9.8	0.0	0.9	0.7	0.0	15.3	0.6	0.5	6.8	0.3	0.5	0.2	2.7	8.5	2.0	3.4	8.4	0.0	0.9	0.4	1.0	0.0	0.9	0.2	11.9	0.2	0.1	0.4	1.0	2.5	0.1	0.5	1.6	0.4	5.3	0.0	0.7	1.0	0.7	0.1	0.1	19.0	3.1	0.0	1.6	0.3	0.2	1.1	0.1	0.3	30.1	31.3	0.6	0.1	5.3	0.6	0.0	3.0	12.2	1.4	5.2	1.6	2.4	1.6	1.7	2.5	1.4	1.4	1.5	14.2	0.9	6.7	0.9	1.0	1.5	7.1	6.9	16.8	8.6	6.3	15.2	4.5	7.7	5.2	3.3	3.0	3.7	11.2	0.2	5.5	2.1	3.7	2.5	4.0	0.0	0.0	0.0	0.1	1.7	0.2	6.7	1.8	0.2	0.0	0.5	0.1	2.6	0.2	16.1	0.8	19.6	0.0	19.0	9.8	41.4	5.9	1.4	32.1	91.1	19.8	1.6	0.0	0.4	0.0	3.2	3.1	0.6	6.5	1.4	1.5	1.2	1.4	0.1	3.2	1.0	0.1
PRNP	"AltPrP, CD230, CJD, GSS, PRIP, PRP"	ENSG00000171867	"Prion protein"	P04156	20	4686236-4701590	"CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell cycle, Growth arrest"	Prion	"Amyloidosis, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Basal keratinocytes: 366.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"basophil: 108.1"	"Lineage enriched"	"Detected in all"	6	"granulocytes: 108.1"	"Cell line enhanced"	"Detected in many"		"WM-115: 116.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA042754, HPA043398"	Enhanced		Approved	"Nuclear membrane,Vesicles,Cytosol"	"Intracellular and membrane"	NA	NA		2200000	"Nuclear membrane, Cytosol"	Vesicles	"HPA042754: AB_10964203, HPA043398: AB_2678461"	"unprognostic (1.50e-1)"	"unprognostic (1.72e-1)"	"prognostic unfavorable (2.96e-4)"	"prognostic unfavorable (4.64e-4)"	"prognostic unfavorable (2.52e-4)"	"unprognostic (1.94e-2)"	"prognostic unfavorable (7.41e-5)"	"unprognostic (7.60e-3)"	"unprognostic (2.50e-1)"	"unprognostic (7.12e-2)"	"unprognostic (3.44e-1)"	"unprognostic (1.04e-1)"	"unprognostic (6.75e-2)"	"unprognostic (7.28e-3)"	"unprognostic (3.37e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.69e-2)"	24.6	27.3	63.4	14.2	73.1	19.8	30.5	87.5	116.1	42.0	43.4	61.6	8.5	10.6	36.3	17.7	23.0	24.1	31.4	54.1	64.6	48.9	38.5	22.2	22.2	14.7	47.2	65.6	49.6	11.8	20.7	24.9	18.7	71.6	43.8	20.9	34.1	17.1	45.0	21.8	26.7	13.5	40.8	53.1	20.3	18.1	19.1	51.4	2.9	25.6	11.8	16.4	27.0	22.3	4.6	10.5	108.1	11.7	3.6	16.7	10.0	24.6	20.3	4.6	7.2	37.9	23.2	4.1	40.8	58.9	19.8	20.2	6.7	19.1	4.5	9.5	79.5	44.9	57.4	5.1	55.6	37.2	3.7	4.4	0.0	2.3	21.0	46.6	8.0	1.8	21.0	80.2	84.7	66.2	29.2	17.0	3.3	2.4	16.0	22.8	5.5	3.1	4.9	3.8	10.8	30.2	3.8	12.4	4.1	9.9	4.4	5.5	0.8	11.6	16.2	58.0	6.7	3.3	4.2	25.5	32.3	14.8	18.0	33.2	7.4	14.9	15.0	26.0	5.9	116.2	108.1	11.7	0.8	11.9	9.7	16.7	4.2	9.8	9.4	10.5	4.6	5.8	6.8	0.7	3.6	7.6	3.7	11.4	10.0	63.4	73.1	87.5	90.4	64.6	48.9	47.2	65.6	71.6	51.4	74.5	42.1	34.0	181.6	366.5	230.5	189.4	33.1	26.8	70.5	31.4	110.0	6.3	10.0	50.5	4.7	46.7	2.0	0.0	12.7	5.7	171.5	79.9	168.6	29.7	58.0	42.9	28.7	42.4	184.5	8.0	132.6	109.3	160.3	13.6	4.9	133.0	16.9	2.9	159.8	69.9	78.9	12.9	124.6	28.3	4.3	248.5	12.0	52.2	6.9	105.0
PROCR	"CCD41, CD201, EPCR"	ENSG00000101000	"Protein C receptor"	Q9UNN8	20	35172073-35216240	"Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Blood coagulation, Hemostasis"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 77.8"	"Cell type enhanced"	"Detected in many"	11	"Extravillous trophoblasts: 89.9;Sertoli cells: 168.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HMC-1: 66.3;HUVEC TERT2: 103.3;TIME: 61.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA039461	Enhanced					NA	NA		1600000000			"HPA039461: AB_10673359"	"unprognostic (1.51e-1)"	"unprognostic (1.03e-1)"	"unprognostic (4.12e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.64e-1)"	"unprognostic (4.69e-2)"	"unprognostic (4.69e-2)"	"unprognostic (1.84e-1)"	"unprognostic (1.52e-1)"	"unprognostic (4.76e-2)"	"unprognostic (5.22e-2)"	"unprognostic (4.27e-1)"	"prognostic unfavorable (7.62e-6)"	"unprognostic (3.37e-2)"	"unprognostic (2.29e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.19e-2)"	51.0	11.9	2.3	10.1	3.2	4.4	24.6	2.9	2.3	16.8	25.0	3.1	14.1	8.7	27.7	44.5	19.4	17.3	13.4	27.4	2.7	2.4	11.7	3.8	10.6	30.3	3.1	2.1	19.3	11.5	2.7	4.7	77.8	7.4	15.5	12.3	16.4	4.2	14.0	17.7	10.4	14.0	20.0	5.8	22.1	10.4	9.1	2.0	0.6	12.1	13.0	3.9	25.8	14.9	1.6	7.3	4.1	1.7	3.4	14.6	2.0	2.5	14.9	0.0	1.6	16.4	13.4	3.4	3.5	15.2	5.8	11.3	19.1	12.9	0.4	10.9	3.5	16.1	8.1	3.4	22.1	4.8	0.1	4.6	5.4	3.6	0.7	4.0	0.2	66.3	11.4	8.3	27.2	22.7	8.5	103.3	0.1	1.9	0.7	5.9	0.8	0.1	0.2	2.1	3.1	15.3	0.1	2.8	0.0	9.8	0.9	0.4	0.2	1.9	4.0	3.1	1.9	1.3	0.8	61.1	14.9	7.5	5.6	5.8	0.0	0.1	0.1	17.1	5.5	3.1	4.1	1.5	0.9	8.3	1.7	14.6	1.0	2.6	5.2	7.3	1.6	0.7	6.3	4.1	3.4	1.4	1.2	2.0	2.0	2.3	3.2	2.9	2.3	2.7	2.4	3.1	2.1	7.4	2.0	0.0	15.9	0.5	14.5	12.4	0.4	1.6	0.0	2.7	7.9	5.2	0.0	9.5	1.7	26.8	0.3	47.6	1.4	0.0	14.7	89.9	27.3	3.7	59.2	1.5	20.7	1.6	5.8	47.9	1.2	1.0	14.4	7.7	3.3	2.8	0.0	0.2	13.9	0.0	2.5	4.2	0.4	168.1	43.8	3.7	7.2	7.3	57.7	6.7	1.6	9.0
PROM1	"AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4"	ENSG00000007062	"Prominin 1"	O43490	4	15963076-16084378	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Cone-rod dystrophy, Disease mutation, Retinitis pigmentosa, Stargardt disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"retina: 52.4;salivary gland: 71.0"	"Group enriched"	"Detected in many"	4	"Cone photoreceptor cells: 547.8;Rod photoreceptor cells: 281.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 13.9;CACO-2: 25.6;CAPAN-2: 10.9;EFO-21: 25.1;NTERA-2: 37.2;RPTEC TERT1: 34.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"HPA004922, CAB011525, HPA031053"	Enhanced					NA	NA					"CAB011525: AB_470302, HPA004922: AB_1846238, HPA031053: AB_2673713"	"unprognostic (6.33e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.53e-1)"	"unprognostic (3.39e-1)"	"unprognostic (2.81e-1)"	"unprognostic (2.16e-1)"	"unprognostic (2.39e-1)"	"unprognostic (6.64e-2)"	"unprognostic (2.18e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.21e-2)"	"unprognostic (9.06e-2)"	"prognostic favorable (2.56e-5)"	"unprognostic (2.16e-2)"	"unprognostic (1.02e-1)"	"unprognostic (9.38e-2)"	"unprognostic (1.17e-1)"	0.5	0.5	2.5	11.5	2.2	1.3	11.2	1.0	2.2	20.1	13.8	2.3	1.6	5.2	4.7	3.1	1.8	1.9	12.6	2.7	3.1	2.1	30.2	1.6	3.6	0.1	2.3	0.6	1.6	10.7	0.0	1.8	12.7	2.1	1.6	7.4	52.4	71.0	2.9	0.7	1.1	13.5	1.7	1.8	0.6	10.9	5.0	0.9	0.3	1.7	3.8	10.2	3.0	0.5	0.0	0.0	0.1	0.0	0.0	0.1	1.0	0.0	0.0	13.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.6	10.9	0.3	25.1	0.0	0.0	0.0	2.6	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	37.2	0.0	0.0	1.0	0.0	0.0	34.5	0.1	4.3	1.5	0.0	0.8	1.0	1.4	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	2.5	2.2	1.0	2.2	3.1	2.1	2.3	0.6	2.1	0.9	3.0	3.7	0.0	0.1	0.0	10.1	7.9	30.6	93.7	22.7	78.5	547.8	0.4	0.0	51.2	32.2	2.5	26.6	0.0	14.0	0.1	0.0	0.9	0.0	0.0	0.1	9.5	42.7	0.6	0.0	34.0	2.8	0.7	0.0	1.0	9.2	47.2	32.3	24.9	6.0	1.4	281.4	0.0	0.3	1.2	0.7	0.0	0.1	0.0	18.0	0.9
PSG1	"CD66f, PBG1, PSBG1, PSGGA"	ENSG00000231924	"Pregnancy specific beta-1-glycoprotein 1"	P11464	19	42866464-42879822	"CD markers, Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	362	"placenta: 497.6"	"Cell type enriched"	"Detected in some"	130	"Syncytiotrophoblasts: 173.1"	"Cancer enhanced"	"Detected in single"		"thyroid cancer: 0.5"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.0"	"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	18	"U-2197: 98.0"									HPA046327	Supported				"Secreted in female reproductive system"	NA	NA					"HPA046327: AB_2679624"					"unprognostic (2.02e-1)"	"unprognostic (3.54e-1)"							"unprognostic (2.44e-7)"			"unprognostic (2.28e-2)"		1.3	0.0	0.1	0.0	0.1	0.0	0.6	0.5	0.2	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.1	0.1	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.1	497.6	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.0	0.0	0.5	0.0	0.0	0.2	0.0	0.2	0.0	1.0	0.3	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	4.2	1.4	0.3	0.5	0.0	0.0	0.0	0.0	4.8	1.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	5.4	0.0	0.0	0.1	0.0	0.0	98.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.1	1.0	0.0	0.3	0.0	0.1	0.0	0.1	0.1	0.5	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.6	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	173.1	0.0	0.0	0.0
PTGDR2	"CD294, CRTH2, DP2, GPR44"	ENSG00000183134	"Prostaglandin D2 receptor 2"	Q9Y5Y4	11	60850940-60855971	"CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 51.8;lymphoid tissue: 28.1"	"Cell type enhanced"	"Detected in some"	17	"Cone photoreceptor cells: 2.0;granulocytes: 4.6;Intestinal endocrine cells: 1.2;Mucus-secreting cells: 1.3;Smooth muscle cells: 1.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	6	"basophil: 35.1;eosinophil: 51.8"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 51.8"	"Cell line enhanced"	"Detected in some"		"HEL: 10.5;Hep G2: 5.1;HMC-1: 6.7;K-562: 4.3;MOLT-4: 3.4;NB-4: 15.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA014259	Uncertain					NA	NA					"HPA014259: AB_1849304"	"unprognostic (9.77e-2)"	"unprognostic (1.35e-3)"	"unprognostic (5.45e-3)"	"unprognostic (1.69e-1)"	"unprognostic (1.90e-1)"	"unprognostic (1.85e-3)"	"unprognostic (1.70e-1)"	"unprognostic (2.30e-4)"	"unprognostic (2.61e-1)"	"unprognostic (7.92e-2)"	"unprognostic (8.68e-3)"	"unprognostic (1.52e-1)"	"unprognostic (1.32e-2)"	"unprognostic (1.52e-1)"	"unprognostic (3.31e-1)"	"unprognostic (1.49e-1)"	"unprognostic (4.99e-2)"	1.2	0.3	3.9	2.3	8.0	0.4	2.8	2.3	8.2	1.7	10.7	4.0	0.3	7.5	0.9	0.6	1.4	1.5	1.6	5.1	4.3	2.8	0.5	0.7	1.4	1.9	4.9	5.9	0.5	1.1	5.9	0.6	1.9	5.7	0.9	7.4	0.6	0.5	0.5	11.3	1.0	10.8	0.9	2.2	1.1	13.3	0.5	0.8	28.1	0.4	5.6	0.6	1.1	0.4	0.0	1.2	51.8	7.8	0.0	0.3	0.4	0.0	0.0	0.1	0.0	0.4	1.6	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	10.5	0.0	5.1	1.2	0.0	6.7	2.2	0.1	0.0	0.0	0.0	0.0	0.3	4.3	0.0	0.0	0.1	3.4	15.2	0.0	0.1	0.2	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	35.1	0.0	51.8	0.0	2.5	0.0	0.0	0.3	0.2	1.2	0.0	0.0	0.0	0.1	0.0	7.8	0.2	0.3	0.4	3.9	8.0	2.3	8.2	4.3	2.8	4.9	5.9	5.7	0.8	0.0	0.0	0.0	0.0	0.3	0.8	0.4	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	4.6	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.3	0.1	0.0	0.0	0.0	0.0	0.3	0.0	1.9	0.0	0.0	0.3	0.0	0.0	0.0	0.0
PTGFRN	"CD315, CD9P-1, EWI-F, FLJ11001, FPRP, KIAA1436, SMAP-6"	ENSG00000134247	"Prostaglandin F2 receptor inhibitor"	Q9P2B2	1	116910057-116990358	"CD markers, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	7	"Basal keratinocytes: 58.7;Cardiomyocytes: 78.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"myeloid DC: 3.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"RH-30: 31.3;U-87 MG: 46.2;WM-115: 34.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA017074	Approved					NA	NA		86000			"HPA017074: AB_1855888"	"unprognostic (1.18e-1)"	"unprognostic (2.11e-3)"	"unprognostic (3.03e-1)"	"unprognostic (8.58e-2)"	"unprognostic (3.20e-1)"	"unprognostic (2.91e-2)"	"unprognostic (1.48e-3)"	"unprognostic (3.39e-2)"	"unprognostic (1.76e-2)"	"unprognostic (7.28e-2)"	"unprognostic (2.77e-2)"	"unprognostic (5.28e-2)"	"prognostic unfavorable (3.98e-4)"	"unprognostic (1.61e-1)"	"unprognostic (1.95e-1)"	"unprognostic (1.12e-1)"	"unprognostic (4.15e-2)"	6.9	14.9	3.7	8.4	4.7	0.0	6.3	1.2	6.6	17.1	26.2	2.5	10.1	6.5	23.9	10.7	23.5	17.8	20.5	29.5	3.0	2.6	3.4	5.3	4.4	1.7	2.8	6.1	15.6	17.1	4.0	3.5	24.6	3.2	13.3	13.2	8.1	13.3	15.0	2.4	12.4	15.3	27.8	3.0	2.5	8.7	6.3	2.2	2.8	5.9	13.5	9.7	15.2	15.3	0.0	3.0	0.0	1.1	0.3	0.9	0.3	11.8	3.1	5.7	13.2	1.0	2.6	0.8	0.8	1.3	4.8	1.8	2.1	2.6	0.0	11.2	3.2	3.9	21.2	12.7	22.7	3.0	0.1	7.7	0.8	7.7	3.3	0.3	0.0	1.2	11.9	20.6	0.6	11.4	6.8	9.2	1.3	4.8	0.0	7.2	15.1	0.0	1.6	6.6	1.0	0.0	0.0	31.3	0.0	16.0	9.8	2.8	6.5	24.4	17.3	6.8	10.5	15.0	3.7	23.6	7.0	10.6	11.5	7.5	0.0	0.0	0.0	46.2	0.0	34.2	0.0	0.8	0.0	0.0	1.1	0.0	0.0	0.0	0.0	3.0	0.0	0.9	0.0	0.0	0.3	0.0	0.0	0.7	0.3	3.7	4.7	1.2	6.6	3.0	2.6	2.8	6.1	3.2	2.2	3.0	5.1	0.0	9.1	58.7	4.4	78.3	12.7	5.3	4.5	3.5	0.0	0.4	1.7	26.5	4.7	10.6	12.9	0.0	27.4	4.1	12.5	11.3	0.0	10.4	3.7	0.0	13.4	2.5	6.7	4.0	17.8	3.4	8.5	4.6	21.7	1.3	25.1	3.5	28.3	0.7	0.1	19.4	12.1	0.5	5.7	39.5	0.7	0.5	23.3	12.6
PTPRJ	"CD148, DEP1, HPTPeta"	ENSG00000149177	"Protein tyrosine phosphatase, receptor type J"	Q12913	11	47980558-48170841	"CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protein phosphatase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	7	"Kupffer cells: 67.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 12.2"	"Group enriched"	"Detected in all"	4	"granulocytes: 12.2;monocytes: 5.3"	"Cell line enhanced"	"Detected in many"		"EFO-21: 25.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006026	Approved				"Intracellular and membrane"	NA	NA		840000000			"HPA006026: AB_1078446"	"unprognostic (1.46e-1)"	"unprognostic (2.21e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.83e-2)"	"unprognostic (3.20e-2)"	"unprognostic (2.99e-2)"	"unprognostic (6.58e-2)"	"unprognostic (2.15e-1)"	"unprognostic (9.64e-3)"	"unprognostic (3.79e-3)"	"unprognostic (5.16e-2)"	"unprognostic (1.89e-1)"	"prognostic favorable (1.13e-5)"	"unprognostic (1.09e-2)"	"unprognostic (7.98e-2)"	"unprognostic (9.18e-2)"	"unprognostic (2.00e-1)"	5.6	3.7	10.4	17.7	13.9	22.6	5.6	4.9	9.5	6.1	9.0	8.8	12.3	8.4	3.9	7.6	2.9	5.0	6.7	5.2	9.5	9.2	13.3	12.2	12.2	22.6	10.8	9.4	3.0	9.1	21.1	14.5	20.3	8.3	7.8	8.1	12.9	12.9	9.0	4.6	4.3	13.4	5.5	6.7	33.0	13.8	3.1	9.9	6.7	18.8	0.9	9.7	6.0	3.9	1.0	1.8	12.2	5.3	1.2	2.1	0.9	3.5	13.5	5.9	3.2	0.9	2.1	2.0	3.6	2.7	6.4	4.8	0.8	20.0	3.3	25.5	9.2	9.6	2.7	9.3	0.9	7.8	21.9	2.5	0.9	16.7	1.2	5.8	1.2	20.8	1.5	0.3	1.7	0.5	15.3	3.9	0.2	1.2	2.2	2.2	7.7	0.0	7.5	4.6	11.5	2.1	0.8	0.7	1.7	24.8	5.3	4.0	1.2	10.1	5.7	9.1	4.5	6.4	9.2	12.5	5.0	5.3	10.0	11.0	0.5	0.7	5.5	5.8	3.8	18.3	0.9	1.5	3.4	2.1	2.5	1.4	1.0	1.2	1.5	1.0	0.7	1.0	1.3	12.2	1.2	5.3	1.8	1.1	0.9	10.4	13.9	4.9	9.4	9.5	9.2	10.8	9.4	8.3	9.9	8.9	21.3	8.0	8.8	0.2	11.1	3.1	17.8	8.1	22.7	36.6	5.9	1.5	0.0	6.5	4.2	2.2	28.4	0.0	4.3	0.6	3.0	20.5	12.8	14.0	26.2	9.5	12.1	2.5	67.6	4.0	0.3	20.6	1.7	10.8	8.5	11.5	8.7	28.1	0.4	10.9	1.0	0.0	3.9	0.2	3.2	0.3	1.6	13.8	5.7	5.4
PVR	"CD155, HVED, Necl-5, NECL5, PVS, Tage4"	ENSG00000073008	"Poliovirus receptor"	P15151	19	44643798-44663583	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 65.6"	"Cell type enhanced"	"Detected in many"	5	"Pancreatic endocrine cells: 48.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"classical monocyte: 6.4;intermediate monocyte: 6.6;myeloid DC: 5.6;non-classical monocyte: 8.1"	"Group enriched"	"Detected in many"	5	"dendritic cells: 5.6;monocytes: 8.1"	"Cell line enhanced"	"Detected in many"		"TIME: 53.4"									"HPA012568, HPA064739"	Approved		Supported	"Nucleoplasm,Vesicles,Plasma membrane"	"Secreted - unknown location"	NA	NA		940000000	"Nucleoplasm, Vesicles, Plasma membrane"		"HPA012568: AB_1846248, HPA064739: "	"unprognostic (2.90e-3)"	"prognostic unfavorable (1.29e-4)"	"unprognostic (3.36e-1)"	"unprognostic (2.34e-1)"	"unprognostic (7.89e-2)"	"unprognostic (2.45e-3)"	"unprognostic (3.06e-2)"	"prognostic unfavorable (9.30e-4)"	"unprognostic (9.05e-3)"	"unprognostic (1.69e-1)"	"unprognostic (2.09e-3)"	"unprognostic (2.64e-3)"	"unprognostic (1.69e-1)"	"unprognostic (4.97e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.04e-3)"	"prognostic unfavorable (2.75e-4)"	10.0	13.9	7.4	7.5	8.1	4.7	9.2	11.0	11.0	6.5	10.6	6.5	4.1	13.7	11.3	5.7	6.6	8.8	9.2	23.5	5.8	10.0	10.6	65.6	14.8	2.4	6.0	6.5	10.4	15.9	9.9	20.7	15.5	9.7	10.4	7.7	6.6	8.5	6.9	19.8	5.5	13.0	11.1	7.0	4.8	12.3	6.0	7.2	2.3	8.5	10.8	3.7	8.3	6.7	0.0	5.6	1.2	8.1	0.6	0.4	2.2	21.8	15.3	1.5	6.1	1.9	2.3	2.6	36.9	10.3	12.1	13.9	8.9	9.3	0.0	21.2	10.7	21.2	14.4	5.2	14.0	8.1	2.6	10.1	3.9	9.6	6.0	12.9	1.5	8.4	2.9	6.9	10.7	21.0	12.1	13.1	2.3	1.8	0.0	5.6	1.9	1.3	1.3	3.4	7.4	11.3	0.0	7.0	2.0	26.0	6.7	6.6	7.7	23.4	14.7	5.2	1.7	8.3	3.7	53.4	14.7	18.1	10.8	28.8	0.0	2.1	0.0	11.7	7.5	8.3	0.0	6.4	0.0	0.2	6.6	0.0	0.0	0.0	0.4	5.6	0.0	0.2	0.1	1.2	0.6	8.1	0.5	0.0	2.2	7.4	8.1	11.0	11.0	5.8	10.0	6.0	6.5	9.7	7.2	14.9	28.0	4.5	12.8	3.2	6.9	11.2	20.4	2.7	18.2	1.8	2.0	2.4	3.3	43.0	8.5	13.5	11.9	0.0	30.3	30.1	5.4	11.3	1.1	36.5	7.4	1.6	12.6	7.4	9.2	10.2	5.2	7.8	1.7	25.2	9.7	1.3	48.8	14.4	14.9	2.8	3.3	0.0	17.8	3.4	1.5	4.8	0.8	0.0	10.6	6.5
RHAG	"CD241, RH50A, SLC42A1"	ENSG00000112077	"Rh associated glycoprotein"	Q02094	6	49605158-49636884	"CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	"Ammonia transport, Transport"		"Disease mutation, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	9	"bone marrow: 54.1"	"Cell type enriched"	"Detected in some"	50	"Erythroid cells: 116.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	190	"HEL: 87.8;K-562: 86.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA046051, HPA055331"	Approved		Approved	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA046051: , HPA055331: AB_2682785"					"unprognostic (8.16e-2)"						"unprognostic (6.86e-2)"	"unprognostic (1.25e-3)"		"unprognostic (1.65e-1)"				1.2	0.2	0.0	1.1	0.5	54.1	3.2	0.0	0.1	2.3	1.0	0.5	1.7	0.2	0.4	0.1	2.6	0.5	0.8	5.3	0.0	0.0	0.1	0.7	3.3	0.1	0.0	0.0	0.1	0.2	0.1	0.1	5.8	0.1	1.3	0.2	0.0	0.2	0.5	0.4	0.1	0.9	0.1	0.0	4.5	0.6	0.2	0.0	1.7	1.8	0.0	0.1	0.8	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	87.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	86.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	116.8	0.2	0.3	0.0	0.0	2.3	0.0	0.4	0.0	0.0	1.8	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
RHCE	"CD240CE, RH"	ENSG00000188672	"Rh blood group CcEe antigens"	P18577	1	25362249-25430192	"Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"Blood group antigen"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	4	"bone marrow: 40.5"	"Cell type enriched"	"Detected in some"	33	"Erythroid cells: 210.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 2.4"	"Lineage enriched"	"Detected in single"	7	"granulocytes: 2.4"	"Cell line enriched"	"Detected in some"	5	"HEL: 44.7"									"HPA060951, HPA077385"	Supported		Uncertain	"Nucleoplasm,Plasma membrane"		NA	NA			"Nucleoplasm, Plasma membrane"		"HPA060951: , HPA077385: "	"unprognostic (1.37e-1)"	"unprognostic (3.53e-1)"	"unprognostic (2.38e-1)"	"unprognostic (6.75e-2)"	"unprognostic (1.41e-2)"	"unprognostic (4.91e-2)"	"unprognostic (7.01e-2)"	"unprognostic (3.12e-2)"	"unprognostic (3.81e-2)"	"unprognostic (1.35e-1)"	"unprognostic (6.08e-2)"	"unprognostic (4.61e-2)"	"unprognostic (5.77e-5)"	"unprognostic (1.38e-1)"	"unprognostic (3.94e-2)"	"unprognostic (7.15e-3)"	"unprognostic (1.63e-1)"	0.6	0.8	2.0	0.6	5.1	40.5	0.9	3.3	4.7	0.8	0.7	3.5	1.0	0.7	0.7	5.2	1.4	1.6	0.8	2.1	2.6	1.5	0.8	2.2	0.7	1.0	2.1	2.5	0.9	9.6	0.5	4.0	1.6	5.9	1.6	0.8	2.2	8.4	0.8	1.9	1.1	0.6	0.5	2.9	2.1	0.8	2.6	1.4	1.2	1.1	1.2	0.8	0.5	0.6	0.1	0.2	2.4	0.2	0.1	0.3	0.9	0.1	0.0	0.1	0.2	0.4	0.3	0.0	0.1	0.1	0.2	0.0	0.0	0.7	0.3	0.5	0.5	0.0	0.1	0.0	0.1	0.1	0.2	0.0	44.7	0.0	0.0	0.6	0.0	0.3	1.0	0.7	0.3	0.2	0.0	0.0	0.3	8.7	0.2	0.2	0.4	0.0	0.3	0.9	0.3	0.2	0.1	0.1	1.2	0.0	0.0	0.3	0.4	0.1	0.1	0.5	0.4	0.2	0.0	0.0	0.1	0.0	0.4	0.0	2.6	0.6	0.5	1.5	0.4	0.2	2.4	0.2	0.6	0.3	0.0	0.3	0.1	0.0	0.1	0.2	0.0	0.2	0.0	1.0	0.1	0.0	0.1	0.3	0.9	2.0	5.1	3.3	4.7	2.6	1.5	2.1	2.5	5.9	1.4	0.0	0.0	0.0	0.5	0.5	3.3	0.4	2.5	0.0	0.0	0.0	0.0	0.7	0.0	0.3	0.8	0.0	0.0	210.2	0.2	0.4	0.2	0.4	4.6	0.4	0.2	6.4	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	4.1	0.4	0.0	0.7	0.0	2.5	6.5	0.0	2.8	5.1	1.3	0.7	0.0	0.1	0.7
RHD	"CD240D, DIIIc, RH, Rh30a, Rh4, RhII, RhPI"	ENSG00000187010	"Rh blood group D antigen"	Q02161	1	25272393-25330445	"Blood group antigen proteins, CD markers, Predicted membrane proteins, Transporters"		"Blood group antigen"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 10.0;bone marrow: 16.5;salivary gland: 7.1"	"Cell type enriched"	"Detected in some"	20	"Erythroid cells: 23.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in many"		"neutrophil: 10.0"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 10.0"	"Group enriched"	"Detected in some"	6	"HEL: 28.2;K-562: 8.7"									"HPA060951, HPA077385"	Supported		Uncertain	"Nucleoplasm,Plasma membrane"		NA	NA			"Nucleoplasm, Plasma membrane"		"HPA060951: , HPA077385: "	"unprognostic (4.75e-3)"	"unprognostic (7.70e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.09e-2)"	"unprognostic (4.84e-2)"	"unprognostic (1.11e-2)"	"unprognostic (5.25e-2)"	"unprognostic (1.11e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.27e-2)"	"unprognostic (1.89e-1)"	"unprognostic (4.96e-3)"	"unprognostic (1.93e-1)"	"unprognostic (8.09e-2)"	"unprognostic (5.53e-2)"	"unprognostic (4.92e-3)"	0.3	0.3	0.3	0.5	0.5	16.5	0.3	1.5	1.4	0.6	0.3	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.4	0.9	0.3	0.2	0.3	0.3	2.5	0.8	0.3	0.3	0.9	0.3	0.1	0.4	0.3	1.1	0.5	0.0	0.3	7.1	0.3	4.1	2.5	0.4	0.3	0.4	1.8	0.3	0.5	0.3	0.3	0.4	2.3	0.3	0.3	0.3	2.0	0.6	10.0	1.4	1.4	1.4	1.2	0.1	0.0	0.2	0.2	0.1	0.0	0.4	0.1	0.1	0.1	0.0	0.1	0.3	0.4	0.1	0.0	0.1	0.2	0.0	0.0	0.0	0.5	0.1	28.2	0.7	0.2	0.0	0.3	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	8.7	0.7	0.0	0.1	0.2	0.2	3.1	0.0	0.1	0.2	0.1	0.1	0.0	0.1	0.5	0.3	0.1	0.2	0.1	0.1	0.2	0.5	0.4	0.5	0.2	0.4	0.1	0.3	0.1	0.1	0.5	0.2	0.1	4.9	1.4	2.8	1.0	0.6	1.1	1.3	1.3	0.8	0.2	2.0	1.4	1.3	10.0	1.4	0.8	0.6	0.9	1.2	0.3	0.5	1.5	1.4	0.3	0.2	0.3	0.3	1.1	0.3	0.0	0.3	0.0	0.1	0.1	0.2	0.8	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	23.3	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0
S1PR1	"CD363, D1S3362, edg-1, EDG1"	ENSG00000170989	"Sphingosine-1-phosphate receptor 1"	P21453	1	101236888-101241518	"Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	"Angiogenesis, Chemotaxis"	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 88.9"	"Group enriched"	"Detected in many"	5	"Endothelial cells: 89.9;Ito cells: 114.2;Muller glia cells: 38.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ: 19.4;HUVEC TERT2: 54.9;TIME: 30.5;U-251 MG: 37.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010104, HPA075568"	Supported		Supported	Vesicles		No	NA			Vesicles		"CAB010104: AB_2238920, HPA075568: AB_2686758"	"unprognostic (1.41e-1)"	"unprognostic (9.35e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.61e-1)"	"unprognostic (9.78e-2)"	"unprognostic (4.49e-3)"	"unprognostic (1.34e-3)"	"unprognostic (1.99e-1)"	"unprognostic (1.36e-1)"	"unprognostic (9.12e-2)"	"unprognostic (2.34e-2)"	"unprognostic (2.23e-1)"	"unprognostic (5.82e-3)"	"unprognostic (2.54e-2)"	"unprognostic (1.04e-1)"	"unprognostic (3.64e-1)"	"prognostic unfavorable (8.78e-4)"	72.3	8.4	24.7	16.6	26.2	9.7	46.3	21.6	21.8	13.3	10.5	9.5	2.5	5.7	12.1	5.0	14.7	11.5	17.6	43.5	22.9	15.4	8.9	20.5	35.7	24.5	23.2	14.0	7.9	11.0	13.4	4.7	29.6	21.2	8.9	7.0	9.3	7.5	5.6	21.7	8.2	9.8	19.0	11.0	35.2	8.0	5.8	13.9	4.4	17.0	8.7	15.7	15.2	18.5	27.4	0.2	88.9	0.2	33.4	49.8	30.8	3.6	0.0	3.9	0.0	0.4	9.3	0.0	19.4	3.5	11.8	4.2	0.0	0.1	0.0	4.8	6.7	0.0	0.0	0.5	0.2	7.9	1.3	0.4	1.3	0.1	0.0	1.8	0.0	0.8	12.5	0.0	0.0	0.9	0.5	54.9	1.1	0.0	4.0	3.7	0.0	4.6	0.0	1.0	0.1	1.3	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	30.5	2.0	0.7	0.4	37.6	0.3	0.0	0.2	0.2	0.0	0.1	88.9	0.1	4.9	49.8	0.1	40.2	25.1	45.3	44.1	0.2	27.4	35.7	36.2	1.4	33.4	0.2	0.2	26.8	30.8	24.7	26.2	21.6	16.8	22.9	15.4	23.2	14.0	21.2	13.9	0.0	12.8	17.1	0.1	6.8	0.0	16.9	2.5	0.0	2.3	0.0	0.0	5.5	0.0	0.0	0.0	89.9	0.0	0.0	0.0	0.3	8.4	0.5	7.0	6.0	7.6	0.0	0.0	114.2	6.9	0.0	0.9	1.5	5.0	14.4	0.0	38.0	0.0	0.0	0.0	0.0	1.0	0.0	1.4	0.4	0.7	4.4	2.2	9.2	0.0	0.4
SDC1	"CD138, SDC, SYND1, syndecan"	ENSG00000115884	"Syndecan 1"	P18827	2	20200797-20225433	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 113.2;placenta: 228.8"	"Cell type enhanced"	"Detected in many"	9	"Cholangiocytes: 298.1;Hepatocytes: 520.4;Urothelial cells: 356.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	17	"memory B-cell: 3.9"	"Lineage enriched"	"Detected in single"	40	"B-cells: 3.9"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 62.1;hTCEpi: 57.5;U-251 MG: 59.2;U-266/70: 61.4;U-266/84: 129.2"	"Group enriched"	"Detected in some"	4	"cerebellum: 10.7;olfactory region: 5.9"	"Not detected"	"Not detected"			"CAB002424, HPA006185, HPA067477"	Enhanced		Approved	"Focal adhesion sites"	"Secreted to blood"	NA	NA	63100000	1600000	"Focal adhesion sites"		"CAB002424: AB_442050, HPA006185: AB_1857705, HPA067477: "	"prognostic unfavorable (2.22e-4)"	"unprognostic (6.80e-3)"	"unprognostic (6.80e-2)"	"unprognostic (7.84e-2)"	"prognostic unfavorable (5.02e-4)"	"unprognostic (1.15e-1)"	"unprognostic (4.02e-2)"	"unprognostic (6.32e-2)"	"unprognostic (1.70e-1)"	"unprognostic (3.66e-1)"	"unprognostic (2.27e-3)"	"unprognostic (1.79e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.94e-2)"	"unprognostic (4.27e-1)"	"unprognostic (1.62e-2)"	"unprognostic (1.52e-1)"	0.8	3.4	0.5	5.4	0.6	0.0	4.5	0.8	0.7	21.4	18.3	0.5	3.5	14.3	2.3	8.7	103.7	1.6	55.3	0.3	0.4	0.5	68.5	113.2	15.8	6.3	1.9	0.4	1.6	7.0	0.6	0.6	228.8	0.7	13.3	6.2	1.5	16.0	5.2	0.5	69.5	21.9	4.3	0.4	3.7	16.3	2.6	0.4	1.5	3.5	62.3	48.4	30.0	37.7	3.9	0.0	0.0	0.0	0.0	0.0	0.5	31.4	17.6	5.6	14.0	1.5	0.2	17.7	8.8	8.5	8.2	7.0	3.7	19.2	0.0	3.2	6.2	4.5	31.1	2.4	62.1	5.5	0.1	1.6	0.0	1.6	18.8	1.3	1.3	0.1	0.8	57.5	7.4	17.6	11.5	0.9	0.0	0.7	12.3	4.4	18.8	0.0	0.3	5.0	24.0	34.2	0.6	2.0	23.8	10.6	47.2	1.6	13.1	6.6	44.8	2.0	2.3	4.4	0.3	1.3	32.7	10.5	1.2	59.2	61.4	129.2	0.1	9.8	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.6	0.8	0.7	0.4	0.5	1.9	0.4	0.7	0.4	86.4	91.4	3.0	135.6	101.2	0.1	0.8	298.1	2.7	63.7	40.1	0.0	2.4	26.6	54.9	0.0	1.1	102.7	23.3	19.0	43.0	9.7	42.4	5.8	520.4	2.2	20.6	10.4	6.7	9.6	0.0	0.6	5.4	20.3	1.0	72.0	0.0	67.3	73.7	1.1	68.3	0.0	0.0	7.1	0.7	12.8	200.1	209.7	4.4	66.5	356.0
SDC2	"CD362, fibroglycan, HSPG, HSPG1, SYND2"	ENSG00000169439	"Syndecan 2"	P34741	8	96493351-96611780	"CD markers, Predicted membrane proteins"	"Differentiation, Neurogenesis"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 115.1;thyroid gland: 111.2"	"Cell type enhanced"	"Detected in many"	5	"Fibroblasts: 194.4;Hepatocytes: 184.9;Smooth muscle cells: 188.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	7	"neutrophil: 13.9"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 13.9"	"Cell line enhanced"	"Detected in many"		"AF22: 102.6;EFO-21: 48.2;fHDF/TERT166: 44.4;RPTEC TERT1: 53.6;U-138 MG: 49.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB025123, HPA044416"	Uncertain		Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"CAB025123: , HPA044416: AB_2678934"	"unprognostic (1.25e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.25e-1)"	"unprognostic (3.61e-2)"	"unprognostic (6.52e-3)"	"unprognostic (4.18e-2)"	"unprognostic (2.43e-1)"	"unprognostic (2.35e-2)"	"unprognostic (2.89e-2)"	"unprognostic (4.56e-1)"	"unprognostic (1.48e-1)"	"unprognostic (6.16e-2)"	"unprognostic (1.56e-2)"	"unprognostic (1.45e-3)"	"unprognostic (1.91e-1)"	"unprognostic (2.50e-2)"	"unprognostic (1.23e-1)"	43.2	9.9	13.9	9.1	16.9	2.5	17.0	12.7	8.4	43.4	18.7	7.3	21.2	5.8	21.9	15.3	13.3	21.0	15.0	19.1	12.0	12.6	23.9	115.1	14.4	4.4	9.7	9.3	45.9	16.8	1.6	24.0	31.3	10.7	25.9	10.7	51.4	6.3	28.1	9.4	6.5	9.6	34.3	9.5	7.5	11.9	8.7	9.3	0.5	111.2	13.8	3.5	35.9	26.3	0.0	1.3	13.9	1.9	0.0	0.2	0.5	0.0	0.0	102.6	0.0	37.1	34.7	0.1	14.8	17.6	8.6	9.6	3.0	0.0	0.0	48.2	44.4	1.2	0.0	17.7	0.2	7.4	0.0	6.9	0.0	9.9	37.7	1.2	0.2	0.4	13.3	0.4	19.5	0.5	33.3	0.3	0.0	9.7	0.0	3.6	0.8	0.0	2.5	10.8	0.0	0.1	0.1	16.1	0.3	53.6	8.7	3.0	8.0	0.0	0.0	0.7	35.9	4.4	11.4	8.0	49.7	15.2	0.2	8.2	0.9	0.0	0.1	15.8	0.0	15.5	0.0	1.9	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.3	0.0	0.2	0.0	13.9	0.0	0.1	0.0	0.0	0.5	13.9	16.9	12.7	8.4	12.0	12.6	9.7	9.3	10.7	9.3	53.6	30.2	4.7	67.2	47.9	22.0	25.8	33.1	5.3	3.4	54.1	11.8	1.8	24.9	11.7	25.6	10.2	0.1	23.3	13.2	2.0	194.4	44.9	1.1	184.9	114.7	4.8	3.4	20.3	22.0	14.5	48.6	87.0	59.1	118.2	0.5	18.4	12.7	0.0	98.6	44.8	10.2	32.3	188.5	3.2	57.1	34.4	3.2	3.2	1.2	14.5
SELE	"CD62E, ELAM, ELAM1, ESEL"	ENSG00000007908	"Selectin E"	P16581	1	169722641-169764705	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"tongue: 50.0"	"Group enriched"	"Detected in many"	5	"Basal keratinocytes: 41.0;Endothelial cells: 101.9;Melanocytes: 43.9;Suprabasal keratinocytes: 41.8"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	4	"pons and medulla: 5.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	5	"HUVEC TERT2: 5.3"	"Not detected"	"Not detected"							CAB002143	Enhanced					NA	NA	8140000	640000000			"CAB002143: AB_563608"	"unprognostic (2.39e-1)"	"unprognostic (2.16e-2)"	"unprognostic (1.37e-2)"	"unprognostic (2.09e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.59e-1)"	"unprognostic (2.94e-1)"	"unprognostic (3.63e-1)"	"unprognostic (3.88e-1)"	"unprognostic (9.74e-2)"	"unprognostic (4.32e-2)"	"unprognostic (1.56e-2)"	"unprognostic (8.13e-3)"	"unprognostic (4.69e-2)"	"unprognostic (4.63e-2)"	"unprognostic (2.55e-1)"	14.9	2.7	0.9	30.4	1.2	0.2	8.3	0.3	1.0	13.7	2.7	1.9	4.4	0.4	18.1	3.2	6.7	20.1	7.4	4.4	0.9	0.9	2.5	4.9	10.6	2.0	1.2	0.0	9.8	1.4	21.0	3.1	0.9	5.4	21.2	1.9	4.3	2.0	4.6	2.2	3.7	2.4	13.1	4.8	0.2	3.4	5.6	0.5	0.9	9.0	50.0	15.5	16.4	4.0	0.0	0.0	0.0	0.0	0.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.9	0.0	0.9	1.2	0.3	1.0	0.9	0.9	1.2	0.0	5.4	0.5	0.0	6.7	0.0	1.0	41.0	0.0	5.0	2.5	0.0	1.2	0.0	0.0	0.0	0.0	0.0	1.3	101.9	0.0	0.0	0.0	0.0	12.4	3.2	1.1	5.9	0.0	0.0	0.0	1.8	0.0	1.6	0.0	0.2	43.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.1	0.0	41.8	0.0	0.0	0.0	0.6
SELL	"CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR"	ENSG00000188404	"Selectin L"	P14151	1	169690667-169711698	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 227.5;lymphoid tissue: 77.8"	"Group enriched"	"Detected in many"	6	"B-cells: 178.5;Kupffer cells: 97.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 7.0;EFO-21: 6.8;JURKAT: 18.6;MOLT-4: 12.8;U-266/70: 24.1;U-698: 11.2;U-937: 7.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB002144, HPA051972"	Enhanced		Uncertain	Cytosol		NA	NA		8100000000	Cytosol		"CAB002144: AB_563862, HPA051972: AB_2797242"	"prognostic favorable (3.76e-4)"	"prognostic favorable (2.25e-4)"	"unprognostic (1.52e-2)"	"unprognostic (2.89e-2)"	"unprognostic (7.87e-3)"	"prognostic favorable (6.43e-4)"	"unprognostic (1.39e-3)"	"unprognostic (3.43e-1)"	"unprognostic (2.70e-3)"	"prognostic favorable (3.14e-4)"	"unprognostic (1.42e-1)"	"unprognostic (4.21e-2)"	"prognostic unfavorable (4.96e-5)"	"unprognostic (4.76e-2)"	"unprognostic (8.71e-3)"	"unprognostic (9.57e-2)"	"unprognostic (1.01e-1)"	6.9	0.9	2.0	25.1	4.6	30.3	1.5	1.1	2.5	0.9	1.4	1.1	0.0	0.4	1.0	1.1	4.2	3.2	5.4	4.1	2.5	2.2	2.3	2.5	11.4	77.8	5.2	0.2	0.8	1.0	10.7	7.9	3.4	2.7	1.2	1.3	3.8	12.1	0.1	0.9	0.8	8.8	2.9	5.2	67.7	1.7	1.0	2.3	43.8	1.9	1.3	64.0	8.1	6.1	40.4	40.7	227.5	49.7	130.8	69.5	90.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.5	0.0	0.2	7.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	4.8	0.8	0.3	0.0	0.0	0.0	0.0	1.2	18.6	0.0	0.9	0.0	0.8	12.8	0.1	0.0	0.2	0.2	4.9	0.1	0.3	3.9	0.2	0.0	0.0	0.0	0.9	0.0	0.5	0.0	0.0	0.0	0.3	0.1	0.0	0.0	24.1	0.0	11.2	1.3	7.0	0.1	170.8	49.7	88.6	16.5	11.2	4.5	33.8	30.7	17.0	40.7	40.4	69.5	39.6	227.5	130.8	4.5	32.8	52.7	90.1	2.0	4.6	1.1	2.5	2.5	2.2	5.2	0.2	2.7	2.3	8.9	20.2	178.5	0.3	0.3	0.0	0.3	2.5	2.7	3.4	10.4	0.0	9.0	0.0	0.1	0.0	2.0	0.0	0.0	0.0	0.6	0.8	0.0	9.3	0.4	5.6	0.0	0.0	1.8	97.5	0.0	0.6	7.5	1.7	0.0	0.0	2.3	0.1	0.0	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.1	23.8	20.3	0.0	0.5
SELP	"CD62, CD62P, GMP140, GRMP, PADGEM, PSEL"	ENSG00000174175	"Selectin P"	P16109	1	169588849-169630193	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"Endothelial cells: 42.8;Ito cells: 14.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	6	"basophil: 6.0;neutrophil: 2.4;T-reg: 8.9"	"Group enriched"	"Detected in many"	8	"granulocytes: 6.0;T-cells: 8.9"	"Group enriched"	"Detected in some"	37	"EFO-21: 25.2;HEL: 22.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB002145, HPA002655, HPA005990"	Enhanced					NA	NA		830000000			"CAB002145: AB_563984, HPA002655: AB_1078480, HPA005990: AB_1078479"	"unprognostic (3.37e-2)"	"unprognostic (2.98e-4)"	"unprognostic (4.11e-1)"	"unprognostic (1.46e-1)"	"unprognostic (9.26e-2)"	"prognostic favorable (3.12e-4)"	"unprognostic (5.30e-4)"	"unprognostic (4.14e-2)"	"unprognostic (3.59e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.93e-2)"	"unprognostic (6.61e-2)"	"unprognostic (1.19e-1)"	"unprognostic (8.24e-3)"	"unprognostic (1.74e-2)"	"unprognostic (7.85e-3)"	"unprognostic (1.66e-1)"	14.2	2.1	0.4	8.4	0.4	1.0	10.9	0.4	0.4	14.8	3.7	0.6	7.5	3.3	10.6	6.2	5.6	7.7	7.0	9.6	0.4	0.4	7.5	4.6	11.3	12.9	0.4	0.4	5.0	1.5	3.8	2.8	7.4	1.3	14.8	2.9	24.7	3.4	4.3	3.7	2.3	5.2	10.5	1.0	1.9	3.5	3.1	0.3	1.4	4.9	7.7	13.0	11.5	27.2	0.9	0.1	6.0	0.5	0.4	8.9	8.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	6.0	0.5	0.7	0.0	0.2	0.0	0.9	0.6	0.3	0.0	0.2	0.2	0.1	2.4	0.4	0.0	0.1	8.9	8.8	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	1.3	0.3	0.0	5.1	0.0	0.0	3.3	0.0	2.0	2.5	0.0	0.0	1.8	0.0	2.4	0.0	0.0	0.9	42.8	0.0	0.0	0.2	0.0	0.8	0.3	0.0	0.5	0.2	0.0	0.0	14.1	0.0	0.0	0.3	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	3.0	3.4	0.0	0.0	0.0
SELPLG	"CD162, PSGL-1"	ENSG00000110876	"Selectin P ligand"	Q14242	12	108622277-108633959	"Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 126.9;lymphoid tissue: 60.5"	"Cell type enhanced"	"Detected in many"	12	"Hofbauer cells: 35.0;Kupffer cells: 84.7;Macrophages: 58.3;monocytes: 101.8;T-cells: 37.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 28.5;HMC-1: 27.7;JURKAT: 22.6;Karpas-707: 43.3;RPMI-8226: 60.2;U-266/70: 70.7;U-266/84: 44.0"									"CAB002431, HPA069062"	Enhanced					NA	NA					"CAB002431: AB_563509, HPA069062: "	"unprognostic (2.32e-2)"	"prognostic favorable (1.46e-4)"	"unprognostic (3.64e-3)"	"unprognostic (1.02e-2)"	"unprognostic (6.32e-2)"	"prognostic favorable (6.94e-4)"	"unprognostic (2.52e-1)"	"unprognostic (1.29e-1)"	"prognostic favorable (2.92e-4)"	"unprognostic (2.26e-1)"	"unprognostic (2.12e-2)"	"unprognostic (3.24e-1)"	"prognostic unfavorable (5.86e-4)"	"unprognostic (5.88e-2)"	"unprognostic (2.37e-2)"	"prognostic favorable (2.74e-4)"	"unprognostic (5.44e-2)"	10.6	5.5	11.3	25.3	8.9	10.7	4.2	2.2	12.5	5.8	5.4	27.2	0.1	5.0	2.9	4.1	5.0	6.8	9.6	5.9	12.1	9.6	4.6	3.9	23.3	46.8	16.2	5.4	2.1	2.9	1.3	3.1	7.3	11.5	3.0	5.2	3.4	5.2	2.5	1.8	2.7	10.3	6.7	19.6	60.5	6.0	2.1	13.5	26.0	3.1	2.8	18.0	14.8	3.0	2.2	50.9	126.9	68.4	28.1	63.2	77.1	0.1	0.0	0.3	0.1	0.1	0.3	0.1	1.0	1.0	0.4	0.3	0.0	0.4	0.1	0.3	1.5	0.4	0.0	0.0	0.0	0.3	28.5	0.0	10.1	0.0	0.0	0.0	7.1	27.7	0.4	0.1	0.5	0.1	1.1	0.0	22.6	0.1	43.3	1.3	0.0	5.7	4.1	0.0	0.0	0.3	0.0	0.1	60.2	0.6	0.0	0.0	0.0	0.1	0.0	0.4	0.7	0.0	9.1	0.3	0.5	0.1	0.7	0.2	70.7	44.0	1.2	0.3	15.2	0.4	126.9	28.1	88.8	43.8	49.5	35.8	2.0	41.8	37.4	29.4	2.2	32.4	34.1	125.8	28.1	68.4	50.9	63.2	77.1	11.3	8.9	2.2	12.5	12.1	9.6	16.2	5.4	11.5	13.5	3.0	18.0	6.0	0.1	3.1	0.0	2.0	5.1	9.4	4.5	0.0	0.0	0.4	0.0	0.3	6.1	1.1	0.0	0.0	0.2	2.1	3.0	0.1	27.8	0.9	35.0	0.0	0.0	1.8	84.7	7.2	0.3	58.3	6.8	101.8	0.0	0.0	0.3	0.0	0.0	0.5	0.1	0.0	1.4	0.1	0.3	1.6	0.8	37.9	0.0	0.0
SEMA4D	"C9orf164, CD100, coll-4, FLJ39737, SEMAJ"	ENSG00000187764	"Semaphorin 4D"	Q92854	9	89360787-89498130	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Differentiation, Neurogenesis"	"Developmental protein, Receptor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 107.1;skeletal muscle: 43.3"	"Cell type enhanced"	"Detected in many"	6	"granulocytes: 41.5;T-cells: 50.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 42.5;HMC-1: 32.8;JURKAT: 29.4;MOLT-4: 38.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015662, HPA023277"	Approved					NA	NA		4100000			"HPA015662: AB_1856671, HPA023277: AB_1856672"	"unprognostic (2.94e-2)"	"prognostic favorable (4.17e-4)"	"unprognostic (1.12e-2)"	"unprognostic (8.22e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.76e-3)"	"unprognostic (1.27e-1)"	"unprognostic (1.58e-1)"	"unprognostic (7.79e-2)"	"unprognostic (2.74e-1)"	"unprognostic (3.18e-3)"	"unprognostic (1.50e-2)"	"unprognostic (2.29e-3)"	"unprognostic (3.05e-2)"	"unprognostic (1.28e-2)"	"unprognostic (2.43e-1)"	"prognostic favorable (4.06e-5)"	3.9	5.6	18.0	18.6	20.7	14.3	3.6	7.7	20.9	4.0	5.9	54.0	3.1	6.1	3.9	7.4	9.3	6.6	7.2	4.9	28.2	18.8	8.4	2.0	6.7	32.0	42.6	15.0	4.1	4.6	4.9	5.3	3.2	27.5	4.9	5.8	2.9	6.7	4.2	43.3	8.8	9.6	3.3	107.1	19.2	9.4	6.1	23.3	25.3	4.9	3.1	27.6	8.3	5.3	2.6	4.6	21.2	4.1	4.7	14.0	7.8	4.0	3.0	2.8	4.1	0.1	0.2	6.4	0.4	0.2	0.8	0.6	2.0	4.5	15.3	1.7	0.0	3.3	2.1	2.5	1.2	0.3	42.5	2.5	6.4	1.0	0.2	0.5	8.5	32.8	0.1	0.9	0.2	0.1	0.1	1.6	29.4	1.5	10.4	0.0	6.6	38.5	10.7	6.9	8.0	0.1	12.3	0.9	4.3	5.5	4.2	6.6	4.4	1.1	3.6	0.1	4.1	3.3	4.6	1.0	0.0	2.6	0.3	1.9	11.7	5.0	2.2	1.9	10.3	2.5	7.3	4.1	20.4	13.3	3.8	8.0	2.6	10.6	11.1	1.5	1.6	12.2	14.0	21.2	4.7	4.1	4.6	9.5	7.8	18.0	20.7	7.7	20.9	28.2	18.8	42.6	15.0	27.5	23.3	6.0	21.5	24.2	2.9	4.0	10.2	14.8	5.1	5.3	9.1	10.4	2.0	7.5	3.3	5.0	1.7	4.9	0.5	0.0	2.9	1.8	4.8	6.7	41.5	1.7	17.0	31.8	1.7	5.5	26.2	2.2	6.9	21.6	1.7	5.4	6.4	8.6	3.2	0.0	14.2	14.4	4.8	0.0	2.1	0.7	22.6	4.6	3.1	50.3	3.3	6.7
SEMA7A	"CD108, H-Sema-L, SEMAL"	ENSG00000138623	"Semaphorin 7A (John Milton Hagen blood group)"	O75326	15	74409289-74433958	"Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins"	"Differentiation, Inflammatory response, Neurogenesis"	"Developmental protein"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 36.4;lymphoid tissue: 34.7;placenta: 54.0"	"Cell type enhanced"	"Detected in many"	13	"Cone photoreceptor cells: 64.8;Extravillous trophoblasts: 51.6;monocytes: 49.5;Pancreatic endocrine cells: 55.5;Rod photoreceptor cells: 57.4;Syncytiotrophoblasts: 139.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"eosinophil: 8.9"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 8.9"	"Cell line enhanced"	"Detected in many"		"HMC-1: 101.9;hTEC/SVTERT24-B: 40.0;U-251 MG: 58.8;U-87 MG: 34.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008210, HPA042273"	Uncertain		Uncertain	Vesicles		NA	NA		29000000	Vesicles		"HPA008210: , HPA042273: AB_10806234"	"unprognostic (2.00e-1)"	"unprognostic (2.72e-1)"	"unprognostic (2.02e-2)"	"unprognostic (5.81e-2)"	"unprognostic (6.49e-2)"	"unprognostic (8.61e-2)"	"unprognostic (2.54e-2)"	"unprognostic (4.18e-3)"	"unprognostic (1.33e-1)"	"unprognostic (1.39e-1)"	"unprognostic (5.18e-3)"	"unprognostic (1.44e-1)"	"prognostic unfavorable (2.45e-11)"	"unprognostic (1.32e-1)"	"unprognostic (2.01e-2)"	"unprognostic (6.25e-2)"	"unprognostic (2.57e-2)"	2.2	1.9	5.4	10.4	13.8	12.8	1.4	22.9	27.3	1.3	1.8	19.9	1.4	2.7	4.3	1.8	3.2	1.2	3.3	1.4	10.8	5.7	1.4	1.5	4.4	19.0	28.5	5.7	5.9	0.9	6.4	1.9	54.0	28.6	1.4	1.8	7.8	1.7	3.5	1.4	4.7	6.0	2.0	36.4	34.7	3.7	23.6	15.4	9.0	1.1	0.4	19.7	4.6	1.7	1.4	1.8	8.9	0.0	0.8	0.2	0.0	5.8	0.0	1.7	0.5	2.2	7.6	14.6	27.1	10.9	5.7	8.8	2.3	9.6	0.0	1.6	12.2	4.6	1.7	0.5	1.7	5.9	0.4	0.3	10.6	0.0	2.9	0.5	0.3	101.9	5.3	0.0	40.0	2.2	14.4	0.0	0.7	6.0	3.7	18.5	0.4	1.4	3.4	1.9	0.1	4.1	0.2	1.2	1.5	2.4	2.5	0.1	0.1	0.2	4.9	2.2	1.6	0.3	2.1	1.0	10.7	7.1	5.1	58.8	0.6	0.4	0.1	34.3	1.2	0.5	3.9	0.0	8.9	0.2	0.0	0.2	1.4	0.0	0.1	0.1	0.2	0.0	0.1	0.1	0.8	0.0	1.8	0.0	0.0	5.4	13.8	22.9	27.3	10.8	5.7	28.5	5.7	28.6	15.4	3.0	0.0	2.7	0.5	0.3	10.9	0.8	0.0	0.0	2.3	1.8	64.8	20.3	0.0	17.3	0.5	2.4	0.0	0.0	12.1	51.6	0.8	1.9	8.1	0.8	6.4	1.6	0.0	0.6	0.8	1.5	3.4	1.2	8.5	49.5	0.0	4.2	55.5	0.0	1.8	0.0	57.4	0.0	0.9	0.7	0.4	1.3	139.1	2.5	0.0	25.3
SIGLEC1	"CD169, dJ1009E24.1, FLJ00051, FLJ00055, FLJ00073, FLJ32150, sialoadhesin, SIGLEC-1, SN"	ENSG00000088827	"Sialic acid binding Ig like lectin 1"	Q9BZZ2	20	3686970-3707128	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Endocytosis"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 35.7"	"Group enriched"	"Detected in some"	10	"Hofbauer cells: 61.4;Kupffer cells: 69.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	16	"classical monocyte: 4.1;intermediate monocyte: 2.5;myeloid DC: 1.9;plasmacytoid DC: 1.2"	"Group enriched"	"Detected in many"	20	"dendritic cells: 1.9;monocytes: 4.1"	"Cell line enriched"	"Detected in single"	18	"THP-1: 6.9"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			HPA053457	Supported				"Intracellular and membrane"	NA	NA		110000			"HPA053457: AB_2682158"	"unprognostic (2.05e-1)"	"unprognostic (9.27e-3)"	"unprognostic (3.83e-4)"	"unprognostic (4.87e-3)"	"unprognostic (3.40e-2)"	"unprognostic (1.06e-1)"	"unprognostic (2.15e-1)"	"unprognostic (6.98e-2)"	"unprognostic (2.27e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.57e-1)"	"prognostic unfavorable (8.69e-5)"	"unprognostic (8.71e-2)"	"prognostic unfavorable (4.36e-4)"	"unprognostic (1.11e-2)"	"unprognostic (9.31e-2)"	11.6	8.0	1.5	4.5	2.0	7.0	4.7	1.5	1.9	1.5	4.4	1.5	1.5	2.9	1.5	1.5	3.1	4.2	5.3	3.5	1.5	0.1	2.9	4.9	9.7	35.7	2.1	1.5	1.6	1.5	0.0	1.5	12.2	3.0	1.5	4.1	1.8	6.3	1.5	3.2	1.5	5.9	4.6	1.5	12.0	2.9	1.5	1.5	2.8	1.9	3.4	1.8	4.8	1.7	0.0	1.9	0.0	4.1	0.0	0.1	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.2	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	2.5	0.1	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	1.2	1.5	2.0	1.5	1.9	1.5	0.1	2.1	1.5	3.0	1.5	3.0	4.1	0.0	0.0	0.3	0.2	2.0	0.0	0.0	1.2	0.0	2.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.7	0.6	0.0	0.0	0.0	61.4	0.0	0.0	0.0	69.1	0.0	0.0	6.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.5	1.6	0.0	0.0	0.0
SIGLEC5	"CD170, CD33L2, OB-BP2, SIGLEC-5"	ENSG00000105501	"Sialic acid binding Ig like lectin 5"	O15389	19	51611927-51645545	"CD markers, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"blood: 46.7;bone marrow: 13.5"	"Group enriched"	"Detected in some"	10	"granulocytes: 8.1;Hofbauer cells: 4.6;Kupffer cells: 8.5;Macrophages: 3.2"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 1.7"					"Cell type enhanced"	"Detected in many"		"neutrophil: 46.7"	"Group enriched"	"Detected in many"	6	"granulocytes: 46.7;monocytes: 13.7"	"Group enriched"	"Detected in some"	6	"HMC-1: 35.8;U-937: 14.8"									"HPA009085, CAB024900"	Supported					NA	NA					"CAB024900: , HPA009085: AB_1079965"	"unprognostic (1.83e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.02e-2)"	"unprognostic (1.03e-2)"	"unprognostic (4.39e-2)"	"unprognostic (1.62e-2)"	"unprognostic (1.73e-1)"	"unprognostic (1.01e-1)"	"unprognostic (3.28e-1)"	"unprognostic (7.44e-2)"	"unprognostic (1.01e-1)"	"unprognostic (4.05e-1)"	"unprognostic (3.71e-4)"	"unprognostic (4.37e-2)"	"unprognostic (3.55e-3)"	"unprognostic (4.02e-1)"	"unprognostic (1.95e-1)"	1.2	0.4	0.4	6.4	0.5	13.5	0.2	0.1	0.2	0.1	0.3			0.0	0.2	0.0	0.2	0.1	0.3	0.3	0.3	0.2	0.2	1.2	1.5	2.5	0.5		0.1	0.2	0.0	0.2	0.5		0.2	0.4		0.4	0.0	0.0	0.1	3.4	0.5	0.7	5.9	0.3	0.7			0.2		1.9	0.8	0.1	0.8	4.7	46.7	13.7	0.2	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.7	35.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.8	0.0	3.6	6.4	0.1	0.0	7.5	0.0	0.8	0.0	0.0	4.7	0.7	0.0	0.0	46.7	0.2	13.7	1.5	0.0	2.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	8.1	0.0	4.6	0.0	0.0	0.0	8.5	0.0	0.3	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0
SIGLEC6	"CD327, CD33L, CD33L1, OB-BP1, SIGLEC-6"	ENSG00000105492	"Sialic acid binding Ig like lectin 6"	O43699	19	51519525-51531856	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	10	"placenta: 87.4"	"Group enriched"	"Detected in some"	12	"Cytotrophoblasts: 56.9;granulocytes: 52.1;Syncytiotrophoblasts: 157.8"	"Cancer enhanced"	"Detected in some"		"thyroid cancer: 2.7"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 6.5;plasmacytoid DC: 6.8"	"Group enriched"	"Detected in many"	33	"B-cells: 6.5;dendritic cells: 6.8;granulocytes: 2.3"	"Cell line enriched"	"Detected in some"	7	"HMC-1: 103.0"									"HPA008945, HPA009084, HPA018198"	Enhanced		Approved	"Plasma membrane,Cytosol"	"Intracellular and membrane"	NA	NA			"Plasma membrane, Cytosol"		"HPA008945: , HPA009084: AB_1079967, HPA018198: AB_1856868"	"unprognostic (1.97e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.38e-3)"	"unprognostic (9.31e-3)"		"unprognostic (8.46e-4)"	"unprognostic (2.91e-1)"	"unprognostic (2.02e-2)"	"unprognostic (2.64e-1)"	"unprognostic (8.96e-2)"	"unprognostic (2.03e-1)"	"unprognostic (6.89e-2)"	"unprognostic (1.10e-2)"	"unprognostic (4.15e-2)"	"unprognostic (4.42e-2)"	"unprognostic (3.28e-2)"	"unprognostic (5.57e-3)"	1.8	0.0	0.0	5.6	0.0	0.1	0.8	0.0	0.1	1.2	1.7	0.0	0.3	0.9	2.0	1.2	1.5	0.5	8.6	0.4	0.0	0.0	0.4	0.1	4.2	1.5	0.0	0.0	0.1	0.3	0.1	0.1	87.4	0.0	3.7	1.5	0.5	1.4	1.0	0.2	1.3	6.0	3.1	0.0	1.3	1.7	1.0	0.0	0.3	0.2	1.0	2.6	2.2	1.9	6.5	6.8	2.3	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.8	0.0	0.0	0.0	0.2	103.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.3	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	1.4	2.8	0.0	0.0	0.0	0.1	0.0	6.8	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	56.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.1	0.0	52.1	0.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	157.8	0.0	0.0	0.0
SIGLEC7	"CD328, p75/AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2"	ENSG00000168995	"Sialic acid binding Ig like lectin 7"	Q9Y286	19	51142299-51153526	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 51.5;lymphoid tissue: 29.4"	"Group enriched"	"Detected in some"	5	"Hofbauer cells: 29.4;Kupffer cells: 51.3;Macrophages: 24.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"eosinophil: 51.5"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"Karpas-707: 31.5;RPMI-8226: 18.3;U-937: 19.4"									HPA075513			Approved	"Vesicles,Plasma membrane"	"Intracellular and membrane"	NA	NA		1100000	"Plasma membrane"	Vesicles	"HPA075513: "	"unprognostic (3.14e-1)"	"unprognostic (5.87e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.66e-1)"	"unprognostic (3.90e-2)"	"unprognostic (1.85e-1)"	"unprognostic (2.53e-1)"	"unprognostic (2.78e-1)"	"unprognostic (1.69e-1)"	"unprognostic (4.95e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.66e-1)"	"unprognostic (8.27e-2)"	"unprognostic (6.61e-2)"	"unprognostic (1.14e-3)"	"unprognostic (2.58e-1)"	"unprognostic (2.26e-2)"	6.9	3.7	1.6	10.0	5.8	3.7	3.0	0.3	2.2	0.9	1.6	1.0	0.6	1.4	0.9	2.1	1.1	1.8	2.4	1.9	0.8	1.0	2.8	9.8	4.7	18.4	3.3	0.0	1.3	0.9	0.2	0.9	5.9	2.9	1.0	2.3	0.7	2.3	0.2	0.4	0.5	2.3	3.5	3.3	29.4	1.1	1.8	2.5	0.7	1.0	0.0	2.1	3.2	1.7	0.6	14.9	51.5	32.0	20.0	4.4	15.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.5	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	18.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.0	0.1	19.4	0.0	0.5	32.0	51.5	2.5	23.0	4.4	0.6	0.0	1.1	14.9	0.0	0.0	1.0	26.8	20.0	9.1	0.6	0.0	15.8	1.6	5.8	0.3	2.2	0.8	1.0	3.3	0.0	2.9	2.5	0.0	2.1	1.4	0.0	0.1	0.0	0.0	0.0	1.4	1.2	1.8	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.2	0.0	1.1	0.6	29.4	0.0	0.0	7.4	51.3	0.0	1.4	24.5	0.0	0.0	0.0	0.0	0.1	0.0	1.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	2.2	0.0	0.0
SIGLEC8	"MGC59785, SAF2, SIGLEC-8, SIGLEC8L"	ENSG00000105366	"Sialic acid binding Ig like lectin 8"	Q9NYZ4	19	51450847-51458456	"CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 63.0"	"Cell type enriched"	"Detected in some"	4	"granulocytes: 42.8"	"Cancer enhanced"	"Detected in many"		"glioma: 7.2"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	42	"eosinophil: 63.0"	"Lineage enriched"	"Detected in single"	623	"granulocytes: 63.0"	"Cell line enriched"	"Detected in some"	45	"HMC-1: 58.8"									HPA012556	Uncertain		Uncertain	Cytosol		NA	NA			Cytosol		"HPA012556: AB_1856869"	"unprognostic (1.27e-1)"	"unprognostic (1.88e-4)"	"unprognostic (1.28e-1)"	"unprognostic (6.70e-2)"	"unprognostic (2.97e-1)"	"unprognostic (1.30e-2)"	"unprognostic (7.84e-2)"	"unprognostic (2.51e-2)"	"unprognostic (2.72e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.10e-1)"	"unprognostic (4.19e-1)"	"unprognostic (8.62e-3)"	"unprognostic (7.18e-2)"	"unprognostic (6.02e-2)"	"unprognostic (4.28e-3)"	"unprognostic (3.29e-1)"	0.6	6.7	5.8	2.4	8.4	0.7	2.3	0.7	7.0	1.4	2.9	7.4	0.0	2.9	1.0	1.1	1.1	1.1	2.7	0.3	8.6	4.8	0.4	1.6	4.1	9.6	8.3	3.6	0.3	0.7	0.7	1.2	0.1	7.5	1.0	2.8	0.1	1.1	0.9	0.3	0.8	4.5	1.5	14.8	9.2	2.1	0.5	6.2	0.6	0.7	0.0	4.1	2.0	0.7	0.0	0.0	63.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	58.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.1	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	1.5	0.1	63.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	5.8	8.4	0.7	5.6	8.6	4.8	8.3	3.6	7.5	6.2	0.0	1.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	42.8	0.0	0.3	0.0	0.0	0.0	10.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
SIRPA	"BIT, CD172a, MFR, MYD-1, P84, PTPNS1, SHPS-1, SHPS1, SIRP, SIRP-ALPHA-1, SIRPalpha, SIRPalpha2"	ENSG00000198053	"Signal regulatory protein alpha"	P78324	20	1894167-1940592	"CD markers, Plasma proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 69.2"	"Cell type enhanced"	"Detected in many"	6	"Hofbauer cells: 89.1;Macrophages: 65.8;monocytes: 84.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"classical monocyte: 10.1;eosinophil: 20.9;myeloid DC: 6.3;neutrophil: 23.5"	"Group enriched"	"Detected in many"	134	"dendritic cells: 6.3;granulocytes: 23.5;monocytes: 10.1"	"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 42.9;RPTEC TERT1: 31.1;SK-MEL-30: 36.1"									"CAB002776, CAB015122, HPA054437, HPA058511"	Enhanced					NA	NA		170000000			"CAB002776: , CAB015122: AB_677430, HPA054437: AB_2682488, HPA058511: AB_2683738"	"unprognostic (9.78e-2)"	"unprognostic (2.67e-1)"	"unprognostic (3.07e-1)"	"unprognostic (1.23e-1)"	"unprognostic (5.56e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.15e-3)"	"unprognostic (4.19e-3)"	"unprognostic (3.48e-2)"	"unprognostic (2.84e-3)"	"unprognostic (3.69e-1)"	"unprognostic (3.33e-2)"	"unprognostic (2.79e-3)"	"unprognostic (1.08e-1)"	"unprognostic (1.55e-2)"	"unprognostic (3.55e-2)"	"unprognostic (2.24e-2)"	23.2	21.7	36.9	24.9	38.8	19.9	14.0	39.1	69.2	9.5	6.7	22.8	3.0	14.1	6.4	11.2	7.2	9.1	14.6	11.9	29.3	18.5	9.6	16.1	22.0	10.3	18.8	50.3	9.7	6.1	2.2	5.5	13.8	14.7	4.9	8.2	9.5	15.0	8.9	5.5	13.6	11.7	11.4	18.0	9.6	5.2	3.9	20.4	1.0	4.1	2.2	8.8	13.2	6.9	0.0	6.3	23.5	10.1	0.0	0.0	3.4	3.4	7.6	3.8	7.1	9.3	8.8	0.5	18.3	15.6	5.0	1.5	4.8	0.1	0.0	4.4	42.9	13.5	3.5	3.0	21.3	2.1	0.0	2.1	0.0	0.9	2.6	11.2	7.1	8.8	7.8	10.1	4.2	5.2	14.4	15.5	0.0	0.4	4.7	6.7	0.2	0.0	10.0	4.2	0.0	3.4	0.0	6.8	4.7	31.1	0.0	0.5	1.1	2.5	0.0	36.1	1.4	1.2	22.9	23.1	22.2	11.5	14.3	9.0	0.0	0.0	0.0	6.9	23.0	2.5	0.1	10.1	20.9	0.0	2.7	0.0	0.0	0.0	0.0	6.3	0.0	0.0	0.0	23.5	0.0	1.0	0.4	0.0	3.4	36.9	38.8	39.1	68.6	29.3	18.5	18.8	50.3	14.7	20.4	3.0	9.2	1.9	10.4	12.7	9.3	9.7	30.6	4.0	5.7	8.7	13.7	16.4	1.7	22.9	0.5	10.8	3.8	0.0	1.8	1.6	22.0	5.7	17.3	23.1	89.1	14.3	9.2	17.8	49.1	0.4	4.6	65.8	21.9	84.8	3.3	21.8	15.8	6.5	1.8	12.8	25.2	6.5	5.2	0.3	7.9	5.8	30.6	1.0	3.0	6.5
SIRPB1	"CD172b, SIRP-BETA-1"	ENSG00000101307	"Signal regulatory protein beta 1"	"O00241, Q5TFQ8"	20	1563521-1620061	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 137.6"	"Cell type enhanced"	"Detected in some"	19	"Hofbauer cells: 14.8;Kupffer cells: 35.5;Macrophages: 18.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 137.6"	"Group enriched"	"Detected in many"	6	"granulocytes: 137.6;monocytes: 43.6"	"Group enriched"	"Detected in some"	4	"HMC-1: 25.3;NB-4: 33.6;THP-1: 26.0"									HPA047463	Uncertain		Uncertain	Vesicles		NA	NA		33000000	Vesicles		"HPA047463: AB_2680057"	"unprognostic (1.88e-2)"	"unprognostic (6.19e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.24e-1)"	"unprognostic (5.38e-2)"	"unprognostic (1.60e-1)"	"unprognostic (4.40e-2)"	"unprognostic (7.18e-2)"	"unprognostic (4.11e-3)"	"unprognostic (9.12e-2)"	"unprognostic (6.31e-2)"	"unprognostic (4.57e-2)"	"unprognostic (2.65e-3)"	"unprognostic (5.76e-2)"	"unprognostic (2.39e-3)"	"unprognostic (5.00e-3)"	"unprognostic (1.19e-2)"	23.7	1.8	2.3	18.7	5.4	31.9	1.8	2.7	3.2	1.1	1.4	1.9	0.1	1.0	1.0	0.5	0.9	2.5	7.6	7.2	2.3	1.6	1.5	7.5	19.4	19.5	6.6	0.7	1.9	0.9	0.1	1.5	3.8	3.7	1.2	1.2	1.7	1.8	0.6	0.9	0.9	2.6	2.1	7.2	28.7	1.2	1.2	3.9	2.5	0.9	0.4	2.9	4.1	1.9	0.2	15.2	137.6	43.6	0.7	1.0	19.2	0.1	0.0	0.1	0.0	0.1	0.2	0.1	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.3	0.1	3.3	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	6.4	25.3	0.0	0.1	0.1	0.0	3.7	0.2	0.5	0.0	0.1	0.2	0.0	0.0	33.6	0.1	0.0	1.5	0.0	0.0	0.0	5.0	0.1	0.0	0.1	0.1	0.0	0.2	0.0	0.0	26.0	0.7	0.3	0.0	0.2	0.1	0.0	0.0	0.0	0.5	6.1	0.1	0.5	43.6	72.5	0.6	36.3	0.9	0.2	0.6	0.5	15.2	0.2	0.8	0.5	137.6	0.7	29.5	14.5	1.0	19.2	2.3	5.4	2.7	3.2	2.3	1.6	6.6	0.7	3.7	3.9	3.0	6.9	0.5	0.0	0.0	0.2	0.4	0.0	1.4	2.3	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	6.9	0.0	14.8	0.0	0.0	3.1	35.5	0.0	0.0	18.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
SIRPG	"bA77C3.1, CD172g, SIRP-B2, SIRPB2, SIRPgamma"	ENSG00000089012	"Signal regulatory protein gamma"	Q9P1W8	20	1629152-1657779	"CD markers, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 60.1;lymphoid tissue: 44.0"	"Group enriched"	"Detected in some"	14	"Early spermatids: 20.5;Late spermatids: 9.7;T-cells: 18.7"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"T-reg: 60.1"	"Lineage enriched"	"Detected in many"	6	"T-cells: 60.1"	"Cell line enhanced"	"Detected in some"		"hTERT-RPE1: 5.5;JURKAT: 12.1;NB-4: 15.0;RT4: 4.0;THP-1: 2.6"															NA	NA						"unprognostic (3.35e-3)"	"unprognostic (4.09e-3)"	"unprognostic (7.32e-3)"	"prognostic favorable (1.05e-6)"	"unprognostic (4.23e-3)"	"prognostic favorable (2.24e-4)"	"unprognostic (4.49e-2)"	"unprognostic (1.30e-2)"	"prognostic favorable (7.36e-7)"	"unprognostic (1.62e-2)"	"unprognostic (6.90e-2)"	"unprognostic (2.52e-1)"	"prognostic unfavorable (1.47e-6)"	"unprognostic (1.03e-1)"	"unprognostic (2.18e-1)"	"unprognostic (1.40e-2)"	"unprognostic (2.95e-3)"	0.8	0.4	0.3	11.7	0.3	1.5	0.5	0.3	0.4	0.7	2.3	0.1	0.4	0.9	0.5	0.6	1.4	0.7	2.1	0.4	0.3	0.3	1.1	1.1	1.4	20.5	0.3	0.1	0.7	0.4	0.0	0.3	0.4	0.2	0.9	1.8	0.6	4.6	0.9	0.4	0.4	8.8	0.6	0.4	14.0	1.6	0.4	0.1	44.0	1.3	0.7	21.3	2.9	0.8	0.1	1.1	1.0	0.2	9.5	60.1	16.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	1.1	0.0	0.0	0.0	0.0	5.5	0.0	12.1	0.0	0.0	0.0	0.0	0.0	15.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.0	0.0	0.1	0.2	0.1	12.3	0.1	34.1	0.1	38.4	29.0	0.1	0.1	40.5	33.3	1.0	9.5	0.1	1.1	60.1	16.7	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.6	9.7	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	18.7	0.0	0.0
SLAMF1	"CD150, SLAM"	ENSG00000117090	"Signaling lymphocytic activation molecule family member 1"	Q13291	1	160608100-160647295	"CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Adaptive immunity, Cell adhesion, Host-virus interaction, Immunity, Innate immunity, Phagocytosis"	"Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 97.8"	"Cell type enhanced"	"Detected in some"	18	"Melanocytes: 13.5;monocytes: 38.7;T-cells: 20.2"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 24.1"	"Group enriched"	"Detected in many"	10	"B-cells: 8.8;T-cells: 24.1"	"Cell line enriched"	"Detected in single"	111	"HDLM-2: 58.4"									"CAB002438, HPA069319"	Enhanced				"Secreted to blood"	NA	NA		590000			"CAB002438: AB_564011, HPA069319: AB_2732129"	"unprognostic (2.99e-3)"	"unprognostic (3.33e-4)"	"unprognostic (2.93e-4)"	"unprognostic (1.38e-4)"	"unprognostic (5.87e-2)"	"unprognostic (6.06e-5)"	"unprognostic (1.64e-2)"	"unprognostic (1.70e-3)"	"unprognostic (1.69e-2)"	"unprognostic (2.74e-4)"	"unprognostic (6.12e-2)"	"unprognostic (3.58e-1)"	"unprognostic (1.24e-7)"	"unprognostic (2.46e-1)"	"unprognostic (8.46e-2)"	"unprognostic (1.22e-1)"	"unprognostic (2.18e-2)"	2.5	0.3	0.3	14.2	0.3	4.4	1.4	0.2	0.3	1.2	2.3	0.4	0.5	2.2	0.5	1.2	2.2	0.8	2.3	1.3	0.2	0.2	2.0	1.0	4.0	14.8	0.2	0.1	0.6	0.9	0.0	0.5	2.3	0.3	1.1	2.1	0.6	4.1	0.6	0.8	1.1	7.6	1.0	0.5	10.6	2.4	0.4	0.2	97.8	1.5	1.9	26.3	3.5	1.1	8.8	1.6	0.2	0.1	0.0	24.1	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	58.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.5	0.0	0.0	0.1	0.0	4.2	0.0	24.1	6.2	17.2	12.1	0.1	8.8	6.6	1.6	0.2	0.0	0.0	1.6	21.5	3.5	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.1	0.3	0.2	0.0	6.9	8.1	0.1	1.8	0.0	0.2	0.0	0.0	1.2	1.8	0.0	0.0	0.0	0.0	3.0	0.2	0.0	0.0	0.0	0.0	0.1	0.1	1.1	0.0	0.3	0.0	0.0	0.0	1.2	6.2	0.0	5.0	13.5	38.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	1.5	0.1	20.2	0.0	0.0
SLAMF6	"CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000"	ENSG00000162739	"SLAM family member 6"	Q96DU3	1	160485030-160523262	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 28.6;lymphoid tissue: 51.9"	"Cell type enhanced"	"Detected in some"	15	"B-cells: 8.3;Early spermatids: 9.3;Late spermatids: 16.5;T-cells: 20.8"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"Daudi: 33.3;U-698: 49.0"									"HPA051363, HPA051903"	Uncertain		Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA051363: AB_2681454, HPA051903: AB_2681658"	"prognostic favorable (9.42e-4)"	"prognostic favorable (2.78e-4)"	"unprognostic (8.65e-2)"	"prognostic favorable (9.53e-4)"	"unprognostic (5.85e-2)"	"prognostic favorable (7.34e-5)"	"unprognostic (3.16e-3)"	"unprognostic (9.78e-2)"	"prognostic favorable (1.25e-4)"	"unprognostic (2.31e-3)"	"unprognostic (2.09e-1)"	"unprognostic (1.57e-1)"	"prognostic unfavorable (2.09e-6)"	"unprognostic (2.78e-1)"	"unprognostic (1.01e-1)"	"unprognostic (2.33e-2)"	"unprognostic (8.21e-3)"	3.9	0.8	0.4	21.0	0.4	1.2	1.0	0.4	0.4	1.1	3.8	0.3	0.4	1.1	1.0	0.6	2.3	1.6	2.8	1.2	0.4	0.4	2.1	1.6	4.7	51.9	0.6	0.4	0.6	0.8	0.0	0.6	1.7	0.7	1.4	1.5	1.5	5.6	1.0	0.5	0.7	11.9	0.4	0.8	29.6	2.3	0.9	0.2	12.9	1.8	0.6	30.4	4.1	1.3	15.2	0.3	8.4	1.0	15.9	28.6	7.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	33.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	2.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.0	0.3	0.0	0.0	0.0	8.0	0.5	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	5.2	49.0	0.0	0.2	0.0	2.5	0.1	8.4	22.9	0.3	15.8	14.7	14.6	28.6	0.1	15.2	8.2	16.4	1.0	15.9	1.0	0.3	16.8	7.4	0.4	0.4	0.4	0.4	0.4	0.4	0.6	0.4	0.7	0.2	0.0	2.2	8.3	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.3	0.0	0.0	0.0	0.2	0.0	0.0	0.2	1.1	0.8	0.9	0.0	0.0	3.7	3.8	16.5	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	20.8	0.0	0.0
SLAMF7	"19A, CD319, CRACC, CS1"	ENSG00000026751	"SLAM family member 7"	Q9NQ25	1	160739057-160754821	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity, Innate immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 32.9;lymphoid tissue: 45.0"	"Cell type enriched"	"Detected in many"	5	"monocytes: 204.6"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in some"	5	"U-266/70: 80.7"					"Low region specificity"	"Detected in all"			"CAB015445, HPA055945, HPA061654"	Enhanced		Approved	Vesicles		NA	NA		620000	Vesicles		"CAB015445: AB_1121905, HPA055945: AB_2682980, HPA061654: AB_2684576"	"unprognostic (5.82e-3)"	"unprognostic (1.81e-2)"	"unprognostic (1.84e-3)"	"unprognostic (2.12e-3)"	"unprognostic (2.75e-1)"	"unprognostic (1.07e-2)"	"unprognostic (7.87e-2)"	"unprognostic (7.19e-2)"	"unprognostic (2.46e-2)"	"prognostic favorable (3.93e-4)"	"unprognostic (1.08e-1)"	"unprognostic (8.13e-2)"	"prognostic unfavorable (8.57e-5)"	"unprognostic (1.35e-1)"	"unprognostic (3.91e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.50e-2)"	5.5	1.0	0.7	28.6	0.7	2.3	3.4	0.6	0.7	4.1	11.9	0.2	0.4	11.1	1.9	1.3	6.7	1.6	6.2	1.0	0.7	0.7	2.4	3.1	10.2	24.6	0.8	0.4	2.5	2.2	0.0	0.9	1.3	0.6	1.8	10.2	2.9	15.1	4.8	0.9	2.0	15.8	0.8	1.2	45.0	11.0	1.5	0.4	5.9	2.1	4.2	38.7	11.5	2.6	3.7	27.4	1.1	14.9	17.3	32.9	8.7	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.2	0.2	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	2.2	0.0	0.7	0.2	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	2.6	0.0	0.2	0.0	0.0	0.0	0.0	16.1	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	80.7	6.8	0.0	2.2	0.0	0.0	0.0	1.6	0.3	32.9	11.0	25.4	3.7	3.5	22.4	7.2	0.6	1.1	13.6	1.1	17.3	14.9	27.4	0.0	8.7	0.7	0.7	0.6	0.7	0.7	0.7	0.8	0.4	0.6	0.4	8.9	8.9	20.2	1.4	0.7	0.0	0.8	0.0	2.7	1.2	0.0	0.0	0.0	0.0	0.5	0.0	0.3	0.0	23.3	2.3	0.1	1.1	1.8	8.1	0.0	8.9	0.0	0.0	0.6	6.0	0.0	0.0	12.8	18.6	204.6	0.0	0.0	6.2	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.4	0.2	39.5	0.0	3.0
SLAMF8	"BLAME, CD353, SBBI42"	ENSG00000158714	"SLAM family member 8"	Q9P0V8	1	159826750-159837249	"CD markers, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 44.1"	"Group enriched"	"Detected in some"	10	"Hofbauer cells: 37.6;Kupffer cells: 13.7;Macrophages: 31.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"myeloid DC: 12.1"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC TERT1: 4.2;HL-60: 3.6;U-138 MG: 5.0;U-87 MG: 2.8;U-937: 2.6"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			HPA067601	Enhanced					NA	NA					"HPA067601: AB_2685870"	"unprognostic (1.04e-1)"	"unprognostic (8.80e-3)"	"unprognostic (5.12e-2)"	"unprognostic (2.14e-3)"	"unprognostic (3.07e-2)"	"unprognostic (3.22e-2)"	"unprognostic (7.87e-2)"	"unprognostic (4.29e-1)"	"unprognostic (2.20e-2)"	"unprognostic (4.56e-2)"	"unprognostic (6.47e-2)"	"unprognostic (1.77e-1)"	"prognostic unfavorable (5.42e-5)"	"unprognostic (3.50e-1)"	"unprognostic (4.42e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.04e-1)"	16.9	4.6	1.5	20.1	3.4	0.4	5.4	8.2	1.6	3.1	6.0	1.4	0.6	4.6	1.8	4.2	3.1	3.6	6.1	7.1	5.2	1.7	7.8	2.2	19.6	44.1	4.1	0.7	3.8	2.0	0.1	4.2	5.4	5.0	2.7	7.1	3.0	4.2	1.0	2.2	3.1	7.0	5.4	4.1	22.7	3.1	2.4	2.7	9.7	4.8	3.0	12.7	8.6	2.8	0.0	12.1	0.5	6.6	8.1	3.8	2.8	0.0	0.1	0.0	0.0	0.5	4.2	0.0	0.1	0.4	0.0	0.2	0.0	0.0	0.0	0.6	0.3	0.0	0.0	0.0	0.0	0.8	0.0	0.1	1.8	0.0	0.0	0.0	3.6	0.7	1.4	0.0	0.3	0.2	0.0	0.0	0.2	0.0	0.8	0.2	0.0	0.1	1.9	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.8	0.0	1.7	0.0	5.0	0.2	0.0	0.9	0.0	0.0	0.0	2.8	2.6	0.0	0.0	5.1	0.0	3.2	6.6	0.2	0.0	1.1	3.8	12.1	0.0	0.2	2.6	0.5	8.1	0.4	0.1	0.0	2.8	1.5	3.4	8.2	1.6	5.2	1.7	4.1	0.7	5.0	2.7	0.0	2.9	0.0	0.0	1.5	0.2	0.2	0.0	1.4	1.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.7	0.0	0.0	0.0	37.6	0.0	0.0	0.0	13.7	0.0	0.3	31.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.9	0.5	0.8	0.0	0.0
SLC3A2	"4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE"	ENSG00000168003	"Solute carrier family 3 member 2"	P08195	11	62856102-62888875	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Amino-acid transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	7	"Syncytiotrophoblasts: 652.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"hTCEpi: 132.2;SiHa: 134.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010455, HPA017980"	Enhanced		Supported	"Nucleoplasm,Plasma membrane"		NA	NA		210000000	"Plasma membrane"	Nucleoplasm	"CAB010455: AB_638288, HPA017980: AB_2669723"	"unprognostic (1.79e-1)"	"unprognostic (9.61e-3)"	"unprognostic (3.59e-1)"	"unprognostic (7.87e-3)"	"unprognostic (2.06e-1)"	"unprognostic (2.41e-3)"	"prognostic unfavorable (8.17e-4)"	"unprognostic (2.09e-3)"	"unprognostic (2.62e-1)"	"unprognostic (4.16e-2)"	"unprognostic (2.29e-2)"	"unprognostic (3.71e-1)"	"prognostic favorable (8.22e-4)"	"unprognostic (2.92e-2)"	"unprognostic (5.52e-3)"	"unprognostic (3.49e-3)"	"prognostic unfavorable (1.48e-4)"	28.5	30.8	34.6	23.0	36.8	62.4	30.8	18.7	34.8	26.0	26.8	25.3	30.4	34.3	29.2	41.2	31.2	23.8	19.9	14.7	31.3	27.1	71.4	31.8	33.5	17.8	37.8	24.1	29.9	39.2	138.6	19.3	75.5	32.9	28.3	13.9	52.5	39.0	27.5	32.5	32.1	33.8	19.6	38.0	21.9	28.2	33.4	30.8	13.6	33.7	33.4	22.2	20.6	56.6	16.6	73.9	11.6	36.2	20.3	39.8	37.3	16.4	69.3	7.1	22.0	8.6	6.9	65.6	28.6	11.0	15.0	13.3	66.2	31.2	18.1	31.8	16.8	28.7	57.0	12.9	56.2	8.0	32.9	12.2	13.0	50.5	29.2	79.9	15.2	19.0	15.1	132.2	18.3	56.1	5.5	8.7	39.4	25.0	40.1	9.2	79.2	15.6	19.4	11.8	20.5	23.5	16.2	10.7	35.4	10.5	9.2	12.1	5.8	134.7	50.5	97.2	12.0	18.1	19.9	16.0	15.3	22.8	22.4	20.1	49.9	55.3	57.4	15.0	23.9	43.6	8.5	36.2	11.6	30.1	34.8	39.8	14.4	27.7	30.8	22.1	16.6	23.5	25.2	7.5	20.3	27.6	73.9	26.2	37.3	34.6	36.8	18.7	34.7	31.3	27.1	37.8	24.1	32.9	30.8	44.7	40.7	54.9	229.6	193.7	59.3	10.9	20.4	36.1	40.9	47.1	62.8	187.9	28.2	148.4	23.7	94.0	85.3	93.5	129.2	134.7	88.4	145.6	82.0	22.5	178.6	50.9	80.9	70.6	47.5	19.5	28.1	97.7	212.6	153.3	33.1	212.1	128.6	31.6	28.7	161.8	52.2	6.5	137.2	12.6	29.8	131.6	652.9	75.6	40.7	193.5
SLC44A1	"CD92, CDw92, CHTL1, CTL1"	ENSG00000070214	"Solute carrier family 44 member 1"	Q8WWI5	9	105244622-105439171	"CD markers, Predicted membrane proteins, Transporters"	Transport			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	4	"brain: 111.6"	"Cell type enhanced"	"Detected in many"	4	"Cone photoreceptor cells: 221.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 73.5;ASC TERT1: 58.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA064714, HPA074007"	Enhanced		Supported	Nucleoplasm,Mitochondria		NA	NA		270000	Mitochondria	Nucleoplasm	"HPA064714: AB_2685334, HPA074007: "	"unprognostic (3.49e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.27e-1)"	"unprognostic (6.54e-3)"	"unprognostic (4.77e-2)"	"unprognostic (1.74e-2)"	"unprognostic (2.21e-2)"	"prognostic unfavorable (4.49e-4)"	"unprognostic (2.48e-1)"	"unprognostic (1.95e-1)"	"unprognostic (1.64e-3)"	"unprognostic (6.20e-2)"	"prognostic favorable (1.85e-4)"	"unprognostic (2.13e-1)"	"unprognostic (2.07e-1)"	"unprognostic (1.33e-1)"	"unprognostic (2.07e-2)"	8.7	7.4	40.0	6.4	48.8	5.3	14.6	7.2	37.0	9.9	26.7	69.5	10.2	12.0	8.8	18.4	10.1	8.5	11.0	6.9	50.0	29.6	12.0	20.3	9.8	4.6	64.3	21.3	8.0	8.0	20.5	3.9	12.3	38.2	6.6	26.9	4.6	6.0	14.8	4.8	11.4	14.0	9.5	111.6	4.8	18.9	2.3	59.4	2.3	24.0	5.1	7.9	12.4	7.9	2.4	3.7	2.5	5.4	8.7	1.8	1.6	6.9	5.8	1.6	1.9	73.5	58.1	5.0	5.8	15.3	3.8	5.1	6.2	18.5	9.2	3.0	22.0	4.3	13.8	4.7	8.4	6.5	8.0	3.8	11.5	4.1	7.7	4.9	2.2	5.9	32.2	6.9	7.3	6.6	9.8	12.0	4.8	0.3	19.2	4.3	9.8	9.1	2.6	8.9	12.3	5.6	1.9	6.1	6.9	5.2	16.3	7.7	3.0	8.2	9.1	8.2	9.9	9.0	6.9	10.2	3.8	3.4	4.1	4.2	14.8	9.8	6.9	7.4	5.0	5.0	2.5	5.4	1.1	1.1	2.1	0.8	2.0	1.2	0.8	3.7	2.4	1.8	0.6	1.0	8.7	1.2	1.3	1.1	1.6	40.0	48.8	7.2	29.8	50.0	29.6	64.3	21.3	38.2	59.4	32.8	21.6	15.9	31.4	62.7	7.6	9.3	56.0	14.7	9.1	101.2	221.9	44.4	3.3	16.4	2.4	38.4	140.4	0.0	31.4	7.9	49.9	25.3	98.1	132.6	20.0	6.4	151.0	54.0	50.8	2.9	101.8	39.6	70.9	122.6	158.5	6.7	33.4	123.8	75.0	23.3	44.8	38.8	27.0	1.4	1.7	65.0	59.0	15.3	134.8	29.5
SLC4A1	"AE1, CD233, DI, EPB3, FR, RTA1A, SW, WD, WR"	ENSG00000004939	"Solute carrier family 4 member 1 (Diego blood group)"	P02730	17	44248385-44268141	"Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Anion exchange, Ion transport, Transport"	"Blood group antigen"	"Disease mutation, Elliptocytosis, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 95.7;placenta: 32.7"	"Cell type enriched"	"Detected in some"	66	"Erythroid cells: 1261.4"	"Cancer enriched"	"Detected in single"	91	"renal cancer: 16.3"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Region enhanced"	"Detected in single"		"cerebellum: 0.4"	"Low region specificity"	"Detected in all"			"HPA015584, CAB034438, HPA063911"	Enhanced					NA	NA		160000000			"CAB034438: AB_2123479, HPA015584: AB_1844824, HPA063911: AB_2685151"	"unprognostic (1.36e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.36e-1)"	"unprognostic (2.44e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.56e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.59e-1)"	"unprognostic (1.68e-1)"	"unprognostic (1.58e-1)"	"unprognostic (6.72e-3)"	"unprognostic (1.19e-1)"	"unprognostic (9.28e-3)"	"unprognostic (1.93e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.13e-1)"	0.9	0.1	0.3	0.2	0.4	95.7	0.2	0.8	0.2	0.1	0.1	0.6	0.0	0.2	0.1	0.4	0.6	0.2	0.2	2.6	0.2	0.3	18.6	1.3	12.9	0.8	0.6	0.1	2.8	0.1	0.0	0.6	32.7	0.9	0.6	0.1	1.2	0.1	0.1	1.2	0.2	0.1	0.0	1.0	8.4	0.1	0.3	0.0	0.7	1.9	0.0	0.2	3.9	11.8	1.8	1.4	6.3	1.2	2.9	1.5	0.7	1.3	0.5	1.4	1.7	0.6	0.7	1.0	0.3	0.4	0.3	0.8	1.4	3.2	0.7	0.6	0.3	0.4	1.4	0.5	0.5	1.1	1.3	1.3	1.7	1.6	2.2	0.0	0.8	2.3	0.8	0.5	0.8	0.8	0.5	0.2	0.6	4.8	3.5	0.4	0.6	1.0	3.5	0.9	0.7	0.5	2.5	0.7	1.9	0.3	0.8	2.2	1.0	1.3	1.4	0.5	0.7	2.5	1.8	1.0	2.4	2.1	1.4	1.4	1.0	2.3	1.1	1.6	2.2	1.1	6.1	1.0	2.0	1.1	0.9	1.0	1.1	1.0	0.9	0.5	1.8	1.5	1.2	6.3	2.9	1.2	1.4	0.7	0.7	0.3	0.4	0.8	0.2	0.2	0.3	0.6	0.1	0.9	0.0	6.0	1.1	0.0	0.9	0.0	0.4	0.7	0.0	0.0	1.2	19.2	0.0	0.3	3.3	0.0	0.5	0.0	0.0	1261.4	0.0	0.9	0.3	0.4	0.0	0.0	1.3	0.0	0.0	0.6	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.2	0.0	0.0	0.2	0.9	0.4	0.0	0.7	0.0	0.0	0.5
SPN	"CD43, GPL115, LSN"	ENSG00000197471	Sialophorin	P16150	16	29662979-29670876	"CD markers, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"blood: 52.1;bone marrow: 33.1;lung: 25.0;lymphoid tissue: 79.7"	"Group enriched"	"Detected in many"	4	"Alveolar cells type 2: 22.9;Erythroid cells: 23.3;granulocytes: 42.7;Hofbauer cells: 27.4;Kupffer cells: 21.5;Macrophages: 52.4;T-cells: 85.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 52.1"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"HEL: 56.1;HL-60: 49.8;HMC-1: 28.1;K-562: 17.4;MOLT-4: 19.3;REH: 17.4;THP-1: 27.0;U-937: 35.5"									"CAB002666, HPA055244"	Enhanced		Approved	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB002666: , HPA055244: AB_2682756"	"prognostic favorable (1.40e-4)"	"unprognostic (1.63e-3)"	"unprognostic (3.14e-2)"	"prognostic favorable (3.08e-5)"	"unprognostic (2.68e-2)"	"unprognostic (2.49e-3)"	"unprognostic (4.02e-2)"	"unprognostic (4.17e-2)"	"prognostic favorable (1.88e-4)"	"unprognostic (1.70e-1)"	"unprognostic (4.67e-2)"	"unprognostic (2.68e-1)"	"unprognostic (2.61e-2)"	"unprognostic (4.52e-2)"	"unprognostic (4.14e-2)"	"unprognostic (5.85e-2)"	"unprognostic (4.72e-2)"	5.7	1.0	1.2	12.9	2.7	33.1	1.6	0.7	1.5	1.3	2.8	2.6	0.0	2.3	1.5	0.6	1.9	1.7	2.8	3.9	1.2	1.4	1.8	1.9	25.0	18.3	3.7	0.2	1.0	1.6	0.2	1.0	0.8	2.3	1.6	2.6	1.6	5.0	0.6	0.8	1.6	6.8	1.0	4.6	15.9	2.0	0.6	1.9	79.7	1.6	1.7	17.4	2.6	1.4	1.0	8.8	3.5	52.1	17.5	26.5	10.7	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	56.1	0.0	0.4	0.0	49.8	28.1	0.0	0.0	0.0	0.0	0.0	0.0	10.9	17.4	13.7	0.1	0.0	19.3	12.5	0.0	0.0	0.0	17.4	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27.0	0.1	0.0	0.0	0.0	0.0	0.1	1.0	7.3	0.0	35.5	0.0	2.4	5.5	3.5	26.5	24.3	14.5	1.0	10.7	18.1	8.8	0.3	7.6	13.2	0.9	17.5	52.1	7.0	9.1	10.7	1.2	2.7	0.7	1.5	1.2	1.4	3.7	0.2	2.3	1.9	8.9	22.9	9.3	0.5	1.9	0.6	5.1	0.0	2.7	4.5	1.8	0.0	0.2	0.0	0.0	0.0	0.7	0.0	23.3	0.0	0.3	2.6	0.4	42.7	0.9	27.4	1.6	0.0	4.3	21.5	0.0	0.0	52.4	1.7	1.8	0.0	0.4	0.0	0.0	0.0	0.3	1.9	0.0	1.7	0.2	0.6	1.8	0.2	85.3	0.0	0.7
TEK	"CD202b, TIE-2, TIE2, VMCM, VMCM1"	ENSG00000120156	"TEK receptor tyrosine kinase"	Q02763	9	27109141-27230175	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Glaucoma"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	8	"Endothelial cells: 58.3;Ito cells: 110.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"neutrophil: 2.2"	"Lineage enhanced"	"Detected in single"		"granulocytes: 2.2"	"Group enriched"	"Detected in some"	4	"HUVEC TERT2: 36.5;NTERA-2: 18.2;TIME: 39.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010359, HPA073265"	Approved		Supported	"Plasma membrane,Centriolar satellite"	"Secreted to blood"	NA	NA	7750000	8300000	"Plasma membrane"	"Centriolar satellite"	"CAB010359: AB_2203226, HPA073265: AB_2686592"	"unprognostic (2.24e-1)"	"unprognostic (1.74e-1)"	"unprognostic (5.55e-2)"	"unprognostic (1.83e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.26e-3)"	"prognostic favorable (2.31e-5)"	"unprognostic (7.48e-2)"	"unprognostic (1.72e-2)"	"unprognostic (1.41e-1)"	"unprognostic (5.58e-2)"	"unprognostic (2.72e-1)"	"prognostic favorable (7.81e-4)"	"unprognostic (7.50e-3)"	"unprognostic (6.87e-3)"	"unprognostic (1.83e-1)"	"unprognostic (5.24e-3)"	28.6	7.8	8.1	4.6	5.9	0.4	17.9	3.4	5.4	10.8	4.7	4.6	3.4	3.2	14.5	5.3	6.7	5.9	9.1	13.0	7.1	6.1	25.4	8.7	27.8	2.9	6.9	3.4	6.1	4.5	3.5	4.0	36.3	6.9	5.4	4.7	12.4	3.4	5.5	7.8	3.0	5.3	10.6	5.3	23.4	4.0	3.7	3.5	0.3	9.7	8.4	2.4	6.4	12.4	0.0	0.1	2.2	0.6	0.0	0.0	0.0	0.1	0.0	1.4	0.0	0.2	2.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	1.0	0.0	0.7	0.0	0.0	0.7	0.0	0.9	0.3	0.0	36.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	18.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	7.8	0.0	0.0	39.6	0.0	0.2	3.6	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	8.1	5.9	3.4	5.4	7.1	6.1	6.9	3.4	6.9	3.5	3.0	2.2	0.0	0.0	1.3	0.0	7.8	0.0	0.0	1.2	1.8	0.0	0.4	0.0	0.0	0.6	58.3	0.0	0.0	0.0	1.5	2.4	0.2	0.0	0.8	0.2	0.0	0.0	110.5	10.4	0.4	0.6	0.9	0.0	0.0	0.0	0.0	0.7	0.0	0.4	0.0	0.2	0.0	0.4	0.0	0.2	1.1	1.1	0.0	0.0	0.0
TFRC	"CD71, p90, TFR1"	ENSG00000072274	"Transferrin receptor"	P02786	3	196027183-196082189	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"	"Endocytosis, Host-virus interaction"	"Host cell receptor for virus entry, Receptor, Transducer"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 110.0"	"Cell type enhanced"	"Detected in many"	10	"Erythroid cells: 560.6;Syncytiotrophoblasts: 420.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000153, HPA028598"	Enhanced		Supported	Endosomes,Lysosomes	"Secreted to blood"	NA	NA	1310000000	14000000	"Endosomes, Lysosomes"		"CAB000153: AB_2533029, HPA028598: AB_10601599"	"unprognostic (2.95e-2)"	"prognostic unfavorable (3.67e-4)"	"unprognostic (2.55e-1)"	"unprognostic (1.48e-2)"	"unprognostic (6.75e-2)"	"unprognostic (7.88e-3)"	"prognostic unfavorable (1.15e-4)"	"unprognostic (6.92e-2)"	"unprognostic (3.30e-3)"	"unprognostic (4.35e-2)"	"unprognostic (1.34e-2)"	"unprognostic (1.14e-2)"	"unprognostic (3.63e-3)"	"unprognostic (3.65e-2)"	"unprognostic (1.19e-2)"	"prognostic unfavorable (2.96e-4)"	"unprognostic (2.62e-2)"	24.3	11.9	11.9	20.6	11.3	73.8	7.6	9.6	17.8	11.8	25.0	9.5	3.8	11.9	12.1	7.5	18.5	11.7	11.4	18.7	9.5	8.3	15.3	13.6	28.1	8.1	7.4	9.5	50.0	7.8	18.0	6.9	110.0	26.5	7.2	19.4	8.5	8.3	5.0	25.6	9.9	37.4	10.9	13.2	7.9	10.0	8.3	6.1	14.3	7.0	10.5	12.9	11.2	8.0	5.7	7.5	2.2	12.4	1.8	6.5	2.1	22.2	20.2	9.3	18.9	20.6	12.0	58.3	31.8	24.2	22.4	37.2	49.3	20.5	22.8	60.4	11.8	49.0	34.3	31.9	10.5	27.5	109.0	10.8	86.4	17.3	22.9	16.3	70.8	17.5	13.5	10.4	19.3	17.4	6.4	7.4	12.6	36.0	21.9	17.5	20.6	23.2	15.0	28.4	29.3	41.5	12.3	13.8	27.3	20.1	56.3	21.3	8.8	30.7	80.8	7.2	16.1	78.4	14.8	9.5	26.7	21.7	23.3	47.6	6.2	48.1	35.6	31.2	19.2	16.1	0.0	1.6	2.2	2.5	7.9	1.7	5.7	2.7	1.7	3.7	3.2	2.5	1.9	0.3	1.8	12.4	7.5	6.5	2.1	11.9	11.3	9.6	17.8	9.5	8.3	7.4	9.5	26.5	6.1	41.7	27.2	29.6	33.6	53.5	48.1	81.5	45.9	28.1	26.1	19.2	139.4	104.0	0.0	43.1	2.6	17.8	72.1	560.6	36.6	18.5	33.8	15.8	22.0	94.1	70.3	12.7	53.9	6.7	33.3	3.9	10.6	89.7	16.9	72.1	50.0	17.3	38.9	52.6	8.1	9.1	42.4	25.8	34.8	22.3	19.3	31.2	420.4	21.8	70.2	22.9
THBD	CD141	ENSG00000178726	Thrombomodulin	P07204	20	23045633-23049741	"Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins"	"Blood coagulation, Hemostasis"	Receptor	"Disease mutation, Hemolytic uremic syndrome, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	12	"Endothelial cells: 100.4;Leydig cells: 121.1;Peritubular cells: 243.6;Suprabasal keratinocytes: 86.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 17.7"	"Group enriched"	"Detected in many"	7	"dendritic cells: 7.8;granulocytes: 17.7;monocytes: 6.2"	"Cell line enhanced"	"Detected in many"		"ASC diff: 12.8;CAPAN-2: 19.9;EFO-21: 17.3;HaCaT: 16.7;hTCEpi: 22.0;hTERT-RPE1: 11.9;OE19: 14.8;THP-1: 12.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002425, HPA002982"	Supported		Approved	Nucleoplasm,Cytosol		NA	NA	5550000	690000	"Nucleoplasm, Cytosol"		"CAB002425: AB_563497, HPA002982: AB_1078444"	"unprognostic (1.96e-1)"	"unprognostic (2.93e-3)"	"unprognostic (8.70e-2)"	"unprognostic (3.00e-2)"	"unprognostic (3.07e-2)"	"unprognostic (1.88e-1)"	"unprognostic (7.81e-3)"	"unprognostic (4.70e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.52e-2)"	"unprognostic (2.30e-1)"	"unprognostic (5.33e-2)"	"unprognostic (2.23e-2)"	"unprognostic (7.35e-3)"	"unprognostic (3.01e-2)"	"unprognostic (7.58e-3)"	"unprognostic (9.71e-2)"	27.0	6.3	1.4	10.5	6.7	6.9	11.8	1.2	2.7	13.2	14.4	1.4	4.3	2.9	9.7	11.5	21.7	15.8	18.2	24.3	5.0	1.5	7.0	10.0	61.9	26.8	2.5	0.1	10.2	7.2	10.0	10.9	16.4	6.2	6.1	3.3	8.8	6.0	4.2	55.5	32.4	14.1	8.5	7.7	44.4	14.4	15.8	2.4	2.1	18.3	32.2	10.4	14.2	10.4	0.0	7.8	17.7	6.2	1.5	0.0	1.1	5.6	5.0	0.1	0.0	12.8	0.7	0.1	0.1	0.0	0.0	0.0	0.0	19.9	0.0	17.3	1.7	0.8	16.7	0.0	0.9	0.0	0.0	0.0	0.0	0.5	0.0	2.4	0.0	0.1	0.5	22.0	0.3	1.4	11.9	5.6	0.0	2.1	0.0	0.5	0.4	0.0	2.0	0.0	14.8	0.8	0.0	0.0	2.4	0.1	8.1	0.3	0.0	4.7	0.6	8.6	1.6	0.0	12.3	10.9	0.0	0.3	1.6	0.0	0.0	0.0	0.0	1.0	2.9	0.4	0.0	2.8	0.0	0.0	6.2	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.0	17.7	1.5	5.8	7.8	0.0	1.1	1.4	6.7	1.2	2.7	5.0	1.5	2.5	0.1	6.2	2.4	20.8	30.8	2.2	6.9	30.5	0.0	9.0	0.0	2.7	18.2	0.0	0.0	2.5	0.0	1.4	0.7	100.4	0.0	0.0	0.2	35.7	22.8	3.0	7.0	0.8	14.1	0.0	0.0	52.2	38.0	4.5	121.1	62.8	15.1	1.0	0.0	0.0	5.3	0.0	243.6	0.2	0.0	6.5	63.8	0.2	0.9	86.2	35.5	0.0	0.0	32.5
THY1	CD90	ENSG00000154096	"Thy-1 cell surface antigen"	P04216	11	119417378-119424985	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 97.7;smooth muscle: 91.5"	"Cell type enhanced"	"Detected in many"	8	"Fibroblasts: 117.3;Leydig cells: 89.2;Muller glia cells: 84.4;Peritubular cells: 72.9;Proximal tubular cells: 127.2;Smooth muscle cells: 114.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"MAIT T-cell: 1.7"	"Lineage enriched"	"Detected in single"	17	"T-cells: 1.7"	"Cell line enhanced"	"Detected in many"		"ASC diff: 53.5;BJ: 83.7;BJ hTERT+: 93.7;fHDF/TERT166: 146.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003733, CAB068243, CAB068244"	Enhanced		Approved	"Nucleoplasm,Plasma membrane"		NA	NA		9800000	Nucleoplasm	"Plasma membrane"	"CAB068243: AB_2665687, CAB068244: AB_2665688, HPA003733: AB_1846340"	"unprognostic (9.98e-2)"	"unprognostic (2.71e-1)"	"unprognostic (5.13e-2)"	"unprognostic (2.61e-1)"	"prognostic unfavorable (6.87e-4)"	"unprognostic (7.43e-2)"	"unprognostic (1.43e-3)"	"unprognostic (2.38e-2)"	"unprognostic (1.29e-1)"	"unprognostic (2.90e-3)"	"unprognostic (3.38e-2)"	"unprognostic (3.52e-1)"	"prognostic unfavorable (2.40e-6)"	"unprognostic (1.75e-2)"	"unprognostic (1.90e-2)"	"unprognostic (3.03e-2)"	"unprognostic (1.14e-2)"	28.7	5.9	42.0	23.2	72.4	0.4	7.0	17.6	97.7	26.9	9.0	7.2	2.1	3.5	20.3	13.9	9.8	7.5	31.6	4.3	63.4	41.1	46.6	2.6	6.5	10.9	29.8	34.8	3.2	5.0	7.3	5.5	19.1	53.8	4.6	13.6	8.5	2.9	15.7	1.4	4.2	4.6	91.5	9.3	6.7	5.7	4.0	6.9	3.1	12.0	1.0	10.8	36.9	7.2	0.0	0.0	0.0	0.0	0.0	1.7	0.3	0.0	0.3	12.5	0.0	53.5	38.7	0.0	83.7	93.7	30.0	33.3	0.0	0.0	0.0	0.0	146.5	14.5	0.1	0.4	0.1	22.9	7.1	0.0	4.4	1.5	0.0	16.5	0.0	0.0	28.7	0.0	38.1	1.3	41.7	0.0	2.6	0.0	0.0	23.1	0.0	0.0	0.0	20.0	0.0	0.1	0.0	5.9	0.0	0.0	0.0	2.1	5.7	0.0	0.0	0.0	4.0	0.1	0.2	0.0	43.2	14.4	12.4	12.3	0.0	2.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	42.0	72.4	17.6	97.7	63.4	41.1	29.8	34.8	53.8	6.9	0.0	2.6	0.0	0.4	15.8	13.9	0.8	0.0	0.0	0.0	8.7	0.0	1.5	18.3	1.1	0.8	14.3	0.0	0.0	0.0	2.3	117.3	0.2	1.1	0.0	3.6	30.2	0.0	27.0	0.0	0.9	89.2	1.4	16.9	0.0	0.0	84.4	0.5	0.0	72.9	127.2	19.0	32.3	114.6	0.4	0.4	15.4	3.3	0.0	0.0	0.1
TLR1	"CD281, KIAA0012, rsc786"	ENSG00000174125	"Toll like receptor 1"	Q15399	4	38790677-38856817	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	"Hydrolase, Receptor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 43.3;lymphoid tissue: 40.4"	"Cell type enhanced"	"Detected in many"	14	"Hofbauer cells: 14.0;Kupffer cells: 33.2;Macrophages: 18.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 43.3"	"Group enriched"	"Detected in all"	6	"granulocytes: 43.3;monocytes: 13.1"	"Cell line enhanced"	"Detected in many"		"Daudi: 9.6;HUVEC TERT2: 11.0;RPMI-8226: 11.9;U-698: 17.8"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (7.82e-2)"	"unprognostic (3.35e-3)"	"unprognostic (4.02e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.85e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.80e-1)"	"unprognostic (3.88e-1)"	"unprognostic (1.04e-1)"	"unprognostic (3.94e-2)"	"unprognostic (1.76e-1)"	"unprognostic (7.25e-3)"	"unprognostic (4.08e-2)"	"unprognostic (1.91e-2)"	"unprognostic (2.08e-1)"	"unprognostic (3.97e-2)"	10.9	4.6	7.1	17.9	11.4	21.0	5.4	2.0	6.0	3.4	3.7	5.9	0.5	4.2	5.8	3.9	3.2	5.3	6.5	4.0	6.5	3.4	4.6	5.8	9.8	26.4	12.9	2.6	7.4	7.7	1.0	4.2	6.6	10.6	3.9	4.6	2.2	11.0	2.5	1.7	3.1	6.7	6.5	19.4	40.4	4.2	1.6	10.9	10.1	2.4	1.7	13.1	6.3	2.8	2.3	4.5	43.3	13.1	1.8	1.1	2.4	0.2	1.7	0.1	0.0	0.2	1.3	0.0	0.0	0.4	0.1	1.0	0.2	4.7	9.6	1.0	0.0	4.7	0.3	0.1	1.2	0.2	1.1	0.5	1.2	0.4	0.0	0.0	1.8	0.5	0.4	0.2	0.4	0.0	0.4	11.0	0.2	1.3	2.9	1.4	0.0	0.4	3.9	0.0	0.0	0.0	6.5	0.1	11.9	1.1	0.0	0.0	1.4	0.0	0.1	0.4	0.1	0.1	2.3	2.8	1.0	0.4	0.1	0.6	1.1	0.1	17.8	2.5	6.6	0.3	0.0	6.8	2.6	1.0	10.4	0.8	2.3	1.1	0.8	4.5	2.0	1.1	0.6	43.3	1.8	13.1	1.5	0.4	2.4	7.1	11.4	2.0	6.0	6.5	3.4	12.9	2.6	10.6	10.9	0.0	1.0	6.4	0.5	0.2	0.2	0.0	0.0	8.1	2.3	1.8	0.0	0.1	1.7	3.9	0.0	2.1	0.2	0.0	3.8	0.2	0.7	1.0	3.5	2.5	14.0	0.0	0.0	0.0	33.2	0.0	0.0	18.2	0.0	2.8	0.3	1.7	1.9	0.0	2.5	1.2	0.2	0.0	0.0	0.1	0.1	0.5	0.1	4.4	1.5	0.9
TLR10	CD290	ENSG00000174123	"Toll like receptor 10"	Q9BXR5	4	38772239-38782990	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	"Hydrolase, Receptor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"blood: 23.5;brain: 11.3;intestine: 11.2;lymphoid tissue: 31.6"	"Cell type enriched"	"Detected in some"	18	"B-cells: 39.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"memory B-cell: 23.5;naive B-cell: 14.9"	"Lineage enriched"	"Detected in many"	6	"B-cells: 23.5"	"Group enriched"	"Detected in some"	55	"Daudi: 38.2;REH: 12.8;U-698: 13.7"					"Low region specificity"	"Detected in all"			HPA066755			Approved	Centrosome,Cytosol		NA	NA			Cytosol	Centrosome	"HPA066755: "	"unprognostic (5.41e-5)"	"unprognostic (2.41e-4)"	"unprognostic (1.91e-3)"	"unprognostic (8.22e-4)"	"unprognostic (6.48e-2)"	"unprognostic (9.98e-4)"	"unprognostic (9.31e-2)"	"unprognostic (8.76e-3)"	"unprognostic (4.08e-3)"	"unprognostic (7.26e-2)"	"unprognostic (8.76e-2)"	"unprognostic (6.90e-2)"	"unprognostic (2.98e-3)"	"unprognostic (3.90e-1)"	"unprognostic (1.81e-2)"	"unprognostic (3.14e-3)"	"unprognostic (1.88e-2)"	0.8	0.5	4.2	24.5	9.4	0.9	0.6	0.6	3.5	0.6	1.0	2.5	0.0	0.9	0.5	0.3	1.7	0.9	1.0	0.5	3.2	1.8	0.8	0.7	1.2	27.0	5.5	0.5	0.5	0.6	0.1	0.7	0.2	4.8	0.8	1.4	0.0	2.6	0.3	0.5	0.5	11.2	0.3	11.3	24.4	1.8	0.4	7.4	2.7	0.9	0.0	31.6	3.2	0.6	23.5	4.0	0.7	1.8	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	38.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	12.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	13.7	0.0	0.0	0.0	0.1	0.2	0.4	0.0	1.5	0.0	23.5	0.0	0.0	3.6	14.9	0.0	0.0	0.7	0.0	1.8	4.0	0.0	0.9	4.2	9.4	0.6	3.5	3.2	1.8	5.5	0.5	4.8	7.4	0.0	1.4	39.2	0.1	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	1.1	0.0	0.7	0.0	1.2	0.6	2.2	0.0	0.0	1.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1
TLR2	"CD282, TIL4"	ENSG00000137462	"Toll like receptor 2"	O60603	4	153684070-153705702	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	"Hydrolase, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 72.9"	"Group enriched"	"Detected in many"	5	"Alveolar cells type 2: 64.7;Kupffer cells: 106.5;Macrophages: 52.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 29.5;intermediate monocyte: 28.1;myeloid DC: 19.1;neutrophil: 72.9;non-classical monocyte: 18.4"	"Group enriched"	"Detected in many"	46	"dendritic cells: 19.1;granulocytes: 72.9;monocytes: 29.5"	"Cell line enhanced"	"Detected in some"		"HL-60: 6.9;HSkMC: 7.5;hTCEpi: 7.5;RPTEC TERT1: 7.7;RT4: 9.5;THP-1: 36.3;U-937: 6.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA060231, HPA071546"			Supported	Nucleoplasm,Mitochondria		No	NA			"Nucleoplasm, Mitochondria"		"HPA060231: , HPA071546: "	"unprognostic (4.15e-1)"	"unprognostic (3.29e-2)"	"unprognostic (5.32e-2)"	"unprognostic (1.52e-2)"	"unprognostic (3.46e-2)"	"unprognostic (4.88e-2)"	"unprognostic (1.39e-2)"	"unprognostic (4.24e-2)"	"unprognostic (2.48e-1)"	"unprognostic (2.02e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.33e-1)"	"prognostic unfavorable (1.11e-4)"	"unprognostic (7.87e-2)"	"unprognostic (3.80e-3)"	"unprognostic (1.42e-1)"	"unprognostic (5.93e-3)"	16.3	6.9	6.9	30.0	11.1	34.6	7.3	1.4	5.3	4.7	4.7	3.0	9.3	2.2	3.1	8.0	3.2	7.2	10.0	7.2	6.7	3.3	9.8	7.3	31.1	37.8	12.4	1.4	4.2	5.1	1.1	4.4	6.4	9.9	5.5	1.9	3.3	15.0	9.9	2.5	3.1	4.0	6.6	21.9	29.3	3.9	4.8	9.5	0.9	3.3	1.0	8.5	7.3	3.5	0.2	19.1	72.9	29.5	0.8	0.2	9.3	4.0	0.0	0.2	0.0	0.5	1.6	0.0	0.0	0.3	0.3	0.5	1.9	0.2	0.0	0.4	0.0	0.0	3.6	0.4	0.3	0.2	0.0	0.0	0.1	0.0	0.4	0.0	6.9	0.5	7.5	7.5	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.4	0.0	1.6	0.1	0.0	0.0	7.7	9.5	0.0	0.2	0.4	0.0	1.8	0.2	0.0	36.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	6.9	0.9	6.2	29.5	0.2	0.0	28.1	0.0	0.0	0.1	0.0	19.1	0.2	0.2	0.0	72.9	0.8	18.4	0.1	0.0	9.3	6.9	11.1	1.4	5.3	6.7	3.3	12.4	1.4	9.9	9.5	6.0	64.7	0.8	1.1	1.0	0.0	1.2	5.1	2.7	12.5	3.5	0.0	0.1	0.0	4.8	0.3	0.6	0.0	0.0	3.2	0.1	0.9	2.0	3.5	0.9	16.3	0.0	0.0	2.5	106.5	0.0	0.6	52.5	1.7	0.0	0.1	0.0	3.1	0.0	0.4	1.0	0.3	12.9	0.4	0.2	0.4	1.0	0.1	0.7	0.0	1.4
TLR3	CD283	ENSG00000164342	"Toll like receptor 3"	O15455	4	186069152-186088069	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	"Receptor, RNA-binding"	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 48.1"	"Cell type enhanced"	"Detected in many"	8	"Early spermatids: 46.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 7.6;memory CD8 T-cell: 8.0"	"Group enriched"	"Detected in many"	7	"dendritic cells: 2.5;T-cells: 8.0"	"Cell line enhanced"	"Detected in many"		"ASC diff: 11.6;ASC TERT1: 12.1;BJ hTERT+ SV40 Large T+ RasG12V: 18.0;CAPAN-2: 28.0;HSkMC: 11.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB025658	Enhanced				"Intracellular and membrane"	NA	NA					"CAB025658: "	"unprognostic (2.13e-2)"	"unprognostic (2.15e-1)"	"unprognostic (7.26e-2)"	"unprognostic (7.47e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.81e-1)"	"unprognostic (6.39e-3)"	"unprognostic (1.56e-2)"	"unprognostic (9.28e-2)"	"unprognostic (2.25e-2)"	"prognostic unfavorable (3.09e-4)"	"unprognostic (1.17e-1)"	"unprognostic (4.72e-3)"	"unprognostic (1.18e-1)"	"unprognostic (4.52e-3)"	"unprognostic (3.89e-2)"	"unprognostic (1.83e-1)"	11.9	10.7	3.1	6.8	5.0	0.0	11.1	1.7	3.5	9.9	20.1	3.0	6.8	13.4	5.6	7.3	12.9	7.8	8.6	7.7	3.5	2.6	12.4	11.2	12.2	1.0	3.3	1.9	8.9	8.2	4.8	2.7	48.1	3.0	11.3	9.5	5.0	8.5	10.2	2.3	3.8	34.9	6.5	8.0	7.0	8.2	5.8	4.2	1.2	11.8	7.6	3.0	10.3	14.6	0.0	2.5	0.5	0.0	0.7	8.0	1.1	1.9	0.5	0.3	0.0	11.6	12.1	0.9	0.1	8.4	5.1	18.0	0.0	28.0	0.0	1.1	1.2	10.2	2.9	0.0	5.8	0.9	10.7	0.1	1.7	0.5	0.0	5.1	1.8	0.7	11.9	2.2	6.8	0.3	3.1	2.4	1.8	0.0	0.0	2.9	0.0	2.0	0.0	0.9	0.0	1.0	2.6	0.0	0.1	4.9	2.7	0.0	0.1	1.5	1.2	2.3	0.1	0.3	0.0	1.7	0.9	0.6	0.0	1.2	0.0	0.0	0.0	2.4	1.2	2.0	0.5	0.0	0.0	7.6	0.0	4.3	0.0	1.8	8.0	2.5	0.0	1.2	3.9	0.3	0.7	0.0	0.0	0.2	1.1	3.1	5.0	1.7	3.5	3.5	2.6	3.3	1.9	3.0	4.2	17.9	5.6	1.3	3.2	3.4	0.0	0.8	17.8	2.7	11.4	14.0	0.0	16.9	0.0	6.4	46.2	3.2	14.4	0.0	8.7	4.6	4.0	2.6	2.3	6.4	2.3	0.0	1.2	6.7	0.3	3.8	7.8	2.5	0.0	0.0	6.7	3.8	6.2	8.6	3.5	5.4	0.4	0.0	1.4	0.0	0.4	0.9	16.4	0.0	4.5	5.0
TLR4	"ARMD10, CD284, hToll, TLR-4"	ENSG00000136869	"Toll like receptor 4"	O00206	9	117704175-117724730	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Immunity, Inflammatory response, Innate immunity"	"Hydrolase, Receptor"	"Age-related macular degeneration, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	15	"Hofbauer cells: 31.7;Ito cells: 59.5;Kupffer cells: 88.0;Macrophages: 33.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 30.1"	"Group enriched"	"Detected in many"	30	"dendritic cells: 7.5;granulocytes: 30.1;monocytes: 21.4"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 29.6;TIME: 21.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB004025, HPA049174"	Approved		Supported	"Golgi apparatus,Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"	"Golgi apparatus"	"CAB004025: , HPA049174: AB_2680662"	"unprognostic (1.60e-1)"	"unprognostic (8.34e-2)"	"unprognostic (7.22e-2)"	"prognostic favorable (6.29e-4)"	"unprognostic (3.39e-1)"	"unprognostic (7.48e-2)"	"unprognostic (8.68e-2)"	"unprognostic (1.80e-1)"	"unprognostic (3.38e-1)"	"unprognostic (5.18e-2)"	"unprognostic (8.00e-2)"	"unprognostic (9.42e-2)"	"unprognostic (4.08e-2)"	"unprognostic (8.63e-2)"	"prognostic unfavorable (3.79e-4)"	"unprognostic (1.09e-2)"	"unprognostic (1.96e-2)"	29.2	12.1	15.5	23.5	12.5	17.8	21.9	9.4	10.3	6.9	6.8	10.6	3.0	4.4	5.8	7.7	5.0	6.8	10.6	10.9	19.9	7.5	9.0	16.5	16.0	30.9	12.4	11.4	6.7	3.0	2.9	3.8	22.8	10.5	5.7	7.4	7.2	9.0	3.6	7.4	5.2	6.6	10.4	11.1	41.4	4.5	2.4	13.0	1.1	8.3	5.6	7.5	12.1	16.1	0.6	7.5	30.1	21.4	0.0	0.0	6.9	0.0	0.0	12.7	0.0	5.9	12.0	0.1	5.0	8.8	1.3	0.7	0.0	1.2	1.7	0.2	13.0	3.9	0.0	0.0	1.1	1.9	0.0	0.0	2.7	2.7	0.1	4.4	9.1	0.0	7.4	0.0	2.8	0.3	11.4	15.5	0.0	0.0	29.6	15.4	0.0	0.0	1.8	1.5	1.2	0.6	0.0	14.3	9.3	0.5	14.8	0.0	0.0	3.2	0.0	0.5	1.2	0.0	5.0	21.4	0.7	9.6	0.0	2.4	0.0	0.0	0.0	0.4	9.6	7.6	17.6	21.4	7.2	0.0	19.6	0.0	0.6	0.0	0.0	7.5	0.2	0.0	0.0	30.1	0.0	20.2	0.3	0.0	6.9	15.5	12.5	9.4	10.3	19.9	7.5	12.4	11.4	10.5	13.0	0.0	5.3	1.5	0.1	0.7	0.2	2.5	5.1	2.7	4.5	0.0	0.0	0.2	0.0	0.0	0.0	19.7	0.3	0.0	0.2	0.2	1.9	0.2	15.1	1.8	31.7	0.0	0.0	59.5	88.0	0.0	0.0	33.1	1.7	0.0	0.6	13.8	0.3	1.7	0.0	0.4	0.8	6.5	0.9	0.0	0.2	0.0	0.7	0.0	0.1	2.2
TLR6	CD286	ENSG00000174130	"Toll like receptor 6"	Q9Y2C9	4	38823715-38856817	"CD markers, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	"Hydrolase, Receptor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 14.2;brain: 16.0;lymphoid tissue: 16.2"	"Cell type enhanced"	"Detected in some"	12	"B-cells: 5.0;Hofbauer cells: 5.9;Kupffer cells: 11.8;Macrophages: 9.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	5	"neutrophil: 14.2"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 14.2"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 12.5;GAMG: 12.9;RPMI-8226: 9.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA062733			Approved	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA062733: AB_2684853"	"unprognostic (9.82e-2)"	"unprognostic (4.76e-2)"	"unprognostic (3.30e-2)"	"unprognostic (3.05e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.87e-2)"	"unprognostic (1.83e-1)"	"unprognostic (4.45e-2)"	"unprognostic (9.26e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.05e-2)"	"unprognostic (2.69e-1)"	"unprognostic (7.62e-7)"	"unprognostic (4.89e-2)"	"unprognostic (1.02e-2)"	"unprognostic (7.78e-2)"	"unprognostic (2.12e-2)"	2.9	2.7	6.1	10.7	7.9	6.4	2.1	2.0	3.9	1.8	1.6	2.6	0.2	1.7	1.4	2.0	1.8	1.9	3.9	1.5	4.5	1.7	1.7	2.1	5.0	11.2	10.6	1.9	1.6	1.2	0.7	1.9	2.8	7.2	1.6	2.4	0.9	4.3	0.5	0.9	1.7	7.8	2.1	16.0	16.2	2.1	0.8	6.8	1.8	1.5	1.1	14.8	5.8	1.9	1.8	1.8	14.2	2.6	0.3	0.4	0.6	1.4	5.7	0.2	0.1	0.3	6.7	0.0	1.6	6.9	0.7	2.3	0.0	12.5	6.9	2.7	0.3	12.9	0.6	0.1	1.2	1.1	0.0	0.5	3.2	6.9	0.2	0.4	3.5	5.2	2.8	1.3	2.8	1.5	0.2	1.4	1.1	3.5	2.2	3.1	0.0	0.0	6.1	0.2	0.0	0.9	3.4	3.1	9.8	0.4	0.1	0.0	0.1	0.2	0.0	0.9	0.3	0.3	1.8	1.9	2.2	7.5	0.9	2.4	0.1	0.0	5.8	5.1	4.1	1.6	0.0	2.6	0.7	0.2	2.4	0.0	1.8	0.1	0.1	1.8	1.2	0.3	0.2	14.2	0.3	1.2	1.3	0.4	0.6	6.1	7.9	2.0	3.9	4.5	1.7	10.6	1.9	7.2	6.8	0.0	0.0	5.0	1.1	0.6	0.7	1.2	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.0	0.0	0.2	0.2	0.8	0.8	2.3	0.0	5.9	0.0	0.0	0.6	11.8	0.0	0.6	9.5	0.0	1.8	0.0	0.0	0.2	0.0	0.7	0.0	0.1	0.0	0.4	0.2	0.0	0.6	0.2	0.0	0.0	0.9
TLR8	CD288	ENSG00000101916	"Toll like receptor 8"	Q9NR97	X	12906620-12923169	"CD markers, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 17.8;lymphoid tissue: 45.6"	"Group enriched"	"Detected in some"	6	"Kupffer cells: 48.1;Macrophages: 13.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	94	"classical monocyte: 10.0;intermediate monocyte: 9.6;myeloid DC: 5.3;neutrophil: 17.8;non-classical monocyte: 9.2"	"Group enriched"	"Detected in many"	100	"dendritic cells: 5.3;granulocytes: 17.8;monocytes: 10.0"	"Cell line enhanced"	"Detected in some"		"HMC-1: 1.2;PC-3: 2.8;THP-1: 1.3"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			HPA001608	Enhanced					NA	NA					"HPA001608: AB_1080295"	"unprognostic (1.32e-1)"	"unprognostic (6.94e-2)"	"unprognostic (3.96e-3)"	"unprognostic (4.43e-2)"	"unprognostic (9.63e-2)"	"unprognostic (2.48e-2)"	"unprognostic (2.59e-1)"	"unprognostic (6.61e-2)"	"unprognostic (1.93e-1)"	"unprognostic (2.23e-1)"	"unprognostic (3.72e-2)"	"unprognostic (2.73e-1)"	"unprognostic (1.74e-2)"	"unprognostic (1.03e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.52e-1)"	"unprognostic (5.66e-2)"	8.5	1.4	0.9	16.0	1.5	4.7	1.2	0.7	1.1	1.0	1.5	0.4	0.0	0.6	1.0	3.2	1.0	2.0	2.4	3.0	2.0	1.0	2.0	4.0	13.7	33.0	1.7	0.1	1.1	1.0	0.2	1.0	4.0	1.9	1.4	1.7	0.9	1.2	0.0	1.4	0.8	2.0	3.5	3.3	45.6	1.3	1.2	1.6	3.5	1.0	1.1	2.4	4.2	2.4	0.1	5.3	17.8	10.0	0.0	0.0	2.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	2.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.3	0.0	0.1	0.2	0.0	0.4	0.2	0.0	0.0	0.3	0.0	0.0	10.0	0.0	0.0	9.6	0.0	0.1	0.0	0.0	5.3	0.0	0.0	0.0	17.8	0.0	9.2	0.0	0.0	2.0	0.9	1.5	0.7	1.1	2.0	1.0	1.7	0.1	1.9	1.6	0.0	4.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	5.0	0.0	0.0	0.6	48.1	0.0	0.0	13.2	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TLR9	CD289	ENSG00000239732	"Toll like receptor 9"	Q9NR96	3	52221080-52226163	"CD markers, FDA approved drug targets, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"blood: 33.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Cell type enriched"	"Detected in some"	10	"plasmacytoid DC: 33.8"	"Lineage enriched"	"Detected in many"	10	"dendritic cells: 33.8"	"Group enriched"	"Detected in some"	12	"Daudi: 24.7;RPMI-8226: 15.7;U-698: 9.5"															NA	NA						"unprognostic (6.03e-2)"	"unprognostic (5.08e-2)"	"unprognostic (3.58e-3)"	"unprognostic (6.69e-7)"	"unprognostic (1.16e-1)"	"unprognostic (1.89e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.58e-1)"	"unprognostic (7.02e-2)"	"unprognostic (1.89e-1)"	"unprognostic (4.40e-2)"	"unprognostic (7.60e-2)"	"unprognostic (2.65e-3)"	"unprognostic (2.44e-2)"	"unprognostic (3.70e-1)"	"unprognostic (2.27e-1)"	"unprognostic (7.91e-3)"	0.5	0.2	0.0	2.8	0.5	2.5	0.4	4.9	0.4	0.8	1.2			0.7	0.9	0.0	0.2	1.0	0.9	0.3	0.2	0.3	0.3	0.1	0.6	6.5	0.1		2.5	0.0	0.0	0.3	0.1		0.9	0.1		1.4	0.4	1.8	0.1	2.2	0.1	0.4	3.9	0.5	0.3			0.7		3.9	1.2	1.2	3.3	33.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.5	0.0	0.1	0.0	0.0	1.3	0.2	0.0	0.0	0.0	0.0	0.0	15.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	1.0	0.7	9.5	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	33.8	0.0	0.1											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TNFRSF10A	"Apo2, CD261, DR4, TRAILR-1, TRAILR1"	ENSG00000104689	"TNF receptor superfamily member 10a"	O00220	8	23190452-23225126	"Cancer-related genes, CD markers, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Suprabasal keratinocytes: 24.0;Urothelial cells: 27.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"											"HPA050958, HPA054475"	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA050958: AB_2681290, HPA054475: AB_2682500"	"unprognostic (3.66e-1)"	"unprognostic (1.02e-1)"	"unprognostic (2.19e-2)"	"unprognostic (4.89e-2)"	"unprognostic (9.44e-2)"	"unprognostic (8.39e-2)"	"unprognostic (5.32e-2)"	"unprognostic (2.18e-2)"	"unprognostic (2.72e-1)"	"unprognostic (4.48e-2)"	"prognostic unfavorable (1.00e-4)"	"unprognostic (1.49e-1)"	"unprognostic (1.99e-3)"	"unprognostic (1.91e-2)"	"unprognostic (1.61e-2)"	"unprognostic (2.35e-1)"	"unprognostic (2.87e-1)"	11.9	4.0	2.1	13.0	3.4	8.4	9.7	2.0	2.8	6.0	10.9	1.4	4.5	5.9	5.3	5.6	13.6	4.1	12.7	6.3	2.2	2.0	10.9	10.6	11.0	12.4	3.0	0.7	2.7	12.9	3.6	1.8	6.9	4.0	5.1	7.2	2.1	8.2	4.3	3.8	7.1	10.2	3.8	2.9	13.2	6.1	2.6	3.0	9.5	5.8	14.9	25.4	6.7	8.7	13.2	4.5	3.8	4.3	3.9	13.9	4.2	8.0	14.5	0.7	0.0	0.5	3.0	0.0	1.6	1.0	0.8	2.4	11.2	14.2	18.6	19.0	1.0	4.1	15.3	13.1	20.8	1.4	4.6	0.1	9.8	8.8	6.3	7.5	5.2	9.4	5.0	17.2	18.5	16.0	2.5	9.8	0.6	15.1	6.7	3.9	6.3	0.2	3.3	10.1	14.3	8.9	0.1	0.0	13.4	11.1	17.4	0.4	0.5	4.1	10.3	0.0	3.2	5.5	4.0	13.8	0.0	0.1	0.8	0.0	7.9	11.1	14.4	0.1	1.7	0.2	2.0	4.3	3.8	3.8	1.9	10.3	10.4	12.3	7.7	4.5	13.2	12.1	7.0	0.5	3.9	1.7	0.0	13.9	4.2	2.1	3.4	2.0	2.8	2.2	2.0	3.0	0.7	4.0	3.0	3.0	8.3	6.4	16.2	20.9	0.1	0.8	12.7	6.7	19.4	10.4	0.0	0.1	0.0	9.2	0.0	11.8	6.2	0.0	3.5	0.4	1.3	10.0	7.0	4.0	3.0	0.0	2.4	1.3	2.1	0.0	0.0	7.1	3.3	1.8	6.0	0.0	14.3	7.4	0.0	2.4	0.0	0.0	1.1	0.0	0.2	24.0	0.0	2.9	6.3	27.1
TNFRSF10B	"CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB"	ENSG00000120889	"TNF receptor superfamily member 10b"	O14763	8	23020133-23069179	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"											HPA023625	Approved					NA	NA					"HPA023625: AB_1847860"	"unprognostic (8.43e-3)"	"unprognostic (7.43e-3)"	"unprognostic (3.04e-2)"	"unprognostic (4.94e-3)"	"unprognostic (1.13e-1)"	"unprognostic (7.74e-2)"	"unprognostic (2.15e-1)"	"unprognostic (9.51e-3)"	"unprognostic (2.70e-1)"	"unprognostic (2.82e-2)"	"unprognostic (2.30e-3)"	"unprognostic (1.96e-2)"	"prognostic unfavorable (1.76e-4)"	"unprognostic (4.01e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.86e-1)"	"unprognostic (5.52e-2)"	29.6	18.5	5.2	16.4	7.3	7.6	19.6	2.3	5.8	11.5	23.1	7.5	13.3	14.1	10.4	13.9	12.1	11.4	22.1	13.2	6.4	3.2	14.3	36.1	21.3	11.6	7.9	2.6	16.2	20.0	14.8	6.1	8.5	8.2	15.1	14.3	7.9	11.5	14.5	15.5	6.1	31.2	10.5	8.6	17.4	11.2	7.8	6.4	4.1	17.7	13.0	15.2	17.9	9.9	3.1	12.1	2.8	12.9	0.8	4.0	5.2	8.6	22.9	33.6	10.3	15.8	20.6	33.0	20.9	26.8	11.3	17.7	9.5	8.7	5.1	14.2	11.3	21.1	8.4	8.8	39.4	20.3	5.1	7.4	0.0	9.0	17.8	52.9	1.9	8.7	30.7	35.4	25.2	26.9	29.0	35.9	6.4	3.6	0.0	22.3	2.8	0.2	2.8	8.4	11.1	8.3	4.6	12.2	3.2	22.0	13.6	0.0	5.7	10.4	3.0	11.1	23.6	5.1	2.5	31.8	16.6	8.6	5.2	15.0	6.7	1.1	2.4	16.9	3.8	23.7	2.8	12.9	0.4	1.6	9.3	2.7	3.1	1.9	1.6	12.1	1.6	4.0	1.6	2.6	0.8	11.9	0.0	1.3	5.2	5.2	7.3	2.3	5.8	6.4	3.2	7.9	2.6	8.2	6.4	11.9	35.2	11.9	24.4	28.0	0.4	3.6	12.7	5.3	17.0	12.2	0.0	3.4	3.3	25.5	0.2	30.1	34.4	0.0	23.0	7.4	22.8	23.9	9.2	23.1	8.8	0.0	0.0	15.4	20.8	1.5	6.6	18.8	18.6	2.8	15.3	3.9	37.2	19.3	6.3	8.2	0.4	0.0	18.9	0.2	2.0	15.8	3.5	6.9	19.1	42.3
TNFRSF10C	"CD263, DcR1, LIT, TRAILR3, TRID"	ENSG00000173535	"TNF receptor superfamily member 10c"	O14798	8	23102590-23117437	"Cancer-related genes, CD markers, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"blood: 173.4"	"Cell type enhanced"	"Detected in some"	8	"Alveolar cells type 1: 6.0;Alveolar cells type 2: 9.3;Cholangiocytes: 5.1;granulocytes: 8.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	7	"neutrophil: 173.4"	"Lineage enriched"	"Detected in many"	113	"granulocytes: 173.4"	"Group enriched"	"Detected in some"	5	"BEWO: 37.9;HUVEC TERT2: 31.6"									CAB025635	Enhanced					NA	NA	14600000				"CAB025635: "	"unprognostic (2.63e-1)"	"unprognostic (4.49e-3)"	"unprognostic (7.21e-3)"	"unprognostic (2.07e-2)"	"unprognostic (3.55e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.81e-2)"	"unprognostic (2.11e-3)"	"unprognostic (5.56e-2)"	"unprognostic (4.37e-2)"	"unprognostic (8.98e-2)"	"unprognostic (1.94e-3)"	"unprognostic (2.74e-3)"	"unprognostic (4.83e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.34e-3)"	"unprognostic (6.54e-2)"	5.5	1.5	1.9	14.0	3.6	12.6	2.0	1.4	3.9	2.9	1.5	0.7	0.1	1.2	1.5	1.2	1.4	3.7	13.5	5.6	1.9	1.1	2.8	3.2	13.7	28.4	9.2	0.0	2.4	2.1	2.5	4.5	12.8	3.1	2.7	1.8	1.7	1.7	0.8	2.3	0.8	2.2	1.9	4.4	26.4	1.8	1.4	2.3	0.8	4.4	0.5	0.9	5.2	1.9	0.0	0.3	173.4	1.5	0.0	0.0	0.4	0.4	1.4	0.5	2.4	0.0	0.4	37.9	1.6	0.0	0.1	0.2	0.0	1.4	0.1	0.8	1.4	0.1	0.2	0.1	0.1	0.1	2.6	0.5	0.1	0.3	1.1	3.7	0.2	1.0	4.2	0.3	0.7	0.3	0.6	31.6	0.0	0.0	0.0	0.2	1.0	0.0	0.9	1.6	0.3	0.1	0.1	0.1	0.0	6.1	0.1	0.0	0.1	0.1	0.2	0.7	2.9	5.2	0.2	6.7	0.6	1.2	1.5	0.1	1.6	0.9	0.0	2.3	0.3	0.9	2.7	1.5	25.4	0.0	0.8	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	173.4	0.0	1.1	0.0	0.0	0.4	1.9	3.6	1.4	3.9	1.9	1.1	9.2	0.0	3.1	2.3	6.0	9.3	0.0	0.5	0.2	0.0	0.3	5.1	1.4	3.4	3.5	0.0	0.8	0.0	0.3	0.8	3.6	0.4	0.0	0.4	0.7	0.3	0.4	8.1	0.0	2.1	0.0	1.7	1.8	1.5	0.0	0.0	2.2	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.9	0.1	0.9	0.0	0.0	0.3
TNFRSF10D	"CD264, DcR2, TRAILR4, TRUNDD"	ENSG00000173530	"TNF receptor superfamily member 10d"	Q9UBN6	8	23135588-23164030	"Cancer-related genes, CD markers, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Endothelial cells: 31.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 9.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 24.5;LHCN-M2: 61.9;WM-115: 58.8"									HPA070971			Approved	"Plasma membrane,Actin filaments"		NA	NA			"Plasma membrane, Actin filaments"		"HPA070971: AB_2686330"	"unprognostic (1.49e-1)"	"prognostic unfavorable (1.70e-4)"	"unprognostic (1.41e-1)"	"unprognostic (8.78e-2)"	"unprognostic (8.13e-2)"	"unprognostic (7.49e-2)"	"unprognostic (2.69e-1)"	"unprognostic (7.06e-2)"	"unprognostic (3.56e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.61e-2)"	"unprognostic (1.32e-1)"	"unprognostic (2.12e-2)"	"unprognostic (2.70e-1)"	"unprognostic (1.35e-2)"	"unprognostic (6.32e-2)"	"unprognostic (1.72e-1)"	16.0	3.1	4.9	7.3	10.0	10.5	10.2	3.4	10.3	5.9	8.5	2.6	5.5	6.2	8.9	5.7	4.1	8.0	11.5	6.5	7.0	3.4	12.1	31.5	12.5	5.1	9.0	0.9	9.8	5.2	2.5	4.3	4.1	9.0	9.0	10.9	3.9	3.9	4.4	3.9	3.1	11.2	10.9	6.3	6.9	7.2	4.3	9.2	2.9	6.0	6.8	6.6	7.3	26.0	2.1	4.5	2.4	3.3	0.3	9.0	2.4	3.5	3.1	4.0	2.3	3.1	12.3	0.0	19.2	7.3	1.4	2.0	5.9	3.0	0.0	4.0	11.4	0.0	1.2	3.3	16.8	12.7	0.0	3.0	1.0	1.8	5.0	13.5	0.6	1.3	15.4	18.8	5.1	3.5	18.0	24.5	0.1	0.0	0.0	61.9	0.0	0.0	1.9	3.2	10.6	0.0	0.7	0.0	0.9	4.7	1.6	0.0	0.0	2.0	0.0	0.0	9.5	0.0	2.4	14.5	0.0	0.0	1.1	0.0	0.0	0.0	0.0	16.0	0.9	58.8	2.4	3.3	1.5	0.0	1.4	0.1	2.1	3.2	1.1	4.5	0.8	9.0	3.5	2.2	0.3	1.9	0.0	1.0	2.4	4.9	10.0	3.4	10.3	7.0	3.4	9.0	0.9	9.0	9.2	0.0	12.7	0.5	3.2	4.4	0.0	1.4	2.5	5.3	5.7	1.8	0.0	0.1	0.0	5.7	0.4	31.4	5.9	0.0	1.8	0.2	2.5	4.7	7.0	6.6	2.6	0.0	1.7	11.6	9.8	0.0	0.3	3.6	8.5	1.0	4.8	0.3	8.4	2.9	0.4	2.1	0.0	0.0	11.7	0.7	2.7	2.0	0.1	1.3	6.3	3.3
TNFRSF11A	"CD265, FEO, LOH18CR1, PDB2, RANK"	ENSG00000141655	"TNF receptor superfamily member 11a"	Q9Y6Q6	18	62325287-62391292	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Deafness, Disease mutation, Osteopetrosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 28.7;intestine: 23.9;salivary gland: 34.3"	"Cell type enhanced"	"Detected in many"	7	"Enterocytes: 21.1;monocytes: 34.3;Mucus-secreting cells: 23.6;Paneth cells: 28.1;Undifferentiated cells: 33.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	8	"NK-cell: 8.9"	"Lineage enriched"	"Detected in many"	8	"NK-cells: 8.9"	"Cell line enriched"	"Detected in some"	6	"HDLM-2: 52.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB010391, HPA047976"	Approved		Supported	"Plasma membrane,Cytosol"	"Intracellular and membrane"	NA	NA			"Plasma membrane"	Cytosol	"CAB010391: AB_2205352, HPA047976: AB_2680227"	"unprognostic (4.08e-1)"	"unprognostic (2.71e-1)"	"unprognostic (3.23e-3)"	"unprognostic (1.73e-1)"	"unprognostic (6.03e-2)"	"unprognostic (1.35e-1)"	"unprognostic (9.96e-4)"	"unprognostic (4.24e-3)"	"unprognostic (7.79e-4)"	"unprognostic (1.52e-1)"	"unprognostic (4.05e-2)"	"unprognostic (2.88e-1)"	"unprognostic (4.69e-5)"	"unprognostic (1.56e-1)"	"unprognostic (1.78e-1)"	"unprognostic (4.02e-2)"	"unprognostic (7.07e-2)"	6.5	1.7	1.7	4.8	1.2	0.2	4.3	0.4	2.3	1.5	18.4	0.8	7.6	23.1	0.9	1.9	3.8	1.3	28.7	1.1	1.3	0.7	0.9	0.8	2.3	7.4	1.0	1.0	0.7	2.9	0.1	10.1	2.8	0.7	2.1	13.9	1.3	34.3	12.9	0.6	3.3	23.9	1.3	2.9	1.2	4.3	1.2	0.8	0.7	2.0	1.8	2.3	2.3	2.3	0.0	0.6	0.2	0.0	8.9	1.0	0.0	1.3	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.2	0.0	1.5	0.1	0.6	0.9	3.5	0.3	0.1	52.5	2.3	0.0	0.5	0.7	0.0	0.2	0.5	0.1	0.1	0.3	1.3	1.8	1.3	0.1	0.0	0.0	0.0	0.4	0.0	0.0	2.5	2.9	8.3	0.1	0.0	0.2	0.6	0.6	8.9	0.3	0.2	1.3	0.0	0.3	0.5	0.1	0.8	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.2	8.9	0.0	0.6	1.0	0.0	1.7	1.2	0.4	2.3	1.3	0.7	1.0	1.0	0.7	0.8	0.0	2.1	0.0	2.9	1.1	0.4	1.1	10.2	0.0	0.0	0.0	0.0	0.1	0.0	7.3	0.2	2.2	21.1	0.0	6.5	0.6	0.3	2.6	0.0	0.0	12.8	3.2	10.4	3.7	15.0	0.0	0.6	2.5	1.7	34.3	23.6	0.0	9.6	28.1	0.0	0.0	0.0	0.0	0.3	0.7	1.4	1.9	0.1	0.0	33.6	3.8
TNFRSF12A	"CD266, FN14, TweakR"	ENSG00000006327	"TNF receptor superfamily member 12A"	Q9NP84	16	3018445-3022383	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Angiogenesis, Apoptosis, Cell adhesion, Differentiation"	"Developmental protein, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 81.3"	"Cell type enhanced"	"Detected in many"	7	"Basal glandular cells: 1094.9;Ductal cells: 954.3;Exocrine glandular cells: 607.7;Pancreatic endocrine cells: 874.5"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in many"	5	"pons and medulla: 25.0"	"Group enriched"	"Detected in many"	8	"eosinophil: 38.1;neutrophil: 29.9"	"Lineage enriched"	"Detected in many"	9	"granulocytes: 38.1"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			HPA007853	Approved		Approved	"Plasma membrane,Cytosol"		NA	Yes		170000	"Plasma membrane, Cytosol"		"HPA007853: AB_1858463"	"unprognostic (1.44e-1)"	"unprognostic (2.46e-3)"	"unprognostic (8.90e-2)"	"unprognostic (2.60e-1)"	"unprognostic (4.06e-3)"	"prognostic unfavorable (5.50e-4)"	"unprognostic (7.04e-3)"	"unprognostic (1.98e-3)"	"unprognostic (4.17e-3)"	"unprognostic (2.85e-1)"	"unprognostic (5.02e-3)"	"unprognostic (3.88e-1)"	"prognostic unfavorable (8.78e-4)"	"unprognostic (2.98e-2)"	"unprognostic (6.00e-2)"	"unprognostic (2.80e-3)"	"unprognostic (2.17e-2)"	10.8	14.2	2.4	11.3	5.1	2.7	21.2	0.9	3.0	8.0	18.9	3.2	4.1	14.5	11.6	10.2	10.7	6.4	28.1	27.0	5.0	2.6	50.4	36.2	23.0	2.6	4.8	0.5	6.4	47.0	51.1	20.0	81.3	25.0	11.1	1.9	2.8	17.3	6.9	23.3	5.0	31.0	16.8	4.3	3.9	13.2	5.3	3.3	1.2	11.5	11.5	4.7	14.8	5.2	0.0	4.1	38.1	3.5	2.0	2.4	1.1	24.5	19.9	2.2	4.1	4.1	9.3	13.2	51.8	37.5	44.4	28.6	8.6	43.9	0.1	68.6	34.4	51.6	27.2	0.5	37.9	17.0	0.9	1.3	0.1	6.7	7.2	28.0	0.4	1.8	8.6	26.3	46.6	55.9	38.3	12.8	0.0	2.7	0.3	46.7	46.5	0.0	3.3	10.7	11.0	43.8	0.2	24.9	1.0	44.9	4.9	2.5	0.9	36.9	17.2	30.5	7.7	9.0	0.7	22.5	80.0	36.9	52.9	84.9	0.8	0.3	0.3	25.0	2.3	62.8	3.5	3.5	38.1	1.8	2.0	2.4	0.0	0.8	1.5	4.1	0.0	0.4	0.8	29.9	2.0	1.3	0.1	1.0	1.1	2.4	5.1	0.9	3.0	5.0	2.6	4.8	0.5	25.0	3.3	95.3	43.1	5.0	1094.9	544.0	0.9	57.7	163.1	50.9	130.8	172.7	2.0	112.5	54.7	954.3	0.6	22.7	41.3	0.0	607.7	131.7	179.4	600.3	58.8	15.3	38.1	0.0	26.1	28.8	4.6	0.4	5.8	29.4	106.3	16.2	4.6	20.6	874.5	25.8	6.3	93.5	5.1	6.5	212.1	7.7	4.1	314.4	158.1	8.6	12.4	560.0
TNFRSF13B	"CD267, IGAD2, TACI"	ENSG00000240505	"TNF receptor superfamily member 13B"	O14836	17	16929816-16972118	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 45.1;lymphoid tissue: 44.6;skeletal muscle: 30.5"	"Group enriched"	"Detected in some"	31	"B-cells: 83.4;Melanocytes: 30.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	42	"memory B-cell: 45.1;naive B-cell: 13.1"	"Lineage enriched"	"Detected in single"	65	"B-cells: 45.1"	"Group enriched"	"Detected in some"	8	"Karpas-707: 55.9;RPMI-8226: 35.1;U-266/70: 24.8"					"Low region specificity"	"Detected in all"			HPA030453	Uncertain					NA	NA					"HPA030453: AB_10601700"	"unprognostic (3.94e-5)"	"unprognostic (1.11e-3)"	"unprognostic (4.88e-2)"	"unprognostic (4.30e-3)"		"unprognostic (1.23e-4)"	"unprognostic (2.16e-1)"	"unprognostic (1.62e-3)"	"unprognostic (1.47e-2)"	"unprognostic (1.61e-4)"	"unprognostic (2.22e-1)"	"unprognostic (9.78e-2)"	"unprognostic (1.59e-5)"	"unprognostic (1.20e-1)"	"unprognostic (4.49e-1)"	"unprognostic (1.39e-1)"	"unprognostic (2.05e-1)"	0.5	0.3	0.4	17.6	0.3	0.2	0.5	0.2	0.3	0.7	3.0	0.1	0.0	1.9	0.3	0.0	2.7	0.5	0.5	2.5	0.3	0.3	0.6	0.5	1.2	12.5	0.3	0.2	0.3	0.3	0.0	0.3	0.0	0.1	0.9	1.2	0.6	9.0	1.1	30.5	0.3	14.8	0.0	0.4	44.6	2.4	0.3	0.1	0.9	0.6	0.9	37.8	2.3	0.4	45.1	0.0	0.1	0.0	0.0	0.6	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	55.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	35.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.8	0.0	4.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	45.1	0.0	0.0	0.0	13.1	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.9	0.4	0.3	0.2	0.3	0.3	0.3	0.3	0.2	0.1	0.1	0.0	0.0	83.4	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.3	0.0	0.0	0.0	30.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.5	0.0	0.0	0.0	0.0
TNFRSF13C	"BAFFR, CD268"	ENSG00000159958	"TNF receptor superfamily member 13C"	Q96RJ3	22	41922023-41926818	"CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 20.3;intestine: 18.9;lymphoid tissue: 69.1"	"Cell type enriched"	"Detected in some"	13	"B-cells: 100.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	51	"memory B-cell: 14.5;naive B-cell: 20.3"	"Lineage enriched"	"Detected in single"	59	"B-cells: 20.3"	"Group enriched"	"Detected in some"	6	"REH: 20.4;U-698: 11.0"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"HPA003246, CAB008380"	Enhanced					NA	NA					"CAB008380: AB_590602, HPA003246: AB_1078264"	"unprognostic (3.43e-4)"	"prognostic favorable (4.44e-7)"	"unprognostic (6.52e-2)"	"unprognostic (9.10e-2)"	"unprognostic (7.64e-3)"	"unprognostic (4.83e-3)"	"unprognostic (2.89e-2)"	"unprognostic (3.78e-3)"	"unprognostic (1.95e-1)"	"unprognostic (1.27e-1)"	"unprognostic (2.51e-2)"	"unprognostic (1.66e-1)"	"unprognostic (4.79e-8)"	"unprognostic (2.21e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.77e-1)"	"unprognostic (9.44e-2)"	0.9	0.8	0.8	41.0	1.0	3.3	0.6	1.0	2.0	0.5	1.2	4.4	0.0	0.7	0.4	0.2	5.0	0.5	0.6	0.6	0.8	0.9	0.9	0.5	1.8	48.4	1.0	0.6	0.4	0.4	0.0	0.4	0.1	1.8	0.6	0.7	0.5	5.8	0.0	1.2	2.0	18.9	0.1	1.1	69.1	1.4	0.7	0.6	2.0	0.8	0.3	51.4	9.5	0.7	20.3	0.2	0.3	0.2	0.2	0.2	0.5	0.3	0.2	1.1	2.3	0.0	0.0	0.5	0.1	0.1	0.2	0.8	0.9	0.5	1.8	0.4	0.2	0.2	0.4	0.7	0.0	0.3	0.4	2.2	0.2	0.3	0.3	0.1	1.6	0.4	0.1	0.0	0.4	0.1	0.1	0.0	0.7	0.4	1.9	0.2	0.7	1.5	1.8	0.8	0.2	0.1	20.4	2.4	1.5	0.0	0.2	1.3	0.3	0.1	0.4	0.3	0.2	0.4	2.2	0.2	0.5	2.6	1.0	0.3	2.1	1.0	11.0	0.1	1.7	0.5	0.3	0.1	0.1	0.1	0.1	0.2	14.5	0.2	0.1	0.0	20.3	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.5	0.8	1.0	1.0	2.0	0.8	0.9	1.0	0.6	1.8	0.6	0.0	1.4	100.8	0.4	0.1	1.1	1.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.0	0.0	0.1	7.9	1.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	1.0	0.9	0.0	0.1	0.0	0.4	0.1
TNFRSF14	"ATAR, CD270, HVEA, HVEM, LIGHTR, TR2"	ENSG00000157873	"TNF receptor superfamily member 14"	Q92956	1	2555639-2565382	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 14.6;HDLM-2: 14.8;HHSteC: 17.3;Karpas-707: 13.6;SK-MEL-30: 28.5"									"HPA006404, CAB026150, CAB030007"	Approved					NA	NA					"CAB026150: , CAB030007: AB_2303380, HPA006404: AB_1851348"	"prognostic favorable (4.39e-5)"	"unprognostic (3.48e-2)"	"unprognostic (1.53e-2)"	"prognostic favorable (8.01e-6)"	"unprognostic (1.11e-2)"	"unprognostic (6.83e-3)"	"unprognostic (9.62e-3)"	"unprognostic (2.32e-1)"	"unprognostic (3.25e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.31e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.86e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.72e-2)"	"unprognostic (1.58e-1)"	"prognostic favorable (7.79e-6)"	15.9	24.9	4.9	38.9	2.8	11.0	21.9	2.0	4.5	16.8	36.3	3.2	18.5	36.3	15.2	20.5	13.7	12.3	36.7	12.7	4.9	2.5	19.3	20.5	30.3	33.2	3.6	5.7	12.8	7.3	3.5	9.3	8.3	3.9	21.5	8.2	44.1	20.9	22.6	5.2	8.4	41.9	14.6	4.1	36.7	16.7	5.9	2.7	23.5	10.8	10.6	25.0	15.4	17.2	18.2	9.7	30.2	25.8	8.1	25.1	14.2	1.3	0.1	0.1	2.4	5.2	2.8	0.8	0.7	2.4	1.4	1.9	0.2	14.6	0.8	0.1	2.2	1.4	1.3	0.0	0.9	0.2	14.8	0.0	8.5	0.4	2.7	17.3	1.1	10.6	2.7	1.4	0.7	0.1	2.1	3.8	0.8	1.2	13.6	1.3	0.0	4.7	1.3	0.0	4.6	1.3	3.8	0.0	4.2	0.2	2.1	0.4	0.0	0.6	0.1	28.5	0.0	0.4	0.3	9.6	0.2	0.6	0.3	0.1	11.1	2.7	0.4	2.4	1.2	1.0	3.0	15.1	8.2	17.2	25.8	14.9	16.6	18.0	14.8	9.7	18.2	17.3	14.9	30.2	8.1	24.1	8.7	25.1	14.2	4.9	2.8	2.0	4.5	4.9	2.5	3.6	5.7	3.9	2.7	17.9	38.9	54.7	30.5	14.5	1.5	6.7	56.0	26.8	31.8	33.2	0.0	1.0	3.3	16.7	0.3	48.4	116.5	0.0	29.0	0.8	16.0	32.4	50.9	18.3	78.8	0.0	34.7	35.0	60.9	1.3	19.2	62.9	43.9	111.0	60.4	15.8	19.7	86.3	13.1	30.9	0.5	19.4	17.5	0.0	0.3	11.7	1.0	77.3	72.2	38.8
TNFRSF17	"BCM, BCMA, CD269, TNFRSF13A"	ENSG00000048462	"TNF receptor superfamily member 17"	Q02223	16	11965107-11968068	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 34.1;intestine: 17.8;lymphoid tissue: 28.8"	"Group enriched"	"Detected in some"	9	"B-cells: 29.3;Erythroid cells: 46.7;Melanocytes: 101.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	59	"memory B-cell: 34.1;naive B-cell: 26.9;plasmacytoid DC: 27.9"	"Group enriched"	"Detected in many"	62	"B-cells: 34.1;dendritic cells: 27.9"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 25.9;RPMI-8226: 40.8;U-266/70: 121.4;U-266/84: 60.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA		2200000				"prognostic favorable (1.35e-5)"	"unprognostic (3.41e-2)"	"unprognostic (4.00e-3)"	"unprognostic (1.41e-2)"	"unprognostic (6.47e-2)"	"prognostic favorable (1.58e-6)"	"unprognostic (9.75e-3)"	"unprognostic (5.93e-2)"	"unprognostic (2.13e-2)"	"unprognostic (7.96e-3)"	"unprognostic (2.46e-1)"	"unprognostic (2.58e-1)"	"unprognostic (2.85e-6)"	"unprognostic (2.06e-1)"	"unprognostic (2.48e-1)"	"unprognostic (3.54e-2)"	"unprognostic (1.10e-1)"	0.6	0.4	0.4	24.0	0.9	0.3	5.4	0.5	0.4	1.5	17.8	0.2	0.2	12.3	0.5	0.2	3.7	1.1	4.9	0.7	0.4	0.4	1.3	0.8	3.0	22.4	0.4	0.2	0.9	3.1	0.0	0.5	0.3	0.2	1.0	9.4	0.6	14.2	0.2	0.4	0.4	11.7	0.2	0.4	22.2	9.4	2.2	0.3	3.1	1.1	1.4	28.8	7.6	0.7	34.1	27.9	0.5	0.1	0.2	0.1	3.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	25.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	121.4	60.3	9.4	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.1	34.1	0.0	0.0	0.0	26.9	0.0	0.0	0.5	0.2	0.0	27.9	0.0	3.7	0.4	0.9	0.5	0.4	0.4	0.4	0.4	0.2	0.2	0.3	0.0	0.0	29.3	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	0.0	0.0	46.7	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	3.6	0.0	0.0	101.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	6.5	0.0	0.5	0.4	0.5	0.0	0.0	0.0	0.0
TNFRSF18	"AITR, CD357, GITR"	ENSG00000186891	"TNF receptor superfamily member 18"	Q9Y5U5	1	1203508-1206691	"CD markers, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 46.6;skin 1: 28.9"	"Group enriched"	"Detected in many"	5	"Basal keratinocytes: 167.9;granulocytes: 46.0;Melanocytes: 47.2;Suprabasal keratinocytes: 131.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"NK-cell: 46.6"	"Group enriched"	"Detected in many"	11	"NK-cells: 46.6;T-cells: 19.0"	"Group enriched"	"Detected in some"	11	"RPMI-8226: 62.6;SCLC-21H: 45.0"									HPA008025	Approved				"Secreted to blood"	NA	NA					"HPA008025: AB_1849696"	"unprognostic (1.20e-3)"	"unprognostic (4.61e-2)"	"unprognostic (4.59e-2)"	"prognostic favorable (7.72e-6)"	"unprognostic (2.73e-4)"	"prognostic favorable (4.12e-4)"	"unprognostic (3.43e-2)"	"unprognostic (2.31e-1)"	"unprognostic (3.33e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.20e-1)"	"prognostic unfavorable (4.40e-11)"	"unprognostic (1.02e-3)"	"unprognostic (2.39e-1)"	"unprognostic (3.74e-1)"	"unprognostic (2.08e-1)"	1.4	0.5	1.0	8.9	1.0	1.9	4.2	4.9	2.5	14.3	8.3	0.3	0.1	5.7	2.1	1.1	4.7	1.0	3.7	0.2	0.5	0.3	1.1	1.7	3.0	9.1	0.4	2.4	0.3	2.7	9.4	3.8	1.3	1.7	1.9	1.2	0.5	9.0	2.6	1.0	28.9	5.0	0.2	0.3	6.7	3.8	0.8	0.1	4.4	0.9	2.7	8.2	1.5	2.2	2.9	0.0	0.2	0.0	46.6	19.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.1	4.7	0.0	0.0	62.6	0.1	0.0	45.0	0.0	0.0	0.1	0.0	0.0	2.4	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	2.0	0.0	3.6	1.3	8.5	1.2	0.0	2.9	0.3	0.4	0.2	46.6	0.0	0.0	19.0	2.1	1.0	1.0	4.9	2.5	0.5	0.3	0.4	2.4	1.7	0.1	0.0	2.2	7.5	10.8	167.9	0.0	2.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.7	0.0	1.0	0.0	0.0	0.5	0.9	11.2	7.3	46.0	0.0	0.8	0.0	3.4	1.3	0.8	0.0	0.0	1.8	47.2	21.6	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	131.6	0.0	20.8	0.0	3.3
TNFRSF1A	"CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60"	ENSG00000067182	"TNF receptor superfamily member 1A"	P19438	12	6328757-6342114	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Apoptosis, Host-virus interaction"	Receptor	"Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 86.5"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004102, CAB010309"	Approved				"Secreted to blood"	NA	NA		170000			"CAB010309: AB_2206639, HPA004102: AB_1846232"	"unprognostic (2.19e-2)"	"unprognostic (3.76e-2)"	"unprognostic (8.14e-2)"	"prognostic favorable (8.22e-4)"	"unprognostic (3.07e-2)"	"prognostic unfavorable (3.68e-4)"	"unprognostic (1.50e-1)"	"unprognostic (1.41e-3)"	"unprognostic (1.00e-1)"	"unprognostic (8.05e-2)"	"unprognostic (4.78e-2)"	"unprognostic (1.54e-2)"	"prognostic unfavorable (2.70e-7)"	"unprognostic (1.43e-2)"	"unprognostic (2.92e-2)"	"unprognostic (5.14e-3)"	"unprognostic (1.74e-1)"	55.1	43.9	16.8	28.9	16.8	13.7	40.6	7.2	15.6	40.3	41.5	14.1	22.6	39.2	38.2	27.5	39.4	34.2	37.1	26.8	14.0	7.5	49.3	61.6	40.9	37.2	19.2	6.4	59.5	21.4	20.3	19.9	45.3	18.3	37.0	23.0	31.1	25.7	22.2	34.2	30.9	81.7	38.8	25.1	43.6	28.2	21.8	15.7	31.6	42.7	25.4	22.3	49.1	58.5	0.0	20.8	86.5	27.1	1.8	11.6	15.9	7.4	57.8	8.1	11.5	56.0	57.3	15.3	15.9	27.5	21.4	18.6	6.9	29.7	0.6	5.5	34.3	17.1	20.8	2.5	18.6	14.8	0.1	4.8	4.1	16.0	15.3	49.7	19.3	13.0	59.0	18.7	17.7	26.1	49.7	26.0	8.0	6.2	5.7	24.5	10.6	6.1	18.2	19.7	27.7	16.9	5.3	12.9	5.7	16.5	13.5	0.0	0.4	22.5	11.8	11.8	21.7	3.2	21.1	28.3	16.8	14.4	12.6	14.7	0.0	1.8	2.4	20.1	18.0	20.8	2.2	27.1	15.0	11.6	21.8	11.1	0.0	4.9	9.5	20.8	0.0	4.5	6.6	86.5	1.8	17.5	6.0	4.8	15.9	16.8	16.8	7.2	15.6	14.0	7.5	19.2	6.4	18.3	15.7	47.6	42.8	9.0	92.6	109.3	0.1	8.4	63.7	10.7	42.1	26.2	0.0	53.2	13.3	86.6	0.6	80.7	166.1	23.3	104.3	104.8	112.3	113.8	7.0	128.2	148.0	0.0	32.3	138.1	133.7	3.3	94.6	103.1	67.4	101.0	44.9	16.3	93.0	210.5	61.9	94.3	0.3	122.9	122.4	0.5	1.1	117.7	124.3	45.7	42.3	123.4
TNFRSF1B	"CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80"	ENSG00000028137	"TNF receptor superfamily member 1B"	P20333	1	12167003-12209228	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 70.1"	"Cell type enhanced"	"Detected in many"	10	"Kupffer cells: 168.8;Macrophages: 143.1;monocytes: 73.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 70.1"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 17.5;K-562: 21.4;THP-1: 25.1;U-87 MG: 17.2;U-937: 18.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA004796	Approved				"Secreted to blood"	NA	NA	3230000	2500000			"HPA004796: AB_1078436"	"unprognostic (4.45e-2)"	"unprognostic (2.27e-3)"	"unprognostic (7.62e-2)"	"unprognostic (3.82e-3)"	"unprognostic (6.30e-2)"	"unprognostic (4.47e-3)"	"unprognostic (5.28e-3)"	"unprognostic (2.79e-1)"	"unprognostic (1.69e-2)"	"unprognostic (1.73e-2)"	"unprognostic (7.26e-2)"	"unprognostic (2.48e-1)"	"prognostic unfavorable (8.35e-5)"	"unprognostic (2.02e-1)"	"prognostic unfavorable (8.68e-4)"	"unprognostic (3.26e-2)"	"unprognostic (1.10e-1)"	43.4	4.7	4.6	44.3	13.8	29.2	42.3	2.1	6.1	13.3	13.1	6.6	1.9	11.9	9.7	10.2	6.5	11.3	11.6	21.8	8.5	6.2	6.2	22.2	24.5	60.6	9.1	2.2	9.4	4.2	2.3	4.4	24.9	15.0	7.3	8.2	8.3	5.7	3.7	11.5	6.2	17.3	11.5	22.6	48.3	10.5	6.0	6.1	10.9	6.2	5.6	16.2	18.3	8.4	2.7	13.2	25.7	70.1	2.5	12.7	19.9	0.0	0.1	2.1	0.0	5.6	7.7	4.4	0.5	1.0	2.0	2.2	0.8	17.5	0.1	0.3	1.8	2.9	0.0	0.4	0.0	1.1	6.9	0.0	0.0	0.1	0.0	13.2	0.1	1.9	7.6	0.0	7.0	0.0	3.6	10.6	0.1	21.4	3.2	0.9	0.0	0.0	4.0	0.1	2.7	0.6	0.5	0.2	12.3	0.0	0.4	0.0	0.0	0.3	0.1	0.6	3.3	0.0	25.1	3.7	3.0	0.1	13.3	0.0	1.0	0.0	0.0	17.2	18.1	0.7	0.0	20.7	3.0	9.4	49.3	5.4	2.7	6.6	7.7	13.2	1.7	2.0	3.0	25.7	2.5	70.1	2.8	12.7	19.9	4.6	13.8	2.1	6.1	8.5	6.2	9.1	2.2	15.0	6.1	8.9	22.3	30.3	2.5	14.9	0.1	2.8	7.6	2.7	11.4	3.5	0.0	0.7	0.0	0.4	0.3	40.2	11.8	23.3	0.5	4.3	9.7	4.3	2.3	14.0	63.4	0.0	0.0	22.7	168.8	0.4	2.0	143.1	15.1	73.9	3.1	0.3	0.5	1.4	0.4	0.3	1.0	32.3	13.7	0.0	0.9	9.3	25.2	58.9	3.9	9.8
TNFRSF21	"CD358, DR6"	ENSG00000146072	"TNF receptor superfamily member 21"	O75509	6	47231532-47309905	"CD markers, Plasma proteins, Predicted membrane proteins"	"Adaptive immunity, Apoptosis, Immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 63.4"	"Cell type enhanced"	"Detected in many"	11	"Basal glandular cells: 142.4;Glandular cells: 135.6;Syncytiotrophoblasts: 149.4;Urothelial cells: 360.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	35	"plasmacytoid DC: 31.6"	"Lineage enriched"	"Detected in single"	309	"dendritic cells: 31.6"	"Cell line enhanced"	"Detected in many"		"OE19: 39.2;RT4: 99.8;SuSa: 43.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA006746, CAB009805"	Approved		Supported	"Plasma membrane,Cytosol"		NA	NA		1300000	"Plasma membrane, Cytosol"		"CAB009805: AB_2206956, HPA006746: AB_1078701"	"unprognostic (1.19e-2)"	"unprognostic (2.70e-1)"	"unprognostic (3.26e-1)"	"unprognostic (7.85e-2)"	"unprognostic (1.44e-1)"	"unprognostic (3.41e-2)"	"unprognostic (9.80e-3)"	"unprognostic (1.11e-1)"	"unprognostic (1.46e-2)"	"unprognostic (7.53e-2)"	"unprognostic (1.38e-3)"	"unprognostic (1.74e-1)"	"prognostic favorable (7.23e-6)"	"unprognostic (1.48e-1)"	"unprognostic (1.34e-1)"	"unprognostic (9.78e-2)"	"unprognostic (1.45e-2)"	25.9	3.7	9.7	8.7	13.6	5.9	7.8	7.4	20.8	9.6	19.3	26.9	1.0	6.4	9.1	3.0	21.8	9.9	18.7	4.1	13.8	16.0	26.2	4.6	9.5	11.5	26.8	7.9	5.0	17.9	35.6	4.4	17.0	29.5	10.2	18.5	3.0	15.2	2.4	3.5	2.7	10.2	8.2	63.4	11.6	30.4	5.8	10.1	11.5	2.9	19.2	16.5	41.2	11.6	0.0	31.6	0.1	0.0	0.0	0.0	0.2	29.2	9.5	9.3	2.9	25.5	7.5	10.5	3.4	6.7	1.0	0.4	16.4	20.7	2.1	13.8	2.4	20.0	17.7	1.3	12.6	0.6	0.0	2.9	0.0	1.2	16.5	14.9	0.4	0.1	13.4	15.1	0.6	11.5	0.8	4.9	1.9	0.7	0.0	0.3	5.7	2.5	0.2	7.3	39.2	9.8	5.4	2.8	3.1	17.7	99.8	6.7	1.4	2.9	2.8	2.4	43.8	2.1	2.0	1.0	2.8	2.5	0.1	3.1	0.0	0.0	3.0	4.5	2.1	7.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	31.6	0.0	0.2	9.7	13.6	7.4	20.8	13.8	16.0	26.8	7.9	29.5	10.1	0.0	12.7	0.0	142.4	21.1	0.6	7.6	35.7	10.7	25.0	1.8	0.0	24.6	13.3	69.3	45.6	5.6	30.3	0.0	25.8	16.8	14.1	135.6	19.6	0.0	20.6	0.0	11.5	1.8	36.8	29.9	2.6	5.8	11.8	0.0	40.2	4.4	63.5	46.7	1.1	48.5	1.3	77.6	16.2	0.6	1.4	8.7	149.4	1.3	14.0	360.8
TNFRSF4	"ACT35, CD134, OX40, TXGP1L"	ENSG00000186827	"TNF receptor superfamily member 4"	P43489	1	1211326-1214138	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 12.5;blood: 18.4;lymphoid tissue: 13.6"	"Cell type enhanced"	"Detected in some"	19	"Endothelial cells: 15.3;granulocytes: 67.9;monocytes: 30.7;T-cells: 15.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in many"		"memory CD4 T-cell: 15.9;T-reg: 18.4"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"MOLT-4: 8.0;NB-4: 15.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			CAB016128	Enhanced					NA	NA					"CAB016128: AB_626897"	"unprognostic (2.24e-1)"	"unprognostic (8.69e-3)"	"unprognostic (1.36e-1)"	"unprognostic (8.55e-3)"	"unprognostic (1.02e-1)"	"prognostic favorable (3.50e-6)"	"prognostic unfavorable (6.03e-4)"	"unprognostic (3.30e-1)"	"unprognostic (1.48e-2)"	"unprognostic (7.04e-3)"	"unprognostic (1.04e-2)"	"unprognostic (1.47e-1)"	"prognostic unfavorable (4.52e-6)"	"unprognostic (1.61e-1)"	"unprognostic (5.46e-2)"	"unprognostic (2.42e-1)"	"unprognostic (5.91e-2)"	12.5	0.2	0.6	8.8	0.4	0.7	7.3	0.3	1.2	1.1	3.1	0.3	0.3	2.6	0.8	0.7	1.7	0.9	0.8	6.7	0.8	0.1	2.2	0.4	5.3	8.4	0.3	0.6	0.5	0.9	0.0	1.3	5.9	0.6	3.2	0.3	0.6	2.2	1.1	4.4	0.8	4.3	0.3	0.3	13.5	3.5	2.0	0.3	13.6	4.1	0.8	10.9	1.4	0.7	0.0	0.6	4.1	0.0	8.1	18.4	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	8.0	15.5	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.1	0.2	0.0	1.8	0.0	15.9	1.7	0.0	0.0	1.5	0.0	0.2	8.1	0.0	0.6	18.4	1.5	0.6	0.4	0.3	1.2	0.8	0.1	0.3	0.6	0.6	0.3	0.0	0.0	2.2	0.3	8.0	0.1	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	15.3	0.0	0.0	0.2	0.4	2.8	0.3	67.9	0.0	1.6	0.0	0.0	8.6	1.0	0.0	0.3	5.8	10.1	30.7	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.7	0.0	0.2	7.3	0.1	15.8	0.0	0.1
TNFRSF8	"CD30, D1S166E, KI-1"	ENSG00000120949	"TNF receptor superfamily member 8"	P28908	1	12063377-12144207	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 33.3"	"Cell type enhanced"	"Detected in some"	14	"Early spermatids: 2.8;Kupffer cells: 6.0;Late spermatids: 7.2"	"Cancer enriched"	"Detected in some"	12	"testis cancer: 9.3"	"Region enriched"	"Detected in single"	14	"basal ganglia: 13.1"	"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 21.7;non-classical monocyte: 33.3"	"Lineage enriched"	"Detected in many"	5	"monocytes: 33.3"	"Cell line enriched"	"Detected in some"	21	"HDLM-2: 112.6"					"Low region specificity"	"Detected in many"			"CAB000016, HPA014823, HPA032081, HPA032082"	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB000016: AB_563546, HPA014823: , HPA032081: AB_2674141, HPA032082: AB_2674142"	"unprognostic (1.07e-2)"	"unprognostic (2.06e-2)"	"unprognostic (2.52e-2)"	"unprognostic (5.98e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.46e-3)"	"unprognostic (2.19e-1)"	"unprognostic (3.93e-2)"	"unprognostic (1.18e-1)"	"unprognostic (9.18e-3)"	"unprognostic (1.86e-1)"	"unprognostic (2.06e-1)"	"unprognostic (3.17e-8)"	"unprognostic (3.31e-1)"	"unprognostic (8.56e-2)"	"unprognostic (2.07e-1)"	"unprognostic (2.31e-2)"	10.7	0.2	0.1	7.2	13.1	1.4	5.8	0.2	0.4	1.1	0.8	0.0	1.5	0.2	1.7	1.3	0.9	2.1	1.4	3.8	0.1	0.2	0.9	0.2	3.9	2.9	0.5	0.5	1.2	0.4	0.0	0.1	6.2	0.5	1.0	0.5	0.0	0.7	0.3	3.1	1.6	1.3	1.3	1.4	2.9	6.4	2.5	0.9	3.0	0.7	2.7	5.3	2.6	3.8	0.0	3.2	6.8	33.3	0.0	0.3	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	2.5	0.0	0.0	0.0	0.0	0.0	0.0	112.6	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.8	5.2	0.3	0.0	0.0	0.3	0.0	4.5	0.0	0.1	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.3	0.0	21.7	0.1	0.0	0.0	0.0	3.2	0.0	0.0	0.0	6.8	0.0	33.3	0.8	0.3	2.7	0.1	13.1	0.2	0.4	0.1	0.2	0.5	0.5	0.5	0.9	0.0	0.0	0.0	0.0	0.2	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.0	0.0	1.4	0.0	0.0	1.3	6.0	7.2	0.3	1.9	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.7	0.1	0.2	0.0	0.0	0.0
TNFRSF9	"4-1BB, CD137, ILA"	ENSG00000049249	"TNF receptor superfamily member 9"	Q07011	1	7915894-7943165	"Cancer-related genes, CD markers, Predicted membrane proteins"		Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"blood: 13.5;lymphoid tissue: 18.3"	"Group enriched"	"Detected in some"	4	"granulocytes: 62.3;monocytes: 53.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	5	"memory CD8 T-cell: 8.0;neutrophil: 6.6;NK-cell: 4.1;T-reg: 13.5"	"Group enriched"	"Detected in many"	5	"granulocytes: 6.6;NK-cells: 4.1;T-cells: 13.5"	"Cell line enriched"	"Detected in some"	8	"HDLM-2: 47.0"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			HPA071425			Approved	"Nucleoli,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoli	"HPA071425: AB_2686394"	"unprognostic (7.23e-2)"	"unprognostic (1.72e-2)"	"unprognostic (8.26e-3)"	"unprognostic (1.32e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.98e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.19e-4)"	"unprognostic (9.47e-3)"	"unprognostic (2.17e-2)"	"unprognostic (2.02e-1)"	"prognostic unfavorable (2.69e-8)"	"unprognostic (1.64e-2)"	"unprognostic (2.25e-2)"	"unprognostic (1.19e-1)"	"unprognostic (9.55e-2)"	0.8	1.0	0.3	11.0	0.3	1.9	0.5	0.2	0.3	0.4	0.5	0.1	0.1	0.6	0.3	0.1	0.6	0.8	1.6	1.8	0.3	1.0	0.7	0.7	2.1	10.8	0.3	0.1	0.3	0.6	0.0	0.5	0.2	0.5	0.4	0.7	0.3	2.1	0.1	0.3	0.5	2.3	0.1	0.3	7.9	0.7	0.5	0.1	18.3	0.7	0.9	17.5	1.4	0.4	0.5	1.1	6.6	1.5	4.1	13.5	1.1	1.2	0.4	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.1	1.0	0.4	0.1	0.4	0.0	0.8	0.2	0.0	0.2	0.5	47.0	0.1	0.2	0.2	0.0	0.9	0.0	0.5	0.1	0.3	0.1	0.1	0.2	0.0	0.0	0.2	0.1	0.0	0.1	0.0	0.2	0.1	0.0	0.0	0.0	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.0	0.7	0.0	0.2	0.2	0.2	1.6	0.1	0.2	0.1	0.1	0.1	5.8	0.2	0.0	1.1	1.5	0.2	1.5	0.4	0.2	0.2	1.0	8.0	1.1	0.5	0.3	1.6	6.6	4.1	0.1	0.3	13.5	1.1	0.3	0.3	0.2	0.3	0.3	1.0	0.3	0.1	0.5	0.1	0.0	1.7	0.0	0.4	0.2	0.0	0.3	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.8	0.0	0.7	0.0	0.0	1.0	0.0	0.4	0.3	62.3	0.0	0.8	0.0	0.0	0.0	0.3	0.0	0.0	1.8	5.0	53.3	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.8	0.1	0.0	0.4	0.0	12.9	0.0	0.3
TNFSF10	"Apo-2L, CD253, TL2, TRAIL"	ENSG00000121858	"TNF superfamily member 10"	P50591	3	172505508-172523507	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"kidney: 115.1"	"Cell type enhanced"	"Detected in many"	6	"Ductal cells: 542.5;Exocrine glandular cells: 368.6;Proximal tubular cells: 449.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"basophil: 42.4;classical monocyte: 25.6;intermediate monocyte: 39.5;neutrophil: 50.3;non-classical monocyte: 38.3"	"Group enriched"	"Detected in all"	5	"granulocytes: 50.3;monocytes: 39.5"	"Cell line enhanced"	"Detected in many"		"BEWO: 21.0;CAPAN-2: 14.9;HaCaT: 14.7;HMC-1: 69.1;RPTEC TERT1: 34.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054938	Uncertain				"Secreted to blood"	NA	NA	67400				"HPA054938: AB_2682643"	"unprognostic (9.16e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.69e-3)"	"unprognostic (2.52e-1)"	"unprognostic (2.67e-1)"	"unprognostic (1.55e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.99e-1)"	"unprognostic (1.71e-2)"	"prognostic unfavorable (9.43e-4)"	"unprognostic (1.04e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.29e-1)"	"unprognostic (3.68e-2)"	"unprognostic (1.32e-1)"	"unprognostic (6.27e-2)"	30.9	22.1	3.4	14.6	4.7	2.0	23.3	3.0	5.4	31.4	25.8	4.4	17.1	20.6	13.0	10.3	33.3	9.6	10.7	9.9	3.8	3.2	115.1	44.4	91.5	23.5	5.5	3.4	13.5	11.6	10.9	6.7	100.8	6.7	37.6	19.5	12.0	50.6	12.9	13.9	13.0	54.0	7.9	5.6	35.8	9.5	6.0	4.6	8.3	28.2	17.7	16.1	22.4	24.0	3.4	9.5	50.3	39.5	9.3	7.0	11.9	3.4	0.1	0.0	0.0	2.4	1.8	21.0	0.0	0.1	1.0	1.6	0.0	14.9	2.1	10.1	0.0	0.9	14.7	0.0	1.8	0.2	5.3	0.0	0.0	0.4	0.3	0.1	3.9	69.1	2.4	2.4	0.4	0.0	0.0	7.6	0.4	0.0	2.5	0.0	0.0	0.5	5.2	0.0	0.1	0.1	0.8	0.0	0.9	34.8	1.3	0.1	0.1	7.7	0.3	0.1	0.1	4.2	2.2	0.3	0.0	0.0	0.0	0.2	2.6	0.3	2.6	0.2	2.2	0.0	42.4	25.6	2.7	2.3	39.5	3.1	3.2	6.4	3.5	9.5	3.4	4.7	1.8	50.3	9.3	38.3	0.6	7.0	11.9	3.4	4.7	3.0	5.4	3.8	3.2	5.5	3.4	6.7	4.6	65.5	119.9	15.2	153.0	19.6	0.1	4.5	63.7	99.0	113.7	62.8	0.0	1.1	38.1	542.5	3.9	163.8	223.5	23.3	368.6	166.3	27.9	96.6	248.5	58.7	22.3	1.6	46.3	140.0	77.7	2.8	17.0	51.4	6.8	16.2	96.5	21.7	249.5	190.0	4.6	449.0	0.8	0.0	10.3	0.0	0.2	22.3	9.2	43.6	68.5	109.1
TNFSF11	"CD254, ODF, OPGL, RANKL, TRANCE"	ENSG00000120659	"TNF superfamily member 11"	O14788	13	42562736-42608013	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Differentiation	"Cytokine, Developmental protein, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Osteopetrosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 14.3;lymphoid tissue: 19.8"	"Cell type enhanced"	"Detected in some"	22	"Ductal cells: 3.3;Early spermatids: 5.8;Late spermatids: 14.2"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	8	"NK-cell: 14.3"	"Lineage enriched"	"Detected in many"	8	"NK-cells: 14.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 1.8;HSkMC: 5.4;NTERA-2: 7.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB009193, HPA045142"	Enhanced				"Secreted to blood"	NA	NA	17200				"CAB009193: , HPA045142: AB_2679231"	"unprognostic (3.97e-4)"	"unprognostic (1.40e-1)"	"unprognostic (9.01e-3)"	"unprognostic (3.81e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.09e-1)"	"unprognostic (7.09e-2)"	"unprognostic (7.70e-2)"	"unprognostic (2.29e-1)"	"unprognostic (1.25e-3)"	"unprognostic (1.00e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.94e-5)"	"unprognostic (1.87e-1)"	"unprognostic (9.67e-2)"	"unprognostic (5.46e-2)"	"unprognostic (7.74e-2)"	0.5	0.2	0.2	19.5	0.2	0.0	4.6	0.1	0.2	0.8	0.8	0.1	2.4	0.2	0.2	0.1	3.7	0.2	1.3	0.3	0.1	0.7	0.6	5.3	0.4	19.8	0.1	0.1	0.1	0.6	0.0	0.3	0.3	0.4	0.5	2.2	0.1	1.6	1.0	0.2	0.5	6.0	0.1	0.1	0.8	0.3	3.3	0.1	2.8	0.4	0.1	5.2	2.3	0.7	0.0	0.1	1.8	0.0	14.3	0.1	0.1	0.0	0.3	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.8	0.0	0.0	0.1	0.2	0.0	0.2	0.0	0.1	0.0	0.1	0.5	0.0	0.6	0.0	0.1	5.4	0.5	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	7.5	0.0	0.1	0.0	0.2	0.0	0.0	0.1	0.1	0.2	0.0	0.0	0.0	0.5	0.0	0.7	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	14.3	0.0	0.0	0.0	0.1	0.2	0.2	0.1	0.2	0.1	0.7	0.1	0.1	0.4	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.4	2.5	0.0	0.0	0.0	0.0	0.0	0.0	3.3	5.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.2	0.0	0.0	14.2	0.0	0.0	0.0	0.0	0.3	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.3	0.0	0.0	0.0	0.0
TNFSF13	"APRIL, CD256"	ENSG00000161955	"TNF superfamily member 13"	O75888	17	7558292-7561608	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	Immunity	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"salivary gland: 102.8"	"Cell type enhanced"	"Detected in some"	12	"Alveolar cells type 1: 6.0;Alveolar cells type 2: 7.2;Ciliated cells: 2.7;Club cells: 3.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 63.5;eosinophil: 22.8;intermediate monocyte: 62.7;myeloid DC: 43.0;non-classical monocyte: 37.3;plasmacytoid DC: 19.8"	"Group enriched"	"Detected in many"	10	"dendritic cells: 43.0;granulocytes: 22.8;monocytes: 63.5"	"Cell line enhanced"	"Detected in many"		"EFO-21: 18.8;RPTEC TERT1: 47.5;U-937: 18.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA004863	Uncertain				"Secreted to blood"	NA	NA	6770000	29000			"HPA004863: AB_1078187"	"unprognostic (2.46e-2)"	"unprognostic (2.20e-1)"	"unprognostic (3.42e-1)"	"unprognostic (6.53e-2)"	"prognostic unfavorable (9.73e-4)"	"unprognostic (3.57e-1)"	"unprognostic (3.32e-2)"	"unprognostic (3.70e-2)"	"unprognostic (3.75e-1)"	"unprognostic (1.15e-1)"	"unprognostic (6.95e-2)"	"unprognostic (2.65e-1)"	"prognostic favorable (1.30e-9)"	"unprognostic (4.69e-2)"	"unprognostic (1.42e-2)"	"unprognostic (3.46e-1)"	"unprognostic (3.38e-2)"	12.1	14.4	18.7	15.4	24.2	18.3	12.9	5.7	15.3	15.7	20.4	8.7	27.4	32.0	7.7	12.8	6.1	14.4	29.1	9.5	11.1	10.7	34.1	11.9	43.0	39.0	14.3	9.4	14.0	20.7	5.7	10.8	6.4	31.6	13.7	18.7	22.0	102.8	69.4	3.0	5.3	18.5	10.9	13.1	16.2	23.4	5.0	9.0	3.3	14.1	8.2	11.5	10.4	8.4	4.1	43.0	22.8	63.5	1.3	0.4	30.6	8.5	3.5	1.2	2.3	1.4	0.7	1.4	1.5	1.1	0.6	0.5	1.9	5.3	3.8	18.8	1.5	2.2	5.5	0.0	1.5	0.6	6.6	2.9	2.4	7.7	4.0	2.9	2.1	2.5	1.5	1.5	0.4	2.5	3.8	2.0	2.7	1.8	1.5	0.5	1.2	0.9	6.7	1.1	8.3	2.5	6.7	1.4	16.2	47.5	5.6	2.2	2.1	3.0	8.0	1.0	1.8	10.7	5.1	1.0	2.0	2.5	0.9	3.3	0.3	1.1	0.9	0.8	18.2	4.0	9.0	63.5	22.8	0.1	62.7	0.1	2.0	0.0	0.1	43.0	4.1	0.4	0.2	8.6	1.3	37.3	19.8	0.1	30.6	18.7	24.2	5.7	15.3	11.1	10.7	14.3	9.4	31.6	9.0	6.0	7.2	0.0	0.2	0.0	0.0	0.0	0.0	2.7	3.4	1.8	0.0	0.0	0.0	0.3	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.2	2.3	0.0	0.4	0.0	1.2	0.0	2.2	0.0	0.0	0.6	0.0	0.0	0.4	0.5	0.1	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1
TNFSF13B	"BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20"	ENSG00000102524	"TNF superfamily member 13b"	Q9Y275	13	108251240-108308484	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 76.5;lymphoid tissue: 39.6"	"Cell type enhanced"	"Detected in many"	23	"Hofbauer cells: 88.9;Kupffer cells: 144.9;Macrophages: 141.3;monocytes: 457.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 76.5"	"Group enriched"	"Detected in many"	10	"dendritic cells: 31.0;granulocytes: 76.5;monocytes: 53.7"	"Cell line enriched"	"Detected in some"	7	"U-937: 61.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB009188, HPA030526"	Enhanced		Supported	"Vesicles,Plasma membrane,Focal adhesion sites"	"Secreted to blood"	NA	NA	393000	530000	"Plasma membrane"	"Vesicles, Focal adhesion sites"	"CAB009188: , HPA030526: "	"unprognostic (6.48e-2)"	"unprognostic (3.05e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.61e-2)"	"unprognostic (7.99e-2)"	"unprognostic (8.19e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.21e-1)"	"prognostic unfavorable (2.53e-11)"	"unprognostic (1.23e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.88e-1)"	"unprognostic (1.25e-1)"	7.2	8.2	3.0	18.5	8.2	13.2	3.4	1.4	5.2	1.6	4.2	2.1	1.0	7.8	1.2	6.5	3.5	2.9	9.4	9.4	5.7	2.9	3.1	5.0	13.2	39.6	7.2	2.6	2.9	2.7	0.5	2.1	6.4	5.7	3.7	6.4	2.6	5.4	1.8	1.6	1.6	6.8	3.5	11.6	23.5	3.4	1.0	4.9	7.2	5.1	1.7	12.7	8.5	3.8	1.0	31.0	76.5	53.7	0.6	5.3	20.8	0.0	0.1	0.0	0.0	0.2	0.3	0.0	0.1	0.3	0.2	0.8	0.0	0.6	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	4.2	0.0	0.3	0.1	0.0	0.1	3.6	0.1	0.7	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.4	0.0	0.0	1.9	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.1	0.5	0.1	0.0	0.0	0.1	0.1	0.0	8.1	0.0	0.1	0.0	0.0	0.1	3.8	0.1	0.0	3.9	61.0	0.6	1.2	53.7	14.4	0.8	39.8	5.3	0.6	3.5	0.7	31.0	1.0	1.7	0.5	76.5	0.6	31.7	11.5	2.8	20.8	3.0	8.2	1.4	5.2	5.7	2.9	7.2	2.6	5.7	4.9	14.9	17.5	3.7	0.7	6.4	0.3	0.5	12.7	2.7	5.7	5.2	0.0	0.5	1.7	2.0	1.0	1.3	0.5	0.0	29.2	0.9	13.3	1.6	4.7	1.5	88.9	0.0	1.2	4.9	144.9	0.2	4.9	141.3	8.5	457.1	0.2	0.4	1.9	0.0	1.8	1.0	0.0	6.5	5.0	0.1	0.1	4.1	0.9	6.2	1.2	1.3
TNFSF14	"CD258, HVEM-L, LIGHT, LTg"	ENSG00000125735	"TNF superfamily member 14"	O43557	19	6661253-6670588	"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		Cytokine		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 50.8;liver: 50.6"	"Cell type enhanced"	"Detected in many"	13	"Alveolar cells type 2: 22.9;granulocytes: 26.4;T-cells: 51.1"	"Cancer enhanced"	"Detected in many"		"liver cancer: 4.4"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 50.8"	"Group enriched"	"Detected in many"	5	"granulocytes: 50.8;T-cells: 16.6"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 21.6;NB-4: 4.8;THP-1: 3.4;U-937: 12.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA012700	Approved				"Secreted to blood"	NA	NA	41000				"HPA012700: AB_1852870"	"unprognostic (2.78e-3)"	"unprognostic (2.11e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.35e-3)"	"unprognostic (3.82e-4)"	"unprognostic (4.51e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.63e-1)"	"unprognostic (1.05e-2)"	"unprognostic (9.23e-2)"	"unprognostic (9.22e-2)"	"unprognostic (3.59e-1)"	"prognostic unfavorable (6.07e-13)"	"unprognostic (1.09e-1)"	"unprognostic (9.56e-3)"	"unprognostic (1.75e-1)"	"unprognostic (3.62e-2)"	11.2	0.9	0.6	4.6	0.6	2.5	1.3	1.2	1.5	0.8	2.4	0.4	0.2	2.8	2.7	2.3	1.8	3.6	2.0	2.1	0.6	0.1	1.0	50.6	4.3	8.3	3.8	0.2	2.9	2.5	0.0	0.9	1.8	1.4	1.2	1.8	1.9	1.4	1.5	0.2	0.7	3.8	1.6	0.3	8.2	1.8	1.6	0.2	1.5	1.4	0.9	5.9	2.1	14.1	0.3	1.7	50.8	4.5	7.2	16.6	2.9	0.0	0.3	0.0	0.1	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.1	0.5	0.0	0.0	0.0	21.6	0.0	0.1	0.2	1.1	0.0	0.6	0.5	0.2	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.1	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	3.4	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.7	12.3	0.0	28.3	4.5	27.4	11.4	1.0	16.6	0.1	4.9	9.2	1.7	0.3	0.8	4.2	50.8	7.2	0.1	0.1	3.9	2.9	0.6	0.6	1.2	1.5	0.6	0.1	3.8	0.2	1.4	0.2	8.9	22.9	0.9	0.5	2.6	0.0	0.8	10.2	1.4	7.9	0.0	0.0	0.1	0.0	2.3	1.0	0.3	0.0	0.0	3.2	0.2	2.4	0.5	26.4	10.6	13.5	0.0	0.0	1.8	3.0	0.0	0.3	8.4	3.3	2.8	0.0	0.0	9.8	0.0	0.0	0.3	0.0	0.0	1.6	0.2	0.2	2.9	0.0	51.1	0.0	0.3
TNFSF4	"CD252, gp34, OX-40L, TXGP1"	ENSG00000117586	"TNF superfamily member 4"	P23510	1	173183734-173207313	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins"		Cytokine	"Cancer-related genes, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 11.5;testis: 14.4"	"Group enriched"	"Detected in some"	4	"Early spermatids: 4.3;monocytes: 12.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"fHDF/TERT166: 18.7;HHSteC: 8.1;HUVEC TERT2: 36.8;LHCN-M2: 30.6"									HPA059579	Approved		Approved	Nucleoplasm,Vesicles		NA	NA			"Nucleoplasm, Vesicles"		"HPA059579: AB_2684071"	"unprognostic (1.88e-2)"	"unprognostic (1.20e-1)"	"unprognostic (4.58e-2)"	"unprognostic (2.74e-1)"	"unprognostic (1.73e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.13e-3)"	"unprognostic (2.13e-1)"	"unprognostic (8.65e-2)"	"unprognostic (5.17e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.11e-7)"	"unprognostic (3.73e-3)"	"unprognostic (2.66e-1)"	"unprognostic (9.49e-2)"	"unprognostic (2.98e-2)"	2.1	4.0	1.7	8.2	2.3	0.9	3.7	4.5	3.4	1.7	1.8	1.0	0.8	0.3	1.5	1.5	1.6	1.4	2.1	2.1	3.0	2.0	1.5	1.6	2.5	11.5	1.9	0.8	2.7	2.1	1.0	3.3	1.2	1.2	2.8	2.5	1.0	0.8	1.0	0.8	0.3	2.5	1.6	1.9	9.7	1.4	14.4	1.2	9.3	0.8	0.8	3.7	1.6	1.6	1.3	2.6	1.7	0.2	3.4	1.2	6.5	0.0	0.0	0.2	0.5	1.3	6.7	0.0	1.8	0.4	0.1	0.1	0.0	0.0	0.0	0.3	18.7	0.1	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.2	0.7	8.1	0.1	0.0	2.9	0.1	0.9	0.1	0.6	36.8	0.7	0.0	0.2	30.6	0.0	0.3	0.1	0.1	0.0	0.3	0.9	0.0	0.2	0.3	0.0	0.0	0.3	0.1	0.1	0.3	0.6	0.0	0.3	0.3	0.0	0.0	0.1	0.1	0.4	0.6	0.1	0.1	3.4	2.0	0.0	0.2	0.3	1.1	0.1	0.8	1.1	0.7	0.9	0.8	1.3	1.2	1.1	1.7	3.4	0.1	2.6	0.9	6.5	1.7	2.3	4.5	3.4	3.0	2.0	1.9	0.8	1.2	1.2	0.0	0.3	0.0	0.4	0.7	0.0	1.2	0.0	1.4	0.0	1.8	0.0	0.1	0.0	0.0	4.3	0.7	0.0	0.0	0.0	0.1	1.2	0.5	0.0	0.9	0.4	0.0	0.0	0.0	0.8	0.9	0.3	0.2	1.7	12.6	0.0	1.0	0.2	0.0	1.8	0.0	0.3	0.0	1.9	0.2	0.2	0.5	0.0	1.5	0.0	0.1
TNFSF8	"CD153, CD30LG"	ENSG00000106952	"TNF superfamily member 8"	P32971	9	114893343-114930595	"Cancer-related genes, CD markers, Predicted membrane proteins"		Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 18.6;lymphoid tissue: 48.1"	"Group enriched"	"Detected in some"	4	"B-cells: 4.4;Hofbauer cells: 3.2;Kupffer cells: 6.5;Macrophages: 4.4;T-cells: 9.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in some"	7	"Daudi: 34.1;SuSa: 16.1;U-698: 28.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (8.82e-2)"	"unprognostic (6.56e-3)"	"unprognostic (7.79e-2)"	"unprognostic (6.05e-2)"	"unprognostic (2.67e-1)"	"unprognostic (5.58e-3)"	"unprognostic (5.26e-3)"	"unprognostic (1.82e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.70e-1)"	"unprognostic (2.02e-1)"	"unprognostic (4.75e-2)"	"unprognostic (3.01e-2)"	"unprognostic (2.76e-2)"	"unprognostic (9.61e-2)"	"unprognostic (1.82e-1)"	3.6	1.7	1.1	12.0	1.7	12.7	1.8	0.5	0.9	1.6	2.4	1.4	0.6	0.3	1.1	2.5	1.4	1.5	4.6	2.8	1.1	1.2	1.8	1.4	4.9	48.1	1.6	0.6	0.9	1.1	0.0	0.8	2.2	1.0	1.3	1.9	1.4	3.7	0.9	0.7	1.0	7.0	1.3	2.8	14.9	1.7	1.1	1.0	45.6	1.6	0.8	18.5	3.2	1.3	1.7	7.3	3.9	14.1	1.0	18.6	8.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	34.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	28.0	0.0	0.0	0.0	0.0	14.1	0.0	4.1	7.3	13.8	1.0	16.4	9.8	7.3	1.7	18.6	13.5	3.9	1.0	0.9	4.0	5.9	8.7	1.1	1.7	0.5	0.9	1.1	1.2	1.6	0.6	1.0	1.0	0.0	0.0	4.4	0.0	0.6	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	3.2	0.0	0.0	1.3	6.5	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	9.2	0.0	0.0
TREM1	"CD354, TREM-1"	ENSG00000124731	"Triggering receptor expressed on myeloid cells 1"	Q9NP99	6	41267926-41286719	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 96.9;bone marrow: 38.5;lung: 34.2"	"Cell type enhanced"	"Detected in some"	15	"Alveolar cells type 2: 31.6;Hofbauer cells: 25.6;Kupffer cells: 32.3;Macrophages: 79.4"	"Cancer enhanced"	"Detected in many"		"lung cancer: 9.6"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	8	"neutrophil: 96.9"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 96.9"	"Group enriched"	"Detected in some"	5	"SuSa: 6.5;U-87 MG: 23.8"									"HPA005563, HPA053612"	Approved		Approved	"Golgi apparatus"	"Intracellular and membrane"	NA	NA			"Golgi apparatus"		"HPA005563: AB_1858259, HPA053612: "	"unprognostic (6.41e-2)"	"unprognostic (1.47e-3)"	"unprognostic (1.22e-1)"	"unprognostic (3.39e-2)"	"unprognostic (6.07e-3)"	"unprognostic (2.97e-2)"	"unprognostic (5.73e-5)"	"unprognostic (1.29e-1)"	"unprognostic (1.24e-2)"	"unprognostic (4.13e-3)"	"unprognostic (2.24e-3)"	"unprognostic (7.65e-2)"	"unprognostic (3.18e-7)"	"unprognostic (6.32e-3)"	"unprognostic (4.95e-2)"	"unprognostic (1.08e-1)"	"unprognostic (7.26e-2)"	10.2	0.6	0.7	21.1	1.5	38.5	1.0	0.6	2.1	0.7	0.9	0.7	0.5	0.1	1.0	1.5	0.6	4.2	5.1	3.7	1.2	0.9	1.1	3.7	34.2	8.0	2.7	0.1	2.1	1.8	0.2	2.7	31.2	2.3	0.9	0.0	2.5	1.3	0.1	2.4	0.4	1.1	3.8	3.9	12.1	1.0	2.6	0.6	0.3	2.2	1.9	1.0	3.9	0.7	0.2	5.0	96.9	12.8	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.3	0.6	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	6.5	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.8	1.5	0.0	0.0	12.8	0.3	0.0	3.1	0.0	0.0	0.0	0.0	5.0	0.2	0.0	0.0	96.9	0.0	1.4	0.1	0.0	4.1	0.7	1.5	0.6	2.1	1.2	0.9	2.7	0.1	2.3	0.6	6.0	31.6	2.7	0.1	0.3	0.0	0.3	2.5	13.4	19.4	0.0	0.0	0.3	0.0	0.3	10.6	0.5	0.0	0.0	0.2	0.9	0.7	0.1	5.8	0.2	25.6	0.0	0.0	1.3	32.3	13.1	0.0	79.4	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	12.2	0.0	0.0	0.0
TSPAN7	"A15, CD231, DXS1692E, MRX58, MXS1, TALLA-1, TM4SF2"	ENSG00000156298	"Tetraspanin 7"	P41732	X	38561370-38688920	"CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	"Host-virus interaction"		"Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 131.1"	"Cell type enhanced"	"Detected in many"	15	"Endothelial cells: 113.7;Ito cells: 372.0"	"Cancer enhanced"	"Detected in all"		"glioma: 71.5"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory CD8 T-cell: 2.9"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"JURKAT: 68.6;MOLT-4: 45.1;SCLC-21H: 25.2;U-266/70: 16.7"									"HPA003140, CAB062566, CAB068245"	Enhanced					NA	NA					"CAB062566: AB_2665608, CAB068245: AB_2665609, HPA003140: AB_1078454"	"unprognostic (1.12e-2)"	"unprognostic (1.42e-2)"	"unprognostic (1.09e-1)"	"prognostic unfavorable (3.40e-4)"	"unprognostic (5.06e-2)"	"unprognostic (3.90e-3)"	"unprognostic (3.88e-3)"	"unprognostic (1.37e-2)"	"unprognostic (1.14e-1)"	"unprognostic (2.01e-2)"	"prognostic favorable (1.70e-4)"	"unprognostic (1.54e-1)"	"prognostic favorable (5.48e-7)"	"unprognostic (5.65e-3)"	"unprognostic (9.53e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.03e-3)"	15.2	28.7	39.6	3.5	83.0	0.8	7.3	83.8	131.1	12.4	18.5	11.5	2.3	7.9	11.6	9.2	7.9	10.5	5.8	17.1	34.5	30.7	15.8	12.0	16.2	8.8	19.4	37.7	5.2	4.4	4.1	11.4	6.6	23.8	5.6	17.3	8.1	3.3	7.4	17.9	4.9	7.8	14.5	11.9	21.3	4.6	1.7	9.5	0.0	11.8	5.4	8.2	8.2	4.2	0.9	0.5	0.3	0.2	0.3	2.9	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.3	0.0	10.9	2.0	0.0	0.0	8.6	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	68.6	0.0	0.0	0.2	0.1	45.1	0.0	2.3	0.0	0.0	2.2	0.9	0.0	1.1	0.2	25.2	2.6	0.0	0.0	0.5	1.5	0.0	0.0	0.0	0.0	0.6	0.0	0.2	16.7	4.7	0.0	1.0	0.1	0.3	0.2	0.1	0.0	0.6	0.2	0.7	0.4	1.1	2.9	0.1	0.9	2.1	1.8	0.3	0.3	0.0	0.5	0.0	0.1	39.6	83.0	83.8	86.3	34.5	30.7	19.4	37.7	23.8	9.5	11.9	18.4	0.5	2.3	9.4	87.2	35.4	2.5	1.4	4.5	10.4	41.2	0.3	19.9	0.4	0.0	113.7	34.6	0.0	0.5	0.4	6.8	2.4	9.3	2.9	33.9	92.2	18.0	372.0	20.5	1.1	0.6	1.5	13.5	0.0	25.1	94.7	1.4	17.3	2.8	8.3	66.4	58.2	4.4	0.6	3.2	5.6	0.7	4.3	31.0	0.9
VCAM1	CD106	ENSG00000162692	"Vascular cell adhesion molecule 1"	P19320	1	100719742-100739045	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	5	"kidney: 69.6;lymphoid tissue: 129.2"	"Cell type enhanced"	"Detected in many"	21	"Ductal cells: 130.8;Ito cells: 82.3;Kupffer cells: 410.3;Proximal tubular cells: 200.7"	"Cancer enriched"	"Detected in all"	8	"renal cancer: 89.5"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	10	"gdT-cell: 1.3;memory CD8 T-cell: 2.9;naive CD8 T-cell: 1.1"	"Lineage enriched"	"Detected in single"	17	"T-cells: 2.9"	"Group enriched"	"Detected in some"	5	"HHSteC: 58.3;HSkMC: 38.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000154, HPA034796, HPA069867"	Enhanced		Supported	"Cell Junctions"		NA	NA	624000000	960000000	"Cell Junctions"		"CAB000154: , HPA034796: AB_2674333, HPA069867: AB_2686215"	"unprognostic (2.96e-1)"	"prognostic favorable (3.82e-4)"	"unprognostic (1.31e-1)"	"unprognostic (7.49e-3)"	"unprognostic (1.04e-1)"	"prognostic favorable (7.19e-5)"	"unprognostic (1.60e-2)"	"unprognostic (2.48e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.20e-1)"	"unprognostic (3.95e-2)"	"unprognostic (8.23e-2)"	"unprognostic (1.80e-1)"	"unprognostic (5.47e-2)"	"unprognostic (1.68e-2)"	"unprognostic (3.12e-2)"	"unprognostic (2.55e-2)"	10.9	18.1	1.5	20.2	3.2	1.3	5.2	0.9	1.1	3.7	5.0	3.3	1.4	3.3	4.9	4.5	5.3	4.9	6.8	7.2	1.7	2.3	69.6	11.8	9.8	26.8	2.8	1.7	11.1	6.6	10.6	3.5	10.9	4.2	8.3	5.5	15.3	4.9	1.1	4.7	1.8	6.3	4.2	3.7	129.2	3.0	2.5	1.6	13.3	3.5	2.8	20.9	8.2	2.8	0.0	0.1	0.0	0.0	0.0	2.9	0.1	0.0	0.0	0.3	0.1	0.2	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	8.4	0.0	0.0	0.0	0.0	58.3	0.0	0.0	38.9	0.0	10.2	0.1	0.0	0.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.7	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.1	2.9	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	1.5	3.2	0.9	1.1	1.7	2.3	2.8	1.7	4.2	1.6	0.0	6.4	2.4	0.1	8.9	0.0	2.0	0.0	2.7	0.0	3.5	0.0	0.9	8.3	130.8	0.1	16.1	0.0	0.0	2.7	0.8	67.5	0.6	1.1	2.5	3.0	0.0	0.0	82.3	410.3	0.0	15.8	1.9	1.7	0.0	0.0	3.0	2.6	0.0	7.1	200.7	0.0	0.0	14.0	0.0	0.0	6.5	2.3	1.5	0.0	0.0
VPREB1	"CD179A, VpreB"	ENSG00000169575	"V-set pre-B cell surrogate light chain 1"	P12018	22	22244675-22245515	"CD markers, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 8.1;bone marrow: 23.8;lymphoid tissue: 4.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"memory B-cell: 5.8;naive B-cell: 8.1"	"Lineage enriched"	"Detected in many"	5	"B-cells: 8.1"	"Group enriched"	"Detected in some"	11	"Daudi: 8.6;MOLT-4: 18.3;RPMI-8226: 4.9"					"Not detected"	"Not detected"			HPA055886	Uncertain				"Intracellular and membrane"	NA	NA					"HPA055886: AB_2682956"																		0.0	0.0	0.0	2.2	0.0	23.8	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.6	0.0	1.3	0.0	4.8	0.0	0.0	1.2	0.0	0.0	8.1	1.6	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.3	0.0	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	0.0	0.0	0.0	8.1	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
